



US 20130203074A1

(19) **United States**

(12) **Patent Application Publication**
Anderberg et al.

(10) **Pub. No.: US 2013/0203074 A1**

(43) **Pub. Date: Aug. 8, 2013**

(54) **METHODS AND COMPOSITIONS FOR
DIAGNOSIS AND PROGNOSIS OF RENAL
INJURY AND RENAL FAILURE**

(75) Inventors: **Joseph Anderberg**, Encinitas, CA (US);
Jeff Gray, Solana Beach, CA (US); **Paul
McPherson**, Encinitas, CA (US); **Kevin
Nakamura**, Cardiff by the Sea, CA
(US); **James Patrick Kampf**, San
Diego, CA (US)

(73) Assignee: **ASTUTE MEDICAL, INC.**, San Diego,
CA (US)

(21) Appl. No.: **13/806,761**

(22) PCT Filed: **Jun. 23, 2011**

(86) PCT No.: **PCT/US11/01125**

§ 371 (c)(1),

(2), (4) Date: **Feb. 7, 2013**

Related U.S. Application Data

(60) Provisional application No. 61/357,956, filed on Jun. 23, 2010, provisional application No. 61/357,965, filed on Jun. 23, 2010, provisional application No. 61/357,966, filed on Jun. 23, 2010, provisional application No. 61/364,296, filed on Jul. 14, 2010, provisional application No. 61/364,305, filed on Jul. 14, 2010.

Publication Classification

(51) **Int. Cl.**

G01N 33/68 (2006.01)

G01N 33/573 (2006.01)

G01N 33/92 (2006.01)

G01N 33/74 (2006.01)

(52) **U.S. Cl.**

CPC **G01N 33/6893** (2013.01); **G01N 33/74**
(2013.01); **G01N 33/573** (2013.01); **G01N**
33/92 (2013.01)

USPC **435/7.4**; **435/7.94**

(57)

ABSTRACT

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Feto-protein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

[0001] The present application claims priority to U.S. Provisional Patent Application No. 61/357,965 filed Jun. 23, 2010; U.S. Provisional Patent Application No. 61/357,956 filed Jun. 23, 2010; U.S. Provisional Patent Application No. 61/357,966 filed Jun. 23, 2010; U.S. Provisional Patent Application No. 61/364,305 filed Jul. 14, 2010; and U.S. Provisional Patent Application No. 61/364,296 filed Jul. 14, 2010, each of which is hereby incorporated in its entirety including all tables, figures, and claims.

BACKGROUND OF THE INVENTION

[0002] The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

[0003] The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by refer-

ence in their entirety. Renal disease and/or injury may be acute or chronic. Acute and chronic kidney disease are described as follows (from Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, which are hereby incorporated by reference in their entirety): "Acute renal failure is worsening of renal function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia. Chronic renal failure (chronic kidney disease) results from an abnormal loss of renal function over months to years".

[0004] Acute renal failure (ARF, also known as acute kidney injury, or AKI) is an abrupt (typically detected within about 48 hours to 1 week) reduction in glomerular filtration. This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in the following table, which is adapted from the Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety:

Type	Risk Factors
Prerenal	
ECF volume depletion	Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states
Low cardiac output	Cardiomyopathy, MI, cardiac tamponade, pulmonary embolism, pulmonary hypertension, positive-pressure mechanical ventilation
Low systemic vascular resistance	Septic shock, liver failure, antihypertensive drugs
Increased renal vascular resistance	NSAIDs, cyclosporines, tacrolimus, hypercalcemia, anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome
Decreased efferent arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis)	ACE inhibitors or angiotensin II receptor blockers
Intrinsic Renal	
Acute tubular injury	Ischemia (prolonged or severe prerenal state); surgery, hemorrhage, arterial or venous obstruction; Toxins: NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin
Acute glomerulonephritis	ANCA-associated: Crescentic glomerulonephritis, polyarteritis nodosa, Wegener's granulomatosis; Anti-GBM glomerulonephritis: Goodpasture's syndrome; Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis

-continued

Type	Risk Factors
Acute tubulointerstitial nephritis	Drug reaction (eg, 13-lactams, NSAIDs, sulfonamides, ciprofloxacin, thiazide diuretics, furosemide, phenytoin, allopurinol, pyelonephritis, papillary necrosis)
Acute vascular nephropathy	Vasculitis, malignant hypertension, thrombotic microangiopathies, scleroderma, atheroembolism
Infiltrative diseases	Lymphoma, sarcoidosis, leukemia
Postrenal	
Tubular precipitation	Uric acid (tumor lysis), sulfonamides, triamterene, acyclovir, indinavir, methotrexate, ethylene glycol ingestion, myeloma protein, myoglobin
Ureteral obstruction	Intrinsic: Calculi, clots, sloughed renal tissue, fungus ball, edema, malignancy, congenital defects; Extrinsic: Malignancy, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury
Bladder obstruction	Mechanical: Benign prostatic hyperplasia, prostate cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter; Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion

[0005] In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.

[0006] Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.

[0007] A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI. The relationship between serum creatinine rise, AKI and the associated health risks are reviewed in Praught and Shlipak, *Curr Opin Nephrol*

Hypertens 14:265-270, 2005 and Chertow et al, *J Am Soc Nephrol* 16: 3365-3370, 2005, which, with the references listed therein, are hereby incorporated by reference in their entirety. As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 days, 3 days, 7 days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.

[0008] One study (Lassnigg et al, *J Am Soc Nephrol* 15:1597-1605, 2004, hereby incorporated by reference in its entirety) investigated both increases and decreases in serum creatinine. Patients with a mild fall in serum creatinine of -0.1 to -0.3 mg/dL following heart surgery had the lowest mortality rate. Patients with a larger fall in serum creatinine (more than or equal to -0.4 mg/dL) or any increase in serum creatinine had a larger mortality rate. These findings caused the authors to conclude that even very subtle changes in renal function (as detected by small creatinine changes within 48 hours of surgery) seriously effect patient's outcomes. In an effort to reach consensus on a unified classification system for using serum creatinine to define AKI in clinical trials and in clinical practice, Bellomo et al., *Crit. Care.* 8(4):R204-12, 2004, which is hereby incorporated by reference in its entirety, proposes the following classifications for stratifying AKI patients:

“Risk”: serum creatinine increased 1.5 fold from baseline OR urine production of <0.5 ml/kg body weight/hr for 6 hours;

“Injury”: serum creatinine increased 2.0 fold from baseline OR urine production <0.5 ml/kg/hr for 12 h;

“Failure”: serum creatinine increased 3.0 fold from baseline OR creatinine >355 $\mu\text{mol/l}$ (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h or anuria for at least 12 hours; And included two clinical outcomes:

“Loss”: persistent need for renal replacement therapy for more than four weeks.

“ESRD”: end stage renal disease—the need for dialysis for more than 3 months.

[0009] These criteria are called the RIFLE criteria, which provide a useful clinical tool to classify renal status. As discussed in Kellum, *Crit. Care Med.* 36: S141-45, 2008 and Ricci et al., *Kidney int.* 73, 538-546, 2008, each hereby incorporated by reference in its entirety, the RIFLE criteria provide a uniform definition of AKI which has been validated in numerous studies.

More recently, Mehta et al., *Crit. Care* 11:R31 (doi:10.1186.cc5713), 2007, hereby incorporated by reference in its entirety, proposes the following similar classifications for stratifying AKI patients, which have been modified from RIFLE:

“Stage I”: increase in serum creatinine of more than or equal to 0.3 mg/dL ($\geq 26.4 \mu\text{mol/L}$) or increase to more than or equal to 150% (1.5-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 6 hours;

“Stage II”: increase in serum creatinine to more than 200% (>2-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 12 hours;

“Stage III”: increase in serum creatinine to more than 300% (>3-fold) from baseline OR serum creatinine $\geq 354 \mu\text{mol/L}$ accompanied by an acute increase of at least 44 $\mu\text{mol/L}$ OR urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.

[0010] The CIN Consensus Working Panel (McCollough et al, *Rev Cardiovasc Med.* 2006; 7(4):177-197, hereby incorporated by reference in its entirety) uses a serum creatinine rise of 25% to define Contrast induced nephropathy (which is a type of AKI). Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL or 25%, are sufficient to detect AKI (worsening renal function) and that the magnitude of the serum creatinine change is an indicator of the severity of the AKI and mortality risk.

[0011] Although serial measurement of serum creatinine over a period of days is an accepted method of detecting and diagnosing AKI and is considered one of the most important tools to evaluate AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to values (e.g., a 0.3 mg/dL or 25% rise) considered diagnostic for AKI can be 48 hours or longer depending on the definition used. Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Some patients with AKI will recover fully, some will need dialysis (either short term or long term) and some will

have other detrimental outcomes including death, major adverse cardiac events and chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited. Knowing these things can be of vital importance in managing and treating patients with AKI. [0012] These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.

BRIEF SUMMARY OF THE INVENTION

[0013] It is an object of the invention to provide methods and compositions for evaluating renal function in a subject. As described herein, measurement of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 (each referred to herein as a “kidney injury marker”) can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).

[0014] The kidney injury markers of the present invention may be used, individually or in panels comprising a plurality of kidney injury markers, for risk stratification (that is, to identify subjects at risk for a future injury to renal function, for future progression to reduced renal function, for future progression to ARF, for future improvement in renal function, etc.); for diagnosis of existing disease (that is, to identify subjects who have suffered an injury to renal function, who have progressed to reduced renal function, who have progressed to ARF, etc.); for monitoring for deterioration or improvement of renal function; and for predicting a future medical outcome, such as improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc.

[0015] In a first aspect, the present invention relates to methods for evaluating renal status in a subject. These meth-

ods comprise performing an assay method that is configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 complex is/are then correlated to the renal status of the subject. This correlation to renal status may include correlating the assay result(s) to one or more of risk stratification, diagnosis, prognosis, staging, classifying and monitoring of the subject as described herein. Thus, the present invention utilizes one or more kidney injury markers of the present invention for the evaluation of renal injury.

[0016] In certain embodiments, the methods for evaluating renal status described herein are methods for risk stratification of the subject; that is, assigning a likelihood of one or more future changes in renal status to the subject. In these embodiments, the assay result(s) is/are correlated to one or more such future changes. The following are preferred risk stratification embodiments.

[0017] In preferred risk stratification embodiments, these methods comprise determining a subject's risk for a future injury to renal function, and the assay result(s) is/are correlated to a likelihood of such a future injury to renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0018] In other preferred risk stratification embodiments, these methods comprise determining a subject's risk for future reduced renal function, and the assay result(s) is/are correlated to a likelihood of such reduced renal function. For example, the measured concentrations may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future reduced renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of future reduced renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0019] In still other preferred risk stratification embodiments, these methods comprise determining a subject's likelihood for a future improvement in renal function, and the assay result(s) is/are correlated to a likelihood of such a future

improvement in renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. For a "negative going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.

[0020] In yet other preferred risk stratification embodiments, these methods comprise determining a subject's risk for progression to ARF, and the result(s) is/are correlated to a likelihood of such progression to ARF. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0021] And in other preferred risk stratification embodiments, these methods comprise determining a subject's outcome risk, and the assay result(s) is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0022] In such risk stratification embodiments, preferably the likelihood or risk assigned is that an event of interest is more or less likely to occur within 180 days of the time at which the body fluid sample is obtained from the subject. In particularly preferred embodiments, the likelihood or risk assigned relates to an event of interest occurring within a shorter time period such as 18 months, 120 days, 90 days, 60 days, 45 days, 30 days, 21 days, 14 days, 7 days, 5 days, 6 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. A risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.

[0023] In preferred risk stratification embodiments, the subject is selected for risk stratification based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF. For example, a subject undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery; a subject having pre-existing congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, or sepsis; or a subject exposed to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, fosfarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin are all preferred subjects for monitoring risks according to the methods described herein. This list is not meant to be limiting. By “pre-existence” in this context is meant that the risk factor exists at the time the body fluid sample is obtained from the subject. In particularly preferred embodiments, a subject is chosen for risk stratification based on an existing diagnosis of injury to renal function, reduced renal function, or ARF.

[0024] In other embodiments, the methods for evaluating renal status described herein are methods for diagnosing a renal injury in the subject; that is, assessing whether or not a subject has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result (s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Feto-protein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred diagnostic embodiments.

[0025] In preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of such an injury. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is

above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0026] In other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing reduced renal function. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0027] In yet other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing ARF. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0028] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal replacement therapy, and the assay result(s) is/are correlated to a need for renal replacement therapy. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentra-

tion is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0029] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal transplantation, and the assay result(s) is/are correlated to a need for renal transplantation. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0030] In still other embodiments, the methods for evaluating renal status described herein are methods for monitoring a renal injury in the subject; that is, assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are corre-

lated to the occurrence or nonoccurrence of a change in renal status. The following are preferred monitoring embodiments.

[0031] In preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0032] In other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0033] In yet other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from acute renal failure, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0034] In other additional preferred monitoring embodiments, these methods comprise monitoring renal status in a subject at risk of an injury to renal function due to the pre-existence of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the thresh-

old, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0035] In still other embodiments, the methods for evaluating renal status described herein are methods for classifying a renal injury in the subject; that is, determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to a particular class and/or subclass. The following are preferred classification embodiments.

[0036] In preferred classification embodiments, these methods comprise determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage, and the assay result(s) is/are correlated to the injury classification for the subject. For example, the measured concentration may be compared to a threshold value, and when the measured concentration is above the threshold, a particular classification is assigned; alternatively, when the measured concentration is below the threshold, a different classification may be assigned to the subject.

[0037] A variety of methods may be used by the skilled artisan to arrive at a desired, threshold value for use in these methods. For example, the threshold value may be determined from a population of normal subjects by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such normal subjects. Alternatively, the threshold value may be determined from a "diseased" population of subjects, e.g., those suffering from an injury or having a predisposition for an injury (e.g., progression to ARF or some other clinical outcome such as death, dialysis, renal transplantation, etc.), by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such subjects. In another alternative, the threshold value may be determined from a prior measurement of a kidney injury marker in the same subject; that is, a temporal change in the level of a kidney injury marker in the subject may be used to assign risk to the subject.

[0038] The foregoing discussion is not meant to imply, however, that the kidney injury markers of the present invention must be compared to corresponding individual thresholds. Methods for combining assay results can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, calculating ratios of markers, etc. This list is not meant to be limiting. In these methods, a composite result which is determined by combining individual markers may be treated as if it is itself a marker; that is, a threshold may be determined for the composite result as described herein for individual markers, and the composite result for an individual patient compared to this threshold.

[0039] The ability of a particular test to distinguish two populations can be established using ROC analysis. For example, ROC curves established from a "first" subpopulation which is predisposed to one or more future changes in renal status, and a "second" subpopulation which is not so predisposed can be used to calculate a ROC curve, and the area under the curve provides a measure of the quality of the test. Preferably, the tests described herein provide a ROC curve area greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.

[0040] In certain aspects, the measured concentration of one or more kidney injury markers, or a composite of such markers, may be treated as continuous variables. For example, any particular concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. In yet another alternative, a threshold that can provide an acceptable level of specificity and sensitivity in separating a population of subjects into "bins" such as a "first" subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a "second" subpopulation which is not so predisposed. A threshold value is selected to separate this first and second population by one or more of the following measures of test accuracy:

an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less;

a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;

a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater

than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;

at least about 75% sensitivity, combined with at least about 75% specificity;

a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or

a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1.

The term “about” in the context of any of the above measurements refers to $\pm 5\%$ of a given measurement.

[0041] Multiple thresholds may also be used to assess renal status in a subject. For example, a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., and a “second” subpopulation which is not so predisposed can be combined into a single group. This group is then subdivided into three or more equal parts (known as tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.

[0042] In certain embodiments, the assay method is an immunoassay. Antibodies for use in such assays will specifically bind a full length kidney injury marker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. Numerous immunoassay formats are known to those of skill in the art. Preferred body fluid samples are selected from the group consisting of urine, blood, serum, saliva, tears, and plasma.

[0043] The foregoing method steps should not be interpreted to mean that the kidney injury marker assay result(s) is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, a risk stratification, diagnostic, classification, monitoring, etc. method may combine the assay result(s) with one or more variables measured for the subject selected from the group consisting of demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score, risk scores of Thakar et al. (J. Am. Soc. Nephrol. 16: 162-68, 2005), Mehran et al. (J. Am. Coll. Cardiol. 44: 1393-99, 2004), Wijeyesundera et al. (JAMA 297: 1801-9, 2007), Goldstein and Chawla (Clin. J. Am. Soc. Nephrol. 5: 943-49,

2010), or Chawla et al. (Kidney Intl. 68: 2274-80, 2005)), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatinine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more kidney injury marker assay result(s) are described hereinafter and in Harrison’s Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.

[0044] When more than one marker is measured, the individual markers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual markers may also be measured on the same or different body fluid samples. For example, one kidney injury marker may be measured in a serum or plasma sample and another kidney injury marker may be measured in a urine sample. In addition, assignment of a likelihood may combine an individual kidney injury marker assay result with temporal changes in one or more additional variables.

[0045] In various related aspects, the present invention also relates to devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.

[0046] In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.

[0047] Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dinitrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).

[0048] Generation of a signal from the signal development element can be performed using various optical, acoustical,

and electrochemical methods well known in the art. Examples of detection modes include fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody is coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.

DETAILED DESCRIPTION OF THE INVENTION

[0049] The present invention relates to methods and compositions for diagnosis, differential diagnosis, risk stratification, monitoring, classifying and determination of treatment regimens in subjects suffering or at risk of suffering from injury to renal function, reduced renal function and/or acute renal failure through measurement of one or more kidney injury markers. In various embodiments, a measured concentration of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 or one or more markers related thereto, are correlated to the renal status of the subject.

[0050] For purposes of this document, the following definitions apply:

[0051] As used herein, an “injury to renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury may be identified, for example, by a decrease in glomerular filtration rate or estimated GFR, a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy, etc. “Improvement in Renal Function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.

[0052] As used herein, “reduced renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL ($\geq 8.8 \mu\text{mol/L}$), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).

[0053] As used herein, “acute renal failure” or “ARF” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl ($\geq 26.4 \mu\text{mol/l}$), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”

[0054] As used herein, the term “C-C motif chemokine 7” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 7 precursor (Swiss-Prot P80098 (SEQ ID NO: 1)).

10 20 30 40 50 60
MKASAALLCL LLTAAAFSPQ GLAQFVGINT STTCCYRFIN KKIPKQRLES YRRTTSSHCP
70 80 90
REAVIFKTKL DKEICADPTQ KKWQDFMKHL DKKTQTPKL

[0055] The following domains have been identified in C-C motif chemokine 7:

Residues	Length	Domain ID
1-23	23	Signal peptide
24-99	76	C-C motif chemokine 7

[0056] As used herein, the term “C-C motif chemokine 26” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 26 precursor (Swiss-Prot Q9Y258 (SEQ ID NO: 2)).

10 20 30 40 50 60
MMGLSLASAV LLASLLSLHL GTATRGSDIS KTCCFQYSHK PLPWTWVRSY EFTSNCSQR
70 80 90
AVIFTTKRGK KVCTHPRKKW VQKYISLLKT PKQL

[0057] The following domains have been identified in C-C motif chemokine 26:

Residues	Length	Domain ID
1-23	23	Signal peptide
24-94	71	C-C motif chemokine 26

[0058] As used herein, the term “Complement C4-B” refers to one or more polypeptides present in a biological sample that are derived from Complement C4-B precursor (Swiss-Prot P0C0L5 (SEQ ID NO: 3)).

10	20	30	40	50	60
MRLWLGLIWA	SSFFTLSLQK	PRLLLFSPSV	VHLGVPLSVG	VQLQDVPRGQ	VVKGSVFLRN
70	80	90	100	110	120
PSRNNVPCSP	KVDFTLSSEK	DFALLSLQVP	LKDAKSCGLH	QLLRGPEVQL	VAHSPWLKDS
130	140	150	160	170	180
LSRTTNIQGI	NLLFSSRRGH	LFLQTDQPIY	NPGQVRVYRV	FALDQKMRPS	TDTITVMVEN
190	200	210	220	230	240
SHGLRVRKKE	VYMPSSIFQD	DFVIPDISEP	GTWKISARFS	DGLESNSSTQ	FEVKKYVLPN
250	260	270	280	290	300
FEVKITPGKP	YILTVPGHLD	EMQLDIQARY	IYGKPVQGVA	YVRFGLLDED	GKKTFFRGLE
310	320	330	340	350	360
SQTKLVNGQS	HISLSKAEFQ	DALEKLNMG	TDLQGLRLYV	AAAIIESPGG	EMEEAELTSW
370	380	390	400	410	420
YFVSSPFSLD	LSKTKRHLVP	GAPFLQALV	REMSGSPASG	IPVKVSATVS	SPGSVPEVQD
430	440	450	460	470	480
IQQNTDGSQG	VSIPIIIPQT	ISELQLSVSA	GSPHPAIARL	TVAAPPSGGP	GFLSIERPDS
490	500	510	520	530	540
RPPRVGDTLN	LNLRVSGSA	TFSHYYMIL	SRGQIVFMNR	EPKRTLTSVS	VFVDHHLAPS
550	560	570	580	590	600
FYFVAFYYHG	DHPVANSLRV	DVQAGACEGK	LELSVDGAKQ	YRNGESVKLH	LETDSLALVA
610	620	630	640	650	660
LGALDTALYA	AGSKSHKPLN	MKGVFAMNS	YDLGCGPGGG	DSALQVFQAA	GLAFSDGDQW
670	680	690	700	710	720
TLSRKRLSCP	KEKTTRKKRN	VNFQKAINKE	LGQYASPTAK	RCCQDGVTRL	PMMRSCQORA
730	740	750	760	770	780
ARVQQPDCRE	PFLSCCQFAE	SLRKSRDKG	QAGLQRALEI	LQEEDLIDED	DIPVRSFFPE
790	800	810	820	830	840
NWLWRVETVD	RFQILTLWLP	DSLTTWEIHG	LSLSKTKGLC	VATPVQLRVF	REFHLHLRLP
850	860	870	880	890	900
MSVRRFEQLE	LRPVLYNYLD	KNLTVSVHVS	PVEGLCLAGG	GGLAQQVLVP	AGSARPVAFS
910	920	930	940	950	960
VVPTAAAVS	LKVVARGSFE	FPVGDAVSKV	LQIEKEGAIH	REELVYELNP	LDHRGRTLEI
970	980	990	1000	1010	1020
PGNSDPNMIP	DGDFNSYVRV	TASDPLDTLG	SEGALSPGGV	ASLLRLPRGC	GEQTMIIYLAP
1030	1040	1050	1060	1070	1080
TLAASRYLDK	TEQWSTLPPE	TKDHAVDLIQ	KGYMRIQQFR	KADGSYAOWL	SRDSSTWLTA
1090	1100	1110	1120	1130	1140
FVLKVLSLAQ	EQVGGSPEKL	QETSNWLLSQ	QQADGSFQDL	SPVIHRSMQG	GLVGNDETVA
1150	1160	1170	1180	1190	1200
LTAFVTIALH	HGLAVQDEG	AEPLKQVEA	SISKANSFLG	EKASAGLLGA	HAAAITAYAL

-continued

1210	1220	1230	1240	1250	1260
SLTKAPVDLL	GVAHNNLMAM	AQETGDNLYW	GSVTGSQSNA	VSPTPAPRNP	SDPMPQAPAL
1270	1280	1290	1300	1310	1320
WIETTAYALL	HLLLHEGKAE	MADQASAWLT	RQGSFQGGFR	STQDTVIALD	ALSAYWIASH
1330	1340	1350	1360	1370	1380
TTEERGLNVT	LSSTGRNGPK	SHALQLNNRQ	IRGLEEELQF	SLGSKINVKV	GGNSKGTCLKV
1390	1400	1410	1420	1430	1440
LRTYNVLDKM	NTTCQDLQIE	VTVKGHVEYT	MEANEDYEDY	EYDELPKDD	PDAPLQPVTP
1450	1460	1470	1480	1490	1500
LQLFEGRRNR	RRREAPKVVE	EQESRVHYTV	CIWRNGKVGL	SGMAIADVTL	LSGFHALRAD
1510	1520	1530	1540	1550	1560
LEKLTSLSDR	YVSHFETEGP	HVLLYFDSVP	TSRECVGFEA	VQEVVGLVQ	PASATLYDYY
1570	1580	1590	1600	1610	1620
NPERRCSVFY	GAPSKSRLLA	TLCSAEVCQC	AEGKCPRQRR	ALERGLQDED	GYRMKFACY
1630	1640	1650	1660	1670	1680
PRVEYGFQVK	VLREDSRAAF	RLFETKITQV	LHFTKDVKAA	ANQMRNFLVR	ASCRLRLPEG
1690	1700	1710	1720	1730	1740
KEYLIMGLDG	ATYDLEGHPQ	YLLDSNSWIE	EMPSERLCRS	TRQRAACAQL	NDFLQEYGTQ

GCQV

[0059] The following domains have been identified in Complement C4-B:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-675	656	Complement C4-B beta chain
676-679	4	Propeptide
680-1446	767	Complement C4-B alpha chain
680-756	77	Complement C4-a anaphylatoxin
757-1446	690	Complement C4b-B

-continued

Residues	Length	Domain ID
957-1336	380	Complement C4d-B
1447-1453	7	propeptide
1454-1744	291	Complement C4-B gamma chain

[0060] As used herein, the term “Corticotropin” refers to one or more polypeptides present in a biological sample that are derived from pro-opiomelanocortin precursor (Swiss-Prot P01189 (SEQ ID NO: 4)) containing one or more epitopes of corticotropin.

10	20	30	40	50	60
MPRSCCSRSG	ALLLALLLQA	SMEVRGWCLE	SSQCQDLTTE	SNLLECIRAC	KPDLAETPM
70	80	90	100	110	120
FPGNGDEQPL	TENPRKYVMG	HFRWDRFGRR	NSSSSGSSGA	GQKREDVSAG	EDCGPLPEGG
130	140	150	160	170	180
PEPRSDGAKP	GPREGKRSYS	MEHFRWGKPV	GKKRRPVKVY	PNGAEDESSE	AFPLEFKREL
190	200	210	220	230	240
TGQRLREGDG	PDGPADDGAG	AQADLEHSL	VAAEKKDEGP	YRMEHFRWGS	PPDKRYGGF
250	260				
MTSEKSQTPL	VTLFKNAIK	NAYKKGE			

[0061] The following domains have been identified in pro-opiomelanocortin:

Residues	Length	Domain ID
1-26	26	Signal peptide
27-102	76	NPP
77-87	11	Melanotropin gamma
105-134	30	peptide
138-176	39	Corticotropin
138-150	13	Melanotropin alpha
156-176	21	Corticotropin-like intermediary peptide

-continued

Residues	Length	Domain ID
179-267	89	Lipotropin beta
179-234	56	Lipotropin gamma
217-234	18	Melanotropin beta
237-267	31	beta endorphin
237-241	5	met enkephalin

[0062] As used herein, the term “Interferon alpha-2” refers to one or more polypeptides present in a biological sample that are derived from the Interferon alpha-2 precursor (Swiss-Prot P01563 (SEQ ID NO: 5)).

10 20 30 40 50 60
MALTFALLVA LLVLSCKSSC SVGCDLPQTH SLGSRRTLML LAQMRKISLF SCLKDRHDFG
70 80 90 100 110 120
FPQEEFGNQF QKAETIPVLH EMIQQIFNLF STKDSSAAWD ETLLDKFYTE LYQQLNDLEA
130 140 150 160 170 180
CVIQGVGVTE TPLMKEDSIL AVRKYFQRIT LYLKEKKYSP CAWEVVRAEI MRSFSLSTNL
QESLRSKE

[0063] The following domains have been identified in Interferon alpha-2:

Residues	Length	Domain ID
1-23	23	Signal peptide
24-188	209	Interferon alpha-2

[0064] As used herein, the term “Interleukin-4 receptor subunit alpha” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-4 receptor subunit alpha precursor (Swiss-Prot P24394 (SEQ ID NO: 6)):

10 20 30 40 50 60
MGWLCSGLLF PVSCVLVLQV ASSGNMKVLQ EPTCVSDYMS ISTCEWKMG PTNCSTELRL
70 80 90 100 110 120
LYQLVFLLE AHTCIPENNG GAGCVCHLLM DDVVSADNYT LDLWAGQQLL WKGSFKPSEH
130 140 150 160 170 180
VKPRAPGNLT VHTNVSDTLL LTWSNPYPFD NYLYNHLYA VNIWSENDPA DFRIYNVTYL
190 200 210 220 230 240
EPSLRIAAST LKSGISYRAR VRAWAQCYNF TWSEWSPSTK WHNSYREPFQ QHLLLVSVS
250 260 270 280 290 300
CIVILAVCLL CYVSITKIKK EWWQIPNPA RSRLVAIIQ DAQGSQWEKR SRQEPAPKCP
310 320 330 340 350 360
HWKNCLTKLL PCFLEHNMR DEDPHKAAKE MPFQSGSKSA WCPVEISKTV LWPESISVVR
370 380 390 400 410 420
CVELFEAPVE CEEEEVEEEE KGSFCASPES SRDDFQEGRE GIVARLTESL FLDLLGEENG
430 440 450 460 470 480
GFCQQDMGES CLLPPSGSTS AHMPWDEFFS AGPKEAPPWG KEQPLHLEPS PPASPTQSPD
490 500 510 520 530 540
NLCTETPLV IAGNPAYRSF SNSLSQSPCP RELGPDPLLA RHLEEVEPEM PCVPQLSEPT
550 560 570 580 590 600
TVPQPEPETW EQILRRNVLQ HGAAAAPVSA PTSGYQEFVH AVEQGGTQAS AVVGLGPPGE

-continued

610 620 630 640 650 660
AGYKAFSSLL ASSAVSPEKC GFGASSGEEG YKPFQDLIPG CPGDPAPVPV PLFTFGLDRE

670 680 690 700 710 720
PPRSPQSSHL PSSSPEHLGL EPGEKVEDMP KPPLPQEQAT DPLVDSLGS G IVYSALTCHL

730 740 750 760 770 780
CGHLKQCHGQ EDGGQTPVMA SPCCGCCCGD RSSPPTTPLR APDPSPGGVP LEASLCPASL

790 800 810 820
APSGISEKSK SSSSFHPAPG NAQSSSQTPK IVNFVSVGPT YMRVS

[0065] Interleukin-4 receptor subunit alpha is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Interleukin-4 receptor subunit alpha generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Interleukin-4 receptor subunit alpha:

Residues	Length	Domain ID
1-25	25	Signal peptide
26-825	800	Interleukin-4 receptor subunit alpha

-continued

Residues	Length	Domain ID
26-232	319	Extracellular domain
233-256	20	Transmembrane domain
257-825	213	Cytoplasmic domain
228-825		Missing in soluble isoform 2
225-227		YRE → NIC in soluble isoform 2

[0066] As used herein, the term “Insulin-like growth factor-binding protein 4” refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 4 precursor (Swiss-Prot P22692 (SEQ ID NO: 7)).

10 20 30 40 50 60
MLPLCLVAAL LLAAGPGPSL GDEAIHCPPC SEEKLARC RP PVGCEELVRE PGCGCCATCA

70 80 90 100 110 120
LGLGMPGCGVY TPRCGSLRC YPPRGVEKPL HTLMHGQGV C MELAEIEAIQ ESLQPSDKDE

130 140 150 160 170 180
GDHPNNSFSP CSAHDRRLQ KHFAKIRDRS TSGGKMKVNG APREDARVP QGSCQSELHR

190 200 210 220 230 240
ALERLAASQS RTHEDLYIIP IPNCDRNGNF HPKQCHPALD GQRGKCWCVD RKTGVKLP GG

250
LEPKGELDCH QLADSFRE

[0067] The following domains have been identified in Insulin-like growth factor-binding protein 4:

Residues	Length	Domain ID
1-21	21	Signal peptide
22-258	237	Insulin-like growth factor-binding protein 4

[0068] As used herein, the term “Insulin-like growth factor-binding protein 5” refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 5 precursor (Swiss-Prot P24593 (SEQ ID NO: 8)).

10 20 30 40 50 60
MVL LTAVLLL LAAYAGPAQS LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA

70 80 90 100 110 120
LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE

-continued

130 140 150 160 170 180
EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA
190 200 210 220 230 240
PEMRQSESEQ PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGIFYKRKQC KPSRGRKRG
250 260 270
CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE

[0069] The following domains have been identified in Insulin-like growth factor-binding protein 5:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-272	252	Insulin-like growth factor-binding protein 5

[0070] As used herein, the term “Interleukin-21” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-21 precursor (Swiss-Prot Q9HBE4 (SEQ ID NO: 8)).

10 20 30 40 50 60
MERIVICLMV IFLGTLVHKS SSQGQDRHMI RMRQLIDIVD QLKNYVNDLV PEFLPAPEDV
70 80 90 100 110 120
ETNCEWSAFS CFQKAQLKSA NTGNNERIIN VSIKKLKRKP PSTNAGRRQK HRLTCPSCDS
130 140 150
YEKKPPKEFL ERFKSLQKM IHQHLSSRTH GSEDS

[0071] The following domains have been identified in Interleukin-21:

Residues	Length	Domain ID
1-22	22	Signal peptide
23-155	133	Interleukin-21

[0072] As used herein, the term “Interleukin-23 subunit alpha” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-23 subunit alpha precursor (Swiss-Prot Q9NPF7 (SEQ ID NO: 9)).

10 20 30 40 50 60
MLGSRVMLL LLLPWTAGQR AVPGGSSPAW TQCQQLSQKL CTLAWSAHPL VGHMDLREEG
70 80 90 100 110 120
DEETTNDVPH IQCGDGCDPQ GLRDNSQFCL QRIHQGLIFY EKLLGSDIFT GEPSLLPDSP
130 140 150 160 170 180
VGQLHASLLG LSQLLQPEGH HWETQQIPSL SPSQPWQRL LRFKILRSLQ AFWAVAARVF
AHGAATLSP

[0073] The following domains have been identified in Interleukin-23 subunit alpha:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-189	170	Interleukin-23 subunit alpha

[0074] As used herein, the term “Interleukin-28A” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-28A precursor (Swiss-Prot Q81ZJ0 (SEQ ID NO: 10)).

```

      10      20      30      40      50      60
MKLDMTGDCT PVLVLMAAVL TVTGAVPVAR LHGALPDARG CHIAQFKSLS PQELQAFKRA

      70      80      90      100     110     120
KDALEESLLL KDCRCHSRLF PRTWDLRQLQ VRERFMALEA ELALTCLKVLE ATADTDPALV

     130     140     150     160     170     180
DVLDDQLHTL HHILSQFRAC IQPQPTAGPR TRGRLLHHWLY RLQEAPKKES PGCLEASVTF

     190     200
NLFRLLTRDL NCVASGDLCV

```

[0075] The following domains have been identified in Interleukin-28A:

Residues	Length	Domain ID
1-25	25	Signal peptide
26-200	175	Interleukin-28A

[0076] As used herein, the term “Interleukin-33” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-33 precursor (Swiss-Prot O95760 (SEQ ID NO: 11)).

```

      10      20      30      40      50      60
MKPKMKYSTN KISTAKWKNT ASKALCFKLG KSQQKAKEVC PMYFMKLRSG LMIKKEACYF

      70      80      90      100     110     120
RRETTKRPSL KTGRKHKRHL VLAACQQQST VECFAFGISG VQKYTRALHD SSITGISPIT

     130     140     150     160     170     180
EYLASLSTYN DQSITFALED ESYEIVVEDL KKDEKKDKVL LSYYESQHPS NESGDGVGDK

     190     200     210     220     230     240
MLMVTLSPTK DFWLHANNKE HSVELHKCEK PLPDQAFFVL HNMHSNCVSF ECKTDPGVFI

     250     260     270
GVKDNHLALI KVDSSENLCT ENILFKLSET

```

[0077] The following domains have been identified in Interleukin-33:

Residues	Length	Domain ID
1-270	270	Interleukin-33

[0078] As used herein, the term “Lutropin subunit beta” refers to one or more polypeptides present in a biological sample that are derived from the Lutropin subunit beta precursor (Swiss-Prot P01229 (SEQ ID NO: 12)).

```

      10      20      30      40      50      60
MEMLQGLLLL LLLSMGAWA SREPLRPWCH PINAILAVEK EGCPVCITVN TTICAGYCPT

      70      80      90     100     110     120
MMRVLQAVLP PLPQVVCTYR DVRFESIRLP GCPRGVDPVV SFPVALSCRC GPCRRSTSDC

     130     140
GGPKDHPLTC DHPQLSGLLF L

```

[0079] The following domains have been identified in Lutropin subunit beta:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-141	121	Lutropin subunit beta

[0080] As used herein, the term “Interstitial collagenase” (also known as MMP-1 and matrix metalloproteinase 1) refers to one or more polypeptides present in a biological sample that are derived from the Interstitial collagenase precursor (Swiss-Prot P03956 (SEQ ID NO: 13)).

```

      10      20      30      40      50      60
MHSFPPLLLL LFWGVVSHSF PATLETQEOD VDLVQKYLEK YYNLKNDGRQ VEKRRNSGPV

      70      80      90     100     110     120
VEKLKQMQUEF FGLKVTGKPD AETLKVMKQP RCGVPDVAQF VLTEGNPRWE QTHLTYRIEN

     130     140     150     160     170     180
YTPDLPRADV DHAIEKAFQL WSNVTPLTFT KVSEGQADIM ISFVRGDHRD NSPFDGPGGN

     190     200     210     220     230     240
LAHAFQPGPG IGGDAHFDDE ERWTNNFREY NLHRVAAHEL GHSLGLSHST DIGALMYPSTY

     250     260     270     280     290     300
TFSGDVQLAQ DDIDGIQAIY GRSQNPVQPI GPQTPKACDS KLTFDAITTI RGEVMFFKDR

     310     320     330     340     350     360
FYMRTNPFYP EVELNFIISVF WPQLPNGLA AYEFADRDEV RFFKGNKYWA VQGQNVLHGY

     370     380     390     400     410     420
PKDIYSSFGF PRTVKHIDAA LSEENTGKTY FFVANKYWRY DEYKRSMDPG YPKMIAHDFP

     430     440     450     460
GIGHKVDAVF MKDGFFYFFH GTRQYKFDPK TKRILTLQKA NSWFNCRKN

```

[0081] The following domains have been identified in Interstitial collagenase:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-99	80	Activation peptide
100-469	370	Interstitial collagenase
100-269	170	22 kDa Interstitial collagenase
270-469	200	27 kDa Interstitial collagenase

[0082] As used herein, the term “Neural cell adhesion molecule 1” refers to one or more polypeptides present in a biological sample that are derived from the Neural cell adhesion molecule 1 precursor (Swiss-Prot P13591 (SEQ ID NO: 14):

```

      10      20      30      40      50      60
MLQTKDLIWT LFFLGTAIVSL QVDIVPSQGE ISVGESKFFL CQVAGDAKDK DISWFSPNGE

      70      80      90     100     110     120
KLTPNQQRIS VVWNDSSST LTIYNANIDD AGIYKCVVTG EDGSESEATV NVKIFQKLMF

     130     140     150     160     170     180
KNAPTPQEFR EGEDAVIVCD VVSSLPPTII WKHKGRDVIL KKDVRFIVLS NNYLQIRGIK

     190     200     210     220     230     240
KTDEGTYRCE GRILARGEIN FKDIQVIVNV PPTIQARQNI VNATANLGQS VTLVCDAEFG

     250     260     270     280     290     300
PEPTMSWTKD GEQIEQEEDD EKYIFSDDSS QLTIKKVDKN DEAEYICIAE NKAGEQDATI

     310     320     330     340     350     360
HLKVFAPKPKI TYVENQTAME LEEQVTLTCE ASGDPIPSIT WRTSTRNISS EEKASWTRPE

     370     380     390     400     410     420
KQETLDGHMV VRSHARVSSL TLKSIQYTDA GEYICTASNT IGQDSQSMYL EVQYAPKLQG

     430     440     450     460     470     480
PVAVYTWEQN QVNITCEVFA YPSATISWFR DGQLLPSSNY SNIKIYNTPS ASYLEVTPDS

     490     500     510     520     530     540
ENDFGNYNCT AVNRIGQESL EFILVQADTP SSPSIDQVEP YSSTAQVQFD EPEATGGVPI

     550     560     570     580     590     600
LKYKAEWRVAV GEEVWHSKWY DAKEASMEGI VTIVGLKPET TYAVRLAALN GKGLGEISAA

     610     620     630     640     650     660
SEFKTQPVQGG EPSAPKLEGG MGEDGNSIKV NLIQDDGGS PIRHYLVRYR ALSSEWKPEI

     670     680     690     700     710     720
RLPSGSDHVM LKSLDWNAEY EVYVVAENQQ GKSKAAHFVF RTSAQPTAIP ANGSPTSGLS

     730     740     750     760     770     780
TGAIVGILIV IFVLLLVVD ITCYFLNKCGL LFMCIAVNLC GKAGPGAKGK DMEEGKAAPS

     790     800     810     820     830     840
KDESKPEIVE VRTEEERTPN HDGGKHTEPN ETTPLTEPEK GPVEAKPECQ ETETKPAPAE

     850
VKTPPN DATQ TKENESKA

```

[0083] Neural cell adhesion molecule 1 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Neural cell adhesion molecule 1 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Neural cell adhesion molecule 1:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-858	839	Neural cell adhesion molecule 1
20-718	699	Extracellular domain
719-739	21	Transmembrane domain
740-858	119	Cytoplasmic domain
354-363		Missing in isoform 2

-continued

Residues	Length	Domain ID
354-363		Missing in isoform 3
609		Q → HSPPPPASASSSTPVPLSPPD TTWPLP ALATTEPAK (SEQ ID NO: 15) in isoform 3

-continued		
Residues	Length	Domain ID
712-736		NGSPTSGSLSTGAIVGILIVIFVLLL (SEQ ID NO: 16) → TLGGNSASYTFVSLLFSAVTLLLLC (SEQ ID NO: 17) in isoform 3
737-858		Missing in isoform 3
354-363		Missing in isoform 4
712-736		NGSPTSGSLSTGAIVGILIVIFVLLL (SEQ ID NO: 18) → TLGGNSASYTFVSLLFSAVTLLLLC ((SEQ ID NO: 19) in isoform 4
737-858		Missing in isoform 4

-continued		
Residues	Length	Domain ID
609-665		QGEPSAPKLE . . . WKPEIRLPSG (SEQ ID NO: 20) → HSPPPPASASSSTPVPLSPDPTTWPLPALATTEPA KNIAQ NHCCNMFQAGLHNALMK (SEQ ID NO: 21) in isoform 5
364		T → V in isoform 6
365-858		Missing in isoform 6

[0084] As used herein, the term “Pigment epithelium-derived factor” refers to one or more polypeptides present in a biological sample that are derived from the Pigment epithelium-derived factor precursor (Swiss-Prot P36955 (SEQ ID NO: 22)).

10	20	30	40	50	60
MQALVLLLCI	GALLGHSSCQ	NPASPPEEGS	PDPDSTGALV	EEEDPFFKVP	VNKLAAAVSN
70	80	90	100	110	120
FGYDLYRVRS	SMSPTTNVLL	SPLSVATALS	ALSLGAEQRT	ESIIHRALYY	DLISSPDIHG
130	140	150	160	170	180
TYKELLDTVT	APQKNLKSAS	RIVFEKKLRI	KSSFVAPLEK	SYGTRPRVLT	GNPRLDLQEI
190	200	210	220	230	240
NNWVQAQMKG	KLARSTKEIP	DEISILLGV	AHFKGQWVTK	FDSRKTSLED	FYLDEERTVR
250	260	270	280	290	300
VPMSDPKAV	LRYGLSDSL	CKIAQLPLTG	SMSIIFFLPL	KVTQNLTLIE	ESLTSEFIHD
310	320	330	340	350	360
IDRELKTVQA	VLTVPKLKLS	YEGEVTKSLQ	EMKLQSLFDS	PDFSKITGKP	IKLTQVEHRA
370	380	390	400	410	
GFEWNEDGAG	TTPSPGLQPA	HLTFPLDYHL	NQPFIFVLRD	TDTGALLFIG	KILDPRGP

[0085] The following domains have been identified in Pigment epithelium-derived factor:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-418	399	Pigment epithelium-derived factor

[0086] As used herein, the term “Platelet-derived growth factor subunit A” refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived growth factor subunit A precursor (Swiss-Prot P04085 (SEQ ID NO: 23)).

10	20	30	40	50	60
MRTLACLALL	GCGYLAHVLA	EEAEIPREVI	ERLARSQIHS	IRDLQRLLEI	DSVGSEDSLD
70	80	90	100	110	120
TSLRAHGVHA	TKHVPEKRPL	PIRRKRSIEE	AVPAVCKTRT	VIYEIPRSQV	DPTSANFLIW
130	140	150	160	170	180
PPCVEVKRCT	GCCNTSSVKC	QPSRVHHRSV	KVAKVEYVRK	KPKLKEVQVR	LEEHLACACA
190	200	210			
TTSLNPDYRE	EDTGRPRESG	KKRKRRLKP	T		

[0087] The following domains have been identified in Platelet-derived growth factor subunit A:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-86	66	Propeptide
87-211	125	Platelet-derived growth factor subunit A

[0088] As used herein, the term “Vascular endothelial growth factor receptor 2” refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 2 precursor (Swiss-Prot P35968 (SEQ ID NO: 24):

```

      10      20      30      40      50      60
MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTLQ ITCRGQRDL
      70      80      90     100     110     120
WLWPNQSGS  EQRVEVECS  DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
     130     140     150     160     170     180
YRSPFIASVS DQHGVDVITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
     190     200     210     220     230     240
SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLS SHGIELSVGE
     250     260     270     280     290     300
KLVNCTART  ELNVGIDFNW  EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
     310     320     330     340     350     360
DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYP
     370     380     390     400     410     420
EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVS
     430     440     450     460     470     480
PQIGEKSLIS PVDSYQYGT  TLTCTVYAI PPPHHIHWY QLEEECANEP SQAVSV
     490     500     510     520     530     540
PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
     550     560     570     580     590     600
RVISFHVTRG PEITLQPDQM PTEQESVSLW CTADRSTFEN LTWYKLGFPQ LPIHVGELPT
     610     620     630     640     650     660
PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHC
     670     680     690     700     710     720
VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPQIMW F
     730     740     750     760     770     780
NLTI
     790     800     810     820     830     840
LLV
     850     860     870     880     890     900
GRGAF
     910     920     930     940     950     960
LLGACTKPGG PLMVIVEFCK FGNLSTYLSR KRNEFVPYKT KGARFRQ
     970     980     990    1000    1010    1020
RRLD
    1030    1040    1050    1060    1070    1080
SRKCIH
    1090    1100    1110    1120    1130    1140
VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TPEMYQTML

```

-continued

1150	1160	1170	1180	1190	1200
DCWHGEPSQR	PTFSELVEHL	GNLLQANAQQ	DGKDYIVLPI	SETLSMEEDS	GLSLPTSPVS
1210	1220	1230	1240	1250	1260
CMEEEEVCDP	KFHYDNTAGI	SQYLQNSKRK	SRPVSVKTFE	DIPLEEEVK	VIPDDNQTDS
1270	1280	1290	1300	1310	1320
GMVLASEELK	TLEDRTKLSP	SFGGMVPSKS	RESVASEGSN	QTSGYQSGYH	SDDTDTTVYS
1330	1340	1350			
SEEAELLKLI	EIGVQTGSTA	QILQPDSGTT	LSSPPV		

[0089] Vascular endothelial growth factor receptor 2 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 2 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 2:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-1356	1337	Vascular endothelial growth factor receptor 2

-continued

Residues	Length	Domain ID
20-764	745	Extracellular domain
765-789	25	Transmembrane domain
790-1356	567	Cytoplasmic domain

[0090] As used herein, the term “Vascular endothelial growth factor receptor 3” refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 3 precursor (Swiss-Prot P35916 (SEQ ID NO: 25):

10	20	30	40	50	60
MQRGAALCLR	LWLCGLLDG	LVSGYSMTTP	TLNITEESHV	IDTGDLSLSIS	CRGQHPLEWA
70	80	90	100	110	120
WPGAQEAPAT	GDKDSEDTGV	VRDCEGTDAR	PYCKVLLLHE	VHANDTGSYV	CYYKYIKARI
130	140	150	160	170	180
EGTTAASSYV	FVRDFEQPFI	NKPDTLNVNR	KDAMWVPCLV	SIPGLNVTLR	SQSSVLWPDG
190	200	210	220	230	240
QEVVWDDRRG	MLVSTPLLHD	ALYLQCETTW	GDQDFLSNPF	LVHITGNELY	DIQLLPKLSL
250	260	270	280	290	300
ELLVGEKLV	NCTVWAEFNS	GVTFDWDYPG	KQAERGKWVP	ERRSQQTHTE	LSSILTIHNV
310	320	330	340	350	360
SQHDLGSYVC	KANNGIQRFR	ESTEVIVHEN	PFISVEWLKG	PILEATAGDE	LVKLVPKLAA
370	380	390	400	410	420
YPPPEFQWYK	DGKALSGRHS	PHALVLKEVT	EASTGTYTLA	LWNSAAGLRR	NISLELVNV
430	440	450	460	470	480
PPQIHEKEAS	SPSIYSRHSR	QALTCTAYGV	PLPLSIQNHV	RPWTPCKMFA	QRSLLRRQQQ
490	500	510	520	530	540
DLMPQCRDWR	AVTTQDAVNP	IESLDTWTEF	VEGKNKTVSK	LVIQANVSA	MYKCVVSNKV
550	560	570	580	590	600
GQDERLIIFY	VTITPDGFTI	ESKPSEELLE	GQPVLLSCQA	DSYKYEHLRW	YRLNLSTLHD
610	620	630	640	650	660
AHGNPLLLDC	KNVHLFATPL	AASLEEAVPG	ARHATLSLSI	PRVAPEHEGH	YVCEVQDRRS
670	680	690	700	710	720
HDKHCHKKYL	SVQALEAPRL	TQNLTDLLVN	VSDSLEMQCL	VAGAHAPSIV	WYKDERLLEE
730	740	750	760	770	780
KSGVDLADSN	QKLSIQRVRE	EDAGRYLCSV	CNAKGCVNSS	ASVAVEGSED	KGSMEIVILV
790	800	810	820	830	840
GTGVIAVFFW	VLLLLIFCNM	RRPAHADIKT	GYLSIIMDPG	EVPLEEQCEY	LSYDASQWEF

-continued

850	860	870	880	890	900
PRERLHLGRV	LGYGAFGKVV	EASAFGIHKG	SSCDTVAVKM	LKEGATASEH	RALMSELKIL
910	920	930	940	950	960
IHIGNHLNVV	NLLGACTKPQ	GPLMVIVEFC	KYGNLSNFLR	AKRDAFSPCA	EKSPEQRGRF
970	980	990	1000	1010	1020
RAMVELARLD	RRRPGSSDRV	LFARFSKTEG	GARRASPDQE	AEDLWLSPLT	MEDLVCYSFQ
1030	1040	1050	1060	1070	1080
VARGMEFLAS	RKCIHRDLAA	RNILLSESDV	VKICDFGLAR	DIYKDPDYVR	KGSARLPLKW
1090	1100	1110	1120	1130	1140
MAPESIFDKV	YTTQSDVWSF	GVLLEWEIFSL	GASPYPGVQI	NEEFCQRLRD	GTRMRAPELA
1150	1160	1170	1180	1190	1200
TPAIRRIMLN	CWSGDPKARP	AFSELVEILG	DLQGRGLQE	EEEVCMAPRS	SQSSEEGSFS
1210	1220	1230	1240	1250	1260
QVSTMALHIA	QADAEDSPPS	LQRHSLAARY	YNWVSFPGCL	ARGAETRGSS	RMKTFEEFPM
1270	1280	1290			
TPTTYKGSVD	NQTDSGMVL	SEEFQIESR	HRQESGFR		

[0091] Vascular endothelial growth factor receptor 3 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 3 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 3:

Residues	Length	Domain ID
1-24	24	Signal peptide
25-1298	1274	Vascular endothelial growth factor receptor 3

-continued

Residues	Length	Domain ID
25-775	751	Extracellular domain
776-797	25	Transmembrane domain
798-1298	501	Cytoplasmic domain

[0092] As used herein, the term “Tumor necrosis factor receptor superfamily member 8” refers to one or more polypeptides present in a biological sample that are derived from the Tumor necrosis factor receptor superfamily member 8 precursor (Swiss-Prot P28908 (SEQ ID NO: 26)):

10	20	30	40	50	60
MRVLLAALGL	LFLGALRAFP	QDRPFEDTCH	GNPSHYDDKA	VRRCCYRCPM	GLFPTQQCPQ
70	80	90	100	110	120
RPTDCRKQCE	PDYYLDEADR	CTACVTCSR	DLVEKTPCAW	NSSRVCECRP	GMFCSTSAVN
130	140	150	160	170	180
SCARCFHHSV	CPAGMIVKFP	GTAQKNTVCE	PASPGVSPAC	ASPENCKEPS	SGTIPQAKPT
190	200	210	220	230	240
PVSPATSSAS	TMPVRGGTRL	AQEAASKLTR	APDSPSSVGR	PSSDPGLSPT	QPCPEGS GDC
250	260	270	280	290	300
RKQCEPDYLL	DEAGRCTACV	SCSRDDLVEK	TPCAWNSSRT	CECRPGMICA	TSATNSCARC
310	320	330	340	350	360
VPYPICAAET	VTKPQDMAEK	DTTFEAPPLG	TQPCNPTPE	NGEAPASTSP	TQSLLVDSQA
370	380	390	400	410	420
SKTLPIPTSA	PVALSSTGKP	VLDAGPVLEW	VILVLVVVVG	SSAFLCHRR	ACRKIRQKL
430	440	450	460	470	480
HLCYPVQTSQ	PKLELVDSRP	RRSSTQLRSG	ASVTEPVAEE	RGLMSQLPME	TCHSVGAAYL
490	500	510	520	530	540
ESLPLQDASP	AGGPSSPRDL	PEPRVSTEHT	NNKIEKIYIM	KADTVIVGTV	KAELEPGRGL

-continued

550 560 570 580 590
AGPAEPELEE ELEADHTPHY PEQETEPPLG SCSDVMLSVE EEGKEDPLPT AASGK

[0093] Tumor necrosis factor receptor superfamily member 8 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Tumor necrosis factor receptor superfamily member 8 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Tumor necrosis factor receptor superfamily member 8:

Residues	Length	Domain ID
1-18	18	Signal peptide
19-595	577	Tumor necrosis factor receptor superfamily member 8

-continued

Residues	Length	Domain ID
19-379	361	Extracellular domain
380-407	28	Transmembrane domain
1-463	463	Missing in short isoform

[0094] As used herein, the term “Alpha-fetoprotein” refers to one or more polypeptides present in a biological sample that are derived from the Alpha-fetoprotein precursor (Swiss-Prot P02771 (SEQ ID NO: 27)):

10 20 30 40 50 60
MKWVESIFLI FLLNFTESRT LHRNEYGIAS ILDSYQCTAE ISLADLATIF FAQFVQEATY

70 80 90 100 110 120
KEVSKMKVDA LTAIEKPTGD EQSSGCLENQ LPAPLEELCH EKEILEKYGH SDCCSQSEEG

130 140 150 160 170 180
RHNCFLAHKK PTPASIPLEQ VPEPVTSCFA YEEDRETFFM KFIYEIARRH PPLYAPTILL

190 200 210 220 230 240
WAARYDKIIP SCCKAENAVE CFQTKAATVT KELRESSLLN QHACAVMKNF GTRTFQAITY

250 260 270 280 290 300
TKLSQKFTKV NFTEIQKLV L DVAHVHEHCC RGDVLDCLQD GEKIMSYICS QQDTLSNKIT

310 320 330 340 350 360
ECCKLTTLER GQCIIHAEND EKPEGLSPNL NRFLGDRDFN QFSSGGEKNIF LASFVHEYSR

370 380 390 400 410 420
RHPQLAVSVI LRVAKGYQEL LEKCFQTENP LECQDKGEEE LQKYIQESQA LAKRSCGLFQ

430 440 450 460 470 480
KLGEYYLQNA FLVAYTKKAP QLTSSSELMAL TRKMAATAAT CCQLSEDKLL ACGEGAADII

490 500 510 520 530 540
IGHLCIRHEM TPVNPVGVC CTSSYANRRP CFSSLVVDCT YVPPAFSDDK FIFHKDLCA

550 560 570 580 590 600
QGVALQTMKQ EFLINLVKQK PQITEEQLEA VIADFSGLE KCCQGQEQEV CFAEEGQKLI

SKTRAALGV

[0095] The following domains have been identified in Alpha-fetoprotein:

Residues	Length	Domain ID
1-18	18	Signal peptide
19-609	591	Alpha-fetoprotein

[0096] As used herein, the term “Thyroxine-binding globulin” refers to one or more polypeptides present in a biological sample that are derived from the Thyroxine-binding globulin precursor (Swiss-Prot P05543 (SEQ ID NO: 28)).

```

      10      20      30      40      50      60
MSPFLYLVL  VLGLHATIH  ASPEGKVTAC HSSQPNATLY KMSSINADFA FNLVRRFTVE

      70      80      90     100     110     120
TPDKNIFFSP VSISAALVML SFGACCSTQT EIVETLGFNL TDTPMVEIQH GFQHLICSLN

     130     140     150     160     170     180
FPKKELELQI GNALFIGKHL KPLAKFLNDV KTLYETEVFS TDFSNISAAK QEINSHVEMQ

     190     200     210     220     230     240
TKGKVVGLIQ DLKPNTIMVL VNYIHFKAQW ANPFDPSKTE DSSSFLIDKT TTVQVPMMHQ

     250     260     270     280     290     300
MEQYYHLVDM ELNCTVLQMD YSKNALALFV LPKEGQMESV EAAMSSKTLK KWNRLQKQGW

     310     320     330     340     350     360
VDLFVPKFISI SATYDLGATL LKMGIQHAYS ENADFSGLTE DNGLKLSNAA HKAVLHIGEK

     370     380     390     400     410
GTEAAAVPEV ELSDQPENTF LHPIIQIDRS FMLLILERST RSILFLGKVV NPTEA

```

[0097] The following domains have been identified in Thyroxine-binding globulin:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-415	395	Thyroxine-binding globulin

[0098] As used herein, the term “Prostate-specific antigen” refers to one or more polypeptides present in a biological sample that are derived from the Prostate-specific antigen precursor (Swiss-Prot P07288 (SEQ ID NO: 29)).

```

      10      20      30      40      50      60
MWVPVVFLTL SVTWIGAAPL ILSRIVGGWE CEKHSQPWQV LVASRGRAVC GGVLVHPQWV

      70      80      90     100     110     120
LTAAHCIRNK SVILLGRHSL FHPEDTGQVF QVSHSFPHPL YDMSLLKNRF LRPGDDSSHD

     130     140     150     160     170     180
LMLLRLSEPA ELTDAVKVMD LPTQEPALGT TCYASGWGSI EPEEFLTPKK LQCVDLHVIS

     190     200     210     220     230     240
NDVCAQVHPQ KVKFMCLCAG RWTGGKSTCS GDSGGPLVCN GVLQGITSWG SEPCALPERP

     250     260
SEYTKVVHYR KWIKDTIVAN P

```

[0099] The following domains have been identified in Prostate-specific antigen:

Residues	Length	Domain ID
1-17	17	Signal peptide
18-24	7	Activation peptide
25-261	237	Prostate-specific antigen

[0100] As used herein, the terms “Apolipoprotein(a)” and “Apolipoprotein A” refer to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein(a) precursor (Swiss-Prot P08519 (SEQ ID NO: 30)).

```

      10      20      30      40      50      60
MEHKEVLLLL LLFLKSAAPE QSHVVQDCYH GDGQSYRGTY STTVTGRTCQ AWSSMTPHQH

      70      80      90     100     110     120
NRTTENYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP

      130     140     150     160     170     180
VPSLEAPSEQ APTEQRPQVQ ECYHNGGQSY RGTYSTTVTG RTCQAWSSMT PSHSRTPEY

      190     200     210     220     230     240
YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA

      250     260     270     280     290     300
PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMPHSHSR TPEYYPNAGL

      310     320     330     340     350     360
IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP

      370     380     390     400     410     420
TEQRPQVQEC YHNGGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR

      430     440     450     460     470     480
NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPQ

      490     500     510     520     530     540
VQECYHNGGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA

      550     560     570     580     590     600
APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPQVQECYH

      610     620     630     640     650     660
GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT

      670     680     690     700     710     720
RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPQVQ ECYHNGGQSY

      730     740     750     760     770     780
RGTYSTTVTG RTCQAWSSMT PSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR

      790     800     810     820     830     840
WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST

      850     860     870     880     890     900
TVTGRTCQAW SSMPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL

      910     920     930     940     950     960
TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPQVQEC YHNGGQSYRG TYSTTVTGRT

      970     980     990    1000    1010    1020
CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA

      1030    1040    1050    1060    1070    1080
EGTAVAPPTV TPVPSLEAPS EQAPTEQRPQ VQECYHNGGQ SYRGTYSTTV TGRTCQAWSS

      1090    1100    1110    1120    1130    1140
MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA

      1150    1160    1170    1180    1190    1200
PPTVTPVPSL EAPSEQAPTE QRPQVQECYH GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH

```

-continued

1210	1220	1230	1240	1250	1260
SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT	RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP
1270	1280	1290	1300	1310	1320
VPSLEAPSEQ	APTEQRPVQ	ECYHNGQSY	RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY
1330	1340	1350	1360	1370	1380
YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR	WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA
1390	1400	1410	1420	1430	1440
PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST	TVTGRTCQAW	SSMTPHSHSR	TPEYYPNAGL
1450	1460	1470	1480	1490	1500
IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL	TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP
1510	1520	1530	1540	1550	1560
TEQRPVGVQEC	YHNGQSYRG	TYSTTVTGRT	CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR
1570	1580	1590	1600	1610	1620
NPDAVAAPYC	YTRDPGVRWE	YCNLTQCSDA	EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRP
1630	1640	1650	1660	1670	1680
VQECYHNGQ	SYRGTYSTTV	TGRTCQAWSS	MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA
1690	1700	1710	1720	1730	1740
APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA	PPTVTPVPSL	EAPSEQAPTE	QRPVGVQECYH
1750	1760	1770	1780	1790	1800
GNGQSYRGTY	STTVTGRTCQ	AWSSMTPHSH	SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT
1810	1820	1830	1840	1850	1860
RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP	VPSLEAPSEQ	APTEQRPVQ	ECYHNGQSY
1870	1880	1890	1900	1910	1920
RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY	YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR
1930	1940	1950	1960	1970	1980
WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA	PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST
1990	2000	2010	2020	2030	2040
TVTGRTCQAW	SSMTPHSHSR	TPEYYPNAGL	IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL
2050	2060	2070	2080	2090	2100
TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP	TEQRPVGVQEC	YHNGQSYRG	TYSTTVTGRT
2110	2120	2130	2140	2150	2160
CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR	NPDAVAAPYC	YTRDPGVRWE	YCNLTQCSDA
2170	2180	2190	2200	2210	2220
EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRP	VQECYHNGQ	SYRGTYSTTV	TGRTCQAWSS
2230	2240	2250	2260	2270	2280
MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA	APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA
2290	2300	2310	2320	2330	2340
PPTVTPVPSL	EAPSEQAPTE	QRPVGVQECYH	GNGQSYRGTY	STTVTGRTCQ	AWSSMTPHSH
2350	2360	2370	2380	2390	2400
SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT	RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP
2410	2420	2430	2440	2450	2460
VPSLEAPSEQ	APTEQRPVQ	ECYHNGQSY	RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY
2470	2480	2490	2500	2510	2520
YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR	WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA
2530	2540	2550	2560	2570	2580
PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST	TVTGRTCQAW	SSMTPHSHSR	TPEYYPNAGL
2590	2600	2610	2620	2630	2640
IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL	TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP
2650	2660	2670	2680	2690	2700
TEQRPVGVQEC	YHNGQSYRG	TYSTTVTGRT	CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR
2710	2720	2730	2740	2750	2760
NPDAVAAPYC	YTRDPGVRWE	YCNLTQCSDA	EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRP

-continued

2770	2780	2790	2800	2810	2820
VQECYHNGGQ	SYRGTYSTTV	TGRTCQAWSS	MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA
2830	2840	2850	2860	2870	2880
APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA	PPTVTPVPSL	EAPSEQAPTE	QRPGVQECYH
2890	2900	2910	2920	2930	2940
GNGQSYRGTY	STTVTGRTCQ	AWSSMTPHSH	SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT
2950	2960	2970	2980	2990	3000
RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP	VPSLEAPSEQ	APTEQRPQVQ	ECYHNGQSY
3010	3020	3030	3040	3050	3060
RGTYSTTVTG	RTCQAWSSMT	PHSHSRTP	YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR
3070	3080	3090	3100	3110	3120
WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA	PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST
3130	3140	3150	3160	3170	3180
TVTGRTCQAW	SSMTPHSHSR	TPEYYPNAGL	IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL
3190	3200	3210	3220	3230	3240
TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP	TEQRPQVQEC	YHNGQSYRG	TYSTTVTGRT
3250	3260	3270	3280	3290	3300
CQAWSSMTPH	SHSRTP	NAGLIMNYCR	NPDAVAAPYC	YTRDPGVRWE	YCNLTQCSDA
3310	3320	3330	3340	3350	3360
EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRP	VQECYHNGGQ	SYRGTYSTTV	TGRTCQAWSS
3370	3380	3390	3400	3410	3420
MTPHSHSRTP	EYYPNAGLIM	NYCRNPDPVA	APYCYTRDPS	VRWEYCNLTQ	CSDAEGTAVA
3430	3440	3450	3460	3470	3480
PPTITPIPSL	EAPSEQAPTE	QRPGVQECYH	GNGQSYQGT	FITVTGRTCQ	AWSSMTPHSH
3490	3500	3510	3520	3530	3540
SRTPAYYPNA	GLIKNYCRNP	DPVAAPWCYT	TDPSVRWEYC	NLRCSDAEW	TAFVPPNVIL
3550	3560	3570	3580	3590	3600
APSLEAFFEQ	ALTEETPGVQ	DCYHYGQSY	RGTYSTTVTG	RTCQAWSSMT	PHQHSRTPEN
3610	3620	3630	3640	3650	3660
YPNAGLTRNY	CRNPDAEIRP	WCYTMDPSVR	WEYCNLTQCL	VTESSVLATL	TVVPDPSTEA
3670	3680	3690	3700	3710	3720
SSEAPTEQS	PGVQDCYHGD	GQSYRGFSFST	TVTGRTCQSW	SSMTPHWHQR	TTEYYPNGGL
3730	3740	3750	3760	3770	3780
TRNYCRNPDA	EISPCWYCTMD	PNVRWEYCNL	TQCPVTESSV	LATSTAVSEQ	APTEQSPTVQ
3790	3800	3810	3820	3830	3840
DCYHGDGQSY	RGSFSTTVTG	RTCQSWSSMT	PHWHQRTTEY	YPNGGLTRNY	CRNPDAEIRP
3850	3860	3870	3880	3890	3900
WCYTMDPSVR	WEYCNLTQCP	VMESTLLTTP	TVVPVPSTEL	PSEAPTEENS	TGVQDCYRGD
3910	3920	3930	3940	3950	3960
GQSYRGTLST	TITGRTCQSW	SSMTPHWHRR	IPLYYPNAGL	TRNYCRNPDA	EIRPWCYTMD
3970	3980	3990	4000	4010	4020
PSVRWEYCNL	TRCPVTESSV	LTTPTVAPVP	STEAPSEQAP	PEKSPVQDC	YHGDGRSYRG
4030	4040	4050	4060	4070	4080
ISSTTVTGRT	CQSWSSMIPH	WHQRTPENYP	NAGLTENYCR	NPDSGKQPCW	YTTDPCVRWE
4090	4100	4110	4120	4130	4140
YCNLTQCSET	ESGVLETPTV	VPVPSMEAHS	EAAPTEQTPV	VRQCYHNGGQ	SYRGTFSTTV
4150	4160	4170	4180	4190	4200
TGRTCQSWSS	MTPHRHQRT	ENYPNDGLTM	NYCRNPDA	GPWCFTMDPS	IRWEYCNLTR
4210	4220	4230	4240	4250	4260
CSDTEGTVA	PPTVIQVPSL	GPPSEQDCMF	GNGKGYRGKK	ATTVTGTQPCQ	EWAAQEPHRH
4270	4280	4290	4300	4310	4320
STFIPGTNKW	AGLEKNYCRN	PDGDINGPWC	YTMNPRKLF	YCDIPLCASS	SFDCGKQVE

-continued

```

      4330      4340      4350      4360      4370      4380
PKKCPGSIVG GCVAHPHSWP WQVSLRTRFG KHFCGGTLIS PEWVLTAHC LKKSSRPSSY

      4390      4400      4410      4420      4430      4440
KVILGAHQEV NLESHVQEIE VSRLFLEPTQ ADIALLLKLSR PAVITDKVMP ACLPSPDYMV

      4450      4460      4470      4480      4490      4500
TARTECYITG WGETQGTFTG GLLKEAQLLV IENEVCNHYK YICAEHLARG TDSCQGDSSG

      4510      4520      4530      4540
PLVCFEKDKY ILQGVTSWGL GCARPKNKPGV YARVSRFVTW IEGMMRNN

```

[0101] The following domains have been identified in Apo-lipoprotein(a):

Residues	Length	Domain ID
1-19	19	Signal peptide
20-4548	4529	Apolipoprotein(a)

[0102] As used herein, the term “Apolipoprotein E” refers to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein E precursor (Swiss-Prot P02649 (SEQ ID NO: 31)).

```

      10      20      30      40      50      60
MKVLWALLV TFLAGCQAKV EQAVETEPEP ELRQQTEWQS GQRWELALGR FWDYLRWVQT

      70      80      90     100     110     120
LSEQVQEELL SSQVTQELRA LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA

      130     140     150     160     170     180
RLGADMEDVC GRLVQYRGEV QAMLGQSTEE LRVRLASHLR KLRKRLLRDA DDLQKRLAVY

      190     200     210     220     230     240
QAGAREGAER GLSAIRERLG PLVEQGRVRA ATVGSLAGQP LQERAQAWGE RLRARMEEMG

      250     260     270     280     290     300
SRTDRDLDEV KEQVAEVRK LEEQAQQIRL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK

      310
VQAAVGTSA PVPDNDH

```

[0103] The following domains have been identified in Apo-lipoprotein E:

Residues	Length	Domain ID
1-18	18	Signal peptide
19-317	299	Apolipoprotein E

[0104] As used herein, the term “Thyrotropin subunit beta” refers to one or more polypeptides present in a biological sample that are derived from the Thyrotropin subunit betaprecursor (Swiss-Prot P01222 (SEQ ID NO: 32)).

```

      10      20      30      40      50      60
MTALFLMSML FGLACQAMS FCIPTeyTMH IERREcAYCL TINTTICAGY CMTRDINGKL

      70      80      90     100     110     120
FLPKYALSQD VCTYRDFIYR TVEIPGCPLH VAPYFSYPVA LSCKCGKCNT DYSDCIHEAI

      130
KTNyCTKPQK SYLVGFSV

```

[0105] The following domains have been identified in Thyrotropin subunit beta:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-132	112	Thyrotropin subunit beta
133-138	6	Propeptide

[0106] As used herein, the term “Platelet-derived Growth Factor B/B dimer” refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived Growth Factor V precursor and that form a homodimer (Swiss-Prot P01127 (SEQ ID NO: 33)).

10	20	30	40	50	60
MNRCWALFLS	LCCYLRLVSA	EGDPIPEELY	EMLSDHSIRS	FDDLQRLHLG	DPGEEDGAEL
70	80	90	100	110	120
DLNMTRSHSG	GELESLARGR	RLGSLTIAE	PAMIAECKTR	TEVFEISRRL	IDRTNANFLV
130	140	150	160	170	180
WPPCVEVQRC	SGCCNNRNVQ	CRPTQVQLRP	VQVRKIEIVR	KKPIFKKATV	TLEDHLACKC
190	200	210	220	230	240
ETVAAARPVT	RSPGGSQEQR	AKTPQTRVTI	RTVRVRRPPK	GKHKRFKHTH	DKTALKETLG

A

[0107] The following domains have been identified in Platelet-derived Growth Factor B:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-81	61	Propeptide
82-190	109	Platelet-derived Growth Factor B
191-241	51	Propeptide

[0108] As used herein, the term “IgG4” refers to subclass 4 of the glycoprotein immunoglobulin G (IgG), a major effector molecule of the humoral immune response in man. Antibodies of the IgG class express their predominant activity during a secondary antibody response. The basic immunoglobulin G molecule has a four-chain structure, comprising two identical heavy (H) chains and two identical light (L) chains, linked together by inter-chain disulfide bonds. Each heavy chain is encoded by 4 distinct types of gene segments, designated V_H (variable), D (diversity), J_H (joining) and C_H (constant). The variable region of the heavy chain is encoded by the V_H , D and J_H segments. The light chains are encoded by the 3 gene segments, V_L , J_L and C_L . The variable region of the light chains is encoded by the V_L and J_L segments.

[0109] The length and flexibility of the hinge region varies among the IgG subclasses. The hinge region of IgG1 encompasses amino acids 216-231 and since it is freely flexible, the Fab fragments can rotate about their axes of symmetry and move within a sphere centered at the first of two inter-heavy chain disulfide bridges (23). IgG2 has a shorter hinge than IgG 1, with 12 amino acid residues and four disulfide bridges. The hinge region of IgG2 lacks a glycine residue, it is relatively short and contains a rigid poly-proline double helix, stabilised by extra inter-heavy chain disulfide bridges. These

properties restrict the flexibility of the IgG2 molecule (24). IgG3 differs from the other subclasses by its unique extended hinge region (about four times as long as the IgG1 hinge), containing 62 amino acids (including 21 prolines and 11 cysteines), forming an inflexible poly-proline double helix (25,26). In IgG3 the Fab fragments are relatively far away from the Fc fragment, giving the molecule a greater flexibility. The elongated hinge in IgG3 is also responsible for its higher molecular weight compared to the other subclasses. The hinge region of IgG4 is shorter than that of IgG 1 and its flexibility is intermediate between that of IgG1 and IgG2.

[0110] The four IgG subclasses also differ with respect to the number of inter-heavy chain disulfide bonds in the hinge region (26). The structural differences between the IgG subclasses are also reflected in their susceptibility to proteolytic

enzymes. IgG3 is very susceptible to cleavage by these enzymes, whereas IgG2 is relatively resistant. IgG1 and IgG4 exhibit an intermediary sensitivity, depending upon the enzyme used. Since these proteolytic enzymes all cleave IgG molecules near or within the hinge region, it is likely that the high sensitivity of IgG3 to enzyme digestion is related to its accessible hinge. Another structural difference between the human IgG subclasses is the linkage of the heavy and light chain by a disulfide bond. This bond links the carboxy-terminal of the light chain with the cysteine residue at position 220 (in IgG) or at position 131 (in IgG2, IgG3 and IgG4) of the CH1 sequence of the heavy chain.

[0111] As a consequence of the structural differences, the four IgG subclasses may be distinguished from one another, for example using antibodies that are specific for differences between the isoforms. In the present application, a level of IgG1 is determined using an assay which distinguishes this subclass, relative to the other subclasses.

[0112] As used herein, the term “relating a signal to the presence or amount” of an analyte reflects the following understanding. Assay signals are typically related to the presence or amount of an analyte through the use of a standard curve calculated using known concentrations of the analyte of interest. As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. Because an antibody epitope is on the order of 8 amino acids, an immunoassay configured to detect a marker of interest will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay. The term “related marker” as used herein with regard to a biomarker such as one of the kidney injury markers described herein refers to one or more fragments, variants, etc., of a particular marker or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also

refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.

[0113] In this regard, the skilled artisan will understand that the signals obtained from an immunoassay are a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., the analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (such as dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.

[0114] The term “positive going” marker as that term is used herein refer to a marker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition. The term “negative going” marker as that term is used herein refer to a marker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

[0115] The term “subject” as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are applicable to both human and veterinary disease. Further, while a subject is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects are humans, and most preferably “patients,” which as used herein refers to living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology.

[0116] Preferably, an analyte is measured in a sample. Such a sample may be obtained from a subject, or may be obtained from biological materials intended to be provided to the subject. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, and an analyte measurement used to evaluate the kidney for preexisting damage. Preferred samples are body fluid samples.

[0117] The term “body fluid sample” as used herein refers to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition. Preferred body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions. In addition, one of skill in the art would realize that certain body fluid samples would be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.

[0118] The term “diagnosis” as used herein refers to methods by which the skilled artisan can estimate and/or determine the probability (“a likelihood”) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes using the results of an assay, most preferably an immunoassay, for a

kidney injury marker of the present invention, optionally together with other clinical characteristics, to arrive at a diagnosis (that is, the occurrence or nonoccurrence) of an acute renal injury or ARF for the subject from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Many biomarkers are indicative of multiple conditions. The skilled clinician does not use biomarker results in an informational vacuum, but rather test results are used together with other clinical indicia to arrive at a diagnosis. Thus, a measured biomarker level on one side of a predetermined diagnostic threshold indicates a greater likelihood of the occurrence of disease in the subject relative to a measured level on the other side of the predetermined diagnostic threshold.

[0119] Similarly, a prognostic risk signals a probability (“a likelihood”) that a given course or outcome will occur. A level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.

[0120] Marker Assays

[0121] In general, immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and *The Immunoassay Handbook*, David Wild, ed. Stockton Press, New York, 1994, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims.

[0122] The assay devices and methods known in the art can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. One skilled in the art also recognizes that robotic instrumentation including but not limited to Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems are among the immunoassay analyzers that are capable of performing immunoassays. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.

[0123] Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in assays. Solid phases that may be used to immobilize specific binding members include those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include membrane filters, cellulose-based

papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.

[0124] Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, metal chelates, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or by a specific binding molecule which itself may be detectable (e.g., biotin, digoxigenin, maltose, oligohistidine, 2,4-dinitrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).

[0125] Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents contain at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups. Maleimides, alkyl and aryl halides, and alpha-haloacyls react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.

[0126] In certain aspects, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses

advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.

[0127] Antibodies

[0128] The term “antibody” as used herein refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. *Fundamental Immunology*, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994); *J. Immunol. Methods* 175:267-273; Yarmush (1992) *J. Biochem. Biophys. Methods* 25:85-97. The term antibody includes antigen-binding portions, i.e., “antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”

[0129] Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In preferred embodiments, Preferred antibodies bind with affinities of at least about 10^7 M^{-1} , and preferably between about 10^8 M^{-1} to about 10^9 M^{-1} , about 10^9 M^{-1} to about 10^{10} M^{-1} , or about 10^{10} M^{-1} to about 10^{12} M^{-1} .

[0130] Affinity is calculated as $K_d = k_{off}/k_{on}$ (k_{off} is the dissociation rate constant, K_{on} is the association rate constant and K_d is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: $r/c = K(n-r)$; where r=moles of bound ligand/mole of receptor at equilibrium; c=free ligand concentration at equilibrium; K=equilibrium association constant; and n=number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., *J. Immunoassay* 12: 425-43, 1991; Nelson and Griswold, *Comput. Methods Programs Biomed.* 27: 65-8, 1988.

[0131] The term “epitope” refers to an antigenic determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics,

as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0132] Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g., Cwirla et al., *Proc. Natl. Acad. Sci. USA* 87, 6378-82, 1990; Devlin et al., *Science* 249, 404-6, 1990; Scott and Smith, *Science* 249, 386-88, 1990; and Ladner et al., U.S. Pat. No. 5,571,698. A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.

[0133] The antibodies that are generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.

[0134] The antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target, protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.

[0135] While the present application describes antibody-based binding assays in detail, alternatives to antibodies as binding species in assays are well known in the art. These include receptors for a particular target, aptamers, etc. Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist. High-affinity aptamers con-

taining modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions, and may include amino acid side chain functionalities.

[0136] Assay Correlations

[0137] The term "correlating" as used herein in reference to the use of biomarkers refers to comparing the presence or amount of the biomarker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.

[0138] Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, cost/benefit analysis is involved in selecting a diagnostic threshold.

[0139] Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction using cardiac troponin is the 97.5th percentile of the concentration seen in a normal population. Another method may be to look at serial samples from the same patient, where a prior "baseline" result is used to monitor for temporal changes in a biomarker level.

[0140] Population studies may also be used to select a decision threshold. Receiver Operating Characteristic ("ROC") arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a "diseased" subpopulation from a "nondiseased" subpopulation. A false positive in this case occurs when the person tests positive, but actually does not have the disease. A false negative, on the other hand, occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease. To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to 1-specificity, the ROC graph is sometimes called the sensitivity vs (1-specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold is selected to provide an acceptable level of specificity and sensitivity.

[0141] In this context, "diseased" is meant to refer to a population having one characteristic (the presence of a disease or condition or the occurrence of some outcome) and "nondiseased" is meant to refer to a population lacking the characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high con-

fidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.

[0142] In addition to threshold comparisons, other methods for correlating assay results to a patient classification (occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject belongs to one classification out of a plurality of classifications.

[0143] Measures of test accuracy may be obtained as described in Fischer et al., *Intensive Care Med.* 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas. The area under the curve ("AUC") of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. The area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.

[0144] As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1.

[0145] Additional clinical indicia may be combined with the kidney injury marker assay result(s) of the present invention. These include other biomarkers related to renal status.

Examples include the following, which recite the common biomarker name, followed by the Swiss-Prot entry number for that biomarker or its parent: Actin (P68133); Adenosine deaminase binding protein (DPP4, P27487); Alpha-1-acid glycoprotein 1 (P02763); Alpha-1-microglobulin (P02760); Albumin (P02768); Angiotensinogenase (Renin, P00797); Annexin A2 (P07355); Beta-glucuronidase (P08236); B-2-microglobulin (P61679); Beta-galactosidase (P16278); BMP-7 (P18075); Brain natriuretic peptide (proBNP, BNP-32, NTproBNP; P16860); Calcium-binding protein Beta (S100-beta, P04271); Carbonic anhydrase (Q16790); Casein Kinase 2 (P68400); Ceruloplasmin (P00450); Clusterin (P10909); Complement C3 (P01024); Cysteine-rich protein (CYR61, 000622); Cytochrome C (P99999); Epidermal growth factor (EGF, P01133); Endothelin-1 (P05305); Exosomal Fetuin-A (P02765); Fatty acid-binding protein, heart (FABP3, P05413); Fatty acid-binding protein, liver (P07148); Ferritin (light chain, P02793; heavy chain P02794); Fructose-1,6-biphosphatase (P09467); GRO-alpha (CXCL1, (P09341); Growth Hormone (P01241); Hepatocyte growth factor (P14210); Insulin-like growth factor I (P01343); Immunoglobulin G; Immunoglobulin Light Chains (Kappa and Lambda); Interferon gamma (P01308); Lysozyme (P61626); Interleukin-1alpha (P01583); Interleukin-2 (P60568); Interleukin-4 (P60568); Interleukin-9 (P15248); Interleukin-12p40 (P29460); Interleukin-13 (P35225); Interleukin-16 (Q14005); L1 cell adhesion molecule (P32004); Lactate dehydrogenase (P00338); Leucine Aminopeptidase (P28838); Meprin A-alpha subunit (Q16819); Meprin A-beta subunit (Q16820); Midkine (P21741); MIP2-alpha (CXCL2, P19875); MMP-2 (P08253); MMP-9 (P14780); Netrin-1 (O95631); Neutral endopeptidase (P08473); Osteopontin (P10451); Renal papillary antigen 1 (RPA1); Renal papillary antigen 2 (RPA2); Retinol binding protein (P09455); Ribonuclease; S100 calcium-binding protein A6 (P06703); Serum Amyloid P Component (P02743); Sodium/Hydrogen exchanger isoform (NHE3, P48764); Spermidine/spermine N1-acetyltransferase (P21673); TGF-Beta1 (P01137); Transferrin (P02787); Trefol factor 3 (TFF3, Q07654); Toll-Like protein 4 (000206); Total protein; Tubulointerstitial nephritis antigen (Q9UJW2); Uromodulin (Tamm-Horsfall protein, P07911).

[0146] For purposes of risk stratification, Adiponectin (Q15848); Alkaline phosphatase P05186); Aminopeptidase N(P15144); CalbindinD28k (P05937); Cystatin C(P01034); 8 subunit of F1FO ATPase (P03928); Gamma-glutamyltransferase (P19440); GSTa (alpha-glutathione-S-transferase, P08263); GSTpi (Glutathione-S-transferase P; GST class-pi; P09211); IGFBP-1 (P08833); IGFBP-2 (P18065); IGFBP-6 (P24592); Integral membrane protein 1 (Itm1, P46977); Interleukin-6 (P05231); Interleukin-8 (P10145); Interleukin-18 (Q14116); IP-10 (10 kDa interferon-gamma-induced protein, P02778); IRPR (IFRD1, O00458); Isovaleryl-CoA dehydrogenase (IVD, P26440); I-TAC/CXCL11 (O14625); Keratin 19 (P08727); Kim-1 (Hepatitis A virus cellular receptor 1, O43656); L-arginine:glycine amidinotransferase (P50440); Leptin (P41159); Lipocalin2 (NGAL, P80188); MCP-1 (P13500); MIG (Gamma-interferon-induced monokine Q07325); MIP-1a (P10147); MIP-3a (P78556); MIP-1beta (P13236); MIP-1d (Q16663); NAG (N-acetyl-beta-D-glucosaminidase, P54802); Organic ion transporter (OCT2, O15244); Osteoprotegerin (O14788); P8 protein (O60356); Plasminogen activator inhibitor 1 (PM-1, P05121); ProANP (1-98) (P01160); Protein phosphatase 1-beta (PPI-beta,

P62140); Rab GDI-beta (P50395); Renal kallikrein (Q86U61); RT1.B-1 (alpha) chain of the integral membrane protein (Q5Y7A8); Soluble tumor necrosis factor receptor superfamily member 1A (sTNFR-I, P19438); Soluble tumor necrosis factor receptor superfamily member 1B (sTNFR-II, P20333); Tissue inhibitor of metalloproteinases 3 (TIMP-3, P35625); uPAR (Q03405) may be combined with the kidney injury marker assay result(s) of the present invention.

[0147] Other clinical indicia which may be combined with the kidney injury marker assay result(s) of the present invention includes demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a urine total protein measurement, a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a renal papillary antigen 1 (RPA1) measurement; a renal papillary antigen 2 (RPA2) measurement; a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatinine ratio, and/or a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine). Other measures of renal function which may be combined with the kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.

[0148] Combining assay results/clinical indicia in this manner can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, etc. This list is not meant to be limiting.

[0149] Diagnosis of Acute Renal Failure

[0150] As noted above, the terms "acute renal (or kidney) injury" and "acute renal (or kidney) failure" as used herein are defined in part in terms of changes in serum creatinine from a baseline value. Most definitions of ARF have common elements, including the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of mL/min:

$$GFR = \frac{\text{Urine Concentration} \times \text{Urine Flow}}{\text{Plasma Concentration}}$$

[0151] By normalizing the GFR to the body surface area, a GFR of approximately 75-100 mL/min per 1.73 m² can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.

[0152] There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.

[0153] Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (U_{Cr}), urine flow rate (V), and creatinine's plasma concentration (P_{Cr}) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (U_{Cr}×V) divided by its plasma concentration. This is commonly represented mathematically as:

$$C_{Cr} = \frac{U_{Cr} \times V}{P_{Cr}}$$

Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:

$$C_{Cr} = \frac{U_{Cr} \times 24\text{-hour volume}}{P_{Cr} \times 24 \times 60 \text{ mins}}$$

To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as mL/min/1.73 m². While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:

$$C_{Cr\text{-corrected}} = \frac{C_{Cr} \times 1.73}{BSA}$$

[0154] The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in

the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.

[0155] For purposes of determining urine output on a Urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, Bagshaw et al., *Nephrol. Dial. Transplant.* 23: 1203-1210, 2008, assumes an average patient weight of 70 kg, and patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure).

[0156] Selecting a Treatment Regimen

[0157] Once a diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. The skilled artisan is aware of appropriate treatments for numerous diseases discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N.J., 1999. In addition, since the methods and compositions described herein provide prognostic information, the markers of the present invention may be used to monitor a course of treatment. For example, improved or worsened prognostic state may indicate that a particular treatment is or is not efficacious.

[0158] One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.

Example 1

Contrast-Induced Nephropathy Sample Collection

[0159] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after receiving intravascular contrast media. Approximately 250 adults undergoing radiographic/angiographic procedures involving intravascular administration of iodinated contrast media are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

[0160] males and females 18 years of age or older; undergoing a radiographic/angiographic procedure (such as a CT scan or coronary intervention) involving the intravascular administration of contrast media; expected to be hospitalized for at least 48 hours after contrast administration. able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

[0161] renal transplant recipients; acutely worsening renal function prior to the contrast procedure;

already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;

expected to undergo a major surgical procedure (such as involving cardiopulmonary bypass) or an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration;

participation in an interventional clinical study with an experimental therapy within the previous 30 days;

known infection with human immunodeficiency virus (1-HV) or a hepatitis virus.

[0162] Immediately prior to the first contrast administration (and after any pre-procedure hydration), an EDTA anticoagulated blood sample (10 mL) and a urine sample (10 mL) are collected from each patient. Blood and urine samples are then collected at 4 (± 0.5), 8 (± 1), 24 (± 2) 48 (± 2), and 72 (± 2) hrs following the last administration of contrast media during the index contrast procedure. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0163] Serum creatinine is assessed at the site immediately prior to the first contrast administration (after any pre-procedure hydration) and at 4 (± 0.5), 8 (± 1), 24 (± 2) and 48 (± 2), and 72 (± 2) hours following the last administration of contrast (ideally at the same time as the study samples are obtained). In addition, each patient's status is evaluated through day 30 with regard to additional serum and urine creatinine measurements, a need for dialysis, hospitalization status, and adverse clinical outcomes (including mortality).

[0164] Prior to contrast administration, each patient is assigned a risk based on the following assessment: systolic blood pressure <80 mm Hg=5 points; intra-arterial balloon pump=5 points; congestive heart failure (Class or history of pulmonary edema)=5 points; age >75 yrs=4 points; hematocrit level <39% for men, <35% for women=3 points; diabetes=3 points; contrast media volume=1 point for each 100 mL; serum creatinine level >1.5 g/dL=4 points OR estimated GFR 40-60 mL/min/1.73 m²=2 points, 20-40 mL/min/1.73 m²=4 points, <20 mL/min/1.73 m²=6 points. The risks assigned are as follows: risk for CIN and dialysis: 5 or less total points=risk of CIN—7.5%, risk of dialysis—0.04%; 6-10 total points=risk of CIN—14%, risk of dialysis—0.12%; 11-16 total points=risk of CIN—26.1%, risk of dialysis—1.09%; >16 total points=risk of CIN—57.3%, risk of dialysis—12.8%.

Example 2

Cardiac Surgery Sample Collection

[0165] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after undergoing cardiovascular surgery, a procedure known to be potentially damaging to kidney function. Approximately 900 adults undergoing such surgery are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

[0166] males and females 18 years of age or older; undergoing cardiovascular surgery; Toronto/Ottawa Predictive Risk Index for Renal Replacement risk score of at least 2 (Wijeysundera et al., *JAMA* 297: 1801-9, 2007); and able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

[0167] known pregnancy; previous renal transplantation; acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria); already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment; currently enrolled in another clinical study or expected to be enrolled in another clinical study within 7 days of cardiac surgery that involves drug infusion or a therapeutic intervention for AKI; known infection with human immunodeficiency virus (HIV) or a hepatitis virus.

[0168] Within 3 hours prior to the first incision (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL), whole blood (3 mL), and a urine sample (35 mL) are collected from each patient. Blood and urine samples are then collected at 3 (± 0.5), 6 (± 0.5), 12 (± 1), 24 (± 2) and 48 (± 2) hrs following the procedure and then daily on days 3 through 7 if the subject remains in the hospital. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.

Example 3

Acutely Ill Subject Sample Collection

[0169] The objective of this study is to collect samples from acutely ill patients. Approximately 1900 adults expected to be in the ICU for at least 48 hours will be enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

[0170] males and females 18 years of age or older; Study population 1: approximately 300 patients that have at least one of: shock (SBP<90 mmHg and/or need for vasopressor support to maintain MAP>60 mmHg and/or documented drop in SBP of at least 40 mmHg); and sepsis; Study population 2: approximately 300 patients that have at least one of: IV antibiotics ordered in computerized physician order entry (CPOE) within 24 hours of enrollment; contrast media exposure within 24 hours of enrollment; increased Intra-Abdominal Pressure with acute decompensated heart failure; and severe trauma as the primary reason for ICU admission and likely to be hospitalized in the ICU for 48 hours after enrollment;

Study population 3: approximately 300 patients expected to be hospitalized through acute care setting (ICU or ED) with a known risk factor for acute renal injury (e.g. sepsis, hypotension/shock (Shock=systolic BP<90 mmHg and/or the need for vasopressor support to maintain a MAP>60 mmHg and/or a documented drop in SBP>40 mmHg), major trauma, hemorrhage, or major surgery); and/or expected to be hospitalized to the ICU for at least 24 hours after enrollment;

Study population 4: approximately 1000 patients that are 21 years of age or older, within 24 hours of being admitted into the ICU, expected to have an indwelling urinary catheter for at least 48 hours after enrollment, and have at least one of the following acute conditions within 24 hours prior to enrollment:

(i) respiratory SOFA score of ≥ 2 (PaO₂/FiO₂<300), (ii) cardiovascular SOFA score of ≥ 1 (MAP<70 mm Hg and/or any vasopressor required).

Exclusion Criteria

[0171] known pregnancy; institutionalized individuals; previous renal transplantation; known acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria); received dialysis (either acute or chronic) within 5 days prior to enrollment or in imminent need of dialysis at the time of enrollment; known infection with human immunodeficiency virus (HIV) or a hepatitis virus; meets any of the following:

(i) active bleeding with an anticipated need for >4 units PRBC in a day; (ii) hemoglobin <7 g/dL; (iii) any other condition that in the physician's opinion would contraindicate drawing serial blood samples for clinical study purposes; meets only the SBP<90 mmHg inclusion criterion set forth above, and does not have shock in the attending physician's or principal investigator's opinion;

[0172] After obtaining informed consent, an EDTA anti-coagulated blood sample (10 mL) and a urine sample (25-50 mL) are collected from each patient. Blood and urine samples are then collected at 4 (± 0.5) and 8 (± 1) hours after contrast administration (if applicable); at 12 (± 1), 24 (± 2), 36 (± 2), 48 (± 2), 60 (± 2), 72 (± 2), and 84 (± 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.

Example 4

Immunoassay Format

[0173] Analytes are measured using standard sandwich enzyme immunoassay techniques. A first antibody which binds the analyte is immobilized in wells of a 96 well polystyrene microplate. Analyte standards and test samples are pipetted into the appropriate wells and any analyte present is bound by the immobilized antibody. After washing away any

unbound substances, a horseradish peroxidase-conjugated second antibody which binds the analyte is added to the wells, thereby forming sandwich complexes with the analyte (if present) and the first antibody. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution comprising tetramethylbenzidine and hydrogen peroxide is added to the wells. Color develops in proportion to the amount of analyte present in the sample. The color development is stopped and the intensity of the color is measured at 540 nm or 570 nm. An analyte concentration is assigned to the test sample by comparison to a standard curve determined from the analyte standards. In the case of kidney injury markers that are membrane proteins, assays are directed to soluble forms thereof as described above.

[0174] Commercially-available reagents were sourced from the following vendors:

Analyte	Assay Source	Catalog number
Platelet-derived growth factor (AB/BB)	Millipore	Cat. # HNDG3-36K
Platelet-derived growth factor subunit A (AA-dimer)	Millipore	Cat. # HNDG3-36K
Immunoglobulin G, subclass 4	Millipore	Cat. # HGAM-301
Interleukin-4 receptor alpha chain	Millipore	Cat. # HSCR-32K
Alpha-Fetoprotein	EMD Chemicals	Cat. # BPHCP001-6
Apolipoprotein E	EMD Chemicals	Cat. # BPHCVD01-7
Apolipoprotein(a)	EMD Chemicals	Cat. # BPHCVD05-8
C-C motif chemokine 26	Millipore	Cat. # MPXHCYP2-62K
C-C motif chemokine 7	Millipore	Cat. # MPXHCYTO-60K
Complement C4-B	Millipore	Cat. # HNDG2-36K
Corticotropin	Millipore	Cat. # HPT-66K
Insulin-like growth factor-binding protein 4	Millipore	Cat. # HIGFBP-53K
Insulin-like growth factor-binding protein 5	Millipore	Cat. # HIGFBP-53K
Interferon alpha-2	Millipore	Cat. # MPXHCYTO-60K
Interleukin 23, alpha subunit	Millipore	Cat. # MPXHCYP2-62K
Interleukin-21	Millipore	Cat. # MPXHCYP2-62K
Interleukin-28A (interferon, lambda 2)	Millipore	Cat. # MPXHCYP2-62K
Interleukin-33 (IL-33)	Millipore	Cat. # MPXHCYP2-62K
Lutropin subunit beta	Millipore	Cat. # HBDP-33K
Matrix Metalloproteinase-1	R&D Systems	Cat. # LMP000
Neural cell adhesion molecule 1	Millipore	Cat. # HNDG3-36K
Pigment epithelium-derived factor	Millipore	Cat. # HNDG2-36K
Platelet-derived growth factor (BB-dimer)	Bio-Rad	Cat. # 171-A4011M
Prostate-specific antigen, free	Millipore	Cat. # HCCBPIMAG-58K
Thyrotropin subunit beta	Millipore	Cat. # HPT-66K
Thyroxine-binding globulin	Rules-Based Medicine	No catalog number
Tumor necrosis factor receptor superfamily member 8	Millipore	Cat. # HSCR-32K

-continued

Analyte	Assay Source	Catalog number
Vascular endothelial growth factor receptor 2	Millipore	Cat. # HSCR-32K
Vascular endothelial growth factor receptor 3	Millipore	Cat. # HSCR-32K

[0175] Units for the concentrations reported in the following data tables are as follows: Tumor necrosis factor receptor superfamily member 8—pg/mL, Alpha-Fetoprotein—ng/mL, Thyroxine-binding globulin—pg/mL, Prostate-specific antigen (free form)—ng/mL, Apolipoprotein A—ng/mL, Apolipoprotein E—ng/mL, Thyrotropin subunit beta—pg/mL, Platelet-derived growth factor BB dimer—pg/mL, C-C motif chemokine 7—pg/mL, C-C motif chemokine 26—pg/mL, Complement C4-B—ng/mL, Corticotropin—ng/mL, Interferon alpha-2—pg/mL, Interleukin-4 receptor alpha chain—pg/mL, Insulin-like growth factor-binding protein 4—ng/mL, Insulin-like growth factor-binding protein 5—ng/mL, Interleukin 21—pg/mL, Interleukin 23 alpha subunit—pg/mL, Interleukin-28A—pg/mL, Interleukin-33—pg/mL, Lutropin subunit beta—mIU/mL, Matrix Metalloproteinase-1—pg/mL, Neural cell adhesion molecule 1—pg/mL, Pigment epithelium-derived factor—ng/mL, Vascular Vascular endothelial growth factor receptor 2—pg/mL, Vascular endothelial growth factor receptor 3—pg/mL, IgG4—ng/mL.

Example 5

Apparently Healthy Donor and Chronic Disease Patient Samples

[0176] Human urine samples from donors with no known chronic or acute disease ("Apparently Healthy Donors") were purchased from two vendors (Golden West Biologicals, Inc., 27625 Commerce Center Dr., Temecula, Calif. 92590 and Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, Va. 23454). The urine samples were shipped and stored frozen at less than -20°C . The vendors supplied demographic information for the individual donors including gender, race (Black/White), smoking status and age.

[0177] Human urine samples from donors with various chronic diseases ("Chronic Disease Patients") including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, Va. 23454. The urine samples were shipped and stored frozen at less than -20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking status and alcohol use, height, weight, chronic disease(s) diagnosis, current medications and previous surgeries.

Example 6

Use of Kidney Injury Markers for Evaluating Renal Status in Patients

[0178] Patients from the intensive care unit (ICU) were enrolled in the following study. Each patient was classified by kidney status as non-injury (O), risk of injury (R), injury (I), and failure (F) according to the maximum stage reached

within 7 days of enrollment as determined by the RIFLE criteria. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) were collected from each patient at enrollment, 4 (± 0.5) and 8 (± 1) hours after contrast administration (if applicable); at 12 (± 1), 24 (± 2), and 48 (± 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Markers were each measured by standard immunoassay methods using commercially available assay reagents in the urine samples and the plasma component of the blood samples collected.

[0179] Two cohorts were defined to represent a “diseased” and a “normal” population. While these terms are used for convenience, “diseased” and “normal” simply represent two cohorts for comparison (say RIFLE 0 vs RIFLE R, I and F; RIFLE 0 vs RIFLE R; RIFLE 0 and R vs RIFLE I and F; etc.). The time “prior max stage” represents the time at which a sample is collected, relative to the time a particular patient reaches the lowest disease stage as defined for that cohort, binned into three groups which are ± 12 hours. For example, “24 hr prior” which uses 0 vs R, I, F as the two cohorts would mean 24 hr (± 12 hours) prior to reaching stage R (or I if no sample at R, or F if no sample at R or I).

[0180] A receiver operating characteristic (ROC) curve was generated for each biomarker measured and the area under each ROC curve (AUC) is determined. Patients in Cohort 2 were also separated according to the reason for adjudication to cohort 2 as being based on serum creatinine measurements (sCr), being based on urine output (UO), or being based on either serum creatinine measurements or urine output. Using the same example discussed above (0 vs R, I, F), for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements alone, the stage 0

cohort may include patients adjudicated to stage R, I, or F on the basis of urine output; for those patients adjudicated to stage R, I, or F on the basis of urine output alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements; and for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements or urine output, the stage 0 cohort contains only patients in stage 0 for both serum creatinine measurements and urine output. Also, in the data for patients adjudicated on the basis of serum creatinine measurements or urine output, the adjudication method which yielded the most severe RIFLE stage is used.

[0181] The ability to distinguish cohort 1 from Cohort 2 was determined using ROC analysis. SE is the standard error of the AUC, n is the number of sample or individual patients (“pts,” as indicated). Standard errors are calculated as described in Hanley, J. A., and McNeil, B. J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 143: 29-36; p values are calculated with a two-tailed Z-test. An AUC<0.5 is indicative of a negative going marker for the comparison, and an AUC>0.5 is indicative of a positive going marker for the comparison.

[0182] Various threshold (or “cutoff”) concentrations were selected, and the associated sensitivity and specificity for distinguishing cohort 1 from cohort 2 are determined. OR is the odds ratio calculated for the particular cutoff concentration, and 95% CI is the confidence interval for the odds ratio.

[0183] FIG. 1: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

Complement C4-B						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	14.6	18.7	14.6	18.9	14.6	22.3
Average	52.6	70.9	52.6	51.2	52.6	47.9
Stdev	134	196	134	98.2	134	92.5
p (t-test)		0.23		0.91		0.81
Min	0.00607	0.383	0.00607	0.211	0.00607	0.448
Max	1950	2000	1950	625	1950	562
n (Samp)	463	119	463	128	463	47
n (Patient)	223	119	223	128	223	47
<u>sCr only</u>						
Median	17.3	14.0	17.3	22.3	17.3	21.1
Average	59.1	23.1	59.1	43.1	59.1	48.7
Stdev	139	29.6	139	84.8	139	65.3
p (t-test)		0.10		0.44		0.70
Min	0.00607	0.754	0.00607	0.211	0.00607	0.448
Max	2000	130	2000	556	2000	252
n (Samp)	1015	40	1015	46	1015	26
n (Patient)	374	40	374	46	374	26
<u>UO only</u>						
Median	17.7	27.6	17.7	19.8	17.7	23.2
Average	53.8	80.7	53.8	53.9	53.8	44.1
Stdev	128	206	128	95.8	128	89.5
p (t-test)		0.090		0.99		0.62
Min	0.00329	0.383	0.00329	0.259	0.00329	0.544
Max	1950	2000	1950	625	1950	562

-continued

n (Samp)	436	107	436	117	436	44			
n (Patient)	173	107	173	117	173	44			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.44	0.56	0.52	0.51	0.50	0.55	0.52	0.51
SE	0.030	0.048	0.032	0.029	0.044	0.030	0.045	0.058	0.046
p	0.041	0.23	0.042	0.51	0.77	0.89	0.25	0.69	0.81
nCohort 1	463	1015	436	463	1015	436	463	1015	436
nCohort 2	119	40	107	128	46	117	47	26	44
Cutoff 1	8.26	4.22	10.2	4.60	5.88	5.01	10.5	6.04	6.59
Sens 1	71%	70%	70%	70%	72%	70%	70%	73%	70%
Spec 1	40%	26%	39%	30%	31%	26%	45%	31%	30%
Cutoff 2	3.27	2.69	4.12	1.77	4.60	2.22	4.27	2.22	3.99
Sens 2	81%	80%	80%	80%	80%	80%	81%	81%	82%
Spec 2	23%	19%	21%	15%	28%	13%	28%	17%	21%
Cutoff 3	1.35	1.88	1.30	0.895	1.66	1.09	3.00	0.995	2.76
Sens 3	91%	90%	91%	91%	91%	91%	91%	92%	91%
Spec 3	12%	15%	9%	8%	14%	7%	22%	9%	15%
Cutoff 4	36.1	41.3	40.6	36.1	41.3	40.6	36.1	41.3	40.6
Sens 4	42%	18%	44%	34%	33%	35%	26%	31%	27%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	60.0	68.7	60.5	60.0	68.7	60.5	60.0	68.7	60.5
Sens 5	28%	8%	34%	23%	13%	26%	21%	23%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	133	144	133	133	144	133	133	144	133
Sens 6	12%	0%	16%	9%	4%	10%	6%	12%	5%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.99	4.1	0.90	0.77	1.3	0.58	1.6	0.83	0.71
p Value	0.98	0.029	0.73	0.36	0.51	0.074	0.34	0.76	0.47
95% CI of	0.54	1.2	0.48	0.43	0.56	0.32	0.60	0.25	0.27
OR Quart 2	1.8	15	1.7	1.4	3.3	1.1	4.3	2.8	1.8
OR Quart 3	1.1	4.9	0.85	1.0	1.8	0.68	2.8	1.2	1.4
p Value	0.65	0.014	0.61	0.91	0.16	0.19	0.025	0.78	0.41
95% CI of	0.64	1.4	0.45	0.59	0.79	0.38	1.1	0.39	0.62
OR Quart 3	2.1	17	1.6	1.8	4.2	1.2	7.0	3.5	3.2
OR Quart 4	1.6	3.8	1.6	1.2	1.00	1.1	1.6	1.3	0.90
p Value	0.097	0.042	0.090	0.51	0.99	0.81	0.34	0.59	0.82
95% CI of	0.92	1.0	0.92	0.70	0.39	0.62	0.60	0.46	0.37
OR Quart 4	2.8	14	2.9	2.1	2.6	1.8	4.3	3.9	2.2

C-C motif chemokine 26

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.0320	0.0240	0.0320	0.0311	0.0320	0.0254
Average	0.0543	0.155	0.0543	0.391	0.0543	0.0836
Stdev	0.424	1.33	0.424	3.72	0.424	0.251
p (t-test)		0.17		0.057		0.64
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	9.14	14.6	9.14	42.3	9.14	1.25
n (Samp)	463	120	463	130	463	46
n (Patient)	223	120	223	130	223	46
sCr only						
Median	0.0368	0.0240	0.0368	0.0311	0.0368	0.0240
Average	0.243	0.0346	0.243	0.0675	0.243	0.0794
Stdev	2.46	0.0171	2.46	0.239	2.46	0.244
p (t-test)		0.59		0.63		0.74
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	42.3	0.0633	42.3	1.65	42.3	1.25
n (Samp)	1019	40	1019	46	1019	25
n (Patient)	375	40	375	46	375	25
UO only						
Median	0.0383	0.0276	0.0383	0.0247	0.0383	0.0240
Average	0.0390	0.387	0.0390	0.473	0.0390	0.0572
Stdev	0.0608	2.15	0.0608	3.94	0.0608	0.184
p (t-test)		7.5E-4		0.022		0.15
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	1.25	14.6	1.25	42.3	1.25	1.25

-continued

	n (Samp)	435	108	435	119	435	44		
	n (Patient)	173	108	173	119	173	44		
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.50	0.47	0.47	0.46	0.43	0.47	0.45	0.40
SE	0.030	0.047	0.031	0.029	0.044	0.030	0.045	0.060	0.047
p	0.78	0.98	0.36	0.29	0.32	0.025	0.46	0.45	0.028
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	46	25	44
Cutoff 1	0.0195	0.0226	0.0195	0.0204	0.0232	0.0204	0.0218	0.0218	0.0204
Sens 1	78%	72%	79%	72%	72%	71%	72%	72%	70%
Spec 1	19%	26%	16%	23%	31%	21%	29%	26%	21%
Cutoff 2	0.0192	0.0195	0.0192	0.0192	0.0195	0.0143	0.0195	0.0204	0.0173
Sens 2	80%	85%	81%	82%	80%	86%	80%	84%	82%
Spec 2	13%	16%	11%	13%	16%	7%	19%	21%	11%
Cutoff 3	0.0143	0.0143	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Sens 3	90%	90%	95%	95%	96%	93%	98%	92%	95%
Spec 3	9%	8%	4%	6%	4%	4%	6%	4%	4%
Cutoff 4	0.0443	0.0443	0.0486	0.0443	0.0443	0.0486	0.0443	0.0443	0.0486
Sens 4	35%	35%	26%	20%	20%	16%	17%	24%	9%
Spec 4	74%	73%	75%	74%	73%	75%	74%	73%	75%
Cutoff 5	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504
Sens 5	22%	28%	22%	14%	9%	15%	13%	16%	9%
Spec 5	84%	83%	81%	84%	83%	81%	84%	83%	81%
Cutoff 6	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526
Sens 6	8%	8%	10%	8%	7%	8%	11%	12%	5%
Spec 6	92%	90%	91%	92%	90%	91%	92%	90%	91%
OR Quart 2	0.54	0.45	0.83	1.6	2.1	1.8	1.7	0.60	3.8
p Value	0.042	0.1	0.54	0.11	0.12	0.049	0.25	0.48	0.021
95% CI of	0.30	0.17	0.45	0.90	0.82	1.0	0.68	0.14	1.2
OR Quart 2	0.98	1.2	1.5	2.8	5.2	3.4	4.3	2.5	12
OR Quart 3	0.60	0.76	0.74	1.2	2.1	1.4	1.9	2.3	3.2
p Value	0.084	0.52	0.35	0.53	0.12	0.34	0.18	0.14	0.048
95% CI of	0.34	0.33	0.40	0.67	0.82	0.72	0.75	0.77	1.0
OR Quart 3	1.1	1.8	1.4	2.2	5.2	2.5	4.6	6.6	10
OR Quart 4	1.1	0.84	1.3	1.6	1.6	2.1	1.4	1.2	3.9
p Value	0.76	0.68	0.37	0.11	0.34	0.018	0.47	0.76	0.020
95% CI of	0.64	0.37	0.74	0.90	0.61	1.1	0.55	0.36	1.2
OR Quart 4	1.8	1.9	2.3	2.8	4.2	3.7	3.7	4.0	12

C-C motif chemokine 7

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.515	0.812	0.515	0.584	0.515	0.584
Average	1.72	3.44	1.72	3.13	1.72	1.59
Stdev	7.00	16.1	7.00	15.0	7.00	3.45
p (t-test)		0.082		0.13		0.90
Min	0.146	0.146	0.146	0.146	0.146	0.146
Max	125	161	125	163	125	13.6
n (Samp)	462	120	462	130	462	47
n (Patient)	223	120	223	130	223	47
<u>sCr only</u>						
Median	0.584	0.604	0.584	0.737	0.584	0.625
Average	2.20	2.18	2.20	3.16	2.20	2.44
Stdev	13.0	6.16	13.0	8.29	13.0	4.49
p (t-test)		0.99		0.62		0.93
Min	0.146	0.146	0.146	0.146	0.146	0.146
Max	291	29.9	291	43.8	291	13.6
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26
<u>UO only</u>						
Median	0.584	0.812	0.584	0.584	0.584	0.484
Average	1.83	5.88	1.83	4.24	1.83	1.66
Stdev	7.17	23.3	7.17	18.7	7.17	5.26
p (t-test)		0.0021		0.030		0.88
Min	0.146	0.146	0.146	0.146	0.146	0.146
Max	125	166	125	163	125	33.0

-continued

n (Samp)	436	108	436	119	436	44			
n (Patient)	173	108	173	119	173	44			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.50	0.60	0.56	0.59	0.51	0.51	0.53	0.46
SE	0.030	0.047	0.031	0.029	0.045	0.030	0.044	0.058	0.047
p	5.6E-4	0.99	9.7E-4	0.054	0.046	0.65	0.81	0.65	0.37
nCohort 1	462	1019	436	462	1019	436	462	1019	436
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	0.551	0.320	0.584	0.336	0.512	0.320	0.336	0.320	0.336
Sens 1	70%	78%	71%	72%	74%	76%	77%	73%	73%
Spec 1	52%	30%	50%	39%	44%	31%	39%	30%	36%
Cutoff 2	0.320	0.319	0.483	0.319	0.336	0.319	0.282	0.319	0.319
Sens 2	81%	82%	81%	82%	80%	82%	85%	81%	82%
Spec 2	35%	26%	44%	29%	34%	27%	18%	26%	23%
Cutoff 3	0.282	0.254	0.282	0.301	0.254	0.301	0.254	0.301	0.264
Sens 3	92%	92%	93%	91%	93%	91%	91%	92%	91%
Spec 3	18%	8%	18%	18%	8%	18%	9%	17%	14%
Cutoff 4	0.816	1.04	1.04	0.816	1.04	1.04	0.816	1.04	1.04
Sens 4	38%	20%	31%	35%	39%	23%	26%	27%	14%
Spec 4	71%	72%	72%	71%	72%	72%	71%	72%	72%
Cutoff 5	1.12	1.12	1.12	1.12	1.12	1.12	1.12	1.12	1.12
Sens 5	27%	20%	31%	22%	33%	20%	17%	23%	14%
Spec 5	83%	81%	80%	83%	81%	80%	83%	81%	80%
Cutoff 6	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59
Sens 6	7%	8%	11%	8%	11%	9%	9%	15%	7%
Spec 6	94%	94%	94%	94%	94%	94%	94%	94%	94%
OR Quart 2	1.7	1.7	2.6	1.8	1.0	2.2	1.1	1.0	1.9
p Value	0.14	0.27	0.0087	0.057	1.0	0.010	0.82	1.0	0.21
95% CI of	0.85	0.68	1.3	0.98	0.37	1.2	0.45	0.29	0.69
OR Quart 2	3.3	4.1	5.2	3.2	2.7	3.9	2.7	3.5	5.4
OR Quart 3	3.7	1.5	2.9	2.0	1.8	1.7	1.8	1.8	3.4
p Value	3.6E-5	0.37	0.0026	0.016	0.20	0.075	0.16	0.29	0.014
95% CI of	2.0	0.61	1.5	1.1	0.74	0.95	0.79	0.60	1.3
OR Quart 3	7.0	3.8	5.8	3.7	4.3	3.2	4.1	5.5	8.8
OR Quart 4	2.4	0.88	3.2	1.7	2.1	1.3	0.88	1.4	1.5
p Value	0.0096	0.80	0.0011	0.077	0.10	0.44	0.80	0.57	0.43
95% CI of	1.2	0.31	1.6	0.94	0.86	0.68	0.35	0.44	0.53
OR Quart 4	4.5	2.4	6.3	3.1	4.9	2.4	2.3	4.5	4.5
Thyrotropin									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.1000	0.118	0.1000	0.106	0.1000	0.124			
Average	0.296	0.126	0.296	0.195	0.296	0.214			
Stdev	1.96	0.0588	1.96	0.250	1.96	0.408			
p (t-test)		0.55		0.71		0.83			
Min	0.0321	0.0383	0.0321	0.0574	0.0321	0.0189			
Max	21.8	0.303	21.8	1.58	21.8	2.18			
n (Samp)	122	47	122	51	122	26			
n (Patient)	99	47	99	51	99	26			
sCr only									
Median	0.106	0.132	0.106	0.123	0.106	0.123			
Average	0.232	0.129	0.232	0.152	0.232	0.130			
Stdev	1.35	0.0472	1.35	0.0958	1.35	0.0635			
p (t-test)		0.78		0.80		0.79			
Min	0.0321	0.0383	0.0321	0.0698	0.0321	0.0189			
Max	21.8	0.198	21.8	0.430	21.8	0.248			
n (Samp)	262	14	262	19	262	13			
n (Patient)	160	14	160	19	160	13			
UO only									
Median	0.109	0.118	0.109	0.105	0.109	0.130			
Average	0.322	0.126	0.322	0.202	0.322	0.234			
Stdev	2.05	0.0582	2.05	0.257	2.05	0.431			
p (t-test)		0.53		0.69		0.84			
Min	0.0230	0.0403	0.0230	0.0574	0.0230	0.0383			
Max	21.8	0.303	21.8	1.58	21.8	2.18			

-continued

n (Samp)	111	44	111	47	111	23			
n (Patient)	86	44	86	47	86	23			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.56	0.52	0.60	0.59	0.57	0.58	0.55	0.59
SE	0.050	0.082	0.052	0.048	0.071	0.051	0.064	0.084	0.068
p	0.22	0.43	0.71	0.036	0.22	0.15	0.19	0.56	0.17
nCohort 1	122	262	111	122	262	111	122	262	111
nCohort 2	47	14	44	51	19	47	26	13	23
Cutoff 1	0.0862	0.114	0.0862	0.0930	0.105	0.0930	0.0862	0.104	0.0950
Sens 1	70%	71%	70%	71%	74%	72%	73%	77%	74%
Spec 1	41%	55%	36%	45%	50%	41%	41%	49%	42%
Cutoff 2	0.0698	0.0808	0.0780	0.0854	0.0918	0.0854	0.0666	0.0877	0.0666
Sens 2	81%	86%	82%	80%	84%	81%	81%	85%	83%
Spec 2	28%	31%	32%	40%	41%	35%	25%	37%	19%
Cutoff 3	0.0617	0.0715	0.0627	0.0717	0.0717	0.0717	0.0509	0.0360	0.0608
Sens 3	91%	93%	91%	92%	95%	91%	92%	92%	91%
Spec 3	21%	23%	18%	29%	23%	24%	11%	2%	17%
Cutoff 4	0.146	0.154	0.151	0.146	0.154	0.151	0.146	0.154	0.151
Sens 4	32%	43%	27%	33%	32%	34%	38%	31%	48%
Spec 4	71%	71%	70%	71%	71%	70%	71%	71%	70%
Cutoff 5	0.161	0.186	0.170	0.161	0.186	0.170	0.161	0.186	0.170
Sens 5	21%	7%	18%	27%	21%	30%	31%	23%	35%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.212	0.248	0.215	0.212	0.248	0.215	0.212	0.248	0.215
Sens 6	6%	0%	7%	22%	11%	23%	15%	0%	17%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	1.0	1.7	2.8	2.6	5.0	0.46	1.5	0.97
p Value	0.79	1.0	0.33	0.052	0.26	0.0032	0.29	0.66	0.96
95% CI of	0.40	0.14	0.59	0.99	0.49	1.7	0.10	0.24	0.25
OR Quart 2	3.4	7.3	4.7	7.7	14	14	2.0	9.3	3.7
OR Quart 3	2.9	2.6	2.1	2.5	4.4	1.4	1.4	2.6	0.56
p Value	0.035	0.26	0.15	0.084	0.068	0.56	0.55	0.27	0.46
95% CI of	1.1	0.49	0.76	0.89	0.90	0.44	0.44	0.48	0.12
OR Quart 3	7.7	14	5.8	7.0	21	4.6	4.6	14	2.6
OR Quart 4	1.8	2.6	1.3	2.7	2.0	3.0	1.7	1.5	2.3
p Value	0.24	0.26	0.63	0.061	0.42	0.050	0.39	0.66	0.17
95% CI of	0.67	0.49	0.45	0.96	0.36	1.00	0.52	0.24	0.70
OR Quart 4	5.0	14	3.7	7.4	11	8.8	5.3	9.3	7.8
Vascular endothelial growth factor receptor 3									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2		Cohort 1	Cohort 2		
sCr or UO									
Median	277	318	277	351		277	366		
Average	300	374	300	365		300	374		
Stdev	237	217	237	181		237	229		
p (t-test)		0.011		0.018			0.096		
Min	1.37	1.37	1.37	1.37		1.37	1.37		
Max	2070	1280	2070	901		2070	942		
n (Samp)	217	90	217	94		217	32		
n (Patient)	128	90	128	94		128	32		
sCr only									
Median	318	359	318	375		318	307		
Average	339	387	339	398		339	372		
Stdev	246	241	246	213		246	295		
p (t-test)		0.32		0.19			0.59		
Min	1.37	2.36	1.37	3.28		1.37	1.37		
Max	2750	901	2750	913		2750	942		
n (Samp)	513	28	513	32		513	18		
n (Patient)	240	28	240	32		240	18		
UO only									
Median	282	346	282	351		282	354		
Average	310	378	310	356		310	375		
Stdev	240	213	240	167		240	200		
p (t-test)		0.026		0.11			0.15		
Min	1.37	1.37	1.37	1.37		1.37	2.01		
Max	2070	1280	2070	901		2070	854		

-continued

n (Samp)	227	80	227	84	227	31			
n (Patient)	122	80	122	84	122	31			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.55	0.62	0.62	0.59	0.61	0.62	0.51	0.62
SE	0.036	0.057	0.038	0.036	0.054	0.037	0.056	0.070	0.057
p	0.0022	0.34	0.0022	7.9E-4	0.100	0.0038	0.039	0.91	0.034
nCohort 1	217	513	227	217	513	227	217	513	227
nCohort 2	90	28	80	94	32	84	32	18	31
Cutoff 1	249	230	249	251	251	277	249	166	282
Sens 1	71%	71%	74%	71%	72%	71%	72%	72%	71%
Spec 1	44%	32%	42%	46%	38%	48%	44%	20%	52%
Cutoff 2	208	179	208	208	208	219	166	130	247
Sens 2	80%	82%	81%	81%	81%	81%	81%	83%	81%
Spec 2	37%	24%	36%	37%	28%	38%	29%	14%	41%
Cutoff 3	136	127	136	161	160	163	39.3	0	130
Sens 3	90%	93%	90%	90%	91%	90%	91%	100%	90%
Spec 3	22%	13%	19%	26%	16%	23%	10%	0%	18%
Cutoff 4	386	414	386	386	414	386	386	414	386
Sens 4	42%	32%	46%	43%	41%	42%	41%	39%	39%
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	71%
Cutoff 5	440	468	440	440	468	440	440	468	440
Sens 5	33%	32%	38%	30%	34%	26%	38%	33%	35%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	496	572	509	496	572	509	496	572	509
Sens 6	26%	21%	24%	24%	25%	17%	25%	28%	23%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.3	1.6	1.7	2.3	1.2	2.0	1.2	0.27	0.98
p Value	0.030	0.40	0.18	0.030	0.78	0.088	0.75	0.11	0.98
95% CI of	1.1	0.52	0.78	1.1	0.38	0.90	0.35	0.056	0.27
OR Quart 2	5.0	5.1	3.7	5.0	3.6	4.4	4.2	1.3	3.6
OR Quart 3	1.9	1.2	1.4	2.8	1.2	2.6	1.9	0.27	1.9
p Value	0.094	0.76	0.44	0.0084	0.78	0.018	0.26	0.11	0.26
95% CI of	0.89	0.36	0.61	1.3	0.38	1.2	0.61	0.056	0.61
OR Quart 3	4.2	4.1	3.1	5.9	3.6	5.6	6.1	1.3	6.1
OR Quart 4	3.1	1.8	3.1	2.8	2.1	2.7	2.7	0.99	2.7
p Value	0.0033	0.28	0.0033	0.0084	0.16	0.012	0.081	0.99	0.082
95% CI of	1.5	0.60	1.5	1.3	0.76	1.2	0.88	0.34	0.88
OR Quart 4	6.6	5.6	6.6	5.9	5.7	5.9	8.1	2.9	8.1
Interferon alpha-2									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.0967	0.0974	0.0967	0.0974	0.0967	5.72			
Average	7.58	12.0	7.58	9.69	7.58	15.2			
Stdev	17.4	24.3	17.4	19.9	17.4	18.2			
p (t-test)		0.023		0.24		0.0045			
Min	0.0238	0.0348	0.0238	0.0238	0.0238	0.0369			
Max	126	125	126	108	126	67.1			
n (Samp)	462	120	462	130	462	47			
n (Patient)	223	120	223	130	223	47			
sCr only									
Median	0.0967	0.0974	0.0967	0.0967	0.0967	0.113			
Average	7.94	7.91	7.94	9.73	7.94	14.4			
Stdev	18.2	16.7	18.2	19.4	18.2	19.7			
p (t-test)		0.99		0.52		0.075			
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0369			
Max	126	60.4	126	77.3	126	67.1			
n (Samp)	1019	40	1019	46	1019	26			
n (Patient)	375	40	375	46	375	26			
UO only									
Median	0.0974	0.0974	0.0974	0.0974	0.0974	2.50			
Average	7.12	13.5	7.12	8.00	7.12	10.7			
Stdev	16.4	26.2	16.4	18.0	16.4	14.9			
p (t-test)		0.0015		0.61		0.16			
Min	0.0238	0.0348	0.0238	0.0238	0.0238	0.0348			
Max	126	125	126	108	126	57.3			

-continued

n (Samp)	436	108	436	119	436	44			
n (Patient)	173	108	173	119	173	44			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.50	0.56	0.52	0.53	0.51	0.65	0.61	0.59
SE	0.030	0.047	0.032	0.029	0.044	0.030	0.045	0.059	0.047
p	0.093	0.92	0.066	0.41	0.45	0.68	6.6E-4	0.061	0.044
nCohort 1	462	1019	436	462	1019	436	462	1019	436
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	0.0724	0.0656	0.0724	0.0709	0.0709	0.0709	0.0815	0.0724	0.0724
Sens 1	73%	75%	74%	70%	72%	71%	70%	77%	70%
Spec 1	39%	29%	36%	36%	37%	33%	47%	41%	36%
Cutoff 2	0.0656	0.0398	0.0709	0.0435	0.0606	0.0435	0.0709	0.0672	0.0656
Sens 2	83%	80%	81%	81%	80%	81%	81%	81%	82%
Spec 2	29%	14%	33%	19%	26%	17%	36%	33%	26%
Cutoff 3	0.0369	0.0348	0.0398	0.0369	0.0369	0.0348	0.0398	0.0398	0.0369
Sens 3	90%	92%	91%	90%	93%	92%	91%	92%	95%
Spec 3	8%	7%	12%	8%	11%	6%	14%	14%	9%
Cutoff 4	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311
Sens 4	26%	22%	30%	29%	30%	28%	60%	46%	50%
Spec 4	71%	73%	72%	71%	73%	72%	71%	73%	72%
Cutoff 5	10.9	12.7	9.75	10.9	12.7	9.75	10.9	12.7	9.75
Sens 5	24%	20%	28%	25%	24%	23%	47%	42%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	28.7	30.2	27.4	28.7	30.2	27.4	28.7	30.2	27.4
Sens 6	20%	15%	21%	15%	15%	11%	21%	19%	14%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.0	0.89	2.9	0.96	1.8	0.95	1.3	1.0	1.0
p Value	0.020	0.81	0.0015	0.89	0.16	0.86	0.61	1.0	1.0
95% CI of	1.1	0.36	1.5	0.55	0.79	0.52	0.47	0.29	0.36
OR Quart 2	3.7	2.2	5.6	1.7	4.2	1.7	3.6	3.5	2.8
OR Quart 3	1.8	1.2	1.9	1.1	1.0	1.2	1.3	0.80	1.0
p Value	0.050	0.67	0.065	0.78	1.0	0.58	0.61	0.74	1.0
95% CI of	1.00	0.51	0.96	0.62	0.39	0.66	0.47	0.21	0.36
OR Quart 3	3.4	2.8	3.8	1.9	2.6	2.1	3.6	3.0	2.8
OR Quart 4	1.7	0.89	2.4	1.2	1.3	1.2	3.6	2.5	2.8
p Value	0.097	0.81	0.011	0.49	0.51	0.58	0.0052	0.096	0.019
95% CI of	0.91	0.36	1.2	0.70	0.56	0.66	1.5	0.85	1.2
OR Quart 4	3.1	2.2	4.7	2.1	3.2	2.1	8.7	7.1	6.6

Insulin-like growth factor-binding protein 4

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.733	0.670	0.733	0.896	0.733	0.957
Average	1.33	1.05	1.33	2.36	1.33	4.27
Stdev	4.52	1.46	4.52	5.77	4.52	17.0
p (t-test)		0.63		0.17		0.072
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0558
Max	53.9	7.51	53.9	42.8	53.9	85.6
n (Samp)	155	61	155	60	155	25
n (Patient)	109	61	109	60	109	25
<u>sCr only</u>						
Median	0.733	0.733	0.733	0.398	0.733	0.660
Average	1.92	1.67	1.92	1.63	1.92	0.908
Stdev	6.94	2.39	6.94	2.27	6.94	1.12
p (t-test)		0.88		0.84		0.59
Min	0.0319	0.0319	0.0319	0.0558	0.0319	0.0319
Max	85.6	9.68	85.6	7.59	85.6	3.90
n (Samp)	338	20	338	23	338	14
n (Patient)	184	20	184	23	184	14
<u>UO only</u>						
Median	0.733	0.733	0.733	0.923	0.733	0.957
Average	1.20	1.20	1.20	2.56	1.20	4.79
Stdev	4.49	1.52	4.49	6.01	4.49	17.6
p (t-test)		1.00		0.079		0.034
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0319
Max	53.9	7.51	53.9	42.8	53.9	85.6

-continued

n (Samp)	155	54	155	56	155	23			
n (Patient)	99	54	99	56	99	23			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.47	0.51	0.55	0.55	0.51	0.61	0.55	0.48	0.63
SE	0.044	0.067	0.046	0.044	0.063	0.045	0.064	0.080	0.066
p	0.44	0.86	0.29	0.23	0.85	0.019	0.39	0.84	0.052
nCohort 1	155	338	155	155	338	155	155	338	155
nCohort 2	61	20	54	60	23	56	25	14	23
Cutoff 1	0.184	0.141	0.141	0.141	0.0585	0.341	0.382	0.141	0.382
Sens 1	72%	70%	76%	72%	78%	71%	72%	71%	74%
Spec 1	25%	28%	30%	25%	16%	39%	32%	28%	39%
Cutoff 2	0.0558	0.0558	0.0558	0.0558	0.0558	0.0558	0.0439	0.0439	0.0439
Sens 2	90%	80%	91%	82%	83%	82%	100%	93%	96%
Spec 2	14%	16%	15%	14%	16%	15%	10%	10%	13%
Cutoff 3	0.0558	0	0.0558	0.0439	0.0439	0	0.0439	0.0439	0.0439
Sens 3	90%	100%	91%	92%	100%	100%	100%	93%	96%
Spec 3	14%	0%	15%	10%	10%	0%	10%	10%	13%
Cutoff 4	0.923	0.957	0.923	0.923	0.957	0.923	0.923	0.957	0.923
Sens 4	25%	40%	31%	43%	35%	43%	52%	21%	57%
Spec 4	72%	76%	74%	72%	76%	74%	72%	76%	74%
Cutoff 5	1.05	1.37	0.957	1.05	1.37	0.957	1.05	1.37	0.957
Sens 5	21%	35%	30%	37%	30%	36%	20%	14%	30%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	2.07	3.12	1.88	2.07	3.12	1.88	2.07	3.12	1.88
Sens 6	20%	20%	28%	27%	17%	29%	12%	7%	22%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.91	0.81	1.4	0.59	0.48	0.59	0.81	1.3	0.56
p Value	0.82	0.74	0.50	0.24	0.24	0.30	0.75	0.70	0.44
95% CI of	0.38	0.24	0.56	0.24	0.14	0.22	0.23	0.29	0.12
OR Quart 2	2.2	2.8	3.3	1.4	1.6	1.6	2.9	6.2	2.5
OR Quart 3	1.4	0.16	0.79	0.59	0.35	1.4	1.4	1.0	1.7
p Value	0.40	0.090	0.63	0.24	0.13	0.41	0.56	1.0	0.37
95% CI of	0.62	0.019	0.31	0.24	0.091	0.60	0.44	0.20	0.52
OR Quart 3	3.3	1.3	2.0	1.4	1.4	3.4	4.4	5.1	5.8
OR Quart 4	1.2	1.3	1.6	1.6	0.99	2.0	1.0	1.3	1.4
p Value	0.67	0.59	0.30	0.26	0.98	0.11	1.0	0.70	0.56
95% CI of	0.52	0.45	0.66	0.71	0.35	0.86	0.30	0.29	0.42
OR Quart 4	2.8	4.1	3.7	3.5	2.8	4.7	3.4	6.2	4.9
Insulin-like growth factor-binding protein 5									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2		Cohort 1	Cohort 2		
sCr or UO									
Median	0.0407	0.0682	0.0407	0.0682		0.0407	0.397		
Average	0.473	0.722	0.473	0.778		0.473	0.991		
Stdev	1.04	1.54	1.04	1.57		1.04	1.96		
p (t-test)		0.17		0.099			0.048		
Min	0.0116	0.0116	0.0116	0.0116		0.0116	0.0393		
Max	5.79	8.53	5.79	8.07		5.79	9.43		
n (Samp)	155	61	155	60		155	25		
n (Patient)	109	61	109	60		109	25		
sCr only									
Median	0.0682	0.0682	0.0682	0.0682		0.0682	0.403		
Average	0.598	1.28	0.598	0.648		0.598	1.32		
Stdev	1.31	2.31	1.31	1.19		1.31	1.56		
p (t-test)		0.034		0.86			0.047		
Min	0.0116	0.0116	0.0116	0.0210		0.0116	0.0116		
Max	9.43	10.0	9.43	4.35		9.43	4.63		
n (Samp)	338	20	338	23		338	14		
n (Patient)	184	20	184	23		184	14		
UO only									
Median	0.0407	0.0682	0.0407	0.0400		0.0407	0.397		
Average	0.402	0.853	0.402	0.737		0.402	0.930		
Stdev	0.925	1.66	0.925	1.54		0.925	2.00		
p (t-test)		0.014		0.056			0.035		
Min	0.0116	0.0116	0.0116	0.0116		0.0116	0.0116		
Max	5.79	8.53	5.79	8.07		5.79	9.43		

-continued

n (Samp)	156	54	156	56	156	23			
n (Patient)	100	54	100	56	100	23			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.55	0.60	0.54	0.56	0.51	0.74	0.71	0.67
SE	0.044	0.068	0.046	0.044	0.064	0.045	0.060	0.079	0.065
p	0.22	0.45	0.027	0.37	0.35	0.74	7.0E-5	0.0068	0.010
nCohort 1	155	338	156	155	338	156	155	338	156
nCohort 2	61	20	54	60	23	56	25	14	23
Cutoff 1	0.0358	0.0400	0.0400	0.0255	0.0358	0.0116	0.0682	0.0838	0.0400
Sens 1	70%	70%	72%	78%	83%	88%	80%	79%	74%
Spec 1	38%	37%	40%	26%	33%	13%	64%	60%	40%
Cutoff 2	0.0255	0.0116	0.0262	0.0116	0.0358	0.0116	0.0682	0.0544	0.0358
Sens 2	87%	80%	91%	92%	83%	88%	80%	86%	87%
Spec 2	26%	10%	26%	9%	33%	13%	64%	46%	38%
Cutoff 3	0.0116	0	0.0262	0.0116	0.0255	0	0.0358	0.0358	0.0116
Sens 3	92%	100%	91%	92%	91%	100%	100%	93%	96%
Spec 3	9%	0%	26%	9%	21%	0%	38%	33%	13%
Cutoff 4	0.0994	0.397	0.0994	0.0994	0.397	0.0994	0.0994	0.397	0.0994
Sens 4	31%	45%	37%	37%	22%	38%	68%	50%	61%
Spec 4	72%	79%	75%	72%	79%	75%	72%	79%	75%
Cutoff 5	0.397	0.465	0.397	0.397	0.465	0.397	0.397	0.465	0.397
Sens 5	26%	45%	30%	23%	22%	23%	32%	43%	26%
Spec 5	82%	80%	85%	82%	80%	85%	82%	80%	85%
Cutoff 6	1.75	1.99	1.58	1.75	1.99	1.58	1.75	1.99	1.58
Sens 6	13%	15%	19%	17%	13%	14%	16%	36%	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	2.2	0.99	2.0	1.2	2.8	0.62	>4.4	1.0	1.3
p Value	0.082	0.99	0.17	0.70	0.13	0.28	<0.19	1.0	0.72
95% CI of	0.90	0.28	0.75	0.50	0.73	0.26	>0.47	0.062	0.28
OR Quart 2	5.4	3.5	5.2	2.8	11	1.5	na	16	6.3
OR Quart 3	2.0	0.19	2.4	1.4	2.1	0.27	>15	5.2	0.98
p Value	0.12	0.13	0.067	0.42	0.31	0.013	<0.012	0.13	0.98
95% CI of	0.83	0.022	0.94	0.60	0.50	0.097	>1.8	0.60	0.19
OR Quart 3	4.9	1.7	6.4	3.3	8.6	0.75	na	46	5.1
OR Quart 4	1.9	1.9	2.4	1.2	2.0	1.4	>13	7.5	5.6
p Value	0.18	0.28	0.075	0.70	0.32	0.42	<0.017	0.062	0.012
95% CI of	0.75	0.60	0.92	0.50	0.50	0.63	>1.6	0.91	1.5
OR Quart 4	4.6	5.8	6.2	2.8	8.5	3.1	na	62	21
Immunoglobulin G4									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	
sCr or UO									
Median	163	269	163	282	163	167			
Average	430	558	430	525	430	487			
Stdev	667	726	667	697	667	702			
p (t-test)		0.069		0.16		0.58			
Min	0.619	1.73	0.619	2.63	0.619	4.92			
Max	2400	2400	2400	2400	2400	2400			
n (Samp)	461	119	461	126	461	47			
n (Patient)	222	119	222	126	222	47			
sCr only									
Median	210	293	210	358	210	291			
Average	479	521	479	589	479	542			
Stdev	689	736	689	742	689	675			
p (t-test)		0.71		0.29		0.65			
Min	0.00642	28.3	0.00642	5.21	0.00642	8.44			
Max	2400	2400	2400	2400	2400	2400			
n (Samp)	1011	40	1011	46	1011	26			
n (Patient)	373	40	373	46	373	26			
UO only									
Median	203	309	203	307	203	172			
Average	482	603	482	552	482	497			
Stdev	702	741	702	708	702	707			
p (t-test)		0.12		0.35		0.89			
Min	0.619	1.73	0.619	2.63	0.619	4.92			
Max	2400	2400	2400	2400	2400	2400			

-continued

n (Samp)	433	107	433	115	433	44			
n (Patient)	171	107	171	115	171	44			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.56	0.58	0.58	0.56	0.56	0.53	0.55	0.50
SE	0.030	0.048	0.032	0.029	0.045	0.031	0.045	0.059	0.046
p	0.0012	0.25	0.0089	0.0055	0.20	0.040	0.49	0.37	0.94
nCohort 1	461	1011	433	461	1011	433	461	1011	433
nCohort 2	119	40	107	126	46	115	47	26	44
Cutoff 1	146	146	181	113	107	129	80.8	120	78.5
Sens 1	71%	70%	70%	71%	72%	70%	70%	73%	70%
Spec 1	47%	40%	49%	42%	33%	38%	34%	36%	30%
Cutoff 2	75.7	108	93.8	80.8	55.4	98.1	55.4	53.9	55.4
Sens 2	81%	80%	80%	80%	80%	80%	81%	81%	82%
Spec 2	34%	33%	32%	34%	23%	32%	29%	23%	25%
Cutoff 3	28.9	48.3	27.6	21.5	27.6	21.3	20.5	11.3	26.1
Sens 3	91%	90%	91%	90%	91%	90%	91%	92%	91%
Spec 3	15%	21%	12%	12%	14%	9%	11%	7%	11%
Cutoff 4	356	402	402	356	402	402	356	402	402
Sens 4	34%	22%	38%	41%	46%	37%	30%	42%	30%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	523	597	587	523	597	587	523	597	587
Sens 5	26%	18%	26%	27%	28%	26%	26%	27%	23%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1470	1640	1910	1470	1640	1910	1470	1640	1910
Sens 6	13%	12%	11%	12%	13%	10%	13%	8%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	0.62	1.5	1.4	0.72	1.6	1.5	0.66	1.6
p Value	0.61	0.40	0.24	0.35	0.49	0.15	0.37	0.53	0.28
95% CI of	0.61	0.20	0.77	0.72	0.28	0.84	0.62	0.18	0.68
OR Quart 2	2.4	1.9	2.9	2.6	1.8	3.0	3.6	2.4	3.9
OR Quart 3	3.3	2.3	2.4	2.4	0.91	2.1	1.4	1.0	1.1
p Value	1.2E-4	0.051	0.0064	0.0033	0.82	0.023	0.50	1.0	0.81
95% CI of	1.8	1.00	1.3	1.3	0.38	1.1	0.56	0.32	0.44
OR Quart 3	6.0	5.5	4.6	4.4	2.2	3.8	3.4	3.1	2.9
OR Quart 4	2.2	1.1	2.1	2.3	1.6	2.1	1.5	1.7	1.2
p Value	0.016	0.81	0.028	0.0070	0.25	0.023	0.37	0.32	0.65
95% CI of	1.2	0.43	1.1	1.3	0.72	1.1	0.62	0.60	0.49
OR Quart 4	4.0	3.0	4.0	4.1	3.4	3.8	3.6	4.7	3.1
Interleukin-21									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	9.57	4.21	9.57	4.50	9.57	5.09			
Average	11.9	7.35	11.9	8.30	11.9	8.54			
Stdev	11.4	8.68	11.4	10.1	11.4	10.4			
p (t-test)		4.2E-5		9.9E-4		0.049			
Min	0.00404	0.00411	0.00404	0.0122	0.00404	0.0210			
Max	87.9	56.2	87.9	59.4	87.9	49.5			
n (Samp)	463	120	463	130	463	47			
n (Patient)	223	120	223	130	223	47			
sCr only									
Median	7.83	7.12	7.83	5.28	7.83	3.77			
Average	10.7	10.9	10.7	8.66	10.7	5.91			
Stdev	11.1	12.0	11.1	8.54	11.1	6.18			
p (t-test)		0.89		0.23		0.030			
Min	0.00404	0.0177	0.00404	0.0122	0.00404	0.0210			
Max	87.9	56.2	87.9	41.5	87.9	20.6			
n (Samp)	1019	40	1019	46	1019	26			
n (Patient)	375	40	375	46	375	26			
UO only									
Median	9.33	3.57	9.33	4.53	9.33	5.20			
Average	11.6	6.81	11.6	8.06	11.6	8.62			
Stdev	11.1	7.25	11.1	9.91	11.1	10.6			
p (t-test)		2.0E-5		0.0016		0.085			
Min	0.00404	0.00404	0.00404	0.0122	0.00404	0.0177			
Max	87.9	30.5	87.9	59.4	87.9	49.5			

-continued

	n (Samp)	435	108	435	119	435	44			
	n (Patient)	173	108	173	119	173	44			
		0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage			
		sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC		0.36	0.50	0.36	0.38	0.47	0.39	0.38	0.37	0.39
SE		0.030	0.047	0.031	0.029	0.044	0.030	0.045	0.059	0.047
p		2.4E-6	0.95	5.5E-6	6.4E-5	0.47	1.4E-4	0.010	0.027	0.024
nCohort 1	463	1019	435	463	1019	435	463	1019	435	
nCohort 2	120	40	108	130	46	119	47	26	44	
Cutoff 1		1.82	3.10	1.62	1.99	3.10	1.76	1.29	0.728	1.57
Sens 1		71%	70%	70%	70%	72%	71%	70%	73%	70%
Spec 1		17%	32%	17%	18%	32%	17%	13%	14%	17%
Cutoff 2		1.05	2.19	1.03	1.37	2.16	1.13	0.689	0.418	0.362
Sens 2		80%	80%	81%	80%	80%	81%	81%	81%	82%
Spec 2		11%	24%	13%	13%	24%	13%	9%	12%	9%
Cutoff 3		0.0528	0.313	0.0528	0.296	0.968	0.227	0.136	0.0350	0.136
Sens 3		90%	90%	91%	90%	91%	91%	91%	92%	91%
Spec 3		4%	11%	6%	7%	15%	9%	6%	5%	8%
Cutoff 4		15.8	13.5	14.9	15.8	13.5	14.9	15.8	13.5	14.9
Sens 4		12%	28%	13%	14%	26%	14%	17%	15%	18%
Spec 4		70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5		19.2	17.9	19.2	19.2	17.9	19.2	19.2	17.9	19.2
Sens 5		11%	22%	9%	10%	17%	9%	13%	4%	14%
Spec 5		80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6		26.2	25.1	25.4	26.2	25.1	25.4	26.2	25.1	25.4
Sens 6		3%	12%	2%	5%	4%	5%	6%	0%	7%
Spec 6		90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2		1.8	0.79	2.1	1.6	0.72	2.0	1.5	3.1	0.87
p Value		0.12	0.63	0.050	0.14	0.49	0.044	0.44	0.17	0.79
95% CI of		0.87	0.31	1.0	0.85	0.29	1.0	0.54	0.61	0.30
OR Quart 2		3.6	2.0	4.4	3.1	1.8	4.0	4.0	15	2.5
OR Quart 3		3.2	1.3	2.9	2.7	1.6	2.6	1.8	3.1	1.6
p Value		6.1E-4	0.52	0.0034	0.0015	0.24	0.0052	0.24	0.17	0.35
95% CI of		1.6	0.57	1.4	1.5	0.73	1.3	0.68	0.61	0.61
OR Quart 3		6.2	3.1	6.0	5.0	3.5	5.0	4.7	15	4.0
OR Quart 4		4.4	0.90	4.8	3.2	0.91	3.9	2.9	6.3	2.3
p Value		9.1E-6	0.82	8.8E-6	1.8E-4	0.83	3.9E-5	0.024	0.017	0.060
95% CI of		2.3	0.36	2.4	1.7	0.38	2.0	1.1	1.4	0.97
OR Quart 4		8.4	2.3	9.7	5.8	2.2	7.4	7.1	28	5.6
Interleukin-23										
		0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
		Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	
sCr or UO										
Median		392	156	392	186			392	127	
Average		625	311	625	330			625	376	
Stdev		802	435	802	412			802	537	
p (t-test)			4.1E-5		5.8E-5				0.038	
Min		0.491	0.564	0.491	0.491			0.491	0.552	
Max		8520	2340	8520	1760			8520	2000	
n (Samp)		463	120	463	130			463	47	
n (Patient)		223	120	223	130			223	47	
sCr only										
Median		272	185	272	167			272	145	
Average		518	343	518	307			518	333	
Stdev		706	468	706	375			706	454	
p (t-test)			0.12		0.044				0.18	
Min		0.491	0.785	0.491	0.552			0.491	0.491	
Max		8520	2000	8520	1370			8520	1820	
n (Samp)		1019	40	1019	46			1019	26	
n (Patient)		375	40	375	46			375	26	
UO only										
Median		385	138	385	150			385	135	
Average		634	287	634	314			634	358	
Stdev		804	401	804	419			804	500	
p (t-test)			1.6E-5		3.3E-5				0.026	
Min		0.491	0.564	0.491	0.491			0.491	0.552	
Max		8520	2340	8520	1760			8520	2000	

-continued

n (Samp)	435	108	435	119	435	44			
n (Patient)	173	108	173	119	173	44			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.38	0.47	0.35	0.39	0.43	0.36	0.39	0.43	0.37
SE	0.030	0.047	0.031	0.029	0.045	0.030	0.045	0.059	0.047
p	9.5E-5	0.50	2.2E-6	1.3E-4	0.14	6.6E-6	0.013	0.21	0.0044
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	38.3	66.6	1.31	3.48	1.41	3.02	1.41	1.41	1.11
Sens 1	70%	70%	72%	70%	74%	71%	72%	73%	70%
Spec 1	25%	32%	19%	21%	25%	20%	20%	25%	17%
Cutoff 2	1.09	21.4	1.05	1.05	1.08	1.01	0.754	1.01	0.723
Sens 2	81%	80%	81%	81%	83%	81%	85%	81%	82%
Spec 2	17%	28%	14%	15%	20%	12%	9%	18%	7%
Cutoff 3	0.844	1.09	0.723	0.723	0.754	0.720	0.720	0.682	0.643
Sens 3	91%	90%	92%	90%	93%	92%	91%	92%	91%
Spec 3	11%	21%	7%	9%	11%	7%	8%	6%	3%
Cutoff 4	735	608	756	735	608	756	735	608	756
Sens 4	11%	20%	9%	14%	17%	13%	19%	23%	16%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	1120	894	1020	1120	894	1020	1120	894	1020
Sens 5	6%	10%	6%	5%	11%	9%	11%	8%	9%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1580	1400	1630	1580	1400	1630	1580	1400	1630
Sens 6	2%	5%	1%	2%	0%	3%	6%	4%	5%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.2	2.0	2.3	1.8	1.8	1.5	1.4	0.66	2.3
p Value	0.036	0.20	0.040	0.079	0.25	0.28	0.47	0.53	0.10
95% CI of	1.1	0.69	1.0	0.94	0.68	0.73	0.55	0.19	0.85
OR Quart 2	4.6	6.0	5.1	3.4	4.5	3.0	3.7	2.4	6.3
OR Quart 3	5.6	4.0	5.1	2.8	2.2	3.7	1.3	1.5	1.0
p Value	6.9E-7	0.0065	1.9E-5	9.9E-4	0.087	7.0E-5	0.63	0.43	1.0
95% CI of	2.8	1.5	2.4	1.5	0.89	1.9	0.48	0.53	0.31
OR Quart 3	11	11	11	5.1	5.5	7.1	3.3	4.3	3.2
OR Quart 4	3.6	1.2	4.9	2.9	1.8	3.4	2.5	1.2	3.6
p Value	4.0E-4	0.76	2.7E-5	6.5E-4	0.25	2.4E-4	0.042	0.77	0.0085
95% CI of	1.8	0.36	2.3	1.6	0.68	1.8	1.0	0.39	1.4
OR Quart 4	7.2	4.0	10	5.3	4.5	6.5	5.9	3.5	9.4
Interleukin-28A									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2		Cohort 1	Cohort 2		
<u>sCr or UO</u>									
Median	20.8	11.8	20.8	10.4		20.8	12.4		
Average	36.5	24.4	36.5	24.9		36.5	26.3		
Stdev	43.7	31.6	43.7	34.6		43.7	39.8		
p (t-test)		0.0048		0.0055			0.12		
Min	0.0254	0.0254	0.0254	0.0254		0.0254	0.0254		
Max	228	168	228	172		228	186		
n (Samp)	463	120	463	130		463	47		
n (Patient)	223	120	223	130		223	47		
<u>sCr only</u>									
Median	16.1	10.1	16.1	10.4		16.1	7.94		
Average	33.0	26.8	33.0	21.8		33.0	20.9		
Stdev	41.3	37.0	41.3	30.9		41.3	29.6		
p (t-test)		0.35		0.071			0.14		
Min	0.0254	0.0777	0.0254	0.0254		0.0254	0.0495		
Max	235	168	235	131		235	89.5		
n (Samp)	1019	40	1019	46		1019	26		
n (Patient)	375	40	375	46		375	26		
<u>UO only</u>									
Median	23.1	11.8	23.1	12.0		23.1	12.3		
Average	37.9	24.0	37.9	25.3		37.9	25.9		
Stdev	44.6	29.8	44.6	34.5		44.6	40.1		
p (t-test)		0.0022		0.0046			0.089		
Min	0.0254	0.0254	0.0254	0.0254		0.0254	0.0254		
Max	228	127	228	172		228	186		

-continued

n (Samp)	435	108	435	119	435	44			
n (Patient)	173	108	173	119	173	44			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.49	0.43	0.44	0.45	0.43	0.43	0.42	0.42
SE	0.030	0.047	0.032	0.029	0.045	0.030	0.045	0.059	0.047
p	0.074	0.87	0.025	0.036	0.28	0.018	0.10	0.18	0.087
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	0.246	0.246	0.243	0.198	0.216	0.198	0.189	0.176	0.198
Sens 1	72%	70%	73%	72%	72%	71%	70%	73%	70%
Spec 1	29%	32%	25%	25%	30%	23%	24%	23%	23%
Cutoff 2	0.182	0.194	0.176	0.176	0.184	0.155	0.134	0.0996	0.142
Sens 2	81%	80%	82%	80%	80%	81%	81%	81%	82%
Spec 2	22%	26%	19%	21%	24%	19%	18%	17%	17%
Cutoff 3	0.0996	0.149	0.0775	0.0854	0.0854	0.0854	0.0775	0.0775	0.0784
Sens 3	91%	95%	91%	93%	93%	91%	91%	92%	93%
Spec 3	16%	20%	7%	12%	12%	11%	7%	6%	10%
Cutoff 4	51.6	45.8	53.1	51.6	45.8	53.1	51.6	45.8	53.1
Sens 4	18%	20%	16%	17%	17%	16%	17%	15%	16%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	68.1	62.2	68.3	68.1	62.2	68.3	68.1	62.2	68.3
Sens 5	11%	15%	10%	11%	9%	11%	15%	15%	14%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	98.2	90.1	96.2	98.2	90.1	96.2	98.2	90.1	96.2
Sens 6	3%	8%	4%	5%	7%	5%	4%	0%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.6	1.6	1.9	1.7	2.7	2.1	1.6	1.5	1.2
p Value	0.12	0.34	0.070	0.092	0.063	0.026	0.32	0.52	0.79
95% CI of	0.88	0.61	0.95	0.92	0.95	1.1	0.61	0.42	0.40
OR Quart 2	3.0	4.2	3.6	3.1	7.7	4.0	4.4	5.4	3.3
OR Quart 3	2.6	2.1	2.8	2.6	3.6	2.5	2.0	1.5	2.1
p Value	0.0013	0.13	0.0017	0.0014	0.014	0.0044	0.17	0.52	0.12
95% CI of	1.5	0.82	1.5	1.4	1.3	1.3	0.75	0.42	0.83
OR Quart 3	4.7	5.2	5.3	4.6	9.8	4.7	5.1	5.4	5.5
OR Quart 4	1.4	1.2	2.0	1.7	2.3	2.4	2.5	2.6	2.3
p Value	0.26	0.79	0.048	0.069	0.14	0.0060	0.053	0.11	0.077
95% CI of	0.77	0.41	1.0	0.96	0.77	1.3	0.99	0.80	0.91
OR Quart 4	2.7	3.2	3.8	3.2	6.6	4.6	6.3	8.3	5.9

Interleukin-33

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	51.7	28.7	51.7	30.6	51.7	28.5
Average	66.3	36.4	66.3	41.3	66.3	35.3
Stdev	72.8	34.8	72.8	37.4	72.8	38.8
p (t-test)		1.4E-5		1.7E-4		0.0041
Min	0.0232	0.0372	0.0232	0.0232	0.0232	0.0232
Max	958	148	958	162	958	155
n (Samp)	463	120	463	130	463	47
n (Patient)	223	120	223	130	223	47
<u>sCr only</u>						
Median	42.7	32.7	42.7	31.8	42.7	18.8
Average	58.1	38.1	58.1	38.9	58.1	33.3
Stdev	62.9	30.5	62.9	34.0	62.9	33.5
p (t-test)		0.046		0.040		0.046
Min	0.0232	0.0743	0.0232	0.0232	0.0232	0.0591
Max	958	138	958	133	958	122
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26
<u>UO only</u>						
Median	50.4	23.2	50.4	28.8	50.4	33.1
Average	67.0	35.9	67.0	39.9	67.0	35.2
Stdev	74.1	38.6	74.1	38.5	74.1	37.5
p (t-test)		2.9E-5		1.3E-4		0.0051
Min	0.0232	0.0372	0.0232	0.0232	0.0232	0.0232
Max	958	203	958	162	958	155

-continued

n (Samp)	435	108	435	119	435	44			
n (Patient)	173	108	173	119	173	44			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.36	0.43	0.35	0.39	0.42	0.38	0.35	0.38	0.35
SE	0.030	0.048	0.031	0.029	0.045	0.030	0.045	0.059	0.047
p	4.7E-6	0.13	8.1E-7	2.2E-4	0.087	4.4E-5	7.1E-4	0.044	9.5E-4
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	12.9	16.3	9.92	16.8	17.0	15.3	4.46	6.25	6.20
Sens 1	70%	70%	71%	70%	74%	71%	70%	73%	70%
Spec 1	21%	27%	18%	24%	28%	21%	14%	18%	15%
Cutoff 2	7.93	12.1	2.92	10.7	6.57	6.58	0.172	2.84	0.172
Sens 2	80%	80%	81%	80%	80%	81%	81%	81%	82%
Spec 2	17%	23%	14%	20%	18%	16%	13%	14%	12%
Cutoff 3	0.0837	7.09	0.0731	0.0768	0.0768	0.0749	0.0591	0.0631	0.0686
Sens 3	90%	90%	91%	90%	91%	92%	91%	96%	91%
Spec 3	11%	19%	6%	9%	10%	8%	5%	6%	5%
Cutoff 4	84.4	74.8	85.3	84.4	74.8	85.3	84.4	74.8	85.3
Sens 4	10%	15%	11%	14%	20%	12%	11%	12%	9%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	109	96.1	109	109	96.1	109	109	96.1	109
Sens 5	4%	2%	5%	8%	7%	9%	6%	8%	7%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	145	130	148	145	130	148	145	130	148
Sens 6	1%	2%	1%	1%	2%	1%	2%	0%	2%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.5	4.1	2.3	1.7	1.1	2.0	1.7	2.4	1.5
p Value	0.012	0.029	0.031	0.11	0.80	0.057	0.39	0.21	0.52
95% CI of	1.2	1.2	1.1	0.89	0.43	0.98	0.53	0.61	0.42
OR Quart 2	5.2	15	5.0	3.2	3.0	4.0	5.2	9.3	5.6
OR Quart 3	3.9	4.9	3.2	3.2	2.2	3.6	2.8	2.4	4.1
p Value	1.2E-4	0.014	0.0019	1.8E-4	0.070	1.5E-4	0.059	0.21	0.014
95% CI of	2.0	1.4	1.5	1.7	0.94	1.9	0.96	0.61	1.3
OR Quart 3	7.9	17	6.7	5.8	5.2	7.0	8.0	9.3	13
OR Quart 4	4.7	3.8	5.5	2.6	1.5	3.6	4.9	3.1	5.5
p Value	1.1E-5	0.042	2.9E-6	0.0022	0.36	1.3E-4	0.0021	0.094	0.0026
95% CI of	2.4	1.0	2.7	1.4	0.61	1.9	1.8	0.83	1.8
OR Quart 4	9.4	14	11	4.8	3.8	7.1	13	12	17
Vascular endothelial growth factor receptor 2									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	393	825	393	599	393	370			
Average	584	1020	584	794	584	576			
Stdev	622	838	622	701	622	601			
p (t-test)		1.3E-6		0.0092		0.95			
Min	0.218	0.218	0.218	0.386	0.218	1.13			
Max	4170	3930	4170	4210	4170	2260			
n (Samp)	212	87	212	93	212	31			
n (Patient)	124	87	124	93	124	31			
sCr only									
Median	647	617	647	587	647	448			
Average	807	876	807	747	807	884			
Stdev	796	985	796	809	796	970			
p (t-test)		0.66		0.68		0.69			
Min	0.218	0.218	0.218	0.386	0.218	1.13			
Max	5940	3930	5940	4210	5940	2720			
n (Samp)	504	28	504	32	504	18			
n (Patient)	236	28	236	32	236	18			
UO only									
Median	407	916	407	665	407	455			
Average	612	1160	612	897	612	639			
Stdev	669	1080	669	987	669	684			
p (t-test)		3.3E-7		0.0042		0.84			
Min	0.218	0.218	0.218	0.616	0.218	0.218			
Max	4210	7140	4210	7060	4210	2820			

-continued

n (Samp)	224	77	224	83	224	30			
n (Patient)	120	77	120	83	120	30			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.49	0.70	0.61	0.48	0.62	0.50	0.48	0.51
SE	0.036	0.056	0.037	0.036	0.053	0.037	0.056	0.070	0.057
p	2.3E-6	0.89	6.1E-8	0.0018	0.65	0.0018	0.99	0.78	0.83
nCohort 1	212	504	224	212	504	224	212	504	224
nCohort 2	87	28	77	93	32	83	31	18	30
Cutoff 1	524	291	606	346	288	346	140	92.0	196
Sens 1	70%	71%	70%	71%	72%	72%	71%	72%	73%
Spec 1	58%	30%	62%	46%	30%	46%	27%	15%	31%
Cutoff 2	252	54.3	495	262	182	234	11.6	22.6	7.42
Sens 2	80%	82%	81%	81%	81%	81%	81%	83%	80%
Spec 2	39%	14%	57%	39%	22%	35%	14%	11%	12%
Cutoff 3	27.3	1.40	140	113	64.5	119	1.40	1.48	1.40
Sens 3	91%	93%	91%	90%	91%	90%	94%	94%	93%
Spec 3	16%	8%	25%	25%	14%	23%	12%	8%	10%
Cutoff 4	708	1010	710	708	1010	710	708	1010	710
Sens 4	61%	29%	66%	43%	28%	47%	35%	39%	37%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	975	1360	1070	975	1360	1070	975	1360	1070
Sens 5	43%	18%	42%	34%	12%	30%	19%	28%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1410	1740	1450	1410	1740	1450	1410	1740	1450
Sens 6	29%	14%	32%	15%	6%	16%	10%	22%	10%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.68	1.4	0.89	1.8	1.6	1.6	0.63	0	0.58
p Value	0.37	0.58	0.81	0.13	0.40	0.25	0.41	na	0.37
95% CI of	0.29	0.46	0.34	0.84	0.52	0.72	0.21	na	0.18
OR Quart 2	1.6	4.0	2.3	3.9	5.1	3.5	1.9	na	1.9
OR Quart 3	2.1	1.0	3.4	2.2	2.5	1.9	0.75	0.56	1.3
p Value	0.051	1.0	0.0030	0.043	0.089	0.094	0.59	0.36	0.61
95% CI of	1.00	0.31	1.5	1.0	0.87	0.89	0.26	0.16	0.48
OR Quart 3	4.4	3.2	7.8	4.6	7.4	4.2	2.2	2.0	3.5
OR Quart 4	3.4	1.4	4.7	3.1	1.4	2.9	1.0	1.0	0.84
p Value	8.5E-4	0.58	1.6E-4	0.0023	0.56	0.0052	0.97	0.99	0.76
95% CI of	1.7	0.46	2.1	1.5	0.44	1.4	0.37	0.34	0.29
OR Quart 4	7.1	4.0	11	6.6	4.6	6.2	2.8	3.0	2.5
Prostate-specific antigen									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.0131	0.0123	0.0131	0.126	nd	nd			
Average	4.19	4.25	4.19	7.92	nd	nd			
Stdev	7.89	8.36	7.89	9.60	nd	nd			
p (t-test)		0.98		0.10	nd	nd			
Min	0.00354	0.00392	0.00354	0.00462	nd	nd			
Max	20.0	20.0	20.0	20.0	nd	nd			
n (Samp)	52	19	52	19	nd	nd			
n (Patient)	41	19	41	19	nd	nd			
UO only									
Median	0.0140	0.0349	0.0140	0.0849	nd	nd			
Average	3.70	4.05	3.70	6.79	nd	nd			
Stdev	7.37	8.26	7.37	9.06	nd	nd			
p (t-test)		0.88		0.15	nd	nd			
Min	0.00354	0.00392	0.00354	0.00462	nd	nd			
Max	20.0	20.0	20.0	20.0	nd	nd			
n (Samp)	44	15	44	20	nd	nd			
n (Patient)	34	15	34	20	nd	nd			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	nd	0.53	0.65	nd	0.63	nd	nd	nd
SE	0.079	nd	0.088	0.077	nd	0.078	nd	nd	nd
p	0.54	nd	0.71	0.046	nd	0.11	nd	nd	nd

-continued

nCohort 1	52	nd	44	52	nd	44	nd	nd	nd
nCohort 2	19	nd	15	19	nd	20	nd	nd	nd
Cutoff 1	0.0105	nd	0.00959	0.0127	nd	0.0135	nd	nd	nd
Sens 1	74%	nd	73%	74%	nd	70%	nd	nd	nd
Spec 1	44%	nd	36%	50%	nd	50%	nd	nd	nd
Cutoff 2	0.00897	nd	0.00870	0.00938	nd	0.0127	nd	nd	nd
Sens 2	84%	nd	87%	84%	nd	80%	nd	nd	nd
Spec 2	33%	nd	25%	37%	nd	45%	nd	nd	nd
Cutoff 3	0.00606	nd	0.00776	0.00776	nd	0.00781	nd	nd	nd
Sens 3	95%	nd	93%	95%	nd	90%	nd	nd	nd
Spec 3	8%	nd	18%	21%	nd	18%	nd	nd	nd
Cutoff 4	0.105	nd	0.127	0.105	nd	0.127	nd	nd	nd
Sens 4	26%	nd	27%	53%	nd	45%	nd	nd	nd
Spec 4	71%	nd	70%	71%	nd	70%	nd	nd	nd
Cutoff 5	11.9	nd	4.24	11.9	nd	4.24	nd	nd	nd
Sens 5	21%	nd	20%	37%	nd	40%	nd	nd	nd
Spec 5	81%	nd	82%	81%	nd	82%	nd	nd	nd
Cutoff 6	20.0	nd	20.0	20.0	nd	20.0	nd	nd	nd
Sens 6	0%	nd	0%	0%	nd	0%	nd	nd	nd
Spec 6	100%	nd	100%	100%	nd	100%	nd	nd	nd
OR Quart 2	3.0	nd	3.0	2.9	nd	2.0	nd	nd	nd
p Value	0.17	nd	0.24	0.25	nd	0.42	nd	nd	nd
95% CI of	0.62	nd	0.48	0.48	nd	0.38	nd	nd	nd
OR Quart 2	14	nd	19	17	nd	10	nd	nd	nd
OR Quart 3	1.8	nd	3.0	2.9	nd	1.4	nd	nd	nd
p Value	0.48	nd	0.24	0.25	nd	0.67	nd	nd	nd
95% CI of	0.36	nd	0.48	0.48	nd	0.27	nd	nd	nd
OR Quart 3	9.1	nd	19	17	nd	7.8	nd	nd	nd
OR Quart 4	1.3	nd	1.5	4.8	nd	4.3	nd	nd	nd
p Value	0.74	nd	0.69	0.081	nd	0.071	nd	nd	nd
95% CI of	0.25	nd	0.21	0.83	nd	0.88	nd	nd	nd
OR Quart 4	7.1	nd	11	28	nd	21	nd	nd	nd

Lutropin subunit beta

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	19.2	16.5	19.2	25.6	nd	nd			
Average	60.1	41.4	60.1	69.5	nd	nd			
Stdev	101	64.5	101	92.5	nd	nd			
p (t-test)		0.20		0.58	nd	nd			
Min	0.0297	0.130	0.0297	0.0746	nd	nd			
Max	400	277	400	325	nd	nd			
n (Samp)	127	59	127	46	nd	nd			
n (Patient)	68	59	68	46	nd	nd			
sCr only									
Median	21.0	5.20	21.0	23.1	21.0	9.45			
Average	60.1	36.1	60.1	77.8	60.1	12.5			
Stdev	92.4	55.8	92.4	91.5	92.4	13.5			
p (t-test)		0.29		0.45		0.21			
Min	0.0297	0.211	0.0297	0.146	0.0297	0.505			
Max	400	179	400	256	400	36.9			
n (Samp)	267	17	267	16	267	6			
n (Patient)	128	17	128	16	128	6			
UO only									
Median	19.4	21.0	19.4	23.6	19.4	16.2			
Average	63.9	48.5	63.9	68.9	63.9	86.8			
Stdev	99.3	74.9	99.3	100	99.3	119			
p (t-test)		0.31		0.76		0.51			
Min	0.0297	0.130	0.0297	0.0746	0.0297	0.463			
Max	400	325	400	393	400	332			
n (Samp)	148	51	148	47	148	9			
n (Patient)	72	51	72	47	72	9			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.39	0.51	0.57	0.54	0.55	nd	0.33	0.57
SE	0.046	0.075	0.047	0.050	0.076	0.049	nd	0.12	0.10
p	0.74	0.16	0.89	0.19	0.63	0.28	nd	0.17	0.51

-continued

nCohort 1	127	267	148	127	267	148	nd	267	148
nCohort 2	59	17	51	46	16	47	nd	6	9
Cutoff 1	4.35	3.23	7.60	10.6	5.10	10.6	nd	3.00	11.6
Sens 1	71%	71%	71%	72%	75%	70%	nd	83%	78%
Spec 1	28%	19%	35%	41%	24%	39%	nd	18%	40%
Cutoff 2	2.03	1.98	4.33	6.10	4.35	6.19	nd	3.00	6.57
Sens 2	81%	82%	80%	80%	81%	81%	nd	83%	89%
Spec 2	16%	15%	26%	37%	22%	34%	nd	18%	34%
Cutoff 3	0.393	0.339	0.986	0.933	0.408	3.86	nd	0.448	0.422
Sens 3	92%	94%	90%	91%	94%	91%	nd	100%	100%
Spec 3	9%	8%	11%	13%	9%	26%	nd	10%	9%
Cutoff 4	38.7	46.3	43.9	38.7	46.3	43.9	nd	46.3	43.9
Sens 4	29%	24%	29%	37%	38%	32%	nd	0%	33%
Spec 4	70%	70%	70%	70%	70%	70%	nd	70%	70%
Cutoff 5	80.9	89.1	134	80.9	89.1	134	nd	89.1	134
Sens 5	14%	18%	10%	28%	38%	19%	nd	0%	33%
Spec 5	80%	80%	80%	80%	80%	80%	nd	80%	80%
Cutoff 6	232	225	217	232	225	217	nd	225	217
Sens 6	5%	0%	8%	11%	6%	13%	nd	0%	22%
Spec 6	91%	90%	91%	91%	90%	91%	nd	90%	91%
OR Quart 2	0.84	0.49	1.7	3.0	0.57	1.8	nd	>1.0	4.3
p Value	0.70	0.41	0.27	0.046	0.46	0.24	nd	<0.98	0.20
95% CI of	0.35	0.086	0.67	1.0	0.13	0.67	nd	>0.063	0.46
OR Quart 2	2.0	2.7	4.2	8.7	2.5	4.9	nd	na	41
OR Quart 3	1.2	0.74	1.7	2.4	0.38	2.0	nd	>2.1	1.0
p Value	0.66	0.70	0.27	0.12	0.25	0.17	nd	<0.55	1.0
95% CI of	0.51	0.16	0.67	0.80	0.071	0.75	nd	>0.19	0.060
OR Quart 3	2.8	3.4	4.2	7.1	2.0	5.3	nd	na	17
OR Quart 4	0.93	2.1	1.1	2.9	1.2	1.6	nd	>3.2	3.1
p Value	0.88	0.24	0.85	0.053	0.77	0.34	nd	<0.32	0.34
95% CI of	0.39	0.61	0.42	0.99	0.35	0.60	nd	>0.32	0.31
OR Quart 4	2.2	7.4	2.9	8.4	4.1	4.4	nd	na	31

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
<u>sCr or UO</u>									
Median	2250	3580	2250	2690	2250	2950			
Average	2910	3890	2910	4150	2910	3090			
Stdev	2240	4020	2240	6560	2240	1780			
p (t-test)		3.9E-4		6.5E-4		0.59			
Min	6.83	221	6.83	216	6.83	293			
Max	22000	40700	22000	55700	22000	6560			
n (Samp)	463	119	463	128	463	47			
n (Patient)	223	119	223	128	223	47			
<u>sCr only</u>									
Median	2830	2300	2830	2420	2830	1930			
Average	3460	2540	3460	3220	3460	2360			
Stdev	3360	1640	3360	2380	3360	1600			
p (t-test)		0.085		0.63		0.097			
Min	6.83	221	6.83	216	6.83	387			
Max	55700	6210	55700	10800	55700	6110			
n (Samp)	1014	40	1014	46	1014	26			
n (Patient)	373	40	373	46	373	26			
<u>UO only</u>									
Median	2400	3900	2400	2850	2400	2920			
Average	2980	4670	2980	4590	2980	3220			
Stdev	2070	4820	2070	7080	2070	1960			
p (t-test)		4.3E-8		4.0E-5		0.45			
Min	173	506	173	224	173	293			
Max	11700	40700	11700	55700	11700	9700			
n (Samp)	436	107	436	117	436	44			
n (Patient)	173	107	173	117	173	44			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.40	0.66	0.56	0.48	0.58	0.56	0.37	0.56
SE	0.030	0.048	0.031	0.029	0.044	0.031	0.045	0.059	0.047
p	1.2E-4	0.043	2.3E-7	0.026	0.61	0.0086	0.20	0.025	0.21

-continued

nCohort 1	463	1014	436	463	1014	436	463	1014	436
nCohort 2	119	40	107	128	46	117	47	26	44
Cutoff 1	2270	1150	2690	1950	1680	2080	2150	1190	2250
Sens 1	71%	70%	70%	70%	72%	70%	70%	73%	70%
Spec 1	51%	14%	56%	42%	25%	43%	48%	14%	46%
Cutoff 2	1550	994	2000	1250	1110	1560	1500	1110	1650
Sens 2	81%	80%	80%	80%	80%	80%	81%	81%	82%
Spec 2	30%	11%	41%	20%	13%	30%	29%	13%	32%
Cutoff 3	919	830	1450	898	883	1030	485	491	881
Sens 3	91%	90%	91%	91%	91%	91%	91%	92%	91%
Spec 3	11%	7%	27%	11%	8%	14%	3%	2%	10%
Cutoff 4	3530	4050	3620	3530	4050	3620	3530	4050	3620
Sens 4	51%	18%	56%	37%	33%	38%	38%	15%	36%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	4180	4930	4360	4180	4930	4360	4180	4930	4360
Sens 5	32%	8%	34%	30%	22%	32%	28%	8%	25%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	5630	6450	6000	5630	6450	6000	5630	6450	6000
Sens 6	17%	0%	23%	20%	9%	20%	9%	0%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	1.5	1.3	0.99	0.74	1.4	1.1	1.0	1.3
p Value	0.63	0.43	0.47	0.98	0.51	0.27	0.83	1.0	0.61
95% CI of	0.61	0.53	0.63	0.55	0.31	0.76	0.44	0.25	0.47
OR Quart 2	2.3	4.3	2.8	1.8	1.8	2.6	2.8	4.0	3.6
OR Quart 3	2.0	1.7	2.8	1.1	1.0	1.4	1.6	2.0	2.5
p Value	0.034	0.31	0.0032	0.79	1.0	0.27	0.28	0.25	0.055
95% CI of	1.1	0.61	1.4	0.61	0.44	0.76	0.68	0.60	0.98
OR Quart 3	3.6	4.7	5.5	1.9	2.3	2.6	3.9	6.8	6.3
OR Quart 4	3.0	2.6	3.9	1.9	1.1	2.3	1.6	2.6	1.8
p Value	3.7E-4	0.052	6.4E-5	0.017	0.84	0.0072	0.29	0.12	0.24
95% CI of	1.6	0.99	2.0	1.1	0.49	1.2	0.67	0.79	0.68
OR Quart 4	5.4	6.8	7.5	3.3	2.4	4.1	3.9	8.3	4.7

Platelet-derived growth factor subunit B (dimer)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.961	1.70	0.961	1.70	0.961	1.75
Average	3.43	3.67	3.43	14.0	3.43	4.02
Stdev	15.8	10.6	15.8	102	15.8	7.14
p (t-test)		0.90		0.060		0.81
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00683
Max	270	86.2	270	935	270	34.8
n (Samp)	365	70	365	84	365	41
n (Patient)	191	70	191	84	191	41
<u>sCr only</u>						
Median	1.06	2.21	1.06	2.31	1.06	2.18
Average	4.26	6.20	4.26	3.16	4.26	4.35
Stdev	35.9	16.9	35.9	3.24	35.9	7.82
p (t-test)		0.79		0.86		0.99
Min	0.00246	0.0144	0.00246	0.0140	0.00246	0.00408
Max	935	86.2	935	16.9	935	34.8
n (Samp)	754	25	754	32	754	21
n (Patient)	295	25	295	32	295	21
<u>UO only</u>						
Median	1.14	1.82	1.14	1.77	1.14	1.63
Average	3.66	3.62	3.66	15.7	3.66	3.35
Stdev	16.6	7.97	16.6	106	16.6	5.16
p (t-test)		0.99		0.054		0.91
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00683
Max	270	59.1	270	935	270	22.1
n (Samp)	317	65	317	77	317	36
n (Patient)	136	65	136	77	136	36
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.66	0.60	0.60	0.67	0.58
SE	0.038	0.060	0.040	0.036	0.053	0.037
p	0.0078	0.0097	0.010	0.0046	0.0015	0.027

-continued

nCohort 1	365	754	317	365	754	317	365	754	317
nCohort 2	70	25	65	84	32	77	41	21	36
Cutoff 1	0.718	1.09	1.14	0.901	1.39	0.965	0.392	1.24	0.353
Sens 1	70%	72%	71%	70%	72%	70%	71%	71%	72%
Spec 1	40%	51%	50%	48%	57%	46%	30%	54%	27%
Cutoff 2	0.483	0.737	0.536	0.273	0.465	0.162	0.286	0.869	0.232
Sens 2	80%	80%	80%	81%	81%	81%	80%	81%	81%
Spec 2	32%	39%	32%	25%	31%	21%	26%	44%	22%
Cutoff 3	0.0238	0.477	0.0238	0.0238	0.278	0.0238	0.0244	0.0244	0.0140
Sens 3	94%	92%	95%	93%	91%	91%	90%	90%	92%
Spec 3	17%	31%	15%	17%	25%	15%	20%	19%	11%
Cutoff 4	1.79	1.99	1.99	1.79	1.99	1.99	1.79	1.99	1.99
Sens 4	47%	64%	49%	48%	62%	45%	46%	62%	42%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	2.54	3.02	3.08	2.54	3.02	3.08	2.54	3.02	3.08
Sens 5	34%	32%	31%	31%	44%	25%	39%	38%	31%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	4.63	4.73	5.05	4.63	4.73	5.05	4.63	4.73	5.05
Sens 6	13%	20%	14%	15%	19%	13%	15%	10%	17%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.99	2.5	1.6	0.57	0.74	0.66	0.99	0.99	0.47
p Value	0.98	0.27	0.30	0.17	0.70	0.30	0.98	0.99	0.19
95% CI of	0.42	0.48	0.67	0.26	0.16	0.30	0.36	0.20	0.15
OR Quart 2	2.3	13	3.7	1.3	3.4	1.5	2.7	5.0	1.4
OR Quart 3	1.9	3.0	1.9	1.6	2.9	1.4	1.0	1.7	0.78
p Value	0.098	0.18	0.15	0.18	0.077	0.37	1.0	0.48	0.62
95% CI of	0.89	0.61	0.80	0.81	0.89	0.68	0.36	0.39	0.29
OR Quart 3	4.1	15	4.3	3.1	9.1	2.8	2.8	7.1	2.1
OR Quart 4	2.4	6.3	2.7	1.8	3.7	1.7	2.3	3.4	1.3
p Value	0.023	0.017	0.017	0.079	0.024	0.13	0.063	0.064	0.52
95% CI of	1.1	1.4	1.2	0.93	1.2	0.85	0.95	0.93	0.55
OR Quart 4	5.0	29	6.0	3.5	11	3.4	5.7	13	3.2

Thyroxine-binding globulin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.0694	0.0901	0.0694	0.106	0.0694	0.148			
Average	0.182	0.240	0.182	0.238	0.182	0.169			
Stdev	0.262	0.381	0.262	0.515	0.262	0.173			
p (t-test)		0.20		0.24		0.80			
Min	0.000191	8.30E-5	0.000191	0.000156	0.000191	0.00190			
Max	1.59	1.86	1.59	3.60	1.59	0.775			
n (Samp)	255	48	255	56	255	27			
n (Patient)	103	48	103	56	103	27			
sCr only									
Median	0.0777	0.0623	0.0777	0.0721	0.0777	0.0390			
Average	0.189	0.0799	0.189	0.162	0.189	0.0671			
Stdev	0.308	0.0770	0.308	0.219	0.308	0.0674			
p (t-test)		0.16		0.70		0.15			
Min	0.000191	8.30E-5	0.000191	0.000156	0.000191	0.00190			
Max	3.60	0.250	3.60	0.792	3.60	0.218			
n (Samp)	447	16	447	20	447	13			
n (Patient)	170	16	170	20	170	13			
UO only									
Median	0.0675	0.0555	0.0675	0.114	0.0675	0.149			
Average	0.172	0.241	0.172	0.249	0.172	0.178			
Stdev	0.259	0.391	0.259	0.537	0.259	0.177			
p (t-test)		0.14		0.14		0.91			
Min	0.000191	0.00106	0.000191	0.00324	0.000191	0.00366			
Max	1.59	1.86	1.59	3.60	1.59	0.775			
n (Samp)	218	46	218	51	218	25			
n (Patient)	87	46	87	51	87	25			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.41	0.51	0.52	0.47	0.53	0.57	0.37	0.60
SE	0.046	0.076	0.047	0.043	0.067	0.045	0.060	0.084	0.063
p	0.66	0.24	0.83	0.69	0.68	0.47	0.28	0.12	0.098

-continued

nCohort 1	255	447	218	255	447	218	255	447	218
nCohort 2	48	16	46	56	20	51	27	13	25
Cutoff 1	0.0279	0.0196	0.0169	0.0293	0.0357	0.0287	0.0617	0.0196	0.0694
Sens 1	71%	75%	72%	71%	70%	71%	70%	77%	72%
Spec 1	30%	23%	22%	31%	33%	32%	47%	23%	52%
Cutoff 2	0.0150	0.0157	0.0138	0.0194	0.0187	0.0164	0.0471	0.00877	0.0547
Sens 2	81%	81%	80%	80%	80%	80%	81%	85%	80%
Spec 2	20%	20%	20%	22%	22%	22%	41%	15%	46%
Cutoff 3	0.00405	0.00990	0.00446	0.00715	0.00325	0.0100	0.00715	0.00319	0.0138
Sens 3	92%	94%	91%	91%	90%	90%	93%	92%	92%
Spec 3	7%	16%	8%	14%	6%	16%	14%	6%	20%
Cutoff 4	0.193	0.198	0.174	0.193	0.198	0.174	0.193	0.198	0.174
Sens 4	35%	12%	39%	30%	25%	37%	33%	8%	44%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.274	0.290	0.248	0.274	0.290	0.248	0.274	0.290	0.248
Sens 5	23%	0%	28%	21%	15%	25%	11%	0%	16%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.448	0.466	0.418	0.448	0.466	0.418	0.448	0.466	0.418
Sens 6	19%	0%	20%	12%	10%	12%	7%	0%	8%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.64	5.2	0.54	0.74	1.5	0.59	2.1	>5.2	1.7
p Value	0.34	0.14	0.18	0.49	0.52	0.26	0.32	<0.13	0.48
95% CI of	0.26	0.60	0.22	0.31	0.42	0.23	0.49	>0.60	0.39
OR Quart 2	1.6	45	1.3	1.7	5.6	1.5	8.6	na	7.4
OR Quart 3	0.89	5.2	0.40	1.3	1.3	1.0	4.6	>4.1	3.3
p Value	0.80	0.14	0.067	0.45	0.73	1.0	0.022	<0.21	0.086
95% CI of	0.38	0.60	0.15	0.62	0.33	0.43	1.2	>0.46	0.84
OR Quart 3	2.1	45	1.1	3.0	4.8	2.3	17	na	13
OR Quart 4	1.1	5.2	1.0	0.90	1.3	0.98	2.1	>4.1	2.9
p Value	0.86	0.13	1.0	0.80	0.72	0.96	0.32	<0.21	0.13
95% CI of	0.47	0.60	0.44	0.39	0.33	0.43	0.49	>0.46	0.72
OR Quart 4	2.5	45	2.3	2.1	4.9	2.3	8.6	na	11

Pigment epithelium-derived factor

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	3.04	4.18	3.04	2.78	3.04	3.54			
Average	20.4	23.7	20.4	22.4	20.4	17.8			
Stdev	49.4	52.1	49.4	51.0	49.4	34.6			
p (t-test)		0.52		0.68		0.72			
Min	0.000563	0.0167	0.000563	0.00102	0.000563	0.159			
Max	400	302	400	400	400	171			
n (Samp)	463	119	463	128	463	47			
n (Patient)	223	119	223	128	223	47			
sCr only									
Median	3.10	3.91	3.10	3.28	3.10	2.70			
Average	18.7	25.3	18.7	27.7	18.7	25.4			
Stdev	45.5	64.6	45.5	53.3	45.5	50.3			
p (t-test)		0.38		0.19		0.46			
Min	0.000401	0.115	0.000401	0.0102	0.000401	0.00102			
Max	400	361	400	302	400	218			
n (Samp)	1015	40	1015	46	1015	26			
n (Patient)	374	40	374	46	374	26			
UO only									
Median	3.33	4.99	3.33	3.59	3.33	6.11			
Average	24.7	27.8	24.7	29.2	24.7	22.5			
Stdev	54.1	56.4	54.1	65.5	54.1	41.4			
p (t-test)		0.60		0.44		0.80			
Min	0.000563	0.0167	0.000563	0.00102	0.000563	0.189			
Max	400	302	400	400	400	171			
n (Samp)	436	107	436	117	436	44			
n (Patient)	173	107	173	117	173	44			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.52	0.56	0.51	0.54	0.52	0.54	0.50	0.55
SE	0.030	0.047	0.032	0.029	0.044	0.030	0.045	0.058	0.047
p	0.081	0.73	0.055	0.70	0.43	0.61	0.39	0.94	0.29

-continued

nCohort 1	463	1015	436	463	1015	436	463	1015	436
nCohort 2	119	40	107	128	46	117	47	26	44
Cutoff 1	1.88	1.94	2.14	1.13	0.884	1.45	1.56	0.913	2.03
Sens 1	71%	70%	70%	70%	72%	70%	70%	73%	70%
Spec 1	41%	40%	41%	31%	25%	33%	38%	26%	40%
Cutoff 2	0.861	0.565	1.30	0.602	0.596	0.751	0.863	0.514	0.874
Sens 2	81%	80%	80%	80%	80%	81%	81%	81%	82%
Spec 2	26%	17%	30%	21%	18%	20%	26%	15%	22%
Cutoff 3	0.329	0.169	0.596	0.283	0.132	0.320	0.361	0.185	0.681
Sens 3	91%	90%	91%	91%	91%	91%	91%	92%	91%
Spec 3	11%	5%	16%	10%	4%	8%	13%	6%	19%
Cutoff 4	9.21	8.99	11.3	9.21	8.99	11.3	9.21	8.99	11.3
Sens 4	36%	30%	40%	32%	41%	34%	30%	31%	36%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	19.2	18.7	27.1	19.2	18.7	27.1	19.2	18.7	27.1
Sens 5	27%	18%	23%	26%	37%	24%	23%	23%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	52.9	45.1	83.6	52.9	45.1	83.6	52.9	45.1	83.6
Sens 6	11%	15%	8%	12%	20%	9%	9%	19%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.3	0.79	1.6	0.99	0.76	1.2	1.5	1.2	0.89
p Value	0.37	0.63	0.16	0.98	0.52	0.55	0.36	0.77	0.81
95% CI of	0.72	0.31	0.84	0.57	0.33	0.67	0.61	0.39	0.35
OR Quart 2	2.4	2.0	3.0	1.7	1.8	2.1	3.9	3.5	2.3
OR Quart 3	1.4	1.1	1.4	0.67	0.30	0.95	1.8	1.0	1.2
p Value	0.29	0.83	0.27	0.18	0.036	0.88	0.19	0.99	0.65
95% CI of	0.76	0.46	0.76	0.37	0.096	0.52	0.74	0.32	0.51
OR Quart 3	2.5	2.6	2.8	1.2	0.92	1.7	4.6	3.2	2.9
OR Quart 4	1.8	1.1	2.0	1.2	1.5	1.3	1.7	1.2	1.3
p Value	0.047	0.83	0.025	0.52	0.28	0.40	0.27	0.77	0.51
95% CI of	1.0	0.46	1.1	0.70	0.72	0.72	0.67	0.39	0.56
OR Quart 4	3.2	2.6	3.8	2.0	3.1	2.3	4.2	3.5	3.2

Tumor necrosis factor receptor superfamily member 8

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
<u>sCr or UO</u>									
Median	15.0	24.9	15.0	19.7	15.0	30.0			
Average	25.2	35.9	25.2	27.2	25.2	32.8			
Stdev	36.7	35.9	36.7	24.9	36.7	25.6			
p (t-test)		0.020		0.63		0.26			
Min	0.0493	0.0493	0.0493	0.121	0.0493	0.196			
Max	277	176	277	111	277	110			
n (Samp)	217	91	217	96	217	32			
n (Patient)	128	91	128	96	128	32			
<u>sCr only</u>									
Median	19.5	19.8	19.5	30.5	19.5	33.4			
Average	31.1	29.5	31.1	43.0	31.1	38.0			
Stdev	48.0	28.0	48.0	60.6	48.0	31.6			
p (t-test)		0.86		0.18		0.55			
Min	0.0493	0.121	0.0493	0.121	0.0493	0.0561			
Max	554	126	554	353	554	110			
n (Samp)	517	28	517	33	517	18			
n (Patient)	242	28	242	33	242	18			
<u>UO only</u>									
Median	13.2	26.6	13.2	19.0	13.2	18.8			
Average	23.7	37.3	23.7	26.7	23.7	27.7			
Stdev	36.2	36.1	36.2	25.8	36.2	24.0			
p (t-test)		0.0040		0.47		0.55			
Min	0.0493	0.0493	0.0493	0.196	0.0493	0.196			
Max	277	176	277	126	277	111			
n (Samp)	227	81	227	86	227	31			
n (Patient)	122	81	122	86	122	31			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.54	0.66	0.57	0.62	0.58	0.65	0.61	0.62
SE	0.036	0.057	0.037	0.036	0.054	0.037	0.056	0.072	0.057
p	4.6E-4	0.46	1.4E-5	0.047	0.025	0.022	0.0079	0.14	0.037

-continued

nCohort 1	217	517	227	217	517	227	217	517	227
nCohort 2	91	28	81	96	33	86	32	18	31
Cutoff 1	12.5	12.5	12.5	9.84	19.8	8.69	18.3	18.3	12.4
Sens 1	71%	71%	70%	71%	73%	71%	72%	72%	71%
Spec 1	47%	39%	49%	36%	52%	39%	53%	46%	48%
Cutoff 2	8.52	5.14	7.30	5.14	12.3	5.14	12.1	5.76	7.30
Sens 2	80%	89%	80%	81%	82%	81%	81%	83%	81%
Spec 2	35%	21%	39%	27%	37%	30%	43%	23%	39%
Cutoff 3	4.86	0.811	4.86	2.45	5.09	2.45	6.53	0.196	5.14
Sens 3	90%	96%	90%	91%	94%	91%	91%	94%	90%
Spec 3	23%	11%	24%	20%	20%	22%	30%	8%	30%
Cutoff 4	27.0	32.9	25.8	27.0	32.9	25.8	27.0	32.9	25.8
Sens 4	45%	36%	53%	39%	39%	41%	53%	50%	45%
Spec 4	70%	71%	70%	70%	71%	70%	70%	71%	70%
Cutoff 5	35.9	42.2	34.0	35.9	42.2	34.0	35.9	42.2	34.0
Sens 5	38%	29%	43%	33%	30%	31%	41%	33%	29%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	53.5	62.7	50.8	53.5	62.7	50.8	53.5	62.7	50.8
Sens 6	20%	14%	21%	15%	12%	13%	12%	22%	10%
Spec 6	90%	90%	91%	90%	90%	91%	90%	90%	91%
OR Quart 2	1.3	1.2	2.3	1.5	1.2	2.2	3.8	0.49	3.3
p Value	0.56	0.78	0.061	0.29	0.74	0.044	0.10	0.41	0.087
95% CI of	0.58	0.38	0.96	0.73	0.33	1.0	0.76	0.088	0.84
OR Quart 2	2.7	3.6	5.5	3.0	4.8	4.6	19	2.7	13
OR Quart 3	1.8	1.2	2.7	1.1	3.2	1.3	5.1	1.2	2.5
p Value	0.14	0.78	0.027	0.85	0.049	0.55	0.043	0.74	0.20
95% CI of	0.84	0.38	1.1	0.52	1.0	0.58	1.1	0.33	0.62
OR Quart 3	3.7	3.6	6.3	2.2	10	2.8	25	4.8	10
OR Quart 4	3.4	1.3	6.0	2.1	3.2	2.8	8.6	1.8	4.6
p Value	7.7E-4	0.59	2.3E-5	0.032	0.051	0.0061	0.0059	0.37	0.023
95% CI of	1.7	0.45	2.6	1.1	1.00	1.3	1.9	0.51	1.2
OR Quart 4	7.1	4.0	14	4.1	10	5.8	40	6.1	17

Alpha-fetoprotein

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.00520	0.00428	0.00520	0.00587	0.00520	0.00587
Average	0.0545	0.0877	0.0545	0.0927	0.0545	0.0161
Stdev	0.124	0.239	0.124	0.347	0.124	0.0327
p (t-test)		0.13		0.18		0.12
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000523
Max	0.803	1.74	0.803	2.85	0.803	0.118
n (Samp)	194	86	194	76	194	26
n (Patient)	123	86	123	76	123	26
<u>sCr only</u>						
Median	0.00520	0.00508	0.00520	0.00428	0.00520	0.00546
Average	0.0560	0.170	0.0560	0.0759	0.0560	0.0270
Stdev	0.186	0.369	0.186	0.199	0.186	0.0391
p (t-test)		0.0052		0.58		0.53
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000523
Max	2.85	1.74	2.85	0.889	2.85	0.109
n (Samp)	428	26	428	28	428	16
n (Patient)	210	26	210	28	210	16
<u>UO only</u>						
Median	0.00505	0.00428	0.00505	0.00624	0.00505	0.00587
Average	0.0557	0.0575	0.0557	0.0924	0.0557	0.107
Stdev	0.132	0.144	0.132	0.343	0.132	0.346
p (t-test)		0.92		0.19		0.14
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	0.803	0.840	0.803	2.85	0.803	1.74
n (Samp)	210	78	210	72	210	27
n (Patient)	119	78	119	72	119	27

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.52	0.46	0.50	0.41	0.57	0.46	0.51	0.52
SE	0.038	0.059	0.039	0.039	0.058	0.040	0.061	0.074	0.060
p	0.25	0.79	0.28	0.99	0.11	0.074	0.47	0.86	0.77

-continued

nCohort 1	194	428	210	194	428	210	194	428	210
nCohort 2	86	26	78	76	28	72	26	16	27
Cutoff 1	0.00296	0.00296	0.00296	0.00367	0.00132	0.00428	0.00367	0.00367	0.00423
Sens 1	74%	73%	72%	71%	86%	71%	73%	75%	70%
Spec 1	19%	21%	21%	30%	13%	42%	30%	32%	32%
Cutoff 2	0.00132	0.00132	0.00132	0.000523	0.00132	0.00296	0.000523	0.00132	0.000523
Sens 2	81%	85%	81%	87%	86%	81%	96%	94%	93%
Spec 2	12%	13%	17%	12%	13%	21%	12%	13%	17%
Cutoff 3	0.000463	0	0.000463	0	0	0.000463	0.000523	0.00132	0.000523
Sens 3	91%	100%	92%	100%	100%	92%	96%	94%	93%
Spec 3	5%	0%	10%	0%	0%	10%	12%	13%	17%
Cutoff 4	0.0385	0.00660	0.0128	0.0385	0.00660	0.0128	0.0385	0.00660	0.0128
Sens 4	29%	35%	27%	30%	18%	43%	12%	31%	22%
Spec 4	71%	71%	70%	71%	71%	70%	71%	71%	70%
Cutoff 5	0.0728	0.0499	0.0641	0.0728	0.0499	0.0641	0.0728	0.0499	0.0641
Sens 5	20%	31%	18%	20%	18%	28%	12%	25%	22%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	0.176	0.162	0.176	0.176	0.162	0.176	0.176	0.162	0.176
Sens 6	14%	31%	10%	8%	14%	8%	0%	0%	7%
Spec 6	90%	91%	90%	90%	91%	90%	90%	91%	90%
OR Quart 2	0.56	0.84	0.57	1.1	1.0	0.98	4.8	1.0	0.22
p Value	0.13	0.76	0.17	0.88	1.0	0.97	0.020	1.0	0.066
95% CI of	0.26	0.27	0.26	0.49	0.28	0.43	1.3	0.24	0.045
OR Quart 2	1.2	2.6	1.3	2.3	3.6	2.2	18	4.1	1.1
OR Quart 3	1.0	0.70	1.2	1.3	1.6	1.8	1.4	1.0	1.5
p Value	1.0	0.55	0.59	0.44	0.40	0.12	0.70	1.0	0.45
95% CI of	0.49	0.22	0.60	0.63	0.52	0.85	0.29	0.24	0.54
OR Quart 3	2.0	2.3	2.5	2.9	5.2	4.0	6.4	4.1	3.9
OR Quart 4	1.1	1.1	1.1	1.2	2.1	1.8	2.5	1.0	0.71
p Value	0.72	0.80	0.71	0.60	0.19	0.14	0.20	1.0	0.55
95% CI of	0.56	0.40	0.56	0.57	0.69	0.83	0.62	0.24	0.23
OR Quart 4	2.3	3.3	2.3	2.6	6.3	3.9	10	4.1	2.2

Apolipoprotein E

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
<u>sCr or UO</u>									
Median	3.26	2.40	3.26	2.03	3.26	2.72			
Average	27.3	21.6	27.3	25.4	27.3	7.72			
Stdev	162	164	162	183	162	12.5			
p (t-test)		0.71		0.90		0.40			
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.000147			
Max	2160	1960	2160	2140	2160	63.1			
n (Samp)	499	143	499	143	499	48			
n (Patient)	235	143	235	143	235	48			
<u>sCr only</u>									
Median	2.68	1.25	2.68	1.18	2.68	2.72			
Average	22.5	3.42	22.5	5.41	22.5	8.50			
Stdev	142	6.10	142	9.08	142	16.4			
p (t-test)		0.36		0.39		0.60			
Min	0.000147	0.000147	0.000147	0.000147	0.000147	0.000147			
Max	2160	33.8	2160	37.9	2160	82.5			
n (Samp)	1100	46	1100	51	1100	28			
n (Patient)	397	46	397	51	397	28			
<u>UO only</u>									
Median	2.97	3.06	2.97	2.03	2.97	2.24			
Average	21.4	25.0	22.4	26.8	22.4	7.59			
Stdev	131	173	131	190	131	13.1			
p (t-test)		0.85		0.75		0.44			
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.00122			
Max	2140	1960	2140	2140	2140	63.1			
n (Samp)	487	130	487	133	487	47			
n (Patient)	190	130	190	133	190	47			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.37	0.49	0.45	0.41	0.45	0.48	0.48	0.46
SE	0.028	0.045	0.029	0.028	0.043	0.029	0.044	0.056	0.045
p	0.20	0.0027	0.80	0.073	0.042	0.082	0.62	0.75	0.34

-continued

nCohort 1	499	1100	487	499	1100	487	499	1100	487
nCohort 2	143	46	130	143	51	133	48	28	47
Cutoff 1	0.858	0.393	0.882	0.737	0.628	0.737	0.942	1.06	0.711
Sens 1	71%	72%	70%	71%	71%	71%	71%	71%	70%
Spec 1	26%	17%	27%	24%	23%	23%	30%	32%	22%
Cutoff 2	0.467	0.103	0.554	0.411	0.404	0.393	0.211	0.103	0.211
Sens 2	80%	80%	80%	80%	80%	80%	81%	82%	81%
Spec 2	19%	8%	19%	18%	17%	15%	12%	8%	11%
Cutoff 3	0.0862	0.0258	0.130	0.0999	0.0258	0.103	0.0520	0.00238	0.0263
Sens 3	91%	91%	90%	90%	90%	90%	92%	93%	91%
Spec 3	8%	6%	10%	9%	6%	10%	8%	4%	8%
Cutoff 4	7.57	7.31	6.96	7.57	7.31	6.96	7.57	7.31	6.96
Sens 4	27%	13%	33%	22%	20%	23%	31%	29%	30%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	13.3	12.7	11.4	13.3	12.7	11.4	13.3	12.7	11.4
Sens 5	17%	4%	22%	17%	16%	18%	17%	14%	19%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	30.2	27.2	28.8	30.2	27.2	28.8	30.2	27.2	28.8
Sens 6	8%	2%	10%	6%	6%	6%	6%	7%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	2.6	0.74	1.2	1.4	1.1	0.59	1.3	0.83
p Value	0.56	0.12	0.28	0.55	0.49	0.66	0.26	0.59	0.67
95% CI of	0.68	0.79	0.43	0.68	0.55	0.64	0.24	0.46	0.34
OR Quart 2	2.0	8.3	1.3	2.1	3.5	2.0	1.5	3.9	2.0
OR Quart 3	1.3	3.6	0.68	1.6	1.8	1.4	1.1	1.2	0.73
p Value	0.34	0.025	0.17	0.079	0.20	0.26	0.84	0.78	0.50
95% CI of	0.76	1.2	0.39	0.95	0.74	0.79	0.49	0.39	0.30
OR Quart 3	2.2	11	1.2	2.8	4.3	2.4	2.4	3.5	1.8
OR Quart 4	1.4	4.8	1.0	1.7	2.3	1.7	1.0	1.2	1.4
p Value	0.27	0.0053	0.97	0.056	0.050	0.056	0.98	0.78	0.41
95% CI of	0.79	1.6	0.60	0.99	1.0	0.99	0.45	0.39	0.63
OR Quart 4	2.3	14	1.7	2.9	5.5	2.9	2.3	3.5	3.1

Apolipoprotein(a)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
<u>sCr or UO</u>									
Median	1.92	2.90	1.92	2.91	1.92	2.09			
Average	26.2	147	26.2	48.0	26.2	32.2			
Stdev	128	1540	128	402	128	151			
p (t-test)		0.092		0.31		0.77			
Min	0.00770	0.00479	0.00770	0.00241	0.00770	0.00838			
Max	1510	17500	1510	4580	1510	1000			
n (Samp)	471	129	471	133	471	45			
n (Patient)	230	129	230	133	230	45			
<u>sCr only</u>									
Median	2.04	1.80	2.04	2.90	2.04	3.02			
Average	45.0	4.31	45.0	9.65	45.0	11.7			
Stdev	578	9.90	578	30.9	578	31.2			
p (t-test)		0.64		0.67		0.77			
Min	0.00241	0.00770	0.00241	0.00241	0.00241	0.00838			
Max	17500	60.7	17500	215	17500	161			
n (Samp)	1040	43	1040	49	1040	26			
n (Patient)	391	43	391	49	391	26			
<u>UO only</u>									
Median	2.11	3.31	2.11	2.86	2.11	2.04			
Average	20.0	172	20.0	50.6	20.0	30.5			
Stdev	111	1630	111	420	111	153			
p (t-test)		0.049		0.16		0.57			
Min	0.00770	0.00479	0.00770	0.00241	0.00770	0.00790			
Max	1510	17500	1510	4580	1510	1000			
n (Samp)	457	115	457	122	457	43			
n (Patient)	185	115	185	122	185	43			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.46	0.61	0.58	0.53	0.58	0.53	0.59	0.51
SE	0.029	0.046	0.031	0.029	0.043	0.030	0.046	0.059	0.046
p	0.0097	0.40	4.2E-4	0.0068	0.48	0.0099	0.50	0.13	0.84

-continued

nCohort 1	471	1040	457	471	1040	457	471	1040	457
nCohort 2	129	43	115	133	49	122	45	26	43
Cutoff 1	1.51	0.917	1.95	1.67	0.863	1.65	1.16	1.67	1.19
Sens 1	71%	72%	70%	71%	71%	72%	71%	73%	72%
Spec 1	42%	29%	49%	46%	27%	44%	34%	45%	33%
Cutoff 2	0.977	0.556	1.23	1.16	0.108	1.24	0.766	1.65	0.766
Sens 2	81%	81%	80%	80%	82%	80%	80%	81%	81%
Spec 2	31%	22%	33%	34%	12%	33%	27%	45%	26%
Cutoff 3	0.108	0.108	0.496	0.108	0.0112	0.430	0.479	0.369	0.479
Sens 3	92%	91%	90%	90%	92%	90%	93%	92%	93%
Spec 3	14%	12%	22%	14%	4%	17%	19%	15%	18%
Cutoff 4	3.77	3.78	3.85	3.77	3.78	3.85	3.77	3.78	3.85
Sens 4	39%	23%	43%	37%	37%	36%	31%	42%	23%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	5.63	5.65	5.30	5.63	5.65	5.30	5.63	5.65	5.30
Sens 5	22%	12%	30%	28%	33%	26%	20%	23%	19%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	16.0	18.3	12.9	16.0	18.3	12.9	16.0	18.3	12.9
Sens 6	12%	7%	17%	11%	8%	11%	13%	15%	14%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	1.9	1.8	1.1	0.28	1.6	1.2	1.2	2.0
p Value	0.28	0.18	0.098	0.76	0.024	0.17	0.64	0.74	0.13
95% CI of	0.76	0.75	0.90	0.60	0.089	0.83	0.50	0.33	0.81
OR Quart 2	2.6	4.8	3.5	2.0	0.85	2.9	3.1	4.7	4.9
OR Quart 3	2.2	1.9	2.4	2.1	1.0	2.0	1.5	1.8	1.4
p Value	0.0072	0.18	0.0088	0.0093	1.0	0.020	0.38	0.37	0.48
95% CI of	1.2	0.75	1.2	1.2	0.47	1.1	0.62	0.51	0.55
OR Quart 3	4.0	4.8	4.6	3.7	2.1	3.7	3.6	6.1	3.6
OR Quart 4	2.2	1.5	3.1	1.9	1.2	2.1	1.4	2.5	1.1
p Value	0.0072	0.46	5.2E-4	0.026	0.59	0.014	0.50	0.12	0.80
95% CI of	1.2	0.54	1.6	1.1	0.59	1.2	0.56	0.79	0.42
OR Quart 4	4.0	3.9	5.8	3.4	2.5	3.9	3.4	8.2	3.0

[0184] FIG. 2: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

Complement C4-B						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	16.8	30.7	16.8	30.3	16.8	11.2
Average	54.2	59.9	54.2	69.1	54.2	35.1
Stdev	132	84.9	132	155	132	61.6
p(t-test)		0.74		0.37		0.37
Min	0.00329	0.161	0.00329	0.211	0.00329	0.00263
Max	2000	417	2000	1150	2000	341
n (Samp)	927	62	927	70	927	39
n (Patient)	360	62	360	70	360	39
<u>sCr only</u>						
Median	17.8	6.31	17.8	5.52	17.8	17.8
Average	59.9	13.8	59.9	29.0	59.9	40.1
Stdev	146	17.1	146	47.7	146	51.7
p(t-test)		0.22		0.37		0.58
Min	0.00329	0.161	0.00329	0.211	0.00329	0.448
Max	2000	47.7	2000	173	2000	146
n (Samp)	1230	15	1230	18	1230	17
n (Patient)	440	15	440	18	440	17
<u>UO only</u>						
Median	17.8	30.6	17.8	33.3	17.8	15.3
Average	55.4	63.6	55.4	72.3	55.4	39.5
Stdev	134	87.3	134	162	134	63.7
p(t-test)		0.65		0.34		0.49
Min	0.00329	0.754	0.00329	0.383	0.00329	0.00263

-continued

Max	2000	417		2000	1150		2000		341
n (Samp)	815	57		815	63		815		34
n (Patient)	282	57		282	63		282		34
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.33	0.59	0.55	0.41	0.56	0.45	0.47	0.48
SE	0.039	0.077	0.041	0.037	0.071	0.039	0.048	0.072	0.051
p	0.071	0.027	0.031	0.13	0.20	0.10	0.29	0.71	0.69
nCohort 1	927	1230	815	927	1230	815	927	1230	815
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	10.5	2.00	13.2	6.41	4.28	7.34	3.33	6.89	4.30
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	41%	15%	43%	32%	25%	33%	22%	31%	25%
Cutoff 2	4.21	0.968	8.26	4.21	3.21	3.60	1.74	1.49	2.00
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	26%	8%	35%	26%	20%	21%	13%	11%	14%
Cutoff 3	0.990	0.587	2.46	1.70	1.66	1.74	0.752	0.544	1.66
Sens 3	90%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	8%	4%	16%	13%	12%	13%	6%	4%	12%
Cutoff 4	38.7	42.6	41.5	38.7	42.6	41.5	38.7	42.6	41.5
Sens 4	44%	13%	40%	40%	22%	43%	26%	35%	32%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	61.6	68.8	65.8	61.6	68.8	65.8	61.6	68.8	65.8
Sens 5	29%	0%	30%	29%	17%	24%	21%	18%	21%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	130	141	130	130	141	130	130	141	130
Sens 6	11%	0%	12%	14%	6%	14%	8%	6%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	>4.1	1.4	1.0	1.0	0.91	0.59	1.3	0.77
p Value	0.84	<0.21	0.50	1.0	1.0	0.83	0.32	0.74	0.62
95% CI of	0.49	>0.45	0.56	0.47	0.20	0.41	0.21	0.33	0.28
OR Quart 2	2.4	na	3.3	2.1	5.0	2.1	1.7	4.7	2.1
OR Quart 3	1.4	>5.1	1.7	1.3	2.4	1.2	1.1	0.75	1.0
p Value	0.44	<0.14	0.21	0.47	0.22	0.70	0.82	0.70	0.99
95% CI of	0.63	>0.59	0.73	0.64	0.61	0.54	0.46	0.17	0.39
OR Quart 3	2.9	na	4.0	2.7	9.2	2.5	2.7	3.4	2.6
OR Quart 4	1.8	>6.1	2.5	1.8	1.7	1.9	1.2	1.3	1.0
p Value	0.11	<0.094	0.027	0.098	0.48	0.088	0.66	0.73	0.99
95% CI of	0.87	>0.73	1.1	0.90	0.40	0.91	0.52	0.33	0.39
OR Quart 4	3.8	na	5.5	3.5	7.1	3.8	2.9	4.7	2.6
C-C motif chemokine 7									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
sCr or UO									
Median	0.584	0.662		0.584	0.643		0.584	0.584	
Average	1.89	5.43		1.89	2.29		1.89	3.19	
Stdev	9.38	13.3		9.38	6.39		9.38	7.98	
p(t-test)		0.0054			0.73			0.39	
Min	0.146	0.146		0.146	0.146		0.146	0.264	
Max	163	61.7		163	45.7		163	33.9	
n (Samp)	930	62		930	70		930	39	
n (Patient)	361	62		361	70		361	39	
sCr only									
Median	0.584	0.812		0.584	0.637		0.584	0.816	
Average	2.24	8.59		2.24	5.64		2.24	3.49	
Stdev	12.2	18.9		12.2	14.5		12.2	8.42	
p(t-test)		0.046			0.24			0.67	
Min	0.146	0.264		0.146	0.282		0.146	0.264	
Max	291	69.7		291	61.7		291	33.9	
n (Samp)	1234	15		1234	18		1234	17	
n (Patient)	441	15		441	18		441	17	
UO only									
Median	0.625	0.662		0.625	0.662		0.625	0.584	
Average	2.01	8.67		2.01	4.29		2.01	2.87	
Stdev	9.92	25.3		9.92	15.7		9.92	7.34	
p(t-test)		2.7E-5			0.095			0.62	
Min	0.146	0.146		0.146	0.146		0.146	0.264	

-continued

Max	163	166	163	114	163	33.0
n (Samp)	819	57	819	63	819	34
n (Patient)	283	57	283	63	283	34
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.65	0.61	0.56	0.59	0.54
SE	0.039	0.078	0.041	0.037	0.071	0.038
p	0.0012	0.059	0.0085	0.12	0.18	0.31
nCohort 1	930	1234	819	930	1234	819
nCohort 2	62	15	57	70	18	63
Cutoff 1	0.551	0.512	0.515	0.320	0.336	0.320
Sens 1	77%	73%	77%	73%	78%	73%
Spec 1	50%	44%	46%	32%	34%	29%
Cutoff 2	0.336	0.424	0.336	0.319	0.320	0.319
Sens 2	81%	80%	81%	86%	83%	87%
Spec 2	36%	39%	34%	28%	30%	26%
Cutoff 3	0.319	0.320	0.319	0.301	0.301	0.301
Sens 3	92%	93%	93%	96%	94%	95%
Spec 3	23%	30%	21%	17%	17%	17%
Cutoff 4	1.04	1.04	1.04	1.04	1.04	1.04
Sens 4	37%	47%	35%	27%	39%	25%
Spec 4	74%	72%	72%	74%	72%	72%
Cutoff 5	1.12	1.12	1.15	1.12	1.12	1.15
Sens 5	37%	47%	32%	26%	39%	22%
Spec 5	82%	81%	84%	82%	81%	84%
Cutoff 6	1.59	1.59	1.59	1.59	1.59	1.59
Sens 6	16%	20%	19%	10%	22%	11%
Spec 6	94%	94%	94%	94%	94%	94%
OR Quart 2	2.6	4.0	3.0	2.2	1.7	2.8
p Value	0.052	0.21	0.024	0.046	0.48	0.017
95% CI of	0.99	0.45	1.2	1.0	0.40	1.2
OR Quart 2	6.8	36	7.7	4.8	7.1	6.4
OR Quart 3	3.2	3.0	2.4	2.2	1.0	2.5
p Value	0.017	0.34	0.075	0.046	1.0	0.034
95% CI of	1.2	0.31	0.91	1.0	0.20	1.1
OR Quart 3	8.1	29	6.4	4.8	5.0	5.9
OR Quart 4	4.1	7.1	3.6	1.9	2.4	1.9
p Value	0.0025	0.067	0.0075	0.12	0.22	0.14
95% CI of	1.6	0.87	1.4	0.84	0.61	0.80
OR Quart 4	10	58	9.1	4.1	9.2	4.6
Vascular endothelial growth factor receptor 3						
0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	304	364	304	318	304	316
Average	314	398	314	379	314	354
Stdev	214	273	214	378	214	221
p(t-test)		0.013		0.056		0.34
Min	1.37	81.1	1.37	1.37	1.37	3.04
Max	2070	1700	2070	2750	2070	913
n (Samp)	470	47	470	53	470	28
n (Patient)	239	47	239	53	239	28
sCr only						
Median	318	354	318	351	318	512
Average	340	395	340	335	340	495
Stdev	248	284	248	113	248	264
p(t-test)		0.51		0.95		0.040
Min	1.37	76.2	1.37	145	1.37	161
Max	2750	901	2750	512	2750	913
n (Samp)	630	9	630	10	630	11
n (Patient)	293	9	293	10	293	11
UO only						
Median	308	364	308	315	308	318
Average	322	394	322	384	322	367
Stdev	217	274	217	402	217	225
p(t-test)		0.042		0.091		0.31

-continued

Min	1.37	81.1	1.37	1.37	1.37	3.04
Max	2070	1700	2070	2750	2070	901
n (Samp)	438	43	438	47	438	25
n (Patient)	209	43	209	47	209	25

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.54	0.58	0.55	0.54	0.54	0.54	0.68	0.55
SE	0.045	0.099	0.047	0.043	0.094	0.045	0.057	0.090	0.061
p	0.039	0.66	0.083	0.22	0.69	0.38	0.45	0.043	0.41
nCohort 1	470	630	438	470	630	438	470	630	438
nCohort 2	47	9	43	53	10	47	28	11	25
Cutoff 1	249	247	242	249	305	249	249	264	277
Sens 1	70%	78%	72%	72%	70%	70%	71%	73%	72%
Spec 1	39%	35%	36%	39%	47%	37%	39%	40%	44%
Cutoff 2	178	76.8	178	174	230	171	166	249	242
Sens 2	83%	89%	81%	81%	80%	81%	82%	82%	80%
Spec 2	25%	11%	23%	24%	33%	22%	24%	37%	36%
Cutoff 3	163	74.3	163	74.3	208	61.2	120	166	120
Sens 3	91%	100%	91%	91%	90%	94%	93%	91%	92%
Spec 3	22%	9%	20%	11%	29%	9%	15%	20%	13%
Cutoff 4	397	414	397	397	414	397	397	414	397
Sens 4	38%	22%	42%	38%	30%	38%	29%	64%	28%
Spec 4	71%	71%	70%	71%	71%	70%	71%	71%	70%
Cutoff 5	445	469	445	445	469	445	445	469	445
Sens 5	28%	22%	30%	26%	10%	32%	25%	55%	24%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	534	574	537	534	574	537	534	574	537
Sens 6	19%	22%	19%	11%	0%	13%	14%	36%	16%
Spec 6	90%	90%	91%	90%	90%	91%	90%	90%	91%
OR Quart 2	1.3	0.49	0.68	1.1	3.0	0.91	1.2	1.0	1.2
p Value	0.63	0.57	0.45	0.84	0.34	0.83	0.79	1.0	0.77
95% CI of	0.48	0.044	0.25	0.46	0.31	0.38	0.38	0.14	0.36
OR Quart 2	3.3	5.5	1.9	2.6	30	2.1	3.6	7.2	4.0
OR Quart 3	2.0	2.0	1.2	1.3	5.1	0.64	1.4	0	1.6
p Value	0.13	0.42	0.65	0.54	0.14	0.35	0.58	na	0.40
95% CI of	0.81	0.36	0.51	0.56	0.59	0.25	0.46	na	0.52
OR Quart 3	4.9	11	2.9	3.0	44	1.6	4.0	na	5.1
OR Quart 4	1.8	0.99	1.4	1.5	1.0	1.4	1.2	3.6	1.2
p Value	0.19	0.99	0.40	0.32	1.0	0.44	0.79	0.11	0.77
95% CI of	0.74	0.14	0.61	0.67	0.062	0.62	0.38	0.73	0.36
OR Quart 4	4.5	7.1	3.4	3.4	16	3.0	3.6	18	4.0

Interferon alpha-2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

<u>sCr or UO</u>						
Median	0.0967	0.104	0.0967	0.0974	0.0967	0.122
Average	7.76	13.4	7.76	8.07	7.76	11.1
Stdev	17.7	23.4	17.7	17.5	17.7	16.9
p(t-test)		0.018		0.89		0.24
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0348
Max	126	99.7	126	77.3	126	74.5
n (Samp)	930	62	930	70	930	39
n (Patient)	361	62	361	70	361	39
<u>sCr only</u>						
Median	0.0967	0.0724	0.0967	0.0864	0.0967	0.0967
Average	7.73	4.18	7.73	9.65	7.73	7.16
Stdev	18.1	13.1	18.1	22.9	18.1	12.2
p(t-test)		0.45		0.66		0.90
Min	0.0238	0.0238	0.0238	0.0348	0.0238	0.0369
Max	126	50.5	126	77.3	126	39.0
n (Samp)	1234	15	1234	18	1234	17
n (Patient)	441	15	441	18	441	17
<u>UO only</u>						
Median	0.0967	0.104	0.0967	0.0974	0.0967	1.02
Average	7.47	15.1	7.47	6.62	7.47	12.4
Stdev	17.2	24.8	17.2	14.3	17.2	18.2

-continued

p(t-test)			0.0019			0.70			0.10
Min	0.0238		0.0348	0.0238		0.0348	0.0238		0.0348
Max	126		99.7	126		66.2	126		74.5
n (Samp)	819		57	819		63	819		34
n (Patient)	283		57	283		63	283		34

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.40	0.59	0.55	0.48	0.55	0.60	0.57	0.61
SE	0.039	0.078	0.041	0.037	0.069	0.039	0.049	0.073	0.052
p	0.062	0.19	0.036	0.19	0.83	0.16	0.041	0.31	0.039
nCohort 1	930	1234	819	930	1234	819	930	1234	819
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	0.0724	0.0606	0.0724	0.0754	0.0435	0.0754	0.0754	0.0754	0.0815
Sens 1	71%	73%	72%	70%	78%	75%	72%	76%	71%
Spec 1	40%	26%	38%	44%	19%	42%	44%	45%	47%
Cutoff 2	0.0656	0.0369	0.0656	0.0709	0.0398	0.0709	0.0435	0.0724	0.0435
Sens 2	84%	80%	82%	81%	83%	83%	82%	82%	82%
Spec 2	29%	11%	27%	36%	15%	34%	19%	41%	17%
Cutoff 3	0.0398	0.0238	0.0398	0.0398	0.0369	0.0398	0.0369	0.0398	0.0369
Sens 3	92%	93%	91%	93%	94%	94%	92%	94%	91%
Spec 3	14%	3%	12%	14%	11%	12%	10%	15%	10%
Cutoff 4	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311
Sens 4	34%	13%	39%	24%	17%	25%	49%	35%	50%
Spec 4	73%	74%	73%	73%	74%	73%	73%	74%	73%
Cutoff 5	10.9	10.8	9.93	10.9	10.8	9.93	10.9	10.8	9.93
Sens 5	32%	13%	37%	20%	17%	21%	38%	29%	44%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	30.2	29.7	30.0	30.2	29.7	30.0	30.2	29.7	30.0
Sens 6	19%	7%	21%	11%	17%	8%	13%	6%	15%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.0	1.0	1.5	1.4	2.0	1.6	0.62	3.0	0.56
p Value	0.090	1.00	0.31	0.44	0.32	0.29	0.40	0.18	0.37
95% CI of	0.90	0.14	0.67	0.63	0.50	0.67	0.20	0.61	0.16
OR Quart 2	4.3	7.2	3.5	2.9	8.1	3.7	1.9	15	2.0
OR Quart 3	1.2	3.6	1.1	2.2	1.0	2.9	1.3	2.0	1.1
p Value	0.66	0.11	0.82	0.030	1.0	0.0089	0.63	0.42	0.79
95% CI of	0.51	0.74	0.46	1.1	0.20	1.3	0.49	0.36	0.41
OR Quart 3	2.9	17	2.7	4.5	5.0	6.3	3.3	11	3.2
OR Quart 4	2.2	2.0	2.2	1.4	2.0	1.8	2.1	2.5	2.2
p Value	0.046	0.42	0.045	0.34	0.32	0.16	0.10	0.27	0.089
95% CI of	1.0	0.37	1.0	0.68	0.50	0.79	0.87	0.48	0.89
OR Quart 4	4.8	11	4.8	3.1	8.1	4.2	4.9	13	5.6

Insulin-like growth factor-binding protein 4						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.733	0.441	0.733	0.923	0.733	0.660
Average	1.83	1.47	1.83	2.61	1.83	0.852
Stdev	6.92	2.61	6.92	4.90	6.92	0.999
p(t-test)		0.77		0.49		0.53
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0319
Max	85.6	13.8	85.6	28.0	85.6	3.77
n (Samp)	322	31	322	40	322	20
n (Patient)	185	31	185	40	185	20
<u>sCr only</u>						
Median	nd	nd	0.733	0.733	0.733	1.80
Average	nd	nd	1.77	2.04	1.77	2.08
Stdev	nd	nd	6.31	3.45	6.31	2.18
p(t-test)	nd	nd		0.91		0.89
Min	nd	nd	0.0319	0.0319	0.0319	0.0612
Max	nd	nd	85.6	9.68	85.6	6.53
n (Samp)	nd	nd	416	7	416	8
n (Patient)	nd	nd	221	7	221	8
<u>UO only</u>						
Median	0.733	0.419	0.733	0.923	0.733	0.733
Average	1.91	1.67	1.91	2.55	1.91	0.946

-continued

Stdev	7.28	3.20	7.28	4.93	7.28	1.21
p(t-test)		0.86		0.60		0.57
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0319
Max	85.6	13.8	85.6	28.0	85.6	4.20
n (Samp)	290	30	290	37	290	19
n (Patient)	158	30	158	37	158	19

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	nd	0.52	0.58	0.54	0.59	0.48	0.66	0.48
SE	0.055	nd	0.056	0.050	0.11	0.052	0.067	0.11	0.069
p	0.69	nd	0.78	0.10	0.75	0.081	0.72	0.13	0.74
nCohort 1	322	nd	290	322	416	290	322	416	290
nCohort 2	31	nd	30	40	7	37	20	8	19
Cutoff 1	0.184	nd	0.141	0.390	0.390	0.390	0.0439	0.390	0.0439
Sens 1	71%	nd	70%	72%	71%	73%	85%	75%	84%
Spec 1	29%	nd	30%	37%	38%	38%	11%	38%	12%
Cutoff 2	0.0585	nd	0.0585	0.184	0.184	0.0585	0.0439	0.141	0.0439
Sens 2	81%	nd	80%	80%	86%	86%	85%	88%	84%
Spec 2	15%	nd	15%	29%	30%	15%	11%	30%	12%
Cutoff 3	0	nd	0	0.0439	0	0.0439	0	0.0585	0
Sens 3	100%	nd	100%	92%	100%	92%	100%	100%	100%
Spec 3	0%	nd	0%	11%	0%	12%	0%	18%	0%
Cutoff 4	0.957	nd	0.957	0.957	0.957	0.957	0.957	0.957	0.957
Sens 4	32%	nd	30%	35%	29%	35%	25%	50%	26%
Spec 4	76%	nd	76%	76%	75%	76%	76%	75%	76%
Cutoff 5	1.37	nd	1.27	1.37	1.46	1.27	1.37	1.46	1.27
Sens 5	26%	nd	23%	35%	29%	35%	20%	50%	21%
Spec 5	80%	nd	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	3.09	nd	3.12	3.09	3.30	3.12	3.09	3.30	3.12
Sens 6	10%	nd	10%	22%	14%	22%	5%	12%	11%
Spec 6	90%	nd	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	nd	1.8	1.6	3.0	0.85	1.0	2.0	0.80
p Value	1.0	nd	0.30	0.34	0.34	0.77	0.98	0.57	0.75
95% CI of	0.36	nd	0.61	0.60	0.31	0.29	0.28	0.18	0.21
OR Quart 2	2.8	nd	5.1	4.4	30	2.5	3.6	23	3.1
OR Quart 3	0.60	nd	0.82	1.2	0.99	1.1	0.59	1.0	0.59
p Value	0.39	nd	0.76	0.79	0.99	0.82	0.47	1.0	0.48
95% CI of	0.19	nd	0.24	0.40	0.061	0.41	0.14	0.062	0.14
OR Quart 3	1.9	nd	2.8	3.3	16	3.1	2.5	16	2.6
OR Quart 4	1.3	nd	1.6	2.2	2.0	1.7	1.5	4.1	1.5
p Value	0.64	nd	0.42	0.12	0.57	0.26	0.54	0.21	0.53
95% CI of	0.47	nd	0.53	0.83	0.18	0.67	0.44	0.45	0.44
OR Quart 4	3.4	nd	4.6	5.6	22	4.4	4.8	37	4.8

Insulin-like growth factor-binding protein 5

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.0682	0.397	0.0682	0.0682	0.0682	0.248
Average	0.587	1.22	0.587	0.858	0.587	0.859
Stdev	1.27	2.10	1.27	1.63	1.27	1.19
p(t-test)		0.014		0.22		0.35
Min	0.0116	0.0116	0.0116	0.0116	0.0116	0.0116
Max	9.43	10.0	9.43	8.53	9.43	3.48
n (Samp)	323	31	323	40	323	20
n (Patient)	186	31	186	40	186	20
sCr only						
Median	nd	nd	0.0682	0.0407	0.0682	0.811
Average	nd	nd	0.624	0.664	0.624	1.23
Stdev	nd	nd	1.30	1.15	1.30	1.34
p(t-test)	nd	nd		0.94		0.19
Min	nd	nd	0.0116	0.0116	0.0116	0.0393
Max	nd	nd	9.43	2.99	9.43	3.48
n (Samp)	nd	nd	417	7	417	8
n (Patient)	nd	nd	222	7	222	8

-continued

UO only								
Median	0.0682	0.397	0.0682	0.0682	0.0682	0.0682	0.0938	
Average	0.598	0.937	0.598	0.815	0.598	0.598	1.22	
Stdev	1.39	1.50	1.39	1.64	1.39	1.39	2.37	
p(t-test)		0.21		0.38			0.073	
Min	0.0116	0.0116	0.0116	0.0116	0.0116	0.0116	0.0116	
Max	10.3	5.59	10.3	8.53	10.3	10.3	10.0	
n (Samp)	291	30	291	37	291	291	19	
n (Patient)	159	30	159	37	159	159	19	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	nd	0.64	0.52	0.48	0.51	0.61	0.73	0.59
SE	0.056	nd	0.057	0.049	0.11	0.051	0.069	0.10	0.071
p	0.0099	nd	0.012	0.66	0.84	0.83	0.12	0.026	0.22
nCohort 1	323	nd	291	323	417	291	323	417	291
nCohort 2	31	nd	30	40	7	37	20	8	19
Cutoff 1	0.0544	nd	0.0544	0.0262	0.0262	0.0262	0.0400	0.0838	0.0358
Sens 1	81%	nd	80%	75%	71%	73%	75%	75%	79%
Spec 1	48%	nd	48%	23%	23%	22%	38%	59%	35%
Cutoff 2	0.0544	nd	0.0544	0.0116	0.0116	0.0116	0.0358	0.0544	0.0262
Sens 2	81%	nd	80%	90%	86%	89%	85%	88%	84%
Spec 2	48%	nd	48%	11%	12%	12%	36%	46%	22%
Cutoff 3	0	nd	0	0.0116	0	0	0.0116	0.0358	0
Sens 3	100%	nd	100%	90%	100%	100%	90%	100%	100%
Spec 3	0%	nd	0%	11%	0%	0%	11%	34%	0%
Cutoff 4	0.397	nd	0.232	0.397	0.397	0.232	0.397	0.397	0.232
Sens 4	39%	nd	57%	32%	29%	35%	30%	50%	47%
Spec 4	79%	nd	70%	79%	77%	70%	79%	77%	70%
Cutoff 5	0.518	nd	0.397	0.518	0.689	0.397	0.518	0.689	0.397
Sens 5	35%	nd	40%	32%	29%	30%	30%	50%	32%
Spec 5	80%	nd	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	1.99	nd	1.99	1.99	2.04	1.99	1.99	2.04	1.99
Sens 6	16%	nd	13%	12%	14%	11%	25%	25%	26%
Spec 6	91%	nd	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.78	nd	0.19	0.69	0.50	0.78	1.3	>1.0	1.7
p Value	0.72	nd	0.13	0.45	0.57	0.62	0.71	<0.99	0.48
95% CI of	0.20	nd	0.022	0.26	0.044	0.29	0.29	>0.062	0.39
OR Quart 2	3.0	nd	1.7	1.8	5.5	2.1	6.1	na	7.3
OR Quart 3	2.1	nd	2.6	0.69	1.0	0.78	1.3	>3.1	1.0
p Value	0.19	nd	0.081	0.45	1.0	0.62	0.71	<0.33	1.0
95% CI of	0.70	nd	0.89	0.26	0.14	0.29	0.29	>0.32	0.20
OR Quart 3	6.5	nd	7.9	1.8	7.2	2.1	6.1	na	5.1
OR Quart 4	2.6	nd	2.6	1.2	1.0	1.1	3.2	>4.1	2.8
p Value	0.087	nd	0.086	0.68	1.0	0.82	0.090	<0.21	0.14
95% CI of	0.87	nd	0.87	0.51	0.14	0.45	0.83	>0.45	0.72
OR Quart 4	7.7	nd	7.8	2.8	7.2	2.8	12	na	11

Immunoglobulin G4

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

sCr or UO						
Median	209	304	209	353	209	170
Average	471	576	471	661	471	294
Stdev	682	766	682	753	682	441
p (t-test)		0.24		0.025		0.11
Min	0.00862	5.90	0.00862	2.63	0.00862	0.203
Max	2400	2400	2400	2400	2400	2400
n (Samp)	922	62	922	70	922	39
n (Patient)	358	62	358	70	358	39

sCr only						
Median	219	288	219	330	219	354
Average	499	473	499	635	499	492
Stdev	704	698	704	799	704	600
p (t-test)		0.89		0.42		0.97
Min	0.00642	27.3	0.00642	11.5	0.00642	8.44
Max	2400	2400	2400	2400	2400	2400
n (Samp)	1225	15	1225	18	1225	17
n (Patient)	438	15	438	18	438	17

-continued

UO only									
Median	227	336	227	384	227	201			
Average	487	639	487	743	487	364			
Stdev	688	802	688	797	688	519			
p (t-test)		0.11		0.0050		0.30			
Min	0.00962	5.90	0.00962	2.63	0.00962	0.203			
Max	2400	2400	2400	2400	2400	2400			
n (Samp)	810	57	810	63	810	34			
n (Patient)	280	57	280	63	280	34			

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.51	0.58	0.60	0.54	0.62	0.45	0.54	0.47
SE	0.039	0.076	0.041	0.037	0.070	0.039	0.048	0.072	0.051
p	0.11	0.88	0.055	0.0084	0.52	0.0019	0.28	0.55	0.60
nCohort 1	922	1225	810	922	1225	810	922	1225	810
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	174	143	189	146	103	182	75.7	118	78.5
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	46%	38%	46%	41%	31%	46%	28%	34%	27%
Cutoff 2	45.1	108	57.6	103	34.8	112	53.9	53.9	67.5
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	20%	32%	23%	32%	15%	33%	22%	21%	25%
Cutoff 3	28.9	36.0	28.0	27.6	21.7	81.1	10.6	11.0	26.3
Sens 3	90%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	13%	15%	12%	13%	10%	27%	6%	6%	11%
Cutoff 4	389	416	409	389	416	409	389	416	409
Sens 4	37%	20%	42%	46%	39%	48%	23%	41%	26%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	581	622	609	581	622	609	581	622	609
Sens 5	21%	13%	25%	33%	28%	38%	8%	29%	12%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1540	2060	1570	1540	2060	1570	1540	2060	1570
Sens 6	15%	7%	16%	16%	11%	17%	3%	6%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.70	1.0	0.65	2.0	0.75	2.8	1.9	0.75	2.0
p Value	0.40	1.0	0.36	0.11	0.70	0.035	0.22	0.70	0.20
95% CI of	0.31	0.20	0.26	0.85	0.17	1.1	0.68	0.17	0.69
OR Quart 2	1.6	5.0	1.6	4.5	3.4	7.3	5.2	3.4	6.1
OR Quart 3	1.5	2.4	1.6	2.0	1.00	2.4	2.2	1.3	2.5
p Value	0.29	0.22	0.20	0.11	1.00	0.075	0.11	0.74	0.093
95% CI of	0.72	0.61	0.77	0.85	0.25	0.91	0.84	0.33	0.86
OR Quart 3	3.0	9.2	3.4	4.5	4.0	6.4	6.0	4.7	7.2
OR Quart 4	1.3	0.66	1.5	3.2	1.8	5.0	1.5	1.2	1.4
p Value	0.47	0.66	0.26	0.0030	0.37	5.2E-4	0.43	0.74	0.56
95% CI of	0.64	0.11	0.72	1.5	0.51	2.0	0.53	0.33	0.44
OR Quart 4	2.7	4.0	3.3	7.1	6.1	12	4.4	4.7	4.5

Interleukin-21						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	8.31	3.89	8.31	5.21	8.31	4.89
Average	11.3	7.73	11.3	7.98	11.3	7.18
Stdev	11.5	9.96	11.5	8.29	11.5	6.85
p (t-test)		0.018		0.019		0.028
Min	0.00404	0.00761	0.00404	0.00404	0.00404	0.0177
Max	87.9	56.2	87.9	33.5	87.9	27.6
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39
sCr only						
Median	7.64	8.82	7.64	7.31	7.64	5.50
Average	10.7	15.1	10.7	9.85	10.7	10.5
Stdev	11.4	15.6	11.4	8.89	11.4	9.11
p (t-test)		0.14		0.76		0.96
Min	0.00404	0.418	0.00404	0.0537	0.00404	1.29
Max	105	56.2	105	29.9	105	27.6
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17

-continued

UO only									
Median	8.23	3.57	8.23	4.60	8.23	3.75			
Average	11.0	6.36	11.0	7.33	11.0	6.34			
Stdev	11.1	6.83	11.1	7.99	11.1	6.02			
p (t-test)		0.0020		0.011		0.016			
Min	0.00404	0.00761	0.00404	0.00404	0.00404	0.0177			
Max	87.9	26.7	87.9	33.5	87.9	19.3			
n (Samp)	817	57	817	63	817	34			
n (Patient)	283	57	283	63	283	34			

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.40	0.58	0.38	0.42	0.50	0.41	0.41	0.53	0.39
SE	0.039	0.078	0.041	0.037	0.069	0.039	0.049	0.072	0.052
p	0.0075	0.29	0.0030	0.031	0.95	0.015	0.058	0.68	0.031
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	1.78	3.73	1.78	2.09	3.24	1.37	2.16	3.10	2.55
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	20%	34%	21%	23%	32%	18%	24%	31%	27%
Cutoff 2	1.26	3.01	1.04	1.13	2.34	1.04	0.728	2.18	0.386
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	16%	31%	16%	16%	26%	16%	13%	25%	12%
Cutoff 3	0.161	1.29	0.161	0.527	0.0537	0.527	0.0528	1.58	0.0528
Sens 3	92%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	9%	18%	10%	12%	7%	13%	6%	21%	7%
Cutoff 4	14.4	13.5	14.2	14.4	13.5	14.2	14.4	13.5	14.2
Sens 4	18%	47%	14%	21%	33%	19%	15%	35%	15%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	18.6	17.9	18.6	18.6	17.9	18.6	18.6	17.9	18.6
Sens 5	16%	47%	11%	13%	17%	11%	8%	24%	6%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	25.8	24.7	25.4	25.8	24.7	25.4	25.8	24.7	25.4
Sens 6	5%	20%	2%	4%	11%	5%	3%	12%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.90	2.5	2.1	1.8	2.0	1.9	4.2	0.80	3.1
p Value	0.82	0.27	0.15	0.15	0.33	0.18	0.029	0.74	0.094
95% CI of	0.36	0.48	0.76	0.80	0.50	0.75	1.2	0.21	0.82
OR Quart 2	2.3	13	5.6	4.2	8.1	4.9	15	3.0	12
OR Quart 3	2.4	0.50	3.6	2.7	1.7	3.2	4.2	0.60	4.2
p Value	0.023	0.57	0.0075	0.013	0.48	0.0091	0.029	0.48	0.029
95% CI of	1.1	0.045	1.4	1.2	0.40	1.3	1.2	0.14	1.2
OR Quart 3	5.2	5.5	9.1	6.0	7.1	7.7	15	2.5	15
OR Quart 4	2.1	3.5	3.4	2.6	1.3	3.4	4.2	1.00	3.5
p Value	0.063	0.12	0.011	0.019	0.71	0.0062	0.028	1.00	0.062
95% CI of	0.96	0.73	1.3	1.2	0.30	1.4	1.2	0.29	0.94
OR Quart 4	4.6	17	8.7	5.8	6.0	8.1	15	3.5	13

Interleukin-23						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	304	141	304	222	304	79.6
Average	548	252	548	379	548	292
Stdev	730	346	730	415	730	518
p (t-test)		0.0016		0.056		0.030
Min	0.491	0.491	0.491	0.564	0.491	0.491
Max	8520	1350	8520	1540	8520	2340
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39
sCr only						
Median	246	105	246	293	246	190
Average	499	379	499	399	499	407
Stdev	691	583	691	423	691	494
p (t-test)		0.50		0.54		0.58
Min	0.491	0.491	0.491	0.564	0.491	0.651
Max	8520	2120	8520	1370	8520	1820

-continued

n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17
UO only						
Median	311	141	311	173	311	75.4
Average	552	248	552	335	552	232
Stdev	733	341	733	398	733	466
p (t-test)		0.0020		0.020		0.012
Min	0.491	0.491	0.491	0.564	0.491	0.491
Max	8520	1350	8520	1540	8520	2340
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.37	0.43	0.36	0.47	0.49	0.44	0.36	0.50	0.32
SE	0.039	0.077	0.041	0.036	0.069	0.039	0.049	0.071	0.052
p	8.8E-4	0.35	6.3E-4	0.36	0.87	0.097	0.0040	0.97	6.3E-4
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	1.06	1.05	1.06	48.7	1.21	16.8	1.06	79.3	1.06
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	18%	19%	18%	29%	24%	25%	18%	35%	18%
Cutoff 2	0.754	0.754	0.754	1.21	1.08	1.08	0.754	1.41	0.754
Sens 2	87%	87%	84%	80%	83%	81%	82%	82%	82%
Spec 2	10%	11%	10%	21%	20%	18%	10%	26%	10%
Cutoff 3	0.682	0.682	0.643	0.844	0.682	0.844	0.552	0.844	0.552
Sens 3	92%	93%	91%	91%	94%	90%	92%	94%	91%
Spec 3	6%	6%	4%	13%	6%	13%	1%	14%	1%
Cutoff 4	640	583	647	640	583	647	640	583	647
Sens 4	13%	27%	11%	26%	39%	19%	13%	29%	6%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	923	857	935	923	857	935	923	857	935
Sens 5	10%	13%	9%	11%	11%	10%	10%	18%	6%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1520	1380	1460	1520	1380	1460	1520	1380	1460
Sens 6	0%	7%	0%	3%	0%	3%	5%	6%	3%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	0.66	1.4	1.9	0.80	2.2	2.0	0.60	3.1
p Value	0.79	0.66	0.58	0.098	0.74	0.070	0.25	0.48	0.17
95% CI of	0.41	0.11	0.46	0.89	0.21	0.94	0.60	0.14	0.61
OR Quart 2	3.2	4.0	4.0	4.0	3.0	5.3	6.8	2.5	15
OR Quart 3	3.7	1.7	3.8	2.1	0.60	2.8	2.8	1.2	5.7
p Value	0.0030	0.48	0.0051	0.052	0.48	0.016	0.078	0.76	0.024
95% CI of	1.6	0.40	1.5	0.99	0.14	1.2	0.89	0.36	1.3
OR Quart 3	8.7	7.1	9.5	4.4	2.5	6.5	9.0	4.0	26
OR Quart 4	3.5	1.7	4.0	1.6	1.2	2.2	4.2	0.60	8.0
p Value	0.0042	0.48	0.0033	0.24	0.76	0.070	0.011	0.48	0.0061
95% CI of	1.5	0.40	1.6	0.73	0.36	0.94	1.4	0.14	1.8
OR Quart 4	8.4	7.1	10	3.5	4.0	5.3	13	2.5	36

Interleukin-28A						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	16.3	11.6	16.3	22.4	16.3	6.62
Average	34.6	24.2	34.6	32.9	34.6	18.5
Stdev	45.7	33.4	45.7	37.2	45.7	24.7
p (t-test)		0.080		0.76		0.029
Min	0.0254	0.0517	0.0254	0.0495	0.0254	0.0517
Max	587	164	587	156	587	82.9
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39
sCr only						
Median	14.7	20.2	14.7	26.1	14.7	22.5
Average	32.5	29.6	32.5	36.7	32.5	27.9
Stdev	43.6	31.8	43.6	38.1	43.6	28.4
p (t-test)		0.80		0.68		0.67
Min	0.0254	0.0777	0.0254	0.0517	0.0254	0.155

-continued

Max	587	105	587	131	587	82.9
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17
UO only						
Median	18.7	8.37	18.7	14.6	18.7	3.36
Average	35.5	22.9	35.5	28.2	35.5	14.5
Stdev	46.4	33.0	46.4	34.9	46.4	19.7
p (t-test)		0.044		0.22		0.0088
Min	0.0254	0.0517	0.0254	0.0495	0.0254	0.0517
Max	587	164	587	156	587	70.2
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.53	0.43	0.52	0.57	0.48	0.41	0.54	0.38
SE	0.039	0.076	0.041	0.036	0.071	0.038	0.049	0.072	0.052
p	0.20	0.70	0.097	0.59	0.34	0.54	0.081	0.62	0.018
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	0.194	4.33	0.194	8.60	16.3	0.243	0.194	4.11	0.194
Sens 1	74%	73%	74%	70%	72%	71%	72%	71%	71%
Spec 1	24%	39%	24%	41%	52%	28%	24%	38%	24%
Cutoff 2	0.176	3.53	0.176	0.194	7.98	0.184	0.142	0.184	0.0896
Sens 2	84%	80%	84%	80%	83%	81%	82%	82%	88%
Spec 2	22%	38%	21%	24%	41%	22%	18%	25%	14%
Cutoff 3	0.0896	0.0896	0.0896	0.142	0.0854	0.0854	0.0854	0.176	0.0854
Sens 3	90%	93%	91%	90%	94%	90%	97%	94%	97%
Spec 3	14%	15%	14%	18%	12%	12%	12%	23%	12%
Cutoff 4	47.5	44.0	50.6	47.5	44.0	50.6	47.5	44.0	50.6
Sens 4	16%	33%	14%	24%	22%	19%	15%	29%	9%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	65.2	61.1	66.6	65.2	61.1	66.6	65.2	61.1	66.6
Sens 5	10%	20%	11%	19%	22%	14%	8%	12%	3%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	90.8	88.8	91.5	90.8	88.8	91.5	90.8	88.8	91.5
Sens 6	5%	7%	4%	9%	11%	6%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.8	2.0	2.4	1.1	0.66	1.9	1.8	1.3	5.2
p Value	0.17	0.42	0.059	0.72	0.65	0.098	0.28	0.70	0.035
95% CI of	0.79	0.36	0.97	0.56	0.11	0.89	0.60	0.30	1.1
OR Quart 2	3.9	11	6.0	2.3	4.0	4.1	5.5	6.0	24
OR Quart 3	1.6	2.5	2.4	1.6	3.1	1.5	2.9	2.0	4.1
p Value	0.23	0.27	0.061	0.18	0.096	0.32	0.044	0.32	0.076
95% CI of	0.73	0.48	0.96	0.81	0.82	0.68	1.0	0.50	0.86
OR Quart 3	3.7	13	5.9	3.1	11	3.3	8.2	8.1	20
OR Quart 4	2.0	2.0	2.7	1.00	1.3	1.5	2.3	1.3	7.5
p Value	0.088	0.42	0.028	0.99	0.71	0.32	0.13	0.71	0.0084
95% CI of	0.90	0.36	1.1	0.48	0.30	0.68	0.78	0.30	1.7
OR Quart 4	4.4	11	6.7	2.1	6.0	3.3	6.6	6.0	33

Interleukin-33

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	43.8	20.7	43.8	37.6	43.8	25.0
Average	60.0	31.0	60.0	44.0	60.0	34.4
Stdev	64.2	30.3	64.2	41.1	64.2	39.8
p (t-test)		4.5E-4		0.041		0.014
Min	0.0232	0.0360	0.0232	0.0232	0.0232	0.0554
Max	958	112	958	235	958	148
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39
sCr only						
Median	41.0	33.6	41.0	43.0	41.0	26.5
Average	56.3	42.0	56.3	44.8	56.3	50.6
Stdev	61.2	34.0	61.2	34.6	61.2	47.5
p (t-test)		0.37		0.43		0.70
Min	0.0232	3.22	0.0232	0.0591	0.0232	0.111

-continued

Max	958	109	958	117	958	146
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17
UO only						
Median	43.9	17.8	43.9	32.9	43.9	19.2
Average	60.2	29.1	60.2	41.1	60.2	32.0
Stdev	65.3	29.7	65.3	41.1	65.3	38.0
p (t-test)		3.8E-4		0.023		0.013
Min	0.0232	0.0360	0.0232	0.0232	0.0232	0.0554
Max	958	112	958	235	958	148
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.36	0.46	0.34	0.44	0.48	0.41	0.36	0.49	0.34
SE	0.039	0.076	0.040	0.037	0.069	0.039	0.049	0.071	0.052
p	2.1E-4	0.64	5.1E-5	0.091	0.77	0.028	0.0046	0.89	0.0028
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	10.4	14.5	7.17	16.2	23.2	14.5	7.06	17.0	7.06
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	21%	26%	18%	26%	34%	24%	18%	29%	18%
Cutoff 2	4.04	14.2	2.67	12.4	13.6	8.99	2.98	10.4	0.0768
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	15%	26%	14%	23%	25%	19%	15%	22%	9%
Cutoff 3	0.0837	10.4	0.0558	0.106	0.0749	0.106	0.0686	5.13	0.0686
Sens 3	90%	93%	91%	91%	94%	90%	95%	94%	94%
Spec 3	11%	22%	4%	11%	9%	11%	6%	17%	6%
Cutoff 4	78.3	73.3	77.4	78.3	73.3	77.4	78.3	73.3	77.4
Sens 4	8%	20%	7%	16%	22%	13%	13%	24%	12%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	99.1	93.9	98.2	99.1	93.9	98.2	99.1	93.9	98.2
Sens 5	5%	13%	4%	9%	11%	6%	10%	24%	9%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	135	127	135	135	127	135	135	127	135
Sens 6	0%	0%	0%	1%	0%	2%	5%	6%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	3.9	2.0	4.9	3.2	2.0	2.8	1.8	1.0	2.0
p Value	0.016	0.42	0.013	0.0092	0.32	0.035	0.37	1.00	0.32
95% CI of	1.3	0.37	1.4	1.3	0.50	1.1	0.51	0.25	0.50
OR Quart 2	12	11	17	7.7	8.2	7.3	6.1	4.0	8.2
OR Quart 3	4.8	3.0	5.7	3.2	2.0	3.6	2.8	1.3	2.7
p Value	0.0053	0.18	0.0064	0.0094	0.32	0.0075	0.078	0.73	0.14
95% CI of	1.6	0.61	1.6	1.3	0.50	1.4	0.89	0.33	0.71
OR Quart 3	14	15	20	7.6	8.1	9.1	9.0	4.7	10
OR Quart 4	6.9	1.5	8.9	3.2	1.0	3.8	4.5	1.0	6.1
p Value	4.2E-4	0.65	4.2E-4	0.0092	1.00	0.0051	0.0075	1.00	0.0043
95% CI of	2.4	0.25	2.6	1.3	0.20	1.5	1.5	0.25	1.8
OR Quart 4	20	9.1	30	7.7	5.0	9.5	14	4.0	21

Interleukin-4 receptor alpha chain

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	46.5	47.2	46.5	69.4	46.5	48.6
Average	56.0	57.0	56.0	76.7	56.0	50.1
Stdev	49.4	56.5	49.4	60.5	49.4	32.8
p (t-test)		0.89		0.0057		0.54
Min	0.839	2.31	0.839	2.31	0.839	4.67
Max	297	293	297	239	297	112
n (Samp)	460	46	460	51	460	28
n (Patient)	234	46	234	51	234	28
sCr only						
Median	47.8	24.4	47.8	76.6	47.8	85.3
Average	58.1	40.6	58.1	68.4	58.1	82.2
Stdev	53.5	34.4	53.5	58.4	53.5	46.3
p (t-test)		0.33		0.53		0.14
Min	0.839	10.3	0.839	4.67	0.839	10.3

-continued

Max	299	97.7	299	200	299	154
n (Samp)	617	9	617	11	617	11
n (Patient)	287	9	287	11	287	11
UO only						
Median	46.2	49.3	46.2	68.0	46.2	49.3
Average	56.2	60.7	56.2	75.6	56.2	50.8
Stdev	50.8	57.8	50.8	60.5	50.8	32.2
p (t-test)		0.59		0.017		0.60
Min	0.839	2.31	0.839	2.31	0.839	4.67
Max	297	293	297	239	297	122
n (Samp)	431	42	431	45	431	25
n (Patient)	206	42	206	45	206	25

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	0.45	0.51	0.61	0.56	0.60	0.50	0.67	0.51
SE	0.045	0.100	0.047	0.044	0.090	0.047	0.056	0.090	0.060
p	0.97	0.60	0.75	0.012	0.53	0.025	0.94	0.057	0.81
nCohort 1	460	617	431	460	617	431	460	617	431
nCohort 2	46	9	42	51	11	45	28	11	25
Cutoff 1	11.8	11.8	19.1	35.1	24.0	35.1	38.0	67.2	38.0
Sens 1	80%	89%	71%	71%	73%	71%	71%	73%	72%
Spec 1	25%	24%	33%	42%	34%	42%	42%	64%	43%
Cutoff 2	11.8	11.8	11.3	11.8	11.8	11.8	11.8	41.5	19.1
Sens 2	80%	89%	81%	86%	82%	84%	86%	82%	80%
Spec 2	25%	24%	21%	25%	24%	25%	25%	46%	33%
Cutoff 3	7.93	9.16	6.56	11.3	6.56	9.16	9.16	11.8	10.3
Sens 3	91%	100%	93%	90%	91%	91%	93%	91%	92%
Spec 3	13%	12%	6%	20%	6%	13%	13%	24%	20%
Cutoff 4	75.2	75.2	75.2	75.2	75.2	75.2	75.2	75.2	75.2
Sens 4	24%	22%	26%	45%	55%	40%	18%	64%	16%
Spec 4	71%	71%	71%	71%	71%	71%	71%	71%	71%
Cutoff 5	93.9	95.7	93.9	93.9	95.7	93.9	93.9	95.7	93.9
Sens 5	22%	11%	24%	31%	18%	33%	14%	45%	12%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	116	126	122	116	126	122	116	126	122
Sens 6	17%	0%	17%	20%	9%	18%	7%	18%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.3	1.0	1.2	1.5	1.0	1.0	2.3	2.0	2.8
p Value	0.50	0.99	0.64	0.46	1.0	1.0	0.16	0.57	0.14
95% CI of	0.57	0.14	0.50	0.54	0.14	0.34	0.70	0.18	0.72
OR Quart 2	3.2	7.2	3.1	3.9	7.2	2.9	7.8	22	11
OR Quart 3	1.4	2.0	1.4	2.3	1.5	2.3	2.9	3.0	3.6
p Value	0.39	0.42	0.49	0.084	0.65	0.080	0.073	0.34	0.059
95% CI of	0.62	0.37	0.55	0.89	0.25	0.91	0.90	0.31	0.95
OR Quart 3	3.4	11	3.4	5.8	9.2	5.9	9.5	30	13
OR Quart 4	0.90	0.50	1.1	3.0	2.0	2.5	1.0	5.1	1.3
p Value	0.83	0.57	0.83	0.018	0.42	0.054	1.0	0.14	0.70
95% CI of	0.35	0.045	0.43	1.2	0.37	0.98	0.24	0.59	0.29
OR Quart 4	2.3	5.6	2.8	7.4	11	6.3	4.1	44	6.2

Vascular endothelial growth factor receptor 2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	545	857	545	746	545	455
Average	735	1230	735	997	735	642
Stdev	803	1210	803	952	803	706
p (t-test)		1.7E-4		0.030		0.56
Min	0.218	1.48	0.218	0.218	0.218	1.48
Max	7140	5940	7140	4750	7140	2820
n (Samp)	462	46	462	51	462	27
n (Patient)	235	46	235	51	235	27
sCr only						
Median	651	806	651	658	651	609
Average	863	1060	863	954	863	522
Stdev	917	1180	917	975	917	406
p (t-test)		0.53		0.76		0.22
Min	0.218	1.48	0.218	1.48	0.218	1.48

-continued

Max	7140	3710	7140	2870	7140	1350
n (Samp)	618	9	618	10	618	11
n (Patient)	288	9	288	10	288	11
UO only						
Median	539	932	539	825	539	495
Average	732	1240	732	1040	732	714
Stdev	805	1170	805	967	805	722
p (t-test)		2.4E-4		0.018		0.91
Min	0.218	10.8	0.218	0.218	0.218	1.48
Max	7140	5940	7140	4750	7140	2820
n (Samp)	433	42	433	45	433	24
n (Patient)	207	42	207	45	207	24

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.54	0.66	0.60	0.53	0.61	0.46	0.41	0.50
SE	0.046	0.099	0.048	0.044	0.093	0.046	0.058	0.091	0.061
p	0.0017	0.72	8.4E-4	0.028	0.78	0.017	0.53	0.30	1.00
nCohort 1	462	618	433	462	618	433	462	618	433
nCohort 2	46	9	42	51	10	45	27	11	24
Cutoff 1	566	189	581	421	421	577	159	164	237
Sens 1	72%	78%	71%	71%	70%	71%	70%	73%	71%
Spec 1	51%	22%	53%	43%	38%	52%	23%	20%	29%
Cutoff 2	292	152	333	304	354	228	106	134	106
Sens 2	80%	89%	81%	80%	80%	80%	81%	82%	83%
Spec 2	34%	20%	37%	35%	35%	27%	20%	18%	18%
Cutoff 3	113	1.48	185	129	321	123	1.48	35.7	1.48
Sens 3	91%	100%	90%	90%	90%	91%	100%	91%	100%
Spec 3	20%	8%	24%	21%	32%	19%	10%	12%	9%
Cutoff 4	907	1070	903	907	1070	903	907	1070	903
Sens 4	48%	33%	50%	39%	20%	44%	26%	9%	29%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	1190	1410	1180	1190	1410	1180	1190	1410	1180
Sens 5	33%	33%	36%	29%	20%	33%	22%	0%	25%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1660	1850	1650	1660	1850	1650	1660	1850	1650
Sens 6	26%	11%	24%	12%	20%	11%	7%	0%	8%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.87	0.33	1.4	1.3	4.1	0.60	0.83	2.0	0.83
p Value	0.79	0.34	0.57	0.63	0.21	0.39	0.77	0.57	0.77
95% CI of	0.30	0.034	0.44	0.48	0.45	0.19	0.25	0.18	0.25
OR Quart 2	2.5	3.2	4.6	3.3	37	1.9	2.8	23	2.8
OR Quart 3	1.7	0.66	2.8	2.1	3.0	2.0	1.2	4.1	1.2
p Value	0.26	0.65	0.061	0.092	0.34	0.13	0.76	0.21	0.76
95% CI of	0.68	0.11	0.96	0.88	0.31	0.81	0.39	0.45	0.39
OR Quart 3	4.2	4.0	8.0	5.2	30	4.9	3.6	37	3.7
OR Quart 4	2.5	0.99	3.8	2.3	2.0	2.3	1.6	4.1	1.0
p Value	0.043	0.99	0.012	0.067	0.57	0.066	0.42	0.21	0.99
95% CI of	1.0	0.20	1.3	0.95	0.18	0.95	0.54	0.45	0.32
OR Quart 4	5.9	5.0	11	5.5	22	5.5	4.5	37	3.2

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	2640	3420	2640	2770	2640	2260
Average	3270	3890	3270	4280	3270	2770
Stdev	2970	2700	2970	6730	2970	2190
p (t-test)		0.11		0.015		0.30
Min	6.83	85.5	6.83	375	6.83	138
Max	48400	15000	48400	55700	48400	9700
n (Samp)	926	62	926	70	926	39
n (Patient)	359	62	359	70	359	39
sCr only						
Median	2800	2420	2800	2590	2800	2370
Average	3450	2380	3450	3790	3450	3200
Stdev	3250	1460	3250	2950	3250	2300
p (t-test)		0.20		0.66		0.75
Min	6.83	301	6.83	921	6.83	932

-continued

Max	55700	4670	55700	10800	55700	8410
n (Samp)	1229	15	1229	18	1229	17
n (Patient)	439	15	439	18	439	17
UO only						
Median	2730	4020	2730	3060	2730	2460
Average	3320	4690	3320	4760	3320	2920
Stdev	2980	4040	2980	7510	2980	2190
p (t-test)		0.0011		0.0016		0.44
Min	0.234	85.5	0.234	375	0.234	138
Max	48400	26600	48400	55700	48400	9700
n (Samp)	814	57	814	63	814	34
n (Patient)	281	57	281	63	281	34

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.39	0.63	0.54	0.53	0.55	0.43	0.47	0.45
SE	0.039	0.078	0.041	0.036	0.070	0.039	0.049	0.072	0.052
p	0.040	0.16	0.0016	0.30	0.70	0.24	0.16	0.71	0.34
nCohort 1	926	1229	814	926	1229	814	926	1229	814
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	2290	1120	2720	2030	2080	2030	1250	1670	1650
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	44%	14%	50%	37%	35%	34%	17%	26%	26%
Cutoff 2	1570	849	1960	1210	1700	1210	962	965	1180
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	26%	8%	32%	17%	27%	16%	11%	10%	15%
Cutoff 3	863	615	1210	1040	1080	986	402	950	402
Sens 3	90%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	9%	4%	16%	13%	13%	11%	2%	10%	2%
Cutoff 4	3860	4020	3910	3860	4020	3910	3860	4020	3910
Sens 4	44%	7%	51%	37%	39%	40%	21%	35%	21%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	4660	4940	4740	4660	4940	4740	4660	4940	4740
Sens 5	34%	0%	42%	29%	28%	32%	18%	24%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	6190	6480	6230	6190	6480	6230	6190	6480	6230
Sens 6	21%	0%	25%	17%	17%	17%	8%	6%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.83	6.1	1.5	1.1	2.0	1.3	0.88	0.16	1.1
p Value	0.66	0.095	0.37	0.71	0.33	0.45	0.80	0.096	0.79
95% CI of	0.35	0.73	0.61	0.56	0.50	0.63	0.31	0.020	0.41
OR Quart 2	1.9	51	3.8	2.3	8.1	2.8	2.5	1.4	3.2
OR Quart 3	1.4	2.0	1.5	1.1	1.3	0.92	1.5	0.83	1.4
p Value	0.34	0.57	0.37	0.85	0.71	0.84	0.36	0.76	0.46
95% CI of	0.68	0.18	0.61	0.52	0.30	0.41	0.62	0.25	0.54
OR Quart 3	3.1	22	3.8	2.2	6.0	2.1	3.8	2.8	3.9
OR Quart 4	2.0	6.1	3.4	1.5	1.7	1.7	1.5	0.83	1.3
p Value	0.058	0.095	0.0036	0.23	0.48	0.16	0.36	0.77	0.61
95% CI of	0.98	0.73	1.5	0.77	0.40	0.82	0.62	0.25	0.47
OR Quart 4	4.1	51	7.7	3.0	7.1	3.4	3.8	2.8	3.6

Platelet-derived growth factor subunit B (dimer)						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	1.16	2.27	1.16	1.69	1.16	2.14
Average	3.31	3.21	3.31	22.5	3.31	2.17
Stdev	12.7	4.27	12.7	137	12.7	1.82
p (t-test)		0.96		5.2E-4		0.64
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00313
Max	270	24.9	270	935	270	8.46
n (Samp)	691	36	691	46	691	28
n (Patient)	280	36	280	46	280	28
sCr only						
Median	1.17	2.02	1.17	2.53	1.17	2.18
Average	4.08	2.61	4.08	5.64	4.08	2.38
Stdev	33.0	1.80	33.0	8.01	33.0	2.33
p (t-test)		0.90		0.87		0.85

-continued

Min	0.00246	0.709	0.00246	0.00741	0.00246	0.166
Max	935	5.92	935	26.6	935	8.93
n (Samp)	899	8	899	12	899	13
n (Patient)	335	8	335	12	335	13
UO only						
Median	1.24	2.75	1.24	1.69	1.24	2.10
Average	3.34	4.89	3.34	25.0	3.34	2.26
Stdev	13.1	10.4	13.1	142	13.1	1.83
p (t-test)		0.49		4.8E-4		0.68
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00313
Max	270	59.1	270	935	270	8.46
n (Samp)	581	35	581	43	581	25
n (Patient)	208	35	208	43	208	25

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.67	0.63	0.57	0.68	0.55	0.59	0.60	0.60
SE	0.051	0.11	0.052	0.045	0.086	0.047	0.058	0.084	0.061
p	0.0079	0.10	0.011	0.12	0.036	0.30	0.12	0.24	0.11
nCohort 1	691	899	581	691	899	581	691	899	581
nCohort 2	36	8	35	46	12	43	28	13	25
Cutoff 1	1.39	1.39	1.66	0.943	1.26	0.536	0.884	0.505	1.04
Sens 1	72%	75%	71%	72%	75%	72%	71%	77%	72%
Spec 1	56%	55%	58%	45%	53%	30%	43%	31%	45%
Cutoff 2	0.621	1.14	0.506	0.447	1.18	0.0558	0.393	0.365	0.742
Sens 2	81%	88%	80%	80%	83%	81%	82%	85%	80%
Spec 2	34%	49%	30%	29%	50%	18%	28%	27%	36%
Cutoff 3	0.0183	0.708	0.0183	0.0140	1.09	0.0140	0.361	0.361	0.392
Sens 3	92%	100%	91%	98%	92%	98%	93%	92%	92%
Spec 3	13%	36%	13%	10%	48%	10%	27%	27%	27%
Cutoff 4	2.13	2.17	2.22	2.13	2.17	2.22	2.13	2.17	2.22
Sens 4	53%	38%	57%	39%	58%	35%	50%	54%	44%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	3.13	3.13	3.15	3.13	3.13	3.15	3.13	3.13	3.15
Sens 5	36%	38%	40%	28%	42%	28%	21%	23%	24%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	5.18	5.05	5.21	5.18	5.05	5.21	5.18	5.05	5.21
Sens 6	14%	12%	17%	9%	25%	12%	4%	8%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.99	>2.0	0.66	0.88	1.00	0.79	4.7	4.1	3.1
p Value	0.99	<0.57	0.52	0.80	1.00	0.63	0.051	0.21	0.17
95% CI of	0.28	>0.18	0.18	0.33	0.062	0.30	0.99	0.45	0.61
OR Quart 2	3.5	na	2.4	2.3	16	2.1	22	37	15
OR Quart 3	1.8	>3.0	1.9	1.6	4.0	1.1	3.1	2.0	4.7
p Value	0.29	<0.34	0.22	0.29	0.21	0.82	0.18	0.57	0.050
95% CI of	0.60	>0.31	0.68	0.68	0.45	0.46	0.61	0.18	1.0
OR Quart 3	5.6	na	5.3	3.8	36	2.7	15	22	22
OR Quart 4	3.6	>3.0	2.5	1.7	6.1	1.4	5.8	6.1	4.1
p Value	0.013	<0.34	0.072	0.21	0.095	0.40	0.024	0.094	0.076
95% CI of	1.3	>0.31	0.92	0.73	0.73	0.62	1.3	0.73	0.86
OR Quart 4	10	na	6.6	4.0	51	3.3	26	51	20

Corticotropin						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.00163	0.00162	0.00163	0.00208	0.00163	0.00175
Average	0.00229	0.00185	0.00229	0.00430	0.00229	0.00180
Stdev	0.00404	0.00124	0.00404	0.00727	0.00404	0.000819
p (t-test)		0.61		0.018		0.63
Min	3.92E-6	0.000273	3.92E-6	0.000388	3.92E-6	0.000570
Max	0.0489	0.00666	0.0489	0.0377	0.0489	0.00318
n (Samp)	249	22	249	32	249	16
n (Patient)	162	22	162	32	162	16
sCr only						
Median	nd	nd	0.00163	0.00293	0.00163	0.00274
Average	nd	nd	0.00223	0.00603	0.00223	0.00742
Stdev	nd	nd	0.00365	0.00820	0.00365	0.0134

-continued

p(t-test)	nd	nd			0.015			9.1E-4
Min	nd	nd	3.92E-6	0.00134		3.92E-6	0.00109	
Max	nd	nd	0.0489	0.0224		0.0489	0.0377	
n (Samp)	nd	nd	315	6		315	7	
n (Patient)	nd	nd	189	6		189	7	
UO only								
Median	0.00163	0.00162	0.00163	0.00204		0.00163	0.00160	
Average	0.00239	0.00186	0.00239	0.00374		0.00239	0.00300	
Stdev	0.00430	0.00126	0.00430	0.00680		0.00430	0.00542	
p (t-test)		0.57		0.14			0.60	
Min	0.000355	0.000273	0.000355	0.000388		0.000355	0.000570	
Max	0.0489	0.00666	0.0489	0.0377		0.0489	0.0224	
n (Samp)	217	22	217	29		217	15	
n (Patient)	135	22	135	29		135	15	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.47	0.62	0.66	0.60	0.50	0.73	0.47
SE	0.065	nd	0.066	0.056	0.12	0.059	0.075	0.11	0.078
p	0.79	nd	0.66	0.025	0.18	0.085	0.97	0.038	0.69
nCohort 1	249	nd	217	249	315	217	249	315	217
nCohort 2	22	nd	22	32	6	29	16	7	15
Cutoff 1	0.00134	nd	0.00134	0.00149	0.00134	0.00149	0.00111	0.00212	0.00111
Sens 1	77%	nd	73%	72%	83%	72%	75%	71%	73%
Spec 1	33%	nd	32%	42%	32%	41%	22%	69%	23%
Cutoff 2	0.00106	nd	0.00106	0.00124	0.00134	0.00111	0.00109	0.00201	0.00109
Sens 2	86%	nd	86%	81%	83%	83%	81%	86%	80%
Spec 2	20%	nd	21%	32%	32%	23%	21%	65%	12%
Cutoff 3	0.000794	nd	0.000794	0.00109	0.00124	0.000888	0.000523	0.00106	0.000523
Sens 3	91%	nd	91%	91%	100%	93%	100%	100%	100%
Spec 3	10%	nd	9%	21%	31%	15%	7%	19%	6%
Cutoff 4	0.00222	nd	0.00227	0.00222	0.00222	0.00227	0.00222	0.00222	0.00227
Sens 4	23%	nd	27%	47%	50%	41%	31%	57%	20%
Spec 4	70%	nd	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.00282	nd	0.00282	0.00282	0.00274	0.00282	0.00282	0.00274	0.00282
Sens 5	9%	nd	9%	34%	50%	28%	12%	43%	13%
Spec 5	80%	nd	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	0.00362	nd	0.00380	0.00362	0.00352	0.00380	0.00362	0.00352	0.00380
Sens 6	5%	nd	5%	28%	50%	14%	0%	14%	7%
Spec 6	91%	nd	91%	91%	90%	91%	91%	90%	91%
OR Quart 2	2.5	nd	4.5	1.0	>3.1	0.39	1.0	0	1.0
p Value	0.20	nd	0.066	1.0	<0.33	0.19	0.98	na	1.0
95% CI of	0.62	nd	0.91	0.31	>0.32	0.097	0.24	na	0.19
OR Quart 2	10	nd	22	3.3	na	1.6	4.2	na	5.2
OR Quart 3	2.5	nd	3.2	1.4	>0	1.3	0.75	2.0	1.4
p Value	0.20	nd	0.16	0.57	<na	0.59	0.71	0.57	0.70
95% CI of	0.62	nd	0.62	0.45	>na	0.46	0.16	0.18	0.29
OR Quart 3	10	nd	17	4.2	na	3.8	3.5	23	6.4
OR Quart 4	1.7	nd	3.3	2.2	>3.1	1.5	1.3	4.1	1.7
p Value	0.46	nd	0.16	0.15	<0.33	0.46	0.71	0.21	0.47
95% CI of	0.40	nd	0.63	0.77	>0.31	0.53	0.33	0.45	0.39
OR Quart 4	7.6	nd	17	6.1	na	4.2	5.0	38	7.6

Thyroxine-binding globulin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.0709	0.0370	0.0709	0.0576	0.0709	0.136
Average	0.176	0.107	0.176	0.246	0.176	0.165
Stdev	0.265	0.203	0.265	0.631	0.265	0.173
p (t-test)		0.20		0.21		0.86
Min	8.30E-5	0.000476	8.30E-5	0.00330	8.30E-5	0.00324
Max	1.86	0.885	1.86	3.60	1.86	0.602
n (Samp)	421	25	421	32	421	17
n (Patient)	165	25	165	32	165	17
sCr only						
Median	nd	nd	0.0749	0.0237	0.0749	0.0201
Average	nd	nd	0.178	0.130	0.178	0.0811

-continued

Stdev	nd	nd	0.294	0.177	0.294	0.107
p (t-test)	nd	nd		0.67		0.38
Min	nd	nd	8.30E-5	0.00330	8.30E-5	0.00324
Max	nd	nd	3.60	0.466	3.60	0.250
n (Samp)	nd	nd	511	7	511	7
n (Patient)	nd	nd	198	7	198	7
UO only						
Median	0.0686	0.0423	0.0686	0.0428	0.0686	0.142
Average	0.178	0.119	0.178	0.251	0.178	0.173
Stdev	0.272	0.204	0.272	0.661	0.272	0.168
p(t-test)		0.28		0.24		0.94
Min	0.000191	0.000476	0.000191	0.00343	0.000191	0.00768
Max	1.86	0.885	1.86	3.60	1.86	0.602
n (Samp)	357	25	357	29	357	17
n (Patient)	135	25	135	29	135	17

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.38	nd	0.41	0.49	0.42	0.49	0.56	0.38	0.60
SE	0.061	nd	0.062	0.053	0.11	0.056	0.073	0.11	0.074
p	0.058	nd	0.15	0.88	0.47	0.85	0.41	0.28	0.19
nCohort 1	421	nd	357	421	511	357	421	511	357
nCohort 2	25	nd	25	32	7	29	17	7	17
Cutoff 1	0.0145	nd	0.0131	0.0184	0.00990	0.0184	0.0617	0.0187	0.109
Sens 1	72%	nd	72%	72%	71%	72%	71%	71%	71%
Spec 1	20%	nd	18%	23%	16%	23%	47%	23%	59%
Cutoff 2	0.0112	nd	0.00915	0.00971	0.00423	0.0158	0.0353	0.0145	0.0497
Sens 2	80%	nd	80%	81%	86%	83%	82%	86%	82%
Spec 2	17%	nd	16%	16%	8%	21%	33%	20%	43%
Cutoff 3	0.00446	nd	0.00423	0.00556	0.00325	0.00556	0.00767	0.00319	0.0196
Sens 3	92%	nd	92%	91%	100%	93%	94%	100%	94%
Spec 3	9%	nd	8%	11%	6%	11%	14%	6%	24%
Cutoff 4	0.179	nd	0.179	0.179	0.179	0.179	0.179	0.179	0.179
Sens 4	16%	nd	20%	34%	29%	34%	24%	29%	24%
Spec 4	70%	nd	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.251	nd	0.249	0.251	0.259	0.249	0.251	0.259	0.249
Sens 5	8%	nd	8%	28%	29%	28%	18%	0%	18%
Spec 5	80%	nd	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.434	nd	0.466	0.434	0.422	0.466	0.434	0.422	0.466
Sens 6	8%	nd	8%	9%	14%	7%	12%	0%	12%
Spec 6	90%	nd	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	3.1	nd	2.5	0.43	0.50	0.38	0.99	0	1.5
p Value	0.17	nd	0.20	0.13	0.57	0.11	0.99	na	0.66
95% CI of	0.62	nd	0.62	0.15	0.045	0.11	0.20	na	0.24
OR Quart 2	16	nd	9.8	1.3	5.6	1.3	5.0	na	9.2
OR Quart 3	3.1	nd	1.7	0.43	0.50	0.47	2.8	0.50	4.9
p Value	0.17	nd	0.47	0.13	0.57	0.19	0.14	0.57	0.047
95% CI of	0.61	nd	0.40	0.15	0.044	0.16	0.72	0.044	1.0
OR Quart 3	16	nd	7.3	1.3	5.5	1.4	11	5.5	23
OR Quart 4	6.0	nd	3.6	1.0	1.5	1.0	0.99	2.0	1.5
p Value	0.021	nd	0.055	0.98	0.65	0.98	0.99	0.41	0.66
95% CI of	1.3	nd	0.97	0.42	0.25	0.40	0.20	0.37	0.24
OR Quart 4	28	nd	14	2.4	9.3	2.6	5.0	11	9.2

Tumor necrosis factor receptor superfamily member 8

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	18.5	33.8	18.5	26.4	18.5	18.6
Average	24.9	46.9	24.9	36.4	24.9	27.1
Stdev	30.5	60.4	30.5	36.8	30.5	27.6
p (t-test)		3.0E-5		0.010		0.70
Min	0.0493	0.121	0.0493	0.0561	0.0493	0.0688
Max	277	350	277	158	277	111
n (Samp)	473	47	473	54	473	28
n (Patient)	240	47	240	54	240	28
sCr only						
Median	19.8	12.5	19.8	32.3	19.8	38.9
Average	31.0	23.4	31.0	59.4	31.0	32.8

-continued

Stdev	46.2	25.8	46.2	98.6	46.2	21.4
p (t-test)		0.62		0.050		0.90
Min	0.0493	0.196	0.0493	12.1	0.0493	0.0688
Max	554	63.3	554	353	554	59.7
n (Samp)	634	9	634	11	634	11
n (Patient)	295	9	295	11	295	11
UO only						
Median	16.9	35.1	16.9	26.4	16.9	18.8
Average	24.3	49.2	24.3	37.3	24.3	27.5
Stdev	31.1	62.2	31.1	38.9	31.1	28.0
p (t-test)		9.9E-6		0.0075		0.62
Min	0.0493	0.121	0.0493	0.0561	0.0493	0.196
Max	277	350	277	158	277	111
n (Samp)	441	43	441	48	441	25
n (Patient)	210	43	210	48	210	25

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.45	0.67	0.60	0.65	0.60	0.53	0.61	0.55
SE	0.045	0.100	0.047	0.043	0.091	0.045	0.057	0.091	0.061
p	0.0018	0.59	2.9E-4	0.021	0.098	0.028	0.59	0.24	0.37
nCohort 1	473	634	441	473	634	441	473	634	441
nCohort 2	47	9	43	54	11	48	28	11	25
Cutoff 1	15.4	5.09	15.4	12.3	23.1	9.75	8.69	18.3	10.4
Sens 1	70%	78%	72%	70%	73%	71%	71%	73%	72%
Spec 1	48%	19%	49%	40%	56%	35%	31%	46%	36%
Cutoff 2	6.53	1.18	12.1	5.14	18.5	5.09	5.76	9.75	6.53
Sens 2	81%	89%	81%	83%	82%	81%	82%	82%	84%
Spec 2	27%	12%	41%	23%	47%	23%	25%	30%	29%
Cutoff 3	1.18	0.121	5.14	1.80	13.6	1.18	0.196	5.76	0.196
Sens 3	94%	100%	91%	91%	91%	94%	93%	91%	96%
Spec 3	14%	6%	25%	16%	43%	15%	9%	23%	11%
Cutoff 4	29.5	32.9	27.0	29.5	32.9	27.0	29.5	32.9	27.0
Sens 4	55%	33%	60%	48%	27%	48%	39%	55%	40%
Spec 4	70%	71%	70%	70%	71%	70%	70%	71%	70%
Cutoff 5	38.9	42.2	37.4	38.9	42.2	37.4	38.9	42.2	37.4
Sens 5	43%	33%	49%	35%	27%	42%	25%	45%	24%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	53.5	63.6	53.5	53.5	63.6	53.5	53.5	63.6	53.5
Sens 6	26%	0%	26%	20%	9%	21%	7%	0%	8%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.8	0	2.3	0.89	>3.1	0.89	1.4	1.0	1.8
p Value	0.24	na	0.13	0.81	<0.34	0.81	0.56	1.0	0.37
95% CI of	0.68	na	0.78	0.37	>0.31	0.35	0.44	0.14	0.51
OR Quart 2	4.7	na	6.9	2.2	na	2.3	4.6	7.2	6.3
OR Quart 3	0.70	0.66	1.0	1.1	>5.2	0.79	1.6	0.50	1.3
p Value	0.56	0.65	1.0	0.84	<0.14	0.62	0.40	0.57	0.73
95% CI of	0.22	0.11	0.28	0.46	>0.60	0.30	0.52	0.045	0.33
OR Quart 3	2.3	4.0	3.5	2.6	na	2.1	5.2	5.5	4.8
OR Quart 4	3.8	1.4	5.2	2.1	>3.0	2.3	1.6	3.1	2.3
p Value	0.0032	0.70	0.0014	0.066	<0.34	0.041	0.41	0.18	0.17
95% CI of	1.6	0.30	1.9	0.95	>0.31	1.0	0.52	0.61	0.70
OR Quart 4	9.2	6.1	14	4.5	na	5.1	5.1	15	7.8

Alpha-fetoprotein

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.00508	0.00505	0.00508	0.00587	0.00508	0.00428
Average	0.0492	0.0230	0.0492	0.109	0.0492	0.0706
Stdev	0.117	0.0651	0.117	0.406	0.117	0.242
p (t-test)		0.17		0.021		0.40
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	0.889	0.280	0.889	2.85	0.889	1.25
n (Samp)	407	39	407	50	407	27
n (Patient)	214	39	214	50	214	27
sCr only						
Median	nd	nd	0.00505	0.00624	0.00505	0.00286
Average	nd	nd	0.0563	0.0846	0.0563	0.0277

-continued

Stdev	nd	nd	0.178	0.126	0.178	0.0583
p (t-test)	nd	nd		0.62		0.60
Min	nd	nd	0.000463	0.000463	0.000463	0.000463
Max	nd	nd	2.85	0.317	2.85	0.185
n (Samp)	nd	nd	535	10	535	11
n (Patient)	nd	nd	256	10	256	11
UO only						
Median	0.00505	0.00505	0.00505	0.00587	0.00505	0.00428
Average	0.0537	0.0230	0.0537	0.111	0.0537	0.0739
Stdev	0.148	0.0651	0.148	0.418	0.148	0.251
p (t-test)		0.20		0.058		0.53
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	1.74	0.280	1.74	2.85	1.74	1.25
n (Samp)	380	39	380	47	380	25
n (Patient)	189	39	189	47	189	25

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.42	nd	0.42	0.52	0.57	0.53	0.43	0.38	0.44
SE	0.050	nd	0.050	0.044	0.095	0.045	0.059	0.091	0.061
p	0.100	nd	0.13	0.57	0.43	0.53	0.22	0.19	0.31
nCohort 1	407	nd	380	407	535	380	407	535	380
nCohort 2	39	nd	39	50	10	47	27	11	25
Cutoff 1	0.00132	nd	0.00132	0.00296	0.00483	0.00296	0.00132	0.00132	0.00132
Sens 1	87%	nd	87%	78%	70%	77%	81%	91%	80%
Spec 1	14%	nd	15%	19%	44%	20%	14%	15%	15%
Cutoff 2	0.00132	nd	0.00132	0.00132	0.00296	0.00132	0.00132	0.00132	0.00132
Sens 2	87%	nd	87%	84%	80%	83%	81%	91%	80%
Spec 2	14%	nd	15%	14%	22%	15%	14%	15%	15%
Cutoff 3	0	nd	0	0.000463	0.000463	0.000463	0.000463	0.00132	0.000463
Sens 3	100%	nd	100%	92%	90%	91%	93%	91%	92%
Spec 3	0%	nd	0%	8%	9%	9%	8%	15%	9%
Cutoff 4	0.0128	nd	0.00660	0.0128	0.00660	0.00660	0.0128	0.00660	0.00660
Sens 4	10%	nd	10%	40%	40%	40%	22%	18%	24%
Spec 4	70%	nd	71%	70%	72%	71%	70%	72%	71%
Cutoff 5	0.0613	nd	0.0613	0.0613	0.0499	0.0613	0.0613	0.0499	0.0613
Sens 5	8%	nd	8%	24%	30%	23%	19%	18%	16%
Spec 5	80%	nd	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.141	nd	0.131	0.141	0.154	0.131	0.141	0.154	0.131
Sens 6	8%	nd	8%	16%	30%	15%	11%	9%	12%
Spec 6	90%	nd	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	5.2	nd	5.2	1.2	1.0	0.99	1.4	0.50	1.4
p Value	0.011	nd	0.011	0.67	1.0	0.98	0.54	0.57	0.54
95% CI of	1.5	nd	1.5	0.52	0.14	0.41	0.44	0.045	0.44
OR Quart 2	19	nd	19	2.8	7.2	2.4	4.7	5.6	4.7
OR Quart 3	3.6	nd	3.6	1.2	1.0	0.99	0.59	1.0	0.80
p Value	0.059	nd	0.058	0.67	1.0	0.98	0.48	1.0	0.74
95% CI of	0.95	nd	0.96	0.52	0.14	0.41	0.14	0.14	0.21
OR Quart 3	13	nd	13	2.8	7.2	2.4	2.5	7.2	3.1
OR Quart 4	4.4	nd	4.4	1.2	2.0	1.3	2.6	3.1	1.9
p Value	0.025	nd	0.024	0.68	0.42	0.54	0.083	0.17	0.27
95% CI of	1.2	nd	1.2	0.51	0.36	0.56	0.88	0.62	0.61
OR Quart 4	16	nd	16	2.8	11	3.0	7.7	16	5.9

Apolipoprotein E						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	2.68	1.90	2.68	1.73	2.68	1.37
Average	21.4	9.42	21.4	34.9	21.4	4.56
Stdev	132	20.1	132	239	132	12.4
p (t-test)		0.45		0.41		0.39
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.000147
Max	2160	135	2160	2140	2160	83.4
n (Samp)	1008	70	1008	80	1008	46
n (Patient)	386	70	386	80	386	46
sCr only						
Median	2.56	0.695	2.56	1.07	2.56	1.79
Average	20.2	1.91	20.2	3.33	20.2	3.52

-continued

Stdev	129	3.03	129	6.71	129	4.87
p (t-test)		0.57		0.55		0.56
Min	0.000147	0.00154	0.000147	0.000147	0.000147	0.000147
Max	2160	10.5	2160	28.7	2160	19.7
n (Samp)	1344	16	1344	21	1344	20
n (Patient)	472	16	472	21	472	20
UO only						
Median	2.57	3.56	2.57	1.85	2.57	1.41
Average	19.5	11.2	19.5	38.5	19.5	4.94
Stdev	120	22.0	120	250	120	13.3
p (t-test)		0.58		0.24		0.44
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.00328
Max	2140	135	2140	2140	2140	83.4
n (Samp)	900	65	900	73	900	40
n (Patient)	310	65	310	73	310	40

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.47	0.29	0.50	0.45	0.34	0.47	0.37	0.40	0.39
SE	0.036	0.074	0.037	0.034	0.066	0.036	0.045	0.067	0.048
p	0.36	0.0050	0.94	0.13	0.016	0.37	0.0052	0.15	0.027
nCohort 1	1008	1344	900	1008	1344	900	1008	1344	900
nCohort 2	70	16	65	80	21	73	46	20	40
Cutoff 1	0.809	0.201	0.825	0.551	0.423	0.422	0.505	0.757	0.515
Sens 1	70%	75%	71%	70%	71%	71%	72%	70%	70%
Spec 1	26%	12%	26%	20%	18%	16%	19%	26%	19%
Cutoff 2	0.393	0.130	0.393	0.153	0.260	0.153	0.172	0.178	0.177
Sens 2	80%	81%	80%	80%	81%	81%	83%	80%	80%
Spec 2	16%	10%	16%	10%	13%	10%	11%	12%	10%
Cutoff 3	0.103	0.00323	0.103	0.00463	0.00129	0.0258	0.0258	0.0258	0.0994
Sens 3	90%	94%	91%	90%	90%	90%	93%	95%	90%
Spec 3	9%	5%	9%	6%	2%	7%	6%	6%	9%
Cutoff 4	7.24	6.96	6.93	7.24	6.96	6.93	7.24	6.96	6.93
Sens 4	33%	12%	37%	26%	14%	29%	15%	20%	15%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	12.6	12.4	11.5	12.6	12.4	11.5	12.6	12.4	11.5
Sens 5	17%	0%	28%	22%	10%	26%	7%	5%	10%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	28.1	26.8	27.0	28.1	26.8	27.0	28.1	26.8	27.0
Sens 6	6%	0%	11%	9%	5%	10%	2%	0%	2%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.63	3.0	0.87	0.94	2.0	0.79	1.5	2.5	1.5
p Value	0.22	0.34	0.71	0.86	0.42	0.50	0.43	0.27	0.43
95% CI of	0.31	0.31	0.43	0.48	0.37	0.40	0.53	0.49	0.53
OR Quart 2	1.3	29	1.8	1.8	11	1.6	4.3	13	4.3
OR Quart 3	0.84	3.0	0.63	0.78	3.0	0.53	2.4	3.6	1.7
p Value	0.61	0.34	0.25	0.48	0.17	0.10	0.076	0.12	0.31
95% CI of	0.43	0.31	0.29	0.39	0.61	0.25	0.91	0.73	0.61
OR Quart 3	1.6	29	1.4	1.6	15	1.1	6.4	17	4.7
OR Quart 4	1.0	9.2	1.3	1.5	4.6	1.3	3.0	3.0	2.6
p Value	0.99	0.036	0.41	0.17	0.052	0.35	0.024	0.18	0.052
95% CI of	0.53	1.2	0.68	0.83	0.99	0.73	1.2	0.61	0.99
OR Quart 4	1.9	73	2.5	2.8	21	2.5	7.7	15	6.8

Apolipoprotein(a)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	2.16	2.88	2.16	3.39	2.16	2.04
Average	46.7	10.1	46.7	23.9	46.7	5.40
Stdev	602	22.6	602	97.8	602	13.0
p(t-test)		0.62		0.74		0.66
Min	0.00241	0.00241	0.00241	0.00838	0.00241	0.00838
Max	17500	118	17500	802	17500	75.7
n (Samp)	953	65	953	75	953	41
n (Patient)	381	65	381	75	381	41
sCr only						
Median	2.09	1.68	2.09	3.09	2.09	2.25
Average	39.7	3.70	39.7	5.16	39.7	11.5

-continued

Stdev	523	6.91	523	8.41	523	21.6
p(t-test)		0.80		0.77		0.81
Min	0.00241	0.0122	0.00241	0.00479	0.00241	0.00838
Max	17500	27.0	17500	37.7	17500	91.1
n (Samp)	1273	14	1273	20	1273	19
n (Patient)	466	14	466	20	466	19
UO only						
Median	2.19	2.95	2.19	3.88	2.19	2.13
Average	46.2	20.7	46.2	26.4	46.2	6.18
Stdev	637	81.1	637	102	637	14.0
p(t-test)		0.76		0.80		0.71
Min	0.00241	0.00241	0.00241	0.00838	0.00241	0.0122
Max	17500	618	17500	802	17500	75.7
n (Samp)	845	61	845	68	845	35
n (Patient)	305	61	305	68	305	35

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.45	0.59	0.60	0.54	0.64	0.49	0.53	0.54
SE	0.038	0.080	0.039	0.036	0.066	0.037	0.046	0.068	0.051
p	0.10	0.49	0.020	0.0058	0.58	2.2E-4	0.89	0.64	0.44
nCohort 1	953	1273	845	953	1273	845	953	1273	845
nCohort 2	65	14	61	75	20	68	41	19	35
Cutoff 1	1.40	0.892	1.82	1.65	1.65	1.82	1.18	0.971	1.38
Sens 1	71%	71%	70%	71%	70%	71%	71%	74%	71%
Spec 1	39%	28%	46%	44%	44%	46%	33%	30%	38%
Cutoff 2	0.917	0.108	0.977	1.20	0.751	1.26	0.826	0.0122	0.977
Sens 2	80%	86%	80%	80%	80%	81%	80%	84%	80%
Spec 2	28%	11%	31%	34%	25%	35%	26%	6%	31%
Cutoff 3	0.108	0.0847	0.108	0.0847	0.0140	0.509	0.182	0.00790	0.699
Sens 3	91%	93%	92%	91%	90%	91%	90%	100%	91%
Spec 3	13%	11%	12%	12%	7%	22%	14%	1%	25%
Cutoff 4	3.89	3.89	3.74	3.89	3.89	3.74	3.89	3.89	3.74
Sens 4	37%	14%	43%	44%	40%	53%	24%	42%	31%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	5.71	5.71	5.25	5.71	5.71	5.25	5.71	5.71	5.25
Sens 5	25%	7%	28%	31%	15%	40%	12%	37%	20%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	17.0	18.8	13.7	17.0	18.8	13.7	17.0	18.8	13.7
Sens 6	15%	7%	18%	15%	5%	19%	5%	16%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	2.0	1.1	1.4	1.0	1.8	1.0	0.80	4.0
p Value	0.85	0.42	0.83	0.42	1.0	0.20	0.99	0.74	0.016
95% CI of	0.48	0.37	0.46	0.62	0.25	0.74	0.39	0.21	1.3
OR Quart 2	2.4	11	2.6	3.1	4.0	4.4	2.6	3.0	12
OR Quart 3	1.7	2.0	2.0	2.1	1.5	2.1	1.8	0.40	1.5
p Value	0.15	0.42	0.089	0.052	0.53	0.100	0.16	0.27	0.53
95% CI of	0.82	0.37	0.90	0.99	0.42	0.87	0.79	0.076	0.42
OR Quart 3	3.6	11	4.4	4.4	5.4	5.0	4.2	2.1	5.4
OR Quart 4	1.7	2.0	2.2	2.6	1.5	4.1	0.77	1.6	2.6
p Value	0.15	0.42	0.046	0.0090	0.53	5.2E-4	0.62	0.40	0.12
95% CI of	0.82	0.37	1.0	1.3	0.42	1.9	0.28	0.52	0.79
OR Quart 4	3.6	11	4.8	5.4	5.4	9.3	2.1	5.0	8.3

[0185] FIG. 3: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

C-C motif chemokine 7						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.737	0.625	0.515	0.428	0.816	0.625
Average	3.18	2.02	2.28	1.04	3.91	1.08
Stdev	15.8	5.30	6.57	1.96	17.8	1.64

-continued

p (t-test)		0.63		0.49		0.38
Min	0.146	0.146	0.146	0.146	0.146	0.264
Max	161	33.0	33.0	7.75	161	7.33
n (Samp)	124	45	49	14	97	31
n (Patient)	124	45	49	14	97	31

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.45	0.44	0.40
SE	0.051	0.089	0.060
p	0.37	0.48	0.086
nCohort 1	124	49	97
nCohort 2	45	14	31
Cutoff 1	0.341	0.319	0.515
Sens 1	71%	79%	71%
Spec 1	25%	20%	27%
Cutoff 2	0.320	0.146	0.336
Sens 2	80%	93%	81%
Spec 2	19%	6%	20%
Cutoff 3	0.264	0.146	0.319
Sens 3	91%	93%	90%
Spec 3	6%	6%	11%
Cutoff 4	1.04	0.812	1.15
Sens 4	22%	21%	13%
Spec 4	73%	73%	77%
Cutoff 5	1.15	1.04	1.29
Sens 5	20%	14%	10%
Spec 5	81%	84%	82%
Cutoff 6	1.59	1.59	6.92
Sens 6	11%	7%	3%
Spec 6	92%	92%	91%
OR Quart 2	0.78	1.4	2.3
p Value	0.64	0.67	0.21
95% CI of	0.27	0.27	0.62
OR Quart 2	2.2	7.8	8.7
OR Quart 3	2.0	1.0	3.2
p Value	0.14	1.0	0.078
95% CI of	0.79	0.17	0.88
OR Quart 3	5.2	5.9	12
OR Quart 4	1.2	1.6	2.7
p Value	0.75	0.60	0.13
95% CI of	0.44	0.29	0.75
OR Quart 4	3.1	8.6	10

Interleukin-33						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	22.3	38.9	18.4	33.3	23.5	39.6
Average	34.5	48.9	32.2	42.7	36.8	54.2
Stdev	34.0	41.1	33.2	33.6	37.8	42.3
p (t-test)		0.023		0.30		0.032
Min	0.0232	0.0591	0.0232	0.0591	0.0232	0.0645
Max	138	148	138	136	203	148
n (Samp)	124	45	49	14	97	31
n (Patient)	124	45	49	14	97	31

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.61	0.62	0.64
SE	0.051	0.089	0.060
p	0.028	0.16	0.020
nCohort 1	124	49	97
nCohort 2	45	14	31
Cutoff 1	23.5	22.7	26.3
Sens 1	71%	71%	71%
Spec 1	52%	55%	54%
Cutoff 2	14.6	18.6	19.4
Sens 2	80%	86%	81%
Spec 2	40%	53%	46%
Cutoff 3	0.0879	12.9	13.7

-continued

Sens 3	91%	93%	90%
Spec 3	14%	39%	37%
Cutoff 4	48.0	46.3	53.0
Sens 4	33%	36%	39%
Spec 4	70%	71%	70%
Cutoff 5	65.3	59.3	70.3
Sens 5	29%	14%	29%
Spec 5	81%	82%	80%
Cutoff 6	82.3	80.5	88.8
Sens 6	18%	7%	19%
Spec 6	90%	92%	91%
OR Quart 2	1.4	3.2	3.2
p Value	0.58	0.34	0.11
95% CI of	0.46	0.30	0.77
OR Quart 2	4.1	35	14
OR Quart 3	3.1	8.4	3.8
p Value	0.031	0.066	0.066
95% CI of	1.1	0.87	0.92
OR Quart 3	8.6	81	16
OR Quart 4	2.2	4.7	5.1
p Value	0.15	0.19	0.023
95% CI of	0.77	0.46	1.3
OR Quart 4	6.1	48	20

Interleukin-4 receptor alpha chain

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	46.2	69.6	47.1	80.3	46.2	69.6
Average	56.0	74.5	53.5	62.1	60.2	80.6
Stdev	50.9	55.4	37.9	40.8	56.9	62.8
p (t-test)		0.081		0.54		0.15
Min	2.31	7.12	2.31	4.67	2.31	10.3
Max	256	239	122	119	256	239
n (Samp)	90	34	34	10	71	12
n (Patient)	90	34	34	10	71	22

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.63	0.57	0.63
SE	0.058	0.11	0.071
p	0.027	0.50	0.066
nCohort 1	90	34	71
nCohort 2	34	10	22
Cutoff 1	40.7	49.3	25.4
Sens 1	71%	70%	73%
Spec 1	39%	56%	37%
Cutoff 2	12.4	11.7	20.5
Sens 2	82%	80%	82%
Spec 2	33%	26%	35%
Cutoff 3	11.8	4.67	11.8
Sens 3	91%	90%	91%
Spec 3	28%	6%	25%
Cutoff 4	69.4	79.9	68.1
Sens 4	50%	50%	55%
Spec 4	70%	71%	70%
Cutoff 5	93.9	94.4	105
Sens 5	35%	10%	27%
Spec 5	80%	82%	80%
Cutoff 6	115	104	137
Sens 6	15%	10%	14%
Spec 6	90%	91%	90%
OR Quart 2	2.3	0.45	3.7
p Value	0.21	0.54	0.14
95% CI of	0.63	0.035	0.66
OR Quart 2	8.8	5.8	21
OR Quart 3	3.2	2.6	3.7
p Value	0.077	0.35	0.14
95% CI of	0.88	0.36	0.66
OR Quart 3	12	18	21
OR Quart 4	4.3	1.7	5.2
p Value	0.026	0.61	0.053

-continued

95% CI of OR Quart 4	1.2 15	0.22 13	0.98 28			
Lutropin subunit beta						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.9	10.4	nd	nd	20.2	27.2
Average	45.9	40.9	nd	nd	41.3	64.1
Stdev	67.7	70.4	nd	nd	61.1	97.6
p (t-test)		0.75	nd	nd		0.27
Min	0.211	0.0858	nd	nd	0.311	0.0858
Max	268	277	nd	nd	268	325
n (Samp)	54	28	nd	nd	40	20
n (Patient)	54	28	nd	nd	40	20

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.45	nd	0.52
SE	0.068	nd	0.080
p	0.42	nd	0.77
nCohort 1	54	nd	40
nCohort 2	28	nd	20
Cutoff 1	4.22	nd	8.91
Sens 1	71%	nd	70%
Spec 1	24%	nd	40%
Cutoff 2	2.03	nd	4.22
Sens 2	82%	nd	80%
Spec 2	19%	nd	20%
Cutoff 3	0.388	nd	0.388
Sens 3	93%	nd	90%
Spec 3	7%	nd	8%
Cutoff 4	42.8	nd	43.5
Sens 4	25%	nd	35%
Spec 4	70%	nd	70%
Cutoff 5	68.4	nd	59.7
Sens 5	14%	nd	25%
Spec 5	81%	nd	80%
Cutoff 6	162	nd	76.4
Sens 6	7%	nd	20%
Spec 6	91%	nd	90%
OR Quart 2	1.3	nd	0.38
p Value	0.66	nd	0.24
95% CI of	0.36	nd	0.073
OR Quart 2	5.0	nd	1.9
OR Quart 3	1.2	nd	1.0
p Value	0.74	nd	1.0
95% CI of	0.34	nd	0.23
OR Quart 3	4.6	nd	4.3
OR Quart 4	1.7	nd	0.75
p Value	0.44	nd	0.71
95% CI of	0.45	nd	0.17
OR Quart 4	6.1	nd	3.3

Platelet-derived growth factor subunit B (dimer)

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.82	2.07	2.78	1.24	1.71	1.76
Average	3.46	2.36	5.94	1.92	2.45	2.25
Stdev	9.80	2.42	15.1	2.62	2.77	2.39
p (t-test)		0.53		0.41		0.76
Min	0.00313	0.00369	0.0244	0.0144	0.00313	0.00369
Max	86.2	10.8	86.2	8.93	17.1	10.8
n (Samp)	77	33	31	10	61	24
n (Patient)	77	33	31	10	61	24

-continued

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.48	0.25	0.49
SE	0.061	0.097	0.070
p	0.73	0.0084	0.84
nCohort 1	77	31	61
nCohort 2	33	10	24
Cutoff 1	0.484	0.463	0.545
Sens 1	73%	70%	71%
Spec 1	18%	3%	21%
Cutoff 2	0.365	0.0244	0.365
Sens 2	82%	80%	83%
Spec 2	17%	3%	20%
Cutoff 3	0.0144	0	0.0244
Sens 3	91%	100%	92%
Spec 3	3%	0%	11%
Cutoff 4	3.07	3.71	3.00
Sens 4	27%	10%	29%
Spec 4	70%	71%	70%
Cutoff 5	3.71	4.20	3.42
Sens 5	21%	10%	25%
Spec 5	81%	81%	80%
Cutoff 6	6.35	8.43	5.18
Sens 6	6%	10%	4%
Spec 6	91%	90%	90%
OR Quart 2	0.89	1.1	1.1
p Value	0.84	0.94	0.92
95% CI of	0.28	0.060	0.28
OR Quart 2	2.8	20	4.0
OR Quart 3	0.46	4.3	0.63
p Value	0.22	0.25	0.53
95% CI of	0.13	0.37	0.15
OR Quart 3	1.6	50	2.6
OR Quart 4	1.5	10	1.6
p Value	0.51	0.060	0.45
95% CI of	0.48	0.91	0.45
OR Quart 4	4.4	110	5.9

Corticotropin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00163	0.00194	nd	nd	0.00163	0.00171
Average	0.00250	0.00276	nd	nd	0.00260	0.00164
Stdev	0.00498	0.00438	nd	nd	0.00550	0.000678
p (t-test)		0.82	nd	nd		0.49
Min	3.92E-6	0.000355	nd	nd	0.000355	0.000355
Max	0.0373	0.0224	nd	nd	0.0373	0.00282
n (Samp)	53	23	nd	nd	43	16
n (Patient)	53	23	nd	nd	43	16

At Enrollment

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.47
SE	0.073	nd	0.086
p	0.66	nd	0.73
nCohort 1	53	nd	43
nCohort 2	23	nd	16
Cutoff 1	0.00119	nd	0.00134
Sens 1	74%	nd	75%
Spec 1	30%	nd	35%
Cutoff 2	0.00111	nd	0.00111
Sens 2	87%	nd	81%
Spec 2	23%	nd	21%
Cutoff 3	0.000909	nd	0.000355
Sens 3	91%	nd	94%
Spec 3	23%	nd	5%
Cutoff 4	0.00222	nd	0.00222
Sens 4	26%	nd	12%
Spec 4	72%	nd	72%
Cutoff 5	0.00291	nd	0.00256

-continued

Sens 5	13%	nd	12%
Spec 5	85%	nd	81%
Cutoff 6	0.00362	nd	0.00304
Sens 6	13%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.0	nd	4.3
p Value	1.0	nd	0.11
95% CI of	0.24	nd	0.71
OR Quart 2	4.2	nd	27
OR Quart 3	1.6	nd	2.4
p Value	0.49	nd	0.37
95% CI of	0.41	nd	0.36
OR Quart 3	6.5	nd	15
OR Quart 4	1.3	nd	2.6
p Value	0.72	nd	0.32
95% CI of	0.32	nd	0.39
OR Quart 4	5.3	nd	17

Thyroxine-binding globulin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0750	0.136	nd	nd	0.0894	0.150
Average	0.225	0.184	nd	nd	0.263	0.191
Stdev	0.373	0.205	nd	nd	0.411	0.184
p (t-test)		0.62	nd	nd		0.50
Min	8.30E-5	0.00330	nd	nd	0.00106	0.00330
Max	1.86	0.748	nd	nd	1.86	0.564
n (Samp)	52	23	nd	nd	43	16
n (Patient)	52	23	nd	nd	43	16

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.52	nd	0.51
SE	0.073	nd	0.085
p	0.83	nd	0.93
nCohort 1	52	nd	43
nCohort 2	23	nd	16
Cutoff 1	0.0183	nd	0.0179
Sens 1	74%	nd	75%
Spec 1	27%	nd	28%
Cutoff 2	0.0138	nd	0.0119
Sens 2	83%	nd	81%
Spec 2	19%	nd	21%
Cutoff 3	0.00575	nd	0.00330
Sens 3	91%	nd	94%
Spec 3	12%	nd	5%
Cutoff 4	0.212	nd	0.296
Sens 4	35%	nd	31%
Spec 4	71%	nd	72%
Cutoff 5	0.369	nd	0.468
Sens 5	13%	nd	12%
Spec 5	83%	nd	81%
Cutoff 6	0.486	nd	0.792
Sens 6	9%	nd	0%
Spec 6	90%	nd	91%
OR Quart 2	0.93	nd	0.62
p Value	0.92	nd	0.59
95% CI of	0.22	nd	0.11
OR Quart 2	4.0	nd	3.5
OR Quart 3	1.5	nd	1.7
p Value	0.56	nd	0.52
95% CI of	0.38	nd	0.35
OR Quart 3	6.1	nd	7.9
OR Quart 4	1.2	nd	0.62
p Value	0.80	nd	0.59
95% CI of	0.29	nd	0.11
OR Quart 4	4.9	nd	3.5

-continued

Alpha-fetoprotein						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00505	0.00587	0.00428	0.0385	0.00486	0.00587
Average	0.0525	0.122	0.0656	0.297	0.0435	0.0801
Stdev	0.106	0.321	0.126	0.568	0.0900	0.196
p (t-test)		0.083		0.037		0.22
Min	0.000463	0.000463	0.000463	0.000523	0.000463	0.000463
Max	0.585	1.74	0.585	1.74	0.507	0.840
n (Samp)	79	40	31	9	62	31
n (Patient)	79	40	31	9	62	31

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.50	0.67	0.50
SE	0.056	0.11	0.064
p	0.99	0.12	0.96
nCohort 1	79	31	62
nCohort 2	40	9	31
Cutoff 1	0.00286	0.00483	0.00132
Sens 1	70%	78%	74%
Spec 1	18%	55%	15%
Cutoff 2	0.000463	0.000523	0.000463
Sens 2	85%	89%	90%
Spec 2	8%	19%	6%
Cutoff 3	0	0.000463	0.000463
Sens 3	100%	100%	90%
Spec 3	0%	19%	6%
Cutoff 4	0.0499	0.0671	0.00660
Sens 4	25%	44%	32%
Spec 4	72%	71%	71%
Cutoff 5	0.0728	0.107	0.0613
Sens 5	22%	44%	19%
Spec 5	81%	81%	81%
Cutoff 6	0.198	0.236	0.130
Sens 6	10%	22%	16%
Spec 6	91%	90%	90%
OR Quart 2	0.43	0	2.2
p Value	0.14	na	0.19
95% CI of	0.14	na	0.67
OR Quart 2	1.3	na	7.4
OR Quart 3	0.82	1.7	0.36
p Value	0.71	0.61	0.19
95% CI of	0.29	0.22	0.081
OR Quart 3	2.3	13	1.6
OR Quart 4	0.71	2.7	1.9
p Value	0.52	0.34	0.31
95% CI of	0.25	0.36	0.56
OR Quart 4	2.0	20	6.2

Apolipoprotein E						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.11	1.74	1.37	1.13	4.13	1.77
Average	24.3	6.24	8.39	3.15	27.8	6.55
Stdev	169	12.6	34.1	6.55	190	13.7
p (t-test)		0.41		0.55		0.46
Min	0.00102	0.000147	0.000147	0.000147	0.00122	0.00129
Max	1960	83.4	254	26.8	1960	83.4
n (Samp)	137	59	56	16	107	43
n (Patient)	137	59	56	16	107	43

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.45	0.44	0.42
SE	0.045	0.083	0.053
p	0.24	0.46	0.15

-continued

nCohort 1	137	56	107
nCohort 2	59	16	43
Cutoff 1	0.957	0.177	1.00
Sens 1	71%	75%	72%
Spec 1	34%	23%	31%
Cutoff 2	0.551	0.0954	0.551
Sens 2	81%	81%	81%
Spec 2	20%	16%	17%
Cutoff 3	0.0862	0.00122	0.0954
Sens 3	92%	94%	91%
Spec 3	9%	5%	7%
Cutoff 4	7.35	3.25	9.11
Sens 4	19%	25%	19%
Spec 4	70%	71%	71%
Cutoff 5	14.2	4.55	17.3
Sens 5	12%	12%	12%
Spec 5	80%	80%	80%
Cutoff 6	25.4	14.2	30.5
Sens 6	7%	6%	2%
Spec 6	91%	91%	91%
OR Quart 2	1.9	1.4	1.2
p Value	0.17	0.67	0.74
95% CI of	0.76	0.27	0.41
OR Quart 2	4.7	7.5	3.6
OR Quart 3	2.3	1.4	2.4
p Value	0.077	0.67	0.084
95% CI of	0.92	0.27	0.89
OR Quart 3	5.6	7.5	6.8
OR Quart 4	1.7	1.9	1.6
p Value	0.25	0.43	0.39
95% CI of	0.68	0.38	0.55
OR Quart 4	4.3	9.6	4.5

[0186] FIG. 4: Comparison of the maximum marker levels in urine samples collected from Cohort I (patients that did not progress beyond RIFLE stage 0) and the maximum values in

urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

Complement C4-B						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	24.7	74.8	24.7	63.2	24.7	53.0
Average	80.6	110	80.6	103	80.6	92.3
Stdev	182	165	182	163	182	110
p (t-test)		0.41		0.52		0.80
Min	0.00607	0.499	0.00607	0.499	0.00607	3.05
Max	1950	827	1950	827	1950	425
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16
sCr only						
Median	35.2	71.6	35.2	71.6	35.2	71.6
Average	106	101	106	101	106	115
Stdev	206	118	206	118	206	142
p (t-test)		0.94		0.94		0.90
Min	0.00607	0.499	0.00607	0.499	0.00607	17.0
Max	2000	425	2000	425	2000	425
n (Samp)	374	13	374	13	374	7
n (Patient)	374	13	374	13	374	7
UO only						
Median	28.0	78.0	28.0	71.6	28.0	63.2
Average	88.7	111	88.7	103	88.7	84.8
Stdev	187	169	187	168	187	72.8
p (t-test)		0.59		0.73		0.94
Min	0.00329	0.904	0.00329	0.672	0.00329	3.05
Max	1950	827	1950	827	1950	236

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.55	0.60	0.59	0.55	0.58	0.63	0.64	0.61
SE	0.058	0.084	0.066	0.058	0.084	0.066	0.077	0.11	0.083
p	0.080	0.54	0.12	0.14	0.54	0.20	0.085	0.22	0.18
nCohort 1	223	374	173	223	374	173	223	374	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	16.9	17.0	16.9	16.9	17.0	16.9	17.8	47.7	30.8
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	44%	34%	38%	44%	34%	38%	45%	56%	51%
Cutoff 2	8.71	5.52	8.98	5.52	5.52	8.71	17.0	32.9	16.9
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	35%	19%	27%	26%	19%	27%	44%	48%	38%
Cutoff 3	2.76	0.923	4.28	2.22	0.923	2.76	4.27	17.0	4.27
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	16%	4%	17%	13%	4%	10%	22%	34%	16%
Cutoff 4	57.6	87.6	63.7	57.6	87.6	63.7	57.6	87.6	63.7
Sens 4	53%	38%	57%	50%	38%	52%	44%	29%	50%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	106	150	128	106	150	128	106	150	128
Sens 5	37%	23%	35%	33%	23%	30%	31%	14%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	213	260	229	213	260	229	213	260	229
Sens 6	10%	8%	9%	7%	8%	4%	12%	14%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	0.65	1.7	1.0	0.65	1.0	1.5	>2.0	0.98
p Value	0.55	0.64	0.47	1.0	0.64	1.0	0.66	<0.56	0.98
95% CI of	0.43	0.11	0.39	0.30	0.11	0.24	0.24	>0.18	0.13
OR Quart 2	4.8	4.0	7.7	3.3	4.0	4.2	9.3	na	7.3
OR Quart 3	0.79	1.3	2.1	0.82	1.3	1.9	2.0	>3.1	2.0
p Value	0.73	0.71	0.30	0.75	0.71	0.34	0.42	<0.33	0.42
95% CI of	0.20	0.29	0.50	0.24	0.29	0.51	0.36	>0.32	0.36
OR Quart 3	3.1	6.1	9.1	2.8	6.1	6.9	12	na	12
OR Quart 4	3.2	1.3	3.4	2.4	1.3	2.2	3.8	>2.0	3.2
p Value	0.034	0.71	0.077	0.095	0.71	0.23	0.11	<0.57	0.17
95% CI of	1.1	0.29	0.87	0.86	0.29	0.61	0.75	>0.18	0.61
OR Quart 4	9.7	6.1	14	6.8	6.1	7.8	19	na	17
C-C motif chemokine 26									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	
sCr or UO									
Median	0.0402	0.0421	0.0402	0.0405	0.0402		0.0402	0.0379	
Average	0.0784	1.93	0.0784	1.93	0.0784		0.0784	0.0347	
Stdev	0.610	8.08	0.610	8.08	0.610		0.610	0.0128	
p (t-test)		7.9E-4		8.0E-4				0.78	
Min	0.00872	0.00872	0.00872	0.00872	0.00872		0.00872	0.0195	
Max	9.14	42.3	9.14	42.3	9.14		9.14	0.0526	
n (Samp)	223	30	223	30	223		223	16	
n (Patient)	223	30	223	30	223		223	16	
sCr only									
Median	0.0438	0.0402	0.0438	0.0402	0.0438		0.0438	0.0443	
Average	0.408	0.0374	0.408	0.0359	0.408		0.408	0.0393	
Stdev	3.41	0.0150	3.41	0.0152	3.41		3.41	0.0124	
p (t-test)		0.70		0.69				0.78	
Min	0.00872	0.00872	0.00872	0.00872	0.00872		0.00872	0.0195	
Max	42.3	0.0633	42.3	0.0633	42.3		42.3	0.0526	
n (Samp)	375	13	375	13	375		375	7	
n (Patient)	375	13	375	13	375		375	7	
UO only									
Median	0.0443	0.0433	0.0443	0.0433	0.0443		0.0443	0.0363	
Average	0.0482	2.91	0.0482	2.83	0.0482		0.0482	0.0340	
Stdev	0.0942	9.28	0.0942	9.23	0.0942		0.0942	0.0117	
p (t-test)		5.6E-5		7.9E-5				0.57	
Min	0.00872	0.0196	0.00872	0.0196	0.00872		0.00872	0.0196	
Max	1.25	42.3	1.25	42.3	1.25		1.25	0.0525	

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.44	0.53	0.51	0.42	0.48	0.47	0.47	0.38
SE	0.057	0.084	0.065	0.057	0.084	0.065	0.076	0.11	0.083
p	0.37	0.48	0.62	0.85	0.37	0.81	0.66	0.79	0.15
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	0.0311	0.0240	0.0386	0.0235	0.0235	0.0232	0.0232	0.0433	0.0232
Sens 1	70%	77%	74%	73%	77%	78%	75%	71%	79%
Spec 1	47%	30%	41%	39%	27%	28%	39%	47%	28%
Cutoff 2	0.0232	0.0232	0.0232	0.0231	0.0232	0.0231	0.0196	0.0232	0.0196
Sens 2	83%	85%	87%	80%	85%	83%	81%	86%	86%
Spec 2	39%	27%	28%	32%	27%	23%	15%	27%	13%
Cutoff 3	0.0196	0.0188	0.0231	0.0195	0.0188	0.0196	0.0195	0.0188	0.0195
Sens 3	90%	92%	91%	93%	92%	91%	94%	100%	100%
Spec 3	15%	8%	23%	15%	8%	13%	15%	8%	13%
Cutoff 4	0.0504	0.0525	0.0525	0.0504	0.0525	0.0525	0.0504	0.0525	0.0525
Sens 4	23%	15%	22%	20%	15%	17%	12%	14%	0%
Spec 4	78%	76%	77%	78%	76%	77%	78%	76%	77%
Cutoff 5	0.0525	0.0526	0.0526	0.0525	0.0526	0.0526	0.0525	0.0526	0.0526
Sens 5	20%	8%	22%	17%	8%	17%	6%	0%	0%
Spec 5	85%	82%	86%	85%	82%	86%	85%	82%	86%
Cutoff 6	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628
Sens 6	17%	8%	22%	13%	8%	17%	0%	0%	0%
Spec 6	95%	90%	92%	95%	90%	92%	95%	90%	92%
OR Quart 2	2.5	1.5	4.4	1.4	1.5	0.78	3.2	3.1	3.1
p Value	0.15	0.65	0.030	0.57	0.65	0.73	0.16	0.33	0.33
95% CI of	0.72	0.25	1.2	0.45	0.25	0.20	0.62	0.32	0.31
OR Quart 2	8.4	9.3	17	4.2	9.3	3.1	17	30	31
OR Quart 3	2.8	3.1	1.0	1.8	3.1	2.3	2.1	2.0	8.0
p Value	0.099	0.17	1.0	0.29	0.17	0.17	0.41	0.57	0.056
95% CI of	0.82	0.62	0.19	0.61	0.62	0.71	0.36	0.18	0.95
OR Quart 3	9.4	16	5.2	5.3	16	7.2	12	13	68
OR Quart 4	1.8	1.0	2.1	0.98	1.0	0.78	2.1	1.0	3.2
p Value	0.36	1.0	0.30	0.98	1.0	0.73	0.40	0.99	0.32
95% CI of	0.50	0.14	0.50	0.30	0.14	0.20	0.37	0.062	0.32
OR Quart 4	6.5	7.2	9.1	3.2	7.2	3.1	12	16	32
C-C motif chemokine 7									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	
sCr or UO									
Median	0.662	1.22	0.662	0.812	0.662	0.625			
Average	2.62	17.1	2.62	9.44	2.62	11.0			
Stdev	9.67	24.1	9.67	18.5	9.67	22.3			
p (t-test)		4.3E-9		0.0017		0.0035			
Min	0.146	0.188	0.146	0.188	0.146	0.319			
Max	125	82.4	125	82.4	125	82.4			
n (Samp)	223	30	223	30	223	16			
n (Patient)	223	30	223	30	223	16			
sCr only									
Median	0.816	1.29	0.816	1.15	0.816	0.625			
Average	3.99	34.0	3.99	12.4	3.99	7.89			
Stdev	19.3	80.2	19.3	20.1	19.3	13.3			
p (t-test)		8.9E-6		0.12		0.59			
Min	0.146	0.188	0.146	0.188	0.146	0.319			
Max	291	293	291	67.6	291	33.9			
n (Samp)	375	13	375	13	375	7			
n (Patient)	375	13	375	13	375	7			
UO only									
Median	0.816	1.15	0.816	0.812	0.816	0.625			
Average	3.35	26.1	3.35	14.4	3.35	8.82			
Stdev	10.9	40.2	10.9	29.5	10.9	22.9			
p (t-test)		7.5E-9		5.7E-4		0.11			
Min	0.146	0.341	0.146	0.319	0.146	0.341			
Max	125	166	125	114	125	82.4			

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.64	0.67	0.62	0.60	0.54	0.59	0.50	0.46
SE	0.055	0.084	0.065	0.058	0.084	0.065	0.077	0.11	0.082
p	9.6E-5	0.088	0.0087	0.038	0.26	0.50	0.22	1.00	0.62
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	0.584	0.380	0.584	0.515	0.380	0.515	0.483	0.336	0.515
Sens 1	73%	77%	78%	70%	77%	74%	75%	86%	71%
Spec 1	46%	29%	31%	43%	29%	29%	43%	22%	29%
Cutoff 2	0.483	0.336	0.515	0.406	0.336	0.499	0.380	0.336	0.380
Sens 2	83%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	43%	22%	29%	41%	22%	28%	41%	22%	25%
Cutoff 3	0.380	0.319	0.499	0.320	0.319	0.320	0.320	0.319	0.320
Sens 3	90%	92%	91%	90%	92%	96%	94%	100%	100%
Spec 3	41%	12%	28%	31%	12%	20%	31%	12%	20%
Cutoff 4	1.04	1.15	1.29	1.04	1.15	1.29	1.04	1.15	1.29
Sens 4	60%	54%	43%	40%	46%	26%	31%	29%	14%
Spec 4	74%	74%	77%	74%	74%	77%	74%	74%	77%
Cutoff 5	1.29	1.29	1.59	1.29	1.29	1.59	1.29	1.29	1.59
Sens 5	43%	46%	43%	27%	38%	26%	25%	29%	14%
Spec 5	84%	81%	87%	84%	81%	87%	84%	81%	87%
Cutoff 6	1.59	7.96	13.6	1.59	7.96	13.6	1.59	7.96	13.6
Sens 6	43%	46%	43%	27%	38%	26%	25%	29%	14%
Spec 6	90%	90%	97%	90%	90%	97%	90%	90%	97%
OR Quart 2	5.1	1.5	3.9	4.2	2.0	2.5	8.9	0.32	1.0
p Value	0.043	0.65	0.100	0.033	0.42	0.15	0.042	0.33	1.0
95% CI of	1.1	0.25	0.77	1.1	0.37	0.72	1.1	0.033	0.13
OR Quart 2	25	9.3	20	16	11	8.9	74	3.2	7.4
OR Quart 3	1.0	0.49	2.1	1.4	0.49	1.0	2.0	0.33	3.9
p Value	1.0	0.57	0.41	0.70	0.57	1.0	0.58	0.34	0.099
95% CI of	0.14	0.044	0.36	0.29	0.044	0.24	0.18	0.033	0.77
OR Quart 3	7.3	5.5	12	6.3	5.5	4.2	23	3.2	20
OR Quart 4	11	3.7	6.0	4.6	3.1	1.6	5.3	0.65	1.6
p Value	0.0019	0.11	0.026	0.023	0.17	0.51	0.13	0.64	0.63
95% CI of	2.4	0.75	1.2	1.2	0.62	0.41	0.60	0.11	0.25
OR Quart 4	50	18	29	17	16	5.9	47	4.0	9.9
Vascular endothelial growth factor receptor 3									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	343	467	343	414	343	414			
Average	340	507	340	494	340	470			
Stdev	278	193	278	207	278	270			
p (t-test)		0.0076		0.017		0.11			
Min	1.37	166	1.37	166	1.37	3.04			
Max	2070	913	2070	913	2070	913			
n (Samp)	128	22	128	21	128	13			
n (Patient)	128	22	128	21	128	13			
sCr only									
Median	397	414	397	401	nd	nd			
Average	405	524	405	494	nd	nd			
Stdev	292	206	292	232	nd	nd			
p (t-test)		0.26		0.40	nd	nd			
Min	1.37	362	1.37	249	nd	nd			
Max	2750	913	2750	913	nd	nd			
n (Samp)	240	8	240	8	nd	nd			
n (Patient)	240	8	240	8	nd	nd			
UO only									
Median	356	509	356	511	356	406			
Average	362	511	362	508	362	437			
Stdev	286	188	286	193	286	245			
p (t-test)		0.039		0.049		0.38			
Min	1.37	166	1.37	166	1.37	3.04			
Max	2070	835	2070	835	2070	835			

-continued

n (Samp)	122	17	122	16	122	12			
n (Patient)	122	17	122	16	122	12			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	0.66	0.73	0.71	0.60	0.72	0.65	nd	0.60
SE	0.064	0.11	0.073	0.067	0.11	0.075	0.086	nd	0.090
p	1.5E-4	0.15	0.0014	0.0017	0.37	0.0031	0.083	nd	0.24
nCohort 1	128	240	122	128	240	122	128	nd	122
nCohort 2	22	8	17	21	8	16	13	nd	12
Cutoff 1	397	397	407	364	358	397	354	nd	354
Sens 1	73%	75%	71%	71%	75%	75%	77%	nd	75%
Spec 1	65%	51%	63%	58%	43%	61%	53%	nd	50%
Cutoff 2	364	366	364	337	295	364	242	nd	236
Sens 2	82%	88%	82%	81%	88%	81%	85%	nd	83%
Spec 2	58%	47%	53%	49%	31%	53%	36%	nd	30%
Cutoff 3	337	358	236	247	247	236	145	nd	145
Sens 3	91%	100%	94%	90%	100%	94%	92%	nd	92%
Spec 3	49%	43%	30%	36%	25%	30%	24%	nd	20%
Cutoff 4	425	486	441	425	486	441	425	nd	441
Sens 4	50%	38%	59%	48%	38%	56%	38%	nd	33%
Spec 4	70%	72%	70%	70%	72%	70%	70%	nd	70%
Cutoff 5	475	534	475	475	534	475	475	nd	475
Sens 5	50%	38%	59%	48%	38%	56%	38%	nd	33%
Spec 5	81%	82%	80%	81%	82%	80%	81%	nd	80%
Cutoff 6	534	651	574	534	651	574	534	nd	574
Sens 6	36%	25%	29%	33%	25%	31%	38%	nd	33%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	3.1	>2.1	3.1	4.4	9.0	3.1	0.49	nd	0.97
p Value	0.34	<0.56	0.34	0.20	0.57	0.34	0.56	nd	0.98
95% CI of	0.31	>0.18	0.31	0.46	0.18	0.31	0.042	nd	0.13
OR Quart 2	31	na	31	41	23	31	5.6	nd	7.3
OR Quart 3	8.4	>3.2	3.1	7.0	2.0	3.2	2.8	nd	2.1
p Value	0.052	<0.33	0.34	0.080	0.57	0.33	0.25	nd	0.40
95% CI of	0.98	>0.32	0.31	0.79	0.18	0.32	0.50	nd	0.36
OR Quart 3	72	na	31	61	23	32	15	nd	13
OR Quart 4	15	>3.2	13	13	3.1	11	2.7	nd	2.1
p Value	0.012	<0.33	0.017	0.018	0.33	0.025	0.26	nd	0.42
95% CI of	1.8	>0.32	1.6	1.6	0.31	1.4	0.48	nd	0.35
OR Quart 4	120	na	110	110	31	96	15	nd	12
Interferon alpha-2									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.122	3.93	0.122	2.03	0.122	9.04			
Average	13.0	10.4	13.0	9.15	13.0	13.7			
Stdev	22.3	12.8	22.3	12.4	22.3	13.6			
p (t-test)		0.53		0.36		0.90			
Min	0.0369	0.0450	0.0369	0.0398	0.0369	0.0450			
Max	126	34.7	126	34.7	126	34.7			
n (Samp)	223	30	223	30	223	16			
n (Patient)	223	30	223	30	223	16			
sCr only									
Median	0.122	5.88	0.122	2.21	0.122	0.122			
Average	14.5	10.5	14.5	8.16	14.5	9.54			
Stdev	24.0	12.9	24.0	11.6	24.0	13.9			
p (t-test)		0.55		0.34		0.59			
Min	0.0238	0.0450	0.0238	0.0450	0.0238	0.0398			
Max	126	34.7	126	34.7	126	34.7			
n (Samp)	375	13	375	13	375	7			
n (Patient)	375	13	375	13	375	7			
UO only									
Median	0.311	5.47	0.311	2.39	0.311	10.8			
Average	14.4	11.0	14.4	10.7	14.4	15.1			
Stdev	22.4	12.9	22.4	13.0	22.4	13.8			
p (t-test)		0.48		0.45		0.91			
Min	0.0348	0.0672	0.0348	0.0398	0.0348	0.104			
Max	126	34.7	126	34.7	126	34.7			

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.57	0.53	0.54	0.52	0.51	0.65	0.46	0.64
SE	0.058	0.084	0.065	0.057	0.083	0.064	0.077	0.11	0.083
p	0.19	0.43	0.67	0.48	0.77	0.93	0.055	0.76	0.095
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	0.0974	0.0974	0.0974	0.0974	0.0967	0.0974	1.45	0.0802	2.24
Sens 1	77%	77%	78%	70%	77%	74%	75%	71%	71%
Spec 1	42%	39%	30%	42%	34%	30%	59%	33%	57%
Cutoff 2	0.0967	0.0967	0.0967	0.0802	0.0724	0.0802	0.112	0.0418	1.45
Sens 2	83%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	34%	34%	25%	33%	24%	24%	48%	13%	54%
Cutoff 3	0.0606	0.0754	0.0606	0.0606	0.0656	0.0606	0.0974	0.0369	0.0974
Sens 3	97%	92%	100%	90%	92%	91%	94%	100%	100%
Spec 3	22%	27%	14%	22%	18%	14%	42%	5%	30%
Cutoff 4	16.0	17.0	20.3	16.0	17.0	20.3	16.0	17.0	20.3
Sens 4	30%	31%	30%	27%	23%	30%	38%	29%	43%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	25.6	30.0	29.7	25.6	30.0	29.7	25.6	30.0	29.7
Sens 5	20%	15%	13%	17%	8%	13%	31%	14%	21%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	40.0	47.3	41.7	40.0	47.3	41.7	40.0	47.3	41.7
Sens 6	0%	0%	0%	0%	0%	0%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	3.1	1.0	1.4	1.0	0.78	3.1	3.1	>2.0
p Value	0.55	0.34	1.0	0.55	1.0	0.73	0.34	0.33	<0.56
95% CI of	0.43	0.31	0.24	0.43	0.14	0.20	0.31	0.32	>0.18
OR Quart 2	4.8	30	4.2	4.8	7.2	3.1	30	30	na
OR Quart 3	1.9	6.3	2.5	2.2	3.7	1.7	6.4	1.0	>8.0
p Value	0.26	0.090	0.15	0.18	0.11	0.38	0.089	1.0	<0.056
95% CI of	0.61	0.75	0.72	0.70	0.75	0.52	0.75	0.062	>0.95
OR Quart 3	6.1	54	8.9	6.8	18	5.7	55	16	na
OR Quart 4	1.9	3.1	1.6	1.7	1.0	1.2	6.4	2.0	>5.5
p Value	0.28	0.34	0.51	0.40	1.0	0.75	0.089	0.56	<0.13
95% CI of	0.60	0.31	0.41	0.51	0.14	0.35	0.75	0.18	>0.61
OR Quart 4	6.0	30	5.9	5.4	7.2	4.3	55	23	na
Insulin-like growth factor-binding protein 4									
0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.923	2.85	0.923	2.84	0.923	2.33			
Average	1.70	4.02	1.70	3.86	1.70	2.23			
Stdev	5.34	3.59	5.34	3.69	5.34	1.89			
p (t-test)		0.13		0.16		0.78			
Min	0.0439	0.0558	0.0439	0.0558	0.0439	0.0558			
Max	53.9	11.4	53.9	11.4	53.9	5.52			
n (Samp)	109	13	109	13	109	8			
n (Patient)	109	13	109	13	109	8			
sCr only									
Median	0.923	2.85	0.923	0.923	nd	nd			
Average	2.46	3.66	2.46	3.36	nd	nd			
Stdev	8.16	3.70	8.16	3.86	nd	nd			
p (t-test)		0.70		0.77	nd	nd			
Min	0.0319	0.0558	0.0319	0.0558	nd	nd			
Max	85.6	9.68	85.6	9.68	nd	nd			
n (Samp)	184	7	184	7	nd	nd			
n (Patient)	184	7	184	7	nd	nd			
UO only									
Median	0.923	4.65	0.923	4.65	0.923	2.43			
Average	1.65	4.84	1.65	4.84	1.65	2.53			
Stdev	5.56	3.27	5.56	3.27	5.56	1.97			
p (t-test)		0.11		0.11		0.70			
Min	0.0439	0.957	0.0439	0.957	0.0439	0.0558			
Max	53.9	11.4	53.9	11.4	53.9	5.52			

-continued

n (Samp)	99	8	99	8	99	6			
n (Patient)	99	8	99	8	99	6			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.62	0.92	0.71	0.55	0.92	0.67	nd	0.74
SE	0.081	0.12	0.068	0.084	0.11	0.068	0.11	nd	0.12
p	0.0016	0.30	8.9E-10	0.010	0.65	8.9E-10	0.11	nd	0.046
nCohort 1	109	184	99	109	184	99	109	nd	99
nCohort 2	13	7	8	13	7	8	8	nd	6
Cutoff 1	0.923	0.733	2.44	0.733	0.670	2.44	0.923	nd	0.923
Sens 1	77%	71%	75%	77%	71%	75%	75%	nd	83%
Spec 1	64%	41%	91%	43%	34%	91%	64%	nd	65%
Cutoff 2	0.733	0.0558	1.94	0.670	0.0558	1.94	0.0558	nd	0.923
Sens 2	85%	86%	88%	85%	86%	88%	88%	nd	83%
Spec 2	43%	6%	89%	36%	6%	89%	6%	nd	65%
Cutoff 3	0.0558	0.0439	0.923	0.0558	0.0439	0.923	0.0439	nd	0.0439
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	6%	1%	65%	6%	1%	65%	1%	nd	1%
Cutoff 4	0.957	1.17	0.957	0.957	1.17	0.957	0.957	nd	0.957
Sens 4	69%	57%	88%	62%	43%	88%	62%	nd	67%
Spec 4	73%	71%	74%	73%	71%	74%	73%	nd	74%
Cutoff 5	1.46	2.33	1.46	1.46	2.33	1.46	1.46	nd	1.46
Sens 5	69%	57%	88%	62%	43%	88%	62%	nd	67%
Spec 5	81%	80%	82%	81%	80%	82%	81%	nd	82%
Cutoff 6	2.50	3.90	2.44	2.50	3.90	2.44	2.50	nd	2.44
Sens 6	62%	43%	75%	54%	43%	75%	50%	nd	50%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.47	0.48	>0	0.97	0.98	>0	0	nd	0
p Value	0.54	0.55	<na	0.97	0.98	<na	na	nd	na
95% CI of	0.040	0.042	>na	0.13	0.13	>na	na	nd	na
OR Quart 2	5.4	5.5	na	7.3	7.2	na	na	nd	na
OR Quart 3	0.48	0	>1.0	0.48	0	>1.0	0.48	nd	1.0
p Value	0.56	na	<1.0	0.56	na	<1.0	0.56	nd	1.0
95% CI of	0.041	na	>0.059	0.041	na	>0.059	0.041	nd	0.059
OR Quart 3	5.6	na	na	5.6	na	na	5.6	nd	17
OR Quart 4	5.7	2.0	>9.1	4.9	1.5	>9.1	2.7	nd	4.3
p Value	0.036	0.42	<0.047	0.059	0.67	<0.047	0.26	nd	0.20
95% CI of	1.1	0.36	>1.0	0.94	0.24	>1.0	0.48	nd	0.45
OR Quart 4	29	12	na	25	9.4	na	15	nd	42
Insulin-like growth factor-binding protein 5									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.0682	1.58	0.0682	1.22	0.0682	2.34			
Average	0.622	1.87	0.622	1.55	0.622	2.16			
Stdev	1.19	1.87	1.19	1.80	1.19	2.03			
p (t-test)		0.0012		0.014		0.0011			
Min	0.0210	0.0210	0.0210	0.0210	0.0210	0.0393			
Max	5.79	5.59	5.79	5.59	5.79	5.59			
n (Samp)	109	13	109	13	109	8			
n (Patient)	109	13	109	13	109	8			
sCr only									
Median	0.0994	1.22	0.0994	0.0938	nd	nd			
Average	0.941	1.76	0.941	1.18	nd	nd			
Stdev	1.65	1.83	1.65	1.60	nd	nd			
p (t-test)		0.20		0.70	nd	nd			
Min	0.0116	0.0210	0.0116	0.0210	nd	nd			
Max	9.43	4.11	9.43	3.48	nd	nd			
n (Samp)	184	7	184	7	nd	nd			
n (Patient)	184	7	184	7	nd	nd			
UO only									
Median	0.0682	1.68	0.0682	1.68	0.0682	2.34			
Average	0.567	1.92	0.567	1.92	0.567	2.29			
Stdev	1.10	1.98	1.10	1.98	1.10	2.14			
p (t-test)		0.0024		0.0024		7.0E-4			
Min	0.0210	0.0210	0.0210	0.0210	0.0210	0.0393			
Max	5.79	5.59	5.79	5.59	5.79	5.59			

-continued

n (Samp)	100	8	100	8	100	6			
n (Patient)	100	8	100	8	100	6			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.61	0.65	0.61	0.50	0.65	0.74	nd	0.73
SE	0.086	0.12	0.11	0.087	0.11	0.11	0.10	nd	0.12
p	0.055	0.33	0.16	0.21	0.97	0.16	0.022	nd	0.054
nCohort 1	109	184	100	109	184	100	109	nd	100
nCohort 2	13	7	8	13	7	8	8	nd	6
Cutoff 1	0.0358	0.0682	0.0358	0.0358	0.0358	0.0358	0.0682	nd	0.0400
Sens 1	85%	71%	88%	77%	71%	88%	75%	nd	83%
Spec 1	29%	46%	26%	29%	22%	26%	54%	nd	28%
Cutoff 2	0.0358	0.0358	0.0358	0.0255	0.0255	0.0358	0.0400	nd	0.0400
Sens 2	85%	86%	88%	85%	86%	88%	88%	nd	83%
Spec 2	29%	22%	26%	19%	14%	26%	32%	nd	28%
Cutoff 3	0	0.0116	0	0	0.0116	0	0.0358	nd	0.0358
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	0%	1%	0%	0%	1%	0%	29%	nd	26%
Cutoff 4	0.397	0.558	0.397	0.397	0.558	0.397	0.397	nd	0.397
Sens 4	62%	57%	62%	54%	43%	62%	62%	nd	67%
Spec 4	76%	70%	78%	76%	70%	78%	76%	nd	78%
Cutoff 5	0.593	1.58	0.465	0.593	1.58	0.465	0.593	nd	0.465
Sens 5	62%	43%	62%	54%	29%	62%	62%	nd	67%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	2.38	3.03	1.76	2.38	3.03	1.76	2.38	nd	1.76
Sens 6	38%	43%	50%	31%	29%	50%	50%	nd	67%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	0.97	0.48	2.1	0.62	0.31	2.1	>2.1	nd	>2.1
p Value	0.97	0.55	0.56	0.62	0.32	0.56	<0.54	nd	<0.56
95% CI of	0.13	0.042	0.18	0.096	0.031	0.18	>0.18	nd	>0.18
OR Quart 2	7.3	5.5	24	4.0	3.1	24	na	nd	na
OR Quart 30	0.48	0	0	0.31	0	0	>1.0	nd	>0
p Value	0.56	na	na	0.32	na	na	<0.98	nd	<na
95% CI of	0.041	na	na	0.030	na	na	>0.062	nd	>na
OR Quart 3	5.6	na	na	3.2	na	na	na	nd	na
OR Quart 4	4.9	2.0	5.9	2.6	0.98	5.9	>5.8	nd	>4.5
p Value	0.059	0.42	0.12	0.20	0.98	0.12	<0.12	nd	<0.19
95% CI of	0.94	0.36	0.64	0.61	0.19	0.64	>0.63	nd	>0.47
OR Quart 4	25	12	54	11	5.1	54	na	nd	na

Interleukin-21

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	13.0	9.95	13.0	7.46	13.0	9.22
Average	15.4	11.4	15.4	9.90	15.4	10.5
Stdev	13.1	9.82	13.1	9.70	13.1	12.0
p (t-test)		0.11		0.027		0.14
Min	0.0191	0.0219	0.0191	0.0219	0.0191	0.0177
Max	87.9	49.5	87.9	49.5	87.9	49.5
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16
sCr only						
Median	13.0	8.34	13.0	8.34	13.0	6.02
Average	15.9	12.5	15.9	12.2	15.9	13.7
Stdev	13.8	12.3	13.8	12.5	13.8	16.7
p (t-test)		0.37		0.33		0.68
Min	0.0122	2.66	0.0122	2.65	0.0122	2.35
Max	87.9	49.5	87.9	49.5	87.9	49.5
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7
UO only						
Median	12.6	8.82	12.6	6.02	12.6	8.02
Average	15.2	10.3	15.2	8.31	15.2	7.93
Stdev	12.9	6.93	12.9	6.17	12.9	6.07
p (t-test)		0.071		0.012		0.037
Min	0.0160	0.0219	0.0160	0.0219	0.0160	0.0177
Max	87.9	24.2	87.9	20.6	87.9	17.2

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	0.42	0.39	0.36	0.41	0.33	0.36	0.42	0.32
SE	0.058	0.084	0.066	0.057	0.084	0.065	0.077	0.11	0.081
p	0.12	0.34	0.10	0.015	0.26	0.0091	0.059	0.46	0.025
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	5.82	5.90	5.32	3.89	5.44	3.50	2.73	5.44	2.95
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	26%	27%	25%	20%	26%	16%	15%	26%	14%
Cutoff 2	3.89	5.44	3.50	2.73	4.24	2.35	2.61	2.61	0.0975
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	20%	26%	16%	15%	21%	12%	14%	13%	3%
Cutoff 3	2.73	4.24	2.22	2.22	2.65	0.689	0.0191	2.34	0.0191
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	15%	21%	12%	13%	13%	5%	0%	12%	1%
Cutoff 4	19.2	19.3	19.6	19.2	19.3	19.6	19.2	19.3	19.6
Sens 4	20%	15%	17%	13%	15%	9%	6%	14%	0%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	24.9	25.4	24.9	24.9	25.4	24.9	24.9	25.4	24.9
Sens 5	3%	8%	0%	3%	8%	0%	6%	14%	0%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	31.3	33.5	31.2	31.3	33.5	31.2	31.3	33.5	31.2
Sens 6	3%	8%	0%	3%	8%	0%	6%	14%	0%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.66	3.1	6.7	1.0	3.1	6.7	4.2	2.0	>3.2
p Value	0.53	0.34	0.084	0.98	0.34	0.084	0.20	0.56	<0.32
95% CI of	0.18	0.31	0.77	0.24	0.31	0.77	0.46	0.18	>0.32
OR Quart 2	2.4	30	58	4.3	30	58	39	23	na
OR Quart 3	2.3	7.5	12	3.2	6.3	9.4	5.4	2.0	>6.9
p Value	0.12	0.062	0.019	0.060	0.090	0.039	0.13	0.57	<0.080
95% CI of	0.80	0.90	1.5	0.95	0.75	1.1	0.61	0.18	>0.79
OR Quart 3	6.5	62	100	11	54	78	47	23	na
OR Quart 4	1.4	2.0	6.7	3.2	3.1	9.4	6.7	2.0	>5.7
p Value	0.55	0.57	0.084	0.060	0.34	0.039	0.083	0.56	<0.12
95% CI of	0.46	0.18	0.77	0.95	0.31	1.1	0.78	0.18	>0.64
OR Quart 4	4.3	23	58	11	30	78	57	23	na
Interleukin-23									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	
sCr or UO									
Median	583	447	583	304	583	562			
Average	800	615	800	483	800	666			
Stdev	942	593	942	512	942	597			
p (t-test)		0.30		0.072		0.58			
Min	0.643	0.552	0.643	0.552	0.643	0.564			
Max	8520	2120	8520	2000	8520	2000			
n (Samp)	223	30	223	30	223	16			
n (Patient)	223	30	223	30	223	16			
sCr only									
Median	588	389	588	229	588	279			
Average	798	520	798	475	798	633			
Stdev	890	559	890	579	890	747			
p (t-test)		0.26		0.20		0.63			
Min	0.552	0.552	0.552	0.552	0.552	1.09			
Max	8520	2000	8520	2000	8520	2000			
n (Samp)	375	13	375	13	375	7			
n (Patient)	375	13	375	13	375	7			
UO only									
Median	652	420	652	329	652	562			
Average	870	608	870	457	870	587			
Stdev	990	598	990	474	990	521			
p (t-test)		0.22		0.050		0.29			
Min	0.564	0.552	0.564	0.552	0.564	0.552			
Max	8520	2120	8520	1450	8520	1450			

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.41	0.41	0.39	0.38	0.34	0.48	0.45	0.41
SE	0.057	0.084	0.066	0.058	0.084	0.065	0.076	0.11	0.083
p	0.39	0.28	0.19	0.059	0.17	0.015	0.80	0.65	0.30
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	233	152	129	135	136	1.61	233	152	214
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	32%	26%	17%	24%	24%	10%	32%	26%	28%
Cutoff 2	129	84.5	0.967	1.61	1.61	0.967	152	1.61	0.967
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	24%	19%	5%	14%	14%	5%	26%	14%	5%
Cutoff 3	0.967	1.09	0.682	0.967	1.09	0.682	0.967	1.06	0.552
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	9%	11%	2%	9%	11%	2%	9%	10%	0%
Cutoff 4	952	977	983	952	977	983	952	977	983
Sens 4	27%	15%	26%	17%	15%	17%	31%	29%	29%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	1390	1360	1390	1390	1360	1390	1390	1360	1390
Sens 5	10%	8%	9%	7%	8%	4%	12%	14%	7%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1830	1900	1960	1830	1900	1960	1830	1900	1960
Sens 6	7%	8%	4%	3%	8%	0%	6%	14%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.86	1.0	0.47	1.2	1.0	0.73	1.0	0.50	0.48
p Value	0.79	1.0	9.30	0.73	1.0	0.70	1.0	0.57	0.41
95% CI of	0.27	0.14	0.11	0.36	0.14	0.16	0.24	0.045	0.083
OR Quart 2	2.7	7.2	2.0	4.3	7.2	3.5	4.2	5.6	2.7
OR Quart 3	1.5	3.1	1.2	2.0	2.6	1.6	1.3	1.0	1.0
p Value	0.42	0.17	0.77	0.25	0.26	0.51	0.73	1.0	1.0
95% CI of	0.55	0.62	0.37	0.62	0.49	0.41	0.32	0.14	0.23
OR Quart 3	4.3	16	3.9	6.2	14	5.9	5.0	7.2	4.3
OR Quart 4	1.0	1.5	1.2	2.2	2.0	2.9	0.75	1.0	1.0
p Value	0.98	0.65	0.77	0.17	0.42	0.093	0.71	0.99	0.97
95% CI of	0.34	0.25	0.37	0.72	0.37	0.84	0.16	0.14	0.24
OR Quart 4	3.1	9.3	3.9	6.9	11	9.9	3.5	1.3	4.4
Interleukin-28A									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2	
sCr or UO									
Median	34.2	30.9	34.2	26.9	34.2	25.5			
Average	48.6	42.1	48.6	34.5	48.6	42.0			
Stdev	50.2	41.0	50.2	38.4	50.2	46.6			
p (t-test)		0.50		0.14		0.61			
Min	0.0495	0.0996	0.0495	0.0854	0.0495	0.155			
Max	228	186	228	186	228	186			
n (Samp)	223	30	223	30	223	16			
n (Patient)	223	30	223	30	223	16			
sCr only									
Median	38.8	28.9	38.8	27.7	38.8	26.1			
Average	51.6	43.5	51.6	40.0	51.6	50.8			
Stdev	50.3	50.2	50.3	50.9	50.3	67.4			
p (t-test)		0.57		0.41		0.96			
Min	0.0254	0.0996	0.0254	0.0996	0.0254	0.0860			
Max	235	186	235	186	235	186			
n (Samp)	375	13	375	13	375	7			
n (Patient)	375	13	375	13	375	7			
UO only									
Median	40.0	29.2	40.0	24.2	40.0	24.5			
Average	54.0	38.1	54.0	29.4	54.0	32.2			
Stdev	52.2	33.0	52.2	27.4	52.2	28.1			
p (t-test)		0.16		0.028		0.12			
Min	0.0517	0.204	0.0517	0.0777	0.0517	0.155			
Max	228	127	228	91.0	228	91.0			

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.45	0.44	0.43	0.43	0.37	0.48	0.46	0.41
SE	0.057	0.083	0.066	0.057	0.084	0.066	0.075	0.11	0.083
p	0.86	0.57	0.37	0.25	0.39	0.045	0.84	0.76	0.25
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	21.6	14.7	18.7	14.1	10.1	0.932	18.7	10.1	18.7
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	40%	33%	32%	35%	30%	22%	38%	30%	32%
Cutoff 2	10.1	10.1	1.80	0.198	1.55	0.198	10.1	1.55	2.62
Sens 2	80%	85%	83%	83%	85%	83%	81%	86%	86%
Spec 2	33%	30%	22%	16%	23%	11%	33%	23%	23%
Cutoff 3	0.198	0.131	0.198	0.131	0.131	0.0854	0.198	0.0854	0.198
Sens 3	93%	92%	100%	90%	92%	91%	94%	100%	93%
Spec 3	16%	11%	11%	14%	11%	8%	16%	7%	11%
Cutoff 4	65.2	70.9	78.3	65.2	70.9	78.3	65.2	70.9	78.3
Sens 4	23%	15%	9%	17%	15%	4%	25%	29%	7%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	92.2	94.0	96.2	92.2	94.0	96.2	92.2	94.0	96.2
Sens 5	7%	8%	4%	3%	8%	0%	6%	14%	0%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	120	123	120	120	123	120	120	123	120
Sens 6	7%	8%	4%	3%	8%	0%	6%	14%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	3.8	1.0	3.3	5.2	0.49	6.7	2.1	0	3.1
p Value	0.050	1.0	0.16	0.041	0.57	0.084	0.41	na	0.33
95% CI of	1.0	0.14	0.63	1.1	0.044	0.77	0.36	na	0.31
OR Quart 2	15	7.2	17	25	5.5	58	12	na	31
OR Quart 3	4.3	3.7	6.0	6.6	3.7	11	4.5	1.5	8.0
p Value	0.031	0.11	0.026	0.017	0.11	0.027	0.066	0.65	0.056
95% CI of	1.1	0.75	1.2	1.4	0.75	1.3	0.91	0.25	0.95
OR Quart 3	16	18	29	31	18	89	22	9.3	68
OR Quart 4	2.1	1.0	2.7	4.5	1.5	8.0	1.0	1.0	3.2
p Value	0.30	1.0	0.25	0.064	0.65	0.056	0.99	0.99	0.32
95% CI of	0.51	0.14	0.49	0.92	0.25	0.95	0.14	0.14	0.32
OR Quart 4	9.0	7.2	14	22	9.3	68	7.5	7.3	32
Interleukin-33									
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	Cohort 1	Cohort 2	Cohort 1	Cohort 2		Cohort 1	Cohort 2		
sCr or UO									
Median	69.0	48.4	69.0	43.9		69.0	54.0		
Average	83.7	58.2	83.7	52.1		83.7	61.6		
Stdev	88.6	45.1	88.6	44.4		88.6	44.2		
p (t-test)		0.12		0.056			0.32		
Min	0.0360	0.0523	0.0360	0.0232		0.0360	0.0523		
Max	958	170	958	170		958	136		
n (Samp)	223	30	223	30		223	16		
n (Patient)	223	30	223	30		223	16		
sCr only									
Median	68.9	45.5	68.9	38.8		68.9	57.9		
Average	82.6	57.8	82.6	55.5		82.6	58.4		
Stdev	79.9	46.6	79.9	47.9		79.9	39.9		
p (t-test)		0.27		0.22			0.42		
Min	0.0232	1.78	0.0232	1.78		0.0232	14.4		
Max	958	170	958	170		958	135		
n (Samp)	375	13	375	13		375	7		
n (Patient)	375	13	375	13		375	7		
UO only									
Median	71.8	50.0	71.8	43.5		71.8	48.0		
Average	91.0	53.0	91.0	45.9		91.0	55.6		
Stdev	95.6	42.0	95.6	39.6		95.6	43.3		
p (t-test)		0.061		0.027			0.17		
Min	0.0447	0.0436	0.0447	0.0232		0.0447	0.0523		
Max	958	136	958	136		958	136		

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	0.40	0.36	0.37	0.38	0.31	0.44	0.41	0.37
SE	0.058	0.084	0.065	0.057	0.084	0.064	0.077	0.11	0.083
p	0.14	0.24	0.029	0.027	0.17	0.0032	0.41	0.45	0.11
nCohort 1	223	375	173	2/3	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	33.2	33.2	14.4	24.0	23.7	14.4	43.4	38.4	43.4
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	27%	26%	12%	20%	19%	12%	35%	31%	31%
Cutoff 2	14.9	23.7	12.3	14.9	22.0	2.92	38.4	23.7	0.0743
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	15%	19%	12%	15%	18%	6%	32%	19%	3%
Cutoff 3	2.92	20.9	0.0743	0.172	12.9	0.0447	0.0558	12.9	0.0558
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	9%	17%	3%	8%	13%	1%	4%	13%	1%
Cutoff 4	103	103	115	103	103	115	103	103	115
Sens 4	23%	15%	9%	17%	15%	9%	25%	14%	14%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	127	127	130	127	127	130	127	127	130
Sens 5	10%	15%	4%	10%	15%	4%	12%	14%	7%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	159	157	176	159	157	176	159	157	176
Sens 6	3%	8%	0%	3%	8%	0%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.2	1.0	3.3	1.6	1.0	2.7	1.4	2.0	1.0
p Value	0.22	1.0	0.16	0.50	1.0	0.25	0.70	0.56	1.0
95% CI of	0.62	0.14	0.63	0.42	0.14	0.49	0.29	0.18	0.13
OR Quart 2	7.7	7.2	17	5.9	7.2	14	6.3	23	7.4
OR Quart 3	2.5	3.1	3.3	2.5	2.6	2.7	2.1	2.0	3.3
p Value	0.15	0.17	0.16	0.15	0.26	0.25	0.31	0.57	0.16
95% CI of	0.73	0.62	0.63	0.73	0.49	0.49	0.50	0.18	0.63
OR Quart 3	8.6	16	17	8.6	14	14	8.9	23	17
OR Quart 4	2.5	1.5	5.3	3.2	2.0	6.8	1.0	2.0	2.1
p Value	0.15	0.65	0.040	0.060	0.42	0.016	0.98	0.56	0.39
95% CI of	0.73	0.25	1.1	0.95	0.37	1.4	0.20	0.18	0.37
OR Quart 4	8.6	9.3	26	11	11	33	5.3	23	12

Vascular endothelial growth factor receptor 2

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	412	1060	412	830	412	752
Average	634	1330	634	1160	634	1150
Stdev	691	962	691	784	691	885
p (t-test)		7.5E-5		0.0019		0.018
Min	0.218	106	0.218	106	0.218	27.3
Max	4170	4230	4170	2820	4170	2820
n (Samp)	124	22	124	21	124	12
n (Patient)	124	22	124	21	124	12
sCr only						
Median	692	1320	692	939	nd	nd
Average	955	1350	955	1200	nd	nd
Stdev	940	841	940	817	nd	nd
p (t-test)		0.24		0.47	nd	nd
Min	0.218	122	0.218	122	nd	nd
Max	5940	2630	5940	2630	nd	nd
n (Samp)	236	8	236	8	nd	nd
n (Patient)	236	8	236	8	nd	nd
UO only						
Median	488	1050	488	939	488	757
Average	706	1350	706	1200	706	1120
Stdev	774	1010	774	811	774	878
p (t-test)		0.0025		0.017		0.097
Min	0.218	106	0.218	106	0.218	27.3
Max	4210	4230	4210	2820	4210	2820

-continued

n (Samp)	120	17	120	16	120	11
n (Patient)	120	17	120	16	120	11
	0 hr prior to AKI stage			24 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	0.67	0.75	0.74	0.63	0.73
SE	0.062	0.11	0.071	0.065	0.11	0.075
p	2.8E-5	0.11	5.4E-4	3.0E-4	0.23	0.0025
nCohort 1	124	236	120	124	236	120
nCohort 2	22	8	17	21	8	16
Cutoff 1	734	825	747	734	741	734
Sens 1	73%	75%	71%	71%	75%	75%
Spec 1	72%	59%	69%	72%	53%	69%
Cutoff 2	623	606	626	623	606	626
Sens 2	82%	88%	82%	81%	88%	81%
Spec 2	62%	44%	61%	62%	44%	61%
Cutoff 3	508	113	508	508	113	508
Sens 3	91%	100%	94%	90%	100%	94%
Spec 3	57%	15%	53%	57%	15%	53%
Cutoff 4	708	1220	757	708	1220	757
Sens 4	73%	50%	65%	71%	38%	62%
Spec 4	70%	70%	70%	70%	70%	70%
Cutoff 5	1130	1600	1220	1130	1600	1220
Sens 5	45%	38%	41%	33%	38%	31%
Spec 5	81%	81%	80%	81%	81%	80%
Cutoff 6	1630	2040	1660	1630	2040	1660
Sens 6	27%	25%	24%	24%	12%	19%
Spec 6	90%	90%	90%	90%	90%	90%
OR Quart 2	0	1.0	1.0	0	1.0	1.0
p Value	na	1.0	1.0	na	1.0	1.0
95% CI of	na	0.061	0.060	na	0.061	0.060
OR Quart 2	na	16	17	na	16	17
OR Quart 3	6.5	2.0	10	5.7	3.1	12
p Value	0.022	0.57	0.034	0.035	0.33	0.023
95% CI of	1.3	0.18	1.2	1.1	0.31	1.4
OR Quart 3	32	23	86	28	31	100
OR Quart 4	6.3	4.2	8.2	6.3	3.1	5.7
p Value	0.024	0.20	0.055	0.024	0.33	0.12
95% CI of	1.3	0.46	0.96	1.3	0.31	0.63
OR Quart 4	31	39	71	31	31	52

Lutropin subunit beta

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	23.7	9.51	23.7	9.51	23.7	8.03
Average	76.3	57.0	76.3	57.0	76.3	79.4
Stdev	120	111	120	111	120	135
p (t-test)		0.58		0.58		0.94
Min	0.0297	0.341	0.0297	0.341	0.0297	0.505
Max	400	393	400	393	400	393
n (Samp)	68	14	68	14	68	9
n (Patient)	68	14	68	14	68	9
sCr only						
Median	29.6	37.1	29.6	37.1	29.6	46.2
Average	78.0	86.3	78.0	86.3	78.0	118
Stdev	110	132	110	132	110	154
p (t-test)		0.83		0.83		0.40
Min	0.0297	0.341	0.0297	0.341	0.0297	4.62
Max	400	393	400	393	400	393
n (Samp)	128	9	128	9	128	6
n (Patient)	128	9	128	9	128	6
UO only						
Median	26.4	4.44	26.4	4.44	nd	nd
Average	85.1	9.51	85.1	9.51	nd	nd
Stdev	120	12.7	120	12.7	nd	nd
p (t-test)		0.10		0.10	nd	nd
Min	0.0297	0.505	0.0297	0.505	nd	nd
Max	400	37.1	400	37.1	nd	nd

-continued

n (Samp)	72	7	72	7	nd	nd			
n (Patient)	72	7	72	7	nd	nd			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.42	0.52	0.25	0.42	0.52	0.25	0.46	0.59	nd
SE	0.087	0.10	0.11	0.087	0.10	0.11	0.10	0.12	nd
p	0.36	0.84	0.021	0.36	0.84	0.021	0.73	0.46	nd
nCohort 1	68	128	72	68	128	72	68	128	nd
nCohort 2	14	9	7	14	9	7	9	6	nd
Cutoff 1	4.35	7.97	3.37	4.35	7.97	3.37	4.35	7.97	nd
Sens 1	71%	78%	71%	71%	78%	71%	78%	83%	nd
Spec 1	21%	30%	19%	21%	30%	19%	21%	30%	nd
Cutoff 2	0.933	4.00	0.840	0.933	4.00	0.840	4.00	7.97	nd
Sens 2	86%	89%	86%	86%	89%	86%	89%	83%	nd
Spec 2	12%	19%	12%	12%	19%	12%	21%	30%	nd
Cutoff 3	0.341	0.311	0.422	0.341	0.311	0.422	0.234	4.00	nd
Sens 3	93%	100%	100%	93%	100%	100%	100%	100%	nd
Spec 3	6%	6%	8%	6%	6%	8%	6%	19%	nd
Cutoff 4	43.9	63.3	68.2	43.9	63.3	68.2	43.9	63.3	nd
Sens 4	29%	22%	0%	29%	22%	0%	33%	33%	nd
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	nd
Cutoff 5	134	139	151	134	139	151	134	139	nd
Sens 5	14%	22%	0%	14%	12%	0%	22%	33%	nd
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	nd
Cutoff 6	315	275	311	315	275	311	315	275	nd
Sens 6	7%	11%	0%	7%	11%	0%	11%	17%	nd
Spec 6	91%	91%	90%	91%	91%	90%	91%	91%	nd
OR Quart 2	0.67	1.0	>1.1	0.67	1.0	>1.1	1.1	0.97	nd
p Value	0.68	1.0	<0.97	0.68	1.0	<0.97	0.96	0.98	nd
95% CI of	0.099	0.13	>0.061	0.099	0.13	>0.061	0.13	0.058	nd
OR Quart 2	4.5	7.5	na	4.5	7.5	na	8.4	16	nd
OR Quart 3	1.0	1.5	>2.2	1.0	1.5	>2.2	0.50	2.1	nd
p Value	1.0	0.64	<0.53	1.0	0.64	<0.53	0.59	0.56	nd
95% CI of	0.18	0.24	>0.19	0.18	0.24	>0.19	0.042	0.18	nd
OR Quart 3	5.6	9.9	na	5.6	9.9	na	6.0	24	nd
OR Quart 4	2.6	0.97	>5.3	2.6	0.97	>5.3	2.4	2.0	nd
p Value	0.23	0.98	<0.15	0.23	0.98	<0.15	0.35	0.58	nd
95% CI of	0.54	0.13	>0.54	0.54	0.13	>0.54	0.38	0.17	nd
OR Quart 4	12	7.3	na	12	7.3	na	15	23	nd

Neural cell adhesion molecule 1

0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2	Cohort 1	Cohort 2		Cohort 1	Cohort 2	
sCr or UO								
Median	2810	4940	2810	4490		2810	3900	
Average	3350	6880	3350	6380		3350	4540	
Stdev	2580	9710	2580	9720		2580	2430	
p (t-test)		1.4E-5		1.8E-4			0.076	
Min	6.83	161	6.83	142		6.83	1650	
Max	22000	55700	22000	55700		22000	9700	
n (Samp)	223	30	223	30		223	16	
n (Patient)	223	30	223	30		223	16	
sCr only								
Median	3740	4080	3740	4080		3740	5050	
Average	4460	4520	4460	4470		4460	5230	
Stdev	4470	2200	4470	2240		4470	1940	
p (t-test)		0.96		0.99			0.65	
Min	6.83	161	6.83	142		6.83	2880	
Max	55700	7860	55700	7860		55700	7860	
n (Samp)	373	13	373	13		373	7	
n (Patient)	373	13	373	13		373	7	
UO only								
Median	3210	5230	3210	5050		3210	4490	
Average	3630	8840	3630	8180		3630	4640	
Stdev	2320	11500	2320	11600		2320	2470	
p (t-test)		3.6E-7		8.1E-6			0.12	
Min	485	1700	485	1120		485	1650	
Max	11700	55700	11700	55700		11700	9700	

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.58	0.74	0.67	0.57	0.68	0.67	0.66	0.63
SE	0.055	0.084	0.062	0.057	0.084	0.065	0.076	0.11	0.083
p	5.5E-5	0.37	8.9E-5	0.0033	0.42	0.0065	0.030	0.16	0.12
nCohort 1	223	373	173	223	373	173	223	373	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	3720	3410	3940	2810	2870	2690	2870	3970	2990
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	65%	46%	65%	51%	37%	44%	53%	56%	49%
Cutoff 2	2870	2870	2990	2210	2810	2160	2690	3720	1720
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	53%	37%	49%	41%	36%	36%	49%	50%	22%
Cutoff 3	2170	2200	2160	1720	2200	1720	1700	2870	1700
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	41%	27%	36%	27%	27%	22%	26%	37%	21%
Cutoff 4	3930	5290	4360	3930	5290	4360	3930	5290	4360
Sens 4	63%	31%	65%	57%	31%	61%	50%	29%	50%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	4960	6450	5580	4960	6450	5580	4960	6450	5580
Sens 5	50%	23%	48%	47%	23%	43%	38%	29%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	6160	7690	6670	6160	7690	6670	6160	7690	6670
Sens 6	33%	15%	35%	30%	15%	35%	25%	29%	21%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	4.1	1.5	2.5	4.1	1.0	3.1	>2.0	0.64
p Value	0.70	0.21	0.65	0.20	0.21	1.0	0.34	<0.56	0.63
95% CI of	0.29	0.45	0.24	0.62	0.45	0.24	0.31	>0.18	0.10
OR Quart 2	6.3	37	9.6	10	37	4.2	30	na	4.0
OR Quart 3	2.5	5.2	3.9	1.7	5.2	1.3	5.3	>3.1	1.3
p Value	0.20	0.13	0.100	0.47	0.13	0.73	0.13	<0.33	0.72
95% CI of	0.62	0.60	0.77	0.39	0.60	0.32	0.60	>0.32	0.28
OR Quart 3	10	46	20	7.5	46	5.1	47	na	6.3
OR Quart 4	6.7	3.0	6.8	6.1	3.0	2.9	7.7	>2.0	1.7
p Value	0.0040	0.34	0.016	0.0061	0.34	0.093	0.061	<0.56	0.48
95% CI of	1.8	0.31	1.4	1.7	0.31	0.84	0.91	>0.18	0.38
OR Quart 4	24	30	33	22	30	9.9	64	na	7.6

Platelet-derived growth factor subunit B (dimer)

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	1.35	3.57	1.35	3.33	1.35	3.23
Average	5.15	52.4	5.15	52.1	5.15	4.20
Stdev	21.4	208	21.4	208	21.4	3.82
p (t-test)		0.0026		0.0028		0.88
Min	0.00246	0.283	0.00246	0.166	0.00246	0.283
Max	270	935	270	935	270	12.9
n (Samp)	191	20	191	20	191	11
n (Patient)	191	20	191	20	191	11
sCr only						
Median	1.68	4.25	1.68	3.52	1.68	2.23
Average	8.22	7.08	8.22	5.72	8.22	4.46
Stdev	57.1	6.03	57.1	5.43	57.1	5.26
p (t-test)		0.95		0.89		0.87
Min	0.00246	0.283	0.00246	0.283	0.00246	0.166
Max	935	16.9	935	16.9	935	12.9
n (Samp)	295	10	295	10	295	6
n (Patient)	295	10	295	10	295	6
UO only						
Median	1.81	4.34	1.81	3.71	1.81	3.71
Average	6.27	71.8	6.27	69.4	6.27	4.77
Stdev	24.9	239	24.9	240	24.9	3.98
p (t-test)		0.0021		0.0031		0.86
Min	0.00246	0.401	0.00246	0.166	0.00246	0.401
Max	270	935	270	935	270	12.9

-continued

n (Samp)	136	15	136	15	136	9
n (Patient)	136	15	136	15	136	9
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.75	0.76	0.71	0.71	0.69
SE	0.065	0.091	0.075	0.068	0.093	0.079
p	1.3E-4	0.0059	6.1E-4	0.0024	0.023	0.014
nCohort 1	191	295	136	191	295	136
nCohort 2	20	10	15	20	10	15
Cutoff 1	2.84	3.05	3.16	2.40	2.50	2.37
Sens 1	70%	70%	73%	70%	70%	73%
Spec 1	75%	71%	74%	71%	65%	65%
Cutoff 2	2.13	2.50	2.84	1.39	2.13	1.39
Sens 2	80%	80%	80%	80%	80%	82%
Spec 2	67%	65%	69%	51%	60%	44%
Cutoff 3	0.903	2.13	0.903	0.392	2.01	0.392
Sens 3	90%	90%	93%	90%	90%	93%
Spec 3	37%	60%	29%	20%	58%	16%
Cutoff 4	2.30	3.00	2.99	2.30	3.00	2.99
Sens 4	75%	70%	73%	70%	60%	67%
Spec 4	70%	70%	71%	70%	70%	71%
Cutoff 5	3.30	3.77	3.85	3.30	3.77	3.85
Sens 5	55%	60%	53%	50%	50%	47%
Spec 5	80%	80%	80%	80%	80%	80%
Cutoff 6	5.81	7.01	6.04	5.81	7.01	6.04
Sens 6	25%	40%	33%	25%	30%	33%
Spec 6	90%	90%	90%	90%	90%	90%
OR Quart 2	0.48	0	0.97	0.64	0	0.97
p Value	0.55	na	0.98	0.63	na	0.98
95% CI of	0.042	na	0.059	0.10	na	0.13
OR Quart 2	5.5	na	16	4.0	na	7.3
OR Quart 3	2.6	3.1	5.5	1.3	4.2	1.5
p Value	0.27	0.33	0.13	0.72	0.21	0.67
95% CI of	0.48	0.31	0.61	0.28	0.45	0.24
OR Quart 3	14	30	49	6.3	38	9.5
OR Quart 4	7.3	6.3	9.6	4.3	5.2	4.7
p Value	0.012	0.091	0.038	0.034	0.14	0.063
95% CI of	1.5	0.74	1.1	1.1	0.59	0.92
OR Quart 4	35	54	81	16	46	24
Corticotropin						
0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.00187	0.00448	0.00187	0.00448	0.00187	0.00227
Average	0.00264	0.00863	0.00264	0.00863	0.00264	0.00340
Stdev	0.00485	0.0109	0.00485	0.0109	0.00485	0.00271
p (t-test)		9.1E-4		9.1E-4		0.68
Min	0.000316	0.00109	0.000316	0.00109	0.000316	0.00111
Max	0.0489	0.0377	0.0489	0.0377	0.0489	0.00909
n (Samp)	99	12	99	12	99	7
n (Patient)	99	12	99	12	99	7
sCr only						
Median	0.00205	0.00713	0.00205	0.00713	nd	nd
Average	0.00292	0.0133	0.00292	0.0133	nd	nd
Stdev	0.00497	0.0141	0.00497	0.0141	nd	nd
p (t-test)		1.0E-5		1.0E-5	nd	nd
Min	0.000316	0.00109	0.000316	0.00109	nd	nd
Max	0.0489	0.0377	0.0489	0.0377	nd	nd
n (Samp)	160	6	160	6	nd	nd
n (Patient)	160	6	160	6	nd	nd
UO only						
Median	0.00182	0.00425	0.00182	0.00425	0.00182	0.00219
Average	0.00266	0.00883	0.00266	0.00883	0.00266	0.00333
Stdev	0.00519	0.0121	0.00519	0.0121	0.00519	0.00296
p (t-test)		0.0066		0.0066		0.76
Min	0.000388	0.00136	0.000388	0.00136	0.000388	0.00111
Max	0.0489	0.0377	0.0489	0.0377	0.0489	0.00909

-continued

n (Samp)	86	8	86	8	86	6			
n (Patient)	86	8	86	8	86	6			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.78	0.82	0.79	0.78	0.82	0.79	0.65	nd	0.62
SE	0.081	0.11	0.097	0.081	0.11	0.097	0.12	nd	0.13
p	5.8E-4	0.0026	0.0027	5.8E-4	0.0026	0.0027	0.19	nd	0.33
nCohort 1	99	160	86	99	160	86	99	nd	86
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.00217	0.00415	0.00217	0.00217	0.00415	0.00217	0.00210	nd	0.00159
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	61%	91%	62%	61%	91%	62%	60%	nd	44%
Cutoff 2	0.00210	0.00415	0.00206	0.00210	0.00415	0.00206	0.00159	nd	0.00159
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	60%	91%	60%	60%	91%	60%	38%	nd	44%
Cutoff 3	0.00124	0.00106	0.00124	0.00124	0.00106	0.00124	0.00109	nd	0.00109
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	30%	11%	31%	30%	11%	31%	15%	nd	19%
Cutoff 4	0.00275	0.00275	0.00274	0.00275	0.00275	0.00274	0.00275	nd	0.00274
Sens 4	67%	83%	62%	67%	83%	62%	43%	nd	33%
Spec 4	72%	71%	71%	72%	71%	71%	72%	nd	71%
Cutoff 5	0.00307	0.00306	0.00285	0.00307	0.00306	0.00285	0.00307	nd	0.00285
Sens 5	67%	83%	62%	67%	83%	62%	43%	nd	33%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	0.00380	0.00404	0.00412	0.00380	0.00404	0.00412	0.00380	nd	0.00412
Sens 6	58%	83%	50%	58%	83%	50%	29%	nd	17%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.96	0	>1.0	0.96	0	>1.0	0.96	nd	1.0
p Value	0.98	na	<1.0	0.98	na	<1.0	0.98	nd	1.0
95% CI of	0.057	na	>0.059	0.057	na	>0.059	0.057	nd	0.059
OR Quart 2	16	na	na	16	na	na	16	nd	17
OR Quart 3	2.0	0	>2.2	2.0	0	>2.2	2.1	nd	2.1
p Value	0.58	na	<0.53	0.58	na	<0.53	0.56	nd	0.56
95% CI of	0.17	na	>0.18	0.17	na	>0.18	0.18	nd	0.18
OR Quart 3	23	na	na	23	na	na	25	nd	25
OR Quart 4	10	5.4	>6.1	10	5.4	>6.1	3.1	nd	2.1
p Value	0.034	0.13	<0.11	0.034	0.13	<0.11	0.34	nd	0.56
95% CI of	1.2	0.60	>0.65	1.2	0.60	>0.65	0.30	nd	0.18
OR Quart 4	90	48	na	90	48	na	32	nd	25

Thyroxine-binding globulin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.155	0.225	0.155	0.197	0.155	0.159
Average	0.268	0.589	0.268	0.610	0.268	0.451
Stdev	0.327	0.955	0.327	0.988	0.327	0.621
p (t-test)		0.011		0.0091		0.16
Min	0.000191	0.00635	0.000191	0.00635	0.000191	0.0485
Max	1.59	3.60	1.59	3.60	1.59	1.88
n (Samp)	103	15	103	14	103	8
n (Patient)	103	15	103	14	103	8
sCr only						
Median	0.182	0.225	0.182	0.225	nd	nd
Average	0.313	0.470	0.313	0.470	nd	nd
Stdev	0.425	0.648	0.425	0.648	nd	nd
p (t-test)		0.35		0.35	nd	nd
Min	0.000191	0.00635	0.000191	0.00635	nd	nd
Max	3.60	1.88	3.60	1.88	nd	nd
n (Samp)	170	7	170	7	nd	nd
n (Patient)	170	7	170	7	nd	nd
UO only						
Median	0.155	0.234	0.155	0.225	0.155	0.128
Average	0.252	0.637	0.252	0.676	0.252	0.260
Stdev	0.323	1.07	0.323	1.13	0.323	0.269
p (t-test)		0.012		0.0088		0.95
Min	0.000191	0.0485	0.000191	0.0485	0.000191	0.0485
Max	1.59	3.60	1.59	3.60	1.59	0.607

-continued

n (Samp)	87	10	87	9	87	6			
n (Patient)	87	10	87	9	87	6			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.57	0.66	0.60	0.57	0.65	0.59	nd	0.54
SE	0.082	0.11	0.098	0.085	0.11	0.10	0.11	nd	0.12
p	0.19	0.57	0.10	0.25	0.57	0.16	0.43	nd	0.74
nCohort 1	103	170	87	103	170	87	103	nd	87
nCohort 2	15	7	10	14	7	9	8	nd	6
Cutoff 1	0.135	0.163	0.135	0.135	0.163	0.104	0.103	nd	0.0496
Sens 1	73%	71%	70%	71%	71%	78%	75%	nd	83%
Spec 1	46%	46%	48%	46%	46%	43%	41%	nd	30%
Cutoff 2	0.103	0.136	0.104	0.0496	0.136	0.0496	0.0496	nd	0.0496
Sens 2	80%	86%	80%	86%	86%	89%	88%	nd	83%
Spec 2	41%	42%	43%	29%	42%	30%	29%	nd	30%
Cutoff 3	0.0462	0.00446	0.0927	0.0462	0.00446	0.0462	0.0462	nd	0.0462
Sens 3	93%	100%	90%	93%	100%	100%	100%	nd	100%
Spec 3	27%	5%	40%	27%	5%	29%	27%	nd	29%
Cutoff 4	0.313	0.356	0.249	0.313	0.356	0.249	0.313	nd	0.249
Sens 4	33%	29%	40%	36%	29%	44%	38%	nd	33%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	0.407	0.448	0.368	0.407	0.448	0.368	0.407	nd	0.368
Sens 5	33%	29%	40%	36%	29%	44%	38%	nd	33%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	0.693	0.750	0.693	0.693	0.750	0.693	0.693	nd	0.693
Sens 6	13%	14%	10%	14%	14%	11%	12%	nd	0%
Spec 6	90%	90%	91%	90%	90%	91%	90%	nd	91%
OR Quart 2	7.0	2.0	>4.8	5.8	2.0	>4.8	>4.5	nd	>4.8
p Value	0.081	0.56	<0.18	0.12	0.56	<0.18	<0.19	nd	<0.17
95% CI of	0.79	0.18	>0.50	0.64	0.18	>0.50	>0.47	nd	>0.50
OR Quart 2	62	23	na	53	23	na	na	nd	na
OR Quart 3	3.2	2.0	>2.2	3.2	2.0	>1.0	>1.0	nd	>0
p Value	0.32	0.56	<0.54	0.32	0.56	<0.98	<1.0	nd	<na
95% CI of	0.32	0.18	>0.18	0.32	0.18	>0.062	>0.059	nd	>na
OR Quart 3	33	23	na	33	23	na	na	nd	na
OR Quart 4	5.6	2.0	>4.6	5.6	2.0	>4.8	>3.2	nd	>2.1
p Value	0.13	0.58	<0.19	0.13	0.58	<0.18	<0.32	nd	<0.56
95% CI of	0.61	0.17	>0.47	0.61	0.17	>0.50	>0.32	nd	>0.18
OR Quart 4	51	23	na	51	23	na	na	nd	na

Pigment epithelium-derived factor

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	3.77	40.6	3.77	34.8	3.77	14.1
Average	25.0	61.2	25.0	54.2	25.0	42.7
Stdev	52.8	66.7	52.8	60.6	52.8	58.4
p (t-test)		7.5E-4		0.0056		0.20
Min	0.00100	0.121	0.00100	0.0312	0.00100	0.683
Max	400	218	400	218	400	218
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16
sCr only						
Median	5.82	58.3	5.82	47.1	5.82	70.8
Average	28.4	66.5	28.4	62.7	28.4	79.6
Stdev	55.5	66.4	55.5	68.0	55.5	71.7
p (t-test)		0.016		0.030		0.017
Min	0.00100	0.121	0.00100	0.0312	0.00100	2.29
Max	400	218	400	218	400	218
n (Samp)	374	13	374	13	374	7
n (Patient)	374	13	374	13	374	7
UO only						
Median	5.79	44.2	5.79	44.2	5.79	10.0
Average	30.8	73.7	30.8	66.7	30.8	42.8
Stdev	60.5	79.4	60.5	73.2	60.5	61.7
p (t-test)		0.0024		0.0099		0.48
Min	0.00106	2.09	0.00106	2.00	0.00106	0.683
Max	400	250	400	250	400	218

-continued

n (Samp)	173	23	173	23	173	14			
n (Patient)	173	23	173	23	173	14			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	0.73	0.74	0.71	0.70	0.71	0.67	0.79	0.62
SE	0.054	0.081	0.062	0.055	0.082	0.063	0.076	0.10	0.083
p	8.8E-6	0.0053	1.2E-4	1.1E-4	0.014	7.3E-4	0.028	0.0041	0.15
nCohort 1	223	374	173	223	374	173	223	374	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	8.99	7.75	8.99	7.24	6.55	7.24	3.22	56.9	6.44
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	62%	55%	59%	59%	52%	55%	47%	87%	53%
Cutoff 2	6.55	6.55	6.44	3.77	4.09	3.77	3.11	18.0	3.11
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	57%	52%	53%	50%	45%	47%	46%	67%	40%
Cutoff 3	2.56	2.25	3.11	2.19	2.25	2.14	1.56	2.25	1.56
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	42%	32%	40%	39%	32%	31%	33%	32%	24%
Cutoff 4	17.4	21.1	20.5	17.4	21.1	20.5	17.4	21.1	20.5
Sens 4	63%	69%	65%	60%	62%	61%	50%	71%	43%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	27.6	32.9	37.5	27.6	32.9	37.5	27.6	32.9	37.5
Sens 5	57%	62%	52%	53%	54%	52%	38%	71%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	70.1	81.7	105	70.1	81.7	105	70.1	81.7	105
Sens 6	33%	23%	30%	33%	23%	30%	31%	29%	14%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	5.3	0.99	>5.6	7.8	2.0	>6.8	4.1	>1.0	0.98
p Value	0.13	0.99	<0.12	0.059	0.57	<0.081	0.21	<0.99	0.98
95% CI of	0.61	0.061	>0.63	0.92	0.18	>0.79	0.45	>0.062	0.13
OR Quart 2	47	16	na	65	22	na	38	na	7.3
OR Quart 3	7.8	2.0	>5.6	6.5	2.0	>4.4	4.1	>1.0	2.6
p Value	0.059	0.57	<0.12	0.087	0.57	<0.20	0.21	<0.99	0.27
95% CI of	0.92	0.18	>0.63	0.76	0.18	>0.47	0.45	>0.062	0.48
OR Quart 3	65	22	na	56	22	na	38	na	14
OR Quart 4	22	9.7	>18	21	8.5	>18	7.7	>5.2	2.6
p Value	0.0030	0.033	<0.0068	0.0039	0.045	<0.0068	0.061	<0.13	0.27
95% CI of	2.9	1.2	>2.2	2.6	1.0	>2.2	0.91	>0.60	0.48
OR Quart 4	170	78	na	160	70	na	64	na	14

Tumor necrosis factor receptor superfamily member 8

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	21.7	39.4	21.7	38.9	21.7	38.9
Average	30.9	55.9	30.9	54.7	30.9	34.7
Stdev	38.1	68.3	38.1	69.1	38.1	22.0
p (t-test)		0.012		0.018		0.72
Min	0.0561	4.17	0.0561	4.17	0.0561	0.196
Max	277	353	277	353	277	68.6
n (Samp)	128	24	128	23	128	13
n (Patient)	128	24	128	23	128	13
sCr only						
Median	27.0	43.9	27.0	43.9	nd	nd
Average	43.4	75.5	43.4	75.5	nd	nd
Stdev	61.9	105	61.9	105	nd	nd
p (t-test)		0.14		0.14	nd	nd
Min	0.0561	25.7	0.0561	25.7	nd	nd
Max	554	353	554	353	nd	nd
n (Samp)	242	9	242	9	nd	nd
n (Patient)	242	9	242	9	nd	nd
UO only						
Median	19.9	39.4	19.9	38.9	19.9	33.1
Average	30.3	44.9	30.3	42.6	30.3	33.8
Stdev	39.0	29.0	39.0	26.7	39.0	22.8
p (t-test)		0.13		0.21		0.76
Min	0.0561	4.17	0.0561	4.17	0.0561	0.196
Max	277	117	277	102	277	68.6

-continued

n (Samp)	122	18	122	17	122	12			
n (Patient)	122	18	122	17	122	12			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.71	0.69	0.71	0.70	0.69	0.69	0.61	nd	0.61
SE	0.063	0.100	0.072	0.065	0.100	0.075	0.087	nd	0.090
p	8.7E-4	0.062	0.0028	0.0025	0.062	0.0096	0.20	nd	0.22
nCohort 1	128	242	122	128	242	122	128	nd	122
nCohort 2	24	9	18	23	9	17	13	nd	12
Cutoff 1	30.9	31.1	30.2	27.2	31.1	27.2	15.0	nd	15.0
Sens 1	71%	78%	72%	74%	78%	71%	77%	nd	75%
Spec 1	66%	57%	67%	61%	57%	64%	38%	nd	39%
Cutoff 2	26.3	26.3	24.9	24.9	26.3	24.5	12.7	nd	12.7
Sens 2	83%	89%	83%	83%	89%	82%	85%	nd	83%
Spec 2	58%	49%	57%	55%	49%	55%	34%	nd	35%
Cutoff 3	24.5	25.6	5.76	19.5	25.6	5.76	6.53	nd	6.53
Sens 3	92%	100%	94%	91%	100%	94%	92%	nd	92%
Spec 3	54%	45%	16%	46%	45%	16%	14%	nd	17%
Cutoff 4	34.0	42.3	32.9	34.0	42.3	32.9	34.0	nd	32.9
Sens 4	62%	56%	67%	57%	56%	59%	54%	nd	50%
Spec 4	70%	70%	71%	70%	70%	71%	70%	nd	71%
Cutoff 5	47.1	53.5	41.1	47.1	53.5	41.1	47.1	nd	41.1
Sens 5	29%	22%	39%	30%	22%	41%	31%	nd	42%
Spec 5	80%	80%	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	58.1	90.9	56.7	58.1	90.9	56.7	58.1	nd	56.7
Sens 6	21%	11%	22%	22%	11%	24%	15%	nd	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	1.0	>2.0	0.49	1.5	>2.0	0.47	1.0	nd	0.97
p Value	1.0	<0.57	0.56	0.67	<0.57	0.55	1.0	nd	0.98
95% CI of	0.13	>0.18	0.042	0.24	>0.18	0.041	0.13	nd	0.13
OR Quart 2	7.5	na	5.6	9.5	na	5.4	7.5	nd	7.3
OR Quart 3	6.4	>4.2	3.4	4.7	>4.2	3.3	1.5	nd	1.0
p Value	0.022	<0.20	0.15	0.063	<0.20	0.16	0.64	nd	1.0
95% CI of	1.3	>0.46	0.64	0.92	>0.46	0.62	0.24	nd	0.13
OR Quart 3	32	na	18	24	na	18	9.9	nd	7.6
OR Quart 4	6.4	>3.1	5.7	6.2	>3.1	4.7	3.3	nd	3.3
p Value	0.022	<0.33	0.035	0.025	<0.33	0.062	0.16	nd	0.16
95% CI of	1.3	>0.31	1.1	1.3	>0.31	0.93	0.62	nd	0.62
OR Quart 4	32	na	29	31	na	24	18	nd	18

Alpha-fetoprotein

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.00587	0.142	0.00587	0.142	0.00587	0.0837
Average	0.0687	0.323	0.0687	0.323	0.0687	0.116
Stdev	0.133	0.650	0.133	0.650	0.133	0.157
p (t-test)		1.6E-4		1.6E-4		0.23
Min	0.000523	0.000523	0.000523	0.000523	0.000523	0.000463
Max	0.803	2.85	0.803	2.85	0.803	0.537
n (Samp)	123	18	123	18	123	13
n (Patient)	123	18	123	18	123	13
sCr only						
Median	0.00660	0.189	0.00660	0.189	0.00660	0.107
Average	0.0908	0.188	0.0908	0.188	0.0908	0.158
Stdev	0.246	0.162	0.246	0.162	0.246	0.189
p (t-test)		0.20		0.20		0.45
Min	0.000523	0.000523	0.000523	0.000523	0.000523	0.000523
Max	2.85	0.537	2.85	0.537	2.85	0.537
n (Samp)	210	11	210	11	210	8
n (Patient)	210	11	210	11	210	8
UO only						
Median	0.00587	0.123	0.00587	0.123	0.00587	0.0604
Average	0.0775	0.406	0.0775	0.406	0.0775	0.0703
Stdev	0.151	0.870	0.151	0.870	0.151	0.0706
p (t-test)		3.8E-4		3.8E-4		0.89
Min	0.000463	0.00286	0.000463	0.00286	0.000463	0.000463
Max	0.803	2.85	0.803	2.85	0.803	0.189

-continued

n (Samp)	119		10		119		10		119		8
n (Patient)	119		10		119		10		119		8
0 hr prior to AKI stage				24 hr prior to AKI stage				48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only		
AUC	0.73	0.71	0.70	0.73	0.71	0.70	0.55	0.58	0.52		
SE	0.071	0.090	0.096	0.071	0.090	0.096	0.086	0.11	0.11		
p	0.0011	0.021	0.040	0.0011	0.021	0.040	0.59	0.48	0.84		
nCohort 1	123	210	119	123	210	119	123	210	119		
nCohort 2	18	11	10	18	11	10	13	8	8		
Cutoff 1	0.0728	0.0880	0.0728	0.0728	0.0880	0.0728	0.00296	0.00296	0.00296		
Sens 1	72%	73%	70%	72%	73%	70%	77%	75%	75%		
Spec 1	76%	78%	76%	76%	78%	76%	11%	10%	10%		
Cutoff 2	0.0309	0.0309	0.0309	0.0309	0.0309	0.0309	0.000523	0.00132	0.000523		
Sens 2	83%	82%	80%	83%	82%	80%	85%	88%	88%		
Spec 2	59%	57%	61%	59%	57%	61%	2%	3%	5%		
Cutoff 3	0.000523	0.00132	0.00296	0.000523	0.00132	0.00296	0.000463	0	0		
Sens 3	94%	91%	90%	94%	91%	90%	92%	100%	100%		
Spec 3	2%	3%	10%	2%	3%	10%	0%	0%	0%		
Cutoff 4	0.0499	0.0728	0.0613	0.0499	0.0728	0.0613	0.0499	0.0728	0.0613		
Sens 4	72%	73%	70%	72%	73%	70%	54%	62%	50%		
Spec 4	71%	73%	71%	71%	73%	71%	71%	73%	71%		
Cutoff 5	0.0842	0.112	0.0880	0.0842	0.112	0.0880	0.0842	0.112	0.0880		
Sens 5	67%	64%	60%	67%	64%	60%	46%	50%	38%		
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%		
Cutoff 6	0.198	0.213	0.259	0.198	0.213	0.259	0.198	0.213	0.259		
Sens 6	33%	36%	20%	33%	36%	20%	15%	25%	0%		
Spec 6	91%	90%	91%	91%	90%	91%	91%	90%	91%		
OR Quart 2	0	0	0	0	0	0	0	0	0		
p Value	na	na	na	na	na	na	na	na	na		
95% CI of	na	na	na	na	na	na	na	na	na		
OR Quart 2	na	na	na	na	na	na	na	na	na		
OR Quart 3	1.0	0.49	0.48	1.0	0.49	0.48	0.18	0	0.30		
p Value	1.0	0.57	0.56	1.0	0.57	0.56	0.12	na	0.31		
95% CI of	0.19	0.043	0.042	0.19	0.043	0.042	0.019	na	0.030		
OR Quart 3	5.3	5.6	5.6	5.3	5.6	5.6	1.6	na	3.1		
OR Quart 4	5.3	4.4	4.0	5.3	4.4	4.0	1.5	1.7	1.3		
p Value	0.017	0.068	0.099	0.017	0.068	0.099	0.53	0.48	0.72		
95% CI of	1.4	0.89	0.77	1.4	0.89	0.77	0.43	0.39	0.27		
OR Quart 4	21	22	21	21	22	21	5.3	7.5	6.5		
Apolipoprotein E											
0 hr prior to AKI stage				24 hr prior to AKI stage				48 hr prior to AKI stage			
		Cohort 1	Cohort 2			Cohort 1	Cohort 2			Cohort 1	Cohort 2
sCr or UO											
Median		5.23	5.48		5.23	4.43		5.23	4.43		
Average		43.6	94.8		43.6	90.7		43.6	10.3		
Stdev		222	370		222	371		222	18.1		
p (t-test)			0.25			0.29			0.49		
Min		0.000147	0.00247		0.000147	0.00247		0.000147	0.211		
Max		2160	2140		2160	2140		2160	82.5		
n (Samp)		235	35		235	35		235	21		
n (Patient)		235	35		235	35		235	21		
sCr only											
Median		5.95	3.82		5.95	3.60		5.95	3.60		
Average		46.5	39.7		46.5	39.0		46.5	4.20		
Stdev		226	143		226	143		226	3.93		
p (t-test)			0.90			0.89			0.54		
Min		0.000147	0.500		0.000147	0.290		0.000147	0.556		
Max		2160	594		2160	594		2160	12.3		
n (Samp)		397	17		397	17		397	11		
n (Patient)		397	17		397	17		397	11		
UO only											
Median		5.32	6.96		5.32	5.48		5.32	4.87		
Average		38.7	110		38.7	104		38.7	12.2		
Stdev		192	425		192	425		192	20.5		
p (t-test)			0.15			0.19			0.58		
Min		0.000147	0.00247		0.000147	0.00247		0.000147	0.211		
Max		2140	2140		2140	2140		2140	82.5		

-continued

n (Samp)	190	25	190	25	190	16			
n (Patient)	190	25	190	25	190	16			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.40	0.54	0.48	0.37	0.51	0.47	0.34	0.47
SE	0.053	0.074	0.063	0.053	0.074	0.062	0.067	0.091	0.076
p	0.78	0.16	0.54	0.75	0.088	0.87	0.63	0.077	0.72
nCohort 1	235	397	190	235	397	190	235	397	190
nCohort 2	35	17	25	35	17	25	21	11	16
Cutoff 1	1.82	1.06	3.39	1.82	1.06	3.25	3.25	0.890	3.25
Sens 1	71%	71%	72%	71%	71%	72%	71%	73%	75%
Spec 1	26%	17%	37%	26%	17%	34%	35%	14%	34%
Cutoff 2	0.882	0.692	1.06	0.626	0.609	0.626	1.76	0.626	2.00
Sens 2	80%	82%	80%	80%	82%	80%	81%	82%	81%
Spec 2	17%	12%	15%	14%	11%	9%	25%	11%	23%
Cutoff 3	0.460	0.554	0.380	0.380	0.380	0.380	0.882	0.609	0.500
Sens 3	91%	94%	92%	91%	94%	92%	90%	91%	94%
Spec 3	11%	10%	7%	10%	8%	7%	17%	11%	8%
Cutoff 4	11.3	14.7	11.3	11.3	14.7	11.3	11.3	14.7	11.3
Sens 4	34%	6%	40%	29%	6%	36%	19%	0%	25%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	19.4	24.7	22.9	19.4	24.7	22.9	19.4	24.7	22.9
Sens 5	23%	6%	32%	20%	6%	28%	14%	0%	19%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	59.6	64.4	57.8	59.6	64.4	57.8	59.6	64.4	57.8
Sens 6	14%	6%	20%	11%	6%	12%	5%	0%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.86	6.4	0.53	0.76	5.3	0.67	2.5	>4.2	1.4
p Value	0.77	0.089	0.33	0.62	0.13	0.52	0.20	<0.21	0.68
95% CI of	0.31	0.75	0.14	0.27	0.60	0.20	0.62	>0.46	0.30
OR Quart 2	2.4	54	1.9	2.2	46	2.3	10	na	6.5
OR Quart 3	0.87	3.1	0.67	1.1	4.1	0.67	2.1	>2.0	1.7
p Value	0.80	0.34	0.52	0.80	0.21	0.52	0.31	<0.56	0.47
95% CI of	0.32	0.31	0.20	0.43	0.45	0.20	0.50	>0.18	0.39
OR Quart 3	2.4	30	2.3	3.0	38	2.3	8.8	na	7.7
OR Quart 4	1.1	7.5	1.3	1.0	7.5	1.1	1.7	>5.3	1.4
p Value	0.83	0.062	0.62	0.97	0.062	0.81	0.47	<0.13	0.68
95% CI of	0.42	0.91	0.45	0.38	0.91	0.38	0.39	>0.60	0.30
OR Quart 4	2.9	62	3.8	2.7	62	3.4	7.5	na	6.5

Apolipoprotein(a)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	2.89	5.31	2.89	5.01	2.89	5.01
Average	45.1	70.6	45.1	67.4	45.1	18.3
Stdev	176	234	176	234	176	34.3
p (t-test)		0.45		0.51		0.49
Min	0.00770	0.123	0.00770	0.0122	0.00770	0.0122
Max	1510	1170	1510	1170	1510	118
n (Samp)	230	35	230	35	230	21
n (Patient)	230	35	230	35	230	21
sCr only						
Median	3.62	7.43	3.62	5.47	3.62	7.43
Average	93.7	10.7	93.7	9.98	93.7	11.5
Stdev	910	12.9	910	13.1	910	15.4
p (t-test)		0.71		0.70		0.76
Min	0.00479	1.16	0.00479	0.0122	0.00479	1.16
Max	17500	54.1	17500	54.1	17500	54.1
n (Samp)	391	17	391	17	391	11
n (Patient)	391	17	391	17	391	11
UO only						
Median	3.46	5.31	3.46	5.31	3.46	5.16
Average	39.4	119	39.4	91.2	39.4	20.4
Stdev	166	293	166	275	166	37.7
p (t-test)		0.045		0.18		0.65
Min	0.00790	0.123	0.00790	0.0122	0.00790	0.0122
Max	1510	1170	1510	1170	1510	118

-continued

n (Samp)	185	25	185	25	185	16			
n (Patient)	185	25	185	25	185	16			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.60	0.60	0.59	0.55	0.58	0.59	0.58	0.56
SE	0.054	0.074	0.063	0.054	0.073	0.063	0.068	0.091	0.077
p	0.024	0.20	0.11	0.10	0.49	0.21	0.20	0.39	0.46
nCohort 1	230	391	185	230	391	185	230	391	185
nCohort 2	35	17	25	35	17	25	21	11	16
Cutoff 1	2.20	4.09	1.80	1.80	3.14	1.80	1.95	3.14	1.24
Sens 1	71%	71%	72%	71%	71%	72%	71%	73%	75%
Spec 1	43%	55%	33%	39%	43%	33%	40%	43%	19%
Cutoff 2	1.25	1.61	1.24	1.25	1.25	1.24	1.25	1.61	1.16
Sens 2	83%	82%	80%	80%	82%	80%	81%	82%	81%
Spec 2	26%	28%	19%	26%	20%	19%	26%	28%	19%
Cutoff 3	1.07	1.16	0.751	0.123	0.893	0.123	1.07	1.25	0.123
Sens 3	91%	94%	92%	91%	94%	92%	90%	91%	94%
Spec 3	23%	19%	15%	12%	16%	8%	23%	20%	8%
Cutoff 4	5.04	7.01	5.73	5.04	7.01	5.73	5.04	7.01	5.73
Sens 4	51%	53%	48%	49%	47%	44%	48%	55%	38%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	9.17	16.0	9.17	9.17	16.0	9.17	9.17	16.0	9.17
Sens 5	37%	24%	40%	31%	24%	36%	29%	27%	31%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	61.4	61.4	52.0	61.4	61.4	52.0	61.4	61.4	52.0
Sens 6	11%	0%	20%	9%	0%	12%	10%	0%	12%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	0.66	0.63	0.69	0.49	0.63	0.72	0.99	0.18
p Value	1.0	0.65	0.49	0.55	0.42	0.49	0.68	0.99	0.13
95% CI of	0.31	0.11	0.17	0.21	0.088	0.17	0.16	0.14	0.021
OR Quart 2	3.3	4.0	2.4	2.3	2.7	2.4	3.4	7.2	1.6
OR Quart 3	1.4	2.1	0.64	1.5	1.5	0.82	1.5	1.5	0.78
p Value	0.57	0.32	0.51	0.44	0.52	0.75	0.53	0.65	0.73
95% CI of	0.45	0.50	0.17	0.54	0.42	0.23	0.41	0.25	0.20
OR Quart 3	4.2	8.5	2.4	4.2	5.6	2.9	5.7	9.3	3.1
OR Quart 4	2.9	2.1	2.0	2.0	1.3	1.8	2.1	2.0	1.2
p Value	0.041	0.32	0.21	0.16	0.73	0.30	0.24	0.42	0.78
95% CI of	1.0	0.50	0.68	0.75	0.33	0.60	0.60	0.36	0.34
OR Quart 4	8.0	8.5	5.9	5.5	4.8	5.3	7.4	11	4.2

[0187] FIG. 5: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

Complement C4-B						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	65500	78300	65500	83200	65500	65900
Average	72500	79400	72500	78500	72500	73500
Stdev	40600	45100	40600	38300	40600	36100
p (t-test)		0.32		0.37		0.91
Min	305	1250	305	10700	305	21500
Max	203000	223000	203000	188000	203000	140000
n (Samp)	121	53	121	53	121	26
n (Patient)	87	53	87	53	87	26
sCr only						
Median	70800	87600	70800	93700	70800	90200
Average	77800	83300	77800	91300	77800	84300
Stdev	42600	39300	42600	43900	42600	46200
p (t-test)		0.61		0.23		0.64
Min	305	7620	305	5510	305	10700

-continued

Max	223000	144000	223000	161000	223000	140000
n (Samp)	288	16	288	15	288	10
n (Patient)	161	16	161	15	161	10
UO only						
Median	65500	64200	65500	77100	65500	62800
Average	71100	78000	71100	75500	71100	67500
Stdev	36500	48100	36500	38900	36500	32700
p (t-test)		0.33		0.46		0.67
Min	305	1250	305	10700	305	21500
Max	160000	223000	160000	188000	160000	136000
n (Samp)	125	43	125	54	125	23
n (Patient)	80	43	80	54	80	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.56	0.53	0.56	0.62	0.53	0.51	0.56	0.47
SE	0.048	0.076	0.052	0.048	0.079	0.047	0.063	0.096	0.066
p	0.34	0.43	0.57	0.23	0.13	0.55	0.83	0.53	0.66
nCohort 1	121	288	125	121	288	125	121	288	125
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	47600	68900	46200	51400	79100	49100	49100	66700	40700
Sens 1	72%	75%	72%	72%	73%	70%	73%	70%	74%
Spec 1	31%	49%	29%	36%	57%	32%	33%	49%	21%
Cutoff 2	39400	46200	36700	43600	77900	41700	39400	42000	38300
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	21%	26%	18%	27%	55%	22%	21%	23%	19%
Cutoff 3	29600	20400	21400	25500	5890	25500	29100	25600	29100
Sens 3	91%	94%	91%	91%	93%	91%	92%	90%	91%
Spec 3	10%	4%	6%	7%	2%	6%	8%	7%	7%
Cutoff 4	86800	99700	87900	86800	99700	87900	86800	99700	87900
Sens 4	42%	38%	40%	43%	40%	35%	35%	40%	26%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	105000	113000	100000	105000	113000	100000	105000	113000	100000
Sens 5	23%	19%	33%	23%	33%	26%	27%	40%	22%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	132000	133000	129000	132000	133000	129000	132000	133000	129000
Sens 6	13%	12%	14%	6%	13%	6%	8%	10%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.97	0.66	1.0	1.2	0.49	1.1	1.2	0.32	0.81
p Value	0.95	0.65	1.0	0.67	0.56	0.87	0.80	0.33	0.74
95% CI of	0.38	0.11	0.38	0.47	0.043	0.43	0.35	0.033	0.22
OR Quart 2	2.5	4.1	2.6	3.3	5.5	2.7	3.9	3.1	2.9
OR Quart 3	1.0	2.5	0.47	1.8	3.7	1.1	0.78	0.66	0.81
p Value	1.0	0.20	0.18	0.24	0.11	0.87	0.71	0.65	0.74
95% CI of	0.39	0.61	0.16	0.69	0.74	0.43	0.22	0.11	0.22
OR Quart 3	2.6	9.9	1.4	4.6	18	2.7	2.8	4.1	2.9
OR Quart 4	1.6	1.4	1.6	1.9	2.6	1.5	1.4	1.3	1.2
p Value	0.29	0.70	0.35	0.18	0.27	0.40	0.59	0.71	0.76
95% CI of	0.66	0.29	0.62	0.74	0.48	0.60	0.43	0.29	0.36
OR Quart 4	4.0	6.3	4.0	4.8	14	3.6	4.5	6.2	4.0

C-C motif chemokine 26

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.725	1.25	0.725	1.62	0.725	5.42
Average	12.8	5.27	12.8	8.50	12.8	11.0
Stdev	65.9	10.1	65.9	14.0	65.9	15.6
p (t-test)		0.45		0.68		0.91
Min	0.0121	0.0232	0.0121	0.0121	0.0121	0.0339
Max	468	55.4	468	51.1	468	53.5
n (Samp)	93	45	93	42	93	18
n (Patient)	64	45	64	42	64	18
sCr only						
Median	0.785	3.74	0.785	3.16	0.785	4.75
Average	8.23	7.35	8.23	11.6	8.23	12.3
Stdev	43.2	9.45	43.2	16.6	43.2	18.3
p (t-test)		0.94		0.74		0.78
Min	0.0121	0.0121	0.0121	0.0232	0.0121	0.0121

-continued

Max	468	29.4	468	51.1	468	50.9
n (Samp)	224	14	224	18	224	9
n (Patient)	131	14	131	18	131	9
UO only						
Median	0.0587	0.725	0.0587	1.48	0.0587	5.00
Average	12.3	3.90	12.3	6.69	12.3	8.29
Stdev	63.1	9.51	63.1	11.4	63.1	13.5
p (t-test)		0.42		0.57		0.81
Min	0.0121	0.0232	0.0121	0.0121	0.0121	0.0325
Max	468	55.4	468	46.1	468	53.5
n (Samp)	102	37	102	41	102	15
n (Patient)	63	37	63	41	63	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.60	0.55	0.60	0.68	0.58	0.76	0.64	0.68
SE	0.053	0.082	0.056	0.054	0.072	0.054	0.070	0.10	0.080
p	0.23	0.25	0.41	0.068	0.015	0.14	2.3E-4	0.17	0.029
nCohort 1	93	224	102	93	224	102	93	224	102
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.0339	0.0503	0.0339	0.0339	1.25	0.0339	4.62	0.0503	0.0587
Sens 1	82%	71%	81%	81%	72%	73%	78%	73%	73%
Spec 1	25%	41%	27%	25%	56%	27%	80%	41%	51%
Cutoff 2	0.0339	0.0232	0.0339	0.0339	0.652	0.0325	1.84	0.0339	0.0339
Sens 2	82%	93%	81%	81%	83%	85%	83%	89%	80%
Spec 2	25%	4%	27%	25%	47%	25%	67%	25%	27%
Cutoff 3	0.0232	0.0232	0.0232	0.0232	0.0339	0.0232	0.0325	0	0.0325
Sens 3	98%	93%	97%	93%	94%	93%	100%	100%	93%
Spec 3	5%	4%	5%	5%	25%	5%	22%	0%	25%
Cutoff 4	2.43	3.90	2.43	2.43	3.90	2.43	2.43	3.90	2.43
Sens 4	36%	50%	27%	43%	44%	44%	78%	56%	67%
Spec 4	71%	70%	72%	71%	70%	72%	71%	70%	72%
Cutoff 5	5.00	6.86	5.00	5.00	6.86	5.00	5.00	6.86	5.00
Sens 5	29%	43%	19%	31%	33%	32%	50%	33%	40%
Spec 5	83%	81%	82%	83%	81%	82%	83%	81%	82%
Cutoff 6	10.6	10.7	13.4	10.6	10.7	13.4	10.6	10.7	13.4
Sens 6	13%	21%	5%	24%	28%	15%	28%	33%	13%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.4	0.64	1.1	1.1	0.98	1.5	0.46	2.0	1.6
p Value	0.48	0.64	0.82	0.83	0.99	0.44	0.54	0.57	0.64
95% CI of	0.52	0.10	0.36	0.37	0.13	0.51	0.039	0.18	0.24
OR Quart 2	4.1	4.0	3.6	3.4	7.2	4.6	5.4	23	10
OR Quart 3	1.0	0.65	2.3	1.5	3.2	1.3	2.7	2.0	0.48
p Value	1.0	0.65	0.13	0.46	0.16	0.61	0.26	0.57	0.56
95% CI of	0.34	0.1	0.78	0.51	0.62	0.43	0.48	0.18	0.041
OR Quart 3	2.9	4.1	6.7	4.4	17	4.1	15	23	5.6
OR Quart 4	2.1	2.5	1.3	2.2	4.4	2.9	6.9	4.1	5.8
p Value	0.16	0.21	0.61	0.14	0.069	0.052	0.020	0.21	0.035
95% CI of	0.76	0.61	0.43	0.77	0.89	0.99	1.4	0.45	1.1
OR Quart 4	5.7	10	4.1	6.2	22	8.3	36	38	30

C-C motif chemokine 7

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.620	0.512	0.620	0.804	0.620	0.512
Average	8.13	7.46	8.13	10.4	8.13	12.7
Stdev	22.1	14.3	22.1	15.1	22.1	21.1
p (t-test)		0.85		0.55		0.42
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	128	79.4	128	60.8	128	75.6
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	0.620	0.712	0.620	0.620	0.620	0.512
Average	9.35	5.26	9.35	23.9	9.35	11.1
Stdev	24.0	8.50	24.0	54.7	24.0	25.1
p (t-test)		0.53		0.031		0.83
Min	0.193	0.193	0.193	0.193	0.193	0.193

-continued

Max	181	26.1	181	219	181	75.6			
n (Samp)	225	14	225	18	225	9			
n (Patient)	132	14	132	18	132	9			
UO only									
Median	0.620	0.512	0.620	0.804	0.620	0.512			
Average	6.86	7.17	6.86	11.9	6.86	8.74			
Stdev	20.9	15.2	20.9	17.6	20.9	15.0			
p (t-test)		0.93		0.18		0.74			
Min	0.193	0.193	0.193	0.193	0.193	0.193			
Max	128	79.4	128	67.3	128	48.7			
n (Samp)	103	37	103	41	103	15			
n (Patient)	64	37	64	41	64	15			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.50	0.50	0.58	0.52	0.64	0.57	0.49	0.57
SE	0.053	0.080	0.056	0.054	0.072	0.053	0.076	0.099	0.082
p	0.87	0.95	0.95	0.16	0.73	0.010	0.34	0.90	0.40
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.193	0.308	0.193	0.193	0.193	0.308	0.308	0.308	0.308
Sens 1	76%	71%	76%	88%	78%	80%	94%	78%	87%
Spec 1	18%	30%	20%	18%	19%	38%	34%	30%	38%
Cutoff 2	0	0.193	0	0.193	0	0.308	0.308	0.193	0.308
Sens 2	100%	86%	100%	88%	100%	80%	94%	89%	87%
Spec 2	0%	19%	0%	18%	0%	38%	34%	19%	38%
Cutoff 3	0	0	0	0	0	0.193	0.308	0	0.193
Sens 3	100%	100%	100%	100%	100%	93%	94%	100%	93%
Spec 3	0%	0%	0%	0%	0%	20%	34%	0%	20%
Cutoff 4	0.804	2.71	0.804	0.804	2.71	0.804	0.804	2.71	0.804
Sens 4	36%	29%	32%	45%	44%	46%	39%	22%	33%
Spec 4	70%	70%	75%	70%	70%	75%	70%	70%	75%
Cutoff 5	8.42	9.52	5.10	8.42	9.52	5.10	8.42	9.52	5.10
Sens 5	31%	29%	27%	38%	39%	41%	33%	22%	33%
Spec 5	84%	80%	81%	84%	80%	81%	84%	80%	81%
Cutoff 6	19.2	28.8	14.4	19.2	28.8	14.4	19.2	28.8	14.4
Sens 6	13%	0%	16%	21%	17%	29%	28%	11%	20%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.38	0.72	0.45	0.86	1.5	1.2	15	1.0	8.5
p Value	0.072	0.68	0.17	0.79	0.53	0.78	0.013	0.99	0.053
95% CI of	0.13	0.15	0.15	0.30	0.41	0.39	1.8	0.14	0.98
OR Quart 2	1.1	3.4	1.4	2.5	5.7	3.5	130	7.5	74
OR Quart 3	0.69	0.72	0.55	0.62	0.23	1.0	0	1.5	2.1
p Value	0.46	0.68	0.28	0.40	0.20	1.0	na	0.65	0.56
95% CI of	0.26	0.15	0.18	0.20	0.025	0.33	na	0.25	0.18
OR Quart 3	1.8	3.4	1.6	1.9	2.2	3.0	na	9.5	24
OR Quart 4	0.93	0.98	1.3	2.1	1.8	2.8	9.0	1.0	5.6
p Value	0.88	0.98	0.61	0.14	0.36	0.049	0.047	0.99	0.13
95% CI of	0.35	0.23	0.48	0.79	0.50	1.0	1.0	0.14	0.61
OR Quart 4	2.4	4.1	3.5	5.8	6.6	7.8	79	7.5	51

Thyrotropin

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	1.37	1.65	1.37	1.55	1.37	1.52
Average	2.10	3.14	2.10	2.51	2.10	2.57
Stdev	2.10	4.63	2.10	2.75	2.10	3.77
p (t-test)		0.092		0.35		0.42
Min	0.0304	0.0228	0.0304	0.174	0.0304	0.101
Max	9.94	20.0	9.94	12.1	9.94	14.7
n (Samp)	85	35	85	42	85	25
n (Patient)	75	35	75	42	75	25
sCr only						
Median	1.55	2.14	1.55	1.82	1.55	1.36
Average	3.21	3.62	3.21	2.43	3.21	1.69
Stdev	5.66	5.87	5.66	2.33	5.66	1.27
p (t-test)		0.82		0.65		0.45
Min	0.0304	0.0228	0.0304	0.244	0.0304	0.101

-continued

Max	60.1	20.0	60.1	8.20	60.1	3.88
n (Samp)	201	10	201	11	201	8
n (Patient)	132	10	132	11	132	8
UO only						
Median	1.37	1.65	1.37	1.40	1.37	1.16
Average	2.63	2.84	2.63	2.61	2.63	2.64
Stdev	3.37	3.87	3.37	2.99	3.37	4.07
p (t-test)		0.79		0.97		0.99
Min	0.0304	0.0956	0.0304	0.174	0.0304	0.106
Max	20.0	19.8	20.0	12.1	20.0	14.7
n (Samp)	77	29	77	43	77	21
n (Patient)	64	29	64	43	64	21

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	0.52	0.52	0.53	0.52	0.51	0.49	0.47	0.47
SE	0.059	0.095	0.063	0.055	0.091	0.055	0.066	0.11	0.072
p	0.57	0.80	0.78	0.57	0.80	0.84	0.91	0.75	0.64
nCohort 1	85	201	77	85	201	77	85	201	77
nCohort 2	35	10	29	42	11	43	25	8	21
Cutoff 1	0.568	1.25	0.568	0.785	1.25	0.785	0.714	1.13	0.714
Sens 1	71%	70%	72%	71%	73%	72%	72%	75%	71%
Spec 1	26%	45%	26%	33%	45%	35%	29%	43%	30%
Cutoff 2	0.395	1.00	0.383	0.463	0.645	0.463	0.463	0.787	0.463
Sens 2	80%	80%	83%	81%	82%	81%	80%	88%	81%
Spec 2	20%	39%	18%	22%	28%	23%	22%	34%	23%
Cutoff 3	0.268	0.380	0.268	0.395	0.418	0.341	0.106	0.0956	0.216
Sens 3	91%	90%	93%	90%	91%	91%	92%	100%	90%
Spec 3	13%	16%	12%	20%	18%	16%	6%	3%	10%
Cutoff 4	2.84	3.09	3.18	2.84	3.09	3.18	2.84	3.09	3.18
Sens 4	34%	20%	24%	29%	27%	28%	24%	25%	19%
Spec 4	71%	70%	70%	71%	70%	70%	71%	70%	70%
Cutoff 5	3.68	4.30	3.82	3.68	4.30	3.82	3.68	4.30	3.82
Sens 5	26%	10%	24%	21%	18%	23%	20%	0%	19%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	4.63	7.46	6.31	4.63	7.46	6.31	4.63	7.46	6.31
Sens 6	14%	10%	10%	17%	9%	14%	8%	0%	10%
Spec 6	91%	90%	91%	91%	90%	91%	91%	90%	91%
OR Quart 2	0.71	0.98	0.78	1.3	1.5	1.2	1.3	3.2	1.8
p Value	0.56	0.98	0.69	0.65	0.65	0.79	0.70	0.32	0.44
95% CI of	0.22	0.13	0.22	0.44	0.25	0.40	0.37	0.32	0.43
OR Quart 2	2.2	7.2	2.7	3.7	9.5	3.3	4.5	32	7.2
OR Quart 3	1.2	2.0	1.4	1.3	2.1	1.3	1.0	3.2	1.7
p Value	0.78	0.42	0.55	0.65	0.41	0.59	1.0	0.32	0.48
95% CI of	0.39	0.36	0.44	0.44	0.36	0.46	0.28	0.32	0.41
OR Quart 3	3.5	12	4.7	3.7	12	3.8	3.6	32	6.8
OR Quart 4	1.0	0.98	0.95	1.3	1.0	1.0	1.0	1.0	1.4
p Value	1.0	0.98	0.93	0.65	1.0	1.0	0.94	0.99	0.66
95% CI of	0.33	0.13	0.28	0.44	0.14	0.34	0.29	0.062	0.32
OR Quart 4	3.0	7.2	3.2	3.7	7.4	2.9	3.8	17	5.9

Vascular endothelial growth factor receptor 3

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	5470	5330	5470	5760	5470	6250
Average	6870	8430	6870	7300	6870	6400
Stdev	5340	7900	5340	5490	5340	2520
p (t-test)		0.17		0.66		0.72
Min	219	1360	219	1000	219	2840
Max	29400	43200	29400	26900	29400	12100
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	6210	5870	6210	5070	6210	3710
Average	7000	8490	7000	7680	7000	4330
Stdev	5110	7420	5110	6800	5110	2310
p (t-test)		0.30		0.60		0.12
Min	219	4080	219	1280	219	1030

-continued

Max	43200	32800	43200	26900	43200	8610
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9
UO only						
Median	5640	5240	5640	5950	5640	6330
Average	7340	7870	7340	6590	7340	6900
Stdev	6250	7620	6250	4150	6250	2300
p (t-test)		0.68		0.48		0.78
Min	219	1360	219	924	219	2840
Max	32800	43200	32800	16600	32800	12100
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.56	0.51	0.52	0.48	0.49	0.54	0.32	0.58
SE	0.053	0.082	0.056	0.054	0.072	0.054	0.076	0.10	0.082
p	0.24	0.47	0.83	0.74	0.80	0.85	0.57	0.074	0.32
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	4260	5140	4160	3490	4050	3400	4580	3020	5450
Sens 1	71%	71%	70%	71%	72%	71%	72%	78%	73%
Spec 1	35%	40%	29%	27%	31%	22%	38%	17%	49%
Cutoff 2	3620	4120	3440	2930	3440	2580	3700	3010	5360
Sens 2	80%	86%	81%	81%	83%	80%	83%	89%	80%
Spec 2	30%	31%	22%	18%	23%	12%	32%	17%	49%
Cutoff 3	2930	4080	2580	2070	1720	1720	2930	1010	4530
Sens 3	91%	93%	92%	90%	94%	90%	94%	100%	93%
Spec 3	18%	31%	12%	11%	7%	7%	18%	4%	31%
Cutoff 4	7770	8350	7770	7770	8350	7770	7770	8350	7770
Sens 4	40%	29%	35%	38%	22%	37%	28%	11%	33%
Spec 4	70%	71%	71%	70%	71%	71%	70%	71%	71%
Cutoff 5	9000	9630	8980	9000	9630	8980	9000	9630	8980
Sens 5	27%	21%	24%	31%	22%	32%	11%	0%	13%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	13200	11800	13800	13200	11800	13800	13200	11800	13800
Sens 6	11%	7%	11%	10%	17%	5%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.4	>7.8	1.3	1.1	0.74	0.51	1.8	>2.1	4.3
p Value	0.092	<0.059	0.60	0.79	0.70	0.20	0.45	<0.55	0.20
95% CI of	0.86	>0.93	0.47	0.41	0.16	0.18	0.39	>0.19	0.45
OR Quart 2	6.9	na	3.8	3.2	3.4	1.4	8.4	na	41
OR Quart 3	0.81	>4.2	0.48	0.74	1.8	0.43	2.3	>3.2	8.9
p Value	0.72	<0.20	0.24	0.58	0.35	0.12	0.28	<0.33	0.048
95% CI of	0.26	>0.46	0.14	0.25	0.51	0.15	0.51	>0.32	1.0
OR Quart 3	2.6	na	1.6	2.2	6.7	1.2	10	na	78
OR Quart 4	2.4	>3.1	1.5	1.5	1.0	1.0	1.4	>4.4	3.1
p Value	0.092	<0.33	0.44	0.44	0.98	1.0	0.69	<0.19	0.34
95% CI of	0.86	>0.31	0.54	0.54	0.24	0.38	0.28	>0.47	0.30
OR Quart 4	6.9	na	4.2	4.1	4.3	2.6	6.9	na	32

Interferon alpha-2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	9.44	17.2	9.44	13.4	9.44	23.0
Average	17.1	19.3	17.1	16.9	17.1	22.5
Stdev	29.3	19.4	29.3	16.2	29.3	10.6
p (t-test)		0.64		0.97		0.44
Min	0.0320	0.0627	0.0320	0.0320	0.0320	0.0627
Max	223	108	223	67.7	223	44.7
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	13.5	10.2	13.5	11.2	13.5	11.8
Average	18.1	17.0	18.1	23.4	18.1	15.4
Stdev	24.6	27.7	24.6	39.4	24.6	10.2
p (t-test)		0.87		0.40		0.74
Min	0.0320	0.0627	0.0320	0.0320	0.0320	5.14

-continued

Max	223	108	223	163	223	35.3
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9
UO only						
Median	7.03	17.2	7.03	13.5	7.03	24.2
Average	15.4	18.8	15.4	17.0	15.4	22.0
Stdev	29.5	14.7	29.5	14.9	29.5	12.8
p (t-test)		0.50		0.74		0.39
Min	0.0320	0.0627	0.0320	0.0320	0.0320	0.0627
Max	223	49.9	223	52.4	223	44.7
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.46	0.64	0.54	0.46	0.61	0.71	0.54	0.73
SE	0.053	0.081	0.055	0.054	0.072	0.054	0.073	0.10	0.078
p	0.13	0.60	0.013	0.43	0.59	0.041	0.0036	0.71	0.0035
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	5.80	4.47	6.46	3.73	0.0324	7.03	19.0	7.76	19.0
Sens 1	71%	71%	70%	71%	89%	71%	72%	78%	73%
Spec 1	40%	33%	49%	33%	2%	50%	70%	40%	77%
Cutoff 2	3.73	0.0764	3.73	0.0627	0.0324	0.0997	13.5	5.98	13.5
Sens 2	80%	93%	81%	86%	89%	80%	83%	89%	80%
Spec 2	33%	17%	38%	16%	2%	27%	60%	37%	65%
Cutoff 3	0.0324	0.0764	0.0324	0.0324	0.0320	0.0627	5.80	4.65	0.0627
Sens 3	100%	93%	100%	95%	94%	93%	94%	100%	93%
Spec 3	2%	17%	2%	2%	1%	17%	40%	34%	17%
Cutoff 4	19.0	23.2	14.8	19.0	23.2	14.8	19.0	23.2	14.8
Sens 4	42%	14%	62%	38%	28%	49%	72%	22%	73%
Spec 4	70%	71%	71%	70%	71%	71%	70%	71%	71%
Cutoff 5	26.9	29.0	20.8	26.9	29.0	20.8	26.9	29.0	20.8
Sens 5	27%	14%	41%	26%	28%	37%	28%	11%	67%
Spec 5	81%	80%	82%	81%	80%	82%	81%	80%	82%
Cutoff 6	36.4	39.9	29.4	36.4	39.9	29.4	36.4	39.9	29.4
Sens 6	18%	7%	24%	10%	11%	20%	6%	0%	33%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.96	2.1	0.83	0.74	0.58	1.0	2.1	>5.4	0.47
p Value	0.94	0.41	0.76	0.58	0.47	1.0	0.56	<0.13	0.54
95% CI of	0.33	0.36	0.25	0.25	0.13	0.33	0.18	>0.61	0.040
OR Quart 2	2.8	12	2.8	2.2	2.5	3.0	24	na	5.4
OR Quart 3	1.6	2.1	1.4	1.3	0.79	1.2	9.0	>3.2	1.0
p Value	0.34	0.41	0.57	0.60	0.73	0.78	0.047	<0.32	1.0
95% CI of	0.59	0.36	0.45	0.47	0.20	0.39	1.0	>0.32	0.13
OR Quart 3	4.6	12	4.3	3.6	3.1	3.5	79	na	7.6
OR Quart 4	1.9	2.1	3.0	1.3	1.2	2.8	11	>1.0	6.8
p Value	0.24	0.40	0.043	0.60	0.73	0.049	0.031	<1.0	0.021
95% CI of	0.67	0.37	1.0	0.47	0.36	1.0	1.2	>0.061	1.3
OR Quart 4	5.1	12	8.7	3.6	4.3	7.8	93	na	34

Insulin-like growth factor-binding protein 4

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	2.93	3.18	2.93	2.93	2.93	2.93
Average	14.5	13.6	14.5	10.9	14.5	6.68
Stdev	26.1	14.8	26.1	12.5	26.1	7.82
p (t-test)		0.82		0.35		0.14
Min	0.0862	0.572	0.0862	0.572	0.0862	0.572
Max	158	57.3	158	52.0	158	24.1
n (Samp)	119	52	119	53	119	26
n (Patient)	87	52	87	53	87	26
sCr only						
Median	2.93	8.11	2.93	2.93	2.93	2.93
Average	12.8	13.3	12.8	13.1	12.8	10.2
Stdev	19.6	13.6	19.6	15.9	19.6	11.9
p (t-test)		0.92		0.95		0.68
Min	0.0862	0.572	0.0862	0.572	0.0862	0.572

-continued

Max	158	46.7	158	52.0	158	30.5
n (Samp)	283	16	283	14	283	10
n (Patient)	161	16	161	14	161	10
UO only						
Median	3.29	3.18	3.29	2.93	3.29	2.93
Average	15.0	13.6	15.0	9.49	15.0	6.86
Stdev	25.6	14.9	25.6	10.6	25.6	7.85
p (t-test)		0.74		0.13		0.13
Min	0.0728	0.572	0.0728	0.572	0.0728	0.572
Max	158	57.3	158	33.5	158	21.7
n (Samp)	123	42	123	54	123	23
n (Patient)	80	42	80	54	80	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.55	0.55	0.52	0.54	0.48	0.50	0.53	0.45
SE	0.048	0.076	0.052	0.048	0.081	0.047	0.063	0.095	0.067
p	0.16	0.52	0.30	0.68	0.66	0.69	0.95	0.76	0.42
nCohort 1	119	283	123	119	283	123	119	283	123
nCohort 2	52	16	42	53	14	54	26	10	23
Cutoff 1	0.971	0.971	0.971	0.971	0.971	0.971	0.971	2.43	0.572
Sens 1	79%	81%	81%	72%	86%	72%	77%	70%	87%
Spec 1	36%	29%	33%	36%	29%	33%	36%	41%	15%
Cutoff 2	0.572	0.971	0.971	0.572	0.971	0.572	0.572	0.971	0.572
Sens 2	88%	81%	81%	83%	86%	83%	92%	90%	87%
Spec 2	16%	29%	33%	16%	29%	15%	16%	29%	15%
Cutoff 3	0.0862	0.0862	0.572	0.0862	0.0862	0.0862	0.572	0.971	0.0862
Sens 3	100%	100%	90%	100%	100%	100%	92%	90%	100%
Spec 3	1%	0%	15%	1%	0%	2%	16%	29%	2%
Cutoff 4	14.4	17.1	16.6	14.4	17.1	16.6	14.4	17.1	16.6
Sens 4	40%	38%	43%	28%	29%	22%	23%	30%	17%
Spec 4	71%	70%	72%	71%	70%	72%	71%	70%	72%
Cutoff 5	23.1	23.1	23.1	23.1	23.1	23.1	23.1	23.1	23.1
Sens 5	25%	31%	24%	21%	29%	17%	4%	30%	0%
Spec 5	81%	81%	80%	81%	81%	80%	81%	81%	80%
Cutoff 6	36.9	31.3	34.8	36.9	31.3	34.8	36.9	31.3	34.8
Sens 6	8%	6%	10%	2%	14%	0%	0%	0%	0%
Spec 6	92%	90%	90%	92%	90%	90%	92%	90%	90%
OR Quart 2	2.8	3.1	1.9	0.79	2.1	1.4	2.8	4.2	1.0
p Value	0.042	0.17	0.21	0.63	0.41	0.44	0.12	0.21	0.97
95% CI of	1.0	0.61	0.69	0.31	0.37	0.57	0.76	0.46	0.24
OR Quart 2	7.4	16	5.3	2.0	12	3.7	9.9	38	4.5
OR Quart 3	1.6	0.99	1.3	1.5	2.1	1.8	2.8	2.0	2.7
p Value	0.34	0.99	0.59	0.37	0.41	0.22	0.12	0.57	0.14
95% CI of	0.59	0.14	0.47	0.62	0.37	0.71	0.76	0.18	0.74
OR Quart 3	4.6	7.2	3.8	3.7	12	4.4	9.9	23	9.5
OR Quart 4	2.3	3.1	1.5	0.89	2.0	1.3	1.0	3.0	1.6
p Value	0.10	0.17	0.47	0.81	0.42	0.59	0.97	0.34	0.47
95% CI of	0.84	0.61	0.52	0.35	0.36	0.51	0.24	0.31	0.42
OR Quart 4	6.1	16	4.1	2.3	11	3.3	4.5	30	6.4

Insulin-like growth factor-binding protein 5

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	21.0	5.45	21.0	9.99	21.0	24.0
Average	37.8	33.6	37.8	36.6	37.8	41.1
Stdev	49.2	53.3	49.2	55.6	49.2	48.4
p (t-test)		0.62		0.89		0.75
Min	0.204	0.204	0.204	0.204	0.204	0.204
Max	257	189	257	228	257	149
n (Samp)	119	52	119	53	119	26
n (Patient)	87	52	87	53	87	26
sCr only						
Median	14.7	0.763	14.7	0.763	14.7	6.07
Average	34.2	29.8	34.2	44.9	34.2	45.5
Stdev	47.7	51.3	47.7	66.8	47.7	62.9
p (t-test)		0.72		0.42		0.47
Min	0.204	0.222	0.204	0.316	0.204	0.222

-continued

Max	257	151	257	177	257	149
n (Samp)	283	16	283	14	283	10
n (Patient)	161	16	161	14	161	10
UO only						
Median	8.50	5.45	8.50	11.4	8.50	8.58
Average	30.2	34.4	30.2	34.0	30.2	33.3
Stdev	47.5	53.1	47.5	50.4	47.5	44.1
p (t-test)		0.64		0.63		0.78
Min	0.204	0.204	0.204	0.204	0.204	0.204
Max	257	189	257	228	257	149
n (Samp)	123	42	123	54	123	23
n (Patient)	80	42	80	54	80	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.44	0.51	0.46	0.52	0.51	0.54	0.53	0.55
SE	0.048	0.076	0.052	0.048	0.080	0.047	0.063	0.094	0.067
p	0.25	0.47	0.89	0.40	0.80	0.79	0.57	0.77	0.43
nCohort 1	119	283	123	119	283	123	119	283	123
nCohort 2	52	16	42	53	14	54	26	10	23
Cutoff 1	0.357	0.316	0.357	0.316	0.357	0.316	0.696	0.357	0.488
Sens 1	73%	75%	71%	75%	71%	70%	73%	70%	74%
Spec 1	22%	22%	28%	18%	26%	24%	32%	26%	41%
Cutoff 2	0.222	0.222	0.222	0.222	0.316	0.222	0.357	0.316	0.222
Sens 2	87%	81%	86%	87%	93%	83%	81%	90%	91%
Spec 2	16%	16%	20%	16%	22%	20%	22%	22%	20%
Cutoff 3	0.204	0.204	0.204	0.204	0.316	0.204	0.222	0.316	0.222
Sens 3	94%	100%	93%	96%	93%	96%	96%	90%	91%
Spec 3	4%	5%	5%	4%	22%	5%	16%	22%	20%
Cutoff 4	47.6	41.5	36.4	47.6	41.5	36.4	47.6	41.5	36.4
Sens 4	19%	31%	29%	26%	36%	28%	35%	30%	30%
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	71%
Cutoff 5	64.4	61.4	49.7	64.4	61.4	49.7	64.4	61.4	49.7
Sens 5	15%	19%	21%	19%	29%	26%	27%	30%	30%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	97.6	97.6	80.9	97.6	97.6	80.9	97.6	97.6	80.9
Sens 6	13%	12%	17%	15%	21%	13%	19%	30%	13%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.3	0.66	1.0	0.89	1.0	0.57	1.5	1.0	1.2
p Value	0.62	0.65	1.0	0.81	1.0	0.24	0.53	1.0	0.78
95% CI of	0.48	0.11	0.38	0.34	0.24	0.22	0.43	0.20	0.33
OR Quart 2	3.4	4.1	2.7	2.3	4.2	1.5	5.2	5.1	4.3
OR Quart 3	2.0	2.5	0.88	1.2	0.24	1.0	1.2	0.32	1.0
p Value	0.16	0.20	0.80	0.64	0.21	1.0	0.74	0.33	1.0
95% CI of	0.76	0.61	0.33	0.50	0.026	0.41	0.34	0.033	0.26
OR Quart 3	5.0	9.9	2.4	3.1	2.2	2.4	4.5	3.2	3.8
OR Quart 4	1.6	1.4	0.85	1.5	1.2	0.87	1.7	0.99	1.4
p Value	0.30	0.69	0.75	0.36	0.75	0.76	0.39	0.99	0.56
95% CI of	0.63	0.30	0.32	0.62	0.32	0.36	0.50	0.19	0.41
OR Quart 4	4.3	6.4	2.3	3.8	4.9	2.1	5.8	5.1	5.1

Immunoglobulin G4

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	416000	348000	416000	364000	416000	325000
Average	815000	435000	815000	451000	815000	395000
Stdev	1020000	366000	1020000	338000	1020000	384000
p (t-test)		0.033		0.035		0.20
Min	15300	2000	15300	14400	15300	18500
Max	5190000	1690000	5190000	1480000	5190000	1070000
n (Samp)	94	35	94	37	94	10
n (Patient)	67	35	67	37	67	10
sCr only						
Median	364000	506000	364000	357000	nd	nd
Average	626000	585000	626000	454000	nd	nd
Stdev	765000	449000	765000	347000	nd	nd
p (t-test)		0.87		0.53	nd	nd
Min	2000	61100	2000	58300	nd	nd

-continued

Max	5190000	1690000	5190000	939000	nd	nd
n (Samp)	205	10	205	8	nd	nd
n (Patient)	126	10	126	8	nd	nd
UO only						
Median	417000	328000	417000	409000	417000	385000
Average	719000	486000	719000	585000	719000	434000
Stdev	858000	677000	858000	651000	858000	371000
p (t-test)		0.19		0.40		0.26
Min	15300	2000	15300	14400	15300	18500
Max	5140000	3560000	5140000	3700000	5140000	1070000
n (Samp)	101	28	101	36	101	12
n (Patient)	65	28	65	36	65	12

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.42	0.57	0.40	0.44	0.48	0.48	0.37	nd	0.41
SE	0.058	0.096	0.063	0.057	0.11	0.056	0.099	nd	0.091
p	0.15	0.49	0.11	0.32	0.82	0.77	0.18	nd	0.30
nCohort 1	94	205	101	94	205	101	94	nd	101
nCohort 2	35	10	28	37	8	36	10	nd	12
Cutoff 1	191000	402000	186000	277000	250000	299000	71200	nd	71200
Sens 1	71%	70%	71%	70%	75%	72%	70%	nd	75%
Spec 1	30%	53%	28%	40%	34%	40%	13%	nd	11%
Cutoff 2	83300	347000	56300	164000	90700	245000	37500	nd	37500
Sens 2	80%	80%	82%	81%	88%	81%	80%	nd	83%
Spec 2	16%	49%	7%	26%	18%	34%	5%	nd	4%
Cutoff 3	33600	191000	15300	38600	58100	38600	18500	nd	18500
Sens 3	91%	90%	93%	92%	100%	92%	90%	nd	92%
Spec 3	4%	29%	1%	5%	12%	4%	1%	nd	1%
Cutoff 4	977000	705000	884000	977000	705000	884000	977000	nd	884000
Sens 4	3%	20%	14%	5%	25%	19%	10%	nd	8%
Spec 4	70%	70%	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	1370000	977000	1080000	1370000	977000	1080000	1370000	nd	1080000
Sens 5	3%	10%	4%	3%	0%	8%	0%	nd	0%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	2130000	1380000	1590000	2130000	1380000	1590000	2130000	nd	1590000
Sens 6	0%	10%	4%	0%	0%	3%	0%	nd	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	6.8	2.0	2.0	4.7	1.0	1.9	3.3	nd	4.7
p Value	0.0063	0.58	0.30	0.016	0.98	0.25	0.32	nd	0.18
95% CI of	1.7	0.18	0.53	1.3	0.14	0.64	0.32	nd	0.49
OR Quart 2	27	23	7.8	17	7.5	5.7	34	nd	45
OR Quart 3	5.2	6.5	2.8	4.1	1.0	1.9	2.1	nd	3.4
p Value	0.020	0.088	0.12	0.027	0.98	0.25	0.56	nd	0.31
95% CI of	1.3	0.75	0.77	1.2	0.14	0.64	0.18	nd	0.33
OR Quart 3	21	56	10	15	7.5	5.7	25	nd	34
OR Quart 4	3.3	0.98	2.4	2.4	1.0	1.0	4.5	nd	4.7
p Value	0.099	0.99	0.19	0.19	0.98	0.95	0.19	nd	0.18
95% CI of	0.80	0.060	0.65	0.65	0.14	0.32	0.47	nd	0.49
OR Quart 4	14	16	9.0	9.0	7.5	3.4	44	nd	45

Interleukin-21

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.694	0.220	0.694	0.631	0.694	1.76
Average	62.7	2.10	62.7	2.18	62.7	2.97
Stdev	560	4.20	560	3.76	560	4.00
p (t-test)		0.47		0.49		0.65
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	18.3	5430	15.6	5430	14.3
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	0.430	1.62	0.430	1.56	0.430	1.36
Average	27.5	4.80	27.5	4.77	27.5	3.68
Stdev	362	6.58	362	7.34	362	5.30
p (t-test)		0.82		0.79		0.84
Min	0.0102	0.0102	0.0102	0.0257	0.0102	0.0102

-continued

Max	5430	18.3	5430	26.6	5430	14.3
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9
UO only						
Median	0.829	0.174	0.829	0.630	0.829	0.829
Average	57.9	1.06	57.9	1.90	57.9	2.24
Stdev	535	2.03	535	3.33	535	3.16
p (t-test)		0.52		0.50		0.69
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	8.97	5430	16.0	5430	11.5
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.58	0.37	0.52	0.68	0.47	0.62	0.63	0.54
SE	0.053	0.082	0.055	0.054	0.072	0.054	0.076	0.10	0.081
p	0.37	0.33	0.020	0.70	0.011	0.56	0.099	0.20	0.63
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.0154	0.0154	0.0154	0.0257	0.231	0.0257	0.605	0.783	0.430
Sens 1	76%	79%	70%	74%	72%	71%	71%	78%	73%
Spec 1	19%	22%	14%	33%	48%	32%	50%	59%	46%
Cutoff 2	0.0142	0.0142	0.0102	0.0182	0.174	0.0154	0.430	0.0182	0.174
Sens 2	82%	86%	89%	83%	89%	85%	83%	89%	80%
Spec 2	15%	14%	5%	24%	43%	14%	49%	29%	36%
Cutoff 3	0.0102	0.0102	0	0.0142	0.0257	0.0142	0.0142	0	0.0142
Sens 3	91%	93%	100%	93%	94%	93%	94%	100%	93%
Spec 3	10%	9%	0%	15%	39%	11%	15%	0%	11%
Cutoff 4	1.77	1.61	2.03	1.77	1.61	2.03	1.77	1.61	2.03
Sens 4	29%	50%	19%	31%	39%	24%	50%	44%	20%
Spec 4	70%	71%	72%	70%	71%	72%	70%	71%	72%
Cutoff 5	2.93	2.46	3.18	2.93	2.46	3.18	2.93	2.46	3.18
Sens 5	16%	43%	8%	24%	39%	17%	22%	22%	20%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	10.6	5.00	14.5	10.6	5.00	14.5	10.6	5.00	14.5
Sens 6	7%	29%	0%	7%	28%	2%	11%	22%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.57	0.47	1.4	1.5	>6.5	1.0	2.2	0.98	3.4
p Value	0.29	0.40	0.55	0.43	<0.087	1.0	0.40	0.99	0.16
95% CI of	0.20	0.083	0.44	0.54	>0.76	0.34	0.36	0.060	0.62
OR Quart 2	1.6	2.7	4.7	4.3	na	2.9	13	16	18
OR Quart 3	1.1	0.23	2.2	1.0	>5.4	1.5	4.3	4.2	2.2
p Value	0.80	0.20	0.17	1.0	<0.13	0.44	0.086	0.20	0.40
95% CI of	0.43	0.025	0.71	0.34	>0.61	0.54	0.81	0.46	0.36
OR Quart 3	3.0	2.1	6.9	2.9	na	4.2	23	39	13
OR Quart 4	1.0	1.8	2.5	1.5	>7.8	1.3	2.8	3.1	1.5
p Value	0.93	0.36	0.11	0.43	<0.059	0.60	0.24	0.34	0.67
95% CI of	0.39	0.50	0.82	0.54	>0.93	0.47	0.50	0.31	0.23
OR Quart 4	2.8	6.6	7.7	4.3	na	3.7	16	30	9.7

Interleukin-23						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.886	1.10	0.886	1.10	0.886	6.06
Average	1780	3580	1780	4170	1780	1560
Stdev	10800	15400	10800	15900	10800	4960
p (t-test)		0.43		0.31		0.93
Min	0.257	0.257	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	20500
n (Samp)	93	45	93	42	93	18
n (Patient)	64	45	64	42	64	18
sCr only						
Median	1.10	0.886	1.10	1.10	1.10	0.603
Average	2750	3820	2750	8680	2750	2270
Stdev	14900	7430	14900	23800	14900	6820
p (t-test)		0.79		0.12		0.92
Min	0.257	0.257	0.257	0.257	0.257	0.257

-continued

Max	100000	20000	100000	100000	100000	20500
n (Samp)	224	14	224	18	224	9
n (Patient)	131	14	131	18	131	9
UO only						
Median	0.995	1.10	0.995	1.10	0.995	44.5
Average	2480	2920	2480	3160	2480	511
Stdev	11000	16400	11000	15600	11000	1650
p (t-test)		0.86		0.77		0.49
Min	0.257	0.257	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	6480
n (Samp)	102	37	102	41	102	15
n (Patient)	63	37	63	41	63	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.50	0.49	0.55	0.60	0.53	0.55	0.34	0.60
SE	0.053	0.080	0.056	0.054	0.073	0.054	0.076	0.10	0.082
p	0.74	0.98	0.79	0.32	0.17	0.56	0.51	0.11	0.24
nCohort 1	93	224	102	93	224	102	93	224	102
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.603	0.603	0.603	0.603	0.770	0.603	0.257	0.257	0.653
Sens 1	78%	79%	76%	79%	78%	80%	100%	89%	80%
Spec 1	25%	22%	24%	25%	38%	24%	18%	13%	41%
Cutoff 2	0.257	0.257	0.257	0.257	0.257	0.603	0.257	0.257	0.653
Sens 2	84%	86%	84%	81%	83%	80%	100%	89%	80%
Spec 2	18%	13%	19%	18%	13%	24%	18%	13%	41%
Cutoff 3	0	0	0	0	0	0	0.257	0	0.257
Sens 3	100%	100%	100%	100%	100%	100%	100%	100%	100%
Spec 3	0%	0%	0%	0%	0%	0%	18%	0%	19%
Cutoff 4	11.0	44.5	55.0	11.0	44.5	55.0	11.0	44.5	55.0
Sens 4	31%	29%	27%	43%	44%	34%	44%	11%	47%
Spec 4	71%	71%	71%	71%	71%	71%	71%	71%	71%
Cutoff 5	501	267	530	501	267	530	501	267	530
Sens 5	16%	29%	8%	29%	39%	24%	11%	11%	7%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	1500	1040	2000	1500	1040	2000	1500	1040	2000
Sens 6	11%	29%	5%	14%	33%	12%	11%	11%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	1.7	2.9	1.1	0.72	1.7	0.34	1.0	1.6
p Value	0.86	0.48	0.065	0.85	0.68	0.33	0.22	0.99	0.64
95% CI of	0.39	0.39	0.94	0.38	0.16	0.59	0.060	0.062	0.24
OR Quart 2	3.1	7.4	8.7	3.2	3.4	4.8	1.9	17	10
OR Quart 3	1.9	0.65	1.7	1.3	0.74	1.5	1.5	2.1	4.3
p Value	0.21	0.65	0.38	0.65	0.70	0.47	0.56	0.56	0.087
95% CI of	0.70	0.11	0.52	0.45	0.16	0.51	0.40	0.18	0.81
OR Quart 3	5.2	4.1	5.3	3.6	3.4	4.3	5.3	23	23
OR Quart 4	0.83	1.3	1.7	1.5	2.1	1.3	0.73	5.5	1.5
p Value	0.73	0.71	0.35	0.48	0.24	0.63	0.67	0.13	0.67
95% CI of	0.29	0.29	0.54	0.51	0.60	0.44	0.17	0.62	0.23
OR Quart 4	2.4	6.2	5.6	4.1	7.4	3.8	3.1	48	9.7

Interleukin-28A						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.168	0.265	0.168	0.265	0.168	12.7
Average	60.1	15.3	60.1	13.9	60.1	26.7
Stdev	387	47.2	387	41.9	387	54.8
p (t-test)		0.44		0.44		0.72
Min	0.0727	0.0727	0.0727	0.0727	0.0727	0.148
Max	3150	246	3150	243	3150	235
n (Samp)	93	45	93	42	93	18
n (Patient)	64	45	64	42	64	18
sCr only						
Median	0.195	0.230	0.195	0.265	0.195	0.265
Average	28.7	36.9	28.7	136	28.7	31.0
Stdev	250	80.9	250	470	250	77.2
p (t-test)		0.90		0.11		0.98
Min	0.0727	0.0727	0.0727	0.148	0.0727	0.0727

-continued

Max	3150	246	3150	2000	3150	235
n (Samp)	224	14	224	18	224	9
n (Patient)	131	14	131	18	131	9
UO only						
Median	0.168	0.265	0.168	0.265	0.168	0.265
Average	57.5	4.69	57.5	7.99	57.5	13.5
Stdev	370	10.1	370	16.8	370	18.3
p (t-test)		0.39		0.39		0.65
Min	0.0727	0.0727	0.0727	0.0727	0.0727	0.0727
Max	3150	49.8	3150	92.3	3150	62.9
n (Samp)	102	37	102	41	102	15
n (Patient)	63	37	63	41	63	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.55	0.61	0.62	0.65	0.62	0.76	0.60	0.69
SE	0.053	0.082	0.056	0.054	0.073	0.053	0.069	0.10	0.080
p	0.072	0.53	0.051	0.026	0.036	0.028	2.1E-4	0.31	0.015
nCohort 1	93	224	102	93	224	102	93	224	102
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.120	0.120	0.120	0.168	0.168	0.148	0.168	0.158	0.168
Sens 1	91%	79%	92%	71%	72%	73%	89%	78%	80%
Spec 1	19%	17%	24%	54%	48%	46%	54%	38%	56%
Cutoff 2	0.120	0	0.120	0.120	0.158	0.120	0.168	0.120	0.168
Sens 2	91%	100%	92%	88%	83%	83%	89%	89%	80%
Spec 2	19%	0%	24%	19%	38%	24%	54%	17%	56%
Cutoff 3	0.120	0	0.120	0	0.120	0	0.148	0	0.120
Sens 3	91%	100%	92%	100%	100%	100%	94%	100%	93%
Spec 3	19%	0%	24%	0%	17%	0%	41%	0%	24%
Cutoff 4	0.265	0.265	0.265	0.265	0.265	0.265	0.265	0.265	0.265
Sens 4	42%	36%	41%	36%	39%	39%	61%	44%	47%
Spec 4	80%	71%	82%	80%	71%	82%	80%	71%	82%
Cutoff 5	3.03	10.2	0.265	3.03	10.2	0.265	3.03	10.2	0.265
Sens 5	33%	36%	41%	33%	28%	39%	56%	33%	47%
Spec 5	81%	80%	82%	81%	80%	82%	81%	80%	82%
Cutoff 6	16.5	19.3	16.5	16.5	19.3	16.5	16.5	19.3	16.5
Sens 6	16%	29%	8%	12%	28%	10%	39%	22%	33%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	5.0	1.3	3.4	0.81	>6.5	0.47	>3.2	1.0	1.0
p Value	0.011	0.71	0.056	0.72	<0.087	0.22	<0.32	0.57	1.0
95% CI of	1.4	0.29	0.97	0.26	>0.76	0.14	>0.32	0.18	0.060
OR Quart 2	17	6.2	12	2.6	na	1.6	na	23	17
OR Quart 3	3.6	0.65	1.9	1.7	>6.7	1.3	>5.9	3.1	7.3
p Value	0.048	0.65	0.36	0.33	<0.084	0.65	<0.12	0.33	0.075
95% CI of	1.0	0.11	0.49	0.59	>0.78	0.45	>0.64	0.31	0.82
OR Quart 3	13	4.1	7.1	4.9	na	3.6	na	31	65
OR Quart 4	6.3	1.7	5.6	2.5	>6.5	2.3	>15	3.1	8.5
p Value	0.0035	0.48	0.0063	0.090	<0.087	0.10	<0.013	0.34	0.053
95% CI of	1.8	0.39	1.6	0.87	>0.76	0.85	>1.8	0.31	0.98
OR Quart 4	22	7.4	19	7.0	na	6.3	na	30	74

Interleukin-33						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.0981	0.0981	0.0981	0.101	0.0981	0.101
Average	481	183	481	184	481	63.4
Stdev	4130	710	4130	626	4130	210
p (t-test)		0.63		0.64		0.67
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4440	40000	3770	40000	892
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	0.0981	0.0762	0.0981	0.0993	0.0981	0.101
Average	327	240	327	844	327	99.4
Stdev	2850	485	2850	2870	2850	297
p (t-test)		0.91		0.46		0.81
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0455

-continued

Max	40000	1270	40000	12300	40000	892
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9
UO only						
Median	0.0981	0.0981	0.0981	0.101	0.0981	0.101
Average	503	132	503	131	503	16.7
Stdev	3950	730	3950	595	3950	38.5
p (t-test)		0.57		0.55		0.64
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4440	40000	3770	40000	149
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.46	0.45	0.55	0.54	0.56	0.62	0.55	0.59
SE	0.053	0.081	0.056	0.054	0.072	0.054	0.076	0.10	0.082
p	0.49	0.63	0.39	0.38	0.59	0.27	0.13	0.61	0.28
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.0455	0.0494	0.0455	0.0494	0.0445	0.0494	0.0996	0.0846	0.0996
Sens 1	73%	71%	73%	76%	83%	83%	83%	78%	73%
Spec 1	24%	21%	23%	24%	10%	23%	55%	36%	60%
Cutoff 2	0.0445	0.0445	0.0445	0.0445	0.0445	0.0494	0.0996	0.0494	0.0543
Sens 2	89%	86%	89%	95%	83%	83%	83%	89%	80%
Spec 2	11%	10%	8%	11%	10%	23%	55%	21%	41%
Cutoff 3	0	0	0	0.0445	0	0.0445	0	0.0445	0
Sens 3	100%	100%	100%	95%	100%	98%	100%	100%	100%
Spec 3	0%	0%	0%	11%	0%	8%	0%	10%	0%
Cutoff 4	2.20	3.29	3.29	2.20	3.29	3.29	2.20	3.29	3.29
Sens 4	24%	29%	19%	43%	44%	39%	39%	11%	40%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	27.4	14.4	33.8	27.4	14.4	33.8	27.4	14.4	33.8
Sens 5	13%	29%	8%	19%	28%	20%	17%	11%	13%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	79.4	76.8	99.5	79.4	76.8	99.5	79.4	76.8	99.5
Sens 6	11%	21%	5%	17%	28%	15%	11%	11%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	0.24	1.4	0.54	0.47	1.8	1.0	2.0	0.47
p Value	1.0	0.20	0.57	0.27	0.30	0.28	1.0	0.58	0.54
95% CI of	0.36	0.026	0.45	0.18	0.11	0.61	0.13	0.18	0.040
OR Quart 2	2.7	2.2	4.3	1.6	2.0	5.4	7.6	23	5.4
OR Quart 3	1.1	1.0	1.8	1.0	0.31	2.1	5.2	5.4	4.3
p Value	0.80	1.0	0.28	1.0	0.16	0.19	0.051	0.13	0.087
95% CI of	0.42	0.24	0.61	0.36	0.059	0.71	0.99	0.61	0.81
OR Quart 3	3.1	4.2	5.5	2.8	1.6	6.1	27	48	23
OR Quart 4	1.0	1.3	1.6	1.3	1.2	1.8	3.5	0.98	2.7
p Value	0.93	0.71	0.41	0.61	0.79	0.28	0.14	0.99	0.26
95% CI of	0.38	0.33	0.53	0.48	0.37	0.61	0.65	0.060	0.48
OR Quart 4	2.9	5.1	4.8	3.5	3.7	5.4	19	16	15

Vascular endothelial growth factor receptor 2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	8090	7910	8090	7810	8090	6760
Average	11100	9090	11100	9460	11100	7180
Stdev	15800	5160	15800	4940	15800	2560
p (t-test)		0.41		0.52		0.30
Min	3720	3140	3720	4110	3720	3790
Max	153000	32000	153000	26100	153000	14300
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	7990	8380	7990	7560	7990	6380
Average	10200	10500	10200	21300	10200	7330
Stdev	14900	7740	14900	49000	14900	2720
p (t-test)		0.94		0.020		0.56
Min	3640	3020	3640	3140	3640	5310

-continued

Max	166000	32000	166000	216000	166000	14300
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9
UO only						
Median	8040	7390	8040	7820	8040	6900
Average	11500	8180	11500	8500	11500	6830
Stdev	15500	3310	15500	3670	15500	2010
p (t-test)		0.20		0.23		0.25
Min	3900	3140	3900	4110	3900	3790
Max	153000	19800	153000	26100	153000	11800
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.51	0.43	0.47	0.51	0.45	0.31	0.34	0.30
SE	0.053	0.080	0.056	0.054	0.071	0.054	0.074	0.10	0.079
p	0.33	0.93	0.19	0.60	0.87	0.33	0.0082	0.11	0.013
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	6200	6200	6340	6710	6110	6690	5920	6010	5440
Sens 1	71%	71%	70%	71%	72%	71%	72%	78%	73%
Spec 1	19%	24%	23%	28%	22%	30%	13%	20%	11%
Cutoff 2	5620	5310	5570	6250	5560	6210	5050	5920	5140
Sens 2	80%	86%	81%	81%	83%	80%	83%	89%	80%
Spec 2	10%	12%	11%	19%	14%	21%	6%	19%	8%
Cutoff 3	5230	4920	5230	5070	4780	5620	3900	5300	4330
Sens 3	91%	93%	92%	90%	94%	90%	94%	100%	93%
Spec 3	7%	7%	9%	6%	6%	12%	2%	11%	2%
Cutoff 4	9710	9520	10000	9710	9520	10000	9710	9520	10000
Sens 4	29%	29%	19%	26%	33%	17%	11%	11%	7%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	11000	10600	11300	11000	10600	11300	11000	10600	11300
Sens 5	16%	21%	11%	21%	33%	12%	11%	11%	7%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	15300	14200	18800	15300	14200	18800	15300	14200	18800
Sens 6	9%	21%	3%	12%	28%	2%	0%	11%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	0.72	1.6	0.74	0.63	1.8	0.48	0	1.0
p Value	0.79	0.68	0.41	0.58	0.49	0.28	0.56	na	0.98
95% CI of	0.41	0.15	0.53	0.25	0.17	0.61	0.041	na	0.062
OR Quart 2	3.2	3.4	4.8	2.2	2.4	5.4	5.6	na	17
OR Quart 3	1.0	0.72	1.4	1.7	0.31	2.3	4.3	4.2	8.8
p Value	1.0	0.68	0.57	0.31	0.16	0.12	0.086	0.20	0.049
95% CI of	0.35	0.15	0.45	0.61	0.059	0.80	0.81	0.46	1.0
OR Quart 3	2.8	3.4	4.3	4.6	1.6	6.8	23	39	77
OR Quart 4	1.8	0.98	1.8	1.0	0.98	1.6	5.2	4.3	7.6
p Value	0.27	0.98	0.28	1.0	0.98	0.41	0.051	0.20	0.070
95% CI of	0.64	0.23	0.61	0.35	0.30	0.53	0.99	0.47	0.85
OR Quart 4	4.8	4.1	5.5	2.8	3.2	4.8	27	40	67

Lutropin subunit beta						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	4.52	3.87	4.52	4.46	4.52	1.63
Average	7.77	7.10	7.77	5.30	7.77	2.03
Stdev	10.8	10.6	10.8	4.52	10.8	2.17
p (t-test)		0.79		0.25		0.14
Min	0.00783	0.0399	0.00783	0.00467	0.00783	4.11E-5
Max	66.0	50.0	66.0	16.5	66.0	6.33
n (Samp)	68	25	68	27	68	8
n (Patient)	43	25	43	27	43	8
sCr only						
Median	3.65	5.59	3.65	4.50	nd	nd
Average	7.37	6.27	7.37	5.90	nd	nd
Stdev	11.4	4.33	11.4	4.44	nd	nd
p (t-test)		0.80		0.74	nd	nd
Min	4.11E-5	1.36	4.11E-5	1.58	nd	nd

-continued

Max	66.0	15.3	66.0	14.5	nd	nd
n (Samp)	153	7	153	7	nd	nd
n (Patient)	89	7	89	7	nd	nd
UO only						
Median	4.52	3.40	4.52	4.46	4.52	1.22
Average	7.66	7.21	7.66	5.08	7.66	1.87
Stdev	10.3	11.7	10.3	4.52	10.3	2.19
p (t-test)		0.87		0.21		0.12
Min	0.0621	0.0399	0.0621	0.00467	0.0621	4.11E-5
Max	66.0	50.0	66.0	16.5	66.0	6.33
n (Samp)	76	20	76	27	76	8
n (Patient)	43	20	43	27	43	8

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.63	0.42	0.48	0.59	0.45	0.26	nd	0.23
SE	0.068	0.12	0.074	0.066	0.12	0.066	0.10	nd	0.10
p	0.58	0.26	0.30	0.78	0.42	0.46	0.024	nd	0.0062
nCohort 1	68	153	76	68	153	76	68	nd	76
nCohort 2	25	7	20	27	7	27	8	nd	8
Cutoff 1	1.85	5.10	1.85	2.38	3.52	1.54	0.471	nd	0.471
Sens 1	72%	71%	70%	70%	71%	70%	75%	nd	75%
Spec 1	34%	64%	29%	35%	50%	20%	9%	nd	7%
Cutoff 2	1.17	4.12	0.544	1.40	2.38	1.32	4.11E-5	nd	4.11E-5
Sens 2	80%	86%	80%	81%	86%	81%	88%	nd	88%
Spec 2	25%	55%	9%	25%	41%	20%	0%	nd	0%
Cutoff 3	0.218	1.17	0.134	0.218	1.54	0.158	0	nd	0
Sens 3	92%	100%	90%	93%	100%	93%	100%	nd	100%
Spec 3	6%	29%	4%	6%	33%	4%	0%	nd	0%
Cutoff 4	6.94	6.28	6.94	6.94	6.28	6.94	6.94	nd	6.94
Sens 4	20%	29%	20%	26%	29%	22%	0%	nd	0%
Spec 4	71%	71%	71%	71%	71%	71%	71%	nd	71%
Cutoff 5	11.6	9.89	9.89	11.6	9.89	9.89	11.6	nd	9.89
Sens 5	20%	14%	20%	15%	14%	15%	0%	nd	0%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	22.6	18.0	20.6	22.6	18.0	20.6	22.6	nd	20.6
Sens 6	4%	0%	10%	0%	0%	0%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	1.3	>1.0	1.0	1.2	>3.2	1.2	>1.1	nd	>1.0
p Value	0.67	<0.99	1.0	0.75	<0.32	0.75	<0.97	nd	<0.97
95% CI of	0.35	>0.062	0.22	0.34	>0.32	0.35	>0.061	nd	>0.061
OR Quart 2	5.2	na	4.6	4.4	na	4.3	na	nd	na
OR Quart 3	2.0	>5.7	1.7	1.5	>2.1	0.79	>5.1	nd	>2.2
p Value	0.29	<0.12	0.48	0.53	<0.55	0.73	<0.17	nd	<0.53
95% CI of	0.55	>0.64	0.40	0.43	>0.18	0.21	>0.51	nd	>0.19
OR Quart 3	7.5	na	6.9	5.3	na	3.0	na	nd	na
OR Quart 4	1.3	>1.0	1.7	1.1	>2.1	1.9	>3.6	nd	>6.6
p Value	0.67	<0.99	0.48	0.93	<0.55	0.31	<0.29	nd	<0.10
95% CI of	0.35	>0.062	0.40	0.29	>0.18	0.55	>0.34	nd	>0.70
OR Quart 4	5.2	na	6.9	3.9	na	6.4	na	nd	na

Interstitial collagenase

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	54.1	65.2	54.1	46.2	54.1	92.4
Average	136	206	136	149	136	174
Stdev	174	477	174	202	174	294
p (t-test)		0.16		0.68		0.39
Min	0.0125	0.0125	0.0125	0.0125	0.0125	0.0125
Max	764	3260	764	760	764	1230
n (Samp)	121	53	121	52	121	26
n (Patient)	87	53	87	52	87	26
sCr only						
Median	53.7	73.9	53.7	65.2	53.7	56.4
Average	146	98.2	146	145	146	121
Stdev	271	103	271	213	271	156
p (t-test)		0.49		0.99		0.77
Min	0.0125	0.0125	0.0125	0.0131	0.0125	0.0125

-continued

Max	3260	332	3260	760	3260	488
n (Samp)	287	16	287	15	287	10
n (Patient)	161	16	161	15	161	10
UO only						
Median	47.3	82.2	47.3	54.7	47.3	110
Average	113	236	113	149	113	195
Stdev	157	524	157	189	157	309
p (t-test)		0.020		0.19		0.056
Min	0.0125	0.0131	0.0125	0.0125	0.0125	4.10
Max	711	3260	711	741	711	1230
n (Samp)	125	43	125	53	125	23
n (Patient)	80	43	80	53	80	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	0.49	0.59	0.48	0.48	0.54	0.51	0.47	0.61
SE	0.048	0.075	0.052	0.048	0.077	0.048	0.063	0.095	0.067
p	0.84	0.86	0.080	0.62	0.78	0.39	0.87	0.73	0.12
nCohort 1	121	287	125	121	287	125	121	287	125
nCohort 2	53	16	43	52	15	53	26	10	23
Cutoff 1	18.5	2.35	31.6	18.2	2.08	20.2	24.3	12.0	38.7
Sens 1	72%	75%	72%	71%	73%	72%	73%	70%	74%
Spec 1	24%	15%	39%	23%	15%	33%	31%	23%	43%
Cutoff 2	5.04	2.08	17.3	1.65	1.45	8.43	10.4	0.0270	24.3
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	13%	15%	30%	12%	14%	23%	18%	10%	37%
Cutoff 3	0.0281	0.0243	1.65	0.0131	0.0131	0.0270	4.08	0.0125	8.08
Sens 3	91%	94%	91%	92%	93%	91%	92%	90%	91%
Spec 3	10%	7%	18%	5%	6%	13%	12%	1%	22%
Cutoff 4	167	129	105	167	129	105	167	129	105
Sens 4	34%	31%	47%	29%	33%	34%	27%	40%	52%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	232	218	198	232	218	198	232	218	198
Sens 5	21%	12%	30%	25%	20%	26%	12%	20%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	354	406	333	354	406	333	354	406	333
Sens 6	11%	0%	14%	19%	13%	21%	12%	10%	13%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.48	4.4	1.3	0.92	1.0	1.1	0.97	0.24	2.6
p Value	0.14	0.069	0.60	0.87	0.98	0.87	0.96	0.21	0.19
95% CI of	0.18	0.89	0.47	0.36	0.24	0.43	0.28	0.027	0.63
OR Quart 2	1.3	21	3.8	2.3	4.2	2.7	3.3	2.2	11
OR Quart 3	1.1	0.49	1.5	0.92	0.49	1.0	1.9	0.24	2.6
p Value	0.82	0.57	0.44	0.87	0.41	1.0	0.29	0.21	0.19
95% CI of	0.46	0.044	0.54	0.36	0.086	0.39	0.59	0.027	0.63
OR Quart 3	2.7	5.6	4.2	2.3	2.7	2.6	5.8	2.2	11
OR Quart 4	0.78	2.6	2.1	1.3	1.3	1.5	0.61	1.0	2.2
p Value	0.59	0.25	0.14	0.59	0.72	0.40	0.47	0.98	0.29
95% CI of	0.32	0.50	0.78	0.52	0.33	0.60	0.16	0.24	0.50
OR Quart 4	1.9	14	5.8	3.1	5.0	3.6	2.4	4.2	9.5

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	186000	192000	186000	182000	186000	174000
Average	194000	192000	194000	191000	194000	182000
Stdev	76100	67500	76100	71400	76100	61100
p (t-test)		0.86		0.86		0.46
Min	73000	63300	73000	93300	73000	49200
Max	520000	371000	520000	506000	520000	297000
n (Samp)	120	53	120	53	120	26
n (Patient)	86	53	86	53	86	26
sCr only						
Median	181000	199000	181000	206000	181000	183000
Average	186000	200000	186000	219000	186000	189000
Stdev	67200	62800	67200	99400	67200	58600
p (t-test)		0.44		0.080		0.92
Min	49200	118000	49200	105000	49200	108000

-continued

Max	520000	316000	520000	506000	520000	280000
n (Samp)	287	16	287	15	287	10
n (Patient)	160	16	160	15	160	10
UO only						
Median	180000	182000	180000	182000	180000	172000
Average	191000	187000	191000	184000	191000	178000
Stdev	77000	69700	77000	54300	77000	59400
p (t-test)		0.72		0.52		0.44
Min	73000	63300	73000	93300	73000	49200
Max	520000	371000	520000	337000	520000	297000
n (Samp)	124	43	124	54	124	23
n (Patient)	79	43	79	54	79	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	0.57	0.49	0.49	0.59	0.50	0.48	0.52	0.48
SE	0.048	0.076	0.051	0.048	0.079	0.047	0.063	0.094	0.066
p	0.84	0.33	0.91	0.88	0.23	0.98	0.80	0.80	0.80
nCohort 1	120	287	124	120	287	124	120	287	124
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	151000	160000	141000	161000	166000	161000	147000	169000	147000
Sens 1	72%	75%	72%	72%	73%	70%	73%	70%	74%
Spec 1	31%	36%	23%	36%	40%	37%	26%	40%	28%
Cutoff 2	133000	125000	119000	135000	164000	133000	125000	144000	125000
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	18%	16%	11%	18%	38%	21%	12%	25%	15%
Cutoff 3	105000	118000	105000	111000	129000	111000	115000	115000	119000
Sens 3	91%	94%	91%	91%	93%	91%	92%	90%	91%
Spec 3	8%	13%	6%	8%	18%	7%	10%	13%	11%
Cutoff 4	212000	207000	209000	212000	207000	209000	212000	207000	209000
Sens 4	30%	44%	33%	30%	47%	26%	35%	30%	35%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	227000	227000	228000	227000	227000	228000	227000	227000	228000
Sens 5	25%	38%	21%	26%	40%	24%	35%	30%	35%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	262000	263000	257000	262000	263000	257000	262000	263000	257000
Sens 6	13%	12%	14%	8%	13%	9%	12%	20%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.80	0.48	1.0	0.66	1.3	1.0	0.18	1.5	0.21
p Value	0.64	0.40	1.0	0.39	0.71	0.94	0.039	0.65	0.058
95% CI of	0.32	0.085	0.38	0.26	0.29	0.42	0.037	0.25	0.041
OR Quart 2	2.0	2.7	2.6	1.7	6.2	2.5	0.92	9.4	1.1
OR Quart 3	0.80	0.99	0.77	0.84	0.66	0.81	0.86	1.0	0.85
p Value	0.64	0.98	0.61	0.70	0.65	0.64	0.78	1.0	0.77
95% CI of	0.32	0.24	0.28	0.34	0.11	0.32	0.29	0.14	0.27
OR Quart 3	2.0	4.1	2.1	2.1	4.1	2.0	2.5	7.3	2.6
OR Quart 4	1.1	1.5	1.2	0.93	2.1	1.0	0.75	1.5	0.72
p Value	0.88	0.53	0.75	0.88	0.32	0.94	0.61	0.66	0.59
95% CI of	0.44	0.41	0.45	0.38	0.50	0.42	0.25	0.24	0.22
OR Quart 4	2.6	5.6	3.1	2.3	8.5	2.5	2.3	9.2	2.3

Platelet-derived growth factor subunit B (dimer)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	358	321	358	367	358	468
Average	426	373	426	433	426	470
Stdev	264	206	264	405	264	204
p (t-test)		0.19		0.89		0.45
Min	39.4	33.7	39.4	0.189	39.4	91.4
Max	1540	854	1540	2690	1540	836
n (Samp)	119	52	119	49	119	24
n (Patient)	85	52	85	49	85	24
sCr only						
Median	348	260	348	283	348	425
Average	399	346	399	503	399	454
Stdev	245	218	245	670	245	238
p (t-test)		0.40		0.17		0.49
Min	0.189	43.4	0.189	33.7	0.189	129

-continued

Max	1540	807	1540	2690	1540	836
n (Samp)	278	16	278	14	278	10
n (Patient)	157	16	157	14	157	10
UO only						
Median	321	321	321	363	321	463
Average	378	377	378	399	378	444
Stdev	249	208	249	249	249	209
p (t-test)		0.99		0.61		0.25
Min	28.1	33.7	28.1	0.189	28.1	48.9
Max	1540	854	1540	1260	1540	813
n (Samp)	123	42	123	50	123	21
n (Patient)	78	42	78	50	78	21

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.44	0.52	0.47	0.45	0.53	0.58	0.58	0.61
SE	0.048	0.076	0.052	0.049	0.081	0.049	0.066	0.096	0.070
p	0.31	0.43	0.72	0.54	0.54	0.56	0.21	0.42	0.11
nCohort 1	119	278	123	119	278	123	119	278	123
nCohort 2	52	16	42	49	14	50	24	10	21
Cutoff 1	238	194	238	250	220	250	301	277	300
Sens 1	71%	75%	71%	71%	71%	70%	71%	70%	71%
Spec 1	24%	21%	32%	27%	25%	35%	35%	37%	45%
Cutoff 2	218	192	220	202	150	218	259	247	259
Sens 2	81%	81%	81%	82%	86%	80%	83%	80%	81%
Spec 2	22%	21%	29%	19%	15%	29%	32%	29%	41%
Cutoff 3	135	117	135	122	145	122	229	242	211
Sens 3	90%	94%	90%	92%	93%	90%	92%	90%	90%
Spec 3	10%	11%	15%	8%	14%	12%	24%	28%	27%
Cutoff 4	539	497	475	539	497	475	539	497	475
Sens 4	21%	31%	24%	18%	21%	34%	38%	50%	43%
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	71%
Cutoff 5	618	599	544	618	599	544	618	599	544
Sens 5	13%	19%	21%	16%	14%	18%	21%	40%	33%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	741	721	673	741	721	673	741	721	673
Sens 6	10%	6%	14%	8%	14%	14%	8%	10%	14%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.3	0.75	2.5	2.9	0.66	1.1	1.2	4.2	1.4
p Value	0.63	0.71	0.081	0.035	0.65	0.80	0.76	0.21	0.69
95% CI of	0.49	0.16	0.89	1.1	0.11	0.42	0.31	0.46	0.28
OR Quart 2	3.2	3.5	7.1	7.7	4.1	3.0	5.1	38	6.6
OR Quart 3	1.4	1.0	2.0	1.5	1.7	2.2	1.6	1.0	2.7
p Value	0.48	1.0	0.19	0.44	0.47	0.11	0.53	1.0	0.18
95% CI of	0.55	0.24	0.70	0.54	0.39	0.85	0.40	0.061	0.63
OR Quart 3	3.6	4.2	5.8	4.2	7.5	5.5	6.0	16	11
OR Quart 4	1.5	1.3	1.3	1.9	1.4	1.2	2.6	4.2	2.7
p Value	0.43	0.72	0.62	0.21	0.70	0.67	0.15	0.21	0.18
95% CI of	0.57	0.33	0.44	0.69	0.29	0.47	0.71	0.46	0.63
OR Quart 4	3.7	5.0	4.0	5.2	6.3	3.3	9.3	38	11

Thyroxine-binding globulin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	38.2	37.2	38.2	33.1	38.2	32.2
Average	39.2	36.8	39.2	34.5	39.2	34.4
Stdev	11.0	10.3	11.0	9.68	11.0	9.33
p (t-test)		0.15		0.0040		0.034
Min	13.4	12.8	13.4	13.9	13.4	16.3
Max	75.8	56.7	75.8	56.1	75.8	51.1
n (Samp)	262	51	262	55	262	26
n (Patient)	110	51	110	55	110	26
sCr only						
Median	36.0	33.2	36.0	33.2	36.0	33.2
Average	37.2	36.1	37.2	35.1	37.2	35.6
Stdev	11.3	10.9	11.3	9.71	11.3	7.59
p (t-test)		0.69		0.42		0.63
Min	12.8	23.2	12.8	22.7	12.8	26.8

-continued

Max	75.8	63.7	75.8	62.0	75.8	51.1
n (Samp)	466	18	466	20	466	13
n (Patient)	180	18	180	20	180	13
UO only						
Median	36.8	34.2	36.8	33.2	36.8	32.1
Average	38.0	35.7	38.0	34.3	38.0	34.2
Stdev	10.4	10.8	10.4	9.95	10.4	10.2
p (t-test)		0.17		0.023		0.099
Min	13.4	12.8	13.4	13.9	13.4	16.3
Max	75.8	56.7	75.8	56.1	75.8	51.1
n (Samp)	221	50	221	52	221	23
n (Patient)	91	50	91	52	91	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.45	0.44	0.38	0.43	0.40	0.37	0.46	0.40
SE	0.045	0.071	0.046	0.043	0.068	0.045	0.061	0.083	0.065
p	0.22	0.52	0.23	0.0041	0.30	0.030	0.037	0.61	0.14
nCohort 1	262	466	221	262	466	221	262	466	221
nCohort 2	51	18	50	55	20	52	26	13	23
Cutoff 1	29.1	28.0	29.1	28.7	28.5	27.9	28.1	29.8	28.0
Sens 1	71%	72%	70%	71%	70%	71%	73%	77%	74%
Spec 1	19%	22%	22%	18%	24%	16%	15%	28%	16%
Cutoff 2	26.5	26.7	26.5	26.5	28.3	25.0	27.8	29.4	27.4
Sens 2	80%	83%	80%	80%	80%	81%	81%	85%	87%
Spec 2	11%	18%	12%	11%	23%	10%	14%	27%	14%
Cutoff 3	24.2	24.4	23.7	22.5	25.7	21.4	26.5	27.8	17.9
Sens 3	90%	94%	90%	91%	90%	90%	92%	92%	91%
Spec 3	7%	12%	6%	5%	15%	4%	11%	21%	2%
Cutoff 4	44.9	43.4	43.6	44.9	43.4	43.6	44.9	43.4	43.6
Sens 4	25%	22%	28%	18%	20%	19%	19%	15%	22%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	47.3	46.4	46.3	47.3	46.4	46.3	47.3	46.4	46.3
Sens 5	14%	17%	20%	11%	10%	15%	8%	15%	22%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	52.5	50.3	49.9	52.5	50.3	49.9	52.5	50.3	49.9
Sens 6	6%	11%	10%	4%	5%	6%	0%	8%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	1.7	0.65	1.6	0.75	1.1	0.79	1.5	0.58
p Value	0.80	0.48	0.35	0.33	0.71	0.78	0.73	0.65	0.47
95% CI of	0.47	0.40	0.26	0.62	0.16	0.45	0.20	0.25	0.13
OR Quart 2	2.6	7.3	1.6	4.2	3.4	2.9	3.1	9.2	2.5
OR Quart 3	0.73	1.0	0.91	1.9	1.5	1.3	1.4	3.1	1.5
p Value	0.50	1.0	0.82	0.16	0.52	0.62	0.55	0.17	0.54
95% CI of	0.29	0.20	0.38	0.76	0.42	0.51	0.44	0.61	0.43
OR Quart 3	1.8	5.1	2.2	4.9	5.5	3.2	4.8	16	4.9
OR Quart 4	1.6	2.4	1.3	3.3	1.8	2.3	2.2	1.0	1.7
p Value	0.29	0.21	0.50	0.0089	0.35	0.058	0.18	0.99	0.38
95% CI of	0.69	0.61	0.58	1.3	0.52	0.97	0.70	0.14	0.52
OR Quart 4	3.5	9.6	3.0	7.9	6.4	5.4	6.7	7.3	5.5

Pigment epithelium-derived factor

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	1630	1820	1630	1420	1630	1640
Average	1720	2180	1720	1690	1720	1580
Stdev	753	1290	753	987	753	695
p (t-test)		0.0042		0.78		0.36
Min	445	317	445	339	445	347
Max	4240	5620	4240	4750	4240	3400
n (Samp)	121	53	121	53	121	26
n (Patient)	87	53	87	53	87	26
sCr only						
Median	1660	1950	1660	1670	1660	1960
Average	1920	2130	1920	1820	1920	2000
Stdev	1150	1270	1150	1050	1150	998
p (t-test)		0.47		0.77		0.82
Min	84.2	328	84.2	629	84.2	813

-continued

Max	7450	4300	7450	4910	7450	4360
n (Samp)	288	16	288	15	288	10
n (Patient)	161	16	161	15	161	10
UO only						
Median	1560	1740	1560	1400	1560	1510
Average	1720	2200	1720	1690	1720	1480
Stdev	787	1320	787	1020	787	701
p (t-test)		0.0046		0.87		0.19
Min	328	317	328	339	328	347
Max	4510	5620	4510	4750	4510	3400
n (Samp)	125	43	125	54	125	23
n (Patient)	80	43	80	54	80	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.55	0.59	0.44	0.49	0.45	0.47	0.57	0.43
SE	0.048	0.076	0.052	0.048	0.077	0.047	0.063	0.096	0.067
p	0.082	0.52	0.067	0.24	0.88	0.28	0.63	0.49	0.30
nCohort 1	121	288	125	121	288	125	121	288	125
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	1310	1170	1340	1150	1280	1150	1190	1770	1040
Sens 1	72%	75%	72%	72%	73%	70%	73%	70%	74%
Spec 1	32%	26%	35%	22%	32%	22%	27%	58%	18%
Cutoff 2	1060	1080	1060	813	1220	812	1030	1450	760
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	19%	22%	20%	8%	29%	7%	17%	41%	7%
Cutoff 3	974	529	999	733	760	677	591	852	529
Sens 3	91%	94%	91%	91%	93%	91%	92%	90%	91%
Spec 3	13%	4%	15%	7%	9%	6%	3%	10%	2%
Cutoff 4	1970	2080	1970	1970	2080	1970	1970	2080	1970
Sens 4	45%	44%	44%	25%	33%	28%	27%	30%	17%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	2210	2510	2160	2210	2510	2160	2210	2510	2160
Sens 5	38%	31%	40%	21%	13%	26%	12%	10%	9%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	2820	3520	2830	2820	3520	2830	2820	3520	2830
Sens 6	25%	31%	23%	11%	7%	13%	4%	10%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.68	0.74	0.64	0.72	1.7	0.43	2.7	0.49	1.9
p Value	0.43	0.70	0.42	0.51	0.47	0.095	0.14	0.56	0.33
95% CI of	0.26	0.16	0.22	0.28	0.39	0.16	0.74	0.043	0.51
OR Quart 2	1.8	3.4	1.9	1.9	7.4	1.2	9.5	5.5	7.2
OR Quart 3	0.70	1.0	0.87	1.1	1.4	0.90	1.6	2.1	1.3
p Value	0.47	1.0	0.79	0.82	0.70	0.82	0.50	0.41	0.72
95% CI of	0.27	0.24	0.31	0.45	0.29	0.37	0.41	0.37	0.32
OR Quart 3	1.8	4.2	2.4	2.8	6.3	2.2	6.2	12	5.2
OR Quart 4	1.9	1.3	2.2	1.4	1.0	1.3	2.0	1.5	1.9
p Value	0.15	0.73	0.11	0.45	0.99	0.60	0.31	0.66	0.33
95% CI of	0.80	0.33	0.85	0.58	0.20	0.53	0.53	0.24	0.51
OR Quart 4	4.6	4.9	5.6	3.5	5.2	3.0	7.5	9.2	7.2

Tumor necrosis factor receptor superfamily member 8

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	96.5	104	96.5	122	96.5	123
Average	184	201	184	187	184	122
Stdev	461	420	461	202	461	70.9
p (t-test)		0.83		0.97		0.57
Min	12.8	19.4	12.8	12.8	12.8	4.06
Max	3360	2810	3360	1040	3360	288
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18
sCr only						
Median	101	97.7	101	163	101	103
Average	199	192	199	343	199	115
Stdev	425	225	425	395	425	71.5
p (t-test)		0.95		0.17		0.55
Min	4.06	39.7	4.06	33.2	4.06	56.2

-continued

Max	3360	726	3360	1460	3360	288
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9
UO only						
Median	100	96.4	100	101	100	116
Average	211	184	211	129	211	110
Stdev	468	447	468	102	468	66.6
p (t-test)		0.76		0.27		0.41
Min	12.8	19.4	12.8	12.8	12.8	4.06
Max	3360	2810	3360	595	3360	208
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.51	0.50	0.62	0.66	0.51	0.54	0.46	0.47
SE	0.053	0.080	0.056	0.054	0.072	0.054	0.076	0.10	0.081
p	0.32	0.94	0.93	0.031	0.025	0.85	0.56	0.67	0.74
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	76.5	76.5	75.6	96.4	104	83.2	84.9	65.4	56.2
Sens 1	71%	71%	70%	71%	72%	71%	72%	78%	73%
Spec 1	36%	33%	33%	50%	51%	40%	44%	23%	18%
Cutoff 2	74.6	62.3	73.4	83.2	82.7	68.4	56.2	56.6	54.3
Sens 2	80%	86%	81%	81%	83%	80%	83%	89%	80%
Spec 2	34%	20%	31%	41%	36%	28%	19%	16%	17%
Cutoff 3	62.3	53.7	62.3	68.4	50.8	47.2	34.2	54.3	36.7
Sens 3	91%	93%	92%	90%	94%	90%	94%	100%	93%
Spec 3	24%	13%	23%	31%	12%	15%	10%	14%	11%
Cutoff 4	145	151	149	145	151	149	145	151	149
Sens 4	29%	21%	19%	33%	56%	20%	33%	11%	40%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	178	205	192	178	205	192	178	205	192
Sens 5	16%	21%	11%	24%	33%	15%	22%	11%	13%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	258	285	318	258	285	318	258	285	318
Sens 6	11%	21%	3%	17%	33%	5%	6%	11%	0%
Spec 6	90%	91%	90%	90%	91%	90%	90%	91%	90%
OR Quart 2	5.5	0.72	3.2	4.1	1.5	1.8	0.17	4.3	1.0
p Value	0.0040	0.68	0.039	0.028	0.66	0.30	0.12	0.20	0.96
95% CI of	1.7	0.15	1.1	1.2	0.24	0.61	0.019	0.47	0.23
OR Quart 2	17	3.4	9.8	14	9.3	5.0	1.6	40	4.6
OR Quart 3	3.4	0.98	1.9	5.2	2.6	2.2	1.5	1.0	0.22
p Value	0.039	0.98	0.26	0.0091	0.27	0.13	0.52	1.0	0.19
95% CI of	1.1	0.23	0.62	1.5	0.48	0.79	0.42	0.061	0.024
OR Quart 3	11	4.1	6.1	18	14	6.3	5.6	16	2.1
OR Quart 4	2.3	0.72	1.2	4.1	4.4	0.84	1.0	3.2	1.7
p Value	0.17	0.68	0.76	0.028	0.069	0.77	1.0	0.32	0.45
95% CI of	0.70	0.15	0.36	1.2	0.89	0.27	0.25	0.32	0.42
OR Quart 4	7.7	3.4	4.0	14	22	2.6	3.9	31	6.8

Alpha-fetoprotein						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.324	0.333	0.324	0.394	0.324	0.477
Average	0.366	0.334	0.366	0.418	0.366	0.480
Stdev	0.364	0.323	0.364	0.325	0.364	0.292
p (t-test)		0.58		0.37		0.14
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.31	1.81	1.53	1.81	1.42
n (Samp)	121	53	121	53	121	26
n (Patient)	87	53	87	53	87	26
sCr only						
Median	0.329	0.438	0.329	0.547	0.329	0.484
Average	0.355	0.401	0.355	0.502	0.355	0.488
Stdev	0.344	0.363	0.344	0.401	0.344	0.316
p (t-test)		0.61		0.11		0.23
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580

-continued

Max	1.81	1.11	1.81	1.40	1.81	0.979
n (Samp)	288	16	288	15	288	10
n (Patient)	161	16	161	15	161	10
UO only						
Median	0.309	0.289	0.309	0.400	0.309	0.445
Average	0.341	0.311	0.341	0.444	0.341	0.437
Stdev	0.366	0.308	0.366	0.352	0.366	0.303
p (t-test)		0.63		0.082		0.24
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.31	1.81	1.53	1.81	1.42
n (Samp)	125	43	125	54	125	23
n (Patient)	80	43	80	54	80	23

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.56	0.49	0.57	0.61	0.60	0.64	0.65	0.62
SE	0.048	0.076	0.051	0.048	0.079	0.047	0.063	0.096	0.067
p	0.70	0.47	0.81	0.16	0.18	0.028	0.029	0.12	0.073
nCohort 1	121	288	125	121	288	125	121	288	125
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	0.00580	0.00580	0.00580	0.272	0.207	0.272	0.347	0.392	0.272
Sens 1	79%	88%	79%	72%	73%	72%	73%	70%	74%
Spec 1	16%	16%	19%	42%	39%	46%	55%	62%	46%
Cutoff 2	0	0.00580	0	0.00580	0	0.00580	0.272	0.387	0.173
Sens 2	100%	88%	100%	89%	100%	93%	81%	80%	83%
Spec 2	0%	16%	0%	16%	0%	19%	42%	61%	42%
Cutoff 3	0	0	0	0	0	0.00580	0.0850	0.00580	0.0687
Sens 3	100%	100%	100%	100%	100%	93%	92%	90%	91%
Spec 3	0%	0%	0%	0%	0%	19%	31%	16%	38%
Cutoff 4	0.446	0.485	0.446	0.446	0.485	0.446	0.446	0.485	0.446
Sens 4	32%	50%	28%	38%	60%	39%	50%	50%	48%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.607	0.585	0.588	0.607	0.585	0.588	0.607	0.585	0.588
Sens 5	17%	31%	14%	21%	40%	26%	27%	40%	22%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.836	0.767	0.836	0.836	0.767	0.836	0.836	0.767	0.836
Sens 6	8%	12%	7%	8%	20%	11%	8%	20%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.3	2.1	1.5	1.8	0.24	1.6	6.8	0	8.4
p Value	0.59	0.41	0.45	0.24	0.20	0.34	0.084	na	0.052
95% CI of	0.52	0.37	0.54	0.67	0.026	0.60	0.77	na	0.98
OR Quart 2	3.1	12	4.0	5.0	2.2	4.5	59	na	72
OR Quart 3	0.79	2.6	1.6	2.6	0.73	2.7	13	2.1	8.4
p Value	0.63	0.26	0.32	0.058	0.69	0.043	0.018	0.41	0.052
95% CI of	0.31	0.49	0.61	0.97	0.16	1.0	1.6	0.37	0.98
OR Quart 3	2.0	14	4.4	6.9	3.4	7.2	110	12	72
OR Quart 4	1.2	2.6	1.0	2.5	1.8	2.7	11	2.0	9.9
p Value	0.76	0.26	1.0	0.068	0.36	0.043	0.026	0.42	0.035
95% CI of	0.46	0.49	0.35	0.94	0.50	1.0	1.3	0.36	1.2
OR Quart 4	2.9	14	2.8	6.7	6.4	7.2	94	11	84

Apolipoprotein E

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	53900	51900	53900	41500	53900	28700
Average	66800	69000	66800	53100	66800	33700
Stdev	47000	50500	47000	43200	47000	20200
p (t-test)		0.76		0.051		4.4E-4
Min	8630	13000	8630	10300	8630	4980
Max	260000	244000	260000	232000	260000	73300
n (Samp)	145	64	145	62	145	27
n (Patient)	111	64	111	62	111	27
sCr only						
Median	49300	50300	49300	51700	49300	49300
Average	61100	60300	61100	70300	61100	47800
Stdev	44800	37100	44800	61900	44800	22100
p (t-test)		0.94		0.38		0.29
Min	1940	20700	1940	13500	1940	4980

-continued

Max	260000	147000	260000	232000	260000	75700
n (Samp)	341	19	341	20	341	13
n (Patient)	193	19	193	20	193	13
UO only						
Median	53200	49900	53200	41200	53200	26000
Average	64500	69900	64500	45600	64500	28600
Stdev	43200	52200	43200	26400	43200	15400
p (t-test)		0.46		0.0024		8.5E-5
Min	4980	13000	4980	10300	4980	5170
Max	218000	244000	218000	132000	218000	68300
n (Samp)	151	54	151	56	151	24
n (Patient)	103	54	103	56	103	24

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	0.51	0.51	0.39	0.50	0.37	0.23	0.46	0.18
SE	0.043	0.068	0.046	0.044	0.067	0.045	0.056	0.083	0.055
p	0.99	0.91	0.81	0.0095	0.95	0.0039	2.0E-6	0.65	8.4E-9
nCohort 1	145	341	151	145	341	151	145	341	151
nCohort 2	64	19	54	62	20	56	27	13	24
Cutoff 1	39600	29600	39600	25800	33900	27000	23900	34000	19800
Sens 1	70%	74%	70%	71%	70%	71%	70%	77%	75%
Spec 1	31%	22%	33%	8%	29%	14%	7%	30%	9%
Cutoff 2	27200	25600	29100	19600	20200	23500	16400	28600	16500
Sens 2	81%	84%	81%	81%	80%	80%	81%	85%	83%
Spec 2	10%	16%	17%	6%	11%	10%	5%	20%	7%
Cutoff 3	20700	23900	20200	14300	19100	13800	8630	15100	13800
Sens 3	91%	95%	91%	90%	90%	91%	93%	92%	92%
Spec 3	6%	14%	9%	3%	10%	3%	1%	7%	3%
Cutoff 4	76000	67600	76000	76000	67600	76000	76000	67600	76000
Sens 4	34%	32%	35%	19%	35%	14%	0%	23%	0%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	90100	86400	92000	90100	86400	92000	90100	86400	92000
Sens 5	27%	26%	26%	11%	30%	4%	0%	0%	0%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	131000	113000	120000	131000	113000	120000	131000	113000	120000
Sens 6	12%	11%	13%	6%	20%	2%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.70	0.48	1.2	1.2	0.65	2.0	>7.0	>7.7	>2.1
p Value	0.40	0.31	0.66	0.65	0.52	0.15	<0.078	<0.059	<0.55
95% CI of	0.30	0.12	0.51	0.50	0.18	0.77	>0.80	>0.93	>0.18
OR Quart 2	1.6	2.0	2.9	3.0	2.4	5.4	na	na	na
OR Quart 3	0.63	0.65	0.80	1.1	0.65	2.0	>5.7	>3.1	>6.9
p Value	0.29	0.52	0.64	0.82	0.52	0.15	<0.12	<0.33	<0.079
95% CI of	0.27	0.18	0.32	0.45	0.18	0.77	>0.63	>0.32	>0.80
OR Quart 3	1.5	2.4	2.0	2.7	2.4	5.4	na	na	na
OR Quart 4	1.1	1.0	1.2	2.7	0.99	3.5	>25	>3.1	>26
p Value	0.89	1.0	0.70	0.020	0.98	0.0083	<0.0022	<0.33	<0.0021
95% CI of	0.47	0.31	0.50	1.2	0.31	1.4	>3.2	>0.32	>3.3
OR Quart 4	2.4	3.2	2.8	6.4	3.2	9.1	na	na	na

Apolipoprotein(a)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	47000	38500	47000	29800	47000	41500
Average	76700	78000	76700	72900	76700	82500
Stdev	99200	105000	99200	123000	99200	106000
p (t-test)		0.93		0.82		0.78
Min	7.99	1060	7.99	20.1	7.99	341
Max	631000	560000	631000	722000	631000	382000
n (Samp)	145	64	145	62	145	27
n (Patient)	111	64	111	62	111	27
sCr only						
Median	41400	53200	41400	46900	41400	49600
Average	80100	84900	80100	109000	80100	94500
Stdev	102000	88500	102000	167000	102000	129000
p (t-test)		0.84		0.24		0.62
Min	7.99	2390	7.99	20.1	7.99	341

-continued

Max	631000	309000	631000	722000	631000	382000
n (Samp)	341	19	341	20	341	13
n (Patient)	193	19	193	20	193	13
UO only						
Median	51100	29500	51100	22200	51100	29300
Average	75400	68600	75400	61700	75400	55600
Stdev	94800	104000	94800	92400	94800	68400
p (t-test)		0.66		0.35		0.33
Min	7.99	1060	7.99	977	7.99	1300
Max	631000	560000	631000	512000	631000	290000
n (Samp)	151	54	151	56	151	24
n (Patient)	103	54	103	56	103	24

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.55	0.43	0.44	0.53	0.41	0.49	0.49	0.43
SE	0.044	0.070	0.046	0.044	0.068	0.046	0.061	0.082	0.065
p	0.75	0.48	0.12	0.20	0.63	0.052	0.88	0.89	0.27
nCohort 1	145	341	151	145	341	151	145	341	151
nCohort 2	64	19	54	62	20	56	27	13	24
Cutoff 1	14100	32400	11100	10500	25900	8730	16800	4700	15300
Sens 1	70%	74%	70%	71%	70%	71%	70%	77%	71%
Spec 1	29%	45%	19%	21%	40%	15%	32%	11%	28%
Cutoff 2	8730	15600	6840	5630	15300	5630	5630	4300	5630
Sens 2	81%	84%	81%	81%	80%	80%	81%	85%	83%
Spec 2	18%	31%	11%	12%	31%	9%	12%	9%	9%
Cutoff 3	4980	2640	4320	2640	4700	2640	1810	1680	3010
Sens 3	91%	95%	91%	90%	90%	91%	93%	92%	92%
Spec 3	8%	6%	5%	6%	11%	4%	6%	4%	5%
Cutoff 4	80900	89900	81800	80900	89900	81800	80900	89900	81800
Sens 4	27%	32%	22%	23%	30%	23%	33%	31%	25%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	122000	125000	112000	122000	125000	112000	122000	125000	112000
Sens 5	19%	21%	19%	16%	30%	18%	22%	23%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	209000	214000	180000	209000	214000	180000	209000	214000	180000
Sens 6	11%	11%	11%	10%	15%	7%	11%	15%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.85	1.7	0.91	0.90	1.3	0.55	0.58	0.75	0.46
p Value	0.71	0.47	0.85	0.82	0.73	0.23	0.37	0.71	0.30
95% CI of	0.36	0.40	0.35	0.38	0.33	0.20	0.17	0.16	0.11
OR Quart 2	2.0	7.4	2.4	2.2	4.9	1.5	1.9	3.5	2.0
OR Quart 3	1.0	2.1	1.6	1.2	1.3	1.5	0.71	0.49	1.4
p Value	0.95	0.31	0.34	0.67	0.73	0.39	0.56	0.42	0.56
95% CI of	0.45	0.50	0.63	0.52	0.33	0.62	0.22	0.087	0.44
OR Quart 3	2.4	8.6	3.8	2.8	4.9	3.4	2.3	2.7	4.5
OR Quart 4	1.2	1.7	2.0	1.6	1.5	1.6	1.0	1.0	1.2
p Value	0.63	0.47	0.11	0.26	0.53	0.26	1.0	0.99	0.73
95% CI of	0.54	0.40	0.84	0.70	0.41	0.70	0.34	0.24	0.38
OR Quart 4	2.8	7.4	4.9	3.7	5.6	3.8	3.0	4.2	4.0

[0188] FIG. 6: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

Complement C4-B						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	70800	86100	70800	78800	70800	59900
Average	76600	85000	76600	83100	76600	71500
Stdev	39900	53500	39900	52600	39900	39100
p (t-test)		0.42		0.43		0.58

-continued

Min	305	7620	305	5510	305	10700
Max	223000	172000	223000	214000	223000	140000
n (Samp)	282	16	282	28	282	20
n (Patient)	160	16	160	28	160	20
sCr only						
Median	nd	nd	nd	nd	72400	112000
Average	nd	nd	nd	nd	77600	104000
Stdev	nd	nd	nd	nd	41600	51900
p (t-test)	nd	nd	nd	nd	nd	0.13
Min	nd	nd	nd	nd	305	15300
Max	nd	nd	nd	nd	223000	161000
n (Samp)	nd	nd	nd	nd	353	6
n (Patient)	nd	nd	nd	nd	193	6
UO only						
Median	66200	84700	66200	67900	66200	59300
Average	73700	80900	73700	81800	73700	69000
Stdev	38600	57100	38600	54200	38600	35600
p (t-test)		0.53		0.33		0.62
Min	305	7620	305	5510	305	10700
Max	223000	172000	223000	214000	223000	126000
n (Samp)	258	13	258	26	258	17
n (Patient)	140	13	140	26	140	17

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.54	nd	0.52	0.52	nd	0.52	0.47	0.68	0.47
SE	0.076	nd	0.083	0.058	nd	0.060	0.068	0.12	0.073
p	0.57	nd	0.83	0.74	nd	0.75	0.67	0.14	0.73
nCohort 1	282	nd	258	282	nd	258	282	353	258
nCohort 2	16	nd	13	28	nd	26	20	6	17
Cutoff 1	39400	nd	32200	46200	nd	45900	50900	81100	50900
Sens 1	75%	nd	77%	71%	nd	73%	70%	83%	71%
Spec 1	19%	nd	13%	24%	nd	26%	30%	57%	33%
Cutoff 2	32200	nd	29600	34900	nd	34900	39400	81100	39400
Sens 2	81%	nd	85%	82%	nd	81%	80%	83%	82%
Spec 2	12%	nd	10%	15%	nd	16%	19%	57%	20%
Cutoff 3	7620	nd	7620	23300	nd	23300	21400	13500	21400
Sens 3	94%	nd	92%	93%	nd	92%	90%	100%	94%
Spec 3	2%	nd	3%	6%	nd	6%	5%	4%	5%
Cutoff 4	96100	nd	90900	96100	nd	90900	96100	100000	90900
Sens 4	38%	nd	38%	36%	nd	42%	35%	50%	29%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	111000	nd	108000	111000	nd	108000	111000	113000	108000
Sens 5	31%	nd	38%	32%	nd	35%	25%	50%	24%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	132000	nd	131000	132000	nd	131000	132000	132000	131000
Sens 6	25%	nd	23%	14%	nd	12%	5%	33%	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	0.19	nd	0.19	0.59	nd	0.84	0.80	0	0.74
p Value	0.13	nd	0.13	0.38	nd	0.77	0.75	na	0.70
95% CI of	0.021	nd	0.021	0.18	nd	0.27	0.21	na	0.16
OR Quart 2	1.6	nd	1.6	1.9	nd	2.6	3.1	na	3.4
OR Quart 3	0.79	nd	0.38	0.73	nd	0.40	1.0	2.0	1.5
p Value	0.73	nd	0.25	0.58	nd	0.20	1.0	0.57	0.51
95% CI of	0.20	nd	0.070	0.24	nd	0.100	0.28	0.18	0.42
OR Quart 3	3.1	nd	2.0	2.2	nd	1.6	3.6	22	5.7
OR Quart 4	1.2	nd	0.98	1.1	nd	1.5	1.2	3.0	1.0
p Value	0.77	nd	0.98	0.82	nd	0.44	0.74	0.34	0.98
95% CI of	0.35	nd	0.27	0.41	nd	0.54	0.36	0.31	0.24
OR Quart 4	4.1	nd	3.6	3.1	nd	4.2	4.2	30	4.2

C-C motif chemokine 7

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.620	0.804	0.620	0.712	0.620	0.620
Average	7.83	22.1	7.83	11.9	7.83	10.9
Stdev	19.8	46.2	19.8	21.0	19.8	18.8
p (t-test)		0.015		0.31		0.54

-continued

Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	166	181	166	79.4	166	60.8
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
UO only						
Median	0.620	0.804	0.620	0.512	0.620	0.620
Average	8.13	24.1	8.13	10.6	8.13	10.8
Stdev	21.4	51.2	21.4	20.6	21.4	19.8
p (t-test)		0.022		0.56		0.65
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	166	181	166	79.4	166	60.8
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	nd	0.56	0.52	nd	0.51	0.57	nd	0.55
SE	0.077	nd	0.085	0.059	nd	0.058	0.075	nd	0.079
p	0.30	nd	0.48	0.69	nd	0.93	0.37	nd	0.57
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.308	nd	0	0.193	nd	0.193	0.308	nd	0.308
Sens 1	75%	nd	100%	86%	nd	86%	88%	nd	87%
Spec 1	30%	nd	0%	18%	nd	20%	30%	nd	32%
Cutoff 2	0	nd	0	0.193	nd	0.193	0.308	nd	0.308
Sens 2	100%	nd	100%	86%	nd	86%	88%	nd	87%
Spec 2	0%	nd	0%	18%	nd	20%	30%	nd	32%
Cutoff 3	0	nd	0	0	nd	0	0.193	nd	0.193
Sens 3	100%	nd	100%	100%	nd	100%	94%	nd	93%
Spec 3	0%	nd	0%	0%	nd	0%	18%	nd	20%
Cutoff 4	2.71	nd	2.32	2.71	nd	2.32	2.71	nd	2.32
Sens 4	44%	nd	38%	32%	nd	34%	29%	nd	27%
Spec 4	71%	nd	71%	71%	nd	71%	71%	nd	71%
Cutoff 5	11.7	nd	9.52	11.7	nd	9.52	11.7	nd	9.52
Sens 5	38%	nd	31%	29%	nd	24%	29%	nd	27%
Spec 5	80%	nd	81%	80%	nd	81%	80%	nd	81%
Cutoff 6	19.2	nd	18.9	19.2	nd	18.9	19.2	nd	18.9
Sens 6	31%	nd	31%	25%	nd	21%	24%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.48	nd	0.24	0.72	nd	1.3	8.9	nd	3.2
p Value	0.41	nd	0.20	0.57	nd	0.59	0.042	nd	0.17
95% CI of	0.085	nd	0.025	0.23	nd	0.46	1.1	nd	0.61
OR Quart 2	2.7	nd	2.2	2.2	nd	3.9	74	nd	17
OR Quart 3	1.0	nd	1.0	0.72	nd	0.69	3.1	nd	1.5
p Value	1.0	nd	1.0	0.57	nd	0.54	0.33	nd	0.65
95% CI of	0.24	nd	0.24	0.23	nd	0.20	0.31	nd	0.25
OR Quart 3	4.2	nd	4.2	2.2	nd	2.3	31	nd	9.5
OR Quart 4	1.5	nd	1.0	0.98	nd	1.2	5.3	nd	2.0
p Value	0.53	nd	1.0	0.97	nd	0.78	0.13	nd	0.42
95% CI of	0.41	nd	0.24	0.34	nd	0.39	0.60	nd	0.36
OR Quart 4	5.7	nd	4.2	2.8	nd	3.5	47	nd	12

Vascular endothelial growth factor receptor 3						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	6100	5150	6100	5290	6100	5450
Average	7380	6360	7380	6050	7380	6270
Stdev	5900	3290	5900	3460	5900	3330
p (t-test)		0.49		0.24		0.44
Min	219	1190	219	1360	219	1500
Max	43200	12400	43200	16600	43200	12900
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
UO only						
Median	6100	5110	6100	5810	6100	5450
Average	7350	6420	7350	6480	7350	6490
Stdev	5870	3590	5870	3710	5870	3400
p (t-test)		0.58		0.44		0.58

-continued

Min	219	1190	219	1360	219	1500
Max	43200	12400	43200	16600	43200	12900
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	nd	0.49	0.45	nd	0.48	0.47	nd	0.49
SE	0.075	nd	0.083	0.059	nd	0.058	0.074	nd	0.078
p	0.90	nd	0.89	0.38	nd	0.71	0.70	nd	0.93
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	4400	nd	4400	3920	nd	3920	3700	nd	4610
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	32%	nd	31%	28%	nd	28%	27%	nd	34%
Cutoff 2	4100	nd	4050	3400	nd	3400	3140	nd	3230
Sens 2	81%	nd	85%	82%	nd	83%	82%	nd	80%
Spec 2	29%	nd	29%	21%	nd	21%	17%	nd	18%
Cutoff 3	1630	nd	1630	1810	nd	1810	2780	nd	2780
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	6%	nd	6%	6%	nd	7%	12%	nd	13%
Cutoff 4	8170	nd	8170	8170	nd	8170	8170	nd	8170
Sens 4	31%	nd	38%	21%	nd	24%	29%	nd	33%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	9670	nd	9630	9670	nd	9630	9670	nd	9630
Sens 5	25%	nd	31%	14%	nd	17%	18%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	12600	nd	12600	12600	nd	12600	12600	nd	12600
Sens 6	0%	nd	0%	4%	nd	7%	6%	nd	7%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.39	nd	0	0.83	nd	1.0	0.59	nd	0.38
p Value	0.27	nd	na	0.77	nd	1.0	0.48	nd	0.27
95% CI of	0.072	nd	na	0.24	nd	0.33	0.13	nd	0.071
OR Quart 2	2.1	nd	na	2.9	nd	3.1	2.6	nd	2.1
OR Quart 3	1.5	nd	1.2	1.8	nd	1.2	0.79	nd	0.78
p Value	0.52	nd	0.75	0.27	nd	0.78	0.73	nd	0.73
95% CI of	0.44	nd	0.35	0.62	nd	0.39	0.20	nd	0.20
OR Quart 3	5.0	nd	4.3	5.4	nd	3.5	3.1	nd	3.1
OR Quart 4	0.39	nd	0.38	1.2	nd	1.0	1.0	nd	0.80
p Value	0.27	nd	0.26	0.75	nd	1.0	0.98	nd	0.75
95% CI of	0.072	nd	0.070	0.38	nd	0.33	0.28	nd	0.20
OR Quart 4	2.1	nd	2.0	3.8	nd	3.1	3.7	nd	3.2

Interferon alpha-2						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	13.4	13.5	13.4	8.40	13.4	16.4
Average	17.6	19.9	17.6	14.8	17.6	16.6
Stdev	24.2	25.8	24.2	23.0	24.2	10.9
p (t-test)		0.72		0.56		0.86
Min	0.0320	0.0627	0.0320	0.0627	0.0320	0.0627
Max	223	95.9	223	121	223	35.3
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
<u>UO only</u>						
Median	12.2	8.40	12.2	8.40	12.2	17.2
Average	16.8	19.1	16.8	16.5	16.8	17.7
Stdev	24.8	28.6	24.8	23.8	24.8	11.7
p (t-test)		0.75		0.95		0.89
Min	0.0320	0.0627	0.0320	0.0627	0.0320	0.0627
Max	223	95.9	223	121	223	35.3
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	nd	0.49	0.46	nd	0.50	0.56	nd	0.60
SE	0.075	nd	0.083	0.059	nd	0.058	0.075	nd	0.080
p	0.89	nd	0.87	0.45	nd	0.97	0.45	nd	0.21
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	4.47	nd	0.0764	4.03	nd	4.03	9.68	nd	9.68
Sens 1	75%	nd	85%	71%	nd	72%	71%	nd	73%
Spec 1	34%	nd	18%	31%	nd	34%	45%	nd	48%
Cutoff 2	0.0627	nd	0.0764	0.0627	nd	0.0764	5.98	nd	8.88
Sens 2	88%	nd	85%	86%	nd	86%	82%	nd	80%
Spec 2	16%	nd	18%	16%	nd	18%	38%	nd	46%
Cutoff 3	0.0324	nd	0.0324	0.0324	nd	0.0324	0.0627	nd	0.0764
Sens 3	100%	nd	100%	100%	nd	100%	94%	nd	93%
Spec 3	3%	nd	3%	3%	nd	3%	16%	nd	18%
Cutoff 4	23.2	nd	20.8	23.2	nd	20.8	23.2	nd	20.8
Sens 4	19%	nd	31%	14%	nd	28%	18%	nd	47%
Spec 4	71%	nd	71%	71%	nd	71%	71%	nd	71%
Cutoff 5	28.1	nd	27.4	28.1	nd	27.4	28.1	nd	27.4
Sens 5	19%	nd	15%	11%	nd	14%	18%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	38.0	nd	36.7	38.0	nd	36.7	38.0	nd	36.7
Sens 6	12%	nd	15%	4%	nd	7%	0%	nd	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.0	nd	1.5	1.9	nd	1.8	2.0	nd	1.5
p Value	1.0	nd	0.65	0.34	nd	0.29	0.42	nd	0.66
95% CI of	0.24	nd	0.25	0.52	nd	0.61	0.36	nd	0.24
OR Quart 2	4.2	nd	9.5	6.8	nd	5.4	12	nd	9.4
OR Quart 3	1.3	nd	2.7	2.8	nd	1.4	4.5	nd	3.3
p Value	0.73	nd	0.26	0.093	nd	0.57	0.065	nd	0.16
95% CI of	0.32	nd	0.49	0.84	nd	0.45	0.91	nd	0.63
OR Quart 3	5.0	nd	14	9.6	nd	4.3	22	nd	17
OR Quart 4	0.72	nd	1.5	1.9	nd	0.82	1.5	nd	2.0
p Value	0.68	nd	0.65	0.34	nd	0.75	0.66	nd	0.42
95% CI of	0.15	nd	0.25	0.52	nd	0.23	0.24	nd	0.36
OR Quart 4	3.4	nd	9.5	6.8	nd	2.8	9.3	nd	12

Insulin-like growth factor-binding protein 4

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	2.93	20.4	2.93	8.48	2.93	2.93
Average	12.2	19.6	12.2	15.8	12.2	10.9
Stdev	19.3	15.9	19.3	17.1	19.3	11.5
p (t-test)		0.15		0.34		0.75
Min	0.0728	2.43	0.0728	0.572	0.0728	0.572
Max	158	47.3	158	57.3	158	33.5
n (Samp)	278	15	278	28	278	20
n (Patient)	160	15	160	28	160	20
sCr only						
Median	nd	nd	nd	nd	2.93	13.3
Average	nd	nd	nd	nd	12.7	13.9
Stdev	nd	nd	nd	nd	18.5	13.3
p (t-test)	nd	nd	nd	nd		0.87
Min	nd	nd	nd	nd	0.0728	0.572
Max	nd	nd	nd	nd	158	26.9
n (Samp)	nd	nd	nd	nd	347	6
n (Patient)	nd	nd	nd	nd	193	6
UO only						
Median	2.93	21.7	2.93	8.48	2.93	2.93
Average	12.2	20.2	12.2	15.2	12.2	9.66
Stdev	19.5	14.3	19.5	16.1	19.5	11.1
p (t-test)		0.16		0.45		0.60
Min	0.0728	2.43	0.0728	0.572	0.0728	0.572
Max	158	47.3	158	57.3	158	33.5
n (Samp)	254	12	254	26	254	17
n (Patient)	140	12	140	26	140	17

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.68	nd	0.71	0.58	nd	0.57	0.54	0.54	0.51
SE	0.078	nd	0.086	0.059	nd	0.061	0.068	0.12	0.073
p	0.018	nd	0.015	0.19	nd	0.23	0.60	0.76	0.84
nCohort 1	278	nd	254	278	nd	254	278	347	254
nCohort 2	15	nd	12	28	nd	26	20	6	17
Cutoff 1	2.43	nd	10.7	0.971	nd	0.971	0.971	0.971	2.43
Sens 1	73%	nd	75%	79%	nd	77%	85%	83%	71%
Spec 1	41%	nd	61%	30%	nd	29%	30%	27%	39%
Cutoff 2	0.971	nd	0.971	0.572	nd	0.572	0.971	0.971	0.971
Sens 2	100%	nd	100%	89%	nd	88%	85%	83%	82%
Spec 2	30%	nd	29%	15%	nd	15%	30%	27%	29%
Cutoff 3	0.971	nd	0.971	0.0862	nd	0.0862	0.572	0.0862	0.0862
Sens 3	100%	nd	100%	100%	nd	100%	90%	100%	100%
Spec 3	30%	nd	29%	1%	nd	1%	15%	1%	1%
Cutoff 4	14.4	nd	14.4	14.4	nd	14.4	14.4	16.6	14.4
Sens 4	53%	nd	58%	46%	nd	46%	40%	50%	35%
Spec 4	71%	nd	71%	71%	nd	71%	71%	71%	71%
Cutoff 5	21.4	nd	20.4	21.4	nd	20.4	21.4	23.1	20.4
Sens 5	47%	nd	50%	32%	nd	38%	25%	50%	24%
Spec 5	81%	nd	80%	81%	nd	80%	81%	81%	80%
Cutoff 6	30.3	nd	28.1	30.3	nd	28.1	30.3	31.3	28.1
Sens 6	27%	nd	25%	18%	nd	23%	10%	0%	12%
Spec 6	90%	nd	91%	90%	nd	91%	90%	90%	91%
OR Quart 2	>5.4	nd	>3.1	1.2	nd	1.4	3.7	2.0	2.8
p Value	<0.13	nd	<0.33	0.77	nd	0.55	0.11	0.57	0.14
95% CI of	>0.61	nd	>0.31	0.35	nd	0.44	0.74	0.18	0.72
OR Quart 2	na	nd	na	4.1	nd	4.8	18	23	11
OR Quart 3	>2.1	nd	>2.1	1.2	nd	0.79	2.6	0	0.65
p Value	<0.56	nd	<0.56	0.75	nd	0.73	0.26	na	0.64
95% CI of	>0.18	nd	>0.18	0.36	nd	0.20	0.49	na	0.10
OR Quart 3	na	nd	na	4.2	nd	3.1	14	na	4.0
OR Quart 4	>8.8	nd	>7.7	2.4	nd	2.2	3.1	3.0	1.3
p Value	<0.042	nd	<0.060	0.13	nd	0.18	0.17	0.34	0.71
95% CI of	>1.1	nd	>0.92	0.78	nd	0.70	0.61	0.31	0.29
OR Quart 4	na	nd	na	7.2	nd	6.7	16	30	6.2

Insulin-like growth factor-binding protein 5						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	14.4	0.488	14.4	0.488	14.4	10.7
Average	37.5	22.2	37.5	30.1	37.5	27.4
Stdev	52.0	40.5	52.0	49.6	52.0	39.9
p (t-test)		0.26		0.47		0.40
Min	0.204	0.222	0.204	0.204	0.204	0.222
Max	257	151	257	177	257	149
n (Samp)	278	15	278	28	278	20
n (Patient)	160	15	160	28	160	20
sCr only						
Median	nd	nd	nd	nd	12.8	20.6
Average	nd	nd	nd	nd	34.3	50.2
Stdev	nd	nd	nd	nd	48.7	64.5
p (t-test)	nd	nd	nd	nd		0.43
Min	nd	nd	nd	nd	0.204	0.357
Max	nd	nd	nd	nd	257	149
n (Samp)	nd	nd	nd	nd	347	6
n (Patient)	nd	nd	nd	nd	193	6
UO only						
Median	8.54	1.20	8.54	0.488	8.54	0.488
Average	32.1	15.1	32.1	24.5	32.1	14.6
Stdev	49.2	21.2	49.2	38.7	49.2	19.0
p (t-test)		0.24		0.44		0.15
Min	0.204	0.222	0.204	0.204	0.204	0.222
Max	257	66.0	257	126	257	51.0
n (Samp)	254	12	254	26	254	17
n (Patient)	140	12	140	26	140	17

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	nd	0.44	0.43	nd	0.44	0.46	0.59	0.42
SE	0.079	nd	0.088	0.059	nd	0.061	0.068	0.12	0.075
p	0.27	nd	0.47	0.23	nd	0.35	0.51	0.46	0.29
nCohort 1	278	nd	254	278	nd	254	278	347	254
nCohort 2	15	nd	12	28	nd	26	20	6	17
Cutoff 1	0.316	nd	0.316	0.316	nd	0.222	0.316	0.357	0.222
Sens 1	80%	nd	83%	71%	nd	77%	75%	83%	82%
Spec 1	22%	nd	25%	22%	nd	18%	22%	28%	18%
Cutoff 2	0.316	nd	0.316	0.204	nd	0.204	0.222	0.357	0.222
Sens 2	80%	nd	83%	93%	nd	92%	85%	83%	82%
Spec 2	22%	nd	25%	5%	nd	6%	17%	28%	18%
Cutoff 3	0.204	nd	0.204	0.204	nd	0.204	0.204	0.316	0.204
Sens 3	100%	nd	100%	93%	nd	92%	100%	100%	100%
Spec 3	5%	nd	6%	5%	nd	6%	5%	23%	6%
Cutoff 4	43.8	nd	35.0	43.8	nd	35.0	43.8	40.2	35.0
Sens 4	13%	nd	8%	25%	nd	31%	20%	33%	24%
Spec 4	71%	nd	70%	71%	nd	70%	71%	70%	70%
Cutoff 5	64.4	nd	55.8	64.4	nd	55.8	64.4	61.6	55.8
Sens 5	13%	nd	8%	18%	nd	19%	10%	33%	0%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	125	nd	105	125	nd	105	125	105	105
Sens 6	7%	nd	0%	11%	nd	8%	5%	33%	0%
Spec 6	90%	nd	91%	90%	nd	91%	90%	90%	91%
OR Quart 2	2.1	nd	4.3	0.83	nd	0.65	2.1	>3.1	3.2
p Value	0.40	nd	0.20	0.77	nd	0.51	0.30	<0.33	0.16
95% CI of	0.37	nd	0.46	0.24	nd	0.17	0.51	>0.32	0.62
OR Quart 2	12	nd	39	2.9	nd	2.4	8.8	na	16
OR Quart 3	1.0	nd	5.3	1.0	nd	1.4	1.7	>1.0	1.5
p Value	0.99	nd	0.13	1.0	nd	0.57	0.47	<0.99	0.65
95% CI of	0.14	nd	0.60	0.31	nd	0.45	0.39	>0.062	0.25
OR Quart 3	7.4	nd	47	3.2	nd	4.2	7.4	na	9.4
OR Quart 4	3.8	nd	2.1	2.0	nd	1.4	2.1	>2.0	3.2
p Value	0.10	nd	0.56	0.19	nd	0.57	0.30	<0.57	0.16
95% CI of	0.77	nd	0.18	0.70	nd	0.45	0.51	>0.18	0.63
OR Quart 4	19	nd	23	5.7	nd	4.2	8.8	na	17

Immunoglobulin G4						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	414000	444000	414000	250000	414000	70300
Average	667000	519000	667000	415000	667000	205000
Stdev	807000	481000	807000	406000	807000	245000
p (t-test)		0.59		0.17		0.11
Min	2000	30100	2000	4650	2000	18500
Max	5190000	1210000	5190000	1350000	5190000	681000
n (Samp)	205	9	205	20	205	8
n (Patient)	127	9	127	20	127	8
UO only						
Median	412000	444000	412000	250000	412000	90700
Average	642000	519000	642000	442000	642000	227000
Stdev	750000	481000	750000	418000	750000	255000
p (t-test)		0.63		0.27		0.15
Min	2000	30100	2000	4650	2000	18500
Max	5140000	1210000	5140000	1350000	5140000	681000
n (Samp)	191	9	191	18	191	7
n (Patient)	113	9	113	18	113	7

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	nd	0.47	0.39	nd	0.42	0.24	nd	0.27
SE	0.10	nd	0.10	0.070	nd	0.073	0.10	nd	0.11
p	0.71	nd	0.73	0.12	nd	0.26	0.0093	nd	0.034
nCohort 1	205	nd	191	205	nd	191	205	nd	191
nCohort 2	9	nd	9	20	nd	18	8	nd	7
Cutoff 1	83300	nd	83300	206000	nd	206000	37500	nd	37500

-continued

Sens 1	78%	nd	78%	70%	nd	72%	75%	nd	71%
Spec 1	14%	nd	14%	25%	nd	27%	6%	nd	6%
Cutoff 2	51700	nd	51700	59500	nd	59500	33600	nd	33600
Sens 2	89%	nd	89%	80%	nd	83%	88%	nd	86%
Spec 2	7%	nd	7%	10%	nd	10%	5%	nd	5%
Cutoff 3	29400	nd	29400	52400	nd	8490	17900	nd	17900
Sens 3	100%	nd	100%	90%	nd	94%	100%	nd	100%
Spec 3	4%	nd	5%	7%	nd	2%	3%	nd	3%
Cutoff 4	731000	nd	731000	731000	nd	731000	731000	nd	731000
Sens 4	33%	nd	33%	15%	nd	17%	0%	nd	0%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	935000	nd	935000	935000	nd	935000	935000	nd	935000
Sens 5	33%	nd	33%	15%	nd	17%	0%	nd	0%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	1490000	nd	1380000	1490000	nd	1380000	1490000	nd	1380000
Sens 6	0%	nd	0%	0%	nd	0%	0%	nd	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.67	nd	0.65	1.4	nd	1.4	>2.1	nd	>2.1
p Value	0.66	nd	0.65	0.68	nd	0.68	<0.55	nd	<0.54
95% CI of	0.11	nd	0.10	0.30	nd	0.30	>0.19	nd	>0.19
OR Quart 2	4.2	nd	4.1	6.5	nd	6.5	na	nd	na
OR Quart 3	0	nd	0	2.6	nd	2.2	>1.0	nd	>1.0
p Value	na	nd	na	0.19	nd	0.29	<0.98	nd	<0.99
95% CI of	na	nd	na	0.63	nd	0.51	>0.063	nd	>0.062
OR Quart 3	na	nd	na	10	nd	9.2	na	nd	na
OR Quart 4	1.4	nd	1.4	2.2	nd	1.8	>5.6	nd	>4.4
p Value	0.68	nd	0.70	0.29	nd	0.45	<0.12	nd	<0.19
95% CI of	0.30	nd	0.29	0.51	nd	0.40	>0.63	nd	>0.48
OR Quart 4	6.5	nd	6.4	9.1	nd	7.8	na	nd	na

Interleukin-21

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.430	0.784	0.430	0.630	0.430	1.63
Average	28.3	2.46	28.3	2.05	28.3	11.1
Stdev	369	3.78	369	3.54	369	31.5
p (t-test)		0.78		0.71		0.85
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	12.6	5430	15.6	5430	132
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
<u>UO only</u>						
Median	0.430	0.605	0.430	0.630	0.430	0.964
Average	30.7	1.70	30.7	1.61	30.7	11.4
Stdev	385	2.93	385	2.31	385	33.6
p (t-test)		0.79		0.68		0.85
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	9.84	5430	8.04	5430	132
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.46	0.50	nd	0.50	0.62	nd	0.58
SE	0.076	nd	0.084	0.058	nd	0.058	0.075	nd	0.080
p	0.67	nd	0.67	0.97	nd	0.94	0.11	nd	0.33
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.0182	nd	0.0154	0.0257	nd	0.0257	0.783	nd	0.174
Sens 1	75%	nd	85%	71%	nd	72%	71%	nd	80%
Spec 1	26%	nd	18%	35%	nd	36%	55%	nd	40%
Cutoff 2	0.0154	nd	0.0154	0.0154	nd	0.0154	0.174	nd	0.174
Sens 2	88%	nd	85%	82%	nd	83%	82%	nd	80%
Spec 2	18%	nd	18%	18%	nd	18%	40%	nd	40%
Cutoff 3	0	nd	0	0.0102	nd	0.0102	0	nd	0
Sens 3	100%	nd	100%	93%	nd	93%	100%	nd	100%
Spec 3	0%	nd	0%	7%	nd	6%	0%	nd	0%
Cutoff 4	1.89	nd	1.89	1.89	nd	1.89	1.89	nd	1.89
Sens 4	38%	nd	23%	29%	nd	31%	29%	nd	27%

-continued

Spec 4	72%	nd	72%	72%	nd	72%	72%	nd	72%
Cutoff 5	2.75	nd	2.81	2.75	nd	2.81	2.75	nd	2.81
Sens 5	19%	nd	15%	21%	nd	17%	29%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	6.18	nd	7.58	6.18	nd	7.58	6.18	nd	7.58
Sens 6	12%	nd	8%	11%	nd	7%	29%	nd	27%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.48	nd	1.4	1.2	nd	0.69	0.32	nd	0.64
p Value	0.41	nd	0.70	0.77	nd	0.54	0.32	nd	0.63
95% CI of	0.085	nd	0.29	0.38	nd	0.20	0.032	nd	0.10
OR Quart 2	2.7	nd	6.4	3.8	nd	2.3	3.1	nd	4.0
OR Quart 3	1.3	nd	0.65	1.4	nd	1.7	2.9	nd	2.1
p Value	0.73	nd	0.65	0.57	nd	0.31	0.13	nd	0.30
95% CI of	0.32	nd	0.10	0.45	nd	0.61	0.74	nd	0.50
OR Quart 3	5.0	nd	4.1	4.3	nd	4.8	12	nd	9.0
OR Quart 4	1.2	nd	1.4	1.2	nd	0.84	1.7	nd	1.3
p Value	0.75	nd	0.70	0.79	nd	0.77	0.48	nd	0.72
95% CI of	0.32	nd	0.29	0.37	nd	0.26	0.39	nd	0.28
OR Quart 4	4.9	nd	6.4	3.7	nd	2.7	7.5	nd	6.3

Interleukin-23

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.886	1.10	0.886	1.10	0.886	1.10
Average	1270	8060	1270	5040	1270	13400
Stdev	7660	25000	7660	19200	7660	33000
p (t-test)		0.0080		0.053		3.5E-5
Min	0.257	0.653	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	100000
n (Samp)	216	16	216	28	216	17
n (Patient)	132	16	132	28	132	17
<u>UO only</u>						
Median	0.886	1.10	0.886	1.10	0.886	72.6
Average	1350	8370	1350	4290	1350	13800
Stdev	7990	27600	7990	18500	7990	35000
p (t-test)		0.017		0.14		1.2E-4
Min	0.257	0.653	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	100000
n (Samp)	198	13	198	29	198	15
n (Patient)	117	13	117	29	117	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	nd	0.60	0.54	nd	0.52	0.62	nd	0.63
SE	0.077	nd	0.085	0.059	nd	0.058	0.075	nd	0.080
p	0.082	nd	0.24	0.51	nd	0.77	0.12	nd	0.097
nCohort 1	216	nd	198	216	nd	198	216	nd	198
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.770	nd	0.603	0.603	nd	0.603	0.770	nd	0.770
Sens 1	75%	nd	100%	75%	nd	72%	71%	nd	73%
Spec 1	41%	nd	23%	25%	nd	23%	41%	nd	41%
Cutoff 2	0.603	nd	0.603	0	nd	0	0.603	nd	0.603
Sens 2	100%	nd	100%	100%	nd	100%	88%	nd	93%
Spec 2	25%	nd	23%	0%	nd	0%	25%	nd	23%
Cutoff 3	0.603	nd	0.603	0	nd	0	0.257	nd	0.603
Sens 3	100%	nd	100%	100%	nd	100%	100%	nd	93%
Spec 3	25%	nd	23%	0%	nd	0%	15%	nd	23%
Cutoff 4	1.10	nd	1.10	1.10	nd	1.10	1.10	nd	1.10
Sens 4	38%	nd	31%	43%	nd	41%	47%	nd	53%
Spec 4	71%	nd	70%	71%	nd	70%	71%	nd	70%
Cutoff 5	179	nd	267	179	nd	267	179	nd	267
Sens 5	25%	nd	23%	32%	nd	24%	35%	nd	20%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	1040	nd	1040	1040	nd	1040	1040	nd	1040
Sens 6	25%	nd	23%	14%	nd	14%	24%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	>6.7	nd	>5.4	0.84	nd	0.71	1.5	nd	2.1
p Value	<0.083	nd	<0.13	0.77	nd	0.55	0.65	nd	0.41
95% CI of	>0.78	nd	>0.61	0.27	nd	0.23	0.25	nd	0.36

-continued

OR Quart 2	na	nd	na	2.7	nd	2.2	9.5	nd	12
OR Quart 3	>5.5	nd	>5.4	0.69	nd	0.58	2.6	nd	1.5
p Value	<0.13	nd	<0.13	0.54	nd	0.36	0.26	nd	0.65
95% CI of	>0.62	nd	>0.61	0.21	nd	0.18	0.49	nd	0.25
OR Quart 3	na	nd	na	2.3	nd	1.9	14	nd	9.5
OR Quart 4	>5.5	nd	>3.1	1.5	nd	1.3	3.8	nd	3.2
p Value	<0.13	nd	<0.33	0.43	nd	0.64	0.11	nd	0.17
95% CI of	>0.62	nd	>0.31	0.54	nd	0.46	0.75	nd	0.61
OR Quart 4	na	nd	na	4.3	nd	3.5	19	nd	17

Interleukin-28A									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	0.195	0.148		0.195	0.265		0.195	2.92	
Average	31.1	18.2		31.1	12.7		31.1	26.0	
Stdev	255	61.1		255	45.7		255	58.2	
p (t-test)		0.84			0.70			0.93	
Min	0.0727	0.0727		0.0727	0.0727		0.0727	0.0727	
Max	3150	246		3150	243		3150	235	
n (Samp)	216	16		216	28		216	17	
n (Patient)	132	16		132	28		132	17	
<u>UO only</u>									
Median	0.195	0.148		0.195	0.265		0.195	0.195	
Average	32.4	2.50		32.4	4.50		32.4	12.9	
Stdev	266	5.90		266	8.06		266	23.4	
p (t-test)		0.69			0.57			0.78	
Min	0.0727	0.0727		0.0727	0.0727		0.0727	0.0727	
Max	3150	20.8		3150	35.6		3150	71.6	
n (Samp)	198	13		198	29		198	15	
n (Patient)	117	13		117	29		117	15	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.43	nd	0.35	0.54	nd	0.58	0.60	nd	0.57
SE	0.077	nd	0.085	0.059	nd	0.059	0.075	nd	0.080
p	0.34	nd	0.081	0.45	nd	0.17	0.16	nd	0.35
nCohort 1	216	nd	198	216	nd	198	216	nd	198
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0	nd	0	0.158	nd	0.158	0.158	nd	0.158
Sens 1	100%	nd	100%	71%	nd	72%	76%	nd	73%
Spec 1	0%	nd	0%	38%	nd	41%	38%	nd	41%
Cutoff 2	0	nd	0	0.120	nd	0.120	0.120	nd	0.120
Sens 2	100%	nd	100%	86%	nd	86%	82%	nd	80%
Spec 2	0%	nd	0%	17%	nd	19%	17%	nd	19%
Cutoff 3	0	nd	0	0	nd	0	0	nd	0
Sens 3	100%	nd	100%	100%	nd	100%	100%	nd	100%
Spec 3	0%	nd	0%	0%	nd	0%	0%	nd	0%
Cutoff 4	0.265	nd	0.265	0.265	nd	0.265	0.265	nd	0.265
Sens 4	38%	nd	23%	32%	nd	34%	53%	nd	40%
Spec 4	71%	nd	75%	71%	nd	75%	71%	nd	75%
Cutoff 5	10.2	nd	5.01	10.2	nd	5.01	10.2	nd	5.01
Sens 5	19%	nd	15%	21%	nd	31%	41%	nd	33%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	21.9	nd	20.8	21.9	nd	20.8	21.9	nd	20.8
Sens 6	6%	nd	0%	7%	nd	3%	24%	nd	20%
Spec 6	91%	nd	90%	91%	nd	90%	91%	nd	90%
OR Quart 2	0.48	nd	0	2.2	nd	1.8	0.74	nd	1.7
p Value	0.41	nd	na	0.23	nd	0.36	0.70	nd	0.47
95% CI of	0.085	nd	na	0.61	nd	0.50	0.16	nd	0.39
OR Quart 2	2.7	nd	na	7.6	nd	6.6	3.4	nd	7.7
OR Quart 3	1.3	nd	1.7	1.8	nd	2.4	0.74	nd	0.32
p Value	0.73	nd	0.47	0.35	nd	0.16	0.70	nd	0.33
95% CI of	0.32	nd	0.39	0.51	nd	0.70	0.16	nd	0.032
OR Quart 3	5.0	nd	7.7	6.7	nd	8.4	3.4	nd	3.2
OR Quart 4	1.3	nd	1.8	2.5	nd	2.4	1.8	nd	2.1
p Value	0.73	nd	0.45	0.15	nd	0.16	0.36	nd	0.32
95% CI of	0.32	nd	0.40	0.72	nd	0.70	0.50	nd	0.49
OR Quart 4	5.0	nd	7.8	8.5	nd	8.4	6.6	nd	8.8

-continued

Interleukin-33						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.0981	0.0981	0.0981	0.0981	0.0981	2.20
Average	244	336	244	222	244	1080
Stdev	2720	1030	2720	849	2720	3330
p (t-test)		0.89		0.97		0.23
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4130	40000	4440	40000	13500
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
UO only						
Median	0.0981	0.0981	0.0981	0.0981	0.0981	2.20
Average	264	351	264	196	264	1160
Stdev	2850	1140	2850	828	2850	3540
p (t-test)		0.91		0.90		0.25
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4130	40000	4440	40000	13500
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.52	0.51	nd	0.52	0.64	nd	0.66
SE	0.076	nd	0.084	0.058	nd	0.058	0.075	nd	0.079
p	0.72	nd	0.81	0.82	nd	0.79	0.053	nd	0.042
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.0494	nd	0.0494	0.0494	nd	0.0494	0.0996	nd	0.0996
Sens 1	88%	nd	92%	71%	nd	72%	71%	nd	73%
Spec 1	23%	nd	21%	23%	nd	21%	57%	nd	58%
Cutoff 2	0.0494	nd	0.0494	0.0445	nd	0.0445	0.0494	nd	0.0846
Sens 2	88%	nd	92%	93%	nd	93%	88%	nd	80%
Spec 2	23%	nd	21%	10%	nd	9%	23%	nd	39%
Cutoff 3	0	nd	0.0494	0.0445	nd	0.0445	0	nd	0.0494
Sens 3	100%	nd	92%	93%	nd	93%	100%	nd	93%
Spec 3	0%	nd	21%	10%	nd	9%	0%	nd	21%
Cutoff 4	0.821	nd	0.101	0.821	nd	0.101	0.821	nd	0.101
Sens 4	31%	nd	31%	39%	nd	41%	59%	nd	60%
Spec 4	71%	nd	70%	71%	nd	70%	71%	nd	70%
Cutoff 5	10.4	nd	13.1	10.4	nd	13.1	10.4	nd	13.1
Sens 5	25%	nd	23%	25%	nd	24%	35%	nd	33%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	58.1	nd	58.1	58.1	nd	58.1	58.1	nd	58.1
Sens 6	25%	nd	23%	14%	nd	14%	24%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	4.5	nd	7.9	0.86	nd	0.86	1.5	nd	0.48
p Value	0.065	nd	0.057	0.78	nd	0.78	0.66	nd	0.56
95% CI of	0.91	nd	0.94	0.29	nd	0.29	0.24	nd	0.042
OR Quart 2	22	nd	67	2.5	nd	2.5	9.3	nd	5.5
OR Quart 3	0.49	nd	2.0	0.59	nd	0.72	2.6	nd	3.9
p Value	0.57	nd	0.57	0.38	nd	0.57	0.26	nd	0.10
95% CI of	0.043	nd	0.18	0.18	nd	0.23	0.49	nd	0.77
OR Quart 3	5.6	nd	23	1.9	nd	2.2	14	nd	20
OR Quart 4	2.6	nd	3.1	0.98	nd	1.0	3.8	nd	2.6
p Value	0.27	nd	0.33	0.97	nd	1.0	0.11	nd	0.27
95% CI of	0.48	nd	0.31	0.34	nd	0.35	0.75	nd	0.48
OR Quart 4	14	nd	31	2.8	nd	2.9	19	nd	14

Interleukin-4 receptor alpha chain						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	218	269	218	218	218	228
Average	288	396	288	297	288	332

-continued

Stdev	210	321	210	271	210	233
p (t-test)		0.057		0.83		0.40
Min	49.7	111	49.7	3.27	49.7	103
Max	1200	1090	1200	1210	1200	997
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
UO only						
Median	229	298	229	191	229	228
Average	297	442	297	286	297	341
Stdev	215	336	215	268	215	247
p (t-test)		0.024		0.82		0.45
Min	49.7	138	49.7	3.27	49.7	84.5
Max	1200	1090	1200	1210	1200	997
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	nd	0.64	0.48	nd	0.44	0.56	nd	0.54
SE	0.077	nd	0.085	0.059	nd	0.059	0.075	nd	0.079
p	0.26	nd	0.11	0.72	nd	0.32	0.44	nd	0.58
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	195	nd	204	148	nd	142	178	nd	170
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	43%	nd	42%	23%	nd	19%	35%	nd	30%
Cutoff 2	153	nd	195	104	nd	104	165	nd	165
Sens 2	81%	nd	85%	89%	nd	93%	82%	nd	80%
Spec 2	25%	nd	40%	6%	nd	6%	30%	nd	29%
Cutoff 3	111	nd	153	83.5	nd	104	121	nd	121
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	6%	nd	24%	3%	nd	6%	9%	nd	8%
Cutoff 4	299	nd	317	299	nd	317	299	nd	317
Sens 4	44%	nd	46%	39%	nd	28%	47%	nd	47%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	380	nd	400	380	nd	400	380	nd	400
Sens 5	31%	nd	38%	18%	nd	17%	35%	nd	33%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	529	nd	560	529	nd	560	529	nd	560
Sens 6	25%	nd	23%	11%	nd	10%	18%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.4	nd	1.5	0.74	nd	0.54	1.7	nd	1.7
p Value	0.70	nd	0.65	0.59	nd	0.35	0.48	nd	0.48
95% CI of	0.29	nd	0.25	0.24	nd	0.15	0.39	nd	0.39
OR Quart 2	6.4	nd	9.5	2.3	nd	2.0	7.5	nd	7.5
OR Quart 3	1.0	nd	1.5	0.60	nd	1.2	1.0	nd	0.32
p Value	1.0	nd	0.65	0.40	nd	0.78	1.0	nd	0.33
95% CI of	0.19	nd	0.25	0.19	nd	0.39	0.19	nd	0.032
OR Quart 3	5.2	nd	9.5	2.0	nd	3.5	5.2	nd	3.2
OR Quart 4	2.1	nd	2.7	1.2	nd	1.5	2.1	nd	2.1
p Value	0.32	nd	0.26	0.77	nd	0.43	0.32	nd	0.32
95% CI of	0.49	nd	0.49	0.42	nd	0.53	0.49	nd	0.49
OR Quart 4	8.7	nd	14	3.3	nd	4.3	8.7	nd	8.8

Vascular endothelial growth factor receptor 2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	7910	9090	7910	7270	7910	7250
Average	9670	9560	9670	8430	9670	17800
Stdev	11000	4770	11000	3820	11000	38600
p (t-test)		0.97		0.55		0.028
Min	3640	3140	3640	4110	3640	3340
Max	153000	18000	153000	19800	153000	166000
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
UO only						
Median	7930	9140	7930	7590	7930	7250
Average	9820	9510	9820	8350	9820	19000

-continued

	11400	4780	11400	3590	11400	41100
Stdev						
p (t-test)		0.92		0.49		0.025
Min	3640	3140	3640	4110	3640	4480
Max	153000	18000	153000	19800	153000	166000
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.54	0.45	nd	0.45	0.45	nd	0.44
SE	0.076	nd	0.084	0.059	nd	0.059	0.075	nd	0.079
p	0.71	nd	0.67	0.38	nd	0.41	0.47	nd	0.46
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	5760	nd	5620	5720	nd	5720	6010	nd	6010
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	15%	nd	14%	15%	nd	15%	18%	nd	18%
Cutoff 2	5620	nd	5310	5610	nd	5610	5140	nd	5880
Sens 2	81%	nd	85%	82%	nd	83%	82%	nd	80%
Spec 2	14%	nd	9%	14%	nd	14%	8%	nd	16%
Cutoff 3	4780	nd	4730	5140	nd	5140	4330	nd	5030
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	6%	nd	5%	8%	nd	7%	4%	nd	6%
Cutoff 4	9260	nd	9260	9260	nd	9260	9260	nd	9260
Sens 4	44%	nd	46%	25%	nd	24%	29%	nd	27%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	10300	nd	10500	10300	nd	10500	10300	nd	10500
Sens 5	25%	nd	23%	21%	nd	21%	29%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	14000	nd	14400	14000	nd	14400	14000	nd	14400
Sens 6	25%	nd	23%	14%	nd	7%	18%	nd	13%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.15	nd	0	1.2	nd	1.2	0.19	nd	0.24
p Value	0.086	nd	na	0.75	nd	0.77	0.13	nd	0.21
95% CI of	0.018	nd	na	0.38	nd	0.37	0.021	nd	0.026
OR Quart 2	1.3	nd	na	3.8	nd	3.8	1.7	nd	2.2
OR Quart 3	0.64	nd	0.78	0.48	nd	0.82	0.79	nd	1.0
p Value	0.51	nd	0.73	0.32	nd	0.75	0.73	nd	1.0
95% CI of	0.17	nd	0.20	0.12	nd	0.23	0.20	nd	0.24
OR Quart 3	2.4	nd	3.1	2.0	nd	2.8	3.1	nd	4.2
OR Quart 4	0.80	nd	0.78	2.3	nd	2.0	1.5	nd	1.6
p Value	0.73	nd	0.73	0.12	nd	0.19	0.52	nd	0.49
95% CI of	0.23	nd	0.20	0.80	nd	0.70	0.44	nd	0.42
OR Quart 4	2.8	nd	3.1	6.5	nd	5.9	5.0	nd	6.0

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	185000	178000	185000	185000	185000	165000
Average	192000	187000	192000	195000	192000	164000
Stdev	67100	63200	67100	86900	67100	55500
p (t-test)		0.77		0.84		0.067
Min	63300	93200	63300	81100	63300	49200
Max	520000	316000	520000	506000	520000	280000
n (Samp)	281	16	281	28	281	20
n (Patient)	159	16	159	28	159	20
<u>sCr only</u>						
Median	nd	nd	nd	nd	181000	181000
Average	nd	nd	nd	nd	187000	203000
Stdev	nd	nd	nd	nd	65700	57300
p (t-test)	nd	nd	nd	nd		0.55
Min	nd	nd	nd	nd	49200	140000
Max	nd	nd	nd	nd	520000	280000
n (Samp)	nd	nd	nd	nd	352	6
n (Patient)	nd	nd	nd	nd	192	6
<u>UO only</u>						
Median	184000	172000	184000	177000	184000	156000
Average	191000	168000	191000	173000	191000	155000

-continued

Stdev	69000	51800	69000	56900	69000	47600
p (t-test)		0.24		0.20		0.032
Min	63300	93200	63300	81100	63300	49200
Max	520000	282000	520000	331000	520000	230000
n (Samp)	257	13	257	26	257	17
n (Patient)	139	13	139	26	139	17

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.40	0.48	nd	0.42	0.37	0.58	0.35
SE	0.075	nd	0.085	0.058	nd	0.061	0.069	0.12	0.074
p	0.84	nd	0.24	0.73	nd	0.21	0.069	0.54	0.037
nCohort 1	281	nd	257	281	nd	257	281	352	257
nCohort 2	16	nd	13	28	nd	26	20	6	17
Cutoff 1	152000	nd	133000	158000	nd	130000	144000	166000	144000
Sens 1	75%	nd	77%	71%	nd	73%	70%	83%	71%
Spec 1	29%	nd	19%	31%	nd	18%	23%	40%	25%
Cutoff 2	133000	nd	121000	125000	nd	121000	121000	166000	107000
Sens 2	81%	nd	85%	82%	nd	81%	80%	83%	82%
Spec 2	18%	nd	13%	12%	nd	13%	11%	40%	8%
Cutoff 3	95600	nd	95600	105000	nd	105000	106000	140000	91800
Sens 3	94%	nd	92%	93%	nd	92%	90%	100%	94%
Spec 3	4%	nd	4%	6%	nd	7%	7%	23%	3%
Cutoff 4	214000	nd	215000	214000	nd	215000	214000	207000	215000
Sens 4	25%	nd	8%	29%	nd	19%	15%	33%	12%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	233000	nd	234000	233000	nd	234000	233000	228000	234000
Sens 5	19%	nd	8%	14%	nd	12%	10%	33%	0%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	266000	nd	266000	266000	nd	266000	266000	262000	266000
Sens 6	12%	nd	8%	11%	nd	4%	10%	33%	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	0.75	nd	3.1	1.0	nd	1.8	1.0	2.0	1.5
p Value	0.71	nd	0.33	0.98	nd	0.35	0.99	0.57	0.64
95% CI of	0.16	nd	0.32	0.34	nd	0.51	0.20	0.18	0.25
OR Quart 2	3.5	nd	31	3.0	nd	6.6	5.2	22	9.6
OR Quart 3	1.3	nd	5.3	0.86	nd	1.5	2.5	1.0	3.8
p Value	0.72	nd	0.13	0.79	nd	0.51	0.20	1.0	0.11
95% CI of	0.33	nd	0.60	0.27	nd	0.42	0.62	0.062	0.76
OR Quart 3	5.0	nd	47	2.7	nd	5.7	10	16	19
OR Quart 4	1.0	nd	4.3	1.2	nd	2.5	2.5	2.0	2.7
p Value	0.98	nd	0.20	0.77	nd	0.15	0.20	0.57	0.25
95% CI of	0.24	nd	0.46	0.40	nd	0.72	0.62	0.18	0.50
OR Quart 4	4.2	nd	39	3.4	nd	8.4	10	22	14

Platelet-derived growth factor subunit B (dimer)						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	357	228	357	346	357	448
Average	410	280	410	523	410	398
Stdev	246	155	246	668	246	234
p (t-test)		0.039		0.067		0.84
Min	28.1	33.7	28.1	74.0	28.1	45.0
Max	1540	601	1540	2720	1540	750
n (Samp)	274	16	274	27	274	19
n (Patient)	158	16	158	27	158	19
<u>sCr only</u>						
Median	nd	nd	nd	nd	342	357
Average	nd	nd	nd	nd	391	385
Stdev	nd	nd	nd	nd	245	160
p (t-test)	nd	nd	nd	nd		0.95
Min	nd	nd	nd	nd	0.189	220
Max	nd	nd	nd	nd	1540	609
n (Samp)	nd	nd	nd	nd	341	6
n (Patient)	nd	nd	nd	nd	188	6
<u>UO only</u>						
Median	334	224	334	346	334	352
Average	389	283	389	456	389	385

-continued

Stdev	238	171	238	532	238	247
p (t-test)		0.12		0.25		0.95
Min	28.1	33.7	28.1	74.0	28.1	45.0
Max	1540	601	1540	2720	1540	750
n (Samp)	250	13	250	25	250	16
n (Patient)	138	13	138	25	138	16

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.34	nd	0.36	0.46	nd	0.47	0.50	0.52	0.49
SE	0.076	nd	0.085	0.059	nd	0.061	0.069	0.12	0.075
p	0.030	nd	0.11	0.50	nd	0.67	0.95	0.86	0.94
nCohort 1	274	nd	250	274	nd	250	274	341	250
nCohort 2	16	nd	13	27	nd	25	19	6	16
Cutoff 1	192	nd	171	220	nd	220	242	247	229
Sens 1	75%	nd	77%	70%	nd	72%	74%	83%	75%
Spec 1	19%	nd	18%	23%	nd	26%	26%	31%	27%
Cutoff 2	171	nd	165	155	nd	155	122	247	122
Sens 2	81%	nd	85%	81%	nd	80%	84%	83%	81%
Spec 2	16%	nd	18%	15%	nd	16%	10%	31%	11%
Cutoff 3	138	nd	138	88.8	nd	88.8	88.8	220	88.8
Sens 3	94%	nd	92%	93%	nd	92%	95%	100%	94%
Spec 3	12%	nd	13%	5%	nd	5%	5%	27%	5%
Cutoff 4	504	nd	478	504	nd	478	504	496	478
Sens 4	12%	nd	23%	22%	nd	24%	42%	33%	44%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	613	nd	569	613	nd	569	613	583	569
Sens 5	0%	nd	8%	22%	nd	24%	16%	17%	25%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	728	nd	697	728	nd	697	728	704	697
Sens 6	0%	nd	0%	19%	nd	20%	11%	0%	19%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	4.2	nd	1.0	1.2	nd	1.2	1.0	>3.1	0.59
p Value	0.20	nd	1.0	0.75	nd	0.77	0.98	<0.34	0.48
95% CI of	0.46	nd	0.14	0.38	nd	0.38	0.28	>0.31	0.14
OR Quart 2	39	nd	7.3	3.8	nd	3.7	3.7	na	2.6
OR Quart 3	3.1	nd	1.5	0.83	nd	0.82	0.80	>2.0	0.79
p Value	0.33	nd	0.65	0.77	nd	0.75	0.75	<0.57	0.73
95% CI of	0.31	nd	0.25	0.24	nd	0.24	0.21	>0.18	0.20
OR Quart 3	30	nd	9.4	2.9	nd	2.8	3.1	na	3.1
OR Quart 4	9.0	nd	3.3	1.6	nd	1.2	1.0	>1.0	0.80
p Value	0.041	nd	0.16	0.40	nd	0.75	0.98	<1.0	0.75
95% CI of	1.1	nd	0.63	0.54	nd	0.38	0.28	>0.062	0.21
OR Quart 4	74	nd	17	4.7	nd	3.8	3.7	na	3.1

Corticotropin						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.000668	0.00344	0.000668	0.00402	0.000668	0.00254
Average	0.00568	0.00650	0.00568	0.00599	0.00568	0.00960
Stdev	0.0263	0.00561	0.0263	0.00669	0.0263	0.0224
p (t-test)		0.93		0.96		0.56
Min	3.38E-6	6.17E-6	3.38E-6	3.38E-6	3.38E-6	3.38E-6
Max	0.292	0.0140	0.292	0.0251	0.292	0.0908
n (Samp)	197	7	197	20	197	16
n (Patient)	131	7	131	20	131	16
<u>UO only</u>						
Median	nd	nd	0.000881	0.00389	0.000881	0.00297
Average	nd	nd	0.00636	0.00721	0.00636	0.0115
Stdev	nd	nd	0.0280	0.00813	0.0280	0.0246
p (t-test)	nd	nd		0.90		0.52
Min	nd	nd	3.38E-6	3.38E-6	3.38E-6	3.38E-6
Max	nd	nd	0.292	0.0251	0.292	0.0908
n (Samp)	nd	nd	173	18	173	13
n (Patient)	nd	nd	111	18	111	13

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	nd	nd	0.67	nd	0.67	0.56	nd	0.63
SE	0.11	nd	nd	0.069	nd	0.072	0.077	nd	0.086
p	0.026	nd	nd	0.016	nd	0.016	0.46	nd	0.12
nCohort 1	197	nd	nd	197	nd	173	197	nd	173
nCohort 2	7	nd	nd	20	nd	18	16	nd	13
Cutoff 1	0.00317	nd	nd	0.000466	nd	0.000293	4.31E-6	nd	0.00192
Sens 1	71%	nd	nd	70%	nd	72%	75%	nd	77%
Spec 1	76%	nd	nd	45%	nd	42%	16%	nd	64%
Cutoff 2	0.00183	nd	nd	0.000278	nd	0.000278	3.38E-6	nd	4.31E-6
Sens 2	86%	nd	nd	85%	nd	89%	88%	nd	85%
Spec 2	66%	nd	nd	41%	nd	39%	5%	nd	16%
Cutoff 3	4.31E-6	nd	nd	4.31E-6	nd	4.31E-6	0	nd	3.38E-6
Sens 3	100%	nd	nd	90%	nd	94%	100%	nd	92%
Spec 3	16%	nd	nd	16%	nd	16%	0%	nd	5%
Cutoff 4	0.00221	nd	nd	0.00221	nd	0.00297	0.00221	nd	0.00297
Sens 4	71%	nd	nd	60%	nd	61%	56%	nd	46%
Spec 4	70%	nd	nd	70%	nd	72%	70%	nd	72%
Cutoff 5	0.00423	nd	nd	0.00423	nd	0.00486	0.00423	nd	0.00486
Sens 5	43%	nd	nd	50%	nd	44%	31%	nd	31%
Spec 5	80%	nd	nd	80%	nd	80%	80%	nd	80%
Cutoff 6	0.00829	nd	nd	0.00829	nd	0.00914	0.00829	nd	0.00914
Sens 6	43%	nd	nd	35%	nd	33%	19%	nd	23%
Spec 6	90%	nd	nd	90%	nd	90%	90%	nd	90%
OR Quart 2	0	nd	nd	1.4	nd	2.0	0	nd	0
p Value	na	nd	nd	0.70	nd	0.42	na	nd	na
95% CI of	na	nd	nd	0.29	nd	0.36	na	nd	na
OR Quart 2	na	nd	nd	6.4	nd	12	na	nd	na
OR Quart 3	2.0	nd	nd	0.65	nd	1.5	0.64	nd	1.7
p Value	0.57	nd	nd	0.65	nd	0.67	0.51	nd	0.46
95% CI of	0.18	nd	nd	0.10	nd	0.24	0.17	nd	0.39
OR Quart 3	23	nd	nd	4.1	nd	9.4	2.4	nd	7.8
OR Quart 4	4.3	nd	nd	4.2	nd	5.2	0.98	nd	1.7
p Value	0.20	nd	nd	0.034	nd	0.042	0.97	nd	0.48
95% CI of	0.46	nd	nd	1.1	nd	1.1	0.29	nd	0.38
OR Quart 4	39	nd	nd	16	nd	25	3.3	nd	7.6

Thyroxine-binding globulin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	36.9	34.2	36.9	29.8	36.9	30.0
Average	37.8	35.8	37.8	33.3	37.8	35.1
Stdev	10.8	10.4	10.8	12.0	10.8	12.8
p (t-test)		0.36		0.026		0.31
Min	12.8	15.2	12.8	14.2	12.8	16.3
Max	75.8	57.7	75.8	63.7	75.8	62.0
n (Samp)	437	26	437	32	437	17
n (Patient)	174	26	174	32	174	17
<u>sCr only</u>						
Median	36.2	28.7	36.2	30.3	36.2	33.2
Average	37.0	31.4	37.0	33.8	37.0	34.0
Stdev	11.1	12.8	11.1	14.8	11.1	14.2
p (t-test)		0.22		0.42		0.47
Min	12.8	18.0	12.8	15.9	11.8	15.2
Max	75.8	56.0	75.8	63.7	75.8	62.0
n (Samp)	535	6	535	8	535	7
n (Patient)	207	6	207	8	207	7
<u>UO only</u>						
Median	35.6	32.5	35.6	28.5	35.6	30.0
Average	36.9	34.7	36.9	31.9	36.9	34.0
Stdev	10.6	9.63	10.6	10.5	10.6	12.5
p (t-test)		0.30		0.011		0.26
Min	12.8	15.2	12.8	14.2	12.8	16.3
Max	75.8	57.7	75.8	57.0	75.8	56.0
n (Samp)	363	26	363	31	363	17
n (Patient)	141	26	141	31	141	17

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.32	0.43	0.36	0.39	0.34	0.42	0.40	0.42
SE	0.060	0.12	0.060	0.054	0.11	0.055	0.074	0.11	0.074
p	0.28	0.15	0.24	0.013	0.29	0.0049	0.31	0.36	0.26
nCohort 1	437	535	363	437	535	363	437	535	363
nCohort 2	26	6	26	32	8	31	17	7	17
Cutoff 1	28.4	26.8	28.4	25.7	28.4	26.4	28.2	29.8	27.4
Sens 1	73%	83%	73%	72%	75%	71%	71%	71%	71%
Spec 1	19%	18%	21%	12%	24%	15%	19%	28%	16%
Cutoff 2	27.6	26.8	27.6	23.9	22.2	24.7	23.8	26.9	22.2
Sens 2	85%	83%	81%	81%	88%	81%	82%	86%	82%
Spec 2	17%	18%	18%	8%	8%	11%	8%	18%	6%
Cutoff 3	26.5	17.9	26.5	20.5	15.8	20.5	19.6	15.0	19.6
Sens 3	92%	100%	92%	91%	100%	90%	94%	100%	94%
Spec 3	14%	4%	15%	5%	3%	6%	4%	1%	4%
Cutoff 4	43.6	42.9	42.2	43.6	42.9	42.2	43.6	42.9	42.2
Sens 4	19%	17%	23%	19%	25%	16%	29%	14%	35%
Spec 4	70%	71%	71%	70%	71%	71%	70%	71%	71%
Cutoff 5	46.7	46.3	46.0	46.7	46.3	46.0	46.7	46.3	46.0
Sens 5	15%	17%	15%	12%	12%	10%	18%	14%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	50.4	50.1	49.7	50.4	50.1	49.7	50.4	50.1	49.7
Sens 6	12%	17%	8%	9%	12%	6%	12%	14%	18%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.79	0	1.3	1.0	0	1.5	0.75	1.0	0.39
p Value	0.73	na	0.72	0.99	na	0.51	0.71	1.00	0.26
95% CI of	0.21	na	0.33	0.32	na	0.42	0.16	0.062	0.073
OR Quart 2	3.0	na	4.9	3.2	na	5.7	3.4	16	2.0
OR Quart 3	1.6	2.0	2.1	0.66	1.0	1.3	1.0	3.0	0.39
p Value	0.40	0.57	0.24	0.53	1.0	0.73	1.0	0.34	0.26
95% CI of	0.52	0.18	0.61	0.18	0.14	0.33	0.24	0.31	0.073
OR Quart 3	5.2	23	7.3	2.4	7.2	4.9	4.1	30	2.0
OR Quart 4	1.9	3.1	2.4	3.0	2.0	4.6	1.5	2.0	1.7
p Value	0.27	0.33	0.16	0.029	0.41	0.0081	0.51	0.57	0.39
95% CI of	0.61	0.32	0.71	1.1	0.37	1.5	0.42	0.18	0.52
OR Quart 4	5.8	30	8.1	7.8	11	14	5.6	23	5.3

Tumor necrosis factor receptor superfamily member 8

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	101	105	101	98.7	101	69.9
Average	201	193	201	156	201	244
Stdev	415	178	415	144	415	637
p (t-test)		0.94		0.57		0.69
Min	12.8	53.7	12.8	12.8	12.8	4.06
Max	3360	611	3360	595	3360	2700
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17
<u>UO only</u>						
Median	101	105	101	104	101	67.7
Average	205	201	205	148	205	250
Stdev	431	189	431	137	431	680
p (t-test)		0.98		0.48		0.71
Min	12.8	53.7	12.8	12.8	12.8	4.06
Max	3360	611	3360	595	3360	2700
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	nd	0.58	0.49	nd	0.49	0.38	nd	0.34
SE	0.077	nd	0.085	0.058	nd	0.058	0.075	nd	0.079
p	0.39	nd	0.32	0.85	nd	0.89	0.12	nd	0.042
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	75.4	nd	75.4	65.4	nd	68.4	47.2	nd	47.2

-continued

Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	29%	nd	30%	24%	nd	26%	13%	nd	13%
Cutoff 2	74.6	nd	74.6	54.3	nd	54.3	37.8	nd	37.8
Sens 2	81%	nd	85%	86%	nd	86%	82%	nd	80%
Spec 2	29%	nd	29%	15%	nd	15%	9%	nd	10%
Cutoff 3	53.7	nd	64.9	36.7	nd	36.7	36.7	nd	36.7
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	15%	nd	23%	8%	nd	9%	8%	nd	9%
Cutoff 4	148	nd	148	148	nd	148	148	nd	148
Sens 4	38%	nd	38%	29%	nd	24%	24%	nd	20%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	192	nd	192	192	nd	192	192	nd	192
Sens 5	31%	nd	31%	29%	nd	24%	12%	nd	7%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	285	nd	285	285	nd	285	285	nd	285
Sens 6	19%	nd	15%	18%	nd	14%	12%	nd	7%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.4	nd	1.5	0.74	nd	1.2	1.0	nd	0.67
p Value	0.70	nd	0.65	0.59	nd	0.78	0.98	nd	0.66
95% CI of	0.29	nd	0.25	0.24	nd	0.39	0.20	nd	0.11
OR Quart 2	6.4	nd	9.5	2.3	nd	3.5	5.3	nd	4.2
OR Quart 3	1.4	nd	2.1	0.74	nd	0.84	1.4	nd	1.0
p Value	0.70	nd	0.41	0.59	nd	0.77	0.70	nd	1.0
95% CI of	0.29	nd	0.36	0.24	nd	0.26	0.29	nd	0.19
OR Quart 3	6.4	nd	12	2.3	nd	2.7	6.3	nd	5.2
OR Quart 4	1.7	nd	2.1	1.0	nd	1.2	2.6	nd	2.6
p Value	0.48	nd	0.41	0.97	nd	0.78	0.19	nd	0.19
95% CI of	0.39	nd	0.36	0.36	nd	0.39	0.63	nd	0.63
OR Quart 4	7.5	nd	12	2.9	nd	3.5	10	nd	11

Alpha-fetoprotein

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.321	0.00880	0.321	0.410	0.321	0.441			
Average	0.350	0.327	0.350	0.470	0.350	0.497			
Stdev	0.333	0.467	0.333	0.436	0.333	0.351			
p (t-test)		0.79		0.078		0.058			
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580			
Max	1.81	1.63	1.81	1.53	1.81	1.19			
n (Samp)	282	16	282	28	282	20			
n (Patient)	160	16	160	28	160	20			
sCr only									
Median	nd	nd	nd	nd	0.327	0.484			
Average	nd	nd	nd	nd	0.355	0.487			
Stdev	nd	nd	nd	nd	0.348	0.303			
p (t-test)	nd	nd	nd	nd		0.35			
Min	nd	nd	nd	nd	0.00580	0.00580			
Max	nd	nd	nd	nd	1.81	0.924			
n (Samp)	nd	nd	nd	nd	353	6			
n (Patient)	nd	nd	nd	nd	193	6			
UO only									
Median	0.321	0.00880	0.321	0.376	0.321	0.445			
Average	0.342	0.279	0.342	0.438	0.342	0.527			
Stdev	0.333	0.504	0.333	0.420	0.333	0.418			
p (t-test)		0.52		0.18		0.030			
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580			
Max	1.81	1.63	1.81	1.53	1.81	1.31			
n (Samp)	258	13	258	26	258	17			
n (Patient)	140	13	140	26	140	17			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.43	nd	0.38	0.58	nd	0.56	0.64	0.64	0.65
SE	0.076	nd	0.085	0.059	nd	0.061	0.069	0.12	0.074
p	0.38	nd	0.15	0.19	nd	0.31	0.035	0.26	0.050
nCohort 1	282	nd	258	282	nd	258	282	353	258
nCohort 2	16	nd	13	28	nd	26	20	6	17
Cutoff 1	0.00580	nd	0	0.0947	nd	0.00580	0.392	0.392	0.381

-continued

Sens 1	75%	nd	100%	71%	nd	85%	70%	83%	71%
Spec 1	16%	nd	0%	32%	nd	17%	62%	61%	59%
Cutoff 2	0	nd	0	0.00580	nd	0.00580	0.221	0.392	0.00580
Sens 2	100%	nd	100%	86%	nd	85%	80%	83%	94%
Spec 2	0%	nd	0%	16%	nd	17%	41%	61%	17%
Cutoff 3	0	nd	0	0	nd	0	0.00580	0	0.00580
Sens 3	100%	nd	100%	100%	nd	100%	95%	100%	94%
Spec 3	0%	nd	0%	0%	nd	0%	16%	0%	17%
Cutoff 4	0.496	nd	0.502	0.496	nd	0.502	0.496	0.509	0.502
Sens 4	31%	nd	23%	43%	nd	42%	45%	50%	47%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	0.581	nd	0.581	0.581	nd	0.581	0.581	0.607	0.581
Sens 5	25%	nd	23%	36%	nd	35%	35%	33%	41%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	0.767	nd	0.767	0.767	nd	0.767	0.767	0.803	0.767
Sens 6	12%	nd	15%	21%	nd	19%	20%	17%	24%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	0.75	nd	0.32	0.54	nd	1.8	4.1	0	4.1
p Value	0.71	nd	0.33	0.34	nd	0.35	0.21	na	0.21
95% CI of	0.16	nd	0.033	0.15	nd	0.51	0.45	na	0.45
OR Quart 2	3.5	nd	3.2	1.9	nd	6.6	38	na	38
OR Quart 3	0.74	nd	1.7	0.85	nd	1.5	7.6	3.0	5.2
p Value	0.70	nd	0.47	0.77	nd	0.51	0.061	0.34	0.14
95% CI of	0.16	nd	0.39	0.27	nd	0.42	0.91	0.31	0.60
OR Quart 3	3.4	nd	7.5	2.6	nd	5.7	64	30	46
OR Quart 4	1.6	nd	1.4	1.6	nd	2.4	8.7	2.0	7.6
p Value	0.50	nd	0.68	0.33	nd	0.16	0.044	0.57	0.062
95% CI of	0.42	nd	0.30	0.60	nd	0.71	1.1	0.18	0.90
OR Quart 4	5.8	nd	6.4	4.5	nd	8.3	71	22	63

Apolipoprotein E

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	51700	43400	51700	47500	51700	32700			
Average	63800	54300	63800	55300	63800	37200			
Stdev	46700	35100	46700	43000	46700	23500			
p (t-test)		0.30		0.31		0.014			
Min	4980	14500	4980	10500	4980	1940			
Max	260000	141000	260000	232000	260000	98400			
n (Samp)	325	27	325	34	325	19			
n (Patient)	192	27	192	34	192	19			
sCr only									
Median	nd	nd	51000	50300	nd	nd			
Average	nd	nd	61200	86900	nd	nd			
Stdev	nd	nd	44000	79800	nd	nd			
p (t-test)	nd	nd		0.16	nd	nd			
Min	nd	nd	1940	27200	nd	nd			
Max	nd	nd	260000	232000	nd	nd			
n (Samp)	nd	nd	417	6	nd	nd			
n (Patient)	nd	nd	228	6	nd	nd			
UO only									
Median	51100	46800	51100	41600	51100	30200			
Average	62700	55800	62700	46200	62700	34900			
Stdev	45100	34800	45100	26700	45100	22900			
p (t-test)		0.44		0.037		0.0100			
Min	4980	14500	4980	10500	4980	1940			
Max	244000	141000	244000	129000	244000	98400			
n (Samp)	295	27	295	34	295	18			
n (Patient)	167	27	167	34	167	18			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	nd	0.47	0.44	0.57	0.40	0.32	nd	0.29
SE	0.059	nd	0.059	0.053	0.12	0.054	0.069	nd	0.070
p	0.37	nd	0.62	0.29	0.59	0.076	0.0077	nd	0.0033
nCohort 1	325	nd	295	325	417	295	325	nd	295
nCohort 2	27	nd	27	34	6	34	19	nd	18
Cutoff 1	29100	nd	30700	31300	33900	29100	25600	nd	25600

-continued

Sens 1	70%	nd	70%	71%	83%	71%	74%	nd	72%
Spec 1	22%	nd	25%	26%	29%	22%	17%	nd	17%
Cutoff 2	25700	nd	25600	24700	33900	20900	16700	nd	16700
Sens 2	81%	nd	81%	82%	83%	82%	84%	nd	83%
Spec 2	17%	nd	17%	16%	29%	14%	9%	nd	9%
Cutoff 3	20700	nd	20700	16700	27000	16700	4980	nd	4980
Sens 3	93%	nd	93%	91%	100%	91%	95%	nd	94%
Spec 3	13%	nd	14%	9%	19%	9%	0%	nd	0%
Cutoff 4	75000	nd	75700	75000	68400	75700	75000	nd	75700
Sens 4	19%	nd	19%	18%	33%	12%	5%	nd	6%
Spec 4	70%	nd	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	90400	nd	90900	90400	87000	90900	90400	nd	90900
Sens 5	11%	nd	11%	12%	33%	6%	5%	nd	6%
Spec 5	80%	nd	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	124000	nd	121000	124000	120000	121000	124000	nd	121000
Sens 6	7%	nd	11%	9%	33%	3%	0%	nd	0%
Spec 6	90%	nd	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	1.4	nd	1.7	1.9	2.0	4.1	3.1	nd	2.1
p Value	0.55	nd	0.38	0.27	0.57	0.035	0.34	nd	0.56
95% CI of	0.44	nd	0.53	0.61	0.18	1.1	0.31	nd	0.18
OR Quart 2	4.7	nd	5.4	5.9	22	15	30	nd	23
OR Quart 3	1.2	nd	1.2	2.1	0.99	2.9	7.5	nd	6.5
p Value	0.76	nd	0.76	0.19	0.99	0.13	0.062	nd	0.087
95% CI of	0.36	nd	0.36	0.70	0.061	0.74	0.91	nd	0.76
OR Quart 3	4.1	nd	4.2	6.5	16	11	63	nd	55
OR Quart 4	1.9	nd	1.7	2.2	2.0	4.6	8.7	nd	10
p Value	0.27	nd	0.38	0.18	0.57	0.022	0.043	nd	0.030
95% CI of	0.61	nd	0.53	0.70	0.18	1.2	1.1	nd	1.3
OR Quart 4	5.9	nd	5.4	6.6	22	17	71	nd	82

Apolipoprotein(a)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
<u>sCr or UO</u>									
Median	52400	30100	52400	41200	52400	15800			
Average	89500	61200	89500	73100	89500	42400			
Stdev	110000	72000	110000	95100	110000	58500			
p (t-test)		0.19		0.41		0.066			
Min	7.99	380	7.99	1030	7.99	1300			
Max	722000	234000	722000	423000	722000	187000			
n (Samp)	325	27	325	34	325	19			
n (Patient)	192	27	192	34	192	19			
<u>sCr only</u>									
Median	nd	nd	45000	30300	nd	nd			
Average	nd	nd	84100	68400	nd	nd			
Stdev	nd	nd	106000	83400	nd	nd			
p (t-test)	nd	nd		0.72	nd	nd			
Min	nd	nd	7.99	968	nd	nd			
Max	nd	nd	722000	200000	nd	nd			
n (Samp)	nd	nd	417	6	nd	nd			
n (Patient)	nd	nd	228	6	nd	nd			
<u>UO only</u>									
Median	47600	30100	47600	31200	47600	13500			
Average	82800	61400	82800	68900	82800	41800			
Stdev	102000	71900	102000	95000	102000	60300			
p (t-test)		0.28		0.45		0.092			
Min	7.99	380	7.99	1030	7.99	1300			
Max	631000	234000	631000	423000	631000	187000			
n (Samp)	295	27	295	34	295	18			
n (Patient)	167	27	167	34	167	18			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	nd	0.42	0.44	0.44	0.44	0.32	nd	0.32
SE	0.060	nd	0.060	0.053	0.12	0.054	0.069	nd	0.071
p	0.12	nd	0.20	0.29	0.60	0.23	0.0084	nd	0.010
nCohort 1	325	nd	295	325	417	295	325	nd	295
nCohort 2	27	nd	27	34	6	34	19	nd	18
Cutoff 1	9720	nd	9720	14100	4320	10500	3140	nd	3010

-continued

Sens 1	70%	nd	70%	71%	83%	71%	74%	nd	72%
Spec 1	16%	nd	17%	24%	9%	19%	5%	nd	6%
Cutoff 2	4320	nd	4320	6200	4320	6120	2260	nd	2260
Sens 2	81%	nd	81%	82%	83%	88%	84%	nd	83%
Spec 2	6%	nd	7%	10%	9%	11%	4%	nd	4%
Cutoff 3	2710	nd	3010	5110	887	5110	1680	nd	1680
Sens 3	93%	nd	93%	91%	100%	91%	95%	nd	94%
Spec 3	4%	nd	6%	7%	2%	7%	4%	nd	4%
Cutoff 4	99500	nd	92000	99500	95700	92000	99500	nd	92000
Sens 4	22%	nd	26%	26%	33%	26%	16%	nd	22%
Spec 4	70%	nd	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	142000	nd	128000	142000	135000	128000	142000	nd	128000
Sens 5	15%	nd	15%	18%	33%	15%	16%	nd	17%
Spec 5	80%	nd	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	235000	nd	219000	235000	225000	219000	235000	nd	219000
Sens 6	0%	nd	7%	6%	0%	6%	0%	nd	0%
Spec 6	90%	nd	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	0.82	nd	0.83	0.42	0	0.74	0.66	nd	0.33
p Value	0.76	nd	0.77	0.16	na	0.59	0.65	nd	0.34
95% CI of	0.24	nd	0.24	0.12	na	0.25	0.11	nd	0.033
OR Quart 2	2.8	nd	2.8	1.4	na	2.2	4.0	nd	3.2
OR Quart 3	1.0	nd	1.0	1.3	1.0	1.2	1.7	nd	1.7
p Value	1.0	nd	1.0	0.64	1.0	0.78	0.47	nd	0.46
95% CI of	0.31	nd	0.31	0.49	0.14	0.42	0.40	nd	0.40
OR Quart 3	3.2	nd	3.2	3.2	7.2	3.2	7.4	nd	7.5
OR Quart 4	1.8	nd	1.8	1.1	1.0	1.5	3.2	nd	3.3
p Value	0.30	nd	0.29	0.79	0.99	0.45	0.087	nd	0.082
95% CI of	0.61	nd	0.62	0.44	0.14	0.55	0.84	nd	0.86
OR Quart 4	5.0	nd	5.2	3.0	7.3	3.8	12	nd	13

[0189] FIG. 7: Comparison of marker levels in EDTA samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

C-C motif chemokine 7						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.512	nd	nd	0.620	0.512
Average	10.9	11.4	nd	nd	11.2	12.4
Stdev	28.1	22.4	nd	nd	30.3	24.3
p (t-test)		0.94	nd	nd		0.90
Min	0.193	0.193	nd	nd	0.193	0.193
Max	166	79.4	nd	nd	166	79.4
n (Samp)	41	19	nd	nd	31	15
n (Patient)	41	19	nd	nd	31	15

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.51	nd	0.49
SE	0.081	nd	0.092
p	0.95	nd	0.93
nCohort 1	41	nd	31
nCohort 2	19	nd	15
Cutoff 1	0.193	nd	0.193
Sens 1	95%	nd	93%
Spec 1	20%	nd	19%
Cutoff 2	0.193	nd	0.193
Sens 2	95%	nd	93%
Spec 2	20%	nd	19%
Cutoff 3	0.193	nd	0.193
Sens 3	95%	nd	93%
Spec 3	20%	nd	19%
Cutoff 4	9.43	nd	9.43
Sens 4	32%	nd	33%
Spec 4	71%	nd	71%

-continued

Cutoff 5	13.9	nd	13.9
Sens 5	21%	nd	20%
Spec 5	80%	nd	81%
Cutoff 6	19.6	nd	19.6
Sens 6	16%	nd	13%
Spec 6	90%	nd	90%
OR Quart 2	1.0	nd	0.75
p Value	1.0	nd	0.75
95% CI of	0.22	nd	0.13
OR Quart 2	4.6	nd	4.5
OR Quart 3	0.73	nd	1.0
p Value	0.69	nd	1.0
95% CI of	0.15	nd	0.18
OR Quart 3	3.5	nd	5.5
OR Quart 4	1.0	nd	1.1
p Value	1.0	nd	0.88
95% CI of	0.22	nd	0.21
OR Quart 4	4.6	nd	6.4

Interleukin-33

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0981	nd	nd	0.0981	0.0543
Average	67.7	946	nd	nd	3.24	1200
Stdev	275	3200	nd	nd	8.39	3590
p (t-test)		0.084	nd	nd		0.067
Min	0.0445	0.0445	nd	nd	0.0445	0.0445
Max	1270	13500	nd	nd	42.0	13500
n (Samp)	41	19	nd	nd	31	15
n (Patient)	41	19	nd	nd	31	15

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.48
SE	0.081	nd	0.092
p	0.82	nd	0.84
nCohort 1	41	nd	31
nCohort 2	19	nd	15
Cutoff 1	0.0445	nd	0.0445
Sens 1	84%	nd	87%
Spec 1	7%	nd	10%
Cutoff 2	0.0445	nd	0.0445
Sens 2	84%	nd	87%
Spec 2	7%	nd	10%
Cutoff 3	0	nd	0
Sens 3	100%	nd	100%
Spec 3	0%	nd	0%
Cutoff 4	0.101	nd	0.101
Sens 4	37%	nd	33%
Spec 4	76%	nd	81%
Cutoff 5	9.78	nd	0.101
Sens 5	21%	nd	33%
Spec 5	80%	nd	81%
Cutoff 6	17.9	nd	9.90
Sens 6	16%	nd	27%
Spec 6	90%	nd	90%
OR Quart 2	1.0	nd	0.14
p Value	1.0	nd	0.10
95% CI of	0.22	nd	0.013
OR Quart 2	4.6	nd	1.5
OR Quart 3	0.31	nd	0.47
p Value	0.21	nd	0.39
95% CI of	0.049	nd	0.082
OR Quart 3	1.9	nd	2.7
OR Quart 4	1.8	nd	1.7
p Value	0.46	nd	0.54
95% CI of	0.40	nd	0.32
OR Quart 4	7.7	nd	8.8

-continued

Interleukin-4 receptor alpha chain						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	208	186	nd	nd	193	193
Average	301	235	nd	nd	289	254
Stdev	242	256	nd	nd	245	278
p (t-test)		0.34	nd	nd		0.67
Min	49.7	3.27	nd	nd	49.7	41.2
Max	1040	1210	nd	nd	1040	1210
n (Samp)	41	19	nd	nd	31	15
n (Patient)	41	19	nd	nd	31	15

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.39	nd	0.45
SE	0.081	nd	0.092
p	0.19	nd	0.59
nCohort 1	41	nd	31
nCohort 2	19	nd	15
Cutoff 1	104	nd	108
Sens 1	79%	nd	73%
Spec 1	7%	nd	6%
Cutoff 2	84.5	nd	104
Sens 2	84%	nd	87%
Spec 2	5%	nd	6%
Cutoff 3	3.27	nd	49.7
Sens 3	95%	nd	93%
Spec 3	0%	nd	3%
Cutoff 4	296	nd	234
Sens 4	21%	nd	33%
Spec 4	71%	nd	71%
Cutoff 5	431	nd	336
Sens 5	5%	nd	13%
Spec 5	80%	nd	81%
Cutoff 6	621	nd	621
Sens 6	5%	nd	7%
Spec 6	90%	nd	90%
OR Quart 2	2.0	nd	1.1
p Value	0.41	nd	0.88
95% CI of	0.38	nd	0.21
OR Quart 2	11	nd	6.4
OR Quart 3	1.5	nd	0.40
p Value	0.67	nd	0.35
95% CI of	0.26	nd	0.058
OR Quart 3	8.0	nd	2.8
OR Quart 4	3.5	nd	1.7
p Value	0.13	nd	0.55
95% CI of	0.69	nd	0.31
OR Quart 4	18	nd	9.0

Lutropin subunit beta						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.69	1.32	nd	nd	nd	nd
Average	7.27	1.57	nd	nd	nd	nd
Stdev	10.3	1.24	nd	nd	nd	nd
p (t-test)		0.16	nd	nd	nd	nd
Min	0.0399	0.0768	nd	nd	nd	nd
Max	50.0	3.61	nd	nd	nd	nd
n (Samp)	30	7	nd	nd	nd	nd
n (Patient)	30	7	nd	nd	nd	nd

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.28	nd	nd
SE	0.12	nd	nd
p	0.057	nd	nd

-continued

nCohort 1	30	nd	nd
nCohort 2	7	nd	nd
Cutoff 1	0.565	nd	nd
Sens 1	71%	nd	nd
Spec 1	23%	nd	nd
Cutoff 2	0.429	nd	nd
Sens 2	86%	nd	nd
Spec 2	17%	nd	nd
Cutoff 3	0.0621	nd	nd
Sens 3	100%	nd	nd
Spec 3	7%	nd	nd
Cutoff 4	5.73	nd	nd
Sens 4	0%	nd	nd
Spec 4	70%	nd	nd
Cutoff 5	14.5	nd	nd
Sens 5	0%	nd	nd
Spec 5	80%	nd	nd
Cutoff 6	17.8	nd	nd
Sens 6	0%	nd	nd
Spec 6	90%	nd	nd
OR Quart 2	>1.2	nd	nd
p Value	<0.88	nd	nd
95% CI of	>0.067	nd	nd
OR Quart 2	na	nd	nd
OR Quart 3	>8.0	nd	nd
p Value	<0.095	nd	nd
95% CI of	>0.70	nd	nd
OR Quart 3	na	nd	nd
OR Quart 4	>2.9	nd	nd
p Value	<0.43	nd	nd
95% CI of	>0.21	nd	nd
OR Quart 4	na	nd	nd

Platelet-derived growth factor subunit B (dimer)

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	347	370	nd	nd	356	390
Average	415	392	nd	nd	425	404
Stdev	228	193	nd	nd	228	215
p (t-test)		0.72	nd	nd		0.78
Min	65.1	152	nd	nd	65.1	152
Max	960	766	nd	nd	960	766
n (Samp)	57	15	nd	nd	43	12
n (Patient)	57	15	nd	nd	43	12

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.47	nd	0.46
SE	0.085	nd	0.096
p	0.77	nd	0.70
nCohort 1	57	nd	43
nCohort 2	15	nd	12
Cutoff 1	235	nd	220
Sens 1	73%	nd	75%
Spec 1	23%	nd	16%
Cutoff 2	220	nd	212
Sens 2	80%	nd	83%
Spec 2	19%	nd	16%
Cutoff 3	195	nd	192
Sens 3	93%	nd	92%
Spec 3	19%	nd	16%
Cutoff 4	515	nd	567
Sens 4	20%	nd	25%
Spec 4	70%	nd	72%
Cutoff 5	609	nd	629
Sens 5	20%	nd	17%
Spec 5	81%	nd	81%
Cutoff 6	782	nd	779
Sens 6	0%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.9	nd	1.0
p Value	0.43	nd	1.0

-continued

95% CI of	0.38	nd	0.16
OR Quart 2	9.6	nd	6.1
OR Quart 3	0.62	nd	0.28
p Value	0.63	nd	0.30
95% CI of	0.091	nd	0.026
OR Quart 3	4.3	nd	3.1
OR Quart 4	1.9	nd	2.3
p Value	0.43	nd	0.34
95% CI of	0.38	nd	0.42
OR Quart 4	9.6	nd	13

Corticotropin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.000624	0.00327	nd	nd	0.000539	0.00321
Average	0.00399	0.00614	nd	nd	0.00371	0.00648
Stdev	0.00894	0.00786	nd	nd	0.00924	0.00821
p (t-test)		0.44	nd	nd		0.42
Min	3.38E-6	4.31E-6	nd	nd	3.38E-6	0.000293
Max	0.0483	0.0251	nd	nd	0.0483	0.0251
n (Samp)	42	13	nd	nd	33	9
n (Patient)	42	13	nd	nd	33	9

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.66	nd	0.74
SE	0.091	nd	0.10
p	0.078	nd	0.021
nCohort 1	42	nd	33
nCohort 2	13	nd	9
Cutoff 1	0.000466	nd	0.00122
Sens 1	77%	nd	78%
Spec 1	45%	nd	61%
Cutoff 2	0.000261	nd	0.000293
Sens 2	85%	nd	89%
Spec 2	40%	nd	45%
Cutoff 3	4.31E-6	nd	0.000261
Sens 3	92%	nd	100%
Spec 3	24%	nd	42%
Cutoff 4	0.00201	nd	0.00183
Sens 4	62%	nd	67%
Spec 4	71%	nd	73%
Cutoff 5	0.00486	nd	0.00329
Sens 5	31%	nd	33%
Spec 5	81%	nd	82%
Cutoff 6	0.00761	nd	0.00658
Sens 6	31%	nd	33%
Spec 6	90%	nd	91%
OR Quart 2	0.92	nd	>2.2
p Value	0.94	nd	<0.54
95% CI of	0.11	nd	>0.17
OR Quart 2	7.7	nd	na
OR Quart 3	2.2	nd	>4.3
p Value	0.42	nd	<0.25
95% CI of	0.33	nd	>0.37
OR Quart 3	15	nd	na
OR Quart 4	3.1	nd	>5.7
p Value	0.24	nd	<0.15
95% CI of	0.47	nd	>0.52
OR Quart 4	20	nd	na

Thyroxine-binding globulin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	36.1	28.0	nd	nd	34.1	30.0
Average	36.5	30.9	nd	nd	36.1	31.3
Stdev	10.8	10.6	nd	nd	11.3	10.6
p (t-test)		0.044	nd	nd		0.14
Min	12.8	14.2	nd	nd	12.8	14.2

-continued

Max	56.7	48.3	nd	nd	56.7	46.0
n (Samp)	55	22	nd	nd	46	16
n (Patient)	55	22	nd	nd	46	16

At Enrollment						
	sCr or UO		sCr only		UO only	
AUC	0.35		nd		0.36	
SE	0.072		nd		0.084	
p	0.043		nd		0.10	
nCohort 1	55		nd		46	
nCohort 2	22		nd		16	
Cutoff 1	24.7		nd		25.2	
Sens 1	73%		nd		75%	
Spec 1	15%		nd		20%	
Cutoff 2	19.7		nd		22.8	
Sens 2	82%		nd		81%	
Spec 2	7%		nd		13%	
Cutoff 3	15.8		nd		15.4	
Sens 3	91%		nd		94%	
Spec 3	5%		nd		7%	
Cutoff 4	43.0		nd		42.3	
Sens 4	18%		nd		25%	
Spec 4	71%		nd		72%	
Cutoff 5	46.9		nd		47.1	
Sens 5	5%		nd		0%	
Spec 5	80%		nd		80%	
Cutoff 6	51.0		nd		51.0	
Sens 6	0%		nd		0%	
Spec 6	91%		nd		91%	
OR Quart 2	1.1		nd		1.1	
p Value	0.94		nd		0.93	
95% CI of	0.23		nd		0.18	
OR Quart 2	5.0		nd		6.4	
OR Quart 3	1.8		nd		2.0	
p Value	0.41		nd		0.42	
95% CI of	0.43		nd		0.38	
OR Quart 3	8.0		nd		10	
OR Quart 4	2.9		nd		2.2	
p Value	0.14		nd		0.36	
95% CI of	0.70		nd		0.42	
OR Quart 4	12		nd		11	

Alpha-fetoprotein						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.331	0.458	nd	nd	0.302	0.452
Average	0.318	0.516	nd	nd	0.298	0.452
Stdev	0.265	0.415	nd	nd	0.238	0.396
p (t-test)		0.023	nd	nd		0.095
Min	0.00580	0.00580	nd	nd	0.00580	0.00580
Max	1.11	1.31	nd	nd	0.997	1.31
n (Samp)	58	16	nd	nd	44	12
n (Patient)	58	16	nd	nd	44	12

At Enrollment						
	sCr or UO		sCr only		UO only	
AUC	0.65		nd		0.62	
SE	0.082		nd		0.096	
p	0.076		nd		0.20	
nCohort 1	58		nd		44	
nCohort 2	16		nd		12	
Cutoff 1	0.225		nd		0.221	
Sens 1	75%		nd		75%	
Spec 1	40%		nd		39%	
Cutoff 2	0.221		nd		0.00580	
Sens 2	81%		nd		92%	
Spec 2	38%		nd		14%	
Cutoff 3	0.00580		nd		0.00580	
Sens 3	94%		nd		92%	
Spec 3	14%		nd		14%	

-continued

Cutoff 4	0.446	nd	0.415
Sens 4	50%	nd	50%
Spec 4	71%	nd	70%
Cutoff 5	0.530	nd	0.513
Sens 5	44%	nd	50%
Spec 5	81%	nd	82%
Cutoff 6	0.598	nd	0.570
Sens 6	38%	nd	33%
Spec 6	91%	nd	91%
OR Quart 2	0.94	nd	0.61
p Value	0.94	nd	0.62
95% CI of	0.16	nd	0.085
OR Quart 2	5.4	nd	4.4
OR Quart 3	1.0	nd	0.28
p Value	1.0	nd	0.30
95% CI of	0.17	nd	0.026
OR Quart 3	5.8	nd	3.1
OR Quart 4	2.9	nd	2.8
p Value	0.18	nd	0.23
95% CI of	0.62	nd	0.52
OR Quart 4	14	nd	14

Apolipoprotein E

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	59000	43100	nd	nd	59600	50600
Average	74200	47600	nd	nd	78300	50500
Stdev	52400	31200	nd	nd	54800	34500
p (t-test)		0.027	nd	nd		0.054
Min	12600	1940	nd	nd	13000	1940
Max	244000	120000	nd	nd	244000	120000
n (Samp)	68	22	nd	nd	53	17
n (Patient)	68	22	nd	nd	53	17

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.35	nd	0.36
SE	0.071	nd	0.081
p	0.029	nd	0.080
nCohort 1	68	nd	53
nCohort 2	22	nd	17
Cutoff 1	23900	nd	27300
Sens 1	73%	nd	71%
Spec 1	13%	nd	11%
Cutoff 2	17400	nd	14200
Sens 2	82%	nd	82%
Spec 2	6%	nd	4%
Cutoff 3	14100	nd	1940
Sens 3	91%	nd	94%
Spec 3	4%	nd	0%
Cutoff 4	85700	nd	91600
Sens 4	14%	nd	18%
Spec 4	71%	nd	72%
Cutoff 5	98600	nd	98600
Sens 5	9%	nd	12%
Spec 5	81%	nd	81%
Cutoff 6	164000	nd	164000
Sens 6	0%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.5	nd	1.1
p Value	0.64	nd	0.94
95% CI of	0.29	nd	0.18
OR Quart 2	7.5	nd	6.2
OR Quart 3	3.6	nd	1.4
p Value	0.094	nd	0.67
95% CI of	0.80	nd	0.27
OR Quart 3	16	nd	7.5
OR Quart 4	3.1	nd	3.5
p Value	0.14	nd	0.12
95% CI of	0.69	nd	0.73
OR Quart 4	14	nd	17

[0190] FIG. 8: Comparison of the maximum marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values

in EDTA samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

Complement C4-B								
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage	
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2
<u>sCr or UO</u>								
Median	65500	61600		65500	61600		nd	nd
Average	73300	68700		73300	68700		nd	nd
Stdev	40400	39200		40400	39200		nd	nd
p (t-test)		0.76			0.76		nd	nd
Min	641	13500		641	13500		nd	nd
Max	203000	125000		203000	125000		nd	nd
n (Samp)	87	8		87	8		nd	nd
n (Patient)	87	8		87	8		nd	nd
<u>UO only</u>								
Median	65700	61600		65700	61600		nd	nd
Average	71600	68700		71600	68700		nd	nd
Stdev	35600	45800		35600	45800		nd	nd
p (t-test)		0.85			0.85		nd	nd
Min	641	13500		641	13500		nd	nd
Max	160000	125000		160000	125000		nd	nd
n (Samp)	80	6		80	6		nd	nd
n (Patient)	80	6		80	6		nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.46	0.48	nd	0.46	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.84	nd	0.76	0.84	nd	0.76	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	57800	nd	29600	57800	nd	29600	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	41%	nd	10%	41%	nd	10%	nd	nd	nd
Cutoff 2	29600	nd	29600	29600	nd	29600	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	10%	nd	10%	10%	nd	10%	nd	nd	nd
Cutoff 3	5890	nd	5890	5890	nd	5890	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	2%	nd	2%	2%	nd	2%	nd	nd	nd
Cutoff 4	86300	nd	87900	86300	nd	87900	nd	nd	nd
Sens 4	25%	nd	33%	25%	nd	33%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	104000	nd	100000	104000	nd	100000	nd	nd	nd
Sens 5	25%	nd	33%	25%	nd	33%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	129000	nd	124000	129000	nd	124000	nd	nd	nd
Sens 6	0%	nd	17%	0%	nd	17%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	0.48	nd	0	0.48	nd	0	nd	nd	nd
p Value	0.56	nd	na	0.56	nd	na	nd	nd	nd
95% CI of	0.040	nd	na	0.040	nd	na	nd	nd	nd
OR Quart 2	5.7	nd	na	5.7	nd	na	nd	nd	nd
OR Quart 3	1.6	nd	1.0	1.6	nd	1.0	nd	nd	nd
p Value	0.64	nd	1.0	0.64	nd	1.0	nd	nd	nd
95% CI of	0.24	nd	0.13	0.24	nd	0.13	nd	nd	nd
OR Quart 3	10	nd	7.8	10	nd	7.8	nd	nd	nd
OR Quart 4	1.0	nd	1.1	1.0	nd	1.1	nd	nd	nd
p Value	0.96	nd	0.96	0.96	nd	0.96	nd	nd	nd
95% CI of	0.13	nd	0.13	0.13	nd	0.13	nd	nd	nd
OR Quart 4	8.1	nd	8.2	8.1	nd	8.2	nd	nd	nd

-continued

C-C motif chemokine 26									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	1.25	4.43		1.25	4.43		1.25	6.99	
Average	18.1	7.55		18.1	7.36		18.1	6.64	
Stdev	79.1	9.61		79.1	9.74		79.1	6.53	
p (t-test)		0.65			0.64			0.71	
Min	0.0121	0.0232		0.0121	0.0232		0.0121	0.652	
Max	468	33.0		468	33.0		468	18.3	
n (Samp)	64	12		64	12		64	7	
n (Patient)	64	12		64	12		64	7	
<u>sCr only</u>									
Median	1.76	1.73		1.76	0.937		nd	nd	
Average	11.9	2.36		11.9	1.99		nd	nd	
Stdev	55.9	2.51		55.9	2.69		nd	nd	
p (t-test)		0.68			0.67		nd	nd	
Min	0.0121	0.0232		0.0121	0.0232		nd	nd	
Max	468	6.99		468	6.99		nd	nd	
n (Samp)	131	6		131	6		nd	nd	
n (Patient)	131	6		131	6		nd	nd	
<u>UO only</u>									
Median	1.25	7.45		1.25	7.45		1.25	7.45	
Average	18.5	10.5		18.5	10.5		18.5	7.54	
Stdev	79.7	10.7		79.7	10.7		79.7	6.66	
p (t-test)		0.78			0.78			0.74	
Min	0.0121	0.652		0.0121	0.652		0.0121	0.652	
Max	468	33.0		468	33.0		468	18.3	
n (Samp)	63	8		63	8		63	6	
n (Patient)	63	8		63	8		63	6	
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.46	0.73	0.59	0.38	0.73	0.65	nd	0.69
SE	0.093	0.12	0.11	0.093	0.13	0.11	0.12	nd	0.12
p	0.15	0.74	0.029	0.33	0.36	0.029	0.19	nd	0.12
nCohort 1	64	131	63	64	131	63	64	nd	63
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.949	0.355	5.00	0.0587	0.0325	5.00	0.949	nd	0.0587
Sens 1	75%	83%	75%	83%	83%	75%	71%	nd	100%
Spec 1	44%	33%	78%	31%	7%	78%	44%	nd	35%
Cutoff 2	0.0587	0.355	0.0587	0.0587	0.0325	0.0587	0.0587	nd	0.0587
Sens 2	92%	83%	100%	83%	83%	100%	100%	nd	100%
Spec 2	31%	33%	35%	31%	7%	35%	31%	nd	35%
Cutoff 3	0.0587	0.0121	0.0587	0.0232	0.0121	0.0587	0.0587	nd	0.0587
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	31%	2%	35%	8%	2%	35%	31%	nd	35%
Cutoff 4	3.61	5.00	3.57	3.61	5.00	3.57	3.61	nd	3.57
Sens 4	50%	17%	75%	50%	17%	75%	57%	nd	67%
Spec 4	70%	71%	71%	70%	71%	71%	70%	nd	71%
Cutoff 5	6.86	7.86	6.86	6.86	7.86	6.86	6.86	nd	6.86
Sens 5	42%	0%	62%	42%	0%	62%	57%	nd	67%
Spec 5	81%	80%	81%	81%	80%	81%	81%	nd	81%
Cutoff 6	14.2	14.2	14.2	14.2	14.2	14.2	14.2	nd	14.2
Sens 6	17%	0%	25%	17%	0%	25%	14%	nd	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	3.4	2.1	>2.1	1.6	1.0	>2.1	>3.4	nd	>2.3
p Value	0.31	0.55	<0.55	0.63	0.98	<0.55	<0.31	nd	<0.52
95% CI of	0.32	0.18	>0.18	0.23	0.062	>0.18	>0.32	nd	>0.19
OR Quart 2	36	25	na	11	17	na	na	nd	na
OR Quart 3	3.4	2.1	>1.0	1.0	2.1	>1.0	>0	nd	>0
p Value	0.31	0.55	<1.0	1.0	0.55	<1.0	<na	nd	<na
95% CI of	0.32	0.18	>0.058	0.13	0.18	>	>na	nd	>na
OR Quart 3	36	25	na	7.9	25	na	na	nd	na
OR Quart 4	6.4	1.0	>6.5	3.0	2.1	>6.5	>4.9	nd	>4.9
p Value	0.11	0.98	<0.10	0.22	0.55	<0.10	<0.18	nd	<0.18
95% CI of	0.67	0.062	>0.68	0.51	0.18	>0.68	>0.49	nd	>0.49
OR Quart 4	61	17	na	18	25	na	na	nd	na

-continued

C-C motif chemokine 7									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	0.804	5.45		0.804	5.45		0.804	10.4	
Average	11.6	36.3		11.6	36.3		11.6	12.6	
Stdev	26.0	65.4		26.0	65.4		26.0	13.3	
p (t-test)		0.026			0.026			0.92	
Min	0.193	0.308		0.193	0.308		0.193	0.308	
Max	128	219		128	219		128	30.8	
n (Samp)	65	12		65	12		65	7	
n (Patient)	65	12		65	12		65	7	
<u>sCr only</u>									
Median	0.804	5.45		0.804	5.45		nd	nd	
Average	13.2	22.1		13.2	22.1		nd	nd	
Stdev	29.3	40.6		29.3	40.6		nd	nd	
p (t-test)		0.48			0.48		nd	nd	
Min	0.193	0.308		0.193	0.308		nd	nd	
Max	181	104		181	104		nd	nd	
n (Samp)	132	6		132	6		nd	nd	
n (Patient)	132	6		132	6		nd	nd	
<u>UO only</u>									
Median	0.804	5.45		0.804	5.45		0.804	5.45	
Average	10.4	39.2		10.4	39.2		10.4	11.9	
Stdev	25.9	75.1		25.9	75.1		25.9	14.5	
p (t-test)		0.028			0.028			0.89	
Min	0.193	0.308		0.193	0.308		0.193	0.308	
Max	128	219		128	219		128	30.8	
n (Samp)	64	8		64	8		64	6	
n (Patient)	64	8		64	8		64	6	
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.50	0.58	0.56	0.50	0.58	0.56	nd	0.55
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.52	1.00	0.47	0.52	1.00	0.47	0.59	nd	0.71
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.308	0.193	0.308	0.308	0.193	0.308	0.308	nd	0.193
Sens 1	75%	100%	75%	75%	100%	75%	71%	nd	100%
Spec 1	25%	3%	28%	25%	3%	28%	25%	nd	3%
Cutoff 2	0.193	0.193	0.193	0.193	0.193	0.193	0.193	nd	0.193
Sens 2	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 2	3%	3%	3%	3%	3%	3%	3%	nd	3%
Cutoff 3	0.193	0.193	0.193	0.193	0.193	0.193	0.193	nd	0.193
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	3%	3%	3%	3%	3%	3%	3%	nd	3%
Cutoff 4	8.40	8.42	4.51	8.40	8.42	4.51	8.40	nd	4.51
Sens 4	50%	50%	50%	50%	50%	50%	57%	nd	50%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	12.2	15.3	8.42	12.2	15.3	8.42	12.2	nd	8.42
Sens 5	42%	33%	50%	42%	33%	50%	43%	nd	50%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	32.2	33.2	18.9	32.2	33.2	18.9	32.2	nd	18.9
Sens 6	25%	17%	38%	25%	17%	38%	0%	nd	33%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	1.0	0.50	1.0	1.0	0.50	1.0	0.47	nd	0.44
p Value	1.0	0.58	1.0	1.0	0.58	1.0	0.55	nd	0.52
95% CI of	0.17	0.043	0.13	0.17	0.043	0.13	0.039	nd	0.036
OR Quart 2	5.7	5.8	8.0	5.7	5.8	8.0	5.7	nd	5.4
OR Quart 3	0	0.49	0	0	0.49	0	0	nd	0
p Value	na	0.56	na	na	0.56	na	na	nd	na
95% CI of	na	0.042	na	na	0.042	na	na	nd	na
OR Quart 3	na	5.6	na	na	5.6	na	na	nd	na
OR Quart 4	2.3	1.0	2.3	2.3	1.0	2.3	2.3	nd	1.5
p Value	0.30	0.98	0.38	0.30	0.98	0.38	0.38	nd	0.68
95% CI of	0.48	0.14	0.36	0.48	0.14	0.36	0.36	nd	0.22
OR Quart 4	11	7.8	14	11	7.8	14	14	nd	10

-continued

Vascular endothelial growth factor receptor 3									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	5220	5750		5220	5190		5220	4620	
Average	7140	7290		7140	7190		7140	6080	
Stdev	5790	4660		5790	4690		5790	2970	
p (t-test)		0.93			0.98			0.64	
Min	565	1740		565	1740		565	3160	
Max	29400	16600		29400	16600		29400	10400	
n (Samp)	65	12		65	12		65	7	
n (Patient)	65	12		65	12		65	7	
<u>sCr only</u>									
Median	6370	4450		6370	4280		nd	nd	
Average	7630	5070		7630	4880		nd	nd	
Stdev	5970	3070		5970	3030		nd	nd	
p (t-test)		0.30			0.27		nd	nd	
Min	565	1740		565	1740		nd	nd	
Max	43200	10400		43200	10400		nd	nd	
n (Samp)	132	6		132	6		nd	nd	
n (Patient)	132	6		132	6		nd	nd	
<u>UO only</u>									
Median	5340	5790		5340	5790		5340	4410	
Average	7390	7970		7390	7970		7390	5350	
Stdev	6200	5200		6200	5200		6200	2480	
p (t-test)		0.80			0.80			0.43	
Min	565	3160		565	3160		565	3160	
Max	32800	16600		32800	16600		32800	9630	
n (Samp)	64	8		64	8		64	6	
n (Patient)	64	8		64	8		64	6	
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.54	0.36	0.53	0.53	0.34	0.53	0.49	nd	0.40
SE	0.092	0.12	0.11	0.092	0.12	0.11	0.12	nd	0.13
p	0.70	0.25	0.79	0.78	0.19	0.79	0.90	nd	0.41
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	3920	3140	3920	3920	3140	3920	3920	nd	3400
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	31%	16%	28%	31%	16%	28%	31%	nd	20%
Cutoff 2	3400	3140	3400	3400	3140	3400	3400	nd	3400
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	23%	16%	20%	23%	16%	20%	23%	nd	20%
Cutoff 3	3140	1720	3140	3140	1720	3140	3140	nd	3140
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	17%	5%	14%	17%	5%	14%	17%	nd	14%
Cutoff 4	7590	8540	7610	7590	8540	7610	7590	nd	7610
Sens 4	33%	17%	38%	33%	17%	38%	29%	nd	17%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	9000	10300	9000	9000	10300	9000	9000	nd	9000
Sens 5	33%	17%	38%	33%	17%	38%	29%	nd	17%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	13800	13200	13800	13800	13200	13800	13800	nd	13800
Sens 6	17%	0%	25%	17%	0%	25%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.63	0	1.0	1.0	0	1.0	0.47	nd	1.1
p Value	0.63	na	1.0	1.0	na	1.0	0.55	nd	0.97
95% CI of	0.092	na	0.13	0.17	na	0.13	0.039	nd	0.061
OR Quart 2	4.3	na	8.0	5.7	na	8.0	5.7	nd	18
OR Quart 3	1.0	2.1	0.47	0.63	2.1	0.47	1.0	nd	2.1
p Value	1.0	0.56	0.55	0.63	0.56	0.55	1.0	nd	0.55
95% CI of	0.17	0.18	0.039	0.092	0.18	0.039	0.13	nd	0.18
OR Quart 3	5.7	24	5.7	4.3	24	5.7	8.0	nd	26
OR Quart 4	1.3	3.3	1.6	1.3	3.3	1.6	1.0	nd	2.3
p Value	0.73	0.31	0.63	0.73	0.31	0.63	1.0	nd	0.52
95% CI of	0.26	0.32	0.23	0.26	0.32	0.23	0.13	nd	0.19
OR Quart 4	6.9	33	11	6.9	33	11	8.0	nd	28

-continued

Interferon alpha-2									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	14.0	23.9		14.0	23.9		14.0	14.0	
Average	22.3	34.7		22.3	34.4		22.3	16.8	
Stdev	33.5	43.9		33.5	44.0		33.5	14.9	
p (t-test)		0.26			0.28			0.67	
Min	0.0320	0.209		0.0320	0.209		0.0320	0.209	
Max	223	163		223	163		223	43.4	
n (Samp)	65	12		65	12		65	7	
n (Patient)	65	12		65	12		65	7	
<u>sCr only</u>									
Median	19.5	23.7		19.5	23.7		nd	nd	
Average	23.8	20.4		23.8	19.7		nd	nd	
Stdev	28.3	15.7		28.3	15.2		nd	nd	
p (t-test)		0.78			0.73		nd	nd	
Min	0.0320	0.209		0.0320	0.209		nd	nd	
Max	223	39.2		223	39.2		nd	nd	
n (Samp)	132	6		132	6		nd	nd	
n (Patient)	132	6		132	6		nd	nd	
<u>UO only</u>									
Median	13.3	23.9		13.3	23.9		13.3	10.6	
Average	21.0	39.9		21.0	39.9		21.0	15.9	
Stdev	35.0	53.2		35.0	53.2		35.0	16.1	
p (t-test)		0.18			0.18			0.73	
Min	0.0320	0.209		0.0320	0.209		0.0320	0.209	
Max	223	163		223	163		223	43.4	
n (Samp)	64	8		64	8		64	6	
n (Patient)	64	8		64	8		64	6	
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.52	0.63	0.61	0.50	0.63	0.48	nd	0.49
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.24	0.90	0.23	0.25	0.98	0.23	0.88	nd	0.91
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	6.46	2.04	6.46	6.46	2.04	6.46	6.46	nd	4.65
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	28%	14%	31%	28%	14%	31%	28%	nd	25%
Cutoff 2	4.65	2.04	4.65	4.65	2.04	4.65	4.65	nd	4.65
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	22%	14%	25%	22%	14%	25%	22%	nd	25%
Cutoff 3	2.04	0.0997	0.0997	2.04	0.0997	0.0997	0.0997	nd	0.0997
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	15%	11%	9%	15%	11%	9%	8%	nd	9%
Cutoff 4	23.8	28.0	19.0	23.8	28.0	19.0	23.8	nd	19.0
Sens 4	50%	33%	62%	50%	33%	62%	29%	nd	33%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	29.2	32.9	26.8	29.2	32.9	26.8	29.2	nd	26.8
Sens 5	42%	17%	38%	33%	17%	38%	14%	nd	17%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	44.4	43.4	34.3	44.4	43.4	34.3	44.4	nd	34.3
Sens 6	17%	0%	38%	17%	0%	38%	0%	nd	17%
Spec 6	92%	90%	91%	92%	90%	91%	92%	nd	91%
OR Quart 2	0.30	0	0.47	0.30	0	0.47	3.4	nd	0.50
p Value	0.31	na	0.55	0.31	na	0.55	0.31	nd	0.59
95% CI of	0.028	na	0.039	0.028	na	0.039	0.32	nd	0.041
OR Quart 2	3.1	na	5.7	3.1	na	5.7	36	nd	6.1
OR Quart 3	1.0	1.0	0.47	1.0	1.5	0.47	1.0	nd	1.0
p Value	1.0	1.0	0.55	1.0	0.64	0.55	1.0	nd	1.0
95% CI of	0.17	0.13	0.039	0.17	0.24	0.039	0.058	nd	0.13
OR Quart 3	5.7	7.5	5.7	5.7	9.9	5.7	17	nd	8.0
OR Quart 4	1.8	0.97	2.3	1.8	0.47	2.3	2.1	nd	0.50
p Value	0.48	0.98	0.38	0.48	0.55	0.38	0.55	nd	0.59
95% CI of	0.36	0.13	0.36	0.36	0.041	0.36	0.18	nd	0.041
OR Quart 4	8.8	7.3	14	8.8	5.4	14	26	nd	6.1

-continued

Insulin-like growth factor-binding protein 4									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	2.43	14.3		2.43	14.3		nd	nd	
Average	12.0	16.2		12.0	16.2		nd	nd	
Stdev	24.2	15.1		24.2	15.1		nd	nd	
p (t-test)		0.63			0.63		nd	nd	
Min	0.572	0.572		0.572	0.572		nd	nd	
Max	158	33.4		158	33.4		nd	nd	
n (Samp)	87	8		87	8		nd	nd	
n (Patient)	87	8		87	8		nd	nd	
<u>UO only</u>									
Median	2.93	15.8		2.93	15.8		nd	nd	
Average	13.3	16.8		13.3	16.8		nd	nd	
Stdev	25.0	16.4		25.0	16.4		nd	nd	
p (t-test)		0.74			0.74		nd	nd	
Min	0.572	0.572		0.572	0.572		nd	nd	
Max	158	33.4		158	33.4		nd	nd	
n (Samp)	80	6		80	6		nd	nd	
n (Patient)	80	6		80	6		nd	nd	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.66	nd	0.61	0.66	nd	0.61	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.14	nd	0.37	0.14	nd	0.37	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	2.43	nd	0.971	2.43	nd	0.971	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	55%	nd	38%	55%	nd	38%	nd	nd	nd
Cutoff 2	0.971	nd	0.971	0.971	nd	0.971	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	43%	nd	38%	43%	nd	38%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	6.75	nd	10.7	6.75	nd	10.7	nd	nd	nd
Sens 4	50%	nd	50%	50%	nd	50%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	19.0	nd	21.4	19.0	nd	21.4	nd	nd	nd
Sens 5	50%	nd	50%	50%	nd	50%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	31.3	nd	34.2	31.3	nd	34.2	nd	nd	nd
Sens 6	25%	nd	0%	25%	nd	0%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	2.0	0	nd	2.0	nd	nd	nd
p Value	na	nd	0.58	na	nd	0.58	nd	nd	nd
95% CI of	na	nd	0.17	na	nd	0.17	nd	nd	nd
OR Quart 2	na	nd	24	na	nd	24	nd	nd	nd
OR Quart 3	3.1	nd	0	3.1	nd	0	nd	nd	nd
p Value	0.34	nd	na	0.34	nd	na	nd	nd	nd
95% CI of	0.30	nd	na	0.30	nd	na	nd	nd	nd
OR Quart 3	33	nd	na	33	nd	na	nd	nd	nd
OR Quart 4	4.4	nd	3.2	4.4	nd	3.2	nd	nd	nd
p Value	0.20	nd	0.34	0.20	nd	0.34	nd	nd	nd
95% CI of	0.45	nd	0.30	0.45	nd	0.30	nd	nd	nd
OR Quart 4	43	nd	33	43	nd	33	nd	nd	nd

Insulin-like growth factor-binding protein 5

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	34.6	48.0	34.6	48.0	nd	nd
Average	47.2	43.5	47.2	43.5	nd	nd

-continued

Stdev	52.3	42.3	52.3	42.3	nd	nd
p (t-test)		0.85		0.85	nd	nd
Min	0.204	0.204	0.204	0.204	nd	nd
Max	257	117	257	117	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd
UO only						
Median	24.6	62.6	24.6	62.6	nd	nd
Average	41.6	52.3	41.6	52.3	nd	nd
Stdev	53.2	44.9	53.2	44.9	nd	nd
p (t-test)		0.63		0.63	nd	nd
Min	0.204	0.204	0.204	0.204	nd	nd
Max	257	117	257	117	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	nd	0.59	0.49	nd	0.59	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.92	nd	0.47	0.92	nd	0.47	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	0.488	nd	0.488	0.488	nd	0.488	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	18%	nd	22%	18%	nd	22%	nd	nd	nd
Cutoff 2	0.204	nd	0.488	0.204	nd	0.488	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	6%	nd	22%	6%	nd	22%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	59.8	nd	47.6	59.8	nd	47.6	nd	nd	nd
Sens 4	50%	nd	67%	50%	nd	67%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	76.0	nd	65.5	76.0	nd	65.5	nd	nd	nd
Sens 5	12%	nd	33%	12%	nd	33%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	124	nd	97.6	124	nd	97.6	nd	nd	nd
Sens 6	0%	nd	17%	0%	nd	17%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	1.0	nd	0.95	1.0	nd	0.95	nd	nd	nd
p Value	1.0	nd	0.97	1.0	nd	0.97	nd	nd	nd
95% CI of	0.13	nd	0.056	0.13	nd	0.056	nd	nd	nd
OR Quart 2	7.7	nd	16	7.7	nd	16	nd	nd	nd
OR Quart 3	1.0	nd	0	1.0	nd	0	nd	nd	nd
p Value	1.0	nd	na	1.0	nd	na	nd	nd	nd
95% CI of	0.13	nd	na	0.13	nd	na	nd	nd	nd
OR Quart 3	7.7	nd	na	7.7	nd	na	nd	nd	nd
OR Quart 4	1.0	nd	4.4	1.0	nd	4.4	nd	nd	nd
p Value	0.96	nd	0.20	0.96	nd	0.20	nd	nd	nd
95% CI of	0.13	nd	0.45	0.13	nd	0.45	nd	nd	nd
OR Quart 4	8.1	nd	44	8.1	nd	44	nd	nd	nd

Interleukin-21

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.783	1.89	0.783	1.75	0.783	1.89
Average	88.7	4.14	88.7	3.98	88.7	2.64
Stdev	673	7.38	673	7.45	673	2.51
p (t-test)		0.67		0.67		0.74
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.829
Max	5430	26.6	5430	26.6	5430	8.25
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7
sCr only						
Median	0.783	2.01	0.783	1.80	nd	nd
Average	45.5	2.67	45.5	2.35	nd	nd

-continued

Stdev	473	2.84	473	3.02	nd	nd
p (t-test)		0.83		0.82	nd	nd
Min	0.0102	0.0102	0.0102	0.0102	nd	nd
Max	5430	8.25	5430	8.25	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd
UO only						
Median	1.02	1.89	1.02	1.89	1.02	1.89
Average	90.5	4.71	90.5	4.71	90.5	1.71
Stdev	678	8.88	678	8.88	678	0.455
p (t-test)		0.72		0.72		0.75
Min	0.0102	0.783	0.0102	0.783	0.0102	0.829
Max	5430	26.6	5430	26.6	5430	2.03
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.69	0.66	0.66	0.65	0.59	0.66	0.74	nd	0.65
SE	0.090	0.12	0.11	0.092	0.12	0.11	0.11	nd	0.13
p	0.038	0.19	0.14	0.10	0.45	0.14	0.034	nd	0.23
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	1.53	1.53	1.53	0.783	0.0314	1.53	1.79	nd	1.53
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	71%	67%	64%	51%	33%	64%	74%	nd	64%
Cutoff 2	0.783	1.53	0.783	0.605	0.0314	0.783	1.53	nd	1.53
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	51%	67%	45%	49%	33%	45%	71%	nd	64%
Cutoff 3	0.605	0.0102	0.605	0.0314	0.0102	0.605	0.783	nd	0.783
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	49%	8%	44%	34%	8%	44%	51%	nd	45%
Cutoff 4	1.53	1.79	1.89	1.53	1.79	1.89	1.53	nd	1.89
Sens 4	75%	67%	38%	67%	50%	38%	86%	nd	33%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	2.03	2.60	3.18	2.03	2.60	3.18	2.03	nd	3.18
Sens 5	25%	17%	12%	17%	17%	12%	14%	nd	0%
Spec 5	80%	81%	81%	80%	81%	81%	80%	nd	81%
Cutoff 6	10.6	5.72	11.4	10.6	5.72	11.4	10.6	nd	11.4
Sens 6	8%	17%	12%	8%	17%	12%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	2.1	0	>2.2	3.4	0.97	>2.2	>1.1	nd	>1.0
p Value	0.55	na	<0.52	0.31	0.98	<0.52	<0.97	nd	<1.0
95% CI of	0.18	na	>0.19	0.32	0.058	>0.19	>0.061	nd	>0.058
OR Quart 2	26	na	na	36	16	na	na	nd	na
OR Quart 3	4.8	2.1	>6.9	4.8	2.1	>6.9	>5.1	nd	>7.1
p Value	0.18	0.56	<0.094	0.18	0.56	<0.094	<0.16	nd	<0.091
95% CI of	0.48	0.18	>0.72	0.48	0.18	>0.72	>0.52	nd	>0.73
OR Quart 3	48	24	na	48	24	na	na	nd	na
OR Quart 4	6.0	3.1	>1.1	4.5	2.0	>1.1	>2.2	nd	>0
p Value	0.12	0.34	<0.97	0.20	0.58	<0.97	<0.52	nd	<na
95% CI of	0.63	0.31	>0.061	0.45	0.17	>0.061	>0.19	nd	>na
OR Quart 4	57	31	na	45	23	na	na	nd	na

Interleukin-23						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.995	256	0.995	216	0.995	22.3
Average	2550	9620	2550	9610	2550	1110
Stdev	13000	28600	13000	28600	13000	2390
p (t-test)		0.17		0.17		0.77
Min	0.257	0.257	0.257	0.257	0.257	0.257
Max	100000	100000	100000	100000	100000	6480
n (Samp)	64	12	64	12	64	7
n (Patient)	64	12	64	12	64	7
sCr only						
Median	1.10	89.5	1.10	50.3	nd	nd
Average	3050	435	3050	421	nd	nd

-continued

Stdev	15200	637	15200	644	nd	nd
p (t-test)		0.68		0.67	nd	nd
Min	0.257	0.257	0.257	0.257	nd	nd
Max	100000	1520	100000	1520	nd	nd
n (Samp)	131	6	131	6	nd	nd
n (Patient)	131	6	131	6	nd	nd
UO only						
Median	1.10	621	1.10	621	1.10	178
Average	3240	14200	3240	14200	3240	1290
Stdev	13600	34800	13600	34800	13600	2560
p (t-test)		0.091		0.091		0.73
Min	0.257	0.257	0.257	0.257	0.257	0.257
Max	100000	100000	100000	100000	100000	6480
n (Samp)	63	8	63	8	63	6
n (Patient)	63	8	63	8	63	6

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.58	0.70	0.66	0.57	0.70	0.62	nd	0.61
SE	0.092	0.12	0.11	0.092	0.12	0.11	0.12	nd	0.13
p	0.070	0.54	0.072	0.072	0.58	0.072	0.32	nd	0.40
nCohort 1	64	131	63	64	131	63	64	nd	63
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.886	0.770	11.0	0.886	0.770	11.0	0.886	nd	0.603
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	50%	32%	67%	50%	32%	67%	50%	nd	35%
Cutoff 2	0.770	0.770	0.603	0.770	0.770	0.603	0.770	nd	0.603
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	36%	32%	35%	36%	32%	35%	36%	nd	35%
Cutoff 3	0	0	0	0	0	0	0	nd	0
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	0%	0%	0%	0%	0%	0%	0%	nd	0%
Cutoff 4	55.0	138	405	55.0	138	405	55.0	nd	405
Sens 4	58%	50%	50%	58%	33%	50%	43%	nd	33%
Spec 4	70%	70%	71%	70%	70%	71%	70%	nd	71%
Cutoff 5	861	637	861	861	637	861	861	nd	861
Sens 5	42%	33%	50%	42%	33%	50%	29%	nd	33%
Spec 5	81%	80%	81%	81%	80%	81%	81%	nd	81%
Cutoff 6	2000	1540	2000	2000	1540	2000	2000	nd	2000
Sens 6	25%	0%	38%	25%	0%	38%	14%	nd	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	0.47	1.0	>2.1	0.47	1.0	>2.1	0.94	nd	>2.3
p Value	0.55	1.0	<0.55	0.55	1.0	<0.55	0.97	nd	<0.52
95% CI of	0.039	0.060	>0.18	0.039	0.060	>0.18	0.054	nd	>0.19
OR Quart 2	5.7	17	na	5.7	17	na	16	nd	na
OR Quart 3	2.3	2.1	>2.1	2.3	7.1	>2.1	3.2	nd	>2.3
p Value	0.38	0.56	<0.55	0.38	0.56	<0.55	0.34	nd	<0.52
95% CI of	0.36	0.18	>0.18	0.36	0.18	>0.18	0.30	nd	>0.19
OR Quart 3	14	24	na	14	24	na	34	nd	na
OR Quart 4	3.0	2.0	>4.9	3.0	2.0	>4.9	2.0	nd	>2.1
p Value	0.22	0.58	<0.18	0.22	0.58	<0.18	0.59	nd	<0.55
95% CI of	0.51	0.17	>0.49	0.51	0.17	>0.49	0.16	nd	>0.18
OR Quart 4	18	23	na	18	23	na	24	nd	na

Interleukin-28A						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.265	12.0	0.265	12.0	0.265	7.61
Average	87.3	181	87.3	181	87.3	14.1
Stdev	465	574	465	574	465	15.5
p (t-test)		0.54		0.54		0.68
Min	0.120	0.148	0.120	0.148	0.120	0.148
Max	3150	2000	3150	2000	3150	35.6
n (Samp)	64	12	64	12	64	7
n (Patient)	64	12	64	12	64	7
sCr only						
Median	0.265	0.626	0.265	0.265	nd	nd
Average	47.7	10.8	47.7	10.7	nd	nd

-continued

Stdev	326	22.2	326	22.3	nd	nd
p (t-test)		0.78		0.78	nd	nd
Min	0.0727	0.148	0.0727	0.148	nd	nd
Max	3150	55.8	3150	55.8	nd	nd
n (Samp)	131	6	131	6	nd	nd
n (Patient)	131	6	131	6	nd	nd
UO only						
Median	0.265	21.0	0.265	21.0	0.265	16.6
Average	90.5	265	90.5	265	90.5	16.4
Stdev	468	703	468	703	468	15.6
p (t-test)		0.35		0.35		0.70
Min	0.120	0.265	0.120	0.265	0.120	0.265
Max	3150	2000	3150	2000	3150	35.6
n (Samp)	63	8	63	8	63	6
n (Patient)	63	8	63	8	63	6

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.73	0.57	0.82	0.70	0.52	0.82	0.68	nd	0.78
SE	0.088	0.12	0.095	0.090	0.12	0.095	0.12	nd	0.11
p	0.0095	0.59	8.5E-4	0.025	0.86	8.5E-4	0.13	nd	0.015
nCohort 1	64	131	63	64	131	63	64	nd	63
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.195	0.195	3.03	0.195	0.168	3.03	0.195	nd	0.195
Sens 1	92%	83%	75%	83%	83%	75%	86%	nd	100%
Spec 1	41%	40%	78%	41%	31%	78%	41%	nd	43%
Cutoff 2	0.195	0.195	0.195	0.195	0.168	0.195	0.195	nd	0.195
Sens 2	92%	83%	100%	83%	83%	100%	86%	nd	100%
Spec 2	41%	40%	43%	41%	31%	43%	41%	nd	43%
Cutoff 3	0.195	0.120	0.195	0.168	0.120	0.195	0.120	nd	0.195
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	41%	2%	43%	34%	2%	43%	2%	nd	43%
Cutoff 4	0.265	10.2	0.265	0.265	10.2	0.265	0.265	nd	0.265
Sens 4	67%	17%	75%	58%	17%	75%	57%	nd	67%
Spec 4	70%	71%	76%	70%	71%	76%	70%	nd	76%
Cutoff 5	12.3	14.3	10.8	12.3	14.3	10.8	12.3	nd	10.8
Sens 5	50%	17%	62%	50%	17%	62%	43%	nd	50%
Spec 5	81%	80%	81%	81%	80%	81%	81%	nd	81%
Cutoff 6	21.6	25.6	21.6	21.6	25.6	21.6	21.6	nd	21.6
Sens 6	42%	17%	50%	42%	17%	50%	43%	nd	50%
Spec 6	91%	91%	90%	91%	91%	90%	91%	nd	90%
OR Quart 2	3.4	0	>2.1	4.8	2.1	>2.1	2.0	nd	>2.3
p Value	0.31	na	<0.55	0.18	0.56	<0.55	0.59	nd	<0.52
95% CI of	0.32	na	>0.18	0.48	0.18	>0.18	0.16	nd	>0.19
OR Quart 2	36	na	na	48	24	na	24	nd	na
OR Quart 3	2.1	4.4	>1.0	1.0	2.1	>1.0	0.94	nd	>0
p Value	0.55	0.20	<1.0	1.0	0.56	<1.0	0.97	nd	<na
95% CI of	0.18	0.47	>0.058	0.058	0.18	>0.058	0.054	nd	>na
OR Quart 3	26	42	na	17	24	na	16	nd	na
OR Quart 4	8.3	0.97	>6.5	8.3	0.97	>6.5	3.2	nd	>4.9
p Value	0.063	0.98	<0.10	0.063	0.98	<0.10	0.34	nd	<0.18
95% CI of	0.89	0.058	>0.68	0.89	0.058	>0.68	0.30	nd	>0.49
OR Quart 4	78	16	na	78	16	na	34	nd	na

Interleukin-33						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	0.101	15.5	0.101	15.5	0.101	9.09
Average	687	1070	687	1070	687	34.8
Stdev	4960	3520	4960	3520	4960	54.3
p (t-test)		0.80		0.80		0.73
Min	0.0445	0.0455	0.0445	0.0455	0.0445	0.0455
Max	40000	12300	40000	12300	40000	149
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7
sCr only						
Median	0.101	6.17	0.101	6.17	nd	nd
Average	489	24.6	489	24.6	nd	nd

-continued

Stdev	3680	44.2	3680	44.2	nd	nd
p (t-test)		0.76		0.76	nd	nd
Min	0.0445	0.0455	0.0445	0.0455	nd	nd
Max	40000	113	40000	113	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd
UO only						
Median	0.0981	39.7	0.0981	39.7	0.0981	12.6
Average	749	1600	749	1600	749	39.1
Stdev	5000	4310	5000	4310	5000	58.2
p (t-test)		0.65		0.65		0.73
Min	0.0445	0.0455	0.0445	0.0455	0.0445	0.0455
Max	40000	12300	40000	12300	40000	149
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.70	0.62	0.75	0.70	0.62	0.75	0.70	nd	0.68
SE	0.090	0.12	0.10	0.090	0.12	0.10	0.12	nd	0.13
p	0.023	0.33	0.018	0.023	0.33	0.018	0.086	nd	0.15
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	2.20	0.0981	2.65	2.20	0.0981	2.65	2.65	nd	2.20
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	68%	42%	67%	68%	42%	67%	68%	nd	67%
Cutoff 2	0.0981	0.0981	2.20	0.0981	0.0981	2.20	2.20	nd	2.20
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	46%	42%	67%	46%	42%	67%	68%	nd	67%
Cutoff 3	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445	nd	0.0445
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	11%	8%	8%	11%	8%	8%	11%	nd	8%
Cutoff 4	4.56	7.37	4.56	4.56	7.37	4.56	4.56	nd	4.56
Sens 4	58%	50%	62%	58%	50%	62%	57%	nd	50%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	20.5	27.4	31.5	20.5	27.4	31.5	20.5	nd	31.5
Sens 5	50%	17%	50%	50%	17%	50%	43%	nd	33%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	89.5	89.5	99.5	89.5	89.5	99.5	89.5	nd	99.5
Sens 6	33%	17%	38%	33%	17%	38%	14%	nd	17%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	2.1	0	>1.1	2.1	0	>1.1	0	nd	>1.0
p Value	0.55	na	<0.97	0.55	na	<0.97	na	nd	<1.0
95% CI of	0.18	na	>0.061	0.18	na	>0.061	na	nd	>0.058
OR Quart 2	26	na	na	26	na	na	na	nd	na
OR Quart 3	3.4	3.2	>3.6	3.4	3.2	>3.6	3.4	nd	>2.3
p Value	0.31	0.33	<0.29	0.31	0.33	<0.29	0.31	nd	<0.52
95% CI of	0.32	0.32	>0.34	0.32	0.32	>0.34	0.32	nd	>0.19
OR Quart 3	36	32	na	36	32	na	36	nd	na
OR Quart 4	7.7	2.0	>5.1	7.7	2.0	>5.1	3.4	nd	>3.4
p Value	0.072	0.58	<0.16	0.072	0.58	<0.16	0.31	nd	<0.31
95% CI of	0.83	0.17	>0.52	0.83	0.17	>0.52	0.32	nd	>0.32
OR Quart 4	72	23	na	72	23	na	36	nd	na

Vascular endothelial growth factor receptor 2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	8020	7370	8020	7130	8020	7560
Average	11300	25200	11300	25100	11300	7430
Stdev	18600	60300	18600	60300	18600	1750
p (t-test)		0.13		0.13		0.59
Min	3720	5310	3720	5310	3720	5310
Max	153000	216000	153000	216000	153000	10600
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7
sCr only						
Median	8020	6320	8020	5950	nd	nd
Average	11200	7000	11200	6800	nd	nd

-continued

Stdev	19000	1860	19000	1900	nd	nd
p (t-test)		0.59		0.57	nd	nd
Min	3720	5750	3720	5750	nd	nd
Max	166000	10600	166000	10600	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd
UO only						
Median	8010	7860	8010	7860	8010	7130
Average	11900	34100	11900	34100	11900	6900
Stdev	19000	73700	19000	73700	19000	1150
p (t-test)		0.049		0.049		0.53
Min	3900	5310	3900	5310	3900	5310
Max	153000	216000	153000	216000	153000	8150
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.31	0.52	0.44	0.28	0.52	0.39	nd	0.34
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.65	0.13	0.86	0.51	0.069	0.86	0.36	nd	0.21
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	5920	5830	6660	5920	5830	6660	6660	nd	5700
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	12%	15%	33%	12%	15%	33%	31%	nd	12%
Cutoff 2	5750	5830	5700	5750	5830	5700	5310	nd	5700
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	11%	15%	12%	11%	15%	12%	11%	nd	12%
Cutoff 3	5310	5720	5230	5310	5720	5230	5230	nd	5230
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	11%	14%	9%	11%	14%	9%	11%	nd	9%
Cutoff 4	9430	9520	9430	9430	9520	9430	9430	nd	9430
Sens 4	33%	17%	38%	33%	17%	38%	14%	nd	0%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	10800	10800	11100	10800	10800	11100	10800	nd	11100
Sens 5	17%	0%	25%	17%	0%	25%	0%	nd	0%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	13800	14200	16000	13800	14200	16000	13800	nd	16000
Sens 6	8%	0%	12%	8%	0%	12%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.67	0	1.0	0.67	0	1.0	1.0	nd	>1.1
p Value	0.68	na	1.0	0.68	na	1.0	1.0	nd	<0.94
95% CI of	0.099	na	0.13	0.099	na	0.13	0.058	nd	>0.065
OR Quart 2	4.5	na	8.0	4.5	na	8.0	17	nd	na
OR Quart 3	1.1	2.1	1.0	0.67	1.0	1.0	3.4	nd	>3.6
p Value	0.95	0.56	1.0	0.68	1.0	1.0	0.31	nd	<0.29
95% CI of	0.19	0.18	0.13	0.099	0.060	0.13	0.32	nd	>0.34
OR Quart 3	6.1	24	8.0	4.5	17	8.0	36	nd	na
OR Quart 4	1.5	3.3	1.0	2.0	4.5	1.0	2.1	nd	>2.4
p Value	0.62	0.31	1.0	0.39	0.19	1.0	0.55	nd	<0.49
95% CI of	0.29	0.32	0.13	0.41	0.48	0.13	0.18	nd	>0.20
OR Quart 4	7.9	33	8.0	10.0	43	8.0	26	nd	na

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	189000	172000	189000	172000	nd	nd
Average	192000	180000	192000	177000	nd	nd
Stdev	74500	49600	74500	44400	nd	nd
p (t-test)		0.65		0.56	nd	nd
Min	73000	111000	73000	111000	nd	nd
Max	520000	256000	520000	245000	nd	nd
n (Samp)	86	8	86	8	nd	nd
n (Patient)	86	8	86	8	nd	nd
UO only						
Median	186000	162000	186000	162000	nd	nd
Average	193000	166000	193000	166000	nd	nd

-continued

Stdev	78400	45100	78400	45100	nd	nd
p (t-test)		0.41		0.41	nd	nd
Min	73000	111000	73000	111000	nd	nd
Max	520000	245000	520000	245000	nd	nd
n (Samp)	79	6	79	6	nd	nd
n (Patient)	79	6	79	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	nd	0.39	0.45	nd	0.39	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.72	nd	0.40	0.67	nd	0.40	nd	nd	nd
nCohort 1	86	nd	79	86	nd	79	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	158000	nd	139000	158000	nd	139000	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	35%	nd	23%	35%	nd	23%	nd	nd	nd
Cutoff 2	139000	nd	139000	139000	nd	139000	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	22%	nd	23%	22%	nd	23%	nd	nd	nd
Cutoff 3	107000	nd	107000	107000	nd	107000	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	9%	nd	9%	9%	nd	9%	nd	nd	nd
Cutoff 4	217000	nd	217000	217000	nd	217000	nd	nd	nd
Sens 4	25%	nd	17%	25%	nd	17%	nd	nd	nd
Spec 4	71%	nd	71%	71%	nd	71%	nd	nd	nd
Cutoff 5	227000	nd	228000	227000	nd	228000	nd	nd	nd
Sens 5	25%	nd	17%	25%	nd	17%	nd	nd	nd
Spec 5	80%	nd	81%	80%	nd	81%	nd	nd	nd
Cutoff 6	272000	nd	262000	272000	nd	262000	nd	nd	nd
Sens 6	0%	nd	0%	0%	nd	0%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	0.50	nd	0	0.50	nd	0	nd	nd	nd
p Value	0.58	nd	na	0.58	nd	na	nd	nd	nd
95% CI of	0.042	nd	na	0.042	nd	na	nd	nd	nd
OR Quart 2	5.9	nd	na	5.9	nd	na	nd	nd	nd
OR Quart 3	1.6	nd	3.5	1.6	nd	3.5	nd	nd	nd
p Value	0.64	nd	0.30	0.64	nd	0.30	nd	nd	nd
95% CI of	0.24	nd	0.33	0.24	nd	0.33	nd	nd	nd
OR Quart 3	10	nd	37	10	nd	37	nd	nd	nd
OR Quart 4	1.0	nd	2.2	1.0	nd	2.2	nd	nd	nd
p Value	0.96	nd	0.53	0.96	nd	0.53	nd	nd	nd
95% CI of	0.13	nd	0.19	0.13	nd	0.19	nd	nd	nd
OR Quart 4	8.1	nd	26	8.1	nd	26	nd	nd	nd

Platelet-derived growth factor subunit B (dimer)						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	468	535	468	535	nd	nd
Average	494	734	494	734	nd	nd
Stdev	267	833	267	833	nd	nd
p (t-test)		0.064		0.064	nd	nd
Min	113	91.9	113	91.9	nd	nd
Max	1540	2720	1540	2720	nd	nd
n (Samp)	85	8	85	8	nd	nd
n (Patient)	85	8	85	8	nd	nd
UO only						
Median	438	535	438	535	nd	nd
Average	463	485	463	485	nd	nd
Stdev	254	247	254	247	nd	nd
p (t-test)		0.83		0.83	nd	nd
Min	113	91.9	113	91.9	nd	nd
Max	1540	721	1540	721	nd	nd
n (Samp)	78	6	78	6	nd	nd
n (Patient)	78	6	78	6	nd	nd

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	nd	0.58	0.55	nd	0.58	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.65	nd	0.52	0.65	nd	0.52	nd	nd	nd
nCohort 1	85	nd	78	85	nd	78	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	326	nd	326	326	nd	326	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	34%	nd	41%	34%	nd	41%	nd	nd	nd
Cutoff 2	238	nd	326	238	nd	326	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	12%	nd	41%	12%	nd	41%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	595	nd	543	595	nd	543	nd	nd	nd
Sens 4	50%	nd	50%	50%	nd	50%	nd	nd	nd
Spec 4	71%	nd	71%	71%	nd	71%	nd	nd	nd
Cutoff 5	660	nd	618	660	nd	618	nd	nd	nd
Sens 5	38%	nd	50%	38%	nd	50%	nd	nd	nd
Spec 5	80%	nd	81%	80%	nd	81%	nd	nd	nd
Cutoff 6	763	nd	747	763	nd	747	nd	nd	nd
Sens 6	12%	nd	0%	12%	nd	0%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	1.0	nd	2.1	1.0	nd	2.1	nd	nd	nd
p Value	1.0	nd	0.56	1.0	nd	0.56	nd	nd	nd
95% CI of	0.13	nd	0.18	0.13	nd	0.18	nd	nd	nd
OR Quart 2	7.8	nd	25	7.8	nd	25	nd	nd	nd
OR Quart 3	0.48	nd	0	0.48	nd	0	nd	nd	nd
p Value	0.56	nd	na	0.56	nd	na	nd	nd	nd
95% CI of	0.040	nd	na	0.040	nd	na	nd	nd	nd
OR Quart 3	5.7	nd	na	5.7	nd	na	nd	nd	nd
OR Quart 4	1.5	nd	3.3	1.5	nd	3.3	nd	nd	nd
p Value	0.67	nd	0.32	0.67	nd	0.32	nd	nd	nd
95% CI of	0.23	nd	0.32	0.23	nd	0.32	nd	nd	nd
OR Quart 4	9.9	nd	35	9.9	nd	35	nd	nd	nd
Corticotropin									
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.00105	0.00369	0.00105	0.00369	nd	nd			
Average	0.00913	0.00636	0.00913	0.00636	nd	nd			
Stdev	0.0411	0.00856	0.0411	0.00856	nd	nd			
p (t-test)		0.86		0.86	nd	nd			
Min	3.38E-6	3.38E-6	3.38E-6	3.38E-6	nd	nd			
Max	0.292	0.0245	0.292	0.0245	nd	nd			
n (Samp)	75	7	75	7	nd	nd			
n (Patient)	75	7	75	7	nd	nd			
UO only									
Median	0.00140	0.00367	0.00140	0.00367	nd	nd			
Average	0.0109	0.00681	0.0109	0.00681	nd	nd			
Stdev	0.0444	0.00929	0.0444	0.00929	nd	nd			
p (t-test)		0.82		0.82	nd	nd			
Min	4.31E-6	3.38E-6	4.31E-6	3.38E-6	nd	nd			
Max	0.292	0.0245	0.292	0.0245	nd	nd			
n (Samp)	64	6	64	6	nd	nd			
n (Patient)	64	6	64	6	nd	nd			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	nd	0.59	0.65	nd	0.59	nd	nd	nd
SE	0.12	nd	0.13	0.12	nd	0.13	nd	nd	nd
p	0.21	nd	0.49	0.21	nd	0.49	nd	nd	nd
nCohort 1	75	nd	64	75	nd	64	nd	nd	nd
nCohort 2	7	nd	6	7	nd	6	nd	nd	nd
Cutoff 1	0.00170	nd	0.000278	0.00170	nd	0.000278	nd	nd	nd

-continued

Sens 1	71%	nd	83%	71%	nd	83%	nd	nd	nd
Spec 1	64%	nd	30%	64%	nd	30%	nd	nd	nd
Cutoff 2	0.000278	nd	0.000278	0.000278	nd	0.000278	nd	nd	nd
Sens 2	86%	nd	83%	86%	nd	83%	nd	nd	nd
Spec 2	36%	nd	30%	36%	nd	30%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	0.00297	nd	0.00345	0.00297	nd	0.00345	nd	nd	nd
Sens 4	57%	nd	50%	57%	nd	50%	nd	nd	nd
Spec 4	71%	nd	70%	71%	nd	70%	nd	nd	nd
Cutoff 5	0.00423	nd	0.00550	0.00423	nd	0.00550	nd	nd	nd
Sens 5	43%	nd	33%	43%	nd	33%	nd	nd	nd
Spec 5	81%	nd	81%	81%	nd	81%	nd	nd	nd
Cutoff 6	0.00767	nd	0.00859	0.00767	nd	0.00859	nd	nd	nd
Sens 6	29%	nd	33%	29%	nd	33%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	0.95	nd	0.94	0.95	nd	0.94	nd	nd	nd
p Value	0.97	nd	0.97	0.97	nd	0.97	nd	nd	nd
95% CI of	0.055	nd	0.054	0.055	nd	0.054	nd	nd	nd
OR Quart 2	16	nd	16	16	nd	16	nd	nd	nd
OR Quart 3	2.1	nd	1.0	2.1	nd	1.0	nd	nd	nd
p Value	0.56	nd	1.0	0.56	nd	1.0	nd	nd	nd
95% CI of	0.18	nd	0.057	0.18	nd	0.057	nd	nd	nd
OR Quart 3	25	nd	17	25	nd	17	nd	nd	nd
OR Quart 4	3.2	nd	3.2	3.2	nd	3.2	nd	nd	nd
p Value	0.34	nd	0.34	0.34	nd	0.34	nd	nd	nd
95% CI of	0.30	nd	0.30	0.30	nd	0.30	nd	nd	nd
OR Quart 4	33	nd	34	33	nd	34	nd	nd	nd

Thyroxine-binding globulin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	43.7	29.2	43.7	28.6	43.7	42.5			
Average	42.7	35.2	42.7	34.5	42.7	42.1			
Stdev	12.2	13.1	12.2	13.5	12.2	14.0			
p (t-test)		0.029		0.017		0.89			
Min	15.5	21.0	15.5	21.0	15.5	24.8			
Max	75.8	63.7	75.8	63.7	75.8	62.0			
n (Samp)	110	15	110	15	110	8			
n (Patient)	110	15	110	15	110	8			
sCr only									
Median	39.3	30.1	39.3	28.6	nd	nd			
Average	41.1	40.0	41.1	38.9	nd	nd			
Stdev	12.1	16.1	12.1	17.1	nd	nd			
p (t-test)		0.82		0.65	nd	nd			
Min	14.2	23.4	14.2	22.3	nd	nd			
Max	75.8	63.7	75.8	63.7	nd	nd			
n (Samp)	180	7	180	7	nd	nd			
n (Patient)	180	7	180	7	nd	nd			
UO only									
Median	43.5	28.8	43.5	28.8	43.5	32.6			
Average	41.9	33.2	41.9	33.0	41.9	37.5			
Stdev	11.8	11.2	11.8	11.3	11.8	12.6			
p (t-test)		0.030		0.026		0.39			
Min	20.4	21.0	20.4	21.0	20.4	24.8			
Max	75.8	56.1	75.8	56.1	75.8	56.1			
n (Samp)	91	10	91	10	91	6			
n (Patient)	91	10	91	10	91	6			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.31	0.45	0.29	0.30	0.43	0.28	0.50	nd	0.41
SE	0.080	0.11	0.095	0.079	0.11	0.095	0.11	nd	0.13
p	0.018	0.66	0.024	0.011	0.54	0.021	1.00	nd	0.45
nCohort 1	110	180	91	110	180	91	110	nd	91
nCohort 2	15	7	10	15	7	10	8	nd	6
Cutoff 1	27.9	28.5	27.9	26.5	28.2	27.4	29.2	nd	29.1

-continued

Sens 1	73%	71%	70%	73%	71%	70%	75%	nd	83%
Spec 1	11%	14%	13%	8%	13%	11%	15%	nd	18%
Cutoff 2	27.4	28.2	27.4	23.7	23.3	26.8	29.1	nd	29.1
Sens 2	80%	86%	80%	80%	86%	80%	88%	nd	83%
Spec 2	9%	13%	11%	5%	7%	10%	15%	nd	18%
Cutoff 3	23.3	23.3	24.6	21.0	21.0	24.6	23.7	nd	24.6
Sens 3	93%	100%	90%	93%	100%	90%	100%	nd	100%
Spec 3	5%	7%	7%	2%	4%	7%	5%	nd	7%
Cutoff 4	48.0	47.1	47.2	48.0	47.1	47.2	48.0	nd	47.2
Sens 4	27%	43%	20%	27%	43%	20%	50%	nd	33%
Spec 4	70%	70%	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	52.3	50.1	50.4	52.3	50.1	50.4	52.3	nd	50.4
Sens 5	13%	29%	10%	13%	29%	10%	25%	nd	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	57.6	56.1	55.2	57.6	56.1	55.2	57.6	nd	55.2
Sens 6	7%	14%	10%	7%	14%	10%	12%	nd	17%
Spec 6	90%	90%	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	0	0	0	0	0	0	0.32	nd	0
p Value	na	na	na	na	na	na	0.34	nd	na
95% CI of	na	na	na	na	na	na	0.031	nd	na
OR Quart 2	na	na	na	na	na	na	3.3	nd	na
OR Quart 3	0.23	0	0.50	0.23	0	0.50	0.31	nd	0.50
p Value	0.21	na	0.58	0.21	na	0.58	0.32	nd	0.58
95% CI of	0.025	na	0.042	0.025	na	0.042	0.030	nd	0.042
OR Quart 3	2.2	na	5.9	2.2	na	5.9	3.2	nd	5.9
OR Quart 4	3.3	1.4	4.7	3.3	1.4	4.7	1.0	nd	1.6
p Value	0.067	0.67	0.073	0.067	0.67	0.073	0.97	nd	0.61
95% CI of	0.92	0.29	0.86	0.92	0.29	0.86	0.19	nd	0.25
OR Quart 4	12	6.6	25	12	6.6	25	5.6	nd	11

Pigment epithelium-derived factor

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	1670	1590	1670	1590	nd	nd
Average	1710	1630	1710	1590	nd	nd
Stdev	774	749	774	788	nd	nd
p (t-test)		0.78		0.67	nd	nd
Min	445	339	445	339	nd	nd
Max	4240	2850	4240	2850	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd
UO only						
Median	1620	1850	1620	1850	nd	nd
Average	1760	1720	1760	1720	nd	nd
Stdev	841	855	841	855	nd	nd
p (t-test)		0.93		0.93	nd	nd
Min	445	339	445	339	nd	nd
Max	4510	2850	4510	2850	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	nd	0.53	0.48	nd	0.53	nd	nd	nd
SE	0.11	nd	0.12	0.11	nd	0.12	nd	nd	nd
p	0.99	nd	0.82	0.82	nd	0.82	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	1280	nd	1280	1280	nd	1280	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	37%	nd	34%	37%	nd	34%	nd	nd	nd
Cutoff 2	1170	nd	1280	756	nd	1280	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	30%	nd	34%	9%	nd	34%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	2020	nd	2030	2020	nd	2030	nd	nd	nd
Sens 4	38%	nd	50%	38%	nd	50%	nd	nd	nd

-continued

Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	2350	nd	2350	2350	nd	2350	nd	nd	nd
Sens 5	12%	nd	17%	12%	nd	17%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	2830	nd	2880	2830	nd	2880	nd	nd	nd
Sens 6	12%	nd	0%	12%	nd	0%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	3.1	nd	0.95	3.3	nd	0.95	nd	nd	nd
p Value	0.34	nd	0.97	0.32	nd	0.97	nd	nd	nd
95% CI of	0.30	nd	0.056	0.32	nd	0.056	nd	nd	nd
OR Quart 2	33	nd	16	34	nd	16	nd	nd	nd
OR Quart 3	3.1	nd	3.3	2.1	nd	3.3	nd	nd	nd
p Value	0.34	nd	0.32	0.56	nd	0.32	nd	nd	nd
95% CI of	0.30	nd	0.32	0.18	nd	0.32	nd	nd	nd
OR Quart 3	33	nd	35	25	nd	35	nd	nd	nd
OR Quart 4	0.96	nd	0.95	2.2	nd	0.95	nd	nd	nd
p Value	0.98	nd	0.97	0.53	nd	0.97	nd	nd	nd
95% CI of	0.056	nd	0.056	0.18	nd	0.056	nd	nd	nd
OR Quart 4	16	nd	16	26	nd	16	nd	nd	nd

Tumor necrosis factor receptor superfamily member 8

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	104	107	104	107	104	93.1
Average	226	271	226	268	226	166
Stdev	549	403	549	404	549	192
p (t-test)		0.78		0.80		0.78
Min	26.3	50.0	26.3	50.0	26.3	50.0
Max	3360	1460	3360	1460	3360	595
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7
<u>sCr only</u>						
Median	117	100	117	94.1	nd	nd
Average	236	107	36	101	nd	nd
Stdev	507	26.7	507	33.0	nd	nd
p (t-test)		0.54		0.52	nd	nd
Min	26.3	82.5	26.3	60.0	nd	nd
Max	3360	152	3360	152	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd
<u>UO only</u>						
Median	115	107	115	107	115	98.7
Average	260	350	260	350	260	180
Stdev	575	483	575	483	575	206
p (t-test)		0.67		0.67		0.74
Min	30.2	50.0	30.2	50.0	30.2	50.0
Max	3360	1460	3360	1460	3360	595
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.42	0.56	0.54	0.38	0.56	0.48	nd	0.46
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.49	0.54	0.62	0.66	0.34	0.62	0.86	nd	0.78
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	89.9	83.2	89.9	83.2	75.6	89.9	83.2	nd	83.2
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	40%	28%	34%	34%	27%	34%	34%	nd	28%
Cutoff 2	83.2	83.2	83.2	75.6	83.2	75.6	75.6	nd	83.2
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	34%	28%	28%	32%	27%	28%	32%	nd	28%
Cutoff 3	75.6	75.6	43.9	56.2	56.6	43.9	47.2	nd	43.9
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	32%	27%	9%	14%	11%	9%	12%	nd	9%
Cutoff 4	165	167	167	165	167	167	165	nd	167
Sens 4	25%	0%	38%	25%	0%	38%	14%	nd	17%

-continued

Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	205	217	217	205	217	217	205	nd	217
Sens 5	25%	0%	38%	25%	0%	38%	14%	nd	17%
Spec 5	82%	80%	81%	82%	80%	81%	82%	nd	81%
Cutoff 6	292	310	323	292	310	323	292	nd	323
Sens 6	25%	0%	25%	25%	0%	25%	14%	nd	17%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	4.8	>2.2	4.9	1.6	>2.2	4.9	2.1	nd	1.1
p Value	0.18	<0.53	0.18	0.63	<0.53	0.18	0.55	nd	0.97
95% CI of	0.48	>0.19	0.49	0.23	>0.19	0.49	0.18	nd	0.061
OR Quart 2	48	na	49	11	na	49	26	nd	18
OR Quart 3	4.8	>4.5	0	2.3	>3.3	0	3.4	nd	3.4
p Value	0.18	<0.19	na	0.38	<0.31	na	0.31	nd	0.31
95% CI of	0.48	>0.48	na	0.36	>0.32	na	0.32	nd	0.32
OR Quart 3	48	na	na	14	na	na	36	nd	36
OR Quart 4	3.2	>0	3.4	1.5	>1.1	3.4	1.0	nd	1.1
p Value	0.34	<na	0.31	0.68	<0.97	0.31	1.0	nd	0.97
95% CI of	0.30	>na	0.32	0.22	>0.064	0.32	0.058	nd	0.061
OR Quart 4	34	na	36	10	na	36	17	nd	18

Alpha-fetoprotein

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.381	0.719	0.381	0.719	nd	nd
Average	0.450	0.803	0.450	0.803	nd	nd
Stdev	0.361	0.466	0.361	0.466	nd	nd
p (t-test)		0.011		0.011	nd	nd
Min	0.00580	0.00880	0.00580	0.00880	nd	nd
Max	1.81	1.53	1.81	1.53	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd
UO only						
Median	0.382	0.719	0.382	0.719	nd	nd
Average	0.449	0.851	0.449	0.851	nd	nd
Stdev	0.372	0.351	0.372	0.351	nd	nd
p (t-test)		0.012		0.012	nd	nd
Min	0.00580	0.583	0.00580	0.583	nd	nd
Max	1.81	1.53	1.81	1.53	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	nd	0.82	0.76	nd	0.82	nd	nd	nd
SE	0.10	nd	0.11	0.10	nd	0.11	nd	nd	nd
p	0.011	nd	0.0024	0.011	nd	0.0024	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	0.620	nd	0.620	0.620	nd	0.620	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	78%	nd	76%	78%	nd	76%	nd	nd	nd
Cutoff 2	0.558	nd	0.620	0.558	nd	0.620	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	74%	nd	76%	74%	nd	76%	nd	nd	nd
Cutoff 3	0.00580	nd	0.558	0.00580	nd	0.558	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	2%	nd	71%	2%	nd	71%	nd	nd	nd
Cutoff 4	0.541	nd	0.558	0.541	nd	0.558	nd	nd	nd
Sens 4	88%	nd	100%	88%	nd	100%	nd	nd	nd
Spec 4	70%	nd	71%	70%	nd	71%	nd	nd	nd
Cutoff 5	0.705	nd	0.741	0.705	nd	0.741	nd	nd	nd
Sens 5	50%	nd	33%	50%	nd	33%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	0.891	nd	0.891	0.891	nd	0.891	nd	nd	nd
Sens 6	38%	nd	33%	38%	nd	33%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	>0	0	nd	>0	nd	nd	nd
p Value	na	nd	<na	na	nd	<na	nd	nd	nd
95% CI of	na	nd	>na	na	nd	>na	nd	nd	nd

-continued

OR Quart 2	na	nd	na	na	nd	na	nd	nd	nd
OR Quart 3	2.0	nd	>2.2	2.0	nd	>2.2	nd	nd	nd
p Value	0.58	nd	<0.53	0.58	nd	<0.53	nd	nd	nd
95% CI of	0.17	nd	>0.19	0.17	nd	>0.19	nd	nd	nd
OR Quart 3	24	nd	na	24	nd	na	nd	nd	nd
OR Quart 4	5.8	nd	>4.7	5.8	nd	>4.7	nd	nd	nd
p Value	0.12	nd	<0.19	0.12	nd	<0.19	nd	nd	nd
95% CI of	0.62	nd	>0.48	0.62	nd	>0.48	nd	nd	nd
OR Quart 4	54	nd	na	54	nd	na	nd	nd	nd

Apolipoprotein E									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	55900	45300		55900	44900		55900	42800	
Average	67400	45200		67400	44600		67400	40300	
Stdev	48000	9980		48000	11000		48000	10100	
p (t-test)		0.11			0.12			0.14	
Min	8630	29200		8630	25800		8630	22400	
Max	260000	59600		260000	59600		260000	52300	
n (Samp)	111	12		111	11		111	7	
n (Patient)	111	12		111	11		111	7	
<u>sCr only</u>									
Median	56700	46700		nd	nd		nd	nd	
Average	69900	47000		nd	nd		nd	nd	
Stdev	49700	10900		nd	nd		nd	nd	
p (t-test)		0.26		nd	nd		nd	nd	
Min	8630	29200		nd	nd		nd	nd	
Max	260000	59600		nd	nd		nd	nd	
n (Samp)	193	6		nd	nd		nd	nd	
n (Patient)	193	6		nd	nd		nd	nd	
<u>UO only</u>									
Median	56300	43900		56300	42800		56300	42800	
Average	67500	43800		67500	41100		67500	39400	
Stdev	43600	8230		43600	10200		43600	10700	
p (t-test)		0.13			0.091			0.12	
Min	8630	31000		8630	25800		8630	22400	
Max	218000	54900		218000	54900		218000	52300	
n (Samp)	103	8		103	8		103	6	
n (Patient)	103	8		103	8		103	6	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.38	0.38	0.34	0.36	nd	0.30	0.32	nd	0.28
SE	0.090	0.12	0.11	0.094	nd	0.11	0.11	nd	0.12
p	0.17	0.34	0.14	0.15	nd	0.066	0.11	nd	0.074
nCohort 1	111	193	103	111	nd	103	111	nd	103
nCohort 2	12	6	8	11	nd	8	7	nd	6
Cutoff 1	41000	41900	41000	41000	nd	33100	41000	nd	30600
Sens 1	75%	83%	75%	73%	nd	75%	71%	nd	83%
Spec 1	34%	32%	33%	34%	nd	22%	34%	nd	17%
Cutoff 2	33100	41900	33100	33100	nd	30600	30600	nd	30600
Sens 2	83%	83%	88%	82%	nd	88%	86%	nd	83%
Spec 2	23%	32%	22%	23%	nd	17%	19%	nd	17%
Cutoff 3	30600	28800	30600	30600	nd	25400	19800	nd	19800
Sens 3	92%	100%	100%	91%	nd	100%	100%	nd	100%
Spec 3	19%	17%	17%	19%	nd	11%	7%	nd	8%
Cutoff 4	76700	79500	79500	76700	nd	79500	76700	nd	79500
Sens 4	0%	0%	0%	0%	nd	0%	0%	nd	0%
Spec 4	71%	70%	72%	71%	nd	72%	71%	nd	72%
Cutoff 5	89800	93400	94900	89800	nd	94900	89800	nd	94900
Sens 5	0%	0%	0%	0%	nd	0%	0%	nd	0%
Spec 5	80%	80%	81%	80%	nd	81%	80%	nd	81%
Cutoff 6	131000	139000	120000	131000	nd	120000	131000	nd	120000
Sens 6	0%	0%	0%	0%	nd	0%	0%	nd	0%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	>3.3	>2.1	>1.0	>3.4	nd	>1.0	>0	nd	>0
p Value	<0.31	<0.55	<0.98	<0.30	nd	<0.98	<na	nd	<na
95% CI of	>0.33	>0.18	>0.062	>0.34	nd	>0.062	>na	nd	>na

-continued

OR Quart 2	na	na	na	na	nd	na	na	nd	na
OR Quart 3	>7.4	>3.2	>6.1	>6.0	nd	>4.7	>6.0	nd	>4.9
p Value	<0.071	<0.32	<0.11	<0.11	nd	<0.18	<0.11	nd	<0.17
95% CI of	>0.84	>0.32	>0.66	>0.65	nd	>0.49	>0.66	nd	>0.51
OR Quart 3	na	na	na	na	nd	na	na	nd	na
OR Quart 4	>3.4	>1.0	>2.2	>3.4	nd	>3.5	>2.2	nd	>2.2
p Value	<0.30	<0.98	<0.52	<0.30	nd	<0.29	<0.52	nd	<0.52
95% CI of	>0.34	>0.063	>0.19	>0.34	nd	>0.34	>0.19	nd	>0.19
OR Quart 4	na	na	na	na	nd	na	na	nd	na

Apolipoprotein(a)									
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
<u>sCr or UO</u>									
Median	51300	43600		51300	44500		51300	94400	
Average	81000	62200		81000	65900		81000	78300	
Stdev	104000	61300		104000	62900		104000	47500	
p (t-test)		0.54			0.64			0.95	
Min	7.99	968		7.99	968		7.99	2260	
Max	631000	200000		631000	200000		631000	125000	
n (Samp)	111	12		111	11		111	7	
n (Patient)	111	12		111	11		111	7	
<u>sCr only</u>									
Median	47400	43600		nd	nd		nd	nd	
Average	84900	45900		nd	nd		nd	nd	
Stdev	109000	33900		nd	nd		nd	nd	
p (t-test)		0.38		nd	nd		nd	nd	
Min	7.99	968		nd	nd		nd	nd	
Max	631000	94400		nd	nd		nd	nd	
n (Samp)	193	6		nd	nd		nd	nd	
n (Patient)	193	6		nd	nd		nd	nd	
<u>UO only</u>									
Median	54000	68600		54000	68600		54000	104000	
Average	81600	76000		81600	75900		81600	79300	
Stdev	103000	69600		103000	69700		103000	52000	
p (t-test)		0.88			0.88			0.96	
Min	7.99	2260		7.99	2260		7.99	2260	
Max	631000	200000		631000	200000		631000	125000	
n (Samp)	103	8		103	8		103	6	
n (Patient)	103	8		103	8		103	6	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.47	0.45	0.52	0.49	nd	0.51	0.60	nd	0.59
SE	0.089	0.12	0.11	0.092	nd	0.11	0.12	nd	0.13
p	0.76	0.68	0.88	0.88	nd	0.89	0.38	nd	0.49
nCohort 1	111	193	103	111	nd	103	111	nd	103
nCohort 2	12	6	8	11	nd	8	7	nd	6
Cutoff 1	18200	18800	26200	25100	nd	25100	69900	nd	25100
Sens 1	75%	83%	75%	73%	nd	75%	71%	nd	83%
Spec 1	31%	33%	37%	37%	nd	36%	66%	nd	36%
Cutoff 2	2260	18800	2260	2260	nd	2260	25100	nd	25100
Sens 2	83%	83%	88%	82%	nd	88%	86%	nd	83%
Spec 2	7%	33%	5%	7%	nd	5%	37%	nd	36%
Cutoff 3	1680	814	1680	1680	nd	1680	1680	nd	1680
Sens 3	92%	100%	100%	91%	nd	100%	100%	nd	100%
Spec 3	7%	3%	5%	7%	nd	5%	7%	nd	5%
Cutoff 4	80900	85400	85400	80900	nd	85400	80900	nd	85400
Sens 4	33%	17%	50%	36%	nd	50%	57%	nd	67%
Spec 4	70%	70%	71%	70%	nd	71%	70%	nd	71%
Cutoff 5	128000	129000	128000	128000	nd	128000	128000	nd	128000
Sens 5	8%	0%	12%	9%	nd	12%	0%	nd	0%
Spec 5	80%	80%	81%	80%	nd	81%	80%	nd	81%
Cutoff 6	210000	221000	198000	210000	nd	198000	210000	nd	198000
Sens 6	0%	0%	12%	0%	nd	12%	0%	nd	0%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.64	>2.1	0.96	0.67	nd	0.96	0.97	nd	1.0
p Value	0.64	<0.55	0.97	0.67	nd	0.97	0.98	nd	1.0
95% CI of	0.100	>0.18	0.13	0.10	nd	0.13	0.058	nd	0.059

-continued

OR Quart 2	4.1	na	7.4	4.3	nd	7.4	16	nd	17
OR Quart 3	1.4	>3.2	0.46	1.0	nd	0.46	2.1	nd	1.0
p Value	0.69	<0.32	0.54	1.0	nd	0.54	0.56	nd	1.0
95% CI of	0.28	>0.32	0.039	0.19	nd	0.039	0.18	nd	0.059
OR Quart 3	6.8	na	5.4	5.4	nd	5.4	24	nd	17
OR Quart 4	1.0	>1.0	1.5	1.0	nd	1.5	3.1	nd	3.1
p Value	0.97	<0.98	0.67	0.97	nd	0.67	0.34	nd	0.34
95% CI of	0.19	>0.063	0.23	0.19	nd	0.23	0.30	nd	0.30
OR Quart 4	5.6	na	9.8	5.6	nd	9.8	32	nd	32

[0191] FIG. 9: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in urine samples

collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.

C-C motif chemokine 7									
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
sCr or UO									
Median	0.584	1.22	0.584	0.618	0.584	0.623			
Average	1.77	17.2	1.77	4.33	1.77	8.93			
Stdev	8.21	24.8	8.21	11.0	8.21	14.1			
p (t-test)		5.0E-16		0.17		0.0064			
Min	0.146	0.188	0.146	0.319	0.146	0.319			
Max	163	82.4	163	45.7	163	33.9			
n (Samp)	1277	22	1277	20	1277	10			
n (Patient)	452	22	452	20	452	10			
sCr only									
Median	0.584	1.22	nd	nd	nd	nd			
Average	2.34	15.5	nd	nd	nd	nd			
Stdev	12.1	24.5	nd	nd	nd	nd			
p (t-test)		0.0024	nd	nd	nd	nd			
Min	0.146	0.188	nd	nd	nd	nd			
Max	291	69.7	nd	nd	nd	nd			
n (Samp)	1341	8	nd	nd	nd	nd			
n (Patient)	467	8	nd	nd	nd	nd			
UO only									
Median	0.584	11.6	0.584	0.625	0.584	0.584			
Average	1.81	30.2	1.81	11.2	1.81	5.17			
Stdev	8.60	45.3	8.60	27.6	8.60	12.3			
p (t-test)		1.1E-25		1.2E-5		0.30			
Min	0.146	0.515	0.146	0.319	0.146	0.341			
Max	163	166	163	114	163	33.0			
n (Samp)	1124	14	1124	19	1124	7			
n (Patient)	362	14	362	19	362	7			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.70	0.78	0.54	nd	0.54	0.60	nd	0.53
SE	0.061	0.10	0.074	0.067	nd	0.068	0.095	nd	0.11
p	3.5E-5	0.054	1.6E-4	0.53	nd	0.58	0.28	nd	0.76
nCohort 1	1277	1341	1124	1277	nd	1124	1277	nd	1124
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	0.584	0.582	0.612	0.336	nd	0.319	0.451	nd	0.451
Sens 1	77%	75%	86%	70%	nd	89%	70%	nd	71%
Spec 1	52%	48%	51%	34%	nd	25%	43%	nd	41%
Cutoff 2	0.582	0.386	0.612	0.319	nd	0.319	0.336	nd	0.336
Sens 2	86%	88%	86%	90%	nd	89%	90%	nd	100%
Spec 2	49%	38%	51%	26%	nd	25%	34%	nd	33%
Cutoff 3	0.512	0.146	0.582	0.319	nd	0.301	0.336	nd	0.336
Sens 3	91%	100%	93%	90%	nd	100%	90%	nd	100%
Spec 3	44%	4%	47%	26%	nd	17%	34%	nd	33%
Cutoff 4	1.04	1.04	1.04	1.04	nd	1.04	1.04	nd	1.04
Sens 4	59%	62%	57%	20%	nd	21%	30%	nd	14%
Spec 4	73%	72%	71%	73%	nd	71%	73%	nd	71%

-continued

Cutoff 5	1.12	1.12	1.12	1.12	nd	1.12	1.12	nd	1.12
Sens 5	59%	62%	57%	20%	nd	21%	30%	nd	14%
Spec 5	81%	81%	80%	81%	nd	80%	81%	nd	80%
Cutoff 6	1.59	1.59	1.59	1.59	nd	1.59	1.59	nd	1.59
Sens 6	41%	38%	50%	15%	nd	21%	30%	nd	14%
Spec 6	94%	93%	94%	94%	nd	94%	94%	nd	94%
OR Quart 2	4.0	2.0	>1.0	3.6	nd	1.2	3.0	nd	>4.0
p Value	0.21	0.57	<1.0	0.12	nd	0.74	0.34	nd	<0.21
95% CI of	0.45	0.18	>0.062	0.73	nd	0.33	0.31	nd	>0.45
OR Quart 2	36	22	na	17	nd	4.7	29	nd	na
OR Quart 3	4.0	0	>5.1	3.6	nd	1.5	3.0	nd	>2.0
p Value	0.21	na	<0.14	0.12	nd	0.53	0.34	nd	<0.57
95% CI of	0.45	na	>0.59	0.73	nd	0.42	0.31	nd	>0.18
OR Quart 3	36	na	na	17	nd	5.4	29	nd	na
OR Quart 4	13	5.0	>8.2	2.0	nd	1.00	3.0	nd	>1.0
p Value	0.012	0.14	<0.048	0.42	nd	1.00	0.34	nd	<1.0
95% CI of	1.8	0.59	>1.0	0.36	nd	0.25	0.31	nd	>0.062
OR Quart 4	100	43	na	11	nd	4.0	29	nd	na

Vascular endothelial growth factor receptor 3

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	317	401	317	318	317	247
Average	334	402	334	351	334	350
Stdev	240	181	240	211	240	334
p (t-test)		0.29		0.79		0.87
Min	1.37	81.1	1.37	1.37	1.37	3.04
Max	2750	711	2750	798	2750	913
n (Samp)	655	14	655	15	655	7
n (Patient)	299	14	299	15	299	7
<u>UO only</u>						
Median	318	521	318	328	nd	nd
Average	341	475	341	359	nd	nd
Stdev	245	178	245	237	nd	nd
p (t-test)		0.10		0.81	nd	nd
Min	1.37	166	1.37	1.37	nd	nd
Max	2750	711	2750	798	nd	nd
n (Samp)	597	9	597	12	nd	nd
n (Patient)	262	9	262	12	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	nd	0.73	0.55	nd	0.55	0.46	nd	nd
SE	0.081	nd	0.096	0.077	nd	0.086	0.11	nd	nd
p	0.11	nd	0.016	0.54	nd	0.58	0.73	nd	nd
nCohort 1	655	nd	597	655	nd	597	655	nd	nd
nCohort 2	14	nd	9	15	nd	12	7	nd	nd
Cutoff 1	315	nd	364	273	nd	273	163	nd	nd
Sens 1	71%	nd	78%	73%	nd	75%	71%	nd	nd
Spec 1	50%	nd	62%	43%	nd	41%	19%	nd	nd
Cutoff 2	247	nd	249	264	nd	171	74.3	nd	nd
Sens 2	86%	nd	89%	80%	nd	83%	86%	nd	nd
Spec 2	35%	nd	36%	40%	nd	20%	9%	nd	nd
Cutoff 3	164	nd	164	0	nd	0	2.36	nd	nd
Sens 3	93%	nd	100%	100%	nd	100%	100%	nd	nd
Spec 3	20%	nd	19%	0%	nd	0%	4%	nd	nd
Cutoff 4	414	nd	414	414	nd	414	414	nd	nd
Sens 4	36%	nd	67%	33%	nd	42%	29%	nd	nd
Spec 4	72%	nd	72%	72%	nd	72%	72%	nd	nd
Cutoff 5	452	nd	455	452	nd	455	452	nd	nd
Sens 5	36%	nd	67%	33%	nd	42%	29%	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	542	nd	542	542	nd	542	542	nd	nd
Sens 6	29%	nd	44%	13%	nd	17%	29%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	1.5	nd	0.99	1.3	nd	0.66	0.50	nd	nd
p Value	0.65	nd	1.00	0.71	nd	0.65	0.57	nd	nd
95% CI of	0.25	nd	0.062	0.29	nd	0.11	0.045	nd	nd
OR Quart 2	9.2	nd	16	6.1	nd	4.0	5.6	nd	nd

-continued

OR Quart 3	2.0	nd	1.0	1.0	nd	0.66	0.50	nd	nd
p Value	0.42	nd	1.0	1.0	nd	0.65	0.57	nd	nd
95% CI of	0.37	nd	0.062	0.20	nd	0.11	0.045	nd	nd
OR Quart 3	11	nd	16	5.0	nd	4.0	5.5	nd	nd
OR Quart 4	2.5	nd	6.2	1.7	nd	1.7	1.5	nd	nd
p Value	0.27	nd	0.094	0.48	nd	0.48	0.65	nd	nd
95% CI of	0.48	nd	0.73	0.39	nd	0.39	0.25	nd	nd
OR Quart 4	13	nd	52	7.1	nd	7.1	9.2	nd	nd

Interferon alpha-2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.0967	0.0970	0.0967	0.0974	0.0967	1.20
Average	7.83	6.68	7.83	2.57	7.83	8.13
Stdev	18.2	10.4	18.2	6.54	18.2	13.0
p (t-test)		0.77		0.20		0.96
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0418
Max	126	31.4	126	24.7	126	34.2
n (Samp)	1277	22	1277	20	1277	10
n (Patient)	452	22	452	20	452	10
<u>sCr only</u>						
Median	0.0967	1.14	nd	nd	nd	nd
Average	7.67	5.56	nd	nd	nd	nd
Stdev	17.9	8.77	nd	nd	nd	nd
p (t-test)		0.74	nd	nd	nd	nd
Min	0.0238	0.0656	nd	nd	nd	nd
Max	126	24.9	nd	nd	nd	nd
n (Samp)	1341	8	nd	nd	nd	nd
n (Patient)	467	8	nd	nd	nd	nd
<u>UO only</u>						
Median	0.0967	0.0739	0.0967	0.0974	0.0967	2.39
Average	7.65	7.02	7.65	3.41	7.65	11.5
Stdev	17.8	11.6	17.8	7.11	17.8	14.5
p (t-test)		0.89		0.30		0.57
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.104
Max	126	31.4	126	24.7	126	34.2
n (Samp)	1124	14	1124	19	1124	7
n (Patient)	362	14	362	19	362	7

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.58	0.49	0.50	nd	0.49	0.69	nd	0.76
SE	0.064	0.11	0.078	0.065	nd	0.067	0.094	nd	0.11
p	0.34	0.48	0.94	0.94	nd	0.89	0.045	nd	0.017
nCohort 1	1277	1341	1124	1277	nd	1124	1277	nd	1124
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	0.0722	0.0672	0.0656	0.0802	nd	0.0722	0.114	nd	1.81
Sens 1	73%	75%	79%	70%	nd	74%	70%	nd	71%
Spec 1	37%	33%	29%	49%	nd	36%	65%	nd	75%
Cutoff 2	0.0656	0.0656	0.0435	0.0722	nd	0.0398	0.0974	nd	0.0974
Sens 2	91%	88%	86%	80%	nd	89%	90%	nd	100%
Spec 2	30%	30%	18%	37%	nd	14%	57%	nd	56%
Cutoff 3	0.0656	0.0606	0.0238	0.0398	nd	0.0369	0.0974	nd	0.0974
Sens 3	91%	100%	100%	90%	nd	95%	90%	nd	100%
Spec 3	30%	26%	3%	15%	nd	11%	57%	nd	56%
Cutoff 4	0.311	0.191	0.311	0.311	nd	0.311	0.311	nd	0.311
Sens 4	41%	50%	36%	15%	nd	21%	60%	nd	71%
Spec 4	74%	70%	74%	74%	nd	74%	74%	nd	74%
Cutoff 5	10.8	10.4	10.9	10.8	nd	10.9	10.8	nd	10.9
Sens 5	27%	25%	29%	10%	nd	16%	30%	nd	43%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	30.7	30.0	29.7	30.7	nd	29.7	30.7	nd	29.7
Sens 6	5%	0%	7%	0%	nd	0%	10%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	4.1	>4.0	0.50	0.75	nd	1.8	0	nd	>0
p Value	0.078	<0.21	0.42	0.70	nd	0.37	na	nd	<na
95% CI of	0.86	>0.45	0.091	0.17	nd	0.51	na	nd	>na
OR Quart 2	19	na	2.7	3.4	nd	6.1	na	nd	na

-continued

OR Quart 3	1.5	>0	1.3	2.5	nd	1.0	5.0	nd	>3.0
p Value	0.66	<na	0.74	0.12	nd	1.0	0.14	nd	<0.34
95% CI of	0.25	>na	0.33	0.79	nd	0.25	0.59	nd	>0.31
OR Quart 3	9.0	na	4.7	8.2	nd	4.0	43	nd	na
OR Quart 4	4.6	>4.0	0.75	0.75	nd	1.0	4.0	nd	>4.0
p Value	0.053	<0.21	0.71	0.70	nd	1.00	0.21	nd	<0.21
95% CI of	0.98	>0.45	0.17	0.17	nd	0.25	0.45	nd	>0.45
OR Quart 4	21	na	3.4	3.4	nd	4.1	36	nd	na

Insulin-like growth factor-binding protein 4

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.733	0.968	0.733	2.01	nd	nd
Average	1.72	1.38	1.72	4.03	nd	nd
Stdev	6.16	1.15	6.16	3.96	nd	nd
p (t-test)		0.88		0.22	nd	nd
Min	0.0319	0.0558	0.0319	0.0612	nd	nd
Max	85.6	2.84	85.6	11.4	nd	nd
n (Samp)	438	8	438	11	nd	nd
n (Patient)	226	8	226	11	nd	nd
<u>UO only</u>						
Median	nd	nd	0.733	3.77	nd	nd
Average	nd	nd	1.77	4.23	nd	nd
Stdev	nd	nd	6.43	3.74	nd	nd
p (t-test)	nd	nd		0.28	nd	nd
Min	nd	nd	0.0319	0.870	nd	nd
Max	nd	nd	85.6	11.4	nd	nd
n (Samp)	nd	nd	399	8	nd	nd
n (Patient)	nd	nd	196	8	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	nd	nd	0.75	nd	0.82	nd	nd	nd
SE	0.11	nd	nd	0.086	nd	0.092	nd	nd	nd
p	0.18	nd	nd	0.0036	nd	4.8E-4	nd	nd	nd
nCohort 1	438	nd	nd	438	nd	399	nd	nd	nd
nCohort 2	8	nd	nd	11	nd	8	nd	nd	nd
Cutoff 1	0.918	nd	nd	0.918	nd	0.870	nd	nd	nd
Sens 1	75%	nd	nd	73%	nd	88%	nd	nd	nd
Spec 1	57%	nd	nd	57%	nd	58%	nd	nd	nd
Cutoff 2	0.0585	nd	nd	0.845	nd	0.870	nd	nd	nd
Sens 2	88%	nd	nd	82%	nd	88%	nd	nd	nd
Spec 2	18%	nd	nd	56%	nd	58%	nd	nd	nd
Cutoff 3	0.0439	nd	nd	0.670	nd	0.845	nd	nd	nd
Sens 3	100%	nd	nd	91%	nd	100%	nd	nd	nd
Spec 3	12%	nd	nd	47%	nd	58%	nd	nd	nd
Cutoff 4	0.957	nd	nd	0.957	nd	0.957	nd	nd	nd
Sens 4	50%	nd	nd	55%	nd	62%	nd	nd	nd
Spec 4	75%	nd	nd	75%	nd	75%	nd	nd	nd
Cutoff 5	1.46	nd	nd	1.46	nd	1.46	nd	nd	nd
Sens 5	38%	nd	nd	55%	nd	62%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	3.30	nd	nd	3.30	nd	3.30	nd	nd	nd
Sens 6	0%	nd	nd	45%	nd	50%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	nd	>1.0	nd	>0	nd	nd	nd
p Value	na	nd	nd	<0.99	nd	<na	nd	nd	nd
95% CI of	na	nd	nd	>0.062	nd	>na	nd	nd	nd
OR Quart 2	na	nd	nd	na	nd	na	nd	nd	nd
OR Quart 3	1.0	nd	nd	>4.1	nd	>3.1	nd	nd	nd
p Value	1.0	nd	nd	<0.21	nd	<0.34	nd	nd	nd
95% CI of	0.14	nd	nd	>0.46	nd	>0.31	nd	nd	nd
OR Quart 3	7.2	nd	nd	na	nd	na	nd	nd	nd
OR Quart 4	2.0	nd	nd	>6.3	nd	>5.2	nd	nd	nd
p Value	0.42	nd	nd	<0.091	nd	<0.14	nd	nd	nd
95% CI of	0.36	nd	nd	>0.74	nd	>0.60	nd	nd	nd
OR Quart 4	11	nd	nd	na	nd	na	nd	nd	nd

-continued

Insulin-like growth factor-binding protein 5						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.0682	0.811	0.0682	0.0682	nd	nd
Average	0.658	1.44	0.658	1.33	nd	nd
Stdev	1.43	1.85	1.43	1.59	nd	nd
p (t-test)		0.13		0.12	nd	nd
Min	0.0116	0.0210	0.0116	0.0210	nd	nd
Max	10.3	5.59	10.3	3.92	nd	nd
n (Samp)	439	8	439	11	nd	nd
n (Patient)	227	8	227	11	nd	nd
UO only						
Median	nd	nd	0.0682	0.808	nd	nd
Average	nd	nd	0.652	1.45	nd	nd
Stdev	nd	nd	1.46	1.66	nd	nd
p (t-test)	nd	nd		0.13	nd	nd
Min	nd	nd	0.0116	0.0210	nd	nd
Max	nd	nd	10.3	3.92	nd	nd
n (Samp)	nd	nd	400	8	nd	nd
n (Patient)	nd	nd	197	8	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	nd	nd	0.57	nd	0.57	nd	nd	nd
SE	0.10	nd	nd	0.091	nd	0.11	nd	nd	nd
p	0.038	nd	nd	0.43	nd	0.50	nd	nd	nd
nCohort 1	439	nd	nd	439	nd	400	nd	nd	nd
nCohort 2	8	nd	nd	11	nd	8	nd	nd	nd
Cutoff 1	0.369	nd	nd	0.0262	nd	0.0116	nd	nd	nd
Sens 1	75%	nd	nd	73%	nd	100%	nd	nd	nd
Spec 1	67%	nd	nd	23%	nd	14%	nd	nd	nd
Cutoff 2	0.0544	nd	nd	0.0116	nd	0.0116	nd	nd	nd
Sens 2	88%	nd	nd	100%	nd	100%	nd	nd	nd
Spec 2	46%	nd	nd	13%	nd	14%	nd	nd	nd
Cutoff 3	0.0116	nd	nd	0.0116	nd	0.0116	nd	nd	nd
Sens 3	100%	nd	nd	100%	nd	100%	nd	nd	nd
Spec 3	13%	nd	nd	13%	nd	14%	nd	nd	nd
Cutoff 4	0.397	nd	nd	0.397	nd	0.397	nd	nd	nd
Sens 4	50%	nd	nd	45%	nd	50%	nd	nd	nd
Spec 4	77%	nd	nd	77%	nd	78%	nd	nd	nd
Cutoff 5	0.762	nd	nd	0.762	nd	0.558	nd	nd	nd
Sens 5	50%	nd	nd	45%	nd	50%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	2.38	nd	nd	2.38	nd	2.38	nd	nd	nd
Sens 6	12%	nd	nd	36%	nd	38%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	nd	0.65	nd	0.33	nd	nd	nd
p Value	na	nd	nd	0.65	nd	0.34	nd	nd	nd
95% CI of	na	nd	nd	0.11	nd	0.033	nd	nd	nd
OR Quart 2	na	nd	nd	4.0	nd	3.2	nd	nd	nd
OR Quart 3	3.0	nd	nd	0.33	nd	0	nd	nd	nd
p Value	0.34	nd	nd	0.34	nd	na	nd	nd	nd
95% CI of	0.31	nd	nd	0.034	nd	na	nd	nd	nd
OR Quart 3	30	nd	nd	3.2	nd	na	nd	nd	nd
OR Quart 4	4.1	nd	nd	1.7	nd	1.3	nd	nd	nd
p Value	0.21	nd	nd	0.48	nd	0.70	nd	nd	nd
95% CI of	0.45	nd	nd	0.39	nd	0.29	nd	nd	nd
OR Quart 4	37	nd	nd	7.2	nd	6.2	nd	nd	nd

Interleukin-33						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	40.9	22.9	40.9	35.9	40.9	21.0
Average	56.0	37.6	56.0	37.0	56.0	34.9

-continued

Stdev	60.8	43.3	60.8	24.9	60.8	42.2
p (t-test)		0.16		0.16		0.27
Min	0.0232	0.0523	0.0232	0.0232	0.0232	0.0688
Max	958	170	958	84.1	958	136
n (Samp)	1275	12	1275	20	1275	10
n (Patient)	452	22	452	20	452	10
sCr only						
Median	40.2	28.8	nd	nd	nd	nd
Average	55.1	51.4	nd	nd	nd	nd
Stdev	59.8	57.8	nd	nd	nd	nd
p (t-test)		0.86	nd	nd	nd	nd
Min	0.0232	1.78	nd	nd	nd	nd
Max	958	170	nd	nd	nd	nd
n (Samp)	1339	8	nd	nd	nd	nd
n (Patient)	467	8	nd	nd	nd	nd
UO only						
Median	41.0	19.8	41.0	27.1	41.0	41.9
Average	56.3	30.4	56.3	32.8	56.3	42.8
Stdev	62.1	31.4	62.1	27.2	62.1	49.0
p (t-test)		0.12		0.10		0.57
Min	0.0232	0.0436	0.0232	0.0232	0.0232	0.0688
Max	958	105	958	84.1	958	136
n (Samp)	1122	14	1122	19	1122	7
n (Patient)	362	14	362	19	362	7

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.40	0.48	0.36	0.43	nd	0.39	0.39	nd	0.43
SE	0.064	0.10	0.080	0.067	nd	0.069	0.095	nd	0.11
p	0.13	0.84	0.080	0.33	nd	0.12	0.23	nd	0.52
nCohort 1	1275	1339	1122	1275	nd	1122	1275	nd	1122
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	12.9	20.9	12.9	23.2	nd	14.3	7.14	nd	6.03
Sens 1	73%	75%	71%	70%	nd	74%	70%	nd	71%
Spec 1	25%	33%	25%	34%	nd	26%	19%	nd	17%
Cutoff 2	4.04	14.5	0.0558	14.9	nd	4.04	6.03	nd	0.0768
Sens 2	82%	88%	86%	80%	nd	84%	80%	nd	86%
Spec 2	16%	27%	5%	26%	nd	16%	18%	nd	10%
Cutoff 3	0.106	1.78	0.0518	7.14	nd	0.0360	0.0768	nd	0.0686
Sens 3	91%	100%	93%	90%	nd	95%	90%	nd	100%
Spec 3	12%	14%	3%	19%	nd	2%	10%	nd	6%
Cutoff 4	73.1	71.8	72.6	73.1	nd	72.6	73.1	nd	72.6
Sens 4	18%	25%	14%	5%	nd	5%	10%	nd	14%
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	93.1	92.2	93.9	93.1	nd	93.9	93.1	nd	93.9
Sens 5	14%	25%	7%	0%	nd	0%	10%	nd	14%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	127	126	127	127	nd	127	127	nd	127
Sens 6	5%	12%	0%	0%	nd	0%	10%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.3	0	3.0	7.1	nd	6.1	3.0	nd	3.0
p Value	0.70	na	0.34	0.067	nd	0.094	0.34	nd	0.34
95% CI of	0.30	na	0.31	0.87	nd	0.73	0.31	nd	0.31
OR Quart 2	6.0	na	29	58	nd	51	29	nd	29
OR Quart 3	3.1	2.5	5.1	9.2	nd	7.2	2.0	nd	0
p Value	0.095	0.27	0.14	0.036	nd	0.066	0.57	nd	na
95% CI of	0.82	0.49	0.59	1.2	nd	0.88	0.18	nd	na
OR Quart 3	11	13	44	73	nd	59	22	nd	na
OR Quart 4	2.0	0.50	5.1	3.0	nd	5.1	4.1	nd	3.0
p Value	0.32	0.57	0.14	0.34	nd	0.14	0.21	nd	0.34
95% CI of	0.50	0.045	0.59	0.31	nd	0.59	0.45	nd	0.31
OR Quart 4	8.2	5.5	44	29	nd	44	36	nd	29

Interleukin-4 receptor alpha chain

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	46.2	65.5	46.2	87.3	46.2	66.6
Average	56.4	62.9	56.4	81.4	56.4	75.3

-continued

Stdev	51.8	42.9	51.8	55.4	51.8	24.6
p (t-test)		0.63		0.066		0.33
Min	0.839	7.12	0.839	7.12	0.839	47.8
Max	299	156	299	230	299	119
n (Samp)	642	15	642	15	642	7
n (Patient)	293	15	293	15	293	7
UO only						
Median	46.2	66.5	46.2	77.9	nd	nd
Average	56.9	73.2	56.9	85.4	nd	nd
Stdev	52.8	49.1	52.8	58.9	nd	nd
p (t-test)		0.36		0.065	nd	nd
Min	0.839	7.12	0.839	7.12	nd	nd
Max	299	156	299	230	nd	nd
n (Samp)	587	9	587	12	nd	nd
n (Patient)	258	9	258	12	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	nd	0.61	0.66	nd	0.67	0.69	nd	nd
SE	0.078	nd	0.10	0.078	nd	0.087	0.11	nd	nd
p	0.37	nd	0.29	0.042	nd	0.057	0.089	nd	nd
nCohort 1	642	nd	587	642	nd	587	642	nd	nd
nCohort 2	15	nd	9	15	nd	12	7	nd	nd
Cutoff 1	50.2	nd	59.3	59.2	nd	59.2	60.1	nd	nd
Sens 1	73%	nd	78%	73%	nd	75%	71%	nd	nd
Spec 1	56%	nd	62%	61%	nd	61%	63%	nd	nd
Cutoff 2	11.8	nd	6.56	50.2	nd	50.2	59.3	nd	nd
Sens 2	80%	nd	100%	80%	nd	83%	86%	nd	nd
Spec 2	25%	nd	6%	56%	nd	56%	62%	nd	nd
Cutoff 3	6.56	nd	6.56	11.3	nd	11.3	46.5	nd	nd
Sens 3	100%	nd	100%	93%	nd	92%	100%	nd	nd
Spec 3	6%	nd	6%	20%	nd	19%	51%	nd	nd
Cutoff 4	75.2	nd	74.6	75.2	nd	74.6	75.2	nd	nd
Sens 4	27%	nd	33%	53%	nd	50%	43%	nd	nd
Spec 4	71%	nd	70%	71%	nd	70%	71%	nd	nd
Cutoff 5	94.3	nd	94.3	94.3	nd	94.3	94.3	nd	nd
Sens 5	20%	nd	33%	33%	nd	42%	29%	nd	nd
Spec 5	81%	nd	80%	81%	nd	80%	81%	nd	nd
Cutoff 6	122	nd	122	122	nd	122	122	nd	nd
Sens 6	13%	nd	11%	13%	nd	17%	0%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	0.33	nd	0	0.50	nd	0	>0	nd	nd
p Value	0.34	nd	na	0.57	nd	na	<na	nd	nd
95% CI of	0.034	nd	na	0.045	nd	na	>na	nd	nd
OR Quart 2	3.2	nd	na	5.5	nd	na	na	nd	nd
OR Quart 3	2.8	nd	2.0	2.0	nd	2.0	>5.2	nd	nd
p Value	0.14	nd	0.42	0.42	nd	0.42	<0.14	nd	nd
95% CI of	0.72	nd	0.37	0.37	nd	0.36	>0.60	nd	nd
OR Quart 3	11	nd	11	11	nd	11	na	nd	nd
OR Quart 4	0.99	nd	1.5	4.1	nd	3.1	>2.0	nd	nd
p Value	0.99	nd	0.65	0.076	nd	0.17	<0.57	nd	nd
95% CI of	0.20	nd	0.25	0.86	nd	0.61	>0.18	nd	nd
OR Quart 4	5.0	nd	9.2	20	nd	15	na	nd	nd

Vascular endothelial growth factor receptor 2

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
sCr or UO						
Median	605	866	605	825	605	561
Average	804	1120	804	888	804	829
Stdev	870	1050	870	798	870	1040
p (t-test)		0.18		0.71		0.94
Min	0.218	106	0.218	27.3	0.218	1.48
Max	7140	4230	7140	2600	7140	2820
n (Samp)	644	14	644	15	644	6
n (Patient)	294	14	294	15	294	6
UO only						
Median	626	1390	626	828	nd	nd
Average	824	1400	824	915	nd	nd

-continued

Stdev	875	1190	875	879	nd	nd
p (t-test)		0.051		0.72	nd	nd
Min	0.218	106	0.218	27.3	nd	nd
Max	7140	4230	7140	2600	nd	nd
n (Samp)	589	9	589	12	nd	nd
n (Patient)	259	9	259	12	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	nd	0.69	0.55	nd	0.53	0.48	nd	nd
SE	0.081	nd	0.099	0.077	nd	0.086	0.12	nd	nd
p	0.15	nd	0.058	0.52	nd	0.73	0.86	nd	nd
nCohort 1	644	nd	589	644	nd	589	644	nd	nd
nCohort 2	14	nd	9	15	nd	12	6	nd	nd
Cutoff 1	626	nd	747	224	nd	182	65.6	nd	nd
Sens 1	71%	nd	78%	73%	nd	75%	83%	nd	nd
Spec 1	51%	nd	58%	26%	nd	21%	16%	nd	nd
Cutoff 2	152	nd	581	182	nd	140	65.6	nd	nd
Sens 2	86%	nd	89%	80%	nd	83%	83%	nd	nd
Spec 2	21%	nd	47%	23%	nd	18%	16%	nd	nd
Cutoff 3	119	nd	106	119	nd	119	1.48	nd	nd
Sens 3	93%	nd	100%	93%	nd	92%	100%	nd	nd
Spec 3	19%	nd	16%	19%	nd	17%	8%	nd	nd
Cutoff 4	981	nd	1020	981	nd	1020	981	nd	nd
Sens 4	43%	nd	56%	40%	nd	42%	17%	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	nd
Cutoff 5	1330	nd	1340	1330	nd	1340	1330	nd	nd
Sens 5	36%	nd	56%	20%	nd	25%	17%	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	1740	nd	1770	1740	nd	1770	1740	nd	nd
Sens 6	14%	nd	22%	13%	nd	17%	17%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	0.33	nd	0.99	0.49	nd	0	2.0	nd	nd
p Value	0.34	nd	1.00	0.42	nd	na	0.57	nd	nd
95% CI of	0.034	nd	0.062	0.089	nd	na	0.18	nd	nd
OR Quart 2	3.2	nd	16	2.7	nd	na	23	nd	nd
OR Quart 3	1.7	nd	2.0	1.2	nd	0.79	1.0	nd	nd
p Value	0.48	nd	0.57	0.74	nd	0.74	1.0	nd	nd
95% CI of	0.40	nd	0.18	0.33	nd	0.21	0.062	nd	nd
OR Quart 3	7.2	nd	22	4.7	nd	3.0	16	nd	nd
OR Quart 4	1.7	nd	5.1	0.99	nd	0.59	2.0	nd	nd
p Value	0.48	nd	0.14	0.99	nd	0.47	0.57	nd	nd
95% CI of	0.39	nd	0.59	0.24	nd	0.14	0.18	nd	nd
OR Quart 4	7.1	nd	44	4.0	nd	2.5	23	nd	nd

Lutropin subunit beta						
	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	nd	nd	19.4	9.51	nd	nd
Average	nd	nd	56.4	42.0	nd	nd
Stdev	nd	nd	86.6	90.9	nd	nd
p (t-test)	nd	nd		0.57	nd	nd
Min	nd	nd	0.0297	0.341	nd	nd
Max	nd	nd	400	325	nd	nd
n (Samp)	nd	nd	353	12	nd	nd
n (Patient)	nd	nd	165	12	nd	nd
<u>UO only</u>						
Median	nd	nd	21.0	4.44	nd	nd
Average	nd	nd	60.2	7.20	nd	nd
Stdev	nd	nd	90.0	8.59	nd	nd
p (t-test)	nd	nd		0.12	nd	nd
Min	nd	nd	0.0297	0.505	nd	nd
Max	nd	nd	400	24.5	nd	nd
n (Samp)	nd	nd	352	7	nd	nd
n (Patient)	nd	nd	156	7	nd	nd

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.41	nd	0.25	nd	nd	nd
SE	nd	nd	nd	0.088	nd	0.11	nd	nd	nd
p	nd	nd	nd	0.28	nd	0.018	nd	nd	nd
nCohort 1	nd	nd	nd	353	nd	352	nd	nd	nd
nCohort 2	nd	nd	nd	12	nd	7	nd	nd	nd
Cutoff 1	nd	nd	nd	1.09	nd	1.09	nd	nd	nd
Sens 1	nd	nd	nd	75%	nd	71%	nd	nd	nd
Spec 1	nd	nd	nd	12%	nd	11%	nd	nd	nd
Cutoff 2	nd	nd	nd	0.840	nd	0.840	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	86%	nd	nd	nd
Spec 2	nd	nd	nd	10%	nd	10%	nd	nd	nd
Cutoff 3	nd	nd	nd	0.463	nd	0.463	nd	nd	nd
Sens 3	nd	nd	nd	92%	nd	100%	nd	nd	nd
Spec 3	nd	nd	nd	9%	nd	9%	nd	nd	nd
Cutoff 4	nd	nd	nd	45.5	nd	49.1	nd	nd	nd
Sens 4	nd	nd	nd	17%	nd	0%	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	70%	nd	nd	nd
Cutoff 5	nd	nd	nd	84.1	nd	92.0	nd	nd	nd
Sens 5	nd	nd	nd	8%	nd	0%	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	nd	nd	nd	179	nd	207	nd	nd	nd
Sens 6	nd	nd	nd	8%	nd	0%	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	nd	nd	nd	1.5	nd	>1.0	nd	nd	nd
p Value	nd	nd	nd	0.64	nd	<0.99	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	>0.062	nd	nd	nd
OR Quart 2	nd	nd	nd	9.4	nd	na	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	>2.0	nd	nd	nd
p Value	nd	nd	nd	0.99	nd	<0.56	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	>0.18	nd	nd	nd
OR Quart 3	nd	nd	nd	7.3	nd	na	nd	nd	nd
OR Quart 4	nd	nd	nd	2.6	nd	>4.2	nd	nd	nd
p Value	nd	nd	nd	0.26	nd	<0.20	nd	nd	nd
95% CI of	nd	nd	nd	0.49	nd	>0.46	nd	nd	nd
OR Quart 4	nd	nd	nd	14	nd	na	nd	nd	nd

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	2720	3990	2720	2660	2720	2100
Average	3320	4390	3320	6260	3320	2840
Stdev	2860	3520	2860	11900	2860	2900
p (t-test)		0.085		4.5E-5		0.60
Min	0.234	142	0.234	375	0.234	138
Max	48400	15000	48400	55700	48400	9700
n (Samp)	1272	27	1272	20	1272	10
n (Patient)	450	22	450	20	450	10
<u>sCr only</u>						
Median	2740	2260	nd	nd	nd	nd
Average	3430	2670	nd	nd	nd	nd
Stdev	3250	2170	nd	nd	nd	nd
p (t-test)		0.51	nd	nd	nd	nd
Min	0.234	142	nd	nd	nd	nd
Max	55700	6800	nd	nd	nd	nd
n (Samp)	1336	8	nd	nd	nd	nd
n (Patient)	465	8	nd	nd	nd	nd
<u>UO only</u>						
Median	2820	4560	2820	4560	2820	3060
Average	3380	6830	3380	8190	3380	3540
Stdev	2830	6750	2830	12900	2830	3190
p (t-test)		1.1E-5		2.2E-10		0.88
Min	0.234	416	0.234	375	0.234	346
Max	48400	26600	48400	55700	48400	9700
n (Samp)	1118	14	1118	19	1118	7
n (Patient)	360	14	360	19	360	7

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.42	0.71	0.55	nd	0.62	0.40	nd	0.48
SE	0.064	0.11	0.079	0.067	nd	0.069	0.095	nd	0.11
p	0.15	0.46	0.0090	0.44	nd	0.079	0.31	nd	0.86
nCohort 1	1272	1336	1118	1272	nd	1118	1272	nd	1118
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	2200	1340	3860	2030	nd	2080	1180	nd	1650
Sens 1	73%	75%	71%	70%	nd	74%	70%	nd	71%
Spec 1	40%	19%	68%	35%	nd	34%	16%	nd	24%
Cutoff 2	1340	623	2310	1740	nd	1740	962	nd	1180
Sens 2	82%	88%	86%	80%	nd	84%	80%	nd	86%
Spec 2	20%	5%	40%	29%	nd	26%	11%	nd	14%
Cutoff 3	623	85.5	1490	1110	nd	1110	341	nd	337
Sens 3	91%	100%	93%	90%	nd	95%	90%	nd	100%
Spec 3	5%	0%	21%	15%	nd	14%	1%	nd	1%
Cutoff 4	3930	3980	3980	3930	nd	3980	3930	nd	3980
Sens 4	55%	12%	64%	45%	nd	58%	20%	nd	29%
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	4840	4910	4890	4840	nd	4890	4840	nd	4890
Sens 5	41%	12%	43%	35%	nd	42%	20%	nd	29%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	6370	6470	6410	6370	nd	6410	6370	nd	6410
Sens 6	23%	12%	36%	20%	nd	32%	10%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.33	2.0	0.50	1.5	nd	1.7	1.0	nd	1.0
p Value	0.17	0.57	0.57	0.53	nd	0.48	1.00	nd	1.00
95% CI of	0.066	0.18	0.045	0.42	nd	0.40	0.14	nd	0.14
OR Quart 2	1.6	22	5.5	5.4	nd	7.1	7.2	nd	7.2
OR Quart 3	0.83	2.0	2.0	0.50	nd	0.33	1.0	nd	0
p Value	0.76	0.57	0.42	0.42	nd	0.34	1.0	nd	na
95% CI of	0.25	0.18	0.37	0.090	nd	0.034	0.14	nd	na
OR Quart 3	2.7	22	11	2.7	nd	3.2	7.1	nd	na
OR Quart 4	1.5	3.0	3.6	2.0	nd	3.4	2.0	nd	1.5
p Value	0.44	0.34	0.12	0.25	nd	0.065	0.42	nd	0.65
95% CI of	0.53	0.31	0.73	0.60	nd	0.93	0.37	nd	0.25
OR Quart 4	4.3	29	17	6.8	nd	13	11	nd	9.1

Platelet-derived growth factor subunit B (dimer)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	1.19	3.23	1.19	1.55	1.19	2.47
Average	3.27	6.13	3.27	68.5	3.27	1.87
Stdev	12.5	8.36	12.5	249	12.5	1.44
p (t-test)		0.41		6.0E-14		0.77
Min	0.00246	1.15	0.00246	0.0144	0.00246	0.371
Max	270	30.4	270	935	270	3.71
n (Samp)	933	13	933	14	933	7
n (Patient)	344	13	344	14	344	7
<u>sCr only</u>						
Median	1.23	2.28	nd	nd	nd	nd
Average	4.24	2.60	nd	nd	nd	nd
Stdev	32.3	1.38	nd	nd	nd	nd
p (t-test)		0.90	nd	nd	nd	nd
Min	0.00246	1.15	nd	nd	nd	nd
Max	935	4.52	nd	nd	nd	nd
n (Samp)	970	6	nd	nd	nd	nd
n (Patient)	354	6	nd	nd	nd	nd
<u>UO only</u>						
Median	1.24	3.58	1.24	2.37	nd	nd
Average	3.30	10.3	3.30	72.4	nd	nd
Stdev	13.0	19.8	13.0	248	nd	nd
p (t-test)		0.13		1.2E-13	nd	nd
Min	0.00246	1.22	0.00246	0.0144	nd	nd
Max	270	59.1	270	935	nd	nd
n (Samp)	800	8	800	14	nd	nd
n (Patient)	263	8	263	14	nd	nd

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.77	0.69	0.80	0.57	nd	0.62	0.56	nd	nd
SE	0.077	0.12	0.095	0.080	nd	0.081	0.11	nd	nd
p	4.6E-4	0.11	0.0018	0.40	nd	0.14	0.59	nd	nd
nCohort 1	933	970	800	933	nd	800	933	nd	nd
nCohort 2	13	6	8	14	nd	14	7	nd	nd
Cutoff 1	2.03	1.39	2.84	0.943	nd	0.938	0.393	nd	nd
Sens 1	77%	83%	75%	71%	nd	71%	71%	nd	nd
Spec 1	67%	54%	76%	44%	nd	43%	27%	nd	nd
Cutoff 2	1.39	1.39	2.03	0.162	nd	0.162	0.392	nd	nd
Sens 2	85%	83%	88%	86%	nd	86%	86%	nd	nd
Spec 2	55%	54%	66%	20%	nd	21%	27%	nd	nd
Cutoff 3	1.20	1.14	1.20	0.0140	nd	0.0140	0.365	nd	nd
Sens 3	92%	100%	100%	100%	nd	100%	100%	nd	nd
Spec 3	50%	48%	49%	11%	nd	12%	26%	nd	nd
Cutoff 4	2.18	2.23	2.22	2.18	nd	2.22	2.18	nd	nd
Sens 4	69%	50%	75%	43%	nd	50%	57%	nd	nd
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	nd
Cutoff 5	3.13	3.16	3.15	3.13	nd	3.15	3.13	nd	nd
Sens 5	54%	33%	62%	29%	nd	43%	14%	nd	nd
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	5.13	5.13	5.05	5.13	nd	5.05	5.13	nd	nd
Sens 6	23%	0%	25%	14%	nd	29%	0%	nd	nd
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	>2.0	>1.0	>1.0	1.00	nd	0.66	>3.0	nd	nd
p Value	<0.57	<1.00	<1.00	1.00	nd	0.65	<0.34	nd	nd
95% CI of	>0.18	>0.062	>0.062	0.20	nd	0.11	>0.31	nd	nd
OR Quart 2	na	na	na	5.0	nd	4.0	na	nd	nd
OR Quart 3	>3.0	>3.0	>1.0	1.00	nd	0.66	>1.0	nd	nd
p Value	<0.34	<0.34	<1.00	1.00	nd	0.65	<1.00	nd	nd
95% CI of	>0.31	>0.31	>0.062	0.20	nd	0.11	>0.062	nd	nd
OR Quart 3	na	na	na	5.0	nd	4.0	na	nd	nd
OR Quart 4	>8.2	>2.0	>6.2	1.7	nd	2.4	>3.0	nd	nd
p Value	<0.048	<0.57	<0.093	0.48	nd	0.22	<0.34	nd	nd
95% CI of	>1.0	>0.18	>0.74	0.40	nd	0.60	>0.31	nd	nd
OR Quart 4	na	na	na	7.1	nd	9.3	na	nd	nd

Corticotropin

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.00162	0.00162	0.00162	0.00425	nd	nd
Average	0.00219	0.00196	0.00219	0.00914	nd	nd
Stdev	0.00354	0.00112	0.00354	0.0119	nd	nd
p (t-test)		0.87		1.1E-7	nd	nd
Min	3.92E-6	0.00109	3.92E-6	0.000794	nd	nd
Max	0.0489	0.00427	0.0489	0.0377	nd	nd
n (Samp)	332	7	332	10	nd	nd
n (Patient)	193	7	193	10	nd	nd
<u>UO only</u>						
Median	nd	nd	0.00163	0.00380	nd	nd
Average	nd	nd	0.00233	0.00797	nd	nd
Stdev	nd	nd	0.00396	0.0123	nd	nd
p (t-test)	nd	nd		3.4E-4	nd	nd
Min	nd	nd	0.000273	0.000794	nd	nd
Max	nd	nd	0.0489	0.0377	nd	nd
n (Samp)	nd	nd	290	8	nd	nd
n (Patient)	nd	nd	162	8	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	nd	nd	0.78	nd	0.72	nd	nd	nd
SE	0.11	nd	nd	0.087	nd	0.10	nd	nd	nd
p	1.00	nd	nd	0.0013	nd	0.032	nd	nd	nd
nCohort 1	332	nd	nd	332	nd	290	nd	nd	nd
nCohort 2	7	nd	nd	10	nd	8	nd	nd	nd
Cutoff 1	0.00134	nd	nd	0.00375	nd	0.00229	nd	nd	nd

-continued

Sens 1	71%	nd	nd	70%	nd	75%	nd	nd	nd
Spec 1	32%	nd	nd	92%	nd	72%	nd	nd	nd
Cutoff 2	0.00106	nd	nd	0.00229	nd	0.00106	nd	nd	nd
Sens 2	100%	nd	nd	80%	nd	88%	nd	nd	nd
Spec 2	19%	nd	nd	73%	nd	20%	nd	nd	nd
Cutoff 3	0.00106	nd	nd	0.00106	nd	0.000687	nd	nd	nd
Sens 3	100%	nd	nd	90%	nd	100%	nd	nd	nd
Spec 3	19%	nd	nd	19%	nd	9%	nd	nd	nd
Cutoff 4	0.00212	nd	nd	0.00212	nd	0.00218	nd	nd	nd
Sens 4	29%	nd	nd	80%	nd	75%	nd	nd	nd
Spec 4	70%	nd	nd	70%	nd	70%	nd	nd	nd
Cutoff 5	0.00274	nd	nd	0.00274	nd	0.00275	nd	nd	nd
Sens 5	14%	nd	nd	70%	nd	62%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	0.00352	nd	nd	0.00352	nd	0.00362	nd	nd	nd
Sens 6	14%	nd	nd	70%	nd	62%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	0.49	nd	nd	0	nd	0	nd	nd	nd
p Value	0.57	nd	nd	na	nd	na	nd	nd	nd
95% CI of	0.044	nd	nd	na	nd	na	nd	nd	nd
OR Quart 2	5.6	nd	nd	na	nd	na	nd	nd	nd
OR Quart 3	1.0	nd	nd	0.49	nd	0.49	nd	nd	nd
p Value	1.0	nd	nd	0.57	nd	0.57	nd	nd	nd
95% CI of	0.14	nd	nd	0.044	nd	0.044	nd	nd	nd
OR Quart 3	73	nd	nd	5.6	nd	5.6	nd	nd	nd
OR Quart 4	1.0	nd	nd	3.7	nd	2.6	nd	nd	nd
p Value	0.99	nd	nd	0.11	nd	0.27	nd	nd	nd
95% CI of	0.14	nd	nd	0.74	nd	0.48	nd	nd	nd
OR Quart 4	7.4	nd	nd	18	nd	14	nd	nd	nd

Pigment epithelium-derived factor

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
<u>sCr or UO</u>									
Median	3.21	8.76	3.21	11.6	3.21	4.86			
Average	20.2	39.5	20.2	41.2	20.2	21.3			
Stdev	47.4	63.3	47.4	54.0	47.4	36.7			
p (t-test)		0.060		0.050		0.94			
Min	0.000401	0.0312	0.000401	0.117	0.000401	0.00102			
Max	400	204	400	168	400	115			
n (Samp)	1273	22	1273	20	1273	10			
n (Patient)	451	22	451	20	451	10			
<u>sCr only</u>									
Median	3.33	12.0	nd	nd	nd	nd			
Average	20.9	37.0	nd	nd	nd	nd			
Stdev	47.9	57.0	nd	nd	nd	nd			
p (t-test)		0.34	nd	nd	nd	nd			
Min	0.000401	0.0312	nd	nd	nd	nd			
Max	400	168	nd	nd	nd	nd			
n (Samp)	1337	8	nd	nd	nd	nd			
n (Patient)	466	8	nd	nd	nd	nd			
<u>UO only</u>									
Median	3.46	19.8	3.46	14.9	3.46	2.22			
Average	22.0	53.2	22.0	55.6	22.0	26.7			
Stdev	50.6	75.1	50.6	71.6	50.6	43.3			
p (t-test)		0.023		0.0045		0.81			
Min	0.000401	0.106	0.000401	0.190	0.000401	0.644			
Max	400	204	400	250	400	115			
n (Samp)	1119	14	1119	19	1119	7			
n (Patient)	361	14	361	19	361	7			
	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.64	0.66	0.64	nd	0.68	0.52	nd	0.53
SE	0.064	0.11	0.080	0.067	nd	0.069	0.093	nd	0.11
p	0.069	0.19	0.048	0.033	nd	0.0099	0.81	nd	0.81
nCohort 1	1273	1337	1119	1273	nd	1119	1273	nd	1119
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	2.66	4.16	3.30	2.20	nd	2.20	1.56	nd	1.56

-continued

Sens 1	73%	75%	71%	70%	nd	74%	70%	nd	71%
Spec 1	46%	55%	49%	43%	nd	41%	36%	nd	34%
Cutoff 2	2.01	2.29	2.01	1.99	nd	1.99	0.682	nd	0.682
Sens 2	82%	88%	86%	80%	nd	84%	80%	nd	86%
Spec 2	41%	43%	39%	41%	nd	39%	21%	nd	19%
Cutoff 3	0.351	0.0292	0.511	1.24	nd	1.24	0.643	nd	0.640
Sens 3	91%	100%	93%	90%	nd	95%	90%	nd	100%
Spec 3	12%	1%	14%	31%	nd	29%	20%	nd	19%
Cutoff 4	10.1	10.5	11.0	10.1	nd	11.0	10.1	nd	11.0
Sens 4	50%	50%	57%	50%	nd	53%	40%	nd	43%
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	21.8	23.1	23.9	21.8	nd	23.9	21.8	nd	23.9
Sens 5	41%	38%	43%	40%	nd	47%	20%	nd	29%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	52.9	58.1	60.9	52.9	nd	60.9	52.9	nd	60.9
Sens 6	23%	25%	29%	30%	nd	32%	20%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.75	1.0	1.5	2.5	nd	5.1	0.66	nd	1.00
p Value	0.70	1.0	0.66	0.27	nd	0.14	0.65	nd	1.00
95% CI of	0.17	0.062	0.25	0.49	nd	0.59	0.11	nd	0.14
OR Quart 2	3.4	16	9.1	13	nd	44	4.0	nd	7.1
OR Quart 3	1.2	2.0	0.50	2.0	nd	4.0	0.66	nd	0.50
p Value	0.74	0.57	0.57	0.42	nd	0.21	0.65	nd	0.57
95% CI of	0.33	0.18	0.045	0.37	nd	0.45	0.11	nd	0.045
OR Quart 3	4.7	22	5.5	11	nd	36	4.0	nd	5.5
OR Quart 4	2.5	4.0	4.1	4.6	nd	9.2	1.00	nd	1.00
p Value	0.12	0.21	0.077	0.053	nd	0.036	1.00	nd	1.00
95% CI of	0.79	0.45	0.86	0.98	nd	1.2	0.20	nd	0.14
OR Quart 4	8.2	36	19	21	nd	73	5.0	nd	7.1

Tumor necrosis factor receptor superfamily member 8

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	19.5	38.9	19.5	19.6	19.5	13.2
Average	29.9	57.9	29.9	29.5	29.9	23.3
Stdev	44.8	86.8	44.8	30.1	44.8	23.1
p (t-test)		0.020		0.97		0.70
Min	0.0493	0.121	0.0493	0.0561	0.0493	0.196
Max	554	353	554	102	554	50.0
n (Samp)	658	15	658	16	658	7
n (Patient)	300	15	300	16	300	7
<u>UO only</u>						
Median	19.5	38.9	19.5	19.8	nd	nd
Average	29.9	44.8	29.9	31.2	nd	nd
Stdev	46.4	32.5	46.4	33.2	nd	nd
p (t-test)		0.34		0.92	nd	nd
Min	0.0493	6.52	0.0493	0.0561	nd	nd
Max	554	117	554	102	nd	nd
n (Samp)	600	9	600	13	nd	nd
n (Patient)	263	9	263	13	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	nd	0.72	0.51	nd	0.51	0.48	nd	nd
SE	0.078	nd	0.098	0.074	nd	0.082	0.11	nd	nd
p	0.053	nd	0.027	0.84	nd	0.86	0.85	nd	nd
nCohort 1	658	nd	600	658	nd	600	658	nd	nd
nCohort 2	15	nd	9	16	nd	13	7	nd	nd
Cutoff 1	25.6	nd	30.2	5.76	nd	4.22	6.53	nd	nd
Sens 1	73%	nd	78%	75%	nd	77%	71%	nd	nd
Spec 1	60%	nd	68%	23%	nd	17%	25%	nd	nd
Cutoff 2	15.4	nd	15.4	4.22	nd	3.98	0.196	nd	nd
Sens 2	80%	nd	89%	81%	nd	85%	86%	nd	nd
Spec 2	44%	nd	45%	16%	nd	16%	8%	nd	nd
Cutoff 3	1.18	nd	5.76	1.80	nd	1.80	0.121	nd	nd
Sens 3	93%	nd	100%	94%	nd	92%	100%	nd	nd
Spec 3	12%	nd	25%	15%	nd	16%	6%	nd	nd
Cutoff 4	32.7	nd	31.4	32.7	nd	31.4	32.7	nd	nd
Sens 4	60%	nd	67%	38%	nd	46%	43%	nd	nd

-continued

Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	nd
Cutoff 5	41.7	nd	41.1	41.7	nd	41.1	41.7	nd	nd
Sens 5	40%	nd	33%	19%	nd	23%	43%	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	62.5	nd	62.5	62.5	nd	62.5	62.5	nd	nd
Sens 6	20%	nd	22%	12%	nd	15%	0%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	0.33	nd	>2.0	0.39	nd	0.49	0	nd	nd
p Value	0.34	nd	<0.57	0.27	nd	0.42	na	nd	nd
95% CI of	0.034	nd	>0.18	0.075	nd	0.089	na	nd	nd
OR Quart 2	3.2	nd	na	2.0	nd	2.7	na	nd	nd
OR Quart 3	1.0	nd	>2.0	0.80	nd	0.49	0.67	nd	nd
p Value	1.0	nd	<0.57	0.74	nd	0.42	0.66	nd	nd
95% CI of	0.20	nd	>0.18	0.21	nd	0.089	0.11	nd	nd
OR Quart 3	5.0	nd	na	3.0	nd	2.7	4.0	nd	nd
OR Quart 4	2.7	nd	>5.1	0.99	nd	1.2	0.67	nd	nd
p Value	0.14	nd	<0.14	0.99	nd	0.74	0.66	nd	nd
95% CI of	0.71	nd	>0.59	0.28	nd	0.33	0.11	nd	nd
OR Quart 4	10	nd	na	3.5	nd	4.7	4.0	nd	nd

Alpha-fetoprotein

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	0.00505	0.00508	0.00505	0.0385	0.00505	0.00446
Average	0.0526	0.0780	0.0526	0.263	0.0526	0.0371
Stdev	0.146	0.123	0.146	0.722	0.146	0.0669
p (t-test)		0.59		1.4E-5		0.77
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	1.74	0.296	1.74	2.85	1.74	0.185
n (Samp)	558	10	558	15	558	8
n (Patient)	262	10	262	15	262	8
<u>sCr only</u>						
Median	nd	nd	nd	nd	0.00505	0.00286
Average	nd	nd	nd	nd	0.0577	0.0473
Stdev	nd	nd	nd	nd	0.187	0.0760
p (t-test)	nd	nd	nd	nd		0.89
Min	nd	nd	nd	nd	0.000463	0.000463
Max	nd	nd	nd	nd	2.85	0.185
n (Samp)	nd	nd	nd	nd	575	6
n (Patient)	nd	nd	nd	nd	269	6
<u>UO only</u>						
Median	nd	nd	0.00505	0.0604	nd	nd
Average	nd	nd	0.0546	0.339	nd	nd
Stdev	nd	nd	0.151	0.885	nd	nd
p (t-test)	nd	nd		3.0E-6	nd	nd
Min	nd	nd	0.000463	0.000463	nd	nd
Max	nd	nd	1.74	2.85	nd	nd
n (Samp)	nd	nd	533	10	nd	nd
n (Patient)	nd	nd	235	10	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	nd	nd	0.60	nd	0.58	0.46	0.40	nd
SE	0.092	nd	nd	0.078	nd	0.095	0.10	0.12	nd
p	0.97	nd	nd	0.22	nd	0.39	0.74	0.40	nd
nCohort 1	558	nd	nd	558	nd	533	558	575	nd
nCohort 2	10	nd	nd	15	nd	10	8	6	nd
Cutoff 1	0.00132	nd	nd	0.00296	nd	0.00296	0.00132	0.00132	nd
Sens 1	90%	nd	nd	73%	nd	70%	88%	83%	nd
Spec 1	15%	nd	nd	22%	nd	23%	15%	14%	nd
Cutoff 2	0.00132	nd	nd	0.00132	nd	0.00132	0.00132	0.00132	nd
Sens 2	90%	nd	nd	80%	nd	80%	88%	83%	nd
Spec 2	15%	nd	nd	15%	nd	17%	15%	14%	nd
Cutoff 3	0.00132	nd	nd	0	nd	0	0	0	nd
Sens 3	90%	nd	nd	100%	nd	100%	100%	100%	nd
Spec 3	15%	nd	nd	0%	nd	0%	0%	0%	nd
Cutoff 4	0.00660	nd	nd	0.00660	nd	0.00660	0.00660	0.00660	nd
Sens 4	30%	nd	nd	60%	nd	60%	25%	33%	nd

-continued

Spec 4	72%	nd	nd	72%	nd	73%	72%	72%	nd
Cutoff 5	0.0499	nd	nd	0.0499	nd	0.0499	0.0499	0.0499	nd
Sens 5	30%	nd	nd	47%	nd	50%	25%	33%	nd
Spec 5	80%	nd	nd	80%	nd	80%	80%	80%	nd
Cutoff 6	0.141	nd	nd	0.141	nd	0.154	0.141	0.141	nd
Sens 6	30%	nd	nd	27%	nd	20%	12%	17%	nd
Spec 6	90%	nd	nd	90%	nd	90%	90%	90%	nd
OR Quart 2	0.66	nd	nd	0.49	nd	0.33	1.0	0	nd
p Value	0.65	nd	nd	0.42	nd	0.33	0.99	na	nd
95% CI of	0.11	nd	nd	0.089	nd	0.033	0.14	na	nd
OR Quart 2	4.0	nd	nd	2.7	nd	3.2	7.3	na	nd
OR Quart 3	0.33	nd	nd	0.24	nd	0.33	0.50	0	nd
p Value	0.34	nd	nd	0.21	nd	0.33	0.57	na	nd
95% CI of	0.034	nd	nd	0.027	nd	0.033	0.045	na	nd
OR Quart 3	3.2	nd	nd	2.2	nd	3.2	5.5	na	nd
OR Quart 4	1.3	nd	nd	2.0	nd	1.7	1.5	2.0	nd
p Value	0.70	nd	nd	0.25	nd	0.48	0.65	0.41	nd
95% CI of	0.30	nd	nd	0.60	nd	0.39	0.25	0.37	nd
OR Quart 4	6.1	nd	nd	6.9	nd	7.2	9.2	11	nd

Apolipoprotein E

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
<u>sCr or UO</u>						
Median	2.46	1.66	2.46	1.59	2.46	1.96
Average	18.0	33.9	18.0	99.3	18.0	3.18
Stdev	114	122	114	435	114	3.65
p (t-test)		0.50		0.0018		0.64
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.00328
Max	2160	594	2160	2140	2160	12.3
n (Samp)	1388	24	1388	24	1388	13
n (Patient)	484	24	484	24	484	13
<u>sCr only</u>						
Median	2.41	0.351	2.41	0.985	2.41	0.907
Average	19.4	75.3	19.4	3.39	19.4	1.85
Stdev	125	210	125	5.64	125	2.68
p (t-test)		0.21		0.75		0.71
Min	0.000147	0.0847	0.000147	0.000147	0.000147	0.0263
Max	2160	594	2160	14.6	2160	7.68
n (Samp)	1455	8	1455	6	1455	7
n (Patient)	500	8	500	6	500	7
<u>UO only</u>						
Median	2.40	1.08	2.40	3.49	2.40	3.25
Average	17.1	17.0	17.1	116	17.1	4.27
Stdev	105	37.4	105	464	105	4.05
p (t-test)		1.00		1.7E-4		0.75
Min	0.000147	0.00122	0.000147	0.00247	0.000147	0.211
Max	2140	135	2140	2140	2140	12.3
n (Samp)	1246	15	1246	21	1246	7
n (Patient)	397	15	397	21	397	7

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.35	0.41	0.46	0.36	0.52	0.42	0.32	0.52
SE	0.061	0.11	0.078	0.061	0.12	0.064	0.083	0.11	0.11
p	0.32	0.16	0.24	0.48	0.26	0.73	0.32	0.12	0.84
nCohort 1	1388	1455	1246	1388	1455	1246	1388	1455	1246
nCohort 2	24	8	15	24	6	21	13	7	7
Cutoff 1	0.404	0.201	0.172	0.309	0.260	0.422	0.207	0.624	2.00
Sens 1	71%	75%	73%	71%	83%	71%	77%	71%	71%
Spec 1	18%	12%	11%	15%	13%	18%	13%	24%	45%
Cutoff 2	0.172	0.130	0.130	0.0258	0.260	0.130	0.0537	0.0258	1.36
Sens 2	83%	88%	80%	83%	83%	81%	85%	100%	86%
Spec 2	11%	10%	10%	7%	13%	10%	8%	7%	38%
Cutoff 3	0.00154	0.0782	0.00129	0.00238	0	0.0258	0.0258	0.0258	0.207
Sens 3	92%	100%	93%	92%	100%	90%	92%	100%	100%
Spec 3	3%	9%	2%	4%	0%	7%	7%	7%	12%
Cutoff 4	6.82	6.82	6.52	6.82	6.82	6.52	6.82	6.82	6.52
Sens 4	25%	12%	33%	33%	17%	43%	15%	14%	14%

-continued

Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	11.8	12.1	11.3	11.8	12.1	11.3	11.8	12.1	11.3
Sens 5	17%	12%	20%	29%	17%	38%	8%	0%	14%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	25.4	26.2	24.2	25.4	26.2	24.2	25.4	26.2	24.2
Sens 6	12%	12%	20%	17%	0%	24%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	2.0	0.25	0.57	1.0	0.11	4.0	>1.0	2.0
p Value	0.76	0.57	0.21	0.37	1.00	0.035	0.21	<1.00	0.57
95% CI of	0.36	0.18	0.028	0.16	0.062	0.014	0.45	>0.063	0.18
OR Quart 2	4.0	22	2.2	2.0	16	0.86	36	na	22
OR Quart 3	0.80	0	0.75	0.28	1.0	0.33	4.0	>3.0	3.0
p Value	0.74	na	0.71	0.12	1.00	0.095	0.21	<0.34	0.34
95% CI of	0.21	na	0.17	0.058	0.062	0.087	0.45	>0.31	0.31
OR Quart 3	3.0	na	3.4	1.4	16	1.2	36	na	29
OR Quart 4	1.8	5.1	1.8	1.6	3.0	0.88	4.0	>3.0	1.00
p Value	0.29	0.14	0.36	0.34	0.34	0.80	0.21	<0.34	1.00
95% CI of	0.60	0.59	0.51	0.61	0.31	0.34	0.45	>0.31	0.062
OR Quart 4	5.5	44	6.1	4.1	29	2.3	36	na	16

[0192] FIG. 10: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in EDTA samples

collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.

C-C motif chemokine 7									
sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
Median	nd	nd	0.758	0.410	nd	nd			
Average	nd	nd	8.98	14.0	nd	nd			
Stdev	nd	nd	22.1	22.1	nd	nd			
p (t-test)	nd	nd		0.59	nd	nd			
Min	nd	nd	0.193	0.193	nd	nd			
Max	nd	nd	181	51.7	nd	nd			
n (Samp)	nd	nd	298	6	nd	nd			
n (Patient)	nd	nd	167	6	nd	nd			

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.47	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.78	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.193	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	17%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.193	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	17%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	0%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	2.71	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	13.1	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	26.6	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0.49	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd

-continued

95% CI of	nd	nd	nd	0.044	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	5.6	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.5	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.65	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	9.4	nd	nd	nd	nd	nd

Vascular endothelial growth factor receptor 3

sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	6150	5990	nd	nd
Average	nd	nd	7130	7240	nd	nd
Stdev	nd	nd	5340	4850	nd	nd
p (t-test)	nd	nd		0.96	nd	nd
Min	nd	nd	219	3540	nd	nd
Max	nd	nd	43200	16600	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

sCr or UO	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.50	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.98	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	3920	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	28%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	3920	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	28%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	3530	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	22%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	8160	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	9630	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	12100	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	16	nd	nd	nd	nd	nd

Interferon alpha-2

sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	12.3	6.12	nd	nd
Average	nd	nd	17.0	10.5	nd	nd
Stdev	nd	nd	23.1	12.0	nd	nd
p (t-test)	nd	nd		0.50	nd	nd
Min	nd	nd	0.0320	0.0627	nd	nd
Max	nd	nd	223	28.5	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

-continued

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.44	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.61	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.0997	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	25%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.0997	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	25%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0.0324	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	2%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	21.2	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	27.4	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	36.4	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	3.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.33	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.31	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	30	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	16	nd	nd	nd	nd	nd

Insulin-like growth factor-binding protein 4

sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	2.93	4.81	nd	nd
Average	nd	nd	12.8	12.6	nd	nd
Stdev	nd	nd	18.4	14.7	nd	nd
p (t-test)	nd	nd		0.98	nd	nd
Min	nd	nd	0.0728	0.572	nd	nd
Max	nd	nd	158	33.4	nd	nd
n (Samp)	nd	nd	361	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.55	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.66	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	361	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	2.43	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	38%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	2.43	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	38%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0.0862	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	1%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	17.1	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	23.5	nd	nd	nd	nd	nd

-continued

Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	30.5	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	22	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0.99	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.99	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	22	nd	nd	nd	nd	nd

Insulin-like growth factor-binding protein 5

sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	11.5	0.763	nd	nd
Average	nd	nd	34.9	22.5	nd	nd
Stdev	nd	nd	49.9	34.1	nd	nd
p (t-test)	nd	nd		0.54	nd	nd
Min	nd	nd	0.204	0.204	nd	nd
Max	nd	nd	257	69.8	nd	nd
n (Samp)	nd	nd	361	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.44	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.61	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	361	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.222	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	18%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.222	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	18%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	0%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	40.2	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	62.1	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	119	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	7.3	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.99	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	7.3	nd	nd	nd	nd	nd

-continued

Interleukin-33									
sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
Median	nd	nd	0.0981	5.87	nd	nd			
Average	nd	nd	278	36.4	nd	nd			
Stdev	nd	nd	2480	73.0	nd	nd			
p (t-test)	nd	nd		0.81	nd	nd			
Min	nd	nd	0.0445	0.0455	nd	nd			
Max	nd	nd	40000	184	nd	nd			
n (Samp)	nd	nd	298	6	nd	nd			
n (Patient)	nd	nd	167	6	nd	nd			

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.67	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.16	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.0996	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	56%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.0996	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	56%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0.0445	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	10%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	1.13	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	67%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	13.1	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	76.8	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	3.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.33	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.31	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	30	nd	nd	nd	nd	nd

Interleukin-4 receptor alpha chain									
sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage				
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2			
Median	nd	nd	219	275	nd	nd			
Average	nd	nd	294	314	nd	nd			
Stdev	nd	nd	230	226	nd	nd			
p (t-test)	nd	nd		0.83	nd	nd			
Min	nd	nd	3.27	84.5	nd	nd			
Max	nd	nd	1210	646	nd	nd			
n (Samp)	nd	nd	298	6	nd	nd			
n (Patient)	nd	nd	167	6	nd	nd			

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.52	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.86	nd	nd	nd	nd	nd

-continued

nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	104	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	7%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	104	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	7%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	83.5	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	4%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	304	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	50%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	376	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	554	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0.49	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.044	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	5.6	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.5	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.65	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	9.4	nd	nd	nd	nd	nd

Vascular endothelial growth factor receptor 2

sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	7870	7420	nd	nd
Average	nd	nd	9920	7340	nd	nd
Stdev	nd	nd	13200	1600	nd	nd
p (t-test)	nd	nd	0.63		nd	nd
Min	nd	nd	3020	5310	nd	nd
Max	nd	nd	166000	9440	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.42	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.54	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	5920	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	20%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	5920	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	20%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	5300	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	11%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	9430	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	10600	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	14300	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	>3.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.33	nd	nd	nd	nd	nd

-continued

95% CI of	nd	nd	nd	>0.32	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	>1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.99	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.062	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	>2.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.56	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.18	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	na	nd	nd	nd	nd	nd

Neural cell adhesion molecule 1

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
sCr or UO	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	182000	166000	nd	nd
Average	nd	nd	189000	177000	nd	nd
Stdev	nd	nd	70000	50000	nd	nd
p (t-test)	nd	nd		0.68	nd	nd
Min	nd	nd	49200	125000	nd	nd
Max	nd	nd	520000	245000	nd	nd
n (Samp)	nd	nd	366	6	nd	nd
n (Patient)	nd	nd	196	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.46	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.75	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	366	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	131000	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	19%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	131000	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	19%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	125000	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	15%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	209000	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	230000	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	268000	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	7.3	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	7.3	nd	nd	nd	nd	nd

Platelet-derived growth factor subunit B (dimer)

	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
sCr or UO	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	337	403	nd	nd
Average	nd	nd	394	748	nd	nd
Stdev	nd	nd	270	983	nd	nd
p (t-test)	nd	nd		0.0034	nd	nd
Min	nd	nd	0.189	91.9	nd	nd

-continued

Max	nd	nd	2690	2720	nd	nd			
n (Samp)	nd	nd	355	6	nd	nd			
n (Patient)	nd	nd	192	6	nd	nd			
0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage			
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.57	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.59	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	355	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	242	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	31%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	242	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	31%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	91.4	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	7%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	495	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	581	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	699	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.062	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	22	nd	nd	nd	nd	nd

Pigment epithelium-derived factor

0 hr prior to AKI stage			24 hr prior to AKI stage		48 hr prior to AKI stage	
sCr or UO	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	1670	1350	nd	nd
Average	nd	nd	1920	1180	nd	nd
Stdev	nd	nd	1130	498	nd	nd
p (t-test)	nd	nd		0.11	nd	nd
Min	nd	nd	84.2	339	nd	nd
Max	nd	nd	7450	1650	nd	nd
n (Samp)	nd	nd	367	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.29	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.086	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	367	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	823	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	10%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	823	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	10%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	328	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	1%	nd	nd	nd	nd	nd

-continued

Cutoff 4	nd	nd	nd	2120	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	2510	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	3550	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	>0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	>4.2	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.20	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.46	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	>2.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.56	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.18	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	na	nd	nd	nd	nd	nd

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0 hr prior to AKI stage		24 hr prior to AKI stage		48 hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	102	71.9	nd	nd
Average	nd	nd	195	189	nd	nd
Stdev	nd	nd	388	223	nd	nd
p (t-test)	nd	nd		0.97	nd	nd
Min	nd	nd	4.06	30.8	nd	nd
Max	nd	nd	3360	595	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

sCr or UO	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.43	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.58	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	54.3	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	14%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	54.3	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	14%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	30.2	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	4%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	149	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	205	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	81%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	305	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0.49	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.044	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	5.6	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.5	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.65	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	9.4	nd	nd	nd	nd	nd

-continued

Alpha-fetoprotein									
sCr or UO	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
Median	nd	nd		0.328	0.608		nd	nd	
Average	nd	nd		0.351	0.738		nd	nd	
Stdev	nd	nd		0.339	0.576		nd	nd	
p (t-test)	nd	nd			0.0065		nd	nd	
Min	nd	nd		0.00580	0.00580		nd	nd	
Max	nd	nd		1.81	1.53		nd	nd	
n (Samp)	nd	nd		367	6		nd	nd	
n (Patient)	nd	nd		197	6		nd	nd	

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.71	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.087	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	367	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.369	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	57%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.369	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	57%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	0%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	0.509	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	67%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	0.598	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	50%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	0.784	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	na
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.062	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	4.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.21	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.45	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	37	nd	nd	nd	nd	nd

Apolipoprotein E									
sCr or UO	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	Cohort 1	Cohort 2		Cohort 1	Cohort 2		Cohort 1	Cohort 2	
Median	51000	28200		51000	42800		nd	nd	
Average	61600	35600		61600	39400		nd	nd	
Stdev	44300	15000		44300	11700		nd	nd	
p (t-test)		0.098			0.19		nd	nd	
Min	1940	22400		1940	25800		nd	nd	
Max	260000	59600		260000	54900		nd	nd	
n (Samp)	434	8		434	7		nd	nd	
n (Patient)	233	8		233	7		nd	nd	
UO only									
Median	nd	nd		48700	37100		nd	nd	
Average	nd	nd		59500	38400		nd	nd	
Stdev	nd	nd		42000	12400		nd	nd	
p (t-test)	nd	nd			0.22		nd	nd	

-continued

Min	nd	nd	1940	25800	nd	nd
Max	nd	nd	244000	54900	nd	nd
n (Samp)	nd	nd	400	6	nd	nd
n (Patient)	nd	nd	205	6	nd	nd

	0 hr prior to AKI stage			24 hr prior to AKI stage			48 hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.30	nd	nd	0.36	nd	0.36	nd	nd	nd
SE	0.10	nd	nd	0.11	nd	0.12	nd	nd	nd
p	0.058	nd	nd	0.21	nd	0.25	nd	nd	nd
nCohort 1	434	nd	nd	434	nd	400	nd	nd	nd
nCohort 2	8	nd	nd	7	nd	6	nd	nd	nd
Cutoff 1	25600	nd	nd	31300	nd	25800	nd	nd	nd
Sens 1	75%	nd	nd	71%	nd	83%	nd	nd	nd
Spec 1	17%	nd	nd	26%	nd	19%	nd	nd	nd
Cutoff 2	23900	nd	nd	25800	nd	25800	nd	nd	nd
Sens 2	88%	nd	nd	86%	nd	83%	nd	nd	nd
Spec 2	15%	nd	nd	18%	nd	19%	nd	nd	nd
Cutoff 3	20900	nd	nd	25800	nd	25800	nd	nd	nd
Sens 3	100%	nd	nd	100%	nd	100%	nd	nd	nd
Spec 3	13%	nd	nd	18%	nd	19%	nd	nd	nd
Cutoff 4	69500	nd	nd	69500	nd	67600	nd	nd	nd
Sens 4	0%	nd	nd	0%	nd	0%	nd	nd	nd
Spec 4	70%	nd	nd	70%	nd	70%	nd	nd	nd
Cutoff 5	87400	nd	nd	87400	nd	86400	nd	nd	nd
Sens 5	0%	nd	nd	0%	nd	0%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	120000	nd	nd	120000	nd	110000	nd	nd	nd
Sens 6	0%	nd	nd	0%	nd	0%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	>2.1	nd	nd	>1.0	nd	>2.1	nd	nd	nd
p Value	<0.56	nd	nd	<0.99	nd	<0.56	nd	nd	nd
95% CI of	>0.18	nd	nd	>0.063	nd	>0.18	nd	nd	nd
OR Quart 2	na	nd	nd	na	nd	na	nd	nd	nd
OR Quart 3	>1.0	nd	nd	>4.2	nd	>2.0	nd	nd	nd
p Value	<0.99	nd	nd	<0.20	nd	<0.56	nd	nd	nd
95% CI of	>0.062	nd	nd	>0.46	nd	>0.18	nd	nd	nd
OR Quart 3	na	nd	nd	na	nd	na	nd	nd	nd
OR Quart 4	>5.3	nd	nd	>2.1	nd	>2.1	nd	nd	nd
p Value	<0.13	nd	nd	<0.56	nd	<0.56	nd	nd	nd
95% CI of	>0.61	nd	nd	>0.18	nd	>0.18	nd	nd	nd
OR Quart 4	na	nd	nd	na	nd	na	nd	nd	nd

[0193] FIG. 11: Comparison of marker levels in enroll urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48 hrs) and in enroll urine samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48 hrs). Enroll samples from patients already at RIFLE stage I or F were included in Cohort 2.

Complement C4-B						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.6	33.8	18.1	31.8	18.9	43.7
Average	59.8	80.1	63.5	70.6	59.4	84.2
Stdev	150	154	154	83.8	152	163
p (t-test)		0.25		0.84		0.21
Min	0.00329	0.00263	0.00263	0.448	0.00329	0.00263
Max	1950	1150	1950	245	1950	1150
n (Samp)	383	92	451	20	296	79
n (Patient)	383	92	451	20	296	79

-continued

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.59	0.57	0.60
SE	0.034	0.068	0.037
p	0.0090	0.33	0.0092
nCohort 1	383	451	296
nCohort 2	92	20	79
Cutoff 1	8.26	9.33	8.97
Sens 1	71%	70%	71%
Spec 1	38%	41%	38%
Cutoff 2	4.30	4.27	5.44
Sens 2	80%	80%	81%
Spec 2	25%	24%	28%
Cutoff 3	1.74	1.07	1.77
Sens 3	90%	90%	91%
Spec 3	15%	9%	14%
Cutoff 4	36.7	44.0	38.7
Sens 4	49%	50%	51%
Spec 4	70%	70%	70%
Cutoff 5	62.0	65.8	62.0
Sens 5	34%	40%	34%
Spec 5	80%	80%	80%
Cutoff 6	147	150	129
Sens 6	15%	20%	18%
Spec 6	90%	90%	90%
OR Quart 2	0.93	0.58	1.1
p Value	0.84	0.47	0.72
95% CI of	0.46	0.14	0.54
OR Quart 2	1.9	2.5	2.5
OR Quart 3	1.1	0.58	1.1
p Value	0.75	0.47	0.72
95% CI of	0.57	0.14	0.54
OR Quart 3	2.2	2.5	2.5
OR Quart 4	2.1	1.8	2.4
p Value	0.023	0.28	0.013
95% CI of	1.1	0.60	1.2
OR Quart 4	3.9	5.7	4.9

C-C motif chemokine 26

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0311	0.0405	0.0320	0.0436	0.0311	0.0402
Average	0.0737	0.647	0.162	0.728	0.0500	0.737
Stdev	0.497	4.50	2.04	2.03	0.177	4.85
p (t-test)		0.015		0.23		0.015
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	9.14	42.3	42.3	7.53	2.75	42.3
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

At Enrollment

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.60	0.66	0.57
SE	0.034	0.068	0.037
p	0.0030	0.020	0.056
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	0.0297	0.0311	0.0291
Sens 1	71%	70%	76%
Spec 1	49%	49%	45%
Cutoff 2	0.0236	0.0262	0.0232
Sens 2	80%	80%	82%
Spec 2	45%	44%	35%
Cutoff 3	0.0195	0.0232	0.0195
Sens 3	95%	90%	94%
Spec 3	18%	35%	18%
Cutoff 4	0.0443	0.0443	0.0443
Sens 4	28%	40%	25%
Spec 4	75%	75%	72%
Cutoff 5	0.0486	0.0486	0.0504

-continued

Sens 5	24%	40%	20%
Spec 5	80%	80%	86%
Cutoff 6	0.0525	0.0525	0.0525
Sens 6	21%	30%	19%
Spec 6	91%	90%	90%
OR Quart 2	2.3	2.0	2.6
p Value	0.031	0.42	0.017
95% CI of	1.1	0.36	1.2
OR Quart 2	5.0	11	5.7
OR Quart 3	3.9	3.1	3.0
p Value	3.0E-4	0.17	0.0047
95% CI of	1.9	0.61	1.4
OR Quart 3	8.1	16	6.6
OR Quart 4	2.5	4.2	1.7
p Value	0.021	0.074	0.22
95% CI of	1.1	0.87	0.73
OR Quart 4	5.3	20	3.8

C-C motif chemokine 7

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.515	0.812	0.515	1.29	0.584	0.625
Average	2.03	14.0	2.82	39.3	2.36	14.4
Stdev	8.31	60.4	15.9	110	9.29	64.5
p (t-test)		2.0E-4		6.4E-9		0.0020
Min	0.146	0.146	0.146	0.188	0.146	0.146
Max	125	488	291	488	125	488
n (Sump)	385	92	453	20	298	79
n (Patient)	385	92	453	20	298	79

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.62	0.76	0.56
SE	0.034	0.064	0.037
p	6.5E-4	5.6E-5	0.11
nCohort 1	385	453	298
nCohort 2	92	20	79
Cutoff 1	0.386	0.812	0.336
Sens 1	71%	70%	73%
Spec 1	47%	65%	33%
Cutoff 2	0.320	0.584	0.319
Sens 2	83%	80%	84%
Spec 2	34%	54%	26%
Cutoff 3	0.264	0.386	0.264
Sens 3	92%	90%	91%
Spec 3	15%	45%	13%
Cutoff 4	0.816	0.816	1.04
Sens 4	45%	60%	38%
Spec 4	73%	70%	76%
Cutoff 5	1.07	1.11	1.15
Sens 5	40%	60%	24%
Spec 5	80%	80%	82%
Cutoff 6	1.59	1.59	1.59
Sens 6	20%	40%	19%
Spec 6	93%	92%	92%
OR Quart 2	2.1	3.1	2.0
p Value	0.052	0.34	0.072
95% CI of	0.99	0.31	0.94
OR Quart 2	4.3	30	4.1
OR Quart 3	1.5	4.1	1.0
p Value	0.34	0.21	1.0
95% CI of	0.68	0.45	0.45
OR Quart 3	3.1	37	2.2
OR Quart 4	3.6	13	2.3
p Value	2.7E-4	0.014	0.026
95% CI of	1.8	1.7	1.1
OR Quart 4	7.3	100	4.7

-continued

Vascular endothelial growth factor receptor 3						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	308	354	315	403	308	348
Average	297	431	322	403	295	437
Stdev	170	381	241	87.3	168	412
p (t-test)		2.1E-4		0.32		5.1E-4
Min	1.37	1.37	1.37	308	1.37	1.37
Max	942	2750	2750	601	942	2750
n (Samp)	196	53	238	9	171	45
n (Patient)	196	53	238	9	171	45

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.63	0.68	0.63
SE	0.045	0.10	0.049
p	0.0029	0.081	0.010
nCohort 1	196	238	171
nCohort 2	53	9	45
Cutoff 1	282	332	273
Sens 1	72%	78%	71%
Spec 1	48%	55%	46%
Cutoff 2	229	315	219
Sens 2	81%	89%	82%
Spec 2	37%	52%	34%
Cutoff 3	163	295	66.4
Sens 3	91%	100%	96%
Spec 3	22%	47%	11%
Cutoff 4	397	414	381
Sens 4	49%	33%	47%
Spec 4	72%	73%	70%
Cutoff 5	440	445	425
Sens 5	36%	11%	40%
Spec 5	81%	81%	81%
Cutoff 6	496	537	486
Sens 6	28%	11%	33%
Spec 6	90%	90%	90%
OR Quart 2	1.6	>1.0	1.3
p Value	0.33	<1.0	0.61
95% CI of	0.61	>0.061	0.47
OR Quart 2	4.3	na	3.6
OR Quart 3	1.6	>6.5	1.0
p Value	0.33	<0.087	1.0
95% CI of	0.61	>0.76	0.35
OR Quart 3	4.3	na	2.9
OR Quart 4	3.4	>2.0	3.1
p Value	0.0087	<0.57	0.017
95% CI of	1.4	>0.18	1.2
OR Quart 4	8.4	na	8.0

Insulin-like growth factor-binding protein 5						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	0.0682	nd	nd	0.0682	0.0682
Average	0.801	0.752	nd	nd	0.788	0.760
Stdev	1.63	1.13	nd	nd	1.66	1.16
p (t-test)		0.87	nd	nd		0.93
Min	0.0116	0.0116	nd	nd	0.0116	0.0116
Max	10.3	3.92	nd	nd	10.3	3.92
n (Samp)	138	32	nd	nd	119	30
n (Patient)	138	32	nd	nd	119	30

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.49	nd	0.49
SE	0.057	nd	0.059
p	0.86	nd	0.86

-continued

nCohort 1	138	nd	119
nCohort 2	32	nd	30
Cutoff 1	0.0116	nd	0.0116
Sens 1	88%	nd	87%
Spec 1	8%	nd	9%
Cutoff 2	0.0116	nd	0.0116
Sens 2	88%	nd	87%
Spec 2	8%	nd	9%
Cutoff 3	0	nd	0
Sens 3	100%	nd	100%
Spec 3	0%	nd	0%
Cutoff 4	0.397	nd	0.397
Sens 4	34%	nd	33%
Spec 4	73%	nd	75%
Cutoff 5	1.43	nd	1.40
Sens 5	19%	nd	23%
Spec 5	81%	nd	81%
Cutoff 6	3.00	nd	3.00
Sens 6	6%	nd	7%
Spec 6	91%	nd	92%
OR Quart 2	0.31	nd	0.54
p Value	0.061	nd	0.29
95% CI of	0.089	nd	0.17
OR Quart 2	1.1	nd	1.7
OR Quart 3	0.57	nd	0.34
p Value	0.29	nd	0.094
95% CI of	0.20	nd	0.096
OR Quart 3	1.6	nd	1.2
OR Quart 4	0.91	nd	1.0
p Value	0.85	nd	0.94
95% CI of	0.34	nd	0.37
OR Quart 4	2.4	nd	2.9

Immunoglobulin G4

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	180	384	203	460	203	405
Average	452	829	508	894	476	853
Stdev	664	921	717	977	671	928
p (t-test)		8.8E-6		0.021		6.1E-5
Min	0.00862	0.00996	0.00862	4.20	0.410	0.00996
Max	2400	2400	2400	2400	2400	2400
n (Samp)	379	92	447	20	292	79
n (Patient)	379	92	447	20	292	79

At Enrollment

	sCr or UO		sCr only		UO only	
AUC	0.62		0.60		0.62	
SE	0.034		0.068		0.037	
p	4.7E-4		0.15		0.0011	
nCohort 1	379		447		292	
nCohort 2	92		20		79	
Cutoff 1	132		241		134	
Sens 1	71%		70%		71%	
Spec 1	42%		54%		40%	
Cutoff 2	76.0		32.8		95.9	
Sens 2	80%		80%		81%	
Spec 2	29%		15%		33%	
Cutoff 3	21.3		20.5		41.4	
Sens 3	90%		90%		91%	
Spec 3	13%		12%		18%	
Cutoff 4	383		431		402	
Sens 4	50%		50%		51%	
Spec 4	70%		70%		70%	
Cutoff 5	597		676		663	
Sens 5	38%		40%		35%	
Spec 5	80%		80%		80%	
Cutoff 6	1470		2150		1510	
Sens 6	26%		25%		25%	
Spec 6	90%		90%		90%	
OR Quart 2	0.99		0		1.2	
p Value	0.98		na		0.70	

-continued

95% CI of	0.47	na	0.52
OR Quart 2	2.1	na	2.6
OR Quart 3	1.5	0.82	1.9
p Value	0.23	0.75	0.10
95% CI of	0.76	0.24	0.88
OR Quart 3	3.1	2.8	4.0
OR Quart 4	2.9	1.5	2.8
p Value	0.0015	0.44	0.0067
95% CI of	1.5	0.53	1.3
OR Quart 4	5.6	4.4	5.7

Interleukin-21

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.33	5.94	7.99	5.73	7.44	5.97
Average	11.0	8.67	10.7	7.27	10.1	8.75
Stdev	10.9	8.64	10.7	6.70	10.1	8.81
p (t-test)		0.055		0.16		0.28
Min	0.0122	0.00404	0.00404	0.0219	0.0122	0.00404
Max	67.7	42.1	67.7	22.6	66.5	42.1
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.43	0.42	0.46
SE	0.034	0.068	0.037
p	0.051	0.22	0.24
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	2.65	2.61	3.08
Sens 1	71%	70%	71%
Spec 1	26%	26%	29%
Cutoff 2	0.596	1.78	0.586
Sens 2	80%	80%	81%
Spec 2	9%	20%	10%
Cutoff 3	0.0247	0.0528	0.0247
Sens 3	92%	90%	92%
Spec 3	3%	5%	3%
Cutoff 4	14.5	13.9	12.8
Sens 4	23%	20%	24%
Spec 4	70%	70%	70%
Cutoff 5	18.0	17.5	16.9
Sens 5	13%	10%	15%
Spec 5	80%	80%	80%
Cutoff 6	24.7	24.2	22.6
Sens 6	5%	0%	6%
Spec 6	90%	90%	90%
OR Quart 2	1.1	0.74	1.0
p Value	0.86	0.70	1.0
95% CI of	0.53	0.16	0.48
OR Quart 2	2.2	3.4	2.1
OR Quart 3	1.8	1.8	1.6
p Value	0.076	0.36	0.22
95% CI of	0.94	0.51	0.77
OR Quart 3	3.5	6.3	3.1
OR Quart 4	1.6	1.5	1.3
p Value	0.17	0.51	0.47
95% CI of	0.82	0.42	0.64
OR Quart 4	3.1	5.6	2.7

Interleukin-23

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	302	96.7	268	3.63	302	102
Average	492	329	466	280	487	327
Stdev	691	526	671	497	700	520
p (t-test)		0.035		0.22		0.059
Min	0.491	0.491	0.491	0.552	0.491	0.491

-continued

Max	8520	3250	8520	1820	8520	3250
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.40	0.35	0.41
SE	0.034	0.068	0.037
p	0.0044	0.028	0.011
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	1.09	0.747	1.30
Sens 1	71%	70%	71%
Spec 1	20%	12%	23%
Cutoff 2	0.844	0.708	1.01
Sens 2	80%	80%	81%
Spec 2	14%	10%	17%
Cutoff 3	0.708	0.552	0.708
Sens 3	90%	95%	94%
Spec 3	10%	1%	9%
Cutoff 4	603	553	608
Sens 4	21%	20%	20%
Spec 4	70%	70%	70%
Cutoff 5	844	794	813
Sens 5	12%	10%	13%
Spec 5	80%	80%	80%
Cutoff 6	1350	1180	1200
Sens 6	5%	10%	5%
Spec 6	90%	90%	90%
OR Quart 2	1.0	1.0	1.2
p Value	1.0	1.0	0.68
95% CI of	0.47	0.20	0.53
OR Quart 2	2.1	5.1	2.6
OR Quart 3	2.3	1.3	2.3
p Value	0.016	0.70	0.032
95% CI of	1.2	0.29	1.1
OR Quart 3	4.4	6.1	4.7
OR Quart 4	2.1	3.6	2.4
p Value	0.031	0.058	0.021
95% CI of	1.1	0.96	1.1
OR Quart 4	4.1	13	5.0

Interleukin-28A						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	17.6	13.7	17.6	3.22	20.5	12.2
Average	32.5	29.4	32.3	20.4	32.6	29.5
Stdev	39.0	38.5	39.2	28.4	38.8	39.7
p (t-test)		0.49		0.18		0.54
Min	0.0254	0.0254	0.0254	0.0495	0.0254	0.0254
Max	197	164	197	91.1	197	164
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.47	0.38	0.47
SE	0.034	0.068	0.037
p	0.43	0.076	0.38
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	0.194	0.0860	0.184
Sens 1	71%	70%	71%
Spec 1	25%	13%	22%
Cutoff 2	0.137	0.0784	0.0928
Sens 2	80%	80%	84%
Spec 2	19%	9%	15%
Cutoff 3	0.0860	0.0775	0.0860
Sens 3	90%	90%	91%
Spec 3	14%	6%	14%

-continued

Cutoff 4	45.8	44.0	45.8
Sens 4	24%	15%	24%
Spec 4	70%	70%	70%
Cutoff 5	59.9	59.5	59.5
Sens 5	17%	10%	18%
Spec 5	80%	80%	80%
Cutoff 6	84.4	84.9	84.4
Sens 6	10%	5%	10%
Spec 6	90%	90%	90%
OR Quart 2	1.3	1.7	1.3
p Value	0.41	0.48	0.47
95% CI of	0.69	0.40	0.64
OR Quart 2	2.5	7.3	2.7
OR Quart 3	1.0	1.0	1.0
p Value	1.0	1.0	1.0
95% CI of	0.51	0.20	0.48
OR Quart 3	2.0	5.1	2.1
OR Quart 4	1.5	3.2	1.6
p Value	0.24	0.088	0.22
95% CI of	0.77	0.84	0.77
OR Quart 4	2.8	12	3.1

Interleukin-33

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	42.8	33.3	41.5	23.7	42.8	36.0
Average	55.8	41.2	53.4	33.2	55.5	42.7
Stdev	66.2	42.0	62.6	45.0	69.4	42.9
p (t-test)		0.045		0.15		0.12
Min	0.0232	0.0232	0.0232	0.0372	0.0232	0.0232
Max	958	227	958	170	958	227
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.42	0.35	0.43
SE	0.034	0.068	0.037
p	0.015	0.025	0.049
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	13.7	1.57	14.3
Sens 1	71%	70%	71%
Spec 1	22%	14%	21%
Cutoff 2	0.0879	0.0645	0.0879
Sens 2	80%	80%	81%
Spec 2	11%	8%	9%
Cutoff 3	0.0538	0.0518	0.0518
Sens 3	90%	90%	92%
Spec 3	4%	4%	3%
Cutoff 4	69.3	67.1	68.2
Sens 4	20%	15%	20%
Spec 4	70%	70%	70%
Cutoff 5	92.2	85.1	88.8
Sens 5	9%	10%	9%
Spec 5	80%	80%	80%
Cutoff 6	120	118	119
Sens 6	7%	10%	6%
Spec 6	90%	90%	90%
OR Quart 2	1.5	0.66	1.4
p Value	0.29	0.65	0.35
95% CI of	0.72	0.11	0.68
OR Quart 2	2.9	4.0	3.0
OR Quart 3	1.6	2.1	1.3
p Value	0.17	0.32	0.45
95% CI of	0.81	0.50	0.63
OR Quart 3	3.2	8.4	2.8
OR Quart 4	2.2	3.2	1.9
p Value	0.022	0.088	0.077
95% CI of	1.1	0.84	0.93
OR Quart 4	4.3	12	3.9

-continued

Vascular endothelial growth factor receptor 2						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	488	849	578	751	488	868
Average	702	1100	767	1250	698	1070
Stdev	724	865	754	1110	722	806
p (t-test)		8.8E-4		0.064		0.0036
Min	0.218	67.0	0.218	122	0.218	67.0
Max	4860	3610	4860	3610	4860	3460
n (Samp)	193	52	235	9	169	44
n (Patient)	193	52	235	9	169	44

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.67	0.67	0.66
SE	0.045	0.10	0.049
p	1.9E-4	0.083	7.9E-4
nCohort 1	193	235	169
nCohort 2	52	9	44
Cutoff 1	598	709	578
Sens 1	71%	78%	70%
Spec 1	58%	63%	55%
Cutoff 2	414	626	370
Sens 2	81%	89%	82%
Spec 2	45%	55%	41%
Cutoff 3	219	106	219
Sens 3	90%	100%	91%
Spec 3	27%	17%	27%
Cutoff 4	809	898	801
Sens 4	52%	44%	55%
Spec 4	70%	71%	70%
Cutoff 5	1310	1370	1250
Sens 5	33%	22%	34%
Spec 5	80%	80%	80%
Cutoff 6	1680	1770	1710
Sens 6	17%	22%	16%
Spec 6	90%	90%	91%
OR Quart 2	1.6	0	1.7
p Value	0.41	na	0.38
95% CI of	0.53	na	0.52
OR Quart 2	4.8	na	5.6
OR Quart 3	4.1	6.5	3.8
p Value	0.0054	0.087	0.017
95% CI of	1.5	0.76	1.3
OR Quart 3	11	56	11
OR Quart 4	3.8	2.0	4.0
p Value	0.0100	0.57	0.012
95% CI of	1.4	0.18	1.4
OR Quart 4	10	23	12

Neural cell adhesion molecule 1						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2390	3490	2600	4140	2460	3690
Average	3020	5420	3300	7660	3060	5620
Stdev	2320	7250	3470	8830	2110	7570
p (t-test)		8.6E-8		9.1E-7		5.2E-7
Min	6.83	138	6.83	142	173	138
Max	22000	55700	55700	31700	15500	55700
n (Samp)	382	92	450	20	295	79
n (Patient)	382	92	450	20	295	79

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.64	0.66	0.64
SE	0.034	0.068	0.037
p	3.9E-5	0.019	1.5E-4

-continued

nCohort 1	382	450	295
nCohort 2	92	20	79
Cutoff 1	2490	2810	2670
Sens 1	71%	70%	71%
Spec 1	52%	54%	53%
Cutoff 2	1880	2200	2060
Sens 2	80%	80%	81%
Spec 2	36%	42%	40%
Cutoff 3	1210	1420	1110
Sens 3	90%	90%	91%
Spec 3	19%	23%	16%
Cutoff 4	3670	3830	3790
Sens 4	48%	50%	47%
Spec 4	70%	70%	70%
Cutoff 5	4530	4660	4720
Sens 5	33%	50%	33%
Spec 5	80%	80%	80%
Cutoff 6	5740	6110	5940
Sens 6	23%	30%	24%
Spec 6	90%	90%	90%
OR Quart 2	1.3	0.99	1.7
p Value	0.57	0.99	0.22
95% CI of	0.57	0.20	0.73
OR Quart 2	2.7	5.0	4.0
OR Quart 3	2.6	1.3	3.1
p Value	0.0078	0.70	0.0063
95% CI of	1.3	0.29	1.4
OR Quart 3	5.4	6.1	6.8
OR Quart 4	3.2	3.5	3.5
p Value	0.0010	0.061	0.0018
95% CI of	1.6	0.94	1.6
OR Quart 4	6.5	13	7.8

Platelet-derived growth factor subunit B (dimer)

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.13	1.32	1.13	2.52	1.17	1.32
Average	2.50	21.1	5.21	20.7	2.59	23.2
Stdev	6.41	120	50.9	47.9	6.55	126
p (t-test)		0.0085		0.28		0.018
Min	0.00246	0.00705	0.00246	0.436	0.00246	0.00705
Max	67.2	935	935	176	67.2	935
n (Samp)	294	62	340	13	215	56
n (Patient)	294	62	340	13	215	56

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.57	0.73	0.56
SE	0.041	0.081	0.044
p	0.11	0.0038	0.18
nCohort 1	294	340	215
nCohort 2	62	13	56
Cutoff 1	0.708	1.39	0.648
Sens 1	71%	77%	71%
Spec 1	35%	57%	34%
Cutoff 2	0.429	0.928	0.392
Sens 2	81%	85%	80%
Spec 2	27%	44%	27%
Cutoff 3	0.0488	0.850	0.0144
Sens 3	90%	92%	91%
Spec 3	16%	41%	11%
Cutoff 4	2.00	2.07	2.13
Sens 4	42%	69%	38%
Spec 4	70%	70%	70%
Cutoff 5	2.99	3.02	3.00
Sens 5	29%	46%	32%
Spec 5	80%	80%	80%
Cutoff 6	4.46	4.75	4.49
Sens 6	19%	31%	21%
Spec 6	90%	90%	90%
OR Quart 2	1.7	>3.1	1.3
p Value	0.22	<0.33	0.53

-continued

95% CI of	0.73	>0.32	0.55
OR Quart 2	3.8	na	3.2
OR Quart 3	1.4	>4.2	1.1
p Value	0.40	<0.20	0.85
95% CI of	0.62	>0.46	0.44
OR Quart 3	3.3	na	2.7
OR Quart 4	1.9	>6.4	2.0
p Value	0.11	<0.090	0.11
95% CI of	0.86	>0.75	0.86
OR Quart 4	4.3	na	4.6

Corticotropin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00174	0.00208	nd	nd	0.00174	0.00208
Average	0.00227	0.00468	nd	nd	0.00252	0.00404
Stdev	0.00351	0.00835	nd	nd	0.00436	0.00776
p (t-test)		0.025	nd	nd		0.22
Min	0.000355	0.000388	nd	nd	0.000355	0.000388
Max	0.0373	0.0377	nd	nd	0.0373	0.0377
n (Samp)	111	24	nd	nd	92	22
n (Patient)	111	24	nd	nd	92	22

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.57	nd	0.58
SE	0.066	nd	0.070
p	0.29	nd	0.28
nCohort 1	111	nd	92
nCohort 2	24	nd	22
Cutoff 1	0.00136	nd	0.00136
Sens 1	71%	nd	73%
Spec 1	28%	nd	28%
Cutoff 2	0.00106	nd	0.00109
Sens 2	92%	nd	82%
Spec 2	17%	nd	18%
Cutoff 3	0.00106	nd	0.00106
Sens 3	92%	nd	91%
Spec 3	17%	nd	18%
Cutoff 4	0.00227	nd	0.00212
Sens 4	42%	nd	50%
Spec 4	70%	nd	71%
Cutoff 5	0.00282	nd	0.00282
Sens 5	29%	nd	27%
Spec 5	82%	nd	82%
Cutoff 6	0.00356	nd	0.00362
Sens 6	25%	nd	23%
Spec 6	90%	nd	90%
OR Quart 2	0.36	nd	0.42
p Value	0.17	nd	0.26
95% CI of	0.084	nd	0.095
OR Quart 2	1.5	nd	1.9
OR Quart 3	0.64	nd	0.80
p Value	0.49	nd	0.74
95% CI of	0.18	nd	0.21
OR Quart 3	2.3	nd	3.0
OR Quart 4	1.3	nd	1.4
p Value	0.61	nd	0.59
95% CI of	0.43	nd	0.41
OR Quart 4	4.1	nd	4.7

Thyroxine-binding globulin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0625	0.225	0.0709	0.432	0.0629	0.240
Average	0.165	0.369	0.192	0.489	0.168	0.380
Stdev	0.254	0.639	0.363	0.493	0.261	0.679
p (t-test)		0.0035		0.027		0.0084
Min	0.000478	0.00343	0.000478	0.00635	0.000478	0.00343

-continued

Max	1.59	3.60	3.60	1.47	1.59	3.60
n (Samp)	139	35	165	8	112	30
n (Patient)	139	35	165	8	112	30

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.63	0.69	0.64
SE	0.055	0.11	0.060
p	0.016	0.080	0.019
nCohort 1	139	165	112
nCohort 2	35	8	30
Cutoff 1	0.0777	0.136	0.109
Sens 1	71%	75%	70%
Spec 1	56%	67%	62%
Cutoff 2	0.0164	0.0115	0.0179
Sens 2	80%	88%	80%
Spec 2	24%	17%	26%
Cutoff 3	0.00635	0.00620	0.00767
Sens 3	91%	100%	90%
Spec 3	11%	10%	11%
Cutoff 4	0.135	0.163	0.142
Sens 4	60%	62%	60%
Spec 4	71%	70%	71%
Cutoff 5	0.259	0.296	0.248
Sens 5	43%	50%	50%
Spec 5	81%	81%	80%
Cutoff 6	0.466	0.486	0.466
Sens 6	23%	50%	20%
Spec 6	91%	90%	90%
OR Quart 2	0.21	0	0.44
p Value	0.057	na	0.27
95% CI of	0.042	na	0.10
OR Quart 2	1.0	na	1.9
OR Quart 3	1.2	0.49	1.2
p Value	0.79	0.56	0.76
95% CI of	0.40	0.043	0.36
OR Quart 3	3.4	5.6	4.0
OR Quart 4	2.5	2.6	3.1
p Value	0.068	0.26	0.046
95% CI of	0.94	0.48	1.0
OR Quart 4	6.7	14	9.3

Pigment epithelium-derived factor						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.47	3.75	2.62	19.9	2.76	3.80
Average	18.9	28.6	19.2	51.2	21.1	29.4
Stdev	44.7	51.4	44.0	72.0	48.8	51.8
p (t-test)		0.071		0.0021		0.19
Min	0.000401	0.00102	0.000401	0.0292	0.000401	0.00102
Max	391	250	391	250	391	250
n (Samp)	383	92	451	20	296	79
n (Patient)	383	92	451	20	296	79

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.57	0.64	0.57
SE	0.034	0.068	0.037
p	0.030	0.040	0.046
nCohort 1	383	451	296
nCohort 2	92	20	79
Cutoff 1	1.71	3.61	1.78
Sens 1	71%	70%	71%
Spec 1	42%	57%	41%
Cutoff 2	0.935	0.613	1.16
Sens 2	80%	80%	81%
Spec 2	32%	22%	32%
Cutoff 3	0.293	0.155	0.346
Sens 3	90%	90%	91%
Spec 3	12%	5%	11%

-continued

Cutoff 4	8.12	8.68	8.83
Sens 4	37%	50%	39%
Spec 4	70%	70%	70%
Cutoff 5	21.8	21.9	23.7
Sens 5	30%	50%	30%
Spec 5	80%	80%	80%
Cutoff 6	51.3	52.3	60.9
Sens 6	15%	25%	13%
Spec 6	90%	90%	90%
OR Quart 2	1.5	0.19	2.0
p Value	0.23	0.13	0.072
95% CI of	0.76	0.022	0.94
OR Quart 2	3.1	1.7	4.2
OR Quart 3	1.6	0.79	1.5
p Value	0.18	0.72	0.34
95% CI of	0.81	0.21	0.67
OR Quart 3	3.2	3.0	3.2
OR Quart 4	2.1	2.1	2.2
p Value	0.036	0.20	0.035
95% CI of	1.0	0.69	1.1
OR Quart 4	4.0	6.3	4.7

Tumor necrosis factor receptor superfamily member 8

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.9	32.3	18.6	29.0	13.2	32.9
Average	22.1	65.9	30.7	56.7	20.5	73.1
Stdev	27.0	110	56.8	105	26.9	117
p (t-test)		6.9E-7		0.18		1.7E-7
Min	0.0493	0.0688	0.0493	0.0688	0.0493	0.196
Max	265	554	554	353	265	554
n (Samp)	197	55	240	10	172	47
n (Patient)	197	55	240	10	172	47

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.63	0.60	0.66
SE	0.044	0.097	0.047
p	0.0023	0.28	7.0E-4
nCohort 1	197	240	172
nCohort 2	55	10	47
Cutoff 1	11.4	24.9	11.4
Sens 1	71%	70%	70%
Spec 1	39%	63%	41%
Cutoff 2	5.14	11.4	5.09
Sens 2	80%	80%	81%
Spec 2	24%	37%	26%
Cutoff 3	1.18	7.30	1.18
Sens 3	91%	90%	91%
Spec 3	15%	31%	17%
Cutoff 4	26.3	27.4	25.7
Sens 4	51%	50%	53%
Spec 4	71%	71%	70%
Cutoff 5	32.6	38.9	31.4
Sens 5	49%	20%	51%
Spec 5	80%	80%	80%
Cutoff 6	46.6	62.5	42.2
Sens 6	31%	10%	36%
Spec 6	90%	90%	90%
OR Quart 2	0.80	2.0	0.98
p Value	0.64	0.58	0.97
95% CI of	0.32	0.18	0.36
OR Quart 2	2.0	23	2.7
OR Quart 3	0.53	4.2	0.50
p Value	0.22	0.20	0.24
95% CI of	0.19	0.46	0.16
OR Quart 3	1.5	39	1.6
OR Quart 4	3.0	3.0	3.9
p Value	0.0077	0.34	0.0029
95% CI of	1.3	0.31	1.6
OR Quart 4	6.7	30	9.4

-continued

Alpha-fetoprotein						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00520	0.00660	nd	nd	0.00554	0.00660
Average	0.0545	0.137	nd	nd	0.0561	0.135
Stdev	0.125	0.473	nd	nd	0.131	0.486
p (t-test)		0.049	nd	nd		0.083
Min	0.000463	0.000463	nd	nd	0.000463	0.000463
Max	0.889	2.85	nd	nd	0.889	2.85
n (Samp)	169	36	nd	nd	150	34
n (Patient)	169	36	nd	nd	150	34

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.57	nd	0.55
SE	0.054	nd	0.056
p	0.21	nd	0.33
nCohort 1	169	nd	150
nCohort 2	36	nd	34
Cutoff 1	0.00483	nd	0.00483
Sens 1	72%	nd	71%
Spec 1	41%	nd	41%
Cutoff 2	0.000523	nd	0.000523
Sens 2	92%	nd	91%
Spec 2	12%	nd	13%
Cutoff 3	0.000523	nd	0.000523
Sens 3	92%	nd	91%
Spec 3	12%	nd	13%
Cutoff 4	0.0444	nd	0.0385
Sens 4	33%	nd	32%
Spec 4	75%	nd	70%
Cutoff 5	0.0728	nd	0.0671
Sens 5	33%	nd	32%
Spec 5	83%	nd	80%
Cutoff 6	0.162	nd	0.162
Sens 6	17%	nd	15%
Spec 6	91%	nd	90%
OR Quart 2	0.72	nd	0.62
p Value	0.57	nd	0.40
95% CI of	0.23	nd	0.20
OR Quart 2	2.2	nd	1.9
OR Quart 3	1.3	nd	0.87
p Value	0.60	nd	0.79
95% CI of	0.47	nd	0.30
OR Quart 3	3.6	nd	2.5
OR Quart 4	1.6	nd	1.3
p Value	0.35	nd	0.61
95% CI of	0.60	nd	0.48
OR Quart 4	4.4	nd	3.5

Apolipoprotein(a)						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.94	3.52	2.13	4.72	2.13	3.58
Average	21.6	26.4	22.1	35.5	14.0	29.9
Stdev	106	108	106	137	76.5	116
p (t-test)		0.69		0.58		0.14
Min	0.00646	0.00838	0.00646	0.00838	0.00646	0.0122
Max	1110	802	1110	631	1000	802
n (Samp)	400	95	469	21	313	82
n (Patient)	400	95	469	21	313	82

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.60	0.61	0.61
SE	0.033	0.067	0.036
p	0.0022	0.085	0.0025

-continued

nCohort 1	400	469	313
nCohort 2	95	21	82
Cutoff 1	1.44	1.84	1.39
Sens 1	71%	71%	71%
Spec 1	40%	48%	38%
Cutoff 2	0.995	1.39	0.977
Sens 2	80%	81%	80%
Spec 2	31%	39%	29%
Cutoff 3	0.479	0.911	0.479
Sens 3	92%	90%	93%
Spec 3	18%	28%	17%
Cutoff 4	3.74	4.16	3.78
Sens 4	48%	52%	49%
Spec 4	70%	70%	70%
Cutoff 5	5.82	6.54	5.56
Sens 5	32%	29%	35%
Spec 5	80%	80%	80%
Cutoff 6	13.5	16.9	10.1
Sens 6	16%	14%	21%
Spec 6	90%	90%	90%
OR Quart 2	1.6	3.1	1.5
p Value	0.17	0.17	0.27
95% CI of	0.81	0.61	0.72
OR Quart 2	3.3	16	3.2
OR Quart 3	1.5	2.0	1.2
p Value	0.29	0.42	0.71
95% CI of	0.72	0.37	0.53
OR Quart 3	3.0	11	2.5
OR Quart 4	2.9	4.7	2.9
p Value	0.0014	0.050	0.0034
95% CI of	1.5	1.0	1.4
OR Quart 4	5.7	22	5.8

[0194] FIG. 12: Comparison of marker levels in enroll EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48 hrs) and in enroll EDTA samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48 hrs). Enroll samples from patients already at stage I or F were included in Cohort 2.

Complement C4-B						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	66700	61400	nd	nd	66100	60500
Average	74900	70900	nd	nd	73000	70800
Stdev	39100	44300	nd	nd	37800	46800
p (t-test)		0.65	nd	nd		0.80
Min	5220	9860	nd	nd	5220	9860
Max	203000	214000	nd	nd	170000	214000
n (Samp)	109	28	nd	nd	98	25
n (Patient)	109	28	nd	nd	98	25

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.47	nd	0.47
SE	0.062	nd	0.066
p	0.62	nd	0.63
nCohort 1	109	nd	98
nCohort 2	28	nd	25
Cutoff 1	48500	nd	45900
Sens 1	71%	nd	72%
Spec 1	26%	nd	26%
Cutoff 2	40100	nd	40100
Sens 2	82%	nd	80%
Spec 2	20%	nd	21%

-continued

Cutoff 3	10700	nd	10700
Sens 3	93%	nd	92%
Spec 3	2%	nd	2%
Cutoff 4	90300	nd	86600
Sens 4	29%	nd	32%
Spec 4	71%	nd	70%
Cutoff 5	114000	nd	112000
Sens 5	14%	nd	16%
Spec 5	81%	nd	81%
Cutoff 6	132000	nd	132000
Sens 6	4%	nd	4%
Spec 6	91%	nd	91%
OR Quart 2	1.3	nd	0.51
p Value	0.71	nd	0.32
95% CI of	0.37	nd	0.13
OR Quart 2	4.2	nd	2.0
OR Quart 3	1.3	nd	1.2
p Value	0.71	nd	0.77
95% CI of	0.37	nd	0.37
OR Quart 3	4.2	nd	3.8
OR Quart 4	1.5	nd	0.86
p Value	0.51	nd	0.81
95% CI of	0.46	nd	0.25
OR Quart 4	4.9	nd	2.9

C-C motif chemokine 26

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.725	1.27	0.689	4.30	0.652	1.27
Average	5.53	5.61	5.23	10.5	5.47	4.12
Stdev	12.0	10.6	11.2	18.1	12.4	5.47
p (t-test)		0.98		0.25		0.62
Min	0.0121	0.0121	0.0121	0.0232	0.0121	0.0121
Max	62.5	50.9	62.5	50.9	62.5	18.3
n (Samp)	89	26	108	7	81	22
n (Patient)	89	26	108	7	81	22

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.52	0.61	0.54
SE	0.065	0.12	0.071
p	0.75	0.35	0.54
nCohort 1	89	108	81
nCohort 2	26	7	22
Cutoff 1	0.0325	2.74	0.0339
Sens 1	77%	71%	73%
Spec 1	18%	67%	23%
Cutoff 2	0.0232	0.0325	0.0232
Sens 2	92%	86%	95%
Spec 2	8%	19%	7%
Cutoff 3	0.0232	0.0121	0.0232
Sens 3	92%	100%	95%
Spec 3	8%	3%	7%
Cutoff 4	3.61	4.10	3.03
Sens 4	42%	57%	41%
Spec 4	71%	70%	70%
Cutoff 5	6.86	6.86	6.58
Sens 5	27%	29%	27%
Spec 5	83%	81%	80%
Cutoff 6	11.9	11.9	11.6
Sens 6	12%	14%	9%
Spec 6	91%	91%	90%
OR Quart 2	0.40	0	0.58
p Value	0.18	na	0.44
95% CI of	0.11	na	0.14
OR Quart 2	1.5	na	2.3
OR Quart 3	0.65	0.96	0.75
p Value	0.49	0.97	0.68
95% CI of	0.19	0.13	0.20
OR Quart 3	2.2	7.4	2.9
OR Quart 4	0.95	1.5	1.2
p Value	0.93	0.67	0.81

-continued

95% CI of OR Quart 4	0.30 3.0	0.23 9.7	0.33 4.1			
C-C motif chemokine 7						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.512	0.804	0.620	4.45	0.512	0.804
Average	7.45	31.8	8.43	82.9	7.42	36.4
Stdev	20.8	88.6	20.4	166	21.5	95.8
p (t-test)		0.017		2.0E-5		0.012
Min	0.193	0.193	0.193	0.308	0.193	0.193
Max	166	449	166	449	166	449
n (Samp)	90	26	109	7	82	22
n (Patient)	90	26	109	7	82	22

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.65	0.67	0.67
SE	0.064	0.12	0.069
p	0.020	0.15	0.014
nCohort 1	90	109	82
nCohort 2	26	7	22
Cutoff 1	0.308	0.308	0.308
Sens 1	81%	86%	82%
Spec 1	38%	35%	39%
Cutoff 2	0.308	0.308	0.308
Sens 2	81%	86%	82%
Spec 2	38%	35%	39%
Cutoff 3	0.193	0.193	0.193
Sens 3	92%	100%	91%
Spec 3	19%	17%	21%
Cutoff 4	0.804	2.71	0.804
Sens 4	46%	57%	45%
Spec 4	71%	71%	73%
Cutoff 5	8.42	14.1	8.42
Sens 5	42%	43%	45%
Spec 5	80%	81%	80%
Cutoff 6	18.4	28.9	17.1
Sens 6	31%	29%	32%
Spec 6	90%	91%	90%
OR Quart 2	1.6	>3.3	0.72
p Value	0.49	<0.31	0.69
95% CI of	0.41	>0.33	0.14
OR Quart 2	6.5	na	3.6
OR Quart 3	1.3	>1.0	1.3
p Value	0.72	<0.98	0.71
95% CI of	0.31	>0.062	0.31
OR Quart 3	5.4	na	5.6
OR Quart 4	3.8	>3.3	3.4
p Value	0.043	<0.31	0.068
95% CI of	1.0	>0.33	0.91
OR Quart 4	14	na	13

Vascular endothelial growth factor receptor 3

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5840	5630	5900	5010	5670	6100
Average	6920	6190	6810	5980	6780	6570
Stdev	4850	3230	4560	4390	4900	3350
p (t-test)		0.47		0.64		0.85
Min	529	1720	529	1740	529	1720
Max	32400	14200	32400	14200	32400	14200
n (Samp)	90	26	109	7	82	22
n (Patient)	90	26	109	7	82	22

-continued

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.48	0.43	0.52
SE	0.065	0.12	0.070
p	0.74	0.52	0.74
nCohort 1	90	109	82
nCohort 2	26	7	22
Cutoff 1	3700	3700	4200
Sens 1	73%	71%	73%
Spec 1	26%	26%	33%
Cutoff 2	2640	2240	2640
Sens 2	85%	86%	86%
Spec 2	10%	9%	10%
Cutoff 3	2240	1720	2240
Sens 3	92%	100%	91%
Spec 3	10%	6%	10%
Cutoff 4	7860	8040	7770
Sens 4	35%	29%	41%
Spec 4	70%	71%	71%
Cutoff 5	9450	9630	9320
Sens 5	23%	14%	32%
Spec 5	80%	81%	80%
Cutoff 6	12600	11600	11600
Sens 6	4%	14%	5%
Spec 6	90%	91%	90%
OR Quart 2	0.82	0	0.43
p Value	0.75	na	0.28
95% CI of	0.24	na	0.096
OR Quart 2	2.8	na	2.0
OR Quart 3	0.82	1.6	1.0
p Value	0.75	0.64	1.0
95% CI of	0.24	0.24	0.28
OR Quart 3	2.8	10	3.6
OR Quart 4	1.0	1.0	1.2
p Value	1.0	1.0	0.75
95% CI of	0.30	0.13	0.35
OR Quart 4	3.3	7.6	4.3

Insulin-like growth factor-binding protein 5

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.1	0.422	nd	nd	2.58	0.488
Average	36.2	16.6	nd	nd	32.4	17.8
Stdev	47.9	29.9	nd	nd	46.8	31.3
p (t-test)		0.041	nd	nd		0.14
Min	0.204	0.204	nd	nd	0.204	0.204
Max	200	117	nd	nd	200	117
n (Samp)	108	28	nd	nd	97	25
n (Patient)	108	28	nd	nd	97	25

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.36	nd	0.40
SE	0.062	nd	0.066
p	0.026	nd	0.12
nCohort 1	108	nd	97
nCohort 2	28	nd	25
Cutoff 1	0.222	nd	0.222
Sens 1	75%	nd	72%
Spec 1	17%	nd	19%
Cutoff 2	0.204	nd	0.204
Sens 2	93%	nd	92%
Spec 2	6%	nd	6%
Cutoff 3	0.204	nd	0.204
Sens 3	93%	nd	92%
Spec 3	6%	nd	6%
Cutoff 4	45.3	nd	40.1
Sens 4	14%	nd	16%
Spec 4	70%	nd	70%
Cutoff 5	72.4	nd	65.5

-continued

Sens 5	7%	nd	8%
Spec 5	81%	nd	80%
Cutoff 6	122	nd	98.6
Sens 6	0%	nd	4%
Spec 6	91%	nd	91%
OR Quart 2	1.9	nd	2.1
p Value	0.33	nd	0.30
95% CI of	0.51	nd	0.53
OR Quart 2	7.4	nd	7.9
OR Quart 3	1.6	nd	1.6
p Value	0.50	nd	0.49
95% CI of	0.41	nd	0.41
OR Quart 3	6.3	nd	6.4
OR Quart 4	3.6	nd	2.5
p Value	0.048	nd	0.18
95% CI of	1.0	nd	0.65
OR Quart 4	13	nd	9.2

Immunoglobulin G4

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	410000	219000	nd	nd	407000	219000
Average	703000	405000	nd	nd	637000	405000
Stdev	888000	472000	nd	nd	737000	472000
p (t-test)		0.18	nd	nd		0.22
Min	16100	15700	nd	nd	16100	15700
Max	5190000	1390000	nd	nd	3700000	1390000
n (Samp)	81	17	nd	nd	74	17
n (Patient)	81	17	nd	nd	74	17

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.37	nd	0.38
SE	0.078	nd	0.079
p	0.092	nd	0.12
nCohort 1	81	nd	74
nCohort 2	17	nd	17
Cutoff 1	162000	nd	162000
Sens 1	71%	nd	71%
Spec 1	25%	nd	26%
Cutoff 2	61100	nd	61100
Sens 2	82%	nd	82%
Spec 2	11%	nd	11%
Cutoff 3	38600	nd	38600
Sens 3	94%	nd	94%
Spec 3	9%	nd	8%
Cutoff 4	767000	nd	766000
Sens 4	18%	nd	18%
Spec 4	70%	nd	70%
Cutoff 5	1020000	nd	995000
Sens 5	18%	nd	18%
Spec 5	80%	nd	81%
Cutoff 6	1480000	nd	1280000
Sens 6	0%	nd	12%
Spec 6	90%	nd	91%
OR Quart 2	0.67	nd	0.63
p Value	0.67	nd	0.64
95% CI of	0.10	nd	0.096
OR Quart 2	4.4	nd	4.2
OR Quart 3	2.9	nd	2.9
p Value	0.17	nd	0.16
95% CI of	0.64	nd	0.65
OR Quart 3	13	nd	13
OR Quart 4	1.9	nd	2.0
p Value	0.41	nd	0.40
95% CI of	0.41	nd	0.41
OR Quart 4	9.2	nd	9.4

-continued

Interleukin-21						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.531	1.03	0.783	1.24	0.806	1.11
Average	4.02	2.04	3.61	3.11	4.36	1.69
Stdev	14.5	3.20	13.2	5.09	15.2	2.12
p (t-test)		0.49		0.92		0.41
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	132	14.3	132	14.3	132	8.25
n (Samp)	90	26	109	7	82	22
n (Patient)	90	26	109	7	82	21

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.50	0.56	0.48
SE	0.065	0.12	0.070
p	0.97	0.59	0.79
nCohort 1	90	109	82
nCohort 2	26	7	22
Cutoff 1	0.0182	0.632	0.0182
Sens 1	73%	71%	73%
Spec 1	23%	50%	23%
Cutoff 2	0.0154	0.0922	0.0154
Sens 2	81%	86%	82%
Spec 2	18%	37%	17%
Cutoff 3	0.0102	0.0102	0.0102
Sens 3	92%	100%	91%
Spec 3	4%	6%	4%
Cutoff 4	2.38	2.03	2.46
Sens 4	23%	29%	23%
Spec 4	70%	71%	72%
Cutoff 5	4.32	3.40	5.00
Sens 5	12%	29%	9%
Spec 5	80%	81%	80%
Cutoff 6	7.58	7.58	8.25
Sens 6	8%	14%	0%
Spec 6	90%	91%	90%
OR Quart 2	1.5	2.1	2.0
p Value	0.54	0.56	0.31
95% CI of	0.43	0.18	0.51
OR Quart 2	4.9	24	8.0
OR Quart 3	0.80	2.1	1.3
p Value	0.74	0.56	0.71
95% CI of	0.21	0.18	0.31
OR Quart 3	3.0	24	5.6
OR Quart 4	1.2	2.1	1.6
p Value	0.75	0.56	0.48
95% CI of	0.35	0.18	0.41
OR Quart 4	4.2	24	6.7

Interleukin-23						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.886	86.1	1.05	633	1.10	51.4
Average	2790	1790	2470	4040	3040	1150
Stdev	15200	4450	13800	7510	15900	2500
p (t-test)		0.74		0.77		0.58
Min	0.257	0.257	0.257	0.257	0.257	0.603
Max	100000	20500	100000	20500	100000	9140
n (Samp)	89	26	108	7	81	22
n (Patient)	89	26	108	7	81	22

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.65	0.73	0.64
SE	0.064	0.11	0.070
p	0.021	0.036	0.049

-continued

nCohort 1	89	108	81
nCohort 2	26	7	22
Cutoff 1	0.603	72.6	0.603
Sens 1	88%	71%	91%
Spec 1	30%	69%	28%
Cutoff 2	0.603	22.3	0.603
Sens 2	88%	86%	91%
Spec 2	30%	66%	28%
Cutoff 3	0.257	0	0.603
Sens 3	96%	100%	91%
Spec 3	21%	0%	28%
Cutoff 4	44.5	99.6	44.5
Sens 4	54%	57%	50%
Spec 4	71%	70%	70%
Cutoff 5	306	306	306
Sens 5	31%	57%	27%
Spec 5	81%	81%	80%
Cutoff 6	1230	1230	1040
Sens 6	19%	43%	18%
Spec 6	91%	91%	90%
OR Quart 2	4.1	0	3.4
p Value	0.096	na	0.16
95% CI of	0.78	na	0.62
OR Quart 2	22	na	19
OR Quart 3	3.4	2.0	2.7
p Value	0.16	0.58	0.26
95% CI of	0.62	0.17	0.48
OR Quart 3	18	23	16
OR Quart 4	7.9	4.3	6.1
p Value	0.012	0.20	0.032
95% CI of	1.6	0.45	1.2
OR Quart 4	40	41	32

Interleukin-28A

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.265	0.230	0.195	2.92	0.195	0.195
Average	4.80	18.3	5.48	44.4	4.31	10.8
Stdev	11.6	47.5	12.7	86.6	11.2	18.5
p (t-test)		0.015		4.2E-5		0.042
Min	0.0727	0.0727	0.0727	0.168	0.0727	0.0727
Max	71.6	235	71.6	235	71.6	62.9
n (Samp)	89	26	108	7	81	22
n (Patient)	89	26	108	7	81	22

At Enrollment

	sCr or UO		sCr only		UO only	
AUC	0.54		0.73		0.52	
SE	0.065		0.11		0.070	
p	0.56		0.039		0.77	
nCohort 1	89		108		81	
nCohort 2	26		7		22	
Cutoff 1	0.0727		0.195		0.0727	
Sens 1	77%		71%		73%	
Spec 1	13%		51%		15%	
Cutoff 2	0		0.168		0	
Sens 2	100%		86%		100%	
Spec 2	0%		43%		0%	
Cutoff 3	0		0.148		0	
Sens 3	100%		100%		100%	
Spec 3	0%		35%		0%	
Cutoff 4	0.265		0.265		0.265	
Sens 4	38%		57%		36%	
Spec 4	76%		75%		78%	
Cutoff 5	6.95		9.20		3.84	
Sens 5	35%		43%		36%	
Spec 5	82%		81%		80%	
Cutoff 6	16.5		18.2		14.3	
Sens 6	19%		29%		23%	
Spec 6	91%		91%		90%	
OR Quart 2	0.78		>2.1		0.75	
p Value	0.70		<0.56		0.68	

-continued

95% CI of	0.23	>0.18	0.20
OR Quart 2	2.7	na	2.9
OR Quart 3	0.48	>2.1	0.41
p Value	0.29	<0.56	0.25
95% CI of	0.12	>0.18	0.091
OR Quart 3	1.9	na	1.9
OR Quart 4	1.3	>3.2	1.4
p Value	0.61	<0.32	0.59
95% CI of	0.42	>0.32	0.41
OR Quart 4	4.3	na	4.9

Interleukin-33

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	2.43	0.0981	12.5	0.0981	2.43
Average	233	89.3	202	181	255	64.5
Stdev	1490	222	1360	326	1560	162
p (t-test)		0.63		0.97		0.57
Min	0.0445	0.0455	0.0445	0.0455	0.0445	0.0543
Max	13500	892	13500	892	13500	730
n (Samp)	90	26	109	7	82	22
n (Patient)	90	26	109	7	82	22

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.67	0.71	0.68
SE	0.064	0.11	0.069
p	0.0084	0.057	0.0097
nCohort 1	90	109	82
nCohort 2	26	7	22
Cutoff 1	0.0981	2.03	0.0981
Sens 1	73%	71%	73%
Spec 1	56%	65%	57%
Cutoff 2	0.0713	0.0981	0.0713
Sens 2	81%	86%	82%
Spec 2	39%	51%	39%
Cutoff 3	0.0494	0.0445	0.0494
Sens 3	96%	100%	100%
Spec 3	26%	5%	24%
Cutoff 4	2.20	7.15	2.20
Sens 4	50%	57%	50%
Spec 4	70%	72%	71%
Cutoff 5	11.1	14.9	11.1
Sens 5	35%	43%	32%
Spec 5	80%	81%	80%
Cutoff 6	41.6	65.9	41.6
Sens 6	23%	43%	23%
Spec 6	90%	91%	90%
OR Quart 2	7.3	0	6.0
p Value	0.075	na	0.12
95% CI of	0.82	na	0.64
OR Quart 2	65	na	55
OR Quart 3	15	2.1	13
p Value	0.014	0.56	0.019
95% CI of	1.7	0.18	1.5
OR Quart 3	120	24	110
OR Quart 4	13	4.5	9.2
p Value	0.021	0.19	0.046
95% CI of	1.5	0.47	1.0
OR Quart 4	110	43	81

Vascular endothelial growth factor receptor 2

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7610	7540	7630	5950	7750	7990
Average	10700	8210	10300	8400	11000	8290
Stdev	17500	3210	16000	3790	18300	3100
p (t-test)		0.47		0.76		0.49
Min	3730	3880	3730	5120	3730	3880

-continued

Max	166000	14800	166000	14300	166000	14800
n (Samp)	90	26	109	7	82	22
n (Patient)	90	26	109	7	82	22

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.47	0.46	0.48
SE	0.065	0.12	0.070
p	0.66	0.71	0.81
nCohort 1	90	109	82
nCohort 2	26	7	22
Cutoff 1	5750	5920	5750
Sens 1	73%	71%	73%
Spec 1	18%	21%	16%
Cutoff 2	5180	5700	5180
Sens 2	81%	86%	82%
Spec 2	10%	19%	9%
Cutoff 3	4850	5110	4850
Sens 3	92%	100%	91%
Spec 3	8%	11%	6%
Cutoff 4	9390	9460	9430
Sens 4	35%	29%	36%
Spec 4	70%	71%	71%
Cutoff 5	10600	10600	10600
Sens 5	23%	29%	23%
Spec 5	80%	81%	80%
Cutoff 6	11300	11800	11800
Sens 6	15%	29%	14%
Spec 6	90%	91%	90%
OR Quart 2	0.82	0.48	1.0
p Value	0.75	0.56	1.0
95% CI of	0.24	0.041	0.28
OR Quart 2	2.8	5.6	3.6
OR Quart 3	0.23	0	0.28
p Value	0.087	na	0.14
95% CI of	0.044	na	0.050
OR Quart 3	1.2	na	1.5
OR Quart 4	1.9	2.2	1.5
p Value	0.26	0.40	0.53
95% CI of	0.62	0.36	0.43
OR Quart 4	6.0	13	5.1

Neural cell adhesion molecule 1

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	187000	166000	nd	nd	182000	165000
Average	190000	163000	nd	nd	188000	158000
Stdev	69400	60900	nd	nd	64200	58500
p (t-test)	0.069		nd	nd	0.040	
Min	69000	77400	nd	nd	69000	77400
Max	494000	331000	nd	nd	461000	331000
n (Samp)	109	28	nd	nd	98	25
n (Patient)	109	28	nd	nd	98	25

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.38	nd	0.35
SE	0.062	nd	0.065
p	0.044	nd	0.021
nCohort 1	109	nd	98
nCohort 2	28	nd	25
Cutoff 1	114000	nd	111000
Sens 1	71%	nd	72%
Spec 1	13%	nd	11%
Cutoff 2	101000	nd	101000
Sens 2	82%	nd	80%
Spec 2	9%	nd	9%
Cutoff 3	82600	nd	82600
Sens 3	93%	nd	92%
Spec 3	6%	nd	5%

-continued

Cutoff 4	216000	nd	220000
Sens 4	18%	nd	12%
Spec 4	71%	nd	70%
Cutoff 5	229000	nd	230000
Sens 5	14%	nd	8%
Spec 5	81%	nd	81%
Cutoff 6	272000	nd	268000
Sens 6	4%	nd	4%
Spec 6	91%	nd	91%
OR Quart 2	1.0	nd	1.8
p Value	0.96	nd	0.45
95% CI of	0.27	nd	0.39
OR Quart 2	4.0	nd	8.3
OR Quart 3	1.8	nd	3.2
p Value	0.33	nd	0.11
95% CI of	0.54	nd	0.77
OR Quart 3	6.3	nd	14
OR Quart 4	2.5	nd	4.0
p Value	0.13	nd	0.056
95% CI of	0.75	nd	0.96
OR Quart 4	8.3	nd	17

Platelet-derived growth factor subunit B (dimer)

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	378	332	nd	nd	337	360
Average	404	362	nd	nd	380	379
Stdev	251	213	nd	nd	237	221
p (t-test)		0.43	nd	nd		0.99
Min	0.189	35.4	nd	nd	0.189	35.4
Max	1310	766	nd	nd	969	766
n (Samp)	104	26	nd	nd	93	23
n (Patient)	104	26	nd	nd	93	23

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.46	nd	0.51
SE	0.064	nd	0.068
p	0.54	nd	0.89
nCohort 1	104	nd	93
nCohort 2	26	nd	23
Cutoff 1	202	nd	202
Sens 1	73%	nd	74%
Spec 1	26%	nd	29%
Cutoff 2	177	nd	155
Sens 2	81%	nd	83%
Spec 2	22%	nd	20%
Cutoff 3	113	nd	113
Sens 3	92%	nd	91%
Spec 3	12%	nd	14%
Cutoff 4	527	nd	504
Sens 4	23%	nd	30%
Spec 4	70%	nd	71%
Cutoff 5	613	nd	575
Sens 5	15%	nd	22%
Spec 5	81%	nd	81%
Cutoff 6	732	nd	716
Sens 6	8%	nd	9%
Spec 6	90%	nd	90%
OR Quart 2	0.83	nd	0.80
p Value	0.78	nd	0.74
95% CI of	0.23	nd	0.21
OR Quart 2	3.1	nd	3.0
OR Quart 3	1.7	nd	1.0
p Value	0.38	nd	1.0
95% CI of	0.52	nd	0.28
OR Quart 3	5.4	nd	3.6
OR Quart 4	1.0	nd	1.0
p Value	0.95	nd	1.0
95% CI of	0.30	nd	0.28
OR Quart 4	3.6	nd	3.6

-continued

Corticotropin						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.000700	0.00350	nd	nd	0.000709	0.00277
Average	0.00668	0.00992	nd	nd	0.00765	0.0108
Stdev	0.0334	0.0200	nd	nd	0.0360	0.0217
p (t-test)		0.68	nd	nd		0.73
Min	3.38E-6	3.38E-6	nd	nd	3.38E-6	3.38E-6
Max	0.292	0.0908	nd	nd	0.292	0.0908
n (Samp)	78	20	nd	nd	67	17
n (Patient)	78	20	nd	nd	67	17

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.70	nd	0.67
SE	0.071	nd	0.078
p	0.0042	nd	0.035
nCohort 1	78	nd	67
nCohort 2	20	nd	17
Cutoff 1	0.00208	nd	0.000539
Sens 1	70%	nd	71%
Spec 1	71%	nd	46%
Cutoff 2	0.000278	nd	0.000278
Sens 2	90%	nd	88%
Spec 2	40%	nd	39%
Cutoff 3	0.000278	nd	3.38E-6
Sens 3	90%	nd	94%
Spec 3	40%	nd	6%
Cutoff 4	0.00208	nd	0.00229
Sens 4	70%	nd	59%
Spec 4	71%	nd	70%
Cutoff 5	0.00381	nd	0.00423
Sens 5	45%	nd	47%
Spec 5	81%	nd	81%
Cutoff 6	0.00772	nd	0.00914
Sens 6	40%	nd	29%
Spec 6	91%	nd	91%
OR Quart 2	2.1	nd	2.2
p Value	0.42	nd	0.39
95% CI of	0.35	nd	0.36
OR Quart 2	13	nd	14
OR Quart 3	2.9	nd	1.6
p Value	0.23	nd	0.64
95% CI of	0.50	nd	0.24
OR Quart 3	17	nd	11
OR Quart 4	6.2	nd	5.8
p Value	0.032	nd	0.042
95% CI of	1.2	nd	1.1
OR Quart 4	33	nd	32

Thyroxine-binding globulin						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	34.2	30.0	33.7	28.5	33.6	30.0
Average	36.0	31.7	35.4	29.6	34.9	31.6
Stdev	10.5	11.5	10.9	7.07	10.0	11.9
p (t-test)		0.032		0.12		0.13
Min	13.5	14.2	13.5	22.3	13.5	14.2
Max	74.3	59.5	74.3	42.5	74.3	59.5
n (Samp)	140	36	166	9	112	31
n (Patient)	140	36	166	9	112	31

At Enrollment			
	sCr or UO	sCr only	UO only
AUC	0.37	0.32	0.39
SE	0.054	0.10	0.059
p	0.016	0.072	0.056

-continued

nCohort 1	140	166	112
nCohort 2	36	9	31
Cutoff 1	23.9	23.3	25.7
Sens 1	72%	78%	71%
Spec 1	11%	11%	14%
Cutoff 2	21.4	22.3	19.8
Sens 2	81%	89%	81%
Spec 2	6%	10%	6%
Cutoff 3	16.3	21.4	16.3
Sens 3	92%	100%	90%
Spec 3	4%	10%	4%
Cutoff 4	41.5	40.9	40.0
Sens 4	17%	11%	23%
Spec 4	71%	70%	71%
Cutoff 5	44.9	44.9	43.4
Sens 5	14%	0%	16%
Spec 5	80%	80%	80%
Cutoff 6	49.5	50.0	48.3
Sens 6	11%	0%	16%
Spec 6	90%	90%	90%
OR Quart 2	1.0	1.0	1.0
p Value	1.0	1.0	1.0
95% CI of	0.30	0.061	0.26
OR Quart 2	3.4	17	3.8
OR Quart 3	1.6	4.3	2.4
p Value	0.40	0.20	0.15
95% CI of	0.53	0.46	0.72
OR Quart 3	5.0	40	7.9
OR Quart 4	3.3	3.2	2.8
p Value	0.029	0.32	0.084
95% CI of	1.1	0.32	0.87
OR Quart 4	9.5	32	9.3

Pigment epithelium-derived factor

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1500	1260	nd	nd	1490	1250
Average	1690	1790	nd	nd	1680	1760
Stdev	869	1370	nd	nd	896	1420
p (t-test)		0.64	nd	nd		0.74
Min	84.2	339	nd	nd	84.2	339
Max	4510	6200	nd	nd	4510	6200
n (Samp)	109	28	nd	nd	98	25
n (Patient)	109	28	nd	nd	98	25

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.45	nd	0.44
SE	0.062	nd	0.066
p	0.41	nd	0.33
nCohort 1	109	nd	98
nCohort 2	28	nd	25
Cutoff 1	1030	nd	1030
Sens 1	71%	nd	72%
Spec 1	19%	nd	21%
Cutoff 2	813	nd	950
Sens 2	82%	nd	80%
Spec 2	10%	nd	17%
Cutoff 3	460	nd	460
Sens 3	93%	nd	92%
Spec 3	3%	nd	3%
Cutoff 4	1800	nd	1770
Sens 4	36%	nd	32%
Spec 4	71%	nd	70%
Cutoff 5	2350	nd	2350
Sens 5	25%	nd	20%
Spec 5	81%	nd	81%
Cutoff 6	2870	nd	3150
Sens 6	14%	nd	16%
Spec 6	91%	nd	91%
OR Quart 2	0.21	nd	0.29
p Value	0.062	nd	0.15

-continued

95% CI of	0.041	nd	0.053
OR Quart 2	1.1	nd	1.6
OR Quart 3	1.2	nd	1.7
p Value	0.73	nd	0.38
95% CI of	0.41	nd	0.52
OR Quart 3	3.6	nd	5.6
OR Quart 4	1.2	nd	1.5
p Value	0.73	nd	0.50
95% CI of	0.41	nd	0.45
OR Quart 4	3.6	nd	5.0

Tumor necrosis factor receptor superfamily member 8

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	100.0	95.1	96.5	110	100.0	95.1
Average	199	149	192	126	204	152
Stdev	378	136	349	79.2	393	143
p (t-test)		0.51		0.62		0.55
Min	12.8	36.8	12.8	54.3	12.8	36.8
Max	2700	595	2700	288	2700	595
n (Samp)	90	26	109	7	82	22
n (Patient)	90	26	109	7	82	22

At Enrollment

	sCr or UO	sCr only	UO only
AUC	0.51	0.53	0.51
SE	0.065	0.11	0.070
p	0.87	0.81	0.86
nCohort 1	90	109	82
nCohort 2	26	7	22
Cutoff 1	56.6	96.5	56.6
Sens 1	73%	71%	73%
Spec 1	23%	50%	23%
Cutoff 2	54.3	59.2	53.7
Sens 2	85%	86%	86%
Spec 2	21%	26%	21%
Cutoff 3	37.8	53.7	37.8
Sens 3	92%	100%	91%
Spec 3	14%	20%	13%
Cutoff 4	149	156	150
Sens 4	38%	14%	41%
Spec 4	70%	71%	71%
Cutoff 5	203	205	203
Sens 5	19%	14%	18%
Spec 5	80%	82%	80%
Cutoff 6	277	305	277
Sens 6	15%	0%	14%
Spec 6	90%	91%	90%
OR Quart 2	0.68	2.1	0.65
p Value	0.54	0.56	0.51
95% CI of	0.20	0.18	0.18
OR Quart 2	2.3	24	2.4
OR Quart 3	0.68	3.2	0.65
p Value	0.54	0.32	0.51
95% CI of	0.20	0.32	0.18
OR Quart 3	2.3	33	2.4
OR Quart 4	0.68	1.0	0.65
p Value	0.54	1.0	0.51
95% CI of	0.20	0.060	0.18
OR Quart 4	2.3	17	2.4

Alpha-fetoprotein

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.316	0.438	nd	nd	0.317	0.438
Average	0.321	0.467	nd	nd	0.326	0.430
Stdev	0.281	0.409	nd	nd	0.306	0.396
p (t-test)		0.028	nd	nd		0.16
Min	0.00580	0.00580	nd	nd	0.00580	0.00580

-continued

Max	1.39	1.53	nd	nd	1.39	1.53
n (Samp)	109	28	nd	nd	98	25
n (Patient)	109	28	nd	nd	98	25
At Enrollment						
	sCr or UO		sCr only		UO only	
AUC	0.62		nd		0.60	
SE	0.062		nd		0.066	
p	0.046		nd		0.14	
nCohort 1	109		nd		98	
nCohort 2	28		nd		25	
Cutoff 1	0.225		nd		0.00580	
Sens 1	71%		nd		92%	
Spec 1	39%		nd		19%	
Cutoff 2	0.00580		nd		0.00580	
Sens 2	93%		nd		92%	
Spec 2	17%		nd		19%	
Cutoff 3	0.00580		nd		0.00580	
Sens 3	93%		nd		92%	
Spec 3	17%		nd		19%	
Cutoff 4	0.438		nd		0.438	
Sens 4	46%		nd		44%	
Spec 4	71%		nd		70%	
Cutoff 5	0.544		nd		0.550	
Sens 5	39%		nd		32%	
Spec 5	81%		nd		81%	
Cutoff 6	0.663		nd		0.687	
Sens 6	25%		nd		24%	
Spec 6	91%		nd		91%	
OR Quart 2	0.62		nd		2.6	
p Value	0.50		nd		0.20	
95% CI of	0.16		nd		0.61	
OR Quart 2	2.4		nd		11	
OR Quart 3	1.2		nd		2.2	
p Value	0.76		nd		0.31	
95% CI of	0.36		nd		0.49	
OR Quart 3	4.1		nd		9.6	
OR Quart 4	2.1		nd		3.7	
p Value	0.19		nd		0.073	
95% CI of	0.69		nd		0.89	
OR Quart 4	6.7		nd		15	
Apolipoprotein(a)						
	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	55700	18600	nd	nd	54000	17200
Average	77500	43100	nd	nd	77800	43100
Stdev	85500	62700	nd	nd	87900	63800
p (t-test)	0.037		nd		0.044	
Min	58.7	968	nd	nd	128	968
Max	411000	314000	nd	nd	411000	314000
n (Samp)	132	31	nd	nd	117	30
n (Patient)	132	31	nd	nd	117	30
At Enrollment						
	sCr or UO		sCr only		UO only	
AUC	0.35		nd		0.35	
SE	0.058		nd		0.059	
p	0.011		nd		0.010	
nCohort 1	132		nd		117	
nCohort 2	31		nd		30	
Cutoff 1	5630		nd		5630	
Sens 1	71%		nd		70%	
Spec 1	15%		nd		15%	
Cutoff 2	4320		nd		4320	
Sens 2	81%		nd		80%	
Spec 2	11%		nd		10%	
Cutoff 3	2710		nd		2710	
Sens 3	90%		nd		90%	
Spec 3	7%		nd		5%	

-continued

Cutoff 4	92400	nd	91700
Sens 4	16%	nd	17%
Spec 4	70%	nd	70%
Cutoff 5	112000	nd	109000
Sens 5	13%	nd	13%
Spec 5	80%	nd	80%
Cutoff 6	210000	nd	227000
Sens 6	3%	nd	3%
Spec 6	90%	nd	91%
OR Quart 2	0.78	nd	0.78
p Value	0.72	nd	0.72
95% CI of	0.19	nd	0.19
OR Quart 2	3.1	nd	3.2
OR Quart 3	2.3	nd	2.1
p Value	0.16	nd	0.24
95% CI of	0.72	nd	0.62
OR Quart 3	7.5	nd	6.9
OR Quart 4	3.1	nd	3.2
p Value	0.056	nd	0.051
95% CI of	0.97	nd	0.99
OR Quart 4	9.8	nd	10

[0195] While the invention has been described and exemplified in sufficient detail for those skilled in this art to make and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.

[0196] It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[0197] All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[0198] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0199] Other embodiments are set forth within the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 35

<210> SEQ ID NO 1

<211> LENGTH: 99

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Met Lys Ala Ser Ala Ala Leu Leu Cys Leu Leu Thr Ala Ala Ala
1 5 10 15

Phe Ser Pro Gln Gly Leu Ala Gln Pro Val Gly Ile Asn Thr Ser Thr
20 25 30

Thr Cys Cys Tyr Arg Phe Ile Asn Lys Lys Ile Pro Lys Gln Arg Leu
35 40 45

Glu Ser Tyr Arg Arg Thr Thr Ser Ser His Cys Pro Arg Glu Ala Val
50 55 60

-continued

```

Ile Phe Lys Thr Lys Leu Asp Lys Glu Ile Cys Ala Asp Pro Thr Gln
65          70          75          80

Lys Trp Val Gln Asp Phe Met Lys His Leu Asp Lys Lys Thr Gln Thr
          85          90          95

Pro Lys Leu

```

```

<210> SEQ ID NO 2
<211> LENGTH: 94
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 2

```

```

Met Met Gly Leu Ser Leu Ala Ser Ala Val Leu Leu Ala Ser Leu Leu
1          5          10          15

Ser Leu His Leu Gly Thr Ala Thr Arg Gly Ser Asp Ile Ser Lys Thr
          20          25          30

Cys Cys Phe Gln Tyr Ser His Lys Pro Leu Pro Trp Thr Trp Val Arg
          35          40          45

Ser Tyr Glu Phe Thr Ser Asn Ser Cys Ser Gln Arg Ala Val Ile Phe
          50          55          60

Thr Thr Lys Arg Gly Lys Lys Val Cys Thr His Pro Arg Lys Lys Trp
65          70          75          80

Val Gln Lys Tyr Ile Ser Leu Leu Lys Thr Pro Lys Gln Leu
          85          90

```

```

<210> SEQ ID NO 3
<211> LENGTH: 1744
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 3

```

```

Met Arg Leu Leu Trp Gly Leu Ile Trp Ala Ser Ser Phe Phe Thr Leu
1          5          10          15

Ser Leu Gln Lys Pro Arg Leu Leu Leu Phe Ser Pro Ser Val Val His
          20          25          30

Leu Gly Val Pro Leu Ser Val Gly Val Gln Leu Gln Asp Val Pro Arg
          35          40          45

Gly Gln Val Val Lys Gly Ser Val Phe Leu Arg Asn Pro Ser Arg Asn
          50          55          60

Asn Val Pro Cys Ser Pro Lys Val Asp Phe Thr Leu Ser Ser Glu Arg
65          70          75          80

Asp Phe Ala Leu Leu Ser Leu Gln Val Pro Leu Lys Asp Ala Lys Ser
          85          90          95

Cys Gly Leu His Gln Leu Leu Arg Gly Pro Glu Val Gln Leu Val Ala
          100          105          110

His Ser Pro Trp Leu Lys Asp Ser Leu Ser Arg Thr Thr Asn Ile Gln
          115          120          125

Gly Ile Asn Leu Leu Phe Ser Ser Arg Arg Gly His Leu Phe Leu Gln
          130          135          140

Thr Asp Gln Pro Ile Tyr Asn Pro Gly Gln Arg Val Arg Tyr Arg Val
145          150          155          160

Phe Ala Leu Asp Gln Lys Met Arg Pro Ser Thr Asp Thr Ile Thr Val
          165          170          175

Met Val Glu Asn Ser His Gly Leu Arg Val Arg Lys Lys Glu Val Tyr
          180          185          190

```

Met	Pro	Ser	Ser	Ile	Phe	Gln	Asp	Asp	Phe	Val	Ile	Pro	Asp	Ile	Ser
		195					200					205			
Glu	Pro	Gly	Thr	Trp	Lys	Ile	Ser	Ala	Arg	Phe	Ser	Asp	Gly	Leu	Glu
	210					215					220				
Ser	Asn	Ser	Ser	Thr	Gln	Phe	Glu	Val	Lys	Lys	Tyr	Val	Leu	Pro	Asn
225					230					235					240
Phe	Glu	Val	Lys	Ile	Thr	Pro	Gly	Lys	Pro	Tyr	Ile	Leu	Thr	Val	Pro
				245					250					255	
Gly	His	Leu	Asp	Glu	Met	Gln	Leu	Asp	Ile	Gln	Ala	Arg	Tyr	Ile	Tyr
			260					265					270		
Gly	Lys	Pro	Val	Gln	Gly	Val	Ala	Tyr	Val	Arg	Phe	Gly	Leu	Leu	Asp
		275					280					285			
Glu	Asp	Gly	Lys	Lys	Thr	Phe	Phe	Arg	Gly	Leu	Glu	Ser	Gln	Thr	Lys
	290					295					300				
Leu	Val	Asn	Gly	Gln	Ser	His	Ile	Ser	Leu	Ser	Lys	Ala	Glu	Phe	Gln
305					310					315					320
Asp	Ala	Leu	Glu	Lys	Leu	Asn	Met	Gly	Ile	Thr	Asp	Leu	Gln	Gly	Leu
				325				330						335	
Arg	Leu	Tyr	Val	Ala	Ala	Ala	Ile	Ile	Glu	Ser	Pro	Gly	Gly	Glu	Met
			340					345					350		
Glu	Glu	Ala	Glu	Leu	Thr	Ser	Trp	Tyr	Phe	Val	Ser	Ser	Pro	Phe	Ser
		355					360					365			
Leu	Asp	Leu	Ser	Lys	Thr	Lys	Arg	His	Leu	Val	Pro	Gly	Ala	Pro	Phe
	370					375					380				
Leu	Leu	Gln	Ala	Leu	Val	Arg	Glu	Met	Ser	Gly	Ser	Pro	Ala	Ser	Gly
385					390					395					400
Ile	Pro	Val	Lys	Val	Ser	Ala	Thr	Val	Ser	Ser	Pro	Gly	Ser	Val	Pro
				405					410					415	
Glu	Val	Gln	Asp	Ile	Gln	Gln	Asn	Thr	Asp	Gly	Ser	Gly	Gln	Val	Ser
			420					425					430		
Ile	Pro	Ile	Ile	Ile	Pro	Gln	Thr	Ile	Ser	Glu	Leu	Gln	Leu	Ser	Val
		435					440					445			
Ser	Ala	Gly	Ser	Pro	His	Pro	Ala	Ile	Ala	Arg	Leu	Thr	Val	Ala	Ala
	450					455					460				
Pro	Pro	Ser	Gly	Gly	Pro	Gly	Phe	Leu	Ser	Ile	Glu	Arg	Pro	Asp	Ser
465					470					475					480
Arg	Pro	Pro	Arg	Val	Gly	Asp	Thr	Leu	Asn	Leu	Asn	Leu	Arg	Ala	Val
				485				490						495	
Gly	Ser	Gly	Ala	Thr	Phe	Ser	His	Tyr	Tyr	Tyr	Met	Ile	Leu	Ser	Arg
			500					505					510		
Gly	Gln	Ile	Val	Phe	Met	Asn	Arg	Glu	Pro	Lys	Arg	Thr	Leu	Thr	Ser
		515					520					525			
Val	Ser	Val	Phe	Val	Asp	His	His	Leu	Ala	Pro	Ser	Phe	Tyr	Phe	Val
	530					535					540				
Ala	Phe	Tyr	Tyr	His	Gly										

-continued

595					600					605					
Tyr	Ala	Ala	Gly	Ser	Lys	Ser	His	Lys	Pro	Leu	Asn	Met	Gly	Lys	Val
610						615					620				
Phe	Glu	Ala	Met	Asn	Ser	Tyr	Asp	Leu	Gly	Cys	Gly	Pro	Gly	Gly	Gly
625					630					635					640
Asp	Ser	Ala	Leu	Gln	Val	Phe	Gln	Ala	Ala	Gly	Leu	Ala	Phe	Ser	Asp
				645					650					655	
Gly	Asp	Gln	Trp	Thr	Leu	Ser	Arg	Lys	Arg	Leu	Ser	Cys	Pro	Lys	Glu
			660					665					670		
Lys	Thr	Thr	Arg	Lys	Lys	Arg	Asn	Val	Asn	Phe	Gln	Lys	Ala	Ile	Asn
			675				680					685			
Glu	Lys	Leu	Gly	Gln	Tyr	Ala	Ser	Pro	Thr	Ala	Lys	Arg	Cys	Cys	Gln
	690					695					700				
Asp	Gly	Val	Thr	Arg	Leu	Pro	Met	Met	Arg	Ser	Cys	Glu	Gln	Arg	Ala
705					710					715					720
Ala	Arg	Val	Gln	Gln	Pro	Asp	Cys	Arg	Glu	Pro	Phe	Leu	Ser	Cys	Cys
				725					730					735	
Gln	Phe	Ala	Glu	Ser	Leu	Arg	Lys	Lys	Ser	Arg	Asp	Lys	Gly	Gln	Ala
			740					745					750		
Gly	Leu	Gln	Arg	Ala	Leu	Glu	Ile	Leu	Gln	Glu	Glu	Asp	Leu	Ile	Asp
		755					760					765			
Glu	Asp	Asp	Ile	Pro	Val	Arg	Ser	Phe	Phe	Pro	Glu	Asn	Trp	Leu	Trp
	770					775					780				
Arg	Val	Glu	Thr	Val	Asp	Arg	Phe	Gln	Ile	Leu	Thr	Leu	Trp	Leu	Pro
785					790					795					800
Asp	Ser	Leu	Thr	Thr	Trp	Glu	Ile	His	Gly	Leu	Ser	Leu	Ser	Lys	Thr
				805					810					815	
Lys	Gly	Leu	Cys	Val	Ala	Thr	Pro	Val	Gln	Leu	Arg	Val	Phe	Arg	Glu
			820					825					830		
Phe	His	Leu	His	Leu	Arg	Leu	Pro	Met	Ser	Val	Arg	Arg	Phe	Glu	Gln
	835						840					845			
Leu	Glu	Leu	Arg	Pro	Val	Leu	Tyr	Asn	Tyr	Leu	Asp	Lys	Asn	Leu	Thr
	850					855					860				
Val	Ser	Val	His	Val	Ser	Pro	Val	Glu	Gly	Leu	Cys	Leu	Ala	Gly	Gly
865					870					875					880
Gly	Gly	Leu	Ala	Gln	Gln	Val	Leu	Val	Pro	Ala	Gly	Ser	Ala	Arg	Pro
				885					890					895	
Val	Ala	Phe	Ser	Val	Val	Pro	Thr	Ala	Ala	Ala	Ala	Val	Ser	Leu	Lys
			900					905					910		
Val	Val	Ala	Arg	Gly	Ser	Phe	Glu	Phe	Pro	Val	Gly	Asp	Ala	Val	Ser
		915					920					925			
Lys	Val	Leu	Gln	Ile	Glu	Lys	Glu	Gly	Ala	Ile	His	Arg	Glu	Glu	Leu
	930					935					940				
Val	Tyr	Glu	Leu	Asn	Pro	Leu	Asp	His	Arg	Gly	Arg	Thr	Leu	Glu	Ile
945					950					955					960
Pro	Gly	Asn	Ser	Asp	Pro	Asn	Met	Ile	Pro	Asp	Gly	Asp	Phe	Asn	Ser
				965					970					975	
Tyr	Val	Arg	Val	Thr	Ala	Ser	Asp	Pro	Leu	Asp	Thr	Leu	Gly	Ser	Glu
			980					985					990		
Gly	Ala	Leu	Ser	Pro	Gly	Gly	Val	Ala	Ser	Leu	Leu	Arg	Leu	Pro	Arg
	995						1000						1005		

-continued

Gly	Cys	Gly	Glu	Gln	Thr	Met	Ile	Tyr	Leu	Ala	Pro	Thr	Leu	Ala
1010						1015					1020			
Ala	Ser	Arg	Tyr	Leu	Asp	Lys	Thr	Glu	Gln	Trp	Ser	Thr	Leu	Pro
1025						1030					1035			
Pro	Glu	Thr	Lys	Asp	His	Ala	Val	Asp	Leu	Ile	Gln	Lys	Gly	Tyr
1040						1045					1050			
Met	Arg	Ile	Gln	Gln	Phe	Arg	Lys	Ala	Asp	Gly	Ser	Tyr	Ala	Ala
1055						1060					1065			
Trp	Leu	Ser	Arg	Asp	Ser	Ser	Thr	Trp	Leu	Thr	Ala	Phe	Val	Leu
1070						1075					1080			
Lys	Val	Leu	Ser	Leu	Ala	Gln	Glu	Gln	Val	Gly	Gly	Ser	Pro	Glu
1085						1090					1095			
Lys	Leu	Gln	Glu	Thr	Ser	Asn	Trp	Leu	Leu	Ser	Gln	Gln	Gln	Ala
1100						1105					1110			
Asp	Gly	Ser	Phe	Gln	Asp	Leu	Ser	Pro	Val	Ile	His	Arg	Ser	Met
1115						1120					1125			
Gln	Gly	Gly	Leu	Val	Gly	Asn	Asp	Glu	Thr	Val	Ala	Leu	Thr	Ala
1130						1135					1140			
Phe	Val	Thr	Ile	Ala	Leu	His	His	Gly	Leu	Ala	Val	Phe	Gln	Asp
1145						1150					1155			
Glu	Gly	Ala	Glu	Pro	Leu	Lys	Gln	Arg	Val	Glu	Ala	Ser	Ile	Ser
1160						1165					1170			
Lys	Ala	Asn	Ser	Phe	Leu	Gly	Glu	Lys	Ala	Ser	Ala	Gly	Leu	Leu
1175						1180					1185			
Gly	Ala	His	Ala	Ala	Ala	Ile	Thr	Ala	Tyr	Ala	Leu	Ser	Leu	Thr
1190						1195					1200			
Lys	Ala	Pro	Val	Asp	Leu	Leu	Gly	Val	Ala	His	Asn	Asn	Leu	Met
1205						1210					1215			
Ala	Met	Ala	Gln	Glu	Thr	Gly	Asp	Asn	Leu	Tyr	Trp	Gly	Ser	Val
1220						1225					1230			
Thr	Gly	Ser	Gln	Ser	Asn	Ala	Val	Ser	Pro	Thr	Pro	Ala	Pro	Arg
1235						1240					1245			
Asn	Pro	Ser	Asp	Pro	Met	Pro	Gln	Ala	Pro	Ala	Leu	Trp	Ile	Glu
1250						1255					1260			
Thr	Thr	Ala	Tyr	Ala	Leu	Leu	His	Leu	Leu	Leu	His	Glu	Gly	Lys
1265						1270					1275			
Ala	Glu	Met	Ala	Asp	Gln	Ala	Ser	Ala	Trp	Leu	Thr	Arg	Gln	Gly
1280						1285					1290			
Ser	Phe	Gln	Gly	Gly	Phe	Arg	Ser	Thr	Gln	Asp	Thr	Val	Ile	Ala
1295						1300					1305			
Leu	Asp	Ala	Leu	Ser	Ala	Tyr	Trp	Ile	Ala	Ser	His	Thr	Thr	Glu
1310						1315					1320			
Glu	Arg	Gly	Leu	Asn	Val	Thr	Leu	Ser	Ser	Thr	Gly	Arg	Asn	Gly
1325						1330					1335			
Phe	Lys	Ser	His	Ala	Leu	Gln	Leu	Asn	Asn	Arg	Gln	Ile	Arg	Gly
1340						1345					1350			
Leu	Glu	Glu	Glu	Leu	Gln	Phe	Ser	Leu	Gly	Ser	Lys	Ile	Asn	Val
1355						1360					1365			
Lys	Val	Gly	Gly	Asn	Ser	Lys	Gly	Thr	Leu	Lys	Val	Leu	Arg	Thr
1370						1375					1380			
Tyr	Asn	Val	Leu	Asp	Met	Lys	Asn	Thr	Thr	Cys	Gln	Asp	Leu	Gln
1385						1390					1395			

-continued

Ile	Glu	Val	Thr	Val	Lys	Gly	His	Val	Glu	Tyr	Thr	Met	Glu	Ala
1400						1405					1410			
Asn	Glu	Asp	Tyr	Glu	Asp	Tyr	Glu	Tyr	Asp	Glu	Leu	Pro	Ala	Lys
1415						1420					1425			
Asp	Asp	Pro	Asp	Ala	Pro	Leu	Gln	Pro	Val	Thr	Pro	Leu	Gln	Leu
1430						1435					1440			
Phe	Glu	Gly	Arg	Arg	Asn	Arg	Arg	Arg	Arg	Glu	Ala	Pro	Lys	Val
1445						1450					1455			
Val	Glu	Glu	Gln	Glu	Ser	Arg	Val	His	Tyr	Thr	Val	Cys	Ile	Trp
1460						1465					1470			
Arg	Asn	Gly	Lys	Val	Gly	Leu	Ser	Gly	Met	Ala	Ile	Ala	Asp	Val
1475						1480					1485			
Thr	Leu	Leu	Ser	Gly	Phe	His	Ala	Leu	Arg	Ala	Asp	Leu	Glu	Lys
1490						1495					1500			
Leu	Thr	Ser	Leu	Ser	Asp	Arg	Tyr	Val	Ser	His	Phe	Glu	Thr	Glu
1505						1510					1515			
Gly	Pro	His	Val	Leu	Leu	Tyr	Phe	Asp	Ser	Val	Pro	Thr	Ser	Arg
1520						1525					1530			
Glu	Cys	Val	Gly	Phe	Glu	Ala	Val	Gln	Glu	Val	Pro	Val	Gly	Leu
1535						1540					1545			
Val	Gln	Pro	Ala	Ser	Ala	Thr	Leu	Tyr	Asp	Tyr	Tyr	Asn	Pro	Glu
1550						1555					1560			
Arg	Arg	Cys	Ser	Val	Phe	Tyr	Gly	Ala	Pro	Ser	Lys	Ser	Arg	Leu
1565						1570					1575			
Leu	Ala	Thr	Leu	Cys	Ser	Ala	Glu	Val	Cys	Gln	Cys	Ala	Glu	Gly
1580						1585					1590			
Lys	Cys	Pro	Arg	Gln	Arg	Arg	Ala	Leu	Glu	Arg	Gly	Leu	Gln	Asp
1595						1600					1605			
Glu	Asp	Gly	Tyr	Arg	Met	Lys	Phe	Ala	Cys	Tyr	Tyr	Pro	Arg	Val
1610						1615					1620			
Glu	Tyr	Gly	Phe	Gln	Val	Lys	Val	Leu	Arg	Glu	Asp	Ser	Arg	Ala
1625						1630					1635			
Ala	Phe	Arg	Leu	Phe	Glu	Thr	Lys	Ile	Thr	Gln	Val	Leu	His	Phe
1640						1645					1650			
Thr	Lys	Asp	Val	Lys	Ala	Ala	Ala	Asn	Gln	Met	Arg	Asn	Phe	Leu
1655						1660					1665			
Val	Arg	Ala	Ser	Cys	Arg	Leu	Arg	Leu	Glu	Pro	Gly	Lys	Glu	Tyr
1670						1675					1680			
Leu	Ile	Met	Gly	Leu	Asp	Gly	Ala	Thr	Tyr	Asp	Leu	Glu	Gly	His
1685						1690					1695			
Pro	Gln	Tyr	Leu	Leu	Asp	Ser	Asn	Ser	Trp	Ile	Glu	Glu	Met	Pro
1700						1705					1710			
Ser	Glu	Arg	Leu	Cys	Arg	Ser	Thr	Arg	Gln	Arg	Ala	Ala	Cys	Ala
1715						1720					1725			
Gln	Leu	Asn	Asp	Phe	Leu	Gln	Glu	Tyr	Gly	Thr	Gln	Gly	Cys	Gln
1730						1735					1740			

Val

<210> SEQ ID NO 4

<211> LENGTH: 267

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 4

```

Met Pro Arg Ser Cys Cys Ser Arg Ser Gly Ala Leu Leu Leu Ala Leu
1      5      10      15
Leu Leu Gln Ala Ser Met Glu Val Arg Gly Trp Cys Leu Glu Ser Ser
20      25      30
Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn Leu Leu Glu Cys Ile Arg
35      40      45
Ala Cys Lys Pro Asp Leu Ser Ala Glu Thr Pro Met Phe Pro Gly Asn
50      55      60
Gly Asp Glu Gln Pro Leu Thr Glu Asn Pro Arg Lys Tyr Val Met Gly
65      70      75      80
His Phe Arg Trp Asp Arg Phe Gly Arg Arg Asn Ser Ser Ser Ser Gly
85      90      95
Ser Ser Gly Ala Gly Gln Lys Arg Glu Asp Val Ser Ala Gly Glu Asp
100     105     110
Cys Gly Pro Leu Pro Glu Gly Gly Pro Glu Pro Arg Ser Asp Gly Ala
115     120     125
Lys Pro Gly Pro Arg Glu Gly Lys Arg Ser Tyr Ser Met Glu His Phe
130     135     140
Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr
145     150     155     160
Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe
165     170     175
Lys Arg Glu Leu Thr Gly Gln Arg Leu Arg Glu Gly Asp Gly Pro Asp
180     185     190
Gly Pro Ala Asp Asp Gly Ala Gly Ala Gln Ala Asp Leu Glu His Ser
195     200     205
Leu Leu Val Ala Ala Glu Lys Lys Asp Glu Gly Pro Tyr Arg Met Glu
210     215     220
His Phe Arg Trp Gly Ser Pro Pro Lys Asp Lys Arg Tyr Gly Gly Phe
225     230     235     240
Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr Leu Phe Lys Asn
245     250     255
Ala Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu
260     265

```

<210> SEQ ID NO 5

<211> LENGTH: 188

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

```

Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu Val Leu Ser Cys
1      5      10      15
Lys Ser Ser Cys Ser Val Gly Cys Asp Leu Pro Gln Thr His Ser Leu
20      25      30
Gly Ser Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser
35      40      45
Leu Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu
50      55      60
Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His
65      70      75      80

```

-continued

Glu	Met	Ile	Gln	Gln	Ile	Phe	Asn	Leu	Phe	Ser	Thr	Lys	Asp	Ser	Ser
			85						90					95	
Ala	Ala	Trp	Asp	Glu	Thr	Leu	Leu	Asp	Lys	Phe	Tyr	Thr	Glu	Leu	Tyr
			100					105					110		
Gln	Gln	Leu	Asn	Asp	Leu	Glu	Ala	Cys	Val	Ile	Gln	Gly	Val	Gly	Val
		115					120					125			
Thr	Glu	Thr	Pro	Leu	Met	Lys	Glu	Asp	Ser	Ile	Leu	Ala	Val	Arg	Lys
	130					135					140				
Tyr	Phe	Gln	Arg	Ile	Thr	Leu	Tyr	Leu	Lys	Glu	Lys	Lys	Tyr	Ser	Pro
145					150					155				160	
Cys	Ala	Trp	Glu	Val	Val	Arg	Ala	Glu	Ile	Met	Arg	Ser	Phe	Ser	Leu
			165					170						175	
Ser	Thr	Asn	Leu	Gln	Glu	Ser	Leu	Arg	Ser	Lys	Glu				
		180						185							

<210> SEQ ID NO 6

<211> LENGTH: 825

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Met	Gly	Trp	Leu	Cys	Ser	Gly	Leu	Leu	Phe	Pro	Val	Ser	Cys	Leu	Val
1				5					10					15	
Leu	Leu	Gln	Val	Ala	Ser	Ser	Gly	Asn	Met	Lys	Val	Leu	Gln	Glu	Pro
		20					25						30		
Thr	Cys	Val	Ser	Asp	Tyr	Met	Ser	Ile	Ser	Thr	Cys	Glu	Trp	Lys	Met
	35					40					45				
Asn	Gly	Pro	Thr	Asn	Cys	Ser	Thr	Glu	Leu	Arg	Leu	Leu	Tyr	Gln	Leu
	50				55					60					
Val	Phe	Leu	Leu	Ser	Glu	Ala	His	Thr	Cys	Ile	Pro	Glu	Asn	Asn	Gly
65				70					75					80	
Gly	Ala	Gly	Cys	Val	Cys	His	Leu	Leu	Met	Asp	Asp	Val	Val	Ser	Ala
			85						90					95	
Asp	Asn	Tyr	Thr	Leu	Asp	Leu	Trp	Ala	Gly	Gln	Gln	Leu	Leu	Trp	Lys
	100						105						110		
Gly	Ser	Phe	Lys	Pro	Ser	Glu	His	Val	Lys	Pro	Arg	Ala	Pro	Gly	Asn
	115					120					125				
Leu	Thr	Val	His	Thr	Asn	Val	Ser	Asp	Thr	Leu	Leu	Leu	Thr	Trp	Ser
	130				135						140				
Asn	Pro	Tyr	Pro	Pro	Asp	Asn	Tyr	Leu	Tyr	Asn	His	Leu	Thr	Tyr	Ala
145				150					155					160	
Val	Asn	Ile	Trp	Ser	Glu	Asn	Asp	Pro	Ala	Asp	Phe	Arg	Ile	Tyr	Asn
		165					170							175	
Val	Thr	Tyr	Leu	Glu	Pro	Ser	Leu	Arg	Ile	Ala	Ala	Ser	Thr	Leu	Lys
	180						185						190		
Ser	Gly	Ile	Ser	Tyr	Arg	Ala	Arg	Val	Arg	Ala	Trp	Ala	Gln	Cys	Tyr
	195					200					205				
Asn	Thr	Thr	Trp	Ser	Glu	Trp	Ser	Pro	Ser	Thr	Lys	Trp	His	Asn	Ser
	210				215						220				
Tyr	Arg	Glu	Pro	Phe	Glu	Gln	His	Leu	Leu	Leu	Gly	Val	Ser	Val	Ser
225				230					235					240	
Cys	Ile	Val	Ile	Leu	Ala	Val	Cys	Leu	Leu	Cys	Tyr	Val	Ser	Ile	Thr
		245						250						255	

-continued

Lys	Ile	Lys	Lys	Glu	Trp	Trp	Asp	Gln	Ile	Pro	Asn	Pro	Ala	Arg	Ser
			260					265						270	
Arg	Leu	Val	Ala	Ile	Ile	Ile	Gln	Asp	Ala	Gln	Gly	Ser	Gln	Trp	Glu
		275					280					285			
Lys	Arg	Ser	Arg	Gly	Gln	Glu	Pro	Ala	Lys	Cys	Pro	His	Trp	Lys	Asn
	290					295					300				
Cys	Leu	Thr	Lys	Leu	Leu	Pro	Cys	Phe	Leu	Glu	His	Asn	Met	Lys	Arg
305					310					315					320
Asp	Glu	Asp	Pro	His	Lys	Ala	Ala	Lys	Glu	Met	Pro	Phe	Gln	Gly	Ser
				325					330					335	
Gly	Lys	Ser	Ala	Trp	Cys	Pro	Val	Glu	Ile	Ser	Lys	Thr	Val	Leu	Trp
			340					345					350		
Pro	Glu	Ser	Ile	Ser	Val	Val	Arg	Cys	Val	Glu	Leu	Phe	Glu	Ala	Pro
		355					360					365			
Val	Glu	Cys	Glu	Glu	Glu	Glu	Val	Glu	Glu	Glu	Lys	Gly	Ser	Phe	
	370					375					380				
Cys	Ala	Ser	Pro	Glu	Ser	Ser	Arg	Asp	Asp	Phe	Gln	Glu	Gly	Arg	Glu
385					390					395					400
Gly	Ile	Val	Ala	Arg	Leu	Thr	Glu	Ser	Leu	Phe	Leu	Asp	Leu	Leu	Gly
				405					410					415	
Glu	Glu	Asn	Gly	Gly	Phe	Cys	Gln	Gln	Asp	Met	Gly	Glu	Ser	Cys	Leu
			420					425					430		
Leu	Pro	Pro	Ser	Gly	Ser	Thr	Ser	Ala	His	Met	Pro	Trp	Asp	Glu	Phe
		435					440					445			
Pro	Ser	Ala	Gly	Pro	Lys	Glu	Ala	Pro	Pro	Trp	Gly	Lys	Glu	Gln	Pro
		450				455					460				
Leu	His	Leu	Glu	Pro	Ser	Pro	Pro	Ala	Ser	Pro	Thr	Gln	Ser	Pro	Asp
465					470					475					480
Asn	Leu	Thr	Cys	Thr	Glu	Thr	Pro	Leu	Val	Ile	Ala	Gly	Asn	Pro	Ala
				485					490					495	
Tyr	Arg	Ser	Phe	Ser	Asn	Ser	Leu	Ser	Gln	Ser	Pro	Cys	Pro	Arg	Glu
			500					505					510		
Leu	Gly	Pro	Asp	Pro	Leu	Leu	Ala	Arg	His	Leu	Glu	Glu	Val	Glu	Pro
		515					520					525			
Glu	Met	Pro	Cys	Val	Pro	Gln	Leu	Ser	Glu	Pro	Thr	Thr	Val	Pro	Gln
	530					535					540				
Pro	Glu	Pro	Glu	Thr	Trp	Glu	Gln	Ile	Leu	Arg	Arg	Asn	Val	Leu	Gln
545					550					555					560
His	Gly	Ala	Ala	Ala	Ala	Pro	Val	Ser	Ala	Pro	Thr	Ser	Gly	Tyr	Gln
				565					570					575	
Glu	Phe	Val	His	Ala	Val	Glu	Gln	Gly	Gly	Thr	Gln	Ala	Ser	Ala	Val
			580					585					590		
Val	Gly	Leu	Gly	Pro	Pro	Gly	Glu	Ala	Gly	Tyr	Lys	Ala	Phe	Ser	Ser
		595					600					605			
Leu	Leu	Ala	Ser	Ser	Ala	Val	Ser	Pro	Glu	Lys	Cys	Gly	Phe	Gly	Ala
	610					615						620			
Ser	Ser	Gly	Glu	Glu	Gly	Tyr	Lys	Pro	Phe	Gln	Asp	Leu	Ile	Pro	Gly
625					630					635					640
Cys	Pro	Gly	Asp	Pro	Ala	Pro	Val	Pro	Val	Pro	Leu	Phe	Thr	Phe	Gly
				645					650					655	
Leu	Asp	Arg	Glu	Pro	Pro	Arg	Ser	Pro	Gln	Ser	Ser	His	Leu	Pro	Ser
			660						665				670		

```
<210> SEQ ID NO 7
<211> LENGTH: 258
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7
```

Met 1	Leu	Pro	Leu	Cys 5	Leu	Val	Ala	Ala	Leu 10	Leu	Leu	Ala	Ala	Gly 15	Pro
Gly	Pro	Ser	Leu 20	Gly	Asp	Glu	Ala	Ile 25	His	Cys	Pro	Pro	Cys 30	Ser	Glu
Glu	Lys 35	Leu	Ala	Arg	Cys	Arg	Pro 40	Pro	Val	Gly	Cys	Glu	Glu	Leu	Val
Arg 50	Glu	Pro	Gly	Cys	Gly	Cys 55	Cys	Ala	Thr	Cys	Ala 60	Leu	Gly	Leu	Gly
Met 65	Pro	Cys	Gly	Val	Tyr 70	Thr	Pro	Arg	Cys	Gly 75	Ser	Gly	Leu	Arg	Cys 80
Tyr	Pro	Pro	Arg	Gly 85	Val	Glu	Lys	Pro	Leu 90	His	Thr	Leu	Met	His 95	Gly
Gln	Gly	Val	Cys 100	Met	Glu	Leu	Ala	Glu 105	Ile	Glu	Ala	Ile	Gln	Glu	Ser
Leu	Gln	Pro	Ser 115	Asp	Lys	Asp	Glu 120	Gly	Asp	His	Pro	Asn 125	Asn	Ser	Phe
Ser 130	Pro	Cys	Ser	Ala	His 135	Asp	Arg	Arg	Cys	Leu	Gln 140	Lys	His	Phe	Ala
Lys 145	Ile	Arg	Asp	Arg	Ser 150	Thr	Ser	Gly	Gly	Lys 155	Met	Lys	Val	Asn	Gly 160
Ala	Pro	Arg	Glu	Asp 165	Ala	Arg	Pro	Val	Pro 170	Gln	Gly	Ser	Cys	Gln	Ser
Glu	Leu	His	Arg 180	Ala	Leu	Glu	Arg	Leu 185	Ala	Ala	Ser	Gln	Ser	Arg	Thr
His	Glu	Asp 195	Leu	Tyr	Ile	Ile	Pro 200	Ile	Pro	Asn	Cys	Asp 205	Arg	Asn	Gly

-continued

Asn Phe His Pro Lys Gln Cys His Pro Ala Leu Asp Gly Gln Arg Gly
 210 215 220

Lys Cys Trp Cys Val Asp Arg Lys Thr Gly Val Lys Leu Pro Gly Gly
 225 230 235 240

Leu Glu Pro Lys Gly Glu Leu Asp Cys His Gln Leu Ala Asp Ser Phe
 245 250 255

Arg Glu

<210> SEQ ID NO 8
 <211> LENGTH: 272
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Met Val Leu Leu Thr Ala Val Leu Leu Leu Leu Ala Ala Tyr Ala Gly
 1 5 10 15

Pro Ala Gln Ser Leu Gly Ser Phe Val His Cys Glu Pro Cys Asp Glu
 20 25 30

Lys Ala Leu Ser Met Cys Pro Pro Ser Pro Leu Gly Cys Glu Leu Val
 35 40 45

Lys Glu Pro Gly Cys Gly Cys Cys Met Thr Cys Ala Leu Ala Glu Gly
 50 55 60

Gln Ser Cys Gly Val Tyr Thr Glu Arg Cys Ala Gln Gly Leu Arg Cys
 65 70 75 80

Leu Pro Arg Gln Asp Glu Glu Lys Pro Leu His Ala Leu Leu His Gly
 85 90 95

Arg Gly Val Cys Leu Asn Glu Lys Ser Tyr Arg Glu Gln Val Lys Ile
 100 105 110

Glu Arg Asp Ser Arg Glu His Glu Glu Pro Thr Thr Ser Glu Met Ala
 115 120 125

Glu Glu Thr Tyr Ser Pro Lys Ile Phe Arg Pro Lys His Thr Arg Ile
 130 135 140

Ser Glu Leu Lys Ala Glu Ala Val Lys Lys Asp Arg Arg Lys Lys Leu
 145 150 155 160

Thr Gln Ser Lys Phe Val Gly Gly Ala Glu Asn Thr Ala His Pro Arg
 165 170 175

Ile Ile Ser Ala Pro Glu Met Arg Gln Glu Ser Glu Gln Gly Pro Cys
 180 185 190

Arg Arg His Met Glu Ala Ser Leu Gln Glu Leu Lys Ala Ser Pro Arg
 195 200 205

Met Val Pro Arg Ala Val Tyr Leu Pro Asn Cys Asp Arg Lys Gly Phe
 210 215 220

Tyr Lys Arg Lys Gln Cys Lys Pro Ser Arg Gly Arg Lys Arg Gly Ile
 225 230 235 240

Cys Trp Cys Val Asp Lys Tyr Gly Met Lys Leu Pro Gly Met Glu Tyr
 245 250 255

Val Asp Gly Asp Phe Gln Cys His Thr Phe Asp Ser Ser Asn Val Glu
 260 265 270

<210> SEQ ID NO 9
 <211> LENGTH: 189
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 9

```

Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Pro Trp Thr
1          5          10          15
Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln
20          25          30
Cys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His
35          40          45
Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr
50          55          60
Thr Asn Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln
65          70          75          80
Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly
85          90          95
Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu
100         105         110
Pro Ser Leu Leu Pro Asp Ser Pro Val Gly Gln Leu His Ala Ser Leu
115         120         125
Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr
130         135         140
Gln Gln Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu
145         150         155         160
Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala
165         170         175
Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro
180         185

```

<210> SEQ ID NO 10

<211> LENGTH: 200

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

```

Met Lys Leu Asp Met Thr Gly Asp Cys Thr Pro Val Leu Val Leu Met
1          5          10          15
Ala Ala Val Leu Thr Val Thr Gly Ala Val Pro Val Ala Arg Leu His
20          25          30
Gly Ala Leu Pro Asp Ala Arg Gly Cys His Ile Ala Gln Phe Lys Ser
35          40          45
Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys Arg Ala Lys Asp Ala Leu
50          55          60
Glu Glu Ser Leu Leu Leu Lys Asp Cys Arg Cys His Ser Arg Leu Phe
65          70          75          80
Pro Arg Thr Trp Asp Leu Arg Gln Leu Gln Val Arg Glu Arg Pro Met
85          90          95
Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala Thr
100         105         110
Ala Asp Thr Asp Pro Ala Leu Val Asp Val Leu Asp Gln Pro Leu His
115         120         125
Thr Leu His His Ile Leu Ser Gln Phe Arg Ala Cys Ile Gln Pro Gln
130         135         140
Pro Thr Ala Gly Pro Arg Thr Arg Gly Arg Leu His His Trp Leu Tyr
145         150         155         160
Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Pro Gly Cys Leu Glu Ala

```

<400> SEQUENCE: 11

<400> SEQUENCE: 12

Met Glu Met Leu Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly
1 5 10 15

-continued

Gly Ala Trp Ala Ser Arg Glu Pro Leu Arg Pro Trp Cys His Pro Ile
 20 25 30
 Asn Ala Ile Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr
 35 40 45
 Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Met Arg Val
 50 55 60
 Leu Gln Ala Val Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg
 65 70 75 80
 Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val
 85 90 95
 Asp Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Gly Pro
 100 105 110
 Cys Arg Arg Ser Thr Ser Asp Cys Gly Gly Pro Lys Asp His Pro Leu
 115 120 125
 Thr Cys Asp His Pro Gln Leu Ser Gly Leu Leu Phe Leu
 130 135 140

<210> SEQ ID NO 13

<211> LENGTH: 469

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

Met His Ser Phe Pro Pro Leu Leu Leu Leu Phe Trp Gly Val Val
 1 5 10 15
 Ser His Ser Phe Pro Ala Thr Leu Glu Thr Gln Glu Gln Asp Val Asp
 20 25 30
 Leu Val Gln Lys Tyr Leu Glu Lys Tyr Tyr Asn Leu Lys Asn Asp Gly
 35 40 45
 Arg Gln Val Glu Lys Arg Arg Asn Ser Gly Pro Val Val Glu Lys Leu
 50 55 60
 Lys Gln Met Gln Glu Phe Phe Gly Leu Lys Val Thr Gly Lys Pro Asp
 65 70 75 80
 Ala Glu Thr Leu Lys Val Met Lys Gln Pro Arg Cys Gly Val Pro Asp
 85 90 95
 Val Ala Gln Phe Val Leu Thr Glu Gly Asn Pro Arg Trp Glu Gln Thr
 100 105 110
 His Leu Thr Tyr Arg Ile Glu Asn Tyr Thr Pro Asp Leu Pro Arg Ala
 115 120 125
 Asp Val Asp His Ala Ile Glu Lys Ala Phe Gln Leu Trp Ser Asn Val
 130 135 140
 Thr Pro Leu Thr Phe Thr Lys Val Ser Glu Gly Gln Ala Asp Ile Met
 145 150 155 160
 Ile Ser Phe Val Arg Gly Asp His Arg Asp Asn Ser Pro Phe Asp Gly
 165 170 175
 Pro Gly Gly Asn Leu Ala His Ala Phe Gln Pro Gly Pro Gly Ile Gly
 180 185 190
 Gly Asp Ala His Phe Asp Glu Asp Glu Arg Trp Thr Asn Asn Phe Arg
 195 200 205
 Glu Tyr Asn Leu His Arg Val Ala Ala His Glu Leu Gly His Ser Leu
 210 215 220
 Gly Leu Ser His Ser Thr Asp Ile Gly Ala Leu Met Tyr Pro Ser Tyr
 225 230 235 240

-continued

Thr Phe Ser Gly Asp Val Gln Leu Ala Gln Asp Asp Ile Asp Gly Ile
 245 250 255
 Gln Ala Ile Tyr Gly Arg Ser Gln Asn Pro Val Gln Pro Ile Gly Pro
 260 265 270
 Gln Thr Pro Lys Ala Cys Asp Ser Lys Leu Thr Phe Asp Ala Ile Thr
 275 280 285
 Thr Ile Arg Gly Glu Val Met Phe Phe Lys Asp Arg Phe Tyr Met Arg
 290 295 300
 Thr Asn Pro Phe Tyr Pro Glu Val Glu Leu Asn Phe Ile Ser Val Phe
 305 310 315 320
 Trp Pro Gln Leu Pro Asn Gly Leu Glu Ala Ala Tyr Glu Phe Ala Asp
 325 330 335
 Arg Asp Glu Val Arg Phe Phe Lys Gly Asn Lys Tyr Trp Ala Val Gln
 340 345 350
 Gly Gln Asn Val Leu His Gly Tyr Pro Lys Asp Ile Tyr Ser Ser Phe
 355 360 365
 Gly Phe Pro Arg Thr Val Lys His Ile Asp Ala Ala Leu Ser Glu Glu
 370 375 380
 Asn Thr Gly Lys Thr Tyr Phe Phe Val Ala Asn Lys Tyr Trp Arg Tyr
 385 390 395 400
 Asp Glu Tyr Lys Arg Ser Met Asp Pro Gly Tyr Pro Lys Met Ile Ala
 405 410 415
 His Asp Phe Pro Gly Ile Gly His Lys Val Asp Ala Val Phe Met Lys
 420 425 430
 Asp Gly Phe Phe Tyr Phe Phe His Gly Thr Arg Gln Tyr Lys Phe Asp
 435 440 445
 Pro Lys Thr Lys Arg Ile Leu Thr Leu Gln Lys Ala Asn Ser Trp Phe
 450 455 460
 Asn Cys Arg Lys Asn
 465

<210> SEQ ID NO 14
 <211> LENGTH: 858
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Met Leu Gln Thr Lys Asp Leu Ile Trp Thr Leu Phe Phe Leu Gly Thr
 1 5 10 15
 Ala Val Ser Leu Gln Val Asp Ile Val Pro Ser Gln Gly Glu Ile Ser
 20 25 30
 Val Gly Glu Ser Lys Phe Phe Leu Cys Gln Val Ala Gly Asp Ala Lys
 35 40 45
 Asp Lys Asp Ile Ser Trp Phe Ser Pro Asn Gly Glu Lys Leu Thr Pro
 50 55 60
 Asn Gln Gln Arg Ile Ser Val Val Trp Asn Asp Asp Ser Ser Ser Thr
 65 70 75 80
 Leu Thr Ile Tyr Asn Ala Asn Ile Asp Asp Ala Gly Ile Tyr Lys Cys
 85 90 95
 Val Val Thr Gly Glu Asp Gly Ser Glu Ser Glu Ala Thr Val Asn Val
 100 105 110
 Lys Ile Phe Gln Lys Leu Met Phe Lys Asn Ala Pro Thr Pro Gln Glu
 115 120 125

Phe 130	Arg	Glu	Gly	Glu	Asp	Ala 135	Val	Ile	Val	Cys	Asp 140	Val	Val	Ser	Ser
Leu 145	Pro	Pro	Thr	Ile	Ile 150	Trp	Lys	His	Lys	Gly 155	Arg	Asp	Val	Ile	Leu 160
Lys	Lys	Asp	Val	Arg 165	Phe	Ile	Val	Leu	Ser 170	Asn	Asn	Tyr	Leu	Gln 175	Ile
Arg	Gly	Ile	Lys 180	Lys	Thr	Asp	Glu	Gly 185	Thr	Tyr	Arg	Cys	Glu 190	Gly	Arg
Ile	Leu	Ala 195	Arg	Gly	Glu	Ile	Asn 200	Phe	Lys	Asp	Ile	Gln 205	Val	Ile	Val
Asn 210	Val	Pro	Pro	Thr	Ile	Gln 215	Ala	Arg	Gln	Asn 220	Ile	Val	Asn	Ala	Thr
Ala 225	Asn	Leu	Gly	Gln	Ser 230	Val	Thr	Leu	Val	Cys 235	Asp	Ala	Glu	Gly	Phe 240
Pro	Glu	Pro	Thr	Met 245	Ser	Trp	Thr	Lys	Asp 250	Gly	Glu	Gln	Ile	Glu 255	Gln
Glu	Glu	Asp	Asp 260	Glu	Lys	Tyr	Ile	Phe 265	Ser	Asp	Asp	Ser	Ser 270	Gln	Leu
Thr	Ile	Lys 275	Lys	Val	Asp	Lys	Asn 280	Asp	Glu	Ala	Glu	Tyr 285	Ile	Cys	Ile
Ala 290	Glu	Asn	Lys	Ala	Gly	Glu 295	Gln	Asp	Ala	Thr	Ile 300	His	Leu	Lys	Val
Phe 305	Ala	Lys	Pro	Lys	Ile 310	Thr	Tyr	Val	Glu	Asn 315	Gln	Thr	Ala	Met	Glu 320
Leu	Glu	Glu	Gln	Val 325	Thr	Leu	Thr	Cys 330	Glu	Ala	Ser	Gly	Asp	Pro 335	Ile
Pro	Ser	Ile	Thr 340	Trp	Arg	Thr	Ser	Thr 345	Arg	Asn	Ile	Ser	Ser 350	Glu	Glu
Lys	Ala	Ser 355	Trp	Thr	Arg	Pro	Glu 360	Lys	Gln	Glu	Thr	Leu 365	Asp	Gly	His
Met 370	Val	Val	Arg	Ser	His 375	Ala	Arg	Val	Ser	Ser	Leu 380	Thr	Leu	Lys	Ser
Ile 385	Gln	Tyr	Thr	Asp	Ala 390	Gly	Glu	Tyr	Ile	Cys 395	Thr	Ala	Ser	Asn	Thr 400
Ile	Gly	Gln	Asp 405	Ser	Gln	Ser	Met	Tyr	Leu 410	Glu	Val	Gln	Tyr	Ala 415	Pro
Lys	Leu	Gln	Gly 420	Pro	Val	Ala	Val	Tyr 425	Thr	Trp	Glu	Gly	Asn 430	Gln	Val
Asn	Ile	Thr 435	Cys	Glu	Val	Phe	Ala 440	Tyr	Pro	Ser	Ala	Thr 445	Ile	Ser	Trp
Phe 450	Arg	Asp	Gly	Gln	Leu	Leu 455	Pro	Ser	Ser	Asn	Tyr	Ser	Asn	Ile	Lys
Ile 465	Tyr	Asn	Thr	Pro	Ser 470	Ala	Ser	Tyr	Leu	Glu 475	Val	Thr	Pro	Asp	Ser 480
Glu	Asn	Asp	Phe 485	Gly	Asn	Tyr	Asn	Cys	Thr	Ala 490	Val	Asn	Arg	Ile 495	Gly
Gln	Glu	Ser	Leu 500	Glu	Phe	Ile	Leu	Val 505	Gln	Ala	Asp	Thr	Pro	Ser	Ser
Pro	Ser	Ile 515	Asp	Gln	Val	Glu	Pro 520	Tyr	Ser	Ser	Thr	Ala 525	Gln	Val	Gln
Phe	Asp	Glu	Pro	Glu	Ala	Thr	Gly	Gly	Val	Pro	Ile	Leu	Lys	Tyr	Lys

-continued

530				535				540							
Ala	Glu	Trp	Arg	Ala	Val	Gly	Glu	Glu	Val	Trp	His	Ser	Lys	Trp	Tyr
545				550						555					560
Asp	Ala	Lys	Glu	Ala	Ser	Met	Glu	Gly	Ile	Val	Thr	Ile	Val	Gly	Leu
				565						570				575	
Lys	Pro	Glu	Thr	Thr	Tyr	Ala	Val	Arg	Leu	Ala	Ala	Leu	Asn	Gly	Lys
				580						585				590	
Gly	Leu	Gly	Glu	Ile	Ser	Ala	Ala	Ser	Glu	Phe	Lys	Thr	Gln	Pro	Val
		595								600				605	
Gln	Gly	Glu	Pro	Ser	Ala	Pro	Lys	Leu	Glu	Gly	Gln	Met	Gly	Glu	Asp
		610				615					620				
Gly	Asn	Ser	Ile	Lys	Val	Asn	Leu	Ile	Lys	Gln	Asp	Asp	Gly	Gly	Ser
		625				630				635					640
Pro	Ile	Arg	His	Tyr	Leu	Val	Arg	Tyr	Arg	Ala	Leu	Ser	Ser	Glu	Trp
				645						650				655	
Lys	Pro	Glu	Ile	Arg	Leu	Pro	Ser	Gly	Ser	Asp	His	Val	Met	Leu	Lys
				660						665				670	
Ser	Leu	Asp	Trp	Asn	Ala	Glu	Tyr	Glu	Val	Tyr	Val	Val	Ala	Glu	Asn
		675					680							685	
Gln	Gln	Gly	Lys	Ser	Lys	Ala	Ala	His	Phe	Val	Phe	Arg	Thr	Ser	Ala
		690					695							700	
Gln	Pro	Thr	Ala	Ile	Pro	Ala	Asn	Gly	Ser	Pro	Thr	Ser	Gly	Leu	Ser
		705				710				715					720
Thr	Gly	Ala	Ile	Val	Gly	Ile	Leu	Ile	Val	Ile	Phe	Val	Leu	Leu	Leu
				725						730				735	
Val	Val	Val	Asp	Ile	Thr	Cys	Tyr	Phe	Leu	Asn	Lys	Cys	Gly	Leu	Phe
				740						745				750	
Met	Cys	Ile	Ala	Val	Asn	Leu	Cys	Gly	Lys	Ala	Gly	Pro	Gly	Ala	Lys
		755					760							765	
Gly	Lys	Asp	Met	Glu	Glu	Gly	Lys	Ala	Ala	Phe	Ser	Lys	Asp	Glu	Ser
		770					775							780	
Lys	Glu	Pro	Ile	Val	Glu	Val	Arg	Thr	Glu	Glu	Glu	Arg	Thr	Pro	Asn
				785			790			795					800
His	Asp	Gly	Gly	Lys	His	Thr	Glu	Pro	Asn	Glu	Thr	Thr	Pro	Leu	Thr
				805						810				815	
Glu	Pro	Glu	Lys	Gly	Pro	Val	Glu	Ala	Lys	Pro	Glu	Cys	Gln	Glu	Thr
				820						825				830	
Glu	Thr	Lys	Pro	Ala	Pro	Ala	Glu	Val	Lys	Thr	Val	Pro	Asn	Asp	Ala
				835			840							845	
Thr	Gln	Thr	Lys	Glu	Asn	Glu	Ser	Lys	Ala						
		850					855								

<210> SEQ ID NO 15

<211> LENGTH: 36

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

His	Ser	Pro	Pro	Pro	Pro	Ala	Ser	Ala	Ser	Ser	Ser	Thr	Pro	Val	Pro
1				5					10					15	

Leu	Ser	Pro	Pro	Asp	Thr	Thr	Trp	Pro	Leu	Pro	Ala	Leu	Ala	Thr	Thr
			20					25					30		

Glu Pro Ala Lys

-continued

35

<210> SEQ ID NO 16
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

Asn Gly Ser Pro Thr Ser Gly Leu Ser Thr Gly Ala Ile Val Gly Ile
1 5 10 15
Leu Ile Val Ile Phe Val Leu Leu Leu
20 25

<210> SEQ ID NO 17
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Thr Leu Gly Gly Asn Ser Ala Ser Tyr Thr Phe Val Ser Leu Leu Phe
1 5 10 15
Ser Ala Val Thr Leu Leu Leu Leu Cys
20 25

<210> SEQ ID NO 18
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

Asn Gly Ser Pro Thr Ser Gly Leu Ser Thr Gly Ala Ile Val Gly Ile
1 5 10 15
Leu Ile Val Ile Phe Val Leu Leu Leu
20 25

<210> SEQ ID NO 19
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

Thr Leu Gly Gly Asn Ser Ala Ser Tyr Thr Phe Val Ser Leu Leu Phe
1 5 10 15
Ser Ala Val Thr Leu Leu Leu Leu Cys
20 25

<210> SEQ ID NO 20
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20

Trp Lys Pro Glu Ile Arg Leu Pro Ser Gly
1 5 10

<210> SEQ ID NO 21
<211> LENGTH: 57
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

-continued

His Ser Pro Pro Pro Pro Ala Ser Ala Ser Ser Ser Thr Pro Val Pro
 1 5 10 15
 Leu Ser Pro Pro Asp Thr Thr Trp Pro Leu Pro Ala Leu Ala Thr Thr
 20 25 30
 Glu Pro Ala Lys Asn Ile Ala Gln Asn His Cys Cys Asn Met Phe Gln
 35 40 45
 Ala Gly Leu His Asn Ala Leu Met Lys
 50 55

 <210> SEQ ID NO 22
 <211> LENGTH: 418
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

 <400> SEQUENCE: 22
 Met Gln Ala Leu Val Leu Leu Leu Cys Ile Gly Ala Leu Leu Gly His
 1 5 10 15
 Ser Ser Cys Gln Asn Pro Ala Ser Pro Pro Glu Glu Gly Ser Pro Asp
 20 25 30
 Pro Asp Ser Thr Gly Ala Leu Val Glu Glu Glu Asp Pro Phe Phe Lys
 35 40 45
 Val Pro Val Asn Lys Leu Ala Ala Ala Val Ser Asn Phe Gly Tyr Asp
 50 55 60
 Leu Tyr Arg Val Arg Ser Ser Met Ser Pro Thr Thr Asn Val Leu Leu
 65 70 75 80
 Ser Pro Leu Ser Val Ala Thr Ala Leu Ser Ala Leu Ser Leu Gly Ala
 85 90 95
 Glu Gln Arg Thr Glu Ser Ile Ile His Arg Ala Leu Tyr Tyr Asp Leu
 100 105 110
 Ile Ser Ser Pro Asp Ile His Gly Thr Tyr Lys Glu Leu Leu Asp Thr
 115 120 125
 Val Thr Ala Pro Gln Lys Asn Leu Lys Ser Ala Ser Arg Ile Val Phe
 130 135 140
 Glu Lys Lys Leu Arg Ile Lys Ser Ser Phe Val Ala Pro Leu Glu Lys
 145 150 155 160
 Ser Tyr Gly Thr Arg Pro Arg Val Leu Thr Gly Asn Pro Arg Leu Asp
 165 170 175
 Leu Gln Glu Ile Asn Asn Trp Val Gln Ala Gln Met Lys Gly Lys Leu
 180 185 190
 Ala Arg Ser Thr Lys Glu Ile Pro Asp Glu Ile Ser Ile Leu Leu Leu
 195 200 205
 Gly Val Ala His Phe Lys Gly Gln Trp Val Thr Lys Phe Asp Ser Arg
 210 215 220
 Lys Thr Ser Leu Glu Asp Phe Tyr Leu Asp Glu Glu Arg Thr Val Arg
 225 230 235 240
 Val Pro Met Met Ser Asp Pro Lys Ala Val Leu Arg Tyr Gly Leu Asp
 245 250 255
 Ser Asp Leu Ser Cys Lys Ile Ala Gln Leu Pro Leu Thr Gly Ser Met
 260 265 270
 Ser Ile Ile Phe Phe Leu Pro Leu Lys Val Thr Gln Asn Leu Thr Leu
 275 280 285
 Ile Glu Glu Ser Leu Thr Ser Glu Phe Ile His Asp Ile Asp Arg Glu
 290 295 300

-continued

```

Leu Lys Thr Val Gln Ala Val Leu Thr Val Pro Lys Leu Lys Leu Ser
305                      310                      315                      320

Tyr Glu Gly Glu Val Thr Lys Ser Leu Gln Glu Met Lys Leu Gln Ser
                      325                      330                      335

Leu Phe Asp Ser Pro Asp Phe Ser Lys Ile Thr Gly Lys Pro Ile Lys
                      340                      345                      350

Leu Thr Gln Val Glu His Arg Ala Gly Phe Glu Trp Asn Glu Asp Gly
                      355                      360                      365

Ala Gly Thr Thr Pro Ser Pro Gly Leu Gln Pro Ala His Leu Thr Phe
                      370                      375                      380

Pro Leu Asp Tyr His Leu Asn Gln Pro Phe Ile Phe Val Leu Arg Asp
385                      390                      395                      400

Thr Asp Thr Gly Ala Leu Leu Phe Ile Gly Lys Ile Leu Asp Pro Arg
                      405                      410                      415

```

Gly Pro

```

<210> SEQ ID NO 23
<211> LENGTH: 211
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

<400> SEQUENCE: 23

```

Met Arg Thr Leu Ala Cys Leu Leu Leu Leu Gly Cys Gly Tyr Leu Ala
1                      5                      10                      15

His Val Leu Ala Glu Glu Ala Glu Ile Pro Arg Glu Val Ile Glu Arg
                      20                      25                      30

Leu Ala Arg Ser Gln Ile His Ser Ile Arg Asp Leu Gln Arg Leu Leu
                      35                      40                      45

Glu Ile Asp Ser Val Gly Ser Glu Asp Ser Leu Asp Thr Ser Leu Arg
50                      55                      60

Ala His Gly Val His Ala Thr Lys His Val Pro Glu Lys Arg Pro Leu
65                      70                      75                      80

Pro Ile Arg Arg Lys Arg Ser Ile Glu Glu Ala Val Pro Ala Val Cys
                      85                      90                      95

Lys Thr Arg Thr Val Ile Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro
100                      105                      110

Thr Ser Ala Asn Phe Leu Ile Trp Pro Pro Cys Val Glu Val Lys Arg
115                      120                      125

Cys Thr Gly Cys Cys Asn Thr Ser Ser Val Lys Cys Gln Pro Ser Arg
130                      135                      140

Val His His Arg Ser Val Lys Val Ala Lys Val Glu Tyr Val Arg Lys
145                      150                      155                      160

Lys Pro Lys Leu Lys Glu Val Gln Val Arg Leu Glu Glu His Leu Glu
                      165                      170                      175

Cys Ala Cys Ala Thr Thr Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp
180                      185                      190

Thr Gly Arg Pro Arg Glu Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu
195                      200                      205

Lys Pro Thr
210

```

```

<210> SEQ ID NO 24
<211> LENGTH: 1356
<212> TYPE: PRT

```

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

```

Met  Gln  Ser  Lys  Val  Leu  Leu  Ala  Val  Ala  Leu  Trp  Leu  Cys  Val  Glu
 1              5              10              15

Thr  Arg  Ala  Ala  Ser  Val  Gly  Leu  Pro  Ser  Val  Ser  Leu  Asp  Leu  Pro
          20          25          30

Arg  Leu  Ser  Ile  Gln  Lys  Asp  Ile  Leu  Thr  Ile  Lys  Ala  Asn  Thr  Thr
          35          40          45

Leu  Gln  Ile  Thr  Cys  Arg  Gly  Gln  Arg  Asp  Leu  Asp  Trp  Leu  Trp  Pro
 50          55          60

Asn  Asn  Gln  Ser  Gly  Ser  Glu  Gln  Arg  Val  Glu  Val  Thr  Glu  Cys  Ser
65          70          75          80

Asp  Gly  Leu  Phe  Cys  Lys  Thr  Leu  Thr  Ile  Pro  Lys  Val  Ile  Gly  Asn
          85          90          95

Asp  Thr  Gly  Ala  Tyr  Lys  Cys  Phe  Tyr  Arg  Glu  Thr  Asp  Leu  Ala  Ser
          100         105         110

Val  Ile  Tyr  Val  Tyr  Val  Gln  Asp  Tyr  Arg  Ser  Pro  Phe  Ile  Ala  Ser
          115         120         125

Val  Ser  Asp  Gln  His  Gly  Val  Val  Tyr  Ile  Thr  Glu  Asn  Lys  Asn  Lys
          130         135         140

Thr  Val  Val  Ile  Pro  Cys  Leu  Gly  Ser  Ile  Ser  Asn  Leu  Asn  Val  Ser
145          150          155          160

Leu  Cys  Ala  Arg  Tyr  Pro  Glu  Lys  Arg  Phe  Val  Pro  Asp  Gly  Asn  Arg
          165          170          175

Ile  Ser  Trp  Asp  Ser  Lys  Lys  Gly  Phe  Thr  Ile  Pro  Ser  Tyr  Met  Ile
          180         185         190

Ser  Tyr  Ala  Gly  Met  Val  Phe  Cys  Glu  Ala  Lys  Ile  Asn  Asp  Glu  Ser
          195         200         205

Tyr  Gln  Ser  Ile  Met  Tyr  Ile  Val  Val  Val  Val  Gly  Tyr  Arg  Ile  Tyr
          210         215         220

Asp  Val  Val  Leu  Ser  Pro  Ser  His  Gly  Ile  Glu  Leu  Ser  Val  Gly  Glu
225          230          235          240

Lys  Leu  Val  Leu  Asn  Cys  Thr  Ala  Arg  Thr  Glu  Leu  Asn  Val  Gly  Ile
          245          250          255

Asp  Phe  Asn  Trp  Glu  Tyr  Pro  Ser  Ser  Lys  His  Gln  His  Lys  Lys  Leu
          260         265         270

Val  Asn  Arg  Asp  Leu  Lys  Thr  Gln  Ser  Gly  Ser  Glu  Met  Lys  Lys  Phe
          275         280         285

Leu  Ser  Thr  Leu  Thr  Ile  Asp  Gly  Val  Thr  Arg  Ser  Asp  Gln  Gly  Leu
          290         295         300

Tyr  Thr  Cys  Ala  Ala  Ser  Ser  Gly  Leu  Met  Thr  Lys  Lys  Asn  Ser  Thr
305          310          315          320

Phe  Val  Arg  Val  His  Glu  Lys  Pro  Phe  Val  Ala  Phe  Gly  Ser  Gly  Met
          325          330          335

Glu  Ser  Leu  Val  Glu  Ala  Thr  Val  Gly  Glu  Arg  Val  Arg  Ile  Pro  Ala
          340          345          350

Lys  Tyr  Leu  Gly  Tyr  Pro  Pro  Pro  Glu  Ile  Lys  Trp  Tyr  Lys  Asn  Gly
          355          360          365

Ile  Pro  Leu  Glu  Ser  Asn  His  Thr  Ile  Lys  Ala  Gly  His  Val  Leu  Thr
          370          375          380

Ile  Met  Glu  Val  Ser  Glu  Arg  Asp  Thr  Gly  Asn  Tyr  Thr  Val  Ile  Leu

```

-continued

385	390	395	400
Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val	405	410	415
Val Tyr Val Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val	420	425	430
Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr	435	440	445
Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu	450	455	460
Glu Cys Ala Asn Glu Pro Ser Gln Ala Val Ser Val Thr Asn Pro Tyr	465	470	475
Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys	485	490	495
Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys	500	505	510
Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr	515	520	525
Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser	530	535	540
Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln	545	550	555
Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser	565	570	575
Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro	580	585	590
Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr	595	600	605
Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile	610	615	620
Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr	625	630	635
Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val	645	650	655
Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn	660	665	670
Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys	675	680	685
Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn	690	695	700
Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg	705	710	715
Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr	725	730	735
Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe	740	745	750
Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu Ile Ile Ile Leu	755	760	765
Val Gly Thr Ala Val Ile Ala Met Phe Phe Trp Leu Leu Leu Val Ile	770	775	780
Ile Leu Arg Thr Val Lys Arg Ala Asn Gly Gly Glu Leu Lys Thr Gly	785	790	795
			800

Tyr	Leu	Ser	Ile	Val	Met	Asp	Pro	Asp	Glu	Leu	Pro	Leu	Asp	Glu	His
805								810				815			
Cys	Glu	Arg	Leu	Pro	Tyr	Asp	Ala	Ser	Lys	Trp	Glu	Phe	Pro	Arg	Asp
			820					825			830				
Arg	Leu	Lys	Leu	Gly	Lys	Pro	Leu	Gly	Arg	Gly	Ala	Phe	Gly	Gln	Val
		835				840						845			
Ile	Glu	Ala	Asp	Ala	Phe	Gly	Ile	Asp	Lys	Thr	Ala	Thr	Cys	Arg	Thr
850						855				860					
Val	Ala	Val	Lys	Met	Leu	Lys	Glu	Gly	Ala	Thr	His	Ser	Glu	His	Arg
865				870						875		880			
Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	Leu	Ile	His	Ile	Gly	His	His	Leu
			885					890			895				
Asn	Val	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Pro	Gly	Gly	Pro	Leu
			900					905				910			
Met	Val	Ile	Val	Glu	Phe	Cys	Lys	Phe	Gly	Asn	Leu	Ser	Thr	Tyr	Leu
		915				920						925			
Arg	Ser	Lys	Arg	Asn	Glu	Phe	Val	Pro	Tyr	Lys	Thr	Lys	Gly	Ala	Arg
930						935				940					
Phe	Arg	Gln	Gly	Lys	Asp	Tyr	Val	Gly	Ala	Ile	Pro	Val	Asp	Leu	Lys
945				950						955		960			
Arg	Arg	Leu	Asp	Ser	Ile	Thr	Ser	Ser	Gln	Ser	Ser	Ala	Ser	Ser	Gly
			965						970				975		
Phe	Val	Glu	Glu	Lys	Ser	Leu	Ser	Asp	Val	Glu	Glu	Glu	Glu	Ala	Pro
			980				985						990		
Glu	Asp	Leu	Tyr	Lys	Asp	Phe	Leu	Thr	Leu	Glu	His	Leu	Ile	Cys	Tyr
		995				1000						1005			
Ser	Phe	Gln	Val	Ala	Lys	Gly	Met	Glu	Phe	Leu	Ala	Ser	Arg	Lys	
1010						1015				1020					
Cys	Ile	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Ile	Leu	Leu	Ser	Glu	
1025						1030				1035					
Lys	Asn	Val	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	
1040						1045				1050					
Tyr	Lys	Asp	Pro	Asp	Tyr	Val	Arg	Lys	Gly	Asp	Ala	Arg	Leu	Pro	
1055						1060				1065					
Leu	Lys	Trp	Met	Ala	Pro	Glu	Thr	Ile	Phe	Asp	Arg	Val	Tyr	Thr	
1070						1075				1080					
Ile	Gln	Ser	Asp	Val	Trp	Ser	Phe	Gly	Val	Leu	Leu	Trp	Glu	Ile	
1085						1090				1095					
Phe	Ser	Leu	Gly	Ala	Ser	Pro	Tyr	Pro	Gly	Val	Lys	Ile	Asp	Glu	
1100						1105				1110					
Glu	Phe	Cys	Arg	Arg	Leu	Lys	Glu	Gly	Thr	Arg	Met	Arg	Ala	Pro	
1115						1120				1125					
Asp	Tyr	Thr	Thr	Pro	Glu	Met	Tyr	Gln	Thr	Met	Leu	Asp	Cys	Trp	
1130						1135				1140					
His	Gly	Glu	Pro	Ser	Gln	Arg	Pro	Thr	Phe	Ser	Glu	Leu	Val	Glu	
1145						1150				1155					
His	Leu	Gly	Asn	Leu	Leu	Gln	Ala	Asn	Ala	Gln	Gln	Asp	Gly	Lys	
1160						1165				1170					
Asp	Tyr	Ile	Val	Leu	Pro</										

-continued

Glu Glu Glu Val Cys Asp Pro Lys Phe His Tyr Asp Asn Thr Ala
 1205 1210 1215
 Gly Ile Ser Gln Tyr Leu Gln Asn Ser Lys Arg Lys Ser Arg Pro
 1220 1225 1230
 Val Ser Val Lys Thr Phe Glu Asp Ile Pro Leu Glu Glu Pro Glu
 1235 1240 1245
 Val Lys Val Ile Pro Asp Asp Asn Gln Thr Asp Ser Gly Met Val
 1250 1255 1260
 Leu Ala Ser Glu Glu Leu Lys Thr Leu Glu Asp Arg Thr Lys Leu
 1265 1270 1275
 Ser Pro Ser Phe Gly Gly Met Val Pro Ser Lys Ser Arg Glu Ser
 1280 1285 1290
 Val Ala Ser Glu Gly Ser Asn Gln Thr Ser Gly Tyr Gln Ser Gly
 1295 1300 1305
 Tyr His Ser Asp Asp Thr Asp Thr Thr Val Tyr Ser Ser Glu Glu
 1310 1315 1320
 Ala Glu Leu Leu Lys Leu Ile Glu Ile Gly Val Gln Thr Gly Ser
 1325 1330 1335
 Thr Ala Gln Ile Leu Gln Pro Asp Ser Gly Thr Thr Leu Ser Ser
 1340 1345 1350
 Pro Pro Val
 1355

<210> SEQ ID NO 25

<211> LENGTH: 1298

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Met Gln Arg Gly Ala Ala Leu Cys Leu Arg Leu Trp Leu Cys Leu Gly
 1 5 10 15
 Leu Leu Asp Gly Leu Val Ser Gly Tyr Ser Met Thr Pro Pro Thr Leu
 20 25 30
 Asn Ile Thr Glu Glu Ser His Val Ile Asp Thr Gly Asp Ser Leu Ser
 35 40 45
 Ile Ser Cys Arg Gly Gln His Pro Leu Glu Trp Ala Trp Pro Gly Ala
 50 55 60
 Gln Glu Ala Pro Ala Thr Gly Asp Lys Asp Ser Glu Asp Thr Gly Val
 65 70 75 80
 Val Arg Asp Cys Glu Gly Thr Asp Ala Arg Pro Tyr Cys Lys Val Leu
 85 90 95
 Leu Leu His Glu Val His Ala Asn Asp Thr Gly Ser Tyr Val Cys Tyr
 100 105 110
 Tyr Lys Tyr Ile Lys Ala Arg Ile Glu Gly Thr Thr Ala Ala Ser Ser
 115 120 125
 Tyr Val Phe Val Arg Asp Phe Glu Gln Pro Phe Ile Asn Lys Pro Asp
 130 135 140
 Thr Leu Leu Val Asn Arg Lys Asp Ala Met Trp Val Pro Cys Leu Val
 145 150 155 160
 Ser Ile Pro Gly Leu Asn Val Thr Leu Arg Ser Gln Ser Ser Val Leu
 165 170 175
 Trp Pro Asp Gly Gln Glu Val Val Trp Asp Asp Arg Arg Gly Met Leu
 180 185 190

Val	Ser	Thr	Pro	Leu	Leu	His	Asp	Ala	Leu	Tyr	Leu	Gln	Cys	Glu	Thr
		195					200					205			
Thr	Trp	Gly	Asp	Gln	Asp	Phe	Leu	Ser	Asn	Pro	Phe	Leu	Val	His	Ile
	210					215					220				
Thr	Gly	Asn	Glu	Leu	Tyr	Asp	Ile	Gln	Leu	Leu	Pro	Arg	Lys	Ser	Leu
225					230					235					240
Glu	Leu	Leu	Val	Gly	Glu	Lys	Leu	Val	Leu	Asn	Cys	Thr	Val	Trp	Ala
				245					250					255	
Glu	Phe	Asn	Ser	Gly	Val	Thr	Phe	Asp	Trp	Asp	Tyr	Pro	Gly	Lys	Gln
			260					265					270		
Ala	Glu	Arg	Gly	Lys	Trp	Val	Pro	Glu	Arg	Arg	Ser	Gln	Gln	Thr	His
		275					280					285			
Thr	Glu	Leu	Ser	Ser	Ile	Leu	Thr	Ile	His	Asn	Val	Ser	Gln	His	Asp
	290					295					300				
Leu	Gly	Ser	Tyr	Val	Cys	Lys	Ala	Asn	Asn	Gly	Ile	Gln	Arg	Phe	Arg
305					310					315					320
Glu	Ser	Thr	Glu	Val	Ile	Val	His	Glu	Asn	Pro	Phe	Ile	Ser	Val	Glu
				325					330					335	
Trp	Leu	Lys	Gly	Pro	Ile	Leu	Glu	Ala	Thr	Ala	Gly	Asp	Glu	Leu	Val
			340					345					350		
Lys	Leu	Pro	Val	Lys	Leu	Ala	Ala	Tyr	Pro	Pro	Pro	Glu	Phe	Gln	Trp
		355					360					365			
Tyr	Lys	Asp	Gly	Lys	Ala	Leu	Ser	Gly	Arg	His	Ser	Pro	His	Ala	Leu
	370					375					380				
Val	Leu	Lys	Glu	Val	Thr	Glu	Ala	Ser	Thr	Gly	Thr	Tyr	Thr	Leu	Ala
385					390					395					400
Leu	Trp	Asn	Ser	Ala	Ala	Gly	Leu	Arg	Arg	Asn	Ile	Ser	Leu	Glu	Leu
			405						410					415	
Val	Val	Asn	Val	Pro	Pro	Gln	Ile	His	Glu	Lys	Glu	Ala	Ser	Ser	Pro
			420					425					430		
Ser	Ile	Tyr	Ser	Arg	His	Ser	Arg	Gln	Ala	Leu	Thr	Cys	Thr	Ala	Tyr
		435					440					445			
Gly	Val	Pro	Leu	Pro	Leu	Ser	Ile	Gln	Trp	His	Trp	Arg	Pro	Trp	Thr
	450					455					460				
Pro	Cys	Lys	Met	Phe	Ala	Gln	Arg	Ser	Leu	Arg	Arg	Arg	Gln	Gln	Gln
465					470					475					480
Asp	Leu	Met	Pro	Gln	Cys	Arg	Asp	Trp	Arg	Ala	Val	Thr	Thr	Gln	Asp
			485						490					495	
Ala	Val	Asn	Pro	Ile	Glu	Ser	Leu	Asp	Thr	Trp	Thr	Glu	Phe	Val	Glu
			500					505					510		
Gly	Lys	Asn	Lys	Thr	Val	Ser	Lys	Leu	Val	Ile	Gln	Asn	Ala	Asn	Val
			515				520					525			
Ser	Ala	Met	Tyr	Lys	Cys	Val	Val	Ser	Asn	Lys	Val	Gly	Gln	Asp	Glu
	530					535					540				
Arg	Leu	I													

-continued

595					600					605					
Asp	Cys	Lys	Asn	Val	His	Leu	Phe	Ala	Thr	Pro	Leu	Ala	Ala	Ser	Leu
610						615					620				
Glu	Glu	Val	Ala	Pro	Gly	Ala	Arg	His	Ala	Thr	Leu	Ser	Leu	Ser	Ile
625					630					635					640
Pro	Arg	Val	Ala	Pro	Glu	His	Glu	Gly	His	Tyr	Val	Cys	Glu	Val	Gln
				645					650					655	
Asp	Arg	Arg	Ser	His	Asp	Lys	His	Cys	His	Lys	Lys	Tyr	Leu	Ser	Val
			660					665					670		
Gln	Ala	Leu	Glu	Ala	Pro	Arg	Leu	Thr	Gln	Asn	Leu	Thr	Asp	Leu	Leu
		675					680					685			
Val	Asn	Val	Ser	Asp	Ser	Leu	Glu	Met	Gln	Cys	Leu	Val	Ala	Gly	Ala
	690					695					700				
His	Ala	Pro	Ser	Ile	Val	Trp	Tyr	Lys	Asp	Glu	Arg	Leu	Leu	Glu	Glu
705					710					715					720
Lys	Ser	Gly	Val	Asp	Leu	Ala	Asp	Ser	Asn	Gln	Lys	Leu	Ser	Ile	Gln
			725						730					735	
Arg	Val	Arg	Glu	Glu	Asp	Ala	Gly	Arg	Tyr	Leu	Cys	Ser	Val	Cys	Asn
			740					745					750		
Ala	Lys	Gly	Cys	Val	Asn	Ser	Ser	Ala	Ser	Val	Ala	Val	Glu	Gly	Ser
		755					760					765			
Glu	Asp	Lys	Gly	Ser	Met	Glu	Ile	Val	Ile	Leu	Val	Gly	Thr	Gly	Val
	770					775					780				
Ile	Ala	Val	Phe	Phe	Trp	Val	Leu	Leu	Leu	Leu	Ile	Phe	Cys	Asn	Met
785					790					795					800
Arg	Arg	Pro	Ala	His	Ala	Asp	Ile	Lys	Thr	Gly	Tyr	Leu	Ser	Ile	Ile
				805					810					815	
Met	Asp	Pro	Gly	Glu	Val	Pro	Leu	Glu	Glu	Gln	Cys	Glu	Tyr	Leu	Ser
			820					825					830		
Tyr	Asp	Ala	Ser	Gln	Trp	Glu	Phe	Pro	Arg	Glu	Arg	Leu	His	Leu	Gly
		835					840					845			
Arg	Val	Leu	Gly	Tyr	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Ala	Ser	Ala
		850				855					860				
Phe	Gly	Ile	His	Lys	Gly	Ser	Ser	Cys	Asp	Thr	Val	Ala	Val	Lys	Met
865					870					875					880
Leu	Lys	Glu	Gly	Ala	Thr	Ala	Ser	Glu	His	Arg	Ala	Leu	Met	Ser	Glu
			885						890					895	
Leu	Lys	Ile	Leu	Ile	His	Ile	Gly	Asn	His	Leu	Asn	Val	Val	Asn	Leu
		900						905					910		
Leu	Gly	Ala	Cys	Thr	Lys	Pro	Gln	Gly	Pro	Leu	Met	Val	Ile	Val	Glu
		915					920					925			
Phe	Cys	Lys	Tyr	Gly	Asn	Leu	Ser	Asn	Phe	Leu	Arg	Ala	Lys	Arg	Asp
		930				935					940				
Ala	Phe	Ser	Pro	Cys	Ala	Glu	Lys	Ser	Pro	Glu	Gln	Arg	Gly	Arg	Phe
945					950					955					960
Arg	Ala	Met	Val	Glu	Leu	Ala	Arg	Leu	Asp	Arg	Arg	Arg	Pro	Gly	Ser
			965						970					975	
Ser	Asp	Arg	Val	Leu	Phe	Ala	Arg	Phe	Ser	Lys	Thr	Glu	Gly	Gly	Ala
			980					985					990		
Arg	Arg	Ala	Ser	Pro	Asp	Gln	Glu	Ala	Glu	Asp	Leu	Trp	Leu	Ser	Pro
		995				1000						1005			

-continued

Leu	Thr	Met	Glu	Asp	Leu	Val	Cys	Tyr	Ser	Phe	Gln	Val	Ala	Arg
1010						1015					1020			
Gly	Met	Glu	Phe	Leu	Ala	Ser	Arg	Lys	Cys	Ile	His	Arg	Asp	Leu
1025						1030					1035			
Ala	Ala	Arg	Asn	Ile	Leu	Leu	Ser	Glu	Ser	Asp	Val	Val	Lys	Ile
1040						1045					1050			
Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	Tyr	Lys	Asp	Pro	Asp	Tyr
1055						1060					1065			
Val	Arg	Lys	Gly	Ser	Ala	Arg	Leu	Pro	Leu	Lys	Trp	Met	Ala	Pro
1070						1075					1080			
Glu	Ser	Ile	Phe	Asp	Lys	Val	Tyr	Thr	Thr	Gln	Ser	Asp	Val	Trp
1085						1090					1095			
Ser	Phe	Gly	Val	Leu	Leu	Trp	Glu	Ile	Phe	Ser	Leu	Gly	Ala	Ser
1100						1105					1110			
Pro	Tyr	Pro	Gly	Val	Gln	Ile	Asn	Glu	Glu	Phe	Cys	Gln	Arg	Leu
1115						1120					1125			
Arg	Asp	Gly	Thr	Arg	Met	Arg	Ala	Pro	Glu	Leu	Ala	Thr	Pro	Ala
1130						1135					1140			
Ile	Arg	Arg	Ile	Met	Leu	Asn	Cys	Trp	Ser	Gly	Asp	Pro	Lys	Ala
1145						1150					1155			
Arg	Pro	Ala	Phe	Ser	Glu	Leu	Val	Glu	Ile	Leu	Gly	Asp	Leu	Leu
1160						1165					1170			
Gln	Gly	Arg	Gly	Leu	Gln	Glu	Glu	Glu	Glu	Val	Cys	Met	Ala	Pro
1175						1180					1185			
Arg	Ser	Ser	Gln	Ser	Ser	Glu	Glu	Gly	Ser	Phe	Ser	Gln	Val	Ser
1190						1195					1200			
Thr	Met	Ala	Leu	His	Ile	Ala	Gln	Ala	Asp	Ala	Glu	Asp	Ser	Pro
1205						1210					1215			
Pro	Ser	Leu	Gln	Arg	His	Ser	Leu	Ala	Ala	Arg	Tyr	Tyr	Asn	Trp
1220						1225					1230			
Val	Ser	Phe	Pro	Gly	Cys	Leu	Ala	Arg	Gly	Ala	Glu	Thr	Arg	Gly
1235						1240					1245			
Ser	Ser	Arg	Met	Lys	Thr	Phe	Glu	Glu	Phe	Pro	Met	Thr	Pro	Thr
1250						1255					1260			
Thr	Tyr	Lys	Gly	Ser	Val	Asp	Asn	Gln	Thr	Asp	Ser	Gly	Met	Val
1265						1270					1275			
Leu	Ala	Ser	Glu	Glu	Phe	Glu	Gln	Ile	Glu	Ser	Arg	His	Arg	Gln
1280						1285					1290			
Glu	Ser	Gly	Phe	Arg										
1295														

<210> SEQ ID NO 26

<211> LENGTH: 595

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

Met	Arg	Val	Leu	Leu	Ala	Ala	Leu	Gly	Leu	Leu	Phe	Leu	Gly	Ala	Leu
1				5					10					15	

Arg	Ala	Phe	Pro	Gln	Asp	Arg	Pro	Phe	Glu	Asp	Thr	Cys	His	Gly	Asn
			20				25						30		

Pro	Ser	His	Tyr	Tyr	Asp	Lys	Ala	Val	Arg	Arg	Cys	Cys	Tyr	Arg	Cys
		35					40					45			

-continued

Pro	Met	Gly	Leu	Phe	Pro	Thr	Gln	Gln	Cys	Pro	Gln	Arg	Pro	Thr	Asp
	50					55					60				
Cys	Arg	Lys	Gln	Cys	Glu	Pro	Asp	Tyr	Tyr	Leu	Asp	Glu	Ala	Asp	Arg
65					70					75					80
Cys	Thr	Ala	Cys	Val	Thr	Cys	Ser	Arg	Asp	Asp	Leu	Val	Glu	Lys	Thr
				85					90					95	
Pro	Cys	Ala	Trp	Asn	Ser	Ser	Arg	Val	Cys	Glu	Cys	Arg	Pro	Gly	Met
			100					105					110		
Phe	Cys	Ser	Thr	Ser	Ala	Val	Asn	Ser	Cys	Ala	Arg	Cys	Phe	Phe	His
		115					120					125			
Ser	Val	Cys	Pro	Ala	Gly	Met	Ile	Val	Lys	Phe	Pro	Gly	Thr	Ala	Gln
	130					135					140				
Lys	Asn	Thr	Val	Cys	Glu	Pro	Ala	Ser	Pro	Gly	Val	Ser	Pro	Ala	Cys
145					150					155					160
Ala	Ser	Pro	Glu	Asn	Cys	Lys	Glu	Pro	Ser	Ser	Gly	Thr	Ile	Pro	Gln
				165					170					175	
Ala	Lys	Pro	Thr	Pro	Val	Ser	Pro	Ala	Thr	Ser	Ser	Ala	Ser	Thr	Met
			180					185					190		
Pro	Val	Arg	Gly	Gly	Thr	Arg	Leu	Ala	Gln	Glu	Ala	Ala	Ser	Lys	Leu
		195					200					205			
Thr	Arg	Ala	Pro	Asp	Ser	Pro	Ser	Ser	Val	Gly	Arg	Pro	Ser	Ser	Asp
	210					215					220				
Pro	Gly	Leu	Ser	Pro	Thr	Gln	Pro	Cys	Pro	Glu	Gly	Ser	Gly	Asp	Cys
225					230					235					240
Arg	Lys	Gln	Cys	Glu	Pro	Asp	Tyr	Tyr	Leu	Asp	Glu	Ala	Gly	Arg	Cys
				245					250					255	
Thr	Ala	Cys	Val	Ser	Cys	Ser	Arg	Asp	Asp	Leu	Val	Glu	Lys	Thr	Pro
			260					265					270		
Cys	Ala	Trp	Asn	Ser	Ser	Arg	Thr	Cys	Glu	Cys	Arg	Pro	Gly	Met	Ile
		275					280					285			
Cys	Ala	Thr	Ser	Ala	Thr	Asn	Ser	Cys	Ala	Arg	Cys	Val	Pro	Tyr	Pro
		290				295					300				
Ile	Cys	Ala	Ala	Glu	Thr	Val	Thr	Lys	Pro	Gln	Asp	Met	Ala	Glu	Lys
305					310					315					320
Asp	Thr	Thr	Phe	Glu	Ala	Pro	Pro	Leu	Gly	Thr	Gln	Pro	Asp	Cys	Asn
				325					330					335	
Pro	Thr	Pro	Glu	Asn	Gly	Glu	Ala	Pro	Ala	Ser	Thr	Ser	Pro	Thr	Gln
			340					345					350		
Ser	Leu	Leu	Val	Asp	Ser	Gln	Ala	Ser	Lys	Thr	Leu	Pro	Ile	Pro	Thr
		355					360					365			
Ser	Ala	Pro	Val	Ala	Leu	Ser	Ser	Thr	Gly	Lys	Pro	Val	Leu	Asp	Ala
		370				375					380				
Gly	Pro	Val	Leu	Phe	Trp	Val	Ile	Leu	Val	Leu	Val	Val	Val	Val	Gly
385					390					395					400
Ser	Ser	Ala	Phe	Leu	Leu	Cys	His	Arg	Arg	Ala	Cys	Arg	Lys	Arg	Ile
				405					410					415	
Arg	Gln	Lys	Leu	His	Leu	Cys	Tyr	Pro	Val	Gln	Thr	Ser	Gln	Pro	Lys
			420					425					430		
Leu	Glu	Leu	Val	Asp	Ser	Arg	Pro	Arg	Arg	Ser	Ser	Thr	Gln	Leu	Arg
			435				440					445			
Ser	Gly	Ala	Ser	Val	Thr	Glu	Pro	Val	Ala	Glu	Glu	Arg	Gly	Leu	Met
						455						460			

-continued

Ser Gln Pro Leu Met Glu Thr Cys His Ser Val Gly Ala Ala Tyr Leu
 465 470 475 480
 Glu Ser Leu Pro Leu Gln Asp Ala Ser Pro Ala Gly Gly Pro Ser Ser
 485 490 495
 Pro Arg Asp Leu Pro Glu Pro Arg Val Ser Thr Glu His Thr Asn Asn
 500 505 510
 Lys Ile Glu Lys Ile Tyr Ile Met Lys Ala Asp Thr Val Ile Val Gly
 515 520 525
 Thr Val Lys Ala Glu Leu Pro Glu Gly Arg Gly Leu Ala Gly Pro Ala
 530 535 540
 Glu Pro Glu Leu Glu Glu Glu Leu Glu Ala Asp His Thr Pro His Tyr
 545 550 555 560
 Pro Glu Gln Glu Thr Glu Pro Pro Leu Gly Ser Cys Ser Asp Val Met
 565 570 575
 Leu Ser Val Glu Glu Glu Gly Lys Glu Asp Pro Leu Pro Thr Ala Ala
 580 585 590
 Ser Gly Lys
 595

<210> SEQ ID NO 27
 <211> LENGTH: 609
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <400> SEQUENCE: 27

Met Lys Trp Val Glu Ser Ile Phe Leu Ile Phe Leu Leu Asn Phe Thr
 1 5 10 15
 Glu Ser Arg Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu
 20 25 30
 Asp Ser Tyr Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr
 35 40 45
 Ile Phe Phe Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser
 50 55 60
 Lys Met Val Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp
 65 70 75 80
 Glu Gln Ser Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu
 85 90 95
 Glu Leu Cys His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp
 100 105 110
 Cys Cys Ser Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His
 115 120 125
 Lys Lys Pro Thr Pro Ala Ser Ile Pro Leu Phe Gln Val Pro Glu Pro
 130 135 140
 Val Thr Ser Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn
 145 150 155 160
 Lys Phe Ile Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro
 165 170 175
 Thr Ile Leu Leu Trp Ala Ala Arg Tyr Asp Lys Ile Ile Pro Ser Cys
 180 185 190
 Cys Lys Ala Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr
 195 200 205
 Val Thr Lys Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys
 210 215 220

-continued

Ala Val Met Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val	
225	230 235 240
Thr Lys Leu Ser Gln Lys Phe Thr Lys Val Asn Phe Thr Glu Ile Gln	
	245 250 255
Lys Leu Val Leu Asp Val Ala His Val His Glu His Cys Cys Arg Gly	
	260 265 270
Asp Val Leu Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile	
	275 280 285
Cys Ser Gln Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys	
	290 295 300
Leu Thr Thr Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp	
305	310 315 320
Glu Lys Pro Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp	
	325 330 335
Arg Asp Phe Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala	
	340 345 350
Ser Phe Val His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser	
	355 360 365
Val Ile Leu Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys	
	370 375 380
Phe Gln Thr Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Glu	
385	390 395 400
Leu Gln Lys Tyr Ile Gln Glu Ser Gln Ala Leu Ala Lys Arg Ser Cys	
	405 410 415
Gly Leu Phe Gln Lys Leu Gly Glu Tyr Tyr Leu Gln Asn Ala Phe Leu	
	420 425 430
Val Ala Tyr Thr Lys Lys Ala Pro Gln Leu Thr Ser Ser Glu Leu Met	
	435 440 445
Ala Ile Thr Arg Lys Met Ala Ala Thr Ala Ala Thr Cys Cys Gln Leu	
	450 455 460
Ser Glu Asp Lys Leu Leu Ala Cys Gly Glu Gly Ala Ala Asp Ile Ile	
465	470 475 480
Ile Gly His Leu Cys Ile Arg His Glu Met Thr Pro Val Asn Pro Gly	
	485 490 495
Val Gly Gln Cys Cys Thr Ser Ser Tyr Ala Asn Arg Arg Pro Cys Phe	
	500 505 510
Ser Ser Leu Val Val Asp Glu Thr Tyr Val Pro Pro Ala Phe Ser Asp	
	515 520 525
Asp Lys Phe Ile Phe His Lys Asp Leu Cys Gln Ala Gln Gly Val Ala	
	530 535 540
Leu Gln Thr Met Lys Gln Glu Phe Leu Ile Asn Leu Val Lys Gln Lys	
545	550 555 560
Pro Gln Ile Thr Glu Glu Gln Leu Glu Ala Val Ile Ala Asp Phe Ser	
	565 570 575
Gly Leu Leu Glu Lys Cys Cys Gln Gly Gln Glu Gln Glu Val Cys Phe	
	580 585 590
Ala Glu Glu Gly Gln Lys Leu Ile Ser Lys Thr Arg Ala Ala Leu Gly	
	595 600 605
Val	

-continued

<211> LENGTH: 415

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28

```

Met Ser Pro Phe Leu Tyr Leu Val Leu Leu Val Leu Gly Leu His Ala
1           5           10           15

Thr Ile His Cys Ala Ser Pro Glu Gly Lys Val Thr Ala Cys His Ser
          20           25           30

Ser Gln Pro Asn Ala Thr Leu Tyr Lys Met Ser Ser Ile Asn Ala Asp
          35           40           45

Phe Ala Phe Asn Leu Tyr Arg Arg Phe Thr Val Glu Thr Pro Asp Lys
          50           55           60

Asn Ile Phe Phe Ser Pro Val Ser Ile Ser Ala Ala Leu Val Met Leu
65           70           75           80

Ser Phe Gly Ala Cys Cys Ser Thr Gln Thr Glu Ile Val Glu Thr Leu
          85           90           95

Gly Phe Asn Leu Thr Asp Thr Pro Met Val Glu Ile Gln His Gly Phe
          100          105          110

Gln His Leu Ile Cys Ser Leu Asn Phe Pro Lys Lys Glu Leu Glu Leu
          115          120          125

Gln Ile Gly Asn Ala Leu Phe Ile Gly Lys His Leu Lys Pro Leu Ala
          130          135          140

Lys Phe Leu Asn Asp Val Lys Thr Leu Tyr Glu Thr Glu Val Phe Ser
145          150          155          160

Thr Asp Phe Ser Asn Ile Ser Ala Ala Lys Gln Glu Ile Asn Ser His
          165          170          175

Val Glu Met Gln Thr Lys Gly Lys Val Val Gly Leu Ile Gln Asp Leu
          180          185          190

Lys Pro Asn Thr Ile Met Val Leu Val Asn Tyr Ile His Phe Lys Ala
          195          200          205

Gln Trp Ala Asn Pro Phe Asp Pro Ser Lys Thr Glu Asp Ser Ser Ser
          210          215          220

Phe Leu Ile Asp Lys Thr Thr Thr Val Gln Val Pro Met Met His Gln
225          230          235          240

Met Glu Gln Tyr Tyr His Leu Val Asp Met Glu Leu Asn Cys Thr Val
          245          250          255

Leu Gln Met Asp Tyr Ser Lys Asn Ala Leu Ala Leu Phe Val Leu Pro
          260          265          270

Lys Glu Gly Gln Met Glu Ser Val Glu Ala Ala Met Ser Ser Lys Thr
          275          280          285

Leu Lys Lys Trp Asn Arg Leu Leu Gln Lys Gly Trp Val Asp Leu Phe
          290          295          300

Val Pro Lys Phe Ser Ile Ser Ala Thr Tyr Asp Leu Gly Ala Thr Leu
305          310          315          320

Leu Lys Met Gly Ile Gln His Ala Tyr Ser Glu Asn Ala Asp Phe Ser
          325          330          335

Gly Leu Thr Glu Asp Asn Gly Leu Lys Leu Ser Asn Ala Ala His Lys
          340          345          350

Ala Val Leu His Ile Gly Glu Lys Gly Thr Glu Ala Ala Ala Val Pro
          355          360          365

Glu Val Glu Leu Ser Asp Gln Pro Glu Asn Thr Phe Leu His Pro Ile
          370          375          380

```

-continued

Ile Gln Ile Asp Arg Ser Phe Met Leu Leu Ile Leu Glu Arg Ser Thr
 385 390 395 400

Arg Ser Ile Leu Phe Leu Gly Lys Val Val Asn Pro Thr Glu Ala
 405 410 415

<210> SEQ ID NO 29
 <211> LENGTH: 261
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Met Trp Val Pro Val Val Phe Leu Thr Leu Ser Val Thr Trp Ile Gly
 1 5 10 15

Ala Ala Pro Leu Ile Leu Ser Arg Ile Val Gly Gly Trp Glu Cys Glu
 20 25 30

Lys His Ser Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly Arg Ala
 35 40 45

Val Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala Ala
 50 55 60

His Cys Ile Arg Asn Lys Ser Val Ile Leu Leu Gly Arg His Ser Leu
 65 70 75 80

Phe His Pro Glu Asp Thr Gly Gln Val Phe Gln Val Ser His Ser Phe
 85 90 95

Pro His Pro Leu Tyr Asp Met Ser Leu Leu Lys Asn Arg Phe Leu Arg
 100 105 110

Pro Gly Asp Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu
 115 120 125

Pro Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr Gln
 130 135 140

Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile
 145 150 155 160

Glu Pro Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu
 165 170 175

His Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val
 180 185 190

Thr Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys Ser Thr
 195 200 205

Cys Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gln
 210 215 220

Gly Ile Thr Ser Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro
 225 230 235 240

Ser Leu Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr
 245 250 255

Ile Val Ala Asn Pro
 260

<210> SEQ ID NO 30
 <211> LENGTH: 4548
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Met Glu His Lys Glu Val Val Leu Leu Leu Leu Leu Phe Leu Lys Ser
 1 5 10 15

-continued

Ala	Ala	Pro	Glu	Gln	Ser	His	Val	Val	Gln	Asp	Cys	Tyr	His	Gly	Asp
			20					25					30		
Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr
		35					40					45			
Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Gln	His	Asn	Arg	Thr	Thr
	50					55					60				
Glu	Asn	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro
65					70					75					80
Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg
				85					90					95	
Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala
			100					105					110		
Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser
		115					120					125			
Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His
	130						135				140				
Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly
145					150					155					160
Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg
				165					170					175	
Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg
		180						185					190		
Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly
		195					200					205			
Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly
	210						215					220			
Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala
225						230				235					240
Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys
				245					250					255	
Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val
			260					265					270		
Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His
		275					280					285			
Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr
	290					295					300				
Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp
305					310					315					320
Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala
				325					330					335	
Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu
			340					345					350		
Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln
		355					360					365			
Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr
	370					375					380				
Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His
385					390					395					400
Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met
				405					410					415	
Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr
			420					425					430		

-continued

Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser
	435						440					445			
Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro
	450					455					460				
Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly
465					470					475					480
Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr
				485					490					495	
Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr
			500					505					510		
Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu
		515					520					525			
Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys
	530					535					540				
Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln
545					550					555					560
Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro
				565					570					575	
Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg
			580					585					590		
Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly
		595					600					605			
Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser
	610					615					620				
Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala
625					630					635					640
Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro
				645					650					655	
Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu
			660					665					670		
Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val
		675					680				685				
Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu
	690					695					700				
Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr
705					710					715					720
Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp
				725					730					735	
Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro
			740					745					750		
Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala
		755					760					765			
Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys
	770					775					780				
Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro
785					790					795					800
Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro
			805						810					815	
Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln
		820						825					830		
Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln

-continued

835					840					845						
Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	
850					855					860						
Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	
865					870					875					880	
Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	
885					890					895						
Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	
900					905					910						
Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	
915					920					925						
Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	
930					935					940						
Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	
945					950					955					960	
Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	
965					970					975						
Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	
980					985					990						
Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	
995					1000					1005						
Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr		
1010					1015					1020						
Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala		
1025					1030					1035						
Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu		
1040					1045					1050						
Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr		
1055					1060					1065						
Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro		
1070					1075					1080						
His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu		
1085					1090					1095						
Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr		
1100					1105					1110						
Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu		
1115					1120					1125						
Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr		
1130					1135					1140						
Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro		
1145					1150					1155						
Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly		
1160					1165					1170						
Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr		
1175					1180					1185						
Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr		
1190					1195					1200						
Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg		
1205					1210					1215						
Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro		
1220					1225					1230						

-continued

Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala
1235						1240					1245			
Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser
1250						1255					1260			
Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly
1265						1270					1275			
Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr
1280						1285					1290			
Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser
1295						1300					1305			
Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn
1310						1315					1320			
Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala
1325						1330					1335			
Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr
1340						1345					1350			
Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala
1355						1360					1365			
Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu
1370						1375					1380			
Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His
1385						1390					1395			
Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr
1400						1405					1410			
Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His
1415						1420					1425			
Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn
1430						1435					1440			
Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr
1445						1450					1455			
Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys
1460						1465					1470			
Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro
1475						1480					1485			
Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln
1490						1495					1500			
Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr
1505						1510					1515			
Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala
1520						1525					1530			
Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr
1535						1540					1545			
Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp
1550						1555					1560			
Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg
1565						1570					1575			
Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr
1580						1585					1590			
Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala
1595						1600					1605			
Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu
1610						1615					1620			

-continued

Cys 1625	Tyr	His	Gly	Asn	Gly	Gln 1630	Ser	Tyr	Arg	Gly	Thr 1635	Tyr	Ser	Thr
Thr 1640	Val	Thr	Gly	Arg	Thr	Cys 1645	Gln	Ala	Trp	Ser	Ser 1650	Met	Thr	Pro
His 1655	Ser	His	Ser	Arg	Thr	Pro 1660	Glu	Tyr	Tyr	Pro	Asn 1665	Ala	Gly	Leu
Ile 1670	Met	Asn	Tyr	Cys	Arg	Asn 1675	Pro	Asp	Ala	Val	Ala 1680	Ala	Pro	Tyr
Cys 1685	Tyr	Thr	Arg	Asp	Pro	Gly 1690	Val	Arg	Trp	Glu	Tyr 1695	Cys	Asn	Leu
Thr 1700	Gln	Cys	Ser	Asp	Ala	Glu 1705	Gly	Thr	Ala	Val	Ala 1710	Pro	Pro	Thr
Val 1715	Thr	Pro	Val	Pro	Ser	Leu 1720	Glu	Ala	Pro	Ser	Glu 1725	Gln	Ala	Pro
Thr 1730	Glu	Gln	Arg	Pro	Gly	Val 1735	Gln	Glu	Cys	Tyr	His 1740	Gly	Asn	Gly
Gln 1745	Ser	Tyr	Arg	Gly	Thr	Tyr 1750	Ser	Thr	Thr	Val	Thr 1755	Gly	Arg	Thr
Cys 1760	Gln	Ala	Trp	Ser	Ser	Met 1765	Thr	Pro	His	Ser	His 1770	Ser	Arg	Thr
Pro 1775	Glu	Tyr	Tyr	Pro	Asn	Ala 1780	Gly	Leu	Ile	Met	Asn 1785	Tyr	Cys	Arg
Asn 1790	Pro	Asp	Ala	Val	Ala	Ala 1795	Pro	Tyr	Cys	Tyr	Thr 1800	Arg	Asp	Pro
Gly 1805	Val	Arg	Trp	Glu	Tyr	Cys 1810	Asn	Leu	Thr	Gln	Cys 1815	Ser	Asp	Ala
Glu 1820	Gly	Thr	Ala	Val	Ala	Pro 1825	Pro	Thr	Val	Thr	Pro 1830	Val	Pro	Ser
Leu 1835	Glu	Ala	Pro	Ser	Glu	Gln 1840	Ala	Pro	Thr	Glu	Gln 1845	Arg	Pro	Gly
Val 1850	Gln	Glu	Cys	Tyr	His	Gly 1855	Asn	Gly	Gln	Ser	Tyr 1860	Arg	Gly	Thr
Tyr 1865	Ser	Thr	Thr	Val	Thr	Gly 1870	Arg	Thr	Cys	Gln	Ala 1875	Trp	Ser	Ser
Met 1880	Thr	Pro	His	Ser	His	Ser 1885	Arg	Thr	Pro	Glu	Tyr 1890	Tyr	Pro	Asn
Ala 1895	Gly	Leu	Ile	Met	Asn	Tyr 1900	Cys	Arg	Asn	Pro	Asp 1905	Ala	Val	Ala
Ala 1910	Pro	Tyr	Cys	Tyr	Thr	Arg 1915	Asp	Pro	Gly	Val	Arg 1920	Trp	Glu	Tyr
Cys 1925	Asn	Leu	Thr	Gln	Cys	Ser 1930	Asp	Ala	Glu	Gly	Thr 1935	Ala	Val	Ala
Pro 1940	Pro	Thr	Val	Thr	Pro	Val 1945	Pro	Ser	Leu	Glu	Ala 1950	Pro	Ser	Glu
Gln 1955	Ala	Pro	Thr	Glu	Gln	Arg 1960	Pro	Gly	Val	Gln	Glu 1965	Cys	Tyr	His
Gly 1970	Asn	Gly	Gln	Ser	Tyr	Arg 1975	Gly	Thr	Tyr	Ser	Thr 1980	Thr	Val	Thr
Gly 1985	Arg	Thr	Cys	Gln	Ala	Trp 1990	Ser	Ser	Met	Thr	Pro 1995	His	Ser	His
Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn

-continued

2000					2005					2010				
Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr
2015						2020					2025			
Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys
2030						2035					2040			
Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro
2045						2050					2055			
Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln
2060						2065					2070			
Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr
2075						2080					2085			
Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala
2090						2095					2100			
Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr
2105						2110					2115			
Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp
2120						2125					2130			
Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg
2135						2140					2145			
Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr
2150						2155					2160			
Ala	Val	Ala	Pro	Pro	Thr	Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala
2165						2170					2175			
Pro	Ser	Glu	Gln	Ala	Pro	Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu
2180						2185					2190			
Cys	Tyr	His	Gly	Asn	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr
2195						2200					2205			
Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro
2210						2215					2220			
His	Ser	His	Ser	Arg	Thr	Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu
2225						2230					2235			
Ile	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr
2240						2245					2250			
Cys	Tyr	Thr	Arg	Asp	Pro	Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu
2255						2260					2265			
Thr	Gln	Cys	Ser	Asp	Ala	Glu	Gly	Thr	Ala	Val	Ala	Pro	Pro	Thr
2270						2275					2280			
Val	Thr	Pro	Val	Pro	Ser	Leu	Glu	Ala	Pro	Ser	Glu	Gln	Ala	Pro
2285						2290					2295			
Thr	Glu	Gln	Arg	Pro	Gly	Val	Gln	Glu	Cys	Tyr	His	Gly	Asn	Gly
2300						2305					2310			
Gln	Ser	Tyr	Arg	Gly	Thr	Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr
2315						2320					2325			
Cys	Gln	Ala	Trp	Ser	Ser	Met	Thr	Pro	His	Ser	His	Ser	Arg	Thr
2330						2335					2340			
Pro	Glu	Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Ile	Met	Asn	Tyr	Cys	Arg
2345						2350					2355			
Asn	Pro	Asp	Ala	Val	Ala	Ala	Pro	Tyr	Cys	Tyr	Thr	Arg	Asp	Pro
2360						2365					2370			
Gly	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys	Ser	Asp	Ala
2375						2380					2385			

-continued

Glu Gly	Thr Ala Val Ala	Pro	Pro Thr Val Thr	Pro	Val Pro Ser
2390		2395		2400	
Leu Glu	Ala Pro Ser Glu Gln	Ala Pro Thr Glu Gln	Arg Pro Gly		
2405		2410		2415	
Val Gln	Glu Cys Tyr His	Gly Asn Gly Gln Ser	Tyr Arg Gly Thr		
2420		2425		2430	
Tyr Ser	Thr Thr Val Thr	Gly Arg Thr Cys Gln Ala	Trp Ser Ser		
2435		2440		2445	
Met Thr	Pro His Ser His	Ser Arg Thr Pro Glu Tyr	Tyr Pro Asn		
2450		2455		2460	
Ala Gly	Leu Ile Met Asn Tyr	Cys Arg Asn Pro Asp	Ala Val Ala		
2465		2470		2475	
Ala Pro	Tyr Cys Tyr Thr	Arg Asp Pro Gly Val Arg	Trp Glu Tyr		
2480		2485		2490	
Cys Asn	Leu Thr Gln Cys	Ser Asp Ala Glu Gly Thr	Ala Val Ala		
2495		2500		2505	
Pro Pro	Thr Val Thr Pro	Val Pro Ser Leu Glu Ala	Pro Ser Glu		
2510		2515		2520	
Gln Ala	Pro Thr Glu Gln Arg	Pro Gly Val Gln Glu	Cys Tyr His		
2525		2530		2535	
Gly Asn	Gly Gln Ser Tyr	Arg Gly Thr Tyr Ser Thr	Thr Val Thr		
2540		2545		2550	
Gly Arg	Thr Cys Gln Ala	Trp Ser Ser Met Thr Pro	His Ser His		
2555		2560		2565	
Ser Arg	Thr Pro Glu Tyr	Tyr Pro Asn Ala Gly Leu	Ile Met Asn		
2570		2575		2580	
Tyr Cys	Arg Asn Pro Asp	Ala Val Ala Ala Pro Tyr	Cys Tyr Thr		
2585		2590		2595	
Arg Asp	Pro Gly Val Arg	Trp Glu Tyr Cys Asn Leu	Thr Gln Cys		
2600		2605		2610	
Ser Asp	Ala Glu Gly Thr	Ala Val Ala Pro Pro Thr	Val Thr Pro		
2615		2620		2625	
Val Pro	Ser Leu Glu Ala	Pro Ser Glu Gln Ala Pro	Thr Glu Gln		
2630		2635		2640	
Arg Pro	Gly Val Gln Glu Cys	Tyr His Gly Asn Gly	Gln Ser Tyr		
2645		2650		2655	
Arg Gly	Thr Tyr Ser Thr	Thr Val Thr Gly Arg Thr	Cys Gln Ala		
2660		2665		2670	
Trp Ser	Ser Met Thr Pro	His Ser His Ser Arg Thr	Pro Glu Tyr		
2675		2680		2685	
Tyr Pro	Asn Ala Gly Leu	Ile Met Asn Tyr Cys Arg	Asn Pro Asp		
2690		2695		2700	
Ala Val	Ala Ala Pro Tyr	Cys Tyr Thr Arg Asp Pro	Gly Val Arg		
2705		2710		2715	
Trp Glu	Tyr Cys Asn Leu Thr	Gln Cys Ser Asp Ala	Glu Gly Thr		
2720		2725		2730	
Ala Val	Ala Pro Pro Thr	Val Thr Pro Val Pro Ser	Leu Glu Ala		
2735		2740		2745	
Pro Ser	Glu Gln Ala Pro	Thr Glu Gln Arg Pro Gly	Val Gln Glu		
2750		2755		2760	
Cys Tyr	His Gly Asn Gly	Gln Ser Tyr Arg Gly Thr	Tyr Ser Thr		
2765		2770		2775	

-continued

Thr Val 2780	Thr Gly Arg Thr Cys 2785	Gln Ala Trp Ser Ser 2790	Met Thr Pro
His Ser 2795	His Ser Arg Thr Pro 2800	Glu Tyr Tyr Pro Asn 2805	Ala Gly Leu
Ile Met 2810	Asn Tyr Cys Arg Asn 2815	Pro Asp Ala Val Ala 2820	Ala Pro Tyr
Cys Tyr 2825	Thr Arg Asp Pro Gly 2830	Val Arg Trp Glu Tyr 2835	Cys Asn Leu
Thr Gln 2840	Cys Ser Asp Ala Glu 2845	Gly Thr Ala Val Ala 2850	Pro Pro Thr
Val Thr 2855	Pro Val Pro Ser Leu 2860	Glu Ala Pro Ser Glu 2865	Gln Ala Pro
Thr Glu 2870	Gln Arg Pro Gly Val 2875	Gln Glu Cys Tyr His 2880	Gly Asn Gly
Gln Ser 2885	Tyr Arg Gly Thr Tyr 2890	Ser Thr Thr Val Thr 2895	Gly Arg Thr
Cys Gln 2900	Ala Trp Ser Ser Met 2905	Thr Pro His Ser His 2910	Ser Arg Thr
Pro Glu 2915	Tyr Tyr Pro Asn Ala 2920	Gly Leu Ile Met Asn 2925	Tyr Cys Arg
Asn Pro 2930	Asp Ala Val Ala Ala 2935	Pro Tyr Cys Tyr Thr 2940	Arg Asp Pro
Gly Val 2945	Arg Trp Glu Tyr Cys 2950	Asn Leu Thr Gln Cys 2955	Ser Asp Ala
Glu Gly 2960	Thr Ala Val Ala Pro 2965	Pro Thr Val Thr Pro 2970	Val Pro Ser
Leu Glu 2975	Ala Pro Ser Glu Gln 2980	Ala Pro Thr Glu Gln 2985	Arg Pro Gly
Val Gln 2990	Glu Cys Tyr His Gly 2995	Asn Gly Gln Ser Tyr 3000	Arg Gly Thr
Tyr Ser 3005	Thr Thr Val Thr Gly 3010	Arg Thr Cys Gln Ala 3015	Trp Ser Ser
Met Thr 3020	Pro His Ser His Ser 3025	Arg Thr Pro Glu Tyr 3030	Tyr Pro Asn
Ala Gly 3035	Leu Ile Met Asn Tyr 3040	Cys Arg Asn Pro Asp 3045	Ala Val Ala
Ala Pro 3050	Tyr Cys Tyr Thr Arg 3055	Asp Pro Gly Val Arg 3060	Trp Glu Tyr
Cys Asn 3065	Leu Thr Gln Cys Ser 3070	Asp Ala Glu Gly Thr 3075	Ala Val Ala
Pro Pro 3080	Thr Val Thr Pro Val 3085	Pro Ser Leu Glu Ala 3090	Pro Ser Glu
Gln Ala 3095	Pro Thr Glu Gln Arg 3100	Pro Gly Val Gln Glu 3105	Cys Tyr His
Gly Asn 3110	Gly Gln Ser Tyr Arg 3115	Gly Thr Tyr Ser Thr 3120	Thr Val Thr
Gly Arg 3125	Thr Cys Gln Ala Trp 3130	Ser Ser Met Thr Pro 3135	His Ser His
Ser Arg 3140	Thr Pro Glu Tyr Tyr 3145	Pro Asn Ala Gly Leu 3150	Ile Met Asn
Tyr Cys	Arg Asn Pro Asp Ala	Val Ala Ala Pro Tyr	Cys Tyr Thr

-continued

3155	3160	3165
Arg Asp Pro Gly Val Arg Trp Glu Tyr Cys Asn Leu Thr Gln Cys 3170	3175	3180
Ser Asp Ala Glu Gly Thr Ala Val Ala Pro Pro Thr Val Thr Pro 3185	3190	3195
Val Pro Ser Leu Glu Ala Pro Ser Glu Gln Ala Pro Thr Glu Gln 3200	3205	3210
Arg Pro Gly Val Gln Glu Cys Tyr His Gly Asn Gly Gln Ser Tyr 3215	3220	3225
Arg Gly Thr Tyr Ser Thr Thr Val Thr Gly Arg Thr Cys Gln Ala 3230	3235	3240
Trp Ser Ser Met Thr Pro His Ser His Ser Arg Thr Pro Glu Tyr 3245	3250	3255
Tyr Pro Asn Ala Gly Leu Ile Met Asn Tyr Cys Arg Asn Pro Asp 3260	3265	3270
Ala Val Ala Ala Pro Tyr Cys Tyr Thr Arg Asp Pro Gly Val Arg 3275	3280	3285
Trp Glu Tyr Cys Asn Leu Thr Gln Cys Ser Asp Ala Glu Gly Thr 3290	3295	3300
Ala Val Ala Pro Pro Thr Val Thr Pro Val Pro Ser Leu Glu Ala 3305	3310	3315
Pro Ser Glu Gln Ala Pro Thr Glu Gln Arg Pro Gly Val Gln Glu 3320	3325	3330
Cys Tyr His Gly Asn Gly Gln Ser Tyr Arg Gly Thr Tyr Ser Thr 3335	3340	3345
Thr Val Thr Gly Arg Thr Cys Gln Ala Trp Ser Ser Met Thr Pro 3350	3355	3360
His Ser His Ser Arg Thr Pro Glu Tyr Tyr Pro Asn Ala Gly Leu 3365	3370	3375
Ile Met Asn Tyr Cys Arg Asn Pro Asp Pro Val Ala Ala Pro Tyr 3380	3385	3390
Cys Tyr Thr Arg Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu 3395	3400	3405
Thr Gln Cys Ser Asp Ala Glu Gly Thr Ala Val Ala Pro Pro Thr 3410	3415	3420
Ile Thr Pro Ile Pro Ser Leu Glu Ala Pro Ser Glu Gln Ala Pro 3425	3430	3435
Thr Glu Gln Arg Pro Gly Val Gln Glu Cys Tyr His Gly Asn Gly 3440	3445	3450
Gln Ser Tyr Gln Gly Thr Tyr Phe Ile Thr Val Thr Gly Arg Thr 3455	3460	3465
Cys Gln Ala Trp Ser Ser Met Thr Pro His Ser His Ser Arg Thr 3470	3475	3480
Pro Ala Tyr Tyr Pro Asn Ala Gly Leu Ile Lys Asn Tyr Cys Arg 3485	3490	3495
Asn Pro Asp Pro Val Ala Ala Pro Trp Cys Tyr Thr Thr Asp Pro 3500	3505	3510
Ser Val Arg Trp Glu Tyr Cys Asn Leu Thr Arg Cys Ser Asp Ala 3515	3520	3525
Glu Trp Thr Ala Phe Val Pro Pro Asn Val Ile Leu Ala Pro Ser 3530	3535	3540

-continued

Leu	Glu	Ala	Phe	Phe	Glu	Gln	Ala	Leu	Thr	Glu	Glu	Thr	Pro	Gly
3545						3550					3555			
Val	Gln	Asp	Cys	Tyr	Tyr	His	Tyr	Gly	Gln	Ser	Tyr	Arg	Gly	Thr
3560						3565					3570			
Tyr	Ser	Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ala	Trp	Ser	Ser
3575						3580					3585			
Met	Thr	Pro	His	Gln	His	Ser	Arg	Thr	Pro	Glu	Asn	Tyr	Pro	Asn
3590						3595					3600			
Ala	Gly	Leu	Thr	Arg	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Glu	Ile
3605						3610					3615			
Arg	Pro	Trp	Cys	Tyr	Thr	Met	Asp	Pro	Ser	Val	Arg	Trp	Glu	Tyr
3620						3625					3630			
Cys	Asn	Leu	Thr	Gln	Cys	Leu	Val	Thr	Glu	Ser	Ser	Val	Leu	Ala
3635						3640					3645			
Thr	Leu	Thr	Val	Val	Pro	Asp	Pro	Ser	Thr	Glu	Ala	Ser	Ser	Glu
3650						3655					3660			
Glu	Ala	Pro	Thr	Glu	Gln	Ser	Pro	Gly	Val	Gln	Asp	Cys	Tyr	His
3665						3670					3675			
Gly	Asp	Gly	Gln	Ser	Tyr	Arg	Gly	Ser	Phe	Ser	Thr	Thr	Val	Thr
3680						3685					3690			
Gly	Arg	Thr	Cys	Gln	Ser	Trp	Ser	Ser	Met	Thr	Pro	His	Trp	His
3695						3700					3705			
Gln	Arg	Thr	Thr	Glu	Tyr	Tyr	Pro	Asn	Gly	Gly	Leu	Thr	Arg	Asn
3710						3715					3720			
Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Glu	Ile	Ser	Pro	Trp	Cys	Tyr	Thr
3725						3730					3735			
Met	Asp	Pro	Asn	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln	Cys
3740						3745					3750			
Pro	Val	Thr	Glu	Ser	Ser	Val	Leu	Ala	Thr	Ser	Thr	Ala	Val	Ser
3755						3760					3765			
Glu	Gln	Ala	Pro	Thr	Glu	Gln	Ser	Pro	Thr	Val	Gln	Asp	Cys	Tyr
3770						3775					3780			
His	Gly	Asp	Gly	Gln	Ser	Tyr	Arg	Gly	Ser	Phe	Ser	Thr	Thr	Val
3785						3790					3795			
Thr	Gly	Arg	Thr	Cys	Gln	Ser	Trp	Ser	Ser	Met	Thr	Pro	His	Trp
3800						3805					3810			
His	Gln	Arg	Thr	Thr	Glu	Tyr	Tyr	Pro	Asn	Gly	Gly	Leu	Thr	Arg
3815						3820					3825			
Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Glu	Ile	Arg	Pro	Trp	Cys	Tyr
3830						3835					3840			
Thr	Met	Asp	Pro	Ser	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Gln
3845						3850					3855			
Cys	Pro	Val	Met	Glu	Ser	Thr	Leu	Leu	Thr	Thr	Pro	Thr	Val	Val
3860						3865					3870			
Pro	Val	Pro	Ser	Thr	Glu	Leu	Pro	Ser	Glu	Glu	Ala	Pro	Thr	Glu
3875						3880					3885			
Asn	Ser	Thr	Gly	Val	Gln	Asp	Cys	Tyr	Arg	Gly	Asp	Gly	Gln	Ser
3890						3895					3900			
Tyr	Arg	Gly	Thr	Leu	Ser	Thr	Thr	Ile	Thr	Gly	Arg	Thr	Cys	Gln
3905						3910					3915			
Ser	Trp	Ser	Ser	Met	Thr	Pro	His	Trp	His	Arg	Arg	Ile	Pro	Leu
3920						3925					3930			

-continued

Tyr	Tyr	Pro	Asn	Ala	Gly	Leu	Thr	Arg	Asn	Tyr	Cys	Arg	Asn	Pro
3935						3940					3945			
Asp	Ala	Glu	Ile	Arg	Pro	Trp	Cys	Tyr	Thr	Met	Asp	Pro	Ser	Val
3950						3955					3960			
Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Arg	Cys	Pro	Val	Thr	Glu	Ser
3965						3970					3975			
Ser	Val	Leu	Thr	Thr	Pro	Thr	Val	Ala	Pro	Val	Pro	Ser	Thr	Glu
3980						3985					3990			
Ala	Pro	Ser	Glu	Gln	Ala	Pro	Pro	Glu	Lys	Ser	Pro	Val	Val	Gln
3995						4000					4005			
Asp	Cys	Tyr	His	Gly	Asp	Gly	Arg	Ser	Tyr	Arg	Gly	Ile	Ser	Ser
4010						4015					4020			
Thr	Thr	Val	Thr	Gly	Arg	Thr	Cys	Gln	Ser	Trp	Ser	Ser	Met	Ile
4025						4030					4035			
Pro	His	Trp	His	Gln	Arg	Thr	Pro	Glu	Asn	Tyr	Pro	Asn	Ala	Gly
4040						4045					4050			
Leu	Thr	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ser	Gly	Lys	Gln	Pro
4055						4060					4065			
Trp	Cys	Tyr	Thr	Thr	Asp	Pro	Cys	Val	Arg	Trp	Glu	Tyr	Cys	Asn
4070						4075					4080			
Leu	Thr	Gln	Cys	Ser	Glu	Thr	Glu	Ser	Gly	Val	Leu	Glu	Thr	Pro
4085						4090					4095			
Thr	Val	Val	Pro	Val	Pro	Ser	Met	Glu	Ala	His	Ser	Glu	Ala	Ala
4100						4105					4110			
Pro	Thr	Glu	Gln	Thr	Pro	Val	Val	Arg	Gln	Cys	Tyr	His	Gly	Asn
4115						4120					4125			
Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Phe	Ser	Thr	Thr	Val	Thr	Gly	Arg
4130						4135					4140			
Thr	Cys	Gln	Ser	Trp	Ser	Ser	Met	Thr	Pro	His	Arg	His	Gln	Arg
4145						4150					4155			
Thr	Pro	Glu	Asn	Tyr	Pro	Asn	Asp	Gly	Leu	Thr	Met	Asn	Tyr	Cys
4160						4165					4170			
Arg	Asn	Pro	Asp	Ala	Asp	Thr	Gly	Pro	Trp	Cys	Phe	Thr	Met	Asp
4175						4180					4185			
Pro	Ser	Ile	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Thr	Arg	Cys	Ser	Asp
4190						4195					4200			
Thr	Glu	Gly	Thr	Val	Val	Ala	Pro	Pro	Thr	Val	Ile	Gln	Val	Pro
4205						4210					4215			
Ser	Leu	Gly	Pro	Pro	Ser	Glu	Gln	Asp	Cys	Met	Phe	Gly	Asn	Gly
4220						4225					4230			
Lys	Gly	Tyr	Arg	Gly	Lys	Lys	Ala	Thr	Thr	Val	Thr	Gly	Thr	Pro
4235						4240					4245			
Cys	Gln	Glu	Trp	Ala	Ala	Gln	Glu	Pro	His	Arg	His	Ser	Thr	Phe
4250						4255					4260			
Ile	Pro	Gly	Thr	Asn	Lys	Trp	Ala	Gly	Leu	Glu	Lys	Asn	Tyr	Cys
4265						4270					4275			
Arg	Asn	Pro	Asp	Gly	Asp	Ile	Asn	Gly	Pro	Trp	Cys	Tyr	Thr	Met
4280						4285					4290			
Asn	Pro	Arg	Lys	Leu	Phe	Asp	Tyr	Cys	Asp	Ile	Pro	Leu	Cys	Ala
4295						4300					4305			
Ser	Ser	Ser	Phe	Asp	Cys	Gly	Lys	Pro	Gln	Val	Glu	Pro	Lys	Lys

-continued

4310	4315	4320
Cys Pro Gly Ser Ile Val	Gly Gly Cys Val Ala His	Pro His Ser
4325	4330	4335
Trp Pro Trp Gln Val Ser	Leu Arg Thr Arg Phe Gly	Lys His Phe
4340	4345	4350
Cys Gly Gly Thr Leu Ile	Ser Pro Glu Trp Val Leu	Thr Ala Ala
4355	4360	4365
His Cys Leu Lys Lys Ser	Ser Arg Pro Ser Ser Tyr	Lys Val Ile
4370	4375	4380
Leu Gly Ala His Gln Glu Val	Asn Leu Glu Ser His	Val Gln Glu
4385	4390	4395
Ile Glu Val Ser Arg Leu Phe	Leu Glu Pro Thr Gln	Ala Asp Ile
4400	4405	4410
Ala Leu Leu Lys Leu Ser	Arg Pro Ala Val Ile Thr	Asp Lys Val
4415	4420	4425
Met Pro Ala Cys Leu Pro	Ser Pro Asp Tyr Met Val	Thr Ala Arg
4430	4435	4440
Thr Glu Cys Tyr Ile Thr	Gly Trp Gly Glu Thr Gln	Gly Thr Phe
4445	4450	4455
Gly Thr Gly Leu Leu Lys	Glu Ala Gln Leu Leu Val	Ile Glu Asn
4460	4465	4470
Glu Val Cys Asn His Tyr Lys	Tyr Ile Cys Ala Glu	His Leu Ala
4475	4480	4485
Arg Gly Thr Asp Ser Cys Gln	Gly Asp Ser Gly Gly	Pro Leu Val
4490	4495	4500
Cys Phe Glu Lys Asp Lys Tyr	Ile Leu Gln Gly Val	Thr Ser Trp
4505	4510	4515
Gly Leu Gly Cys Ala Arg Pro	Asn Lys Pro Gly Val	Tyr Ala Arg
4520	4525	4530
Val Ser Arg Phe Val Thr Trp	Ile Glu Gly Met Met	Arg Asn Asn
4535	4540	4545

<210> SEQ ID NO 31

<211> LENGTH: 317

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
1 5 10 15
Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
20 25 30
Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
35 40 45
Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
50 55 60
Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
65 70 75 80
Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
85 90 95
Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
100 105 110
Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp

-continued

115					120					125						
Val	Cys	Gly	Arg	Leu	Val	Gln	Tyr	Arg	Gly	Glu	Val	Gln	Ala	Met	Leu	
130					135					140						
Gly	Gln	Ser	Thr	Glu	Glu	Leu	Arg	Val	Arg	Leu	Ala	Ser	His	Leu	Arg	
145					150					155					160	
Lys	Leu	Arg	Lys	Arg	Leu	Leu	Arg	Asp	Ala	Asp	Asp	Leu	Gln	Lys	Arg	
				165					170					175		
Leu	Ala	Val	Tyr	Gln	Ala	Gly	Ala	Arg	Glu	Gly	Ala	Glu	Arg	Gly	Leu	
			180					185					190			
Ser	Ala	Ile	Arg	Glu	Arg	Leu	Gly	Pro	Leu	Val	Glu	Gln	Gly	Arg	Val	
			195				200					205				
Arg	Ala	Ala	Thr	Val	Gly	Ser	Leu	Ala	Gly	Gln	Pro	Leu	Gln	Glu	Arg	
			210				215					220				
Ala	Gln	Ala	Trp	Gly	Glu	Arg	Leu	Arg	Ala	Arg	Met	Glu	Glu	Met	Gly	
225					230					235					240	
Ser	Arg	Thr	Arg	Asp	Arg	Leu	Asp	Glu	Val	Lys	Glu	Gln	Val	Ala	Glu	
				245				250						255		
Val	Arg	Ala	Lys	Leu	Glu	Glu	Gln	Ala	Gln	Gln	Ile	Arg	Leu	Gln	Ala	
			260					265					270			
Glu	Ala	Phe	Gln	Ala	Arg	Leu	Lys	Ser	Trp	Phe	Glu	Pro	Leu	Val	Glu	
			275				280					285				
Asp	Met	Gln	Arg	Gln	Trp	Ala	Gly	Leu	Val	Glu	Lys	Val	Gln	Ala	Ala	
			290				295					300				
Val	Gly	Thr	Ser	Ala	Ala	Pro	Val	Pro	Ser	Asp	Asn	His				
305					310					315						

<210> SEQ ID NO 32

<211> LENGTH: 138

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

Met	Thr	Ala	Leu	Phe	Leu	Met	Ser	Met	Leu	Phe	Gly	Leu	Ala	Cys	Gly
1				5					10					15	
Gln	Ala	Met	Ser	Phe	Cys	Ile	Pro	Thr	Glu	Tyr	Thr	Met	His	Ile	Glu
			20					25					30		
Arg	Arg	Glu	Cys	Ala	Tyr	Cys	Leu	Thr	Ile	Asn	Thr	Thr	Ile	Cys	Ala
			35				40					45			
Gly	Tyr	Cys	Met	Thr	Arg	Asp	Ile	Asn	Gly	Lys	Leu	Phe	Leu	Pro	Lys
	50					55					60				
Tyr	Ala	Leu	Ser	Gln	Asp	Val	Cys	Thr	Tyr	Arg	Asp	Phe	Ile	Tyr	Arg
65					70					75				80	
Thr	Val	Glu	Ile	Pro	Gly	Cys	Pro	Leu	His	Val	Ala	Pro	Tyr	Phe	Ser
			85						90					95	
Tyr	Pro	Val	Ala	Leu	Ser	Cys	Lys	Cys	Gly	Lys	Cys	Asn	Thr	Asp	Tyr
			100					105					110		
Ser	Asp	Cys	Ile	His	Glu	Ala	Ile	Lys	Thr	Asn	Tyr	Cys	Thr	Lys	Pro
			115				120					125			
Gln	Lys	Ser	Tyr	Leu	Val	Gly	Phe	Ser	Val						
	130						135								

<210> SEQ ID NO 33

<211> LENGTH: 241

<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 33

```

Met Asn Arg Cys Trp Ala Leu Phe Leu Ser Leu Cys Cys Tyr Leu Arg
 1             5             10             15
Leu Val Ser Ala Glu Gly Asp Pro Ile Pro Glu Glu Leu Tyr Glu Met
          20          25          30
Leu Ser Asp His Ser Ile Arg Ser Phe Asp Asp Leu Gln Arg Leu Leu
          35          40          45
His Gly Asp Pro Gly Glu Glu Asp Gly Ala Glu Leu Asp Leu Asn Met
          50          55          60
Thr Arg Ser His Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg Gly Arg
 65          70          75          80
Arg Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu
          85          90          95
Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp
          100         105         110
Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln
          115         120         125
Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr
          130         135         140
Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg
          145         150         155         160
Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu
          165         170         175
Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr Arg Ser
          180         185         190
Pro Gly Gly Ser Gln Glu Gln Arg Ala Lys Thr Pro Gln Thr Arg Val
          195         200         205
Thr Ile Arg Thr Val Arg Val Arg Arg Pro Pro Lys Gly Lys His Arg
          210         215         220
Lys Phe Lys His Thr His Asp Lys Thr Ala Leu Lys Glu Thr Leu Gly
          225         230         235         240
Ala

```

<210> SEQ ID NO 34

<211> LENGTH: 155

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 34

```

Met Glu Arg Ile Val Ile Cys Leu Met Val Ile Phe Leu Gly Thr Leu
 1             5             10             15
Val His Lys Ser Ser Ser Gln Gly Gln Asp Arg His Met Ile Arg Met
          20          25          30
Arg Gln Leu Ile Asp Ile Val Asp Gln Leu Lys Asn Tyr Val Asn Asp
          35          40          45
Leu Val Pro Glu Phe Leu Pro Ala Pro Glu Asp Val Glu Thr Asn Cys
          50          55          60
Glu Trp Ser Ala Phe Ser Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala
          65          70          75          80
Asn Thr Gly Asn Asn Glu Arg Ile Ile Asn Val Ser Ile Lys Lys Leu
          85          90          95

```

-continued

Lys	Arg	Lys	Pro	Pro	Ser	Thr	Asn	Ala	Gly	Arg	Arg	Gln	Lys	His	Arg
			100					105					110		
Leu	Thr	Cys	Pro	Ser	Cys	Asp	Ser	Tyr	Glu	Lys	Lys	Pro	Pro	Lys	Glu
		115					120					125			
Phe	Leu	Glu	Arg	Phe	Lys	Ser	Leu	Leu	Gln	Lys	Met	Ile	His	Gln	His
	130					135					140				
Leu	Ser	Ser	Arg	Thr	His	Gly	Ser	Glu	Asp	Ser					
145					150				155						

<210> SEQ ID NO 35
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <400> SEQUENCE: 35

Gln	Gly	Glu	Pro	Ser	Ala	Pro	Lys	Leu	Glu
1				5				10	

We claim:

1. A method for evaluating renal status in a subject, comprising:

obtaining a urine sample from a subject selected for evaluation based on a determination that the subject is at risk of a future or current acute renal injury;

performing one or more assays configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 by introducing the urine sample obtained from the subject into an assay instrument which (i) for each analyte binding assay performed, contacts all or a portion of the urine sample with a binding reagent which specifically binds for detection the kidney injury marker which is assayed, and (ii) generates one or more assay results indicative of binding of each biomarker which is assayed to its respective binding reagent and displays the assay results generated in human readable form; and

correlating the assay result(s) generated by the assay instrument to the renal status of the subject.

2. A method according to claim 1, wherein said correlation step comprises correlating the assay results to one or more of risk stratification, diagnosis, staging, prognosis, classifying and monitoring of the renal status of the subject.

3. A method according to claim 1, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future acute renal injury.

4. A method according to claim 3, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).

5. A method according to claim 1, wherein said assay results comprise at least 2, 3, 4, or 5 of:

- a measured concentration of Tumor necrosis factor receptor superfamily member 8,
- a measured concentration of Alpha-Fetoprotein,
- a measured concentration of Thyroxine-binding globulin,
- a measured concentration of Prostate-specific antigen (free form),
- a measured concentration of Apolipoprotein A,
- a measured concentration of Apolipoprotein E,
- a measured concentration of Thyrotropin subunit beta,
- a measured concentration of Platelet-derived growth factor B/B dimer,
- a measured concentration of C-C motif chemokine 7,
- a measured concentration of C-C motif chemokine 26,
- a measured concentration of Complement C4-B,
- a measured concentration of Corticotropin,
- a measured concentration of Interferon alpha-2,
- a measured concentration of Interleukin-4 receptor alpha chain,
- a measured concentration of Insulin-like growth factor-binding protein 4,
- a measured concentration of Insulin-like growth factor-binding protein 5,
- a measured concentration of Interleukin 21,
- a measured concentration of Interleukin 23 alpha subunit,
- a measured concentration of Interleukin-28A,
- a measured concentration of Interleukin-33,
- a measured concentration of Lutropin subunit beta,
- a measured concentration of Matrix Metalloproteinase-1,
- a measured concentration of Neural cell adhesion molecule 1,
- a measured concentration of Pigment epithelium-derived factor,
- a measured concentration of Vascular endothelial growth factor receptor 2,

a measured concentration of Vascular endothelial growth factor receptor 3, and
a measured concentration of IgG4.

6. A method according to claim **5**, wherein a plurality of assay results are combined using a function that converts the plurality of assay results into a single composite result.

7. (canceled)

8. A method according to claim **3**, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future acute renal injury within 30 days of the time at which the urine sample is obtained from the subject.

9. A method according to claim **8**, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future acute renal injury within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.

10. A method according to claim **1**, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

11. A method according to claim **1**, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

12. A method according to claim **1**, wherein each assay is an immunoassay performed by (i) introducing the urine sample into an assay device comprising at least one of which binds to a biomarker which is assayed, and (ii) generating an assay result indicative of binding of each biomarker to its respective antibody.

13. A method according to claim **1**, wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result(s).

14-23. (canceled)

24. A method according to claim **1**, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 72 hours of the time at which the body fluid sample is obtained.

25. A method according to claim **1**, wherein said correlating step comprises correlating the assay results to a likelihood of one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 48 hours of the time at which the body fluid sample is obtained.

26. A method according to claim **1**, wherein correlating step comprises correlating the assay results to a likelihood of one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.

27. A method according to claim **1**, wherein the subject is in RIFLE stage 0 or R.

28. A method according to claim **27**, wherein the subject is in RIFLE stage 0.

29-32. (canceled)

33. A method according to claim **27**, wherein the subject is in RIFLE stage R.

34. (canceled)

35. A method according to claim **1**, wherein the subject is in RIFLE stage 0, R, or I.

36. A method according to claim **35**, wherein the subject is in RIFLE stage I.

37-54. (canceled)

55. A method according to claim **1**, wherein the subject is not in acute renal failure.

56-108. (canceled)

* * * * *